0001493152-24-009955.txt : 20240314 0001493152-24-009955.hdr.sgml : 20240314 20240314160556 ACCESSION NUMBER: 0001493152-24-009955 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 91 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240314 DATE AS OF CHANGE: 20240314 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Co-Diagnostics, Inc. CENTRAL INDEX KEY: 0001692415 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 462609396 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38148 FILM NUMBER: 24749732 BUSINESS ADDRESS: STREET 1: 4049 SOUTH HIGHLAND DRIVE CITY: SALT LAKE CITY STATE: UT ZIP: 84124 BUSINESS PHONE: 8012789769 MAIL ADDRESS: STREET 1: 4049 SOUTH HIGHLAND DRIVE CITY: SALT LAKE CITY STATE: UT ZIP: 84124 10-K 1 form10-k.htm
false FY 0001692415 0001692415 2023-01-01 2023-12-31 0001692415 2023-06-30 0001692415 2024-03-12 0001692415 2022-01-01 2022-12-31 0001692415 2023-12-31 0001692415 2022-12-31 0001692415 CODX:ProductRevenueMember 2023-01-01 2023-12-31 0001692415 CODX:ProductRevenueMember 2022-01-01 2022-12-31 0001692415 CODX:GrantRevenueMember 2023-01-01 2023-12-31 0001692415 CODX:GrantRevenueMember 2022-01-01 2022-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001692415 us-gaap:CommonStockMember 2021-12-31 0001692415 us-gaap:TreasuryStockCommonMember 2021-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001692415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001692415 us-gaap:RetainedEarningsMember 2021-12-31 0001692415 2021-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001692415 us-gaap:CommonStockMember 2022-12-31 0001692415 us-gaap:TreasuryStockCommonMember 2022-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001692415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001692415 us-gaap:RetainedEarningsMember 2022-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001692415 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001692415 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001692415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001692415 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001692415 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001692415 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001692415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001692415 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001692415 us-gaap:CommonStockMember 2023-12-31 0001692415 us-gaap:TreasuryStockCommonMember 2023-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001692415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001692415 us-gaap:RetainedEarningsMember 2023-12-31 0001692415 CODX:CustomersMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2023-01-01 2023-12-31 0001692415 CODX:CustomersMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2022-01-01 2022-12-31 0001692415 CODX:TwoCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001692415 CODX:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001692415 CODX:OneGrantingAgencyMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001692415 CODX:TwoCustomersMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2023-01-01 2023-12-31 0001692415 CODX:TwoCustomersMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2022-01-01 2022-12-31 0001692415 CODX:CustomersTogetherMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2023-01-01 2023-12-31 0001692415 CODX:CustomersTogetherMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2022-01-01 2022-12-31 0001692415 us-gaap:CashMember 2023-12-31 0001692415 us-gaap:CashMember 2023-01-01 2023-12-31 0001692415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001692415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2023-01-01 2023-12-31 0001692415 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001692415 us-gaap:FairValueInputsLevel1Member 2023-01-01 2023-12-31 0001692415 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001692415 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2023-01-01 2023-12-31 0001692415 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001692415 us-gaap:FairValueInputsLevel2Member 2023-01-01 2023-12-31 0001692415 us-gaap:CashMember 2022-12-31 0001692415 us-gaap:CashMember 2022-01-01 2022-12-31 0001692415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001692415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-01-01 2022-12-31 0001692415 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001692415 us-gaap:FairValueInputsLevel1Member 2022-01-01 2022-12-31 0001692415 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001692415 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2022-01-01 2022-12-31 0001692415 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001692415 us-gaap:FairValueInputsLevel2Member 2022-01-01 2022-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 2023-12-31 0001692415 us-gaap:MeasurementInputSharePriceMember 2023-12-31 0001692415 us-gaap:MeasurementInputSharePriceMember 2022-12-31 0001692415 CODX:MeasurementInputStrikePriceMember 2023-12-31 0001692415 CODX:MeasurementInputStrikePriceMember 2022-12-31 0001692415 us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001692415 us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001692415 us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001692415 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001692415 us-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001692415 us-gaap:EquipmentMember srt:MinimumMember 2023-12-31 0001692415 us-gaap:EquipmentMember srt:MaximumMember 2023-12-31 0001692415 us-gaap:EquipmentMember 2023-12-31 0001692415 us-gaap:EquipmentMember 2022-12-31 0001692415 us-gaap:LeaseholdsAndLeaseholdImprovementsMember srt:MinimumMember 2023-12-31 0001692415 us-gaap:LeaseholdsAndLeaseholdImprovementsMember srt:MaximumMember 2023-12-31 0001692415 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001692415 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001692415 us-gaap:OfficeEquipmentMember srt:MinimumMember 2023-12-31 0001692415 us-gaap:OfficeEquipmentMember srt:MaximumMember 2023-12-31 0001692415 us-gaap:OfficeEquipmentMember 2023-12-31 0001692415 us-gaap:OfficeEquipmentMember 2022-12-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2023-01-01 2023-12-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2023-12-31 0001692415 us-gaap:NoncompeteAgreementsMember 2023-12-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2022-01-01 2022-12-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2022-12-31 0001692415 us-gaap:NoncompeteAgreementsMember 2022-12-31 0001692415 country:US us-gaap:ProductMember 2023-01-01 2023-12-31 0001692415 country:US us-gaap:ProductMember 2022-01-01 2022-12-31 0001692415 country:US us-gaap:GrantMember 2023-01-01 2023-12-31 0001692415 country:US us-gaap:GrantMember 2022-01-01 2022-12-31 0001692415 country:US 2023-01-01 2023-12-31 0001692415 country:US 2022-01-01 2022-12-31 0001692415 CODX:RestOfWorldMember us-gaap:ProductMember 2023-01-01 2023-12-31 0001692415 CODX:RestOfWorldMember us-gaap:ProductMember 2022-01-01 2022-12-31 0001692415 CODX:RestOfWorldMember us-gaap:GrantMember 2023-01-01 2023-12-31 0001692415 CODX:RestOfWorldMember us-gaap:GrantMember 2022-01-01 2022-12-31 0001692415 CODX:RestOfWorldMember 2023-01-01 2023-12-31 0001692415 CODX:RestOfWorldMember 2022-01-01 2022-12-31 0001692415 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0001692415 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0001692415 CODX:RestOfWorldMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0001692415 CODX:RestOfWorldMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0001692415 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001692415 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001692415 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001692415 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001692415 CODX:TwoThousandFifteenLongTermIncentivePlanMember 2022-08-31 0001692415 CODX:TwoThousandFifteenLongTermIncentivePlanMember 2023-12-31 0001692415 CODX:StockOptionsMember 2023-01-01 2023-12-31 0001692415 CODX:StockOptionsMember 2022-01-01 2022-12-31 0001692415 CODX:StockOptionsMember 2023-12-31 0001692415 CODX:StockOptionsMember 2022-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001692415 us-gaap:WarrantMember 2023-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001692415 us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0001692415 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0001692415 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-12-31 0001692415 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-12-31 0001692415 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001692415 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001692415 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001692415 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001692415 CODX:LeaseAmendmentMember 2023-12-31 0001692415 2022-03-31 0001692415 CODX:SethEganMember 2023-01-01 2023-12-31 0001692415 CODX:WinstonEganMember 2023-01-01 2023-12-31 0001692415 CODX:CoSaraDiagnosticsPvtLtdMember 2023-01-01 2023-12-31 0001692415 2023-10-01 2023-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549.

 

Form 10-K

 

(Mark One)

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2023

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from_______to_______

 

Commission File Number 001-38148

 

CO-DIAGNOSTICS, INC.

 

(Exact Name of Registrant as Specified in Its Charter)

 

Utah   46-2609396

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification Number)

 

2401 S. Foothill Drive, Salt Lake City, Utah 84109

(Address of principal executive offices and zip code)

 

(801) 438-1036

(Registrant’s telephone number including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   CODX   The Nasdaq Capital Market

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

  Large accelerated filer ☐ Accelerated filer ☐
  Non-accelerated filer ☒ Smaller reporting company ☒
      Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common stock was last sold as of the last business day of the registrant’s most recently completed second fiscal quarter was approximately $33,000,000.

 

As of March 12, 2024, there were 31,259,668 shares of common stock, par value $0.001 per share, outstanding.

 

 

 

 

 

 

Table of Contents

 

    Page
     
PART I  
     
Item 1. Business. 4
     
Item 1A. Risk Factors. 12
     
Item 1B. Unresolved Staff Comments. 23
     
Item 1C. Cybersecurity 24
     
Item 2. Properties. 25
     
Item 3. Legal Proceedings. 25
     
Item 4. Mine Safety Disclosures. 26
     
PART II  
     
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. 27
     
Item 6. [Reserved.] 28
     
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations. 28
     
Item 7A. Quantitative and Qualitative Disclosures About Market Risk. 32
     
Item 8. Financial Statements and Supplementary Data. 33
     
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. 55
     
Item 9A. Controls and Procedures. 55
     
Item 9B. Other Information. 56
     
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. 56
     
PART III  
     
Item 10. Directors, Executive Officers and Corporate Governance. 56
     
Item 11. Executive Compensation. 61
     
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. 64
     
Item 13. Certain Relationships and Related Transactions, and Director Independence. 65
     
Item 14. Principal Accountant Fees and Services. 65
     
PART IV  
     
Item 15. Exhibits and Financial Statement Schedules. 66

 

2
 

 

PART I

 

Forward-Looking Statements

 

This Annual Report on Form 10-K contains “forward-looking statements” that involve risks and uncertainties. All statements other than statements of historical fact contained in this Annual Report and the documents incorporated by reference herein, including statements regarding future events, our future financial performance, business strategy, and plans and objectives of management for future operations, are forward-looking statements. We have attempted to identify forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “should,” or “will” or the negative of these terms or other comparable terminology. Although we do not make forward looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. These statements are only predictions and involve known and unknown risks, uncertainties and other factors which may affect our or our industry’s actual results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Moreover, we operate in a highly regulated, very competitive, and rapidly changing environment. New risks emerge from time to time, and it is not possible for us to predict all risk factors, nor can we address the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause our actual results to differ materially from those contained in any forward-looking statements.

 

We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short term and long-term business operations, and financial needs. These forward-looking statements are subject to certain risks and uncertainties that could cause our actual results to differ materially from those reflected in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this Annual Report, and in particular, the risks discussed under “Item 1, Business,” “Item 1A, Risk Factors,” and “Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and those discussed in other documents we file with the Securities and Exchange Commission (the “SEC”). In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Annual Report may not occur as described and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statement.

 

Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation:

 

  ● the results of clinical evaluations and the regulatory approval process;
     
  ● market acceptance of any products that may be approved for commercialization;
     
  ● our ability to protect our intellectual property rights;
     
  ● the impact of any infringement actions or other litigation brought against us;
     
  ● competition from other providers and products;
     
  ● our ability to develop and commercialize new and improved products and services;
     
  ● changes in government regulation;
     
  ● and other factors (including the risks contained in the section entitled “Risk Factors” in other documents we file with the SEC) relating to our industry, our operations and results of operations.

 

Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

 

Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this Annual Report speak only as of the date of this Annual Report. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

 

3
 

 

As used in this Annual Report, the terms “we”, “us”, “our”, “Company”, “CODX” and “Co-Diagnostics” means Co-Diagnostics, Inc., a Utah corporation and its consolidated subsidiaries (the “Company”), unless otherwise indicated.

 

ITEM 1: BUSINESS

 

Overview

 

Co-Diagnostics, Inc., a Utah corporation (the “Company” or “CODX”), develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Our diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. CODX’s technical advance involves a novel, patented approach to PCR test design of primer and probe structure (“CoPrimers™”) that eliminates one of the key vexing issues of PCR amplification: the exponential growth of primer-dimer pairs (false positives and false negatives) which adversely interferes with identification of the target DNA/RNA. Using our proprietary test design system and proprietary reagents, we have designed and obtained regulatory approval to sell PCR diagnostic tests for the detection of COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the Zika virus. These initial diagnostic tests were cleared for use in clinical labs only and not for point-of-care or at-home use.

 

We are currently developing a unique, groundbreaking portable diagnostic device and test system designed for point-of-care and at-home use. The system is comprised of our PCR instrument that we refer to as the Co-Dx™ PCR Pro™ instrument, our proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device. We refer to the system as the “Co-Dx™ PCR platform that is being designed to bring affordable, reliable polymerase chain reaction (“PCR”) testing to patients in point-of-care and at-home settings. The Co-Dx PCR platform is subject to U.S. Food and Drug Administration (“FDA”) review and is not available for sale at the time of this filing. In December 2023, we submitted the Co-Dx PCR platform for review by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA). The submission included the PCR Pro instrument, Co-Dx PCR COVID-19 detection test cups, and mobile app, all designed for use in point-of-care and at-home settings. There is no guarantee that our Co-Dx PCR platform will receive the necessary regulatory approvals for commercialization, or that, if regulatory approval is received, we will be able to successfully commercialize this platform.

 

Technology

 

We believe our proprietary molecular diagnostics technology is paving the way for innovation in disease detection and life sciences research through our enhanced detection of genetic material. For various reasons, including owning our own platform, we believe we will be able to accomplish this faster and more economically than some competitors, allowing for significant margins while still positioning ourselves as a low-cost provider of molecular diagnostics and screening services. For example, we were the first US-based company to receive a CE-marking for a COVID-19 test in early 2020, as we worked to help slow the spread of the pandemic through our global network of distributors covering clinical labs in more than 50 countries. Our Logix Smart COVID-19 test was designed, developed, submitted for regulatory approval and ready to be used as an in vitro diagnostic or IVD in countries that accept a CE Mark as approval for use of the test in a period of just over 30 days. This is a real-world example of how the CODX technology can be used in an evolving epidemic or pandemic to get diagnostic tools in the hands of medical professionals in a timely manner. It can be similarly used to design a test for mutated strains of the virus should they not be detectable using currently available tests.

 

In addition, continued development has demonstrated the unique properties of our CoPrimer technology that we believe makes it ideally suited for a variety of applications where specificity is key to optimal results, including multiplexing several targets, enhanced Single Nucleotide Polymorphism (“SNP”) detection and enrichment for next generation sequencing.

 

Our scientists use the complex mathematics of DNA/RNA PCR test design to engineer and optimize PCR tests and to automate algorithms that rapidly screen millions of possible options to pinpoint the optimum design. The intellectual property we use in our business, consisting of the predictive mathematical algorithms and patented molecular structure used in the testing process, which together represents a major advance in PCR testing systems. CODX technologies are now protected by more than 20 granted or pending US and foreign patents, as well as certain trade secrets and copyrights. Ownership of our proprietary platform permits us the advantage of avoiding payment of patent royalties required by other PCR test systems, which may allow the sale of diagnostic PCR tests at a lower price than competitors, while enabling us to maintain profit margins.

 

Our proprietary test design process involves identifying the optimal locations on the target genes for amplification and pair the locations with the optimized primer and probe structure to achieve outputs that meet the design input requirements identified from market research. This is done by following planned and documented processes, procedures and testing. In other words, we use the data resulting from our tests to verify whether we succeeded in designing what we intended. Verification involves a series of testing that concludes that the product is ready to proceed to validation in an evaluation either in our laboratory or in an independent laboratory setting using initial production tests to confirm that the product as designed meets the user needs.

 

4
 

 

Using our proprietary test design system and proprietary reagents, we have designed and obtained regulatory approval in the European Community and in India to sell PCR diagnostic tests for the detection of COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the Zika virus. In the United States, we obtained Emergency Use Authorization (“EUA”) for our Logix Smart® COVID-19 detection test from the Food and Drug Administration, or FDA, and we sell that test to qualified labs. In addition, our COVID-19 detection test and certain of our other suite of COVID-19 products have been approved for sale in countries such as the United Kingdom, Australia and Mexico by the regulatory bodies in those countries and have been registered for sale in many more countries. In connection with the sale of our tests we may sell diagnostic equipment from other manufacturers as self-contained lab systems (which we refer to as the “MDx Device”).

 

In addition to testing for infectious disease, the technology lends itself to identifying any section of a DNA or RNA strand that describes any type of genetic trait, which creates several significant applications. We, in conjunction with our customers, have designed and licensed tests that identify genetic traits in plant and animal genomes. We also have three multiplexed tests developed to test mosquitos for the identification of diseases carried by the mosquitos to enable municipalities to concentrate their efforts in managing mosquito populations on the specific areas known to be breeding the mosquitos that carry deadly viruses.

 

Co-Dx PCR Platform

 

We believe the benefits of affordable, high-quality diagnostics should be available to everyone. High-quality point-of-care PCR testing plays a crucial role in healthcare. It enables rapid diagnosis of infectious diseases, such as COVID-19 or tuberculosis, facilitating timely treatment and containment measures. By delivering results on-site, it eliminates the need for sample transportation, reducing the risk that the sample is transported incorrectly or lost enroute, reducing turnaround time to results, and allowing for immediate decision-making. The quality of PCR testing at the point of care ensures reliable detection of pathogens, minimizing incorrect results. In short, high-quality PCR testing at home and at the point of care enhances patient care, public health response, and helps control the spread of infectious diseases. That is why we are developing the Co-Dx PCR platform utilizing our Co-Primers™ real-time PCR technology for at-home and point-of-care testing. Because we believe that testing for COVID-19 and other infectious diseases will continue to be a consideration for public health worldwide, we initiated the Co-Dx PCR platform to facilitate frequent, affordable, reliable polymerase chain reaction (“PCR”) testing to patients in point-of-care and at-home settings, including schools, businesses, and the hospitality industry. We believe this may be accomplished through the development of a testing system comprised of a compact, relatively low-cost testing device, the Co-Dx PCR Pro instrument, together with proprietary diagnostic test cups that work with the Co-Dx Pro instrument and a mobile application, that is easy to use by professionals and non-professionals, that can provide PCR test results in around 30 minutes. We believe that as user test results are gathered in the cloud following completion of tests, the data may be useful for governmental health agencies and the World Health Organization to determine where outbreaks of infectious diseases may be occurring and enable them to act more quickly and efficiently and slow-down or perhaps even prevent further spread.

 

The 6 ½” x 4 1/2” x 6”, 2 lbs. Co-Dx PCR Pro instrument operates via a smartphone app with simple-to-follow instructions that includes videos to walk users through every step, some sample swab collection to the straightforward instrument operation. Results are processed in the cloud and delivered back to the user’s smartphone or tablet in about 30 minutes using software designed from the ground-up for this specific use. The PCR tests themselves (contained in the simple but unique, innovative test collection cups) are powered by patented Co-Dx Co-Primers PCR technology.

 

The initial diagnostic test designed for use on this platform, an at-home and point-of-care COVID-19 PCR test, was ultimately facilitated by our development of a saliva or nasal swab-based PCR test that does not require RNA/DNA extraction. The final result is believed to be approximately equivalent to those processed by a high-complexity clinical laboratory. Our COVID-19 PCR platform test has the advantages of increased speed and ease of handling thanks to lyophilization (or freeze-drying) of our testing reagents to allow for stability at room temperatures. In December 2023, we submitted our proprietary Co-Dx PCR COVID-19 test cups with the Co-Dx PCR Pro instrument and mobile application, all designed for use in point-of-care and at-home settings, for review by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA). We are also preparing a 510K for submission to the FDA should the FDA decline to grant our emergency use authorization request.

 

We expect to develop further diagnostic tests for use with the PCR Pro instrument, including a multiplex test for influenza, RSV and COVID-19. To that effect, we were awarded $1.2 million in funding from the National Institutes of Health (NIH) as part of the Rapid Acceleration of Diagnostics (RADx®) Tech program for completion of our upper respiratory panel diagnostic test for use on the Company’s Co-Dx PCR platform. We will utilize the funds from the RADx Tech award to complete development of our flu A/B, COVID-19, and RSV multiplex test, preparatory for that test to begin clinical trials on the Co-Dx PCR Pro instrument. The NIH launched the RADx initiative on April 29, 2020, with the goal of speeding innovation in the development, commercialization, and implementation of technologies for COVID-19 testing, leveraging the existing NIH Point-of-Care Technology Research Network. The RADx Tech program is managed by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), to support the accelerated development of tests and provide regulatory guidance during the COVID-19 pandemic and beyond.

 

5
 

 

We are also developing diagnostics tests for TB and HPV for use with our Co-Dx PCR platform. We have been awarded two grants in the amounts of $10.23 million and $987,000 by the Bill & Melinda Gates Foundation to support the development and manufacture of TB and HPV tests for our Co-Dx PCR platform. In 2014, all United Nations Member States and the World Health Organization (WHO) committed to ending the global TB epidemic by 2030, before the COVID-19 pandemic slowed, stalled or reversed progress of global TB targets. The WHO estimates that roughly 4.2 million cases of TB went unidentified in 2021 worldwide, representing nearly 40% of actual cases, highlighting the need for a dramatic increase of affordable, high-quality, point-of-care TB diagnostics to enable rapid treatment decisions to be made for a disease that has a mortality rate of about 50% if left untreated. The National Cancer Institute estimates that high-risk HPVs cause roughly 5% of all cancers worldwide, with the rate among women being nearly 10 times higher than that for men and leading to an estimated 264,000 cervical cancer deaths each year according to the WHO. More than 85% of these deaths are in low- and middle-income countries, and all of which the WHO believes can be dramatically reduced by access to diagnostics, vaccinations, and cancer screenings.

 

Infectious Disease Product Offering

 

Using our proprietary test design system and proprietary reagents, we and CoSara Diagnostics Pvt Ltd (“CoSara”), our joint venture for manufacturing in India, design and sell PCR diagnostic tests for detection of diseases and pathogens such as COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus, all of which tests have been designed and verified in our laboratories. Our tuberculosis test and Zika test received a CE Mark in 2018, and a triplex test for Zika, dengue and chikungunya received a CE Mark in 2019, qualifying the tests to be sold throughout the European community and in most countries in Central and South America. In December 2019, CoSara received a license to manufacture and sell tuberculosis, hepatitis B, hepatitis C, human papillomavirus 16/18 and malaria tests in India from the Central Drugs Standard Control Organization (“CDSCO”). In February 2020, we received a CE Mark for our Logix Smart COVID-19 test followed by an EUA by the FDA in April 2020. Also, in April 2020, our COVID-19 test was approved for manufacture and sale in India by the CDSCO and in Mexico by the INDRE, Mexico’s equivalent to the United States Center for Disease Control. In August 2020, we received approval from the Australian Department of Health Therapeutic Goods Division to sell our COVID-19 test in Australia.

 

As explained above, our Logix Smart COVID-19 test was designed, developed, submitted for regulatory approval and ready to be used as an in vitro diagnostic or IVD in countries that accept a CE Mark as approval for use of the test in a period of just over 30 days. This is a real-world example of how the CODX technology can be used in an evolving epidemic or pandemic to get diagnostic tools in the hands of medical professionals in a timely manner. It can be similarly used to design a test for mutated strains of the virus should they not be detectable using currently available tests.

 

Caribbean and Central and South America

 

We began selling PCR diagnostic tests to entities located in South and Central America and the Caribbean in 2018. In some of those countries, there are limited regulatory hurdles, allowing us to begin offering our tests immediately. We have applied for and received registrations for our tests in many of those countries that require registration, and our distributors in those countries have provided us with in-country assistance in completing such registrations.

 

We first offered our Zika test in this region because of the demand for such a test, followed by tests for tuberculosis, and our triplex test for Zika, chikungunya, and dengue. Sales of those tests have not been material, but with the granting of a CE mark for our Logix Smart COVID-19, we experienced an increase in sales in this region.

 

India

 

In January 2017, the Company entered into an agreement to manufacture diagnostics tests for seven infectious diseases with a pharmaceutical manufacturing company in India and formed CoSara as an Indian joint venture. The agreement provided for the construction of a manufacturing plant and the manufacture of the tests named above and the joint sales and marketing of those tests in India. We have received a license for the plant in Ranoli, India to manufacture approved tests and it is being used for testing and manufacturing of our products for the Indian market.

 

As mentioned above, the CDSCO has given us the approval for manufacture and sale of the 15 tests referred to above, and the Company’s joint venture manufactures and sells those tests. The Company manages a reagent rental program in India with thermocyclers purchased from third-party vendors and which we refer to as our MDx Device. The placement of thermocyclers in India has facilitated the sale of the SaraGene PCR tests in India. The WHO 2022 Global Tuberculosis Report indicates that India is the country with the highest number of cases of tuberculosis in the world. WHO tuberculosis statistics for India for 2022 give an estimated incidence figure of 2.82 million cases of tuberculosis for India out of a global incidence of approximately 10.0 million.

 

6
 

 

On March 19, 2020, we announced that CoSara received authorization to manufacture and sell COVID-19 tests in India. Those tests in India are branded as SaraGene COVID-19 tests and are sold exclusively by CoSara. The Indian government places restrictions on the price that could be charged for COVID-19 tests which limited the revenue in India more than we experienced in other parts of the world. At the time of this report, CoSara has received CDSCO clearance for RT-PCR tests for Mycobacterium tuberculosis, malaria, hepatitis B, hepatitis C (including viral load tests for both hepatitis B and C), human papillomavirus (HPV), a test for high-risk HPV, two COVID-19 assays, chikungunya, dengue, a dengue/chikungunya duplex test, an influenza A/influenza B/COVID-19 (“ABC”) multiplex test, and in 2024 CDSCO cleared the manufacture and sell SARAPLEX™ Influenza Multiplex (IFM) Test Kit to clinical laboratories as an in vitro diagnostic for the detection and differentiation of Influenza A and Influenza B.

 

Europe

 

Molecular diagnostics, such as our tests, are governed in Europe by the framework for IVDs, which encompasses diagnostic products such as reagents, instruments and systems intended for use in diagnosis of disease. The regulatory system for some IVDs has historically allowed for a self-certification procedure, placing heavy responsibility on manufacturers. Non self-certified products were subject to the same standards as self-certified products but were also subject to audit and review by a notified body prior to receiving approval to be CE-marked. A CE-marking is a manufacturer’s declaration that a product meets the requirements of the applicable European Commission directive. Examples of current obligations include having in place a qualitative manufacturing process, user instructions that are clear and fit for purpose, and ensuring that the ‘physical’ features of devices and diagnostics do not pose any danger. If a product fulfils these and other related control requirements, it may be CE-marked, as an indication that the product is compliant with EU legislation and sold in the European Union. We have received CE Marks for six of our tests including for COVID-19, COVID-19 (2 gene test), ABC (a triplex test for Flu A, Flu B and COVID-19), a DS (Direct Saliva, extraction-free) COVID-19 test, tuberculosis, Zika, and our Zika, dengue, chikungunya triplex tests. The European Commission has revised its directive governing the CE- marking of IVDs, which included reclassifying which IVDs may be self-certified, and which may not. As a result of this change in directive and reclassification, substantially all of the Company’s products are now subject to audit and review by a notified body, as well as a more rigorous clinical evaluation process, prior to receiving approval to be CE-marked.

 

We are ISO 13485:2016 certified, relating to the design and manufacture of our medical device products. The ISO certification indicates that we meet the standards required to pursue CE-marking for certain of our products and affix a CE-marking for sales of our products in countries accepting CE-marking (not in the United States).

 

United States

 

The FDA has granted permission for us to export all of our IVD products. The FDA’s permission to export was granted under Section 801(e) of the Federal Food, Drug, and Cosmetic Act, as amended (the “FDC Act”). Section 801(e) of the FDA Act covers certain medical devices that have not yet received an approved Premarket Approval in the United States by the FDA, such as our products. We have not commenced any Premarket Approval steps with the FDA. Section 801(e) of the FDA Act applies to medical devices that are acceptable to the importing country and that are manufactured under the FDA’s Good Manufacturing Practices. We have received EUA for our COVID-19 test, which allows sales to qualified labs in the United States and facilitates the registration for sale in other countries as well. Under the FDA’s existing policy, the FDA continues to review a prioritized subset of COVID-19 tests for EUAs, and emphasizes that traditional device premarket review pathways remain open to all developers. We intend to pursue all appropriate FDA review pathways for products under development, including traditional premarket review pathways.

 

Under our EUA, we are actively selling our Logix Smart COVID-19 test to CLIA certified laboratories in the United States. The CLIA labs are able to use our test, or to further validate our COVID-19 tests (or other tests) as Laboratory Developed Tests (LDTs), which refers to a diagnostic test that has been validated for use in the CLIA lab. LDTs may be used by the lab only in that laboratory. CLIA laboratories develop the performance characteristics, perform the analytical validation for their LDTs and obtain licenses to offer them as diagnostic services. We are currently marketing our Logix Smart COVID-19 test to CLIA laboratories throughout the US.

 

7
 

 

Market Opportunity

 

The market opportunity for our tests changed radically with the emergence of the COVID-19 pandemic. Because we were able to respond rapidly and produce a quality product, we have been able to build a worldwide distribution network, most of which have been the sales network that has allowed us to export products throughout the world. Our network of distributors that we have built over the past three years will serve us well in sales and distribution of other diagnostic tests and our forthcoming PCR diagnostic platform.

 

The molecular diagnostics market is a fast-growing portion of the in vitro (test tube-based, controlled environment) diagnostics market. There are several advantages of PCR tests, such as the ones we market and sell, over other forms of diagnostic testing. These advantages include higher specificity and sensitivity, the ability to perform multiplex tests and the ability to test for drug resistance or for individual genes.

 

Mosquito Vector Control Services

 

In response to market demand, in June 2019 we introduced our first diagnostics tests to be used exclusively to test for mosquito borne pathogens in mosquito populations. Municipalities in the US and many other countries in the world are concerned about the diseases carried by mosquitos, which infect the human population. To prevent outbreaks of potentially harmful viruses such as Zika or West Nile from infecting the public, many municipalities conduct mitigation operations to eliminate the mosquito populations carrying the diseases. Because it is too expensive and potentially harmful to the environment to spray all mosquito breeding areas, municipalities identify which particular area has mosquitos that are carrying the harmful viruses. To know where the host mosquitos with the harmful viruses are located, traps are set, mosquitos collected and then tested to find the areas that most needed spraying. There are over 3,000 mosquito abatement districts throughout the United States and almost all of them conduct testing to help make the spraying more effective.

 

Our first vector related test was a triplex test that tests for West Nile, western equine and St. Louis encephalitis. We began shipping the tests in June 2019. We added a second test that tests mosquitos for Zika, chikungunya and dengue in a triplex test. Finally, in November 2019, we completed a test for West Nile, eastern equine and St. Louis encephalitis, specifically for use in the eastern United States. As a result, mosquito abatement districts can test for three target viruses in one test as compared to performing three different tests using other market available tests. Our products allow municipalities to obtain test results in a matter of hours, instead of the weeks they might otherwise have to wait for a central lab to process the mosquito tests.

 

We have sold our Vector Smart™ test products and/or related lab equipment to testing districts in different sections of the country and are marketing our products through trade shows, electronic and regular mail solicitations.

 

Liquid Biopsy for Cancer Screening

 

The enhanced specificity of our technology opens up some unique applications for liquid biopsy, demonstrating its ability to detect small quantities of mutations associated with cancer within an environment of large amounts of normal DNA, as we position the Company to take part in this historic and challenging development in human health care.

 

Agricultural Applications

 

SNP detection is also used in the agricultural industry to identify variations in crop genomes to achieve improved seed viability and other desired characteristics, including drought resistance, disease resistance, pest resistance and higher yield.

 

In mid-2017, the Company was first approached by a large agribusiness to evaluate our ability to multiplex certain target genomes. The results of the development project have successfully demonstrated our ability to not only multiplex the target genomes, but targeted SNP’s as well. The project was undertaken in conjunction with the manufacturer of our CoPrimers tests. The results of the project encouraged the parent of our manufacturer to seek a world-wide licensing arrangement for our CoPrimers in the agricultural industry, which was completed in October 2018. Pursuant to the exclusive license for the agronomics industry, the licensee pays us a royalty for all CoPrimers sold to the licensee’s customers. In January 2019, the licensee formally introduced the product at a large agricultural conference and has branded the product under the name “BHQ CoPrimers”.

 

8
 

 

Additional Licensing and Assay Development

 

We believe the unique properties of our CoPrimers technology make them ideally suited to a variety of applications where sensitivity is key to optimal results, including multiplexing several targets, enhanced SNP detection and enrichment for next generation sequencing. Our licensee for our agricultural testing requested an expansion of our license agreement to include test design services for their customers and potential customers, both in the infectious disease arena as well as for agricultural customers. The license was amended in July 2019 and we expect to derive a license fee from our licensee for its design services. If any of its customers desire to commercialize the tests designed, they will need to seek a commercial license directly from us. Thanks to these unique characteristics of CoPrimers, research companies and institutions have requested that we design diagnostics to locate and identify uncommon gene sequences and SNPs and create tests for the target sequences in a multiplexed reaction. This application of our technology is in its beginning stages, but we believe that the results from our initial research indicate a significant step forward in defining the capabilities of our technology, which we believe can be translated to revenue producing licensing arrangements. However, there can be no guarantee that we will be able to develop the requested capabilities, or that we will be able to successfully commercialize this application of our technology.

 

Competitive Advantages of Co-Diagnostics

 

We believe that we have the following competitive advantages:

 

  ● Affordability: Lower-cost test kits, a low-cost MDx-device, and an affordable Co-Dx PCR platform for at-home and point-of-care testing (the platform is subject to FDA review and not available for sale at the time of this filing).
     
  ● Flexibility: CODX’s tests have been designed to run on many customers’ DNA/RNA diagnostic testing machines. Our technology is well suited to the new generation of point-of-care testing (“POCT”), compact and portable analysis machinery for field, clinical and office applications.
     
  ● Speed: We believe our rapid assay design system software provides shorter time to product release. This has been demonstrated with the conception, design, product manufacture, clinical verification and submission for a CE Mark for our Logix Smart COVID-19 test being approximately 30 days.
     
  ● Accuracy: We believe our technology allows us to build tests that are highly sensitive and specific, the two benchmarks for accuracy in PCR testing.
     
  ● Personalized Medicine: We project that rising health care costs in developed and developing nations will increasingly require that health care systems be patient-specific to eliminate waste, misdiagnoses, and ineffectiveness. A critical component will be accurate, more affordable DNA-based diagnostics, especially in at-home and POCT settings, for which we are developing products.
     
  ● Low-cost Provider: Our platform technology obviates the need to pay patent royalties typically required of our competitors, which use third-party patented test platforms to design their tests.
     
  ● Worldwide Footprint: With a dynamic technology that encompasses markets worldwide, we anticipate that we can identify the best target markets, not only in high burden developing countries but also in developed nations.
     
  ● Data Collection: With the anticipated deployment of the Co-Dx PCR platform we expect to play a role in centralizing global data collection on infectious diseases that may contribute to faster vaccination and therapeutic responses from health authorities.
     
  ● Growth Industry Category: We believe that real-time PCR testing is the fastest-growing segment of in vitro diagnostic testing.
     
  ● Combination Product Offering: Our sensitive tests can be a well-designed match for a new generation of compact and other small POCT devices now entering the market, including our own MDx and Co-Dx PCR Pro instruments. Used together, we believe these affordable tests and devices have the potential to revolutionize the molecular diagnostics industry in cost, speed of test results and simplification.
     
  ● Multiplexing: Our existing multiplexed tests demonstrate that our CoPrimer-designed tests are able to test for multiple targets in the same sample without the distortion caused by false negatives and false positives that often occur in multiplexed tests.

 

9
 

 

Intellectual Property

 

Much of our future success and value depends on our proprietary technology, and therefore, our patent and intellectual property strategy is of critical importance. Currently, our flagship CoPrimers technology is covered by two U.S. patents titled “Cooperative primers, probes, and applications thereof” as well as by granted and pending foreign counterparts. We have another three U.S. patents directed to our earlier work in primer and assay designs. For more recent works, we have filed international and U.S. patent applications directed to “Methods and Compositions for Next Generation Sequencing (NGS) Library Preparation,” “Allele-Specific Design of Cooperative Primers for Improved Nucleic Acid Variant Genotyping,” “Methods and Compositions Related to Cooperative Primers and Reverse Transcription,” and “Systems, Methods, and Apparatus for Automated Self-Contained Biological Analysis” which is the basis of our at-home and point-of-care PCR system. We intend to continue building our patent portfolio as development continues and resources are available.

 

We also protect some of our technology and know-how as trade secrets and, where appropriate, we use and register trademarks to protect and strengthen our products and proprietary brands. All trademarks, trade/product names, graphics and logos of Co-Diagnostics contained herein are trademarks of Co-Diagnostics or its subsidiary, as applicable, in the U.S. and/or other countries. Solely for convenience, we may refer to trademarks in this Annual Report on Form 10-K without the ™ or ® symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent permitted by law, our rights to our trademarks.

 

Major Customers

 

The Company had certain customers which were each responsible for generating 10% or more of the total revenue for the years ended December 31, 2023 and 2022, respectively. Two customers accounted for approximately 28% of product revenue for the year ended December 31, 2023 and one customer accounted for approximately 37% of product revenue for the year ended December 31, 2022. One granting agency accounted for 100% of grant revenue for the year ended December 31, 2023. These customers and granting agencies may not account for the same percentage of product revenue or grant revenue in future periods. If we were to sell nothing to those customers in the future, it would have a material adverse effect on our financial condition unless we were able to replace those customers with others.

 

Competition

 

The molecular diagnostics industry is extremely competitive. There are many firms that provide some or all of the products we provide and provide many diagnostic tests that we have yet to develop. Many of these competitors are larger than us and have significantly greater financial resources. Because we are more recently established, many of our competitors have a competitive advantage in the diagnostic testing industry because they also have other lines of business in the pharmaceutical industry from which they derive revenues and for which they are well known and respected in the medical profession. We will need to overcome the disadvantage of being perceived as a start up with no significant recognition from the medical and testing professionals, although we believe this is changing as we continue to market our Logix Smart COVID-19 tests and other tests in the United States to well-known and successful laboratories. Many of these competitors already have an established customer base with industry standard technology, which we must overcome to be successful. In the diagnostic testing and POCT industries, we compete with such companies as BioMerieux, Siemens, Qiagen, Cue Health, Lumira Dx and Cepheid and with such pharmaceutical companies as Abbott Laboratories, Becton Dickinson and Johnson and Johnson. We also compete with companies from Asia in certain markets who are willing to sell their tests for much less than we sell our tests, which creates competitive price pressure on us in certain regions, particularly Asia and Latin America.

 

10
 

 

We expect competition to continue to increase as other established and emerging companies enter the market, as customer requirements evolve, and as new products, services and technologies are introduced. Some of our existing or new competitors may have strong relationships with current and potential customers, including governmental authorities, and, as a result, may be able to respond more quickly to new or changing regulatory requirements, new or emerging technologies, and changes in customer requirements.

 

Government Regulation

 

In the United States, we are regulated by the FDA and our products must be approved, cleared, or authorized by the FDA before we are allowed to sell our tests in the United States as in vitro diagnostics. The FDA granted us an EUA to manufacture and sell our Logix Smart COVID-19 test to CLIA labs in the United States. We are ISO 13485:2016 certified, relating to the design and manufacture of our medical device products. Being ISO certified greatly facilitates our applications for CE-Marking, which allows us to sell any CE Marked test in most countries in Europe, South America and Asia, depending on the country and following that country’s registration process. We currently have CE Markings issued for our Logix Smart COVID-19 test, tuberculosis test, our Zika virus test, a triplex test that tests for Zika, dengue, and chikungunya simultaneously, a triplex “ABC” test that identifies and distinguishes between Flu A, Flu B and Covid-19, our SARS-CoV-2 2-gene multiplex test, and our DS (Direct Saliva, extraction-free) COVID-19 test. In addition, our Logix Smart COVID-19 has received the required license to manufacture and sell in India from India’s CDSCO, and The National Epidemiology Institute in Mexico evaluated our Logix Smart COVID-19 and ABC tests and approved them for sale in Mexico. We have also received approval to sell in Australia.

 

Employees

 

As of December 31, 2023, we had 155 full-time and part-time employees at our executive offices and lab facilities in Salt Lake City, Utah. We have engaged independent contractors to promote the use of our products and develop outlets for products and employ the services of independent sales representatives on an “as needed” basis.

 

We consider our people and the way we work to support each other and serve our customers to be critical to our success. The key human capital measures and objectives that we focus on in managing our business are: maintaining a strong and collaborative company culture, increasing our diversity, inclusion and belonging, offering fair and competitive compensation and benefits, investing in people and organizational development, protecting and enriching employee health and wellness, and sustaining a culture of respectful and effective communications.

 

Organizational History and Corporate Information

 

We were incorporated as Co-Diagnostics, Inc., in Utah on April 18, 2013. Our principal executive office is located at 2401 S. Foothill Drive, Salt Lake City, Utah 84109. Our telephone number is (801) 438-1036. Our web address is www.codiagnostics.com. The contents of our website are not incorporated by reference in this Annual Report.

 

11
 

 

ITEM 1A. RISK FACTORS

 

Risks Related to Our Business and Industry

 

We have limited commercial history upon which to base our prospects and are not certain that we will achieve profitability in the future.

 

We have a limited operating history. We began operations in April 2013. Our accumulated retained earnings were $4.6 million and $39.9 million as of December 31, 2023 and 2022, respectively. During the calendar years ending December 31, 2023 and 2022 we experienced a decline in demand for our Logix Smart COVID-19 and other COVID-19 tests and operated at a net loss during the periods. We do not have any way of predicting when or if we will achieve profitability again. Potential investors should be aware of the difficulties normally encountered by a new enterprise, many of which are beyond our control, including substantial risks and expenses in the course of developing new diagnostic tests, establishing or entering new markets, organizing operations and marketing procedures. The likelihood of our success must be considered in light of these risks, expenses, complications and delays, and the competitive environment in which we operate. There is, therefore, nothing at this time upon which to base an assumption that our business plan will prove successful, and we may not be able to generate significant revenue, raise additional capital or operate profitably. We will continue to encounter risks and difficulties frequently experienced by early commercial stage companies, including scaling up our infrastructure and headcount, and may encounter unforeseen expenses, difficulties or delays in connection with our growth. In addition, as a result of the start-up nature of our business, we expect to continue to sustain substantial operating expenses and may not be able to continue generating sufficient revenues to cover expenditures. Any investment in our company is therefore highly speculative and could result in the loss of any investment.

 

Our future success is dependent on our development of our Co-Dx PCR platform and securing regulatory approval for the platform including the PCR Pro instrument and related diagnostic tests, demand for infectious disease diagnostics and upon our ability to develop and market other commercially accepted diagnostic tests for our PCR platform.

 

Our future success will depend, in part, on our development of our Co-Dx PCR platform and securing regulatory approval for the platform including the PCR Pro instrument and related diagnostic tests, our ability to develop and sell sufficient quantities of other diagnostics tests, and our ability to successfully and profitably market our Co-Dx PCR platform. Attracting new customers and distribution networks requires substantial time and expense. Any failure to obtain regulatory approval for our product candidates and to increase sales of our diagnostic tests in sufficient quantities to achieve profitability in a timely manner would adversely affect our operating results. Many factors could affect the market acceptance and commercial success of any of our diagnostic tests and devices, including:

 

  ● Our ability to develop additional infectious disease diagnostic tests for which there is a commercial market;
     
  ● Our ability to obtain regulatory clearance to commercialize our product candidates;
     
  ● our ability to convince our potential customers of the advantages and economic value of our tests over competing technologies and diagnostic tests;
     
  ● the breadth of our test menu relative to competitors;
     
  ● changes to policies, procedures or currently accepted best practices in clinical diagnostic testing;
     
  ● the extent and success of our marketing and sales efforts; and
     
  ● our ability to manufacture in quantity our commercial diagnostic tests and meet demand in a timely fashion.

 

12
 

 

The diagnostic market is highly competitive, and we may not be able to compete effectively against the larger, well-established companies that dominate this market or emerging and small innovative companies that may seek to obtain or increase their share of the market.

 

The markets for diagnostic products are intensely competitive, and many of our competitors are much larger and have substantially more financial and human resources than we do. Many have long histories and strong reputations within the industry, and a relatively small number of companies dominate these markets.

 

These companies enjoy significant competitive advantages over us, including:

 

  ● broad product offerings, which address the needs of health care providers in a wide range of applications;
     
  ● products that are supported by long-term clinical data;
     
  ● greater experience in, and resources for, launching, marketing, distributing and selling products, including strong sales forces and established distribution networks;
     
  ● extensive intellectual property portfolios and greater resources for patent protection;
     
  ● greater financial and other resources for product research and development;
     
  ● greater experience in obtaining and maintaining FDA and other regulatory clearances and approvals for products and product enhancements;
     
  ● established manufacturing operations and contract manufacturing relationships;
     
  ● significantly greater name recognition and widely recognized trademarks; and
     
  ● established relationships with healthcare providers and payers.

 

Our products and any product candidates that we may introduce into the market may not enable us to overcome the competitive advantages of these large and dominant companies. In addition, even if we successfully introduce additional product candidates into the market, emerging and small innovative companies may seek to increase their market share and they may eventually possess competitive advantages, which could adversely impact our business. Our competitors may also employ pricing strategies that could adversely affect the pricing of our products.

 

We depend on a limited number of third-party suppliers for key raw materials used in the manufacturing of our products, and the loss of these third-party suppliers or their inability to supply us with adequate raw materials could harm our business.

 

We rely on a limited number of third-party suppliers for the raw materials required for the production of our diagnostic products and product candidates. Our dependence on a limited number of third-party suppliers involves several risks, including limited control over pricing, availability, quality, and delivery schedules for raw materials. We have no supply agreements in place with any of our suppliers and cannot be certain that our current suppliers will continue to provide us with the quantities of raw materials that we require or that satisfy our anticipated specifications and quality requirements. Any supply interruption in limited or single sourced raw materials could materially harm our ability to manufacture our products until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel within a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the production of our products and product candidates and delay the development and commercialization of our product candidates, including limiting supplies necessary for commercial sale, clinical trials and regulatory approvals, which could have a material adverse effect on our business.

 

In order to be successful, we must expand our available product lines by commercializing new product candidates, but we may not be able to do so in a timely fashion and at expected costs, or at all.

 

Although we are currently manufacturing diagnostic kits for commercialization, in order to be successful, we will need to expand our product lines to include other diagnostic products. To succeed in our commercialization efforts, we must effectively continue product development and testing, find new strategic partners, obtain regulatory clearances and approvals, and enhance our sales and marketing capabilities. Because of these uncertainties, there is no assurance that we will succeed in bringing any of our current or future product candidates to market. If we fail in bringing our product candidates to market, or experience delays in doing so, we will not generate revenues as planned and will need to curtail operations or seek additional financing earlier than otherwise anticipated.

 

We are dependent on our senior management team, scientific team, and external advisors, and the loss of any of them could harm our business, including by adversely affecting our ability to effectuate our business strategy.

 

The members of our current senior management team may not be able to successfully implement our strategy. In addition, we have not entered into employment agreements with any of the members of our senior management team. There are no assurances that the services of any of these individuals will be available to us for any specified period of time. The successful integration of our senior management team, the loss of members of our senior management team, scientific team and key external advisors, or our inability to attract or retain other qualified personnel or advisors could have a material adverse effect on our business, financial condition and results of operations. We may not have a sufficient number of qualified personnel to effectuate our business strategy, which could have a material adverse effect on our business, financial condition and results of operations.

 

13
 

 

If we experience significant disruptions in our information technology systems, our business, results of operations and financial condition could be adversely affected.

 

The efficient operation of our business depends on our information technology systems. We rely on our information technology systems to effectively manage our sales and marketing, accounting and financial functions; manufacturing processes; inventory; scientific and product development functions; and our research and development functions. As such, our information technology systems are vulnerable to damage or interruption including from earthquakes, fires, floods and other natural disasters; terrorist attacks and attacks by computer viruses or hackers; power losses; and computer systems, or Internet, telecommunications or data network failures. The failure of our information technology systems to perform as we anticipate or our failure to effectively implement new systems could disrupt our entire operation and could result in decreased sales, increased overhead costs, excess inventory and product shortages, all of which could have a material adverse effect on our reputation, business, results of operations and financial condition.

 

Cybersecurity risks and the failure to maintain the integrity of company, employee or customer data could expose us to data loss, litigation and liability, and our reputation could be significantly harmed.

 

We and third-party service providers collect and retain large volumes of data, including personally identifiable information regarding clinical trial participants and others, for business purposes, including for regulatory, research and development and commercialization purposes, and our collaborators’ various information technology systems enter, process, summarize and report such data. We also maintain personally identifiable information about our employees. The integrity and protection of our company, employee and clinical data is critical to our business. We are subject to significant data security and privacy laws and regulations. These regulations impose significant requirements on how we maintain, use, and protect such information. Maintaining compliance with these evolving regulations and requirements could be difficult and may increase our expenses. In addition, a penetrated or compromised data system or the intentional, inadvertent or negligent release or disclosure of data could result in theft, loss or fraudulent or unlawful use of company, employee or clinical data which could harm our reputation, disrupt our operations, or result in remedial and other costs, fines or lawsuits.

 

Risks Related to Regulatory Approval of Our Products and Other Government Regulations

 

We received Emergency Use Authorization or EUA for our COVID-19 test in US. We applied for Emergency Use Authorization for our PCR platform which included the PCR Pro instrument and the COVID 19 diagnostic test cup and mobile app. The FDA may not timely grant the EUA we filed for the PCR platform or may require that we submit a 510K application rather than EUA. For our existing EUA and any new EUA, the FDA may revoke any EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, which would adversely impact our ability to market our COVID-19 test in the United States.

 

The FDA has the authority to grant an EUA to allow unapproved medical products to be used in an emergency to diagnose, treat or prevent serious or life-threatening diseases or conditions when there are no adequate, approved and available alternatives. During the COVID 19 pandemic the FDA determined that circumstances exist to justify the authorization of emergency use of medical devices, including alternative products used as medical devices, during the COVID-19 pandemic. On April 3, 2020, we received an EUA from the FDA for our Logix Smart Coronavirus Disease 2019 (COVID-19) kit for use on individuals who are suspected of COVID-19 by their healthcare provider. We cannot predict how long the EUA for our COVID-19 test will remain in place. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization. The FDA may take such a position at any time and without notice and, therefore, we cannot predict how long our EUAs will remain in place. The FDA may also revoke an EUA when the circumstances justifying its issuance no longer exist, such as when an alternative is authorized for marketing through the standard procedures, including through a 510(k) clearance.

 

We applied for Emergency Use Authorization for our PCR platform which included the PCR Pro instrument and the COVID 19 diagnostic test cup and mobile app. The FDA may not timely grant the EUA we filed for the PCR platform or may require that we submit a 510K application rather than EUA which could extend the time for authorization to begin commercializing the PCR platform. There can be no assurances that the FDA will authorize any request for additional and/or amended EUAs and if we do not receive the authorization, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected.

 

If either of our existing EUAs is revoked or our existing EUA applications are denied prior to us having received regulatory approval to commercialize our COVID-19 test through a traditional pathway, we may not be able to obtain required clearances or approvals in a timely manner, or at all, and one or more of our competitors may obtain the necessary clearances or approvals for their products before we do. In addition, we would be required to cease our commercialization efforts, which would substantially and negatively impact our business. As a result, any such revocation could adversely impact our business, financial condition and results of operations.

 

14
 

 

Our long-term success depends substantially on our ability to obtain regulatory clearance or approval and thereafter commercialize our product candidates; we cannot be certain that we will be able to do so in a timely manner or at all.

 

The process of obtaining regulatory clearances or approvals to market a medical diagnostic from the FDA or similar regulatory authorities outside of the United States can be costly and time consuming, and there can be no assurance that such clearances or approvals will be granted on a timely basis, or at all. The FDA’s 510(k) clearance process generally takes one to six months from the date of submission, depending on whether a special or traditional 510(k) premarket notification has been submitted, but can take significantly longer. An application for premarket approval, or PMA, must be submitted to the FDA if the device cannot be cleared through the 510(k) clearance process or is not exempt from premarket review by the FDA. The PMA process almost always requires one or more clinical trials and can take two to three years from the date of filing, or even longer.

 

If we are required to obtain approval of any of our products through the PMA process, the costs associated with such a process will be significant, which could adversely affect our financial performance and results of operations. In addition, a submission through the PMA process would require us to delay commercialization of such product candidates until after approval is received, if ever. If we are unable to commercialize our product candidates in a timely manner, or at all, our business will be adversely affected.

 

Similar to our compliance with U.S. regulatory requirements, we must obtain and comply with international requirements, in order to market and sell our products outside of the United States and we may only promote and market our products, if approved, as permitted by applicable regulatory authorities. There is no guarantee that we will receive the necessary regulatory approvals for our product candidates either inside the United States or internationally. If our product candidates do not receive necessary regulatory approvals, our business could be materially and adversely affected.

 

Our current and future relationships with third-party payers and current and potential customers in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm administrative burdens and diminished profits and future earnings.

 

Our current and future arrangements with third-party payers and current and potential customers, including providers and physicians, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, which may constrain the business or financial arrangements and relationships through which we sell, market and distribute our products. In addition, we may be subject to transparency laws and patient privacy regulations by U.S. federal and state governments and by governments in foreign jurisdictions in which we conduct our business. The applicable federal, state and foreign healthcare laws and regulations that may affect our ability to operate include:

 

  ● the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal healthcare programs, such as Medicare and Medicaid;
     
  ● federal civil and criminal false claims laws and civil monetary penalty laws, including the federal False Claims Act, which impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;
     
  ● the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;
     
  ● HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose obligations on covered healthcare providers, health plans, and healthcare clearinghouses, as well as their business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;
     
  ● the Physician Payments Sunshine Act, which requires (i) manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program, with specific exceptions, to report annually to CMS information related to certain “payments or other transfers of value” made to physicians, which is defined to include doctors, dentists, optometrists, podiatrists and chiropractors, and teaching hospitals, (ii) applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held in such entities by physicians and their immediate family members, with data collection beginning on August 1, 2013, (iii) manufacturers to submit reports to CMS by the 90th day of each calendar year, and (iv) disclosure of such information by CMS on a publicly available website; and
     
  ● analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payers, including private insurers; state and foreign laws that require medical device companies to comply with the medical device industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require medical device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.

 

15
 

 

Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, which could have a material adverse effect on our business. If any of the physicians or other healthcare providers or entities with whom we expect to do business, including our collaborators, are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also materially affect our business.

 

We are subject to stringent and changing data protection laws, privacy policies and data protection obligations, which continue to evolve and change over time. The actual or perceived failure by us or our third-party service providers or vendors to comply with such obligations could harm our reputation, subject us to significant fines and liability, or otherwise adversely affect our business.

 

We are subject to numerous data protection laws that govern the processing of individually identifiable information and health information and other sensitive and personal information in the jurisdictions in which we operate. In many instances, these data protection laws, regulations and standards apply not only to disclosures to third parties, but also to transfers of information between or among us and other parties with which we have commercial relationships. The regulatory framework for data privacy, data security and data transfers worldwide is rapidly evolving and, as a result, interpretation and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. These data protection laws may be interpreted and applied differently over time and from jurisdiction to jurisdiction, and it is possible that they will be interpreted and applied in ways that will materially and adversely affect our business, financial condition and results of operations. Failure to comply with any of these data protection laws could result in enforcement actions against us, including fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business.

 

There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. These laws and regulations include the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their implementing regulations, or collectively referred to as the HIPAA Rules, which establish a set of national privacy and security standards to safeguard Protected Health Information, or PHI, by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business associates and their subcontractors with whom such covered entities contract for services that involve the creation, receipt, maintenance or transmission of PHI for or on behalf of a covered entity or another business associate. HIPAA requires covered entities and business associates to, among other things, develop and maintain policies and procedures with respect to PHI that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect such information and ensure the confidentiality, integrity and availability of electronic PHI. As this applies to our business, we are required to maintain security standards for any PHI that we create, receive, maintain or transmit. For example, we plan to offer cloud-based portal software to help our customers more efficiently use our products. The software will maintain security safeguards that are designed to be consistent with the HIPAA Rules, but we cannot guarantee that these safeguards will not fail or that they will not be deemed inadequate in the future. In addition, we could be subject to periodic audits for compliance with the HIPAA Privacy and Security Standards by the U.S. HHS, and our customers. The U.S. HHS Office for Civil Rights may impose significant penalties on entities subject to HIPAA for a failure to comply with a requirement of the HIPAA Rules. If we are unable to properly protect the privacy and security of the PHI of our customers, we could be found to have breached our contracts. Determining whether PHI has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and we cannot be sure how these regulations will be interpreted, enforced or applied to our operations.

 

In addition, many states in which we operate have laws that protect the privacy and security of sensitive and personal information, including health-related information. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to sensitive and personal information than federal, international or other state laws, and such laws may differ from each other, which may complicate compliance efforts.

 

16
 

 

Laws, regulations and standards in many other jurisdictions also apply broadly to the Processing of personal information, which impose significant compliance obligations. Complying with these numerous, complex and often changing regulations is expensive and difficult, and failure to comply with any Data Protection Laws or any security incident or breach involving the misappropriation, loss or other unauthorized use or disclosure of sensitive or confidential information, whether by us, one of our service providers or another third party, could negatively affect our business, financial condition and results of operations, including but not limited to: investigation costs, material fines and penalties; compensatory, special, punitive and statutory damages; litigation; consent orders regarding our privacy and security practices; requirements that we provide notices, credit monitoring services or credit restoration services or other relevant services to impacted individuals; adverse actions against our licenses to do business; and injunctive relief.

 

Many statutory requirements, both in the United States and abroad, include obligations for companies to notify individuals of security breaches involving certain personal information, which could result from breaches experienced by us or our third-party service providers. For example, laws in all 50 U.S. states and the District of Columbia require businesses to provide notice to consumers whose unencrypted personal information has been disclosed as a result of a data breach. These laws are not consistent, and compliance in the event of a widespread data breach is difficult and may be costly. Moreover, states have been frequently amending existing laws, requiring attention to changing regulatory requirements. We also may be contractually required to notify affected customers, regulators, credit reporting agencies or other affected individuals of a security breach. Such notifications are costly, and the disclosures or the failure to comply with such requirements, could lead to material adverse effects, including without limitation, negative publicity, a loss of customer confidence in our services or security measures or breach of contract claims. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages if we fail to comply with applicable Data Protection Laws, Data Protection Obligations or other legal obligations. In addition, although we may have contractual protections with our third-party service providers, contractors and consultants, any actual or perceived security breach by our subcontractors could harm our reputation and brand, expose us to potential liability or require us to expend significant resources on data security and in responding to any such actual or perceived breach. Any contractual protections we may have from our third-party service providers, contractors or consultants may not be sufficient to adequately protect us from any such liabilities and losses, and we may be unable to enforce any such contractual protections.

 

We expect that there will continue to be new proposed laws and regulations concerning data privacy and security, and we cannot yet determine the impact such future laws, regulations and standards may have on our business. New laws, amendments to or re-interpretations of existing laws, regulations, standards and other obligations may require us to incur additional costs and restrict our business operations. Because the interpretation and application of health-related and Data Protection Laws and other obligations are still uncertain, and often contradictory and in flux, it is possible that the scope and requirements of these laws may be interpreted and applied in a manner that is inconsistent with our practices and our efforts to comply with the evolving data protection rules may be unsuccessful. If so, this could result in government-imposed fines or orders requiring that we change our practices, which could adversely affect our business.

 

We cannot assure you that our third-party partners and service providers with access to our or our customers’, suppliers’ and employees’ personally identifiable and other sensitive or confidential information in relation to which we are responsible will not breach contractual obligations imposed by us or violate Data Protection Laws, or that they will not experience security breaches or attempts thereof, which could have a corresponding effect on our business, including putting us in breach of our obligations under the Data Protection Laws, which could in turn adversely affect our business, results of operations and financial condition. We cannot assure you that our contractual measures and our own privacy- and security-related safeguards will protect us from the risks associated with the third-party processing, storage and transmission of such information.

 

We may receive inquiries or be subject to investigations, proceedings or actions, by various government entities regarding our privacy and information security practices and Processing (“Regulatory Proceedings”). These Regulatory Proceedings could result in a material adverse effect, including without limitation, interruptions of, or required changes to, our business practices, the diversion resources and the attention of management from our business, regulatory oversights and audits, discontinuance of necessary Processing, or other remedies that adversely affect our business.

 

17
 

 

In addition to the possibility of fines, lawsuits, regulatory investigations, public censure, other claims and penalties, and significant costs for remediation and damage to our reputation, we could be materially and adversely affected if legislation or regulations are expanded to require changes in our data processing practices and policies or if governing jurisdictions interpret or implement their legislation or regulations in ways that negatively impact our business. Complying with these various laws could cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business. Any inability to adequately address data privacy or security-related concerns, even if unfounded, or to comply with applicable laws, regulations, standards and other obligations relating to data privacy and security, could result in additional cost and liability to us, harm our reputation and brand, damage our relationships with customers and have a material and adverse impact on our business.

 

While we maintain general liability insurance coverage, cyber insurance coverage and other insurance, we cannot assure that such coverage will be adequate or otherwise protect us from or adequately mitigate liabilities or damages with respect to claims, costs, expenses, litigation, fines, penalties, business loss, data loss, regulatory actions or material adverse effects arising out of our privacy and security practices, Processing or security breaches we may experience, or that such coverage will continue to be available on acceptable terms or at all. The successful assertion of one or more large claims against us that exceeds our available insurance coverage, or results in changes to our insurance policies (including premium increases or the imposition of large deductible or co-insurance requirements), could have an adverse effect on our business. In addition, we cannot be sure that our existing insurance coverage will continue to be available on acceptable terms or that our insurers will not deny coverage as to any future claim.

 

We may incur substantial costs in our efforts to comply with evolving global data protection laws and regulations, and any failure or perceived failure by us to comply with such laws and regulations may harm our business and operations.

 

The global data protection landscape is rapidly evolving, and we may be or become subject to or affected by numerous federal, state and foreign laws and regulations, as well as regulatory guidance, governing the collection, use, disclosure, transfer, security and processing of personal data, such as information that we collect about subjects and health care providers in connection with clinical trials. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, which may create uncertainty in our business; affect our or our service providers’ ability to operate in certain jurisdictions or to collect, store, transfer use and share personal data; result in liability; or impose additional compliance or other costs on us. Any failure or perceived failure by us to comply with federal, state, or foreign laws or self-regulatory standards could result in negative publicity, diversion of management time and effort and proceedings against us by governmental entities or others.

 

In the United States, numerous federal and state laws and regulations, including federal health information privacy laws (e.g., the Health Insurance Portability and Accountability Act, as amended by the Health Information Technology for Economic and Clinical Health Act, or collectively HIPAA), state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA or other privacy and data security laws. Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly obtain, use, or disclose protected health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. However, determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation.

 

If we are unable to properly protect the privacy and security of protected health information or other personal, sensitive, or confidential information in our possession, we could be found to have breached our contracts. Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face significant administrative, civil and criminal penalties. Enforcement activity can also result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal and outside resources. Furthermore, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. In addition, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require continuous modifications to our compliance policies, procedures, and systems.

 

18
 

 

Many state laws govern the privacy and security of personal information and data in specified circumstances, many of which differ from each other in significant ways, are often not pre-empted by HIPAA, and may have a more prohibitive effect than HIPAA, thus complicating compliance efforts. For example, the California Consumer Privacy Act of 2018 (the “CCPA”), which went into effect in January 2020 and provides new data privacy rights for consumers and new operational requirements for companies, which may increase our compliance costs and potential liability. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. While there is currently an exception for protected health information that is subject to HIPAA and clinical trial regulations, as currently written, the CCPA may impact certain of our business activities. In addition, the California Consumer Rights Act, or CPRA, was recently enacted to strengthen elements of the CCPA and became effective on January 1, 2023. The CPRA imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data and expands the application of the CCPA to all human resources personal information of California-based employees. In addition, the CPRA created a new California data protection agency authorized to issue substantive regulations and is expected to result in increased privacy and information security enforcement. A number of other states have considered similar privacy proposals, and states have recently enacted their own privacy laws. For example, the Virginia Consumer Data Protection Act became effective on January 1, 2023, and Colorado and Utah enacted similar laws that became effective in 2023, increasing the complexity of compliance and the risk of failures to comply. These privacy laws may impact our business activities and exemplify the vulnerability of our business to the evolving regulatory environment related to personal data.

 

In addition to our operations in the United States, which may be subject to health care and other laws relating to the privacy and security of health information and other personal information, we may be or become subject to European data privacy laws, regulations and guidelines. The General Data Protection Regulation, (EU) 2016/679 (“GDPR”) became effective on May 25, 2018, and deals with the collection, use, storage, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals in the EEA. The GDPR imposes a broad range of strict requirements on companies subject to the GDPR, including requirements relating to having legal bases for processing personal information relating to identifiable individuals and transferring such information outside the EEA, including to the United States, providing details to those individuals regarding the processing of their personal health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, keeping personal information secure, having data processing agreements with third parties who process personal information, responding to individuals’ requests to exercise their rights in respect of their personal information, reporting security breaches involving personal data to the competent national data protection authority and affected individuals, appointing data protection officers, conducting data protection impact assessments, and record-keeping. The GDPR increases substantially the penalties to which we could be subject in the event of any non-compliance, including fines of up to €10,000,000 or up to 2% of our total worldwide annual turnover for certain comparatively minor offenses, or up to €20,000,000 or up to 4% of our total worldwide annual turnover, whichever is greater, for more serious offenses. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers.

 

Following the United Kingdom’s withdrawal from the European Union (i.e., Brexit), and the expiry of the Brexit transition period, which ended on December 31, 2020, the EU GDPR has been implemented in the United Kingdom (as the UK GDPR). The UK GDPR sits alongside the UK Data Protection Act 2018 which implements certain derogations in the EU GDPR into UK law. Under the UK GDPR, companies not established in the UK but who process personal data in relation to the offering of goods or services to individuals in the UK, or to monitor their behavior will be subject to the UK GDPR – the requirements of which are (at this time) largely aligned with those under the EU GDPR and as such, may lead to similar compliance and operational costs with potential fines of up to £17.5 million or 4% of global turnover. In 2022, the government of the United Kingdom proposed and debated the Data Protection and Digital Information Bill to harmonize the 2018 Data Protection Act, UK GDPR, and the Privacy and Electronic Communications Regulations under one legislative framework. However, progress on the bill stalled as the government continues to assess the most optimal approach to data protection reform.

 

19
 

 

We currently sell some of our products in the EEA, and the GDPR increases our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we are required to have in place additional mechanisms and safeguards to ensure compliance with the GDPR, including as implemented by individual countries. Compliance with the GDPR is a rigorous and time-intensive process that increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities. We expect that we will continue to face uncertainty as to whether our efforts to comply with any obligations under European privacy laws will be sufficient. If we are investigated by a European data protection authority, we may face fines and other penalties. Any such investigation or charges by European data protection authorities could have a negative effect on our existing business and on our ability to attract and retain new clients or partners.

 

Risks Related to Our Intellectual Property

 

If the combination of patents, trade secrets and contractual provisions that we rely on to protect our intellectual property is inadequate, our ability to commercialize our products successfully will be harmed, and we may not be able to operate our business profitably.

 

Our success depends significantly on our ability to protect our proprietary rights to the technologies incorporated in our products. We rely on a combination of patent protection, trade secret laws and nondisclosure, confidentiality and other contractual restrictions to protect our proprietary technology. However, these may not adequately protect our rights or permit us to gain or keep any competitive advantage.

 

The issuance of a patent is not conclusive as to its scope, validity or enforceability. The scope, validity or enforceability of our issued patents can be challenged in litigation or proceedings before the U.S. Patent and Trademark Office, or the USPTO, or foreign patent offices. In addition, our pending patent applications include claims to numerous important aspects of our products under development that are not currently protected by any of our issued patents. We cannot assure you that any of our pending patent applications will result in the issuance of patents to us. The USPTO or foreign patent offices may deny or require significant narrowing of claims in our pending patent applications. Patents issued as a result of the pending patent applications, if any, may not provide us with significant commercial protection or be issued in a form that is advantageous to us. Proceedings before the USPTO or foreign patent offices could result in adverse decisions as to the priority of our inventions and the narrowing or invalidation of claims in issued patents. The laws of some foreign countries may not protect our intellectual property rights to the same extent as the laws of the United States, if at all.

 

Our competitors may successfully challenge and invalidate or render unenforceable our issued patents, including any patents that may issue in the future, which could prevent or limit our ability to market our products and could limit our ability to stop competitors from marketing products that are substantially equivalent to ours. In addition, competitors may be able to design around our patents or develop products that provide outcomes that are comparable to our products but that are not covered by our patents.

 

In the event a competitor infringes upon any of our patents or other intellectual property rights, enforcing our rights may be difficult, time-consuming and expensive, and would divert management’s attention from managing our business. There can be no assurance that we will be successful on the merits in any enforcement effort. In addition, we may not have sufficient resources to litigate, enforce or defend our intellectual property rights.

 

We could become subject to intellectual property litigation that could be costly, result in the diversion of management’s time and efforts, require us to pay damages, prevent us from marketing our commercially available products or product candidates and/or reduce the margins we may realize from our products that we may commercialize.

 

Whether a product infringes a patent involves complex legal and factual issues, and the determination is often uncertain. There may be existing patents of which we are unaware that our products under development may inadvertently infringe. The likelihood that patent infringement claims may be brought against us increases as the number of participants in the in vitro diagnostics market increases and as we achieve more visibility in the marketplace and introduce products to market.

 

Any infringement claim against us, even if without merit, may cause us to incur substantial costs, and would place a significant strain on our financial resources, divert the attention of management from our core business, and harm our reputation. In some cases, litigation may be threatened or brought by a patent holding company or other adverse patent owner who has no relevant product revenues and against whom our patents may provide little or no deterrence. If we were found to infringe any patents, we could be required to pay substantial damages, including triple damages if an infringement is found to be willful, and royalties and could be prevented from selling our products unless we obtain a license or are able to redesign our products to avoid infringement. We may not be able to obtain a license enabling us to sell our products on reasonable terms, or at all, and there can be no assurance that we would be able to redesign our products in a way that would not infringe those patents. If we fail to obtain any required licenses or make any necessary changes to our technologies or the products that incorporate them, we may be unable to commercialize one or more of our products or may have to withdraw products from the market, all of which would have a material adverse effect on our business, financial condition and results of operations.

 

20
 

 

We rely substantially on our trademarks and trade names. If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be harmed.

 

We rely substantially upon trademarks to build and maintain the integrity of our brand. Our registered and unregistered trademarks or trade names may be challenged, infringed, circumvented, declared unenforceable or determined to be violating or infringing on other intellectual property rights. We may not be able to protect or enforce our rights to these trademarks and trade names, which we rely upon to build name recognition among potential partners and customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. Asserting claims against such third parties may be prohibitively expensive. In addition, there could be potential trade name or trademark infringement, or dilution claims brought by owners of other trademarks against us. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names or other intellectual property may be ineffective, could result in substantial costs and diversion of resources and could harm our business, financial condition and results of operations.

 

Risks Related to Litigation from Operating Our Business

 

We may become subject to potential product liability claims, and we may be required to pay damages that exceed our insurance coverage.

 

Our business exposes us to potential product liability claims that are inherent in the design, testing, manufacture, sale and distribution of our currently marketed products and each of our product candidates that we are seeking to introduce to the market. Someone may allege that our diagnostic tests identified inaccurate or incomplete information or otherwise failed to perform as designed. We may also be subject to liability for errors in, a misunderstanding of or inappropriate reliance upon, the information we provide in the ordinary course of our business activities. In addition, we may be subject to product liability claims resulting from misuse or off-label use of our products and product candidates. Any product liability claim brought against us, with or without merit, could result in an increase of our product liability insurance rates or in our inability to secure coverage in the future on commercially reasonable terms, if at all. In addition, if our product liability insurance proves to be inadequate to pay a damage award, we may have to pay the excess of this award out of our cash reserves, which could significantly harm our financial condition. A product liability claim, even one without merit, could harm our reputation in the industry, lead to significant legal fees, and result in the diversion of management’s attention from managing our business.

 

Current or future litigation, government investigations and other legal proceedings may harm our business.

 

We have been, currently are and may in the future become, involved in legal proceedings that could have a negative impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. The types of legal proceedings we may be or become subject to include patent and other intellectual property claims, product liability claims, employee claims, tort or contract claims, federal or state regulatory investigations, securities class actions, and other legal proceedings, investigations or claims. For example, we are currently parties to two securities class action claims and three derivative actions. Litigation and other legal proceedings are inherently unpredictable and can result in excessive or unanticipated verdicts and/or injunctive relief that affect how we operate our business. We could incur judgments or enter into settlements of claims for monetary damages or for agreements to change the way we operate our business, or both. There may be an increase in the scope of these matters or there may be additional lawsuits, claims, proceedings or investigations in the future, which could harm our business, financial condition and results of operations. Adverse publicity about regulatory or legal action against us could damage our reputation and brand image, undermine our customers’ confidence and reduce long-term demand for any of our products or other offerings, even if the regulatory or legal action is unfounded or not material to our operations. For additional information, see “Item 3. Legal Proceedings.”

 

21
 

 

General Risk Factors

 

The price of our common stock may fluctuate substantially.

 

The market price of our common stock may be subject to wide fluctuation in response to various factors, some of which are beyond our control. Some factors that may cause the market price of our common stock to fluctuate, in addition to the other risks mentioned in this “Risk Factors” section and elsewhere in this report, are:

 

  ● sales or purchases of our common stock by our shareholders, executives, and directors;
     
  ● our ability to obtain regulatory approval to commercialize our PCR platform on a timely basis or at all;
     
  ● our ability to enter new markets;
     
  ● actual or unanticipated fluctuations in our annual and quarterly financial results;
     
  ● our ability to obtain financings to continue and expand our commercial activities, expand our manufacturing operations, conduct research and development activities including, but not limited to, human clinical trials, and other business activities;
     
  ● our ability to secure resources and the necessary personnel to continue and expand our commercial activities, develop additional diagnostic tests, conduct clinical trials and gain approval for our diagnostic tests on our desired schedule;
     
  ● commencement, enrollment or results of our clinical trials of our diagnostic tests or any future clinical trials we may conduct;
     
  ● changes in the development status of our diagnostic tests;
     
  ● any delays or adverse developments or perceived adverse developments with respect to review by the FDA or other similar foreign regulatory authorities of our planned clinical trials;
     
  ● any delay in our submission for studies or test approvals or adverse regulatory decisions, including failure to receive regulatory approval or clearance for our diagnostic tests;
     
  ● our announcements or our competitors’ announcements regarding new tests, enhancements, significant contracts, acquisitions or strategic investments;
     
  ● failures to meet external expectations or management guidance;
     
  ● changes in our capital structure or dividend policy, including as a result of future issuances of securities and sales of large blocks of common stock by our shareholders;
     
  ● announcements and events surrounding financing efforts, including debt and equity securities;
     
  ● competition from existing technologies and diagnostic tests or new technologies and diagnostic tests that may emerge;
     
  ● announcements of acquisitions, partnerships, collaborations, joint ventures, new diagnostic tests, capital commitments, or other events by us or our competitors;
     
  ● changes in general economic, political and market conditions in any of the regions in which we conduct our business;
     
  ● changes in industry conditions or perceptions;
     
  ● changes in valuations of similar companies or groups of companies;
     
  ● analyst research reports, recommendations and changes in recommendations, price targets and withdrawals of coverage;
     
  ● departures and additions of key personnel;
     
  ● disputes and litigations related to intellectual properties, proprietary rights, and contractual obligations;
     
  ● changes in applicable laws, rules, regulations, or accounting practices and other dynamics;
     
  ● other events or factors, many of which may be out of our control.

 

In addition, if the market for stocks in our industry or industries related to our industry, or the stock market in general, experiences a loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, financial condition and results of operations. If any of the foregoing occurs, it could cause our stock price to fall and may expose us to lawsuits that, even if unsuccessful, could be costly to defend and a distraction to management.

 

22
 

 

Anti-takeover provisions in our charter documents and Utah law could discourage, delay, or prevent a change of control of our Company and may affect the trading price of our common stock.

 

We are a Utah corporation and the anti-takeover provisions of the Utah Control Shares Acquisition Act may discourage, delay or prevent a change of control by limiting the voting rights of control shares acquired in a control share acquisition. In addition, our Articles of Incorporation and Bylaws may discourage, delay or prevent a change in our management or control over us that shareholders may consider favorable. Among other things, our Amended and Restated Articles of Incorporation and Bylaws:

 

  ● authorize the issuance of “blank check” preferred stock that could be issued by our board of directors in response to a takeover attempt;
     
  ● provide that vacancies on our board of directors, including newly created directorships, may be filled only by a majority vote of directors then in office, except a vacancy occurring by reason of the removal of a director without cause shall be filled by vote of the shareholders;
     
  ● no right to cumulative voting;
     
  ● limit who may call special meetings of shareholders; and
     
  ● provide for a staggered board of directors

 

These provisions could have the effect of delaying or preventing a change of control, whether or not it is desired by, or beneficial to, our shareholders.

 

We do not currently intend to pay dividends on our common stock.

 

We do not expect to pay cash dividends on our common stock. Any future dividend payments are within the absolute discretion of our board of directors and will depend on, among other things, our results of operations, working capital requirements, capital expenditure requirements, financial condition, contractual restrictions, business opportunities, anticipated cash needs, provisions of applicable law and other factors that our board of directors may deem relevant. We may not generate sufficient cash from operations in the future to pay dividends on our common stock.

 

We are a “smaller reporting company” and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.

 

We are currently a “smaller reporting company” as defined in the Securities Exchange Act of 1934. Smaller reporting companies are able to provide simplified executive compensation disclosures in their filings, and have certain other decreased disclosure obligations in their SEC filings, including, among other things, only being required to provide two years of audited financial statements in annual reports. We cannot predict whether investors will find our common stock less attractive because of our reliance on any of these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

 

We incur substantial costs as a result of being a public company and our management expects to devote substantial time to public company compliance programs.

 

As a public company, we incur significant legal, insurance, accounting and other expenses, including costs associated with public company reporting. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment will result in increased general and administrative expenses and may divert management’s time and attention from product development and commercialization activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us, and our business may be harmed. These laws and regulations could make it more difficult and costlier for us to obtain director and officer liability insurance for our directors and officers, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified executive officers and qualified members of our board of directors, particularly to serve on our audit and compensation committees. In addition, if we are unable to continue to meet the legal, regulatory and other requirements related to being a public company, we may not be able to maintain the listing of our common stock on The NASDAQ Capital Market, which would likely have a material adverse effect on the trading price of our common stock.

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

None.

 

23
 

 

ITEM 1C. CYBERSECURITY

 

We understand the importance of preventing, identifying, assessing and managing material risks associated with cybersecurity threats. Cybersecurity processes to identify, assess and manage risks from cybersecurity threats have been incorporated as a part of our overall risk assessment process and are designed to help protect our information assets and operations from internal and external cyber threats and protect employee and customer information from unauthorized access or attack, as well as secure our network and systems. The Company’s cybersecurity policies, standards, processes, and practices are based on recognized frameworks established by the National Institute of Standards and Technology (“NIST”) and are included in the Company’s overall risk management system and processes. We have implemented into our operations these cybersecurity processes, technologies and controls to identify, assess and manage material risks. Specifically, we engage a third-party cybersecurity firm to assist with network and endpoint monitoring, cloud system monitoring and assessment of our incident response procedures. Further, we employ periodic internal and external penetration testing by an independent cybersecurity firm to inform our risk identification and assessment of critical, high, medium and minor material cybersecurity threats.

 

To manage our material risks from cybersecurity threats and to protect against, detect, and prepare to respond to cybersecurity incidents, we undertake the below listed activities:

 

  ● Monitor evolving cybersecurity standards and emerging data protection laws and implement changes to our processes to comply;
     
  ● risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise IT environment;
     
  ● The Company leverages third-party vendors to house critical clinical trial data. These vendors are required to be GxP compliant which entails strong cybersecurity controls that are validated by a third-party auditor. Furthermore, the Company has begun performing security risk assessments prior to on-boarding new significant vendors.
     
  ● The Company provides regular, mandatory training for all levels of employees regarding cybersecurity threats as a means to equip the Company’s employees with effective tools to address cybersecurity threats, and to communicate the Company’s evolving information security policies, standards, processes, and practices.
     
  ● Employ multifactor authentication on internal and external systems;
     
  ● Conduct regular phishing email simulations for all employees; and
     
  ● Carry cybersecurity risk insurance that provides protection against the potential losses arising from a cybersecurity incident.

 

Our incident response plan coordinates the activities that we and our third-party cybersecurity providers take to prepare to respond and recover from cybersecurity incidents, which include processes to triage, assess severity, investigate, escalate, contain, and remediate an incident, as well as to comply with potentially applicable legal obligations and mitigate brand and reputational damage.

 

As part of the above processes, we engage with subject matter expert consultants to review our cybersecurity program to help identify areas for continued focus, improvement, and compliance.

 

Our processes also include assessing cybersecurity threat risks associated with our use of third-party services providers in normal course of business use, including those in our supply chain or who have access to patient and employee data or our systems. Third-party risks are included within our risk management process discussed above. In addition, we assess cybersecurity considerations in the selection and oversight of our third-party services providers, including due diligence on the third parties that have access to our systems and facilities that house systems and data.

 

We do not believe that there are currently any known risks from cybersecurity threats that are reasonably likely to materially affect our business strategy, results of operations or financial condition. However, cybersecurity threats may affect our business. See “Cyber security risks and the failure to maintain the integrity of company, employee or guest data could expose us to data loss, litigation and liability, and our reputation could be significantly harmed.” in “Item 1A. Risk Factors” of this Annual Report on Form 10-K.

 

The Audit Committee of the Board of Directors is responsible for oversight of our cybersecurity risk assessment, risk management, incident response procedures and cybersecurity risks and provides updates to the Board of Directors regarding such oversight. Periodically during each year, the Audit Committee receives an overview from our Vice President, Head of Technology of our cybersecurity threat risk management and strategy processes, including potential impact on us, the efforts of management to manage the risks that are identified and our incident response preparations.

 

Our cybersecurity risk assessment, management and strategy processes are led by our Chief Technology Officer. Our Chief Technology Officer has over 15 years of experience in various roles involving managing information security, managing privacy and data protection, developing cybersecurity strategy, and implementing cybersecurity programs. The Chief Technology Officer was recently promoted and is training to be a Certified Information Security Manager (CISM), is informed about and monitors the prevention, mitigation, detection, and remediation of cybersecurity incidents through management of the cybersecurity risk management and strategy processes described above, including our incident response plan.

 

24
 

 

ITEM 2. PROPERTIES

 

Our headquarters are located at 2401 S. Foothill Drive, Salt Lake City, Utah. Our current facilities have approximately 54,000 square feet of laboratory, manufacturing, storage and office space under leases that expire in 2026 through 2028. We believe the facilities we lease are sufficient to meet our needs for the foreseeable future.

 

ITEM 3. LEGAL PROCEEDINGS

 

In the ordinary course of business, we are at times subject to various legal proceedings and disputes, including the proceedings specifically discussed below. We assess our liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that we will incur a loss and the amount of the loss can be reasonably estimated, we record a liability in our consolidated financial statements. These legal reserves may be increased or decreased to reflect any relevant developments on a quarterly basis. Where a loss is not probable or the amount of loss is not estimable, we do not accrue legal reserves. While the outcome of legal proceedings is inherently uncertain, based on information currently available and available insurance coverage, our management believes that it has established appropriate legal reserves. Any incremental liabilities arising from pending legal proceedings are not expected to have a material adverse effect on our consolidated financial position, consolidated results of operations, or consolidated cash flows. However, it is possible that the ultimate resolution of these matters, if unfavorable, may be material to our consolidated financial position, consolidated results of operations, or consolidated cash flows.

 

Class Actions and Shareholder Derivative Suits

 

Gelt Securities Class Action (District of Utah)

 

On June 15, 2020, Gelt Trading Co. (“Gelt”) filed a lawsuit in the United States District Court for the District of Utah (“District of Utah”), against the Company and certain of our directors and officers, on behalf of itself and a putative class, seeking to recover damages for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (“Gelt Litigation”). The complaint alleges that Co-Diagnostics and the individual defendants overstated the accuracy of the Company’s Logix Smart COVID-19 test in statements on April 30, 2020 and May 1, 2020, and that plaintiff suffered losses when the Company’s stock price dropped after public reports questioned the accuracy of the Logix Smart test on May 14, 2020. On July 15, 2020, plaintiff filed an amended complaint. On March 10, 2021, the court appointed Gelt as Lead Plaintiff, and on April 7, 2021, Lead Plaintiff filed a second amended complaint (“SAC”), which asserts the same Sections 10(b) and 20(a) claims against the same defendants on largely the same theory. On May 5, 2021, the defendants moved to dismiss the SAC. On March 9, 2022, the court entered a Decision & Order denying the motion to dismiss, but narrowing the challenged statements to only those made in the May 1, 2020 press release, and on April 13, 2022, the defendants filed an answer to the SAC. On October 17, 2022, Gelt filed a motion to certify the putative class, and on August 18, 2023, the court partially granted that motion, certifying a class of all those who purchased Co-Diagnostics securities between May 1, 2020 and May 14, 2020, dates inclusive, and who were damaged thereby. Fact discovery closed on August 18, 2023 and expert discovery is currently underway. Summary judgment motions and motions to exclude expert testimony are due April 10, 2024; no trial date has yet been set. The defendants believe the claims are without merit and intend to defend vigorously against them, but there can be no assurances as to the outcome.

 

Shareholder Derivative Lawsuits (District of Utah & Utah State Court)

 

On September 17, 2020, a shareholder derivative lawsuit was filed in the District of Utah by Luis Aguilera, allegedly on behalf of Co-Diagnostics, Inc., that substantially piggybacks on the Gelt Litigation referenced above. The lawsuit asserts that the defendants failed to prevent the alleged securities law violations largely asserted in the Gelt Litigation. On December 2, 2020, a second shareholder derivative lawsuit was filed in the District of Utah by Melvyn Klein asserting essentially the same claims, allegedly on behalf of Co-Diagnostics, as the Aguilera shareholder derivative action. And on April 29, 2021, the District of Utah consolidated the two shareholder derivative cases, with the Aguilera case serving as the lead case under the caption In re Co-Diagnostics, Inc. Derivative Litigation. On May 3, 2022, plaintiffs filed an amended complaint asserting claims for breach of fiduciary duty, unjust enrichment, and contribution under Sections 10(b) and 21D of the Securities Exchange Act of 1934. Defendants answered the amended complaint on June 24, 2022. On January 25, 2024, the consolidated Aguilera derivative action was voluntarily dismissed without prejudice.

 

On November 24, 2020, an additional shareholder derivative lawsuit was filed in the District of Utah by Matthew Wallace, allegedly on behalf of Co-Diagnostics, Inc., that also piggybacks on the Gelt Litigation referenced above. It named the same defendants and asserted essentially the same claims, allegedly on behalf of Co-Diagnostics, as in the other District of Utah shareholder derivative actions referenced above. On January 25, 2021, another shareholder derivative lawsuit was filed in the District of Utah by Jason Reagan, asserting essentially the same claims as in the Wallace lawsuit. On March 18, 2021, the court consolidated the two lawsuits, with the Wallace lawsuit serving as the lead case. On April 30, 2021, plaintiffs filed an amended complaint asserting claims for breach of fiduciary duty against defendants and claims for insider trading. On January 26, 2024, the court ordered the parties’ proposed revised case schedule, setting fact and expert discovery deadlines throughout 2024 and early 2025; dispositive motions are due June 1, 2025, but no trial date has yet been set.

 

25
 

 

On March 29, 2021, an additional shareholder derivative lawsuit was filed in the Third District Court in and for Salt Lake County, State of Utah (“Utah State Court”) by Hua Ding, allegedly on behalf of Co-Diagnostics, Inc., that also piggybacks on the Gelt Litigation referenced above. It names the same defendants and asserts essentially the same claims as in In re Co-Diagnostics, Inc. Derivative Litigation pending in the District of Utah referenced above. On December 12, 2022, a second shareholder derivative lawsuit was filed in Utah State Court by Kathryn Matuch asserting essentially the same claims, allegedly on behalf of Co-Diagnostics, as the Ding shareholder derivative action.

 

The defendants believe the claims asserted in all of the shareholder derivative lawsuits referenced above are without merit and intend to defend vigorously against them, but there can be no assurances as to the outcome.

 

Stadium Capital Securities Class Action (Southern District of New York)

 

On August 16, 2022, Stadium Capital LLC (“Stadium”) filed a lawsuit in the United States District Court for the Southern District of New York, against Co-Diagnostics, Inc., and certain of our officers, on behalf of itself and a putative class, seeking to recover damages for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The complaint alleges that Co-Diagnostics and the individual defendants overstated the demand for the Company’s Logix Smart COVID-19 test in statements on May 12, 2022 and June 15, 2022. The complaint alleges that plaintiff suffered losses when the Company’s stock price dropped after the Company disclosed its financial results for the quarter ended June 30, 2022 in a press release on August 11, 2022. On September 19, 2022, a second plaintiff, Drew Lee, filed a similar complaint in the same court against the same defendants alleging essentially the same claims. On August 9, 2023, the court consolidated these two securities class actions into the Stadium action and appointed Stadium as lead plaintiff. On September 21, 2023, Stadium filed a consolidated amended complaint, and on October 20, 2023, defendants moved to dismiss. On February 5, 2024, the Court granted in part and denied in part the defendants’ motion to dismiss. On February 20, 2024, the defendants answered the consolidated amended complaint, and the parties are now engaged in discovery. The defendants believe the claims are without merit and intend to defend vigorously against them, but there can be no assurances as to the outcome.

 

Commercial Litigation

 

Co-Diagnostics, Inc. v. Hukui Technology, Inc., et al. (Third Judicial District Court, Salt Lake County, State of Utah, Civil No. 210902131, filed on April 21, 2021).

 

The Company filed a complaint against Defendants Hukui Technology, Inc., Hukui Tech, Inc., and Hukui Bio Co., Ltd (collectively, “Hukui”) seeking a declaratory judgment that the Company is not obligated to any of them in any amount. On August 24, 2021, Hukui filed their Answer and Counterclaim seeking damages on a number of theories, including breach of contract for letter agreements, breach of oral agreement, promissory estoppel, unjust enrichment, and interference with economic relations. Hukui requested a money judgment against the Company in an amount to be determined at trial. On September 20, 2021, Hukui filed their Unopposed Motion for Leave to Amend Answer to the Complaint, Affirmative Defenses, and Counterclaims and, on October 14, 2021, Hukui filed their Amended Answer and Counterclaims seeking damages on declaratory judgment, as well as breach of contract for letters of authorization, breach of oral agreement, promissory estoppel, unjust enrichment, and interference with economic relations. In 2022 the parties exchanged their initial disclosures, exchanged written discovery requests, and conducted a number of depositions on each side that were concluded in January 2023. On June 1, 2023 the Company filed a Motion for Summary Judgment asking the court for summary judgment on its sole claim for declaratory relief and for summary judgment with respect to all Hukui counterclaims. On November 7, 2023, the Court issued its decision and granted the Company summary judgment on its sole claim for declaratory relief and on all Hukui counterclaims. On December 22, 2023, Hukui filed a notice of appeal of the final judgment in its entirety with the Utah Supreme Court. The Company believes the claims are without merit and intends to defend vigorously against them, but there can be no assurances as to the outcome.

 

Co-Diagnostics, Inc. v. Pantheon International Advisors Ltd. (Third Judicial District Court, Salt Lake County, State of Utah, Civil No. 210902609, filed on May 14, 2021).

 

The Company filed a complaint against Pantheon International Advisors (“Pantheon”) asking the court to declare that the Company has no ongoing contractual business relationship with Pantheon, no monies owing, nor does Pantheon have any interest, right, title or claim to any stock issued by the Company or ownership of any kind in the Company. Pantheon was served with a 30-Day Summons on September 9, 2021 to which it failed to respond, and a default judgement against Pantheon International Advisors was entered by the Court on November 28, 2021. The time to appeal from the judgment or seek to vacate the judgment has passed.

 

After learning that the Company had initiated suit in Utah, and after learning of Company’s intent to serve it with process of that suit, on May 24, 2021, Pantheon filed a claim against the Company in the Royal Courts of Justice Group, Queens Bench Division, Claim No. QB-21-002245, stating that the Company owes Pantheon $2,860,809.79 for alleged breach of contract for failing to make payments purportedly due under a contract allegedly entered into on October 18, 2018. The Company is being represented locally in the UK by Freshfields Bruckhaus Deringer LLP in that matter. The Company intends to vigorously defend against the UK claims and will seek to the full extent possible to enforce its rights under the Declaratory Judgment already obtained in Utah but there can be no assurances as to the outcome.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

26
 

 

PART II

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER EQUITY SECURITIES

 

Market Information

 

Our common stock has been quoted on the NASDAQ market under the symbol “CODX” since July 12, 2017.

 

Holders 

 

As of March 12, 2024, the last reported sales price reported on NASDAQ for our common stock was $1.18 per share. As of March 12, 2024, we had approximately 154 record holders of our common stock. The number of record holders was determined from the records of our transfer agent and does not include beneficial owners of common stock whose shares are held in the names of various security brokers, dealers, and registered clearing agencies. The transfer agent for our common stock is VStock Transfer LLC located at 18 Lafayette Pl, Woodmere, New York 11598.

 

Dividends

 

We have never declared or paid any cash dividends on our capital stock. The payment of dividends on our common stock in the future will depend on our earnings, capital requirements, operating and financial condition and such other factors as our board of directors may consider appropriate. We currently expect to use all available funds to finance the future development and expansion of our business and do not anticipate paying dividends on our common stock in the foreseeable future.

 

Pursuant to Section 16-10a-640 of the Utah Revised Business Corporation Act, no distribution may be made if, after giving it effect:

 

  (a) the corporation would not be able to pay its debts as they become due in the usual course of business; or
     
  (b) the corporation’s total assets would be less than the sum of its total liabilities plus, unless the articles of incorporation permit otherwise, the amount that would be needed, if the corporation were to be dissolved at the time of the distribution, to satisfy the preferential rights upon dissolution of shareholders whose preferential rights are superior to those receiving the distribution.

 

Securities authorized for issuance under equity compensation plans

 

Information about our equity compensation plans in Item 12 of Part III of this Annual Report on Form 10-K is incorporated herein by reference.

 

Recent Sales of Unregistered Securities

 

None.

 

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

 

Share Repurchase Program

 

Issuer Purchase of Equity Securities
Period  (a) Total number of shares purchased (1)   (b) Average price paid per share (1)   (c ) Total number of shares purchased as part of publicly announced plans or programs (1)   (d) Maximum number (or approximate dollar value) of shares that may yet be purchased under the plans or programs (1) 
10/01/23 – 10/31/23   77,676   $1.08    77,676   $14,500,002 
11/01/23 – 11/30/23   -   $-    -   $14,500,002 
12/01/23 – 12/31/23   62,482   $1.21    62,482   $14,424,205 
                     
Total   140,158   $1.14    140,158   $14,424,205 

 

  (1) In March 2022, the company announced that its board of directors authorized the repurchase of up to $30.0 million of the company’s outstanding common stock. The extent to which the company repurchases its shares, and the timing of such repurchases, will depend upon a variety of factors, including trading volume, market conditions, legal requirements, business conditions and other factors. The repurchase program may be discontinued at any time, and the program does not obligate the company to acquire any specific number of shares of its common stock.

 

27
 

 

ITEM 6. RESERVED

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT OF OPERATIONS

 

The following management’s discussion and analysis of financial condition and results of operations describes the principal factors affecting the results of our operations, financial condition, and changes in financial condition. This discussion should be read in conjunction with the accompanying audited financial statements, and notes thereto, included elsewhere in this report. In addition to historical information, this Annual Report contains forward-looking statements that involve risks, uncertainties, and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including but not limited to those set forth under the caption “Item 1A. Risk Factors” in this Annual Report on Form 10-K.

 

Business Overview

 

Co-Diagnostics, Inc., a Utah corporation (the “Company” or “CODX”), develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Our diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. CODX’s technical advance involves a novel, patented approach to PCR test design of primer and probe structure (“CoPrimers™”) that eliminates one of the key vexing issues of PCR amplification: the exponential growth of primer-dimer pairs (false positives and false negatives) which adversely interferes with identification of the target DNA/RNA. Using our proprietary test design system and proprietary reagents, we have designed and obtained regulatory approval to sell PCR diagnostic tests for the detection of COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the Zika virus. These initial diagnostic tests were cleared for use in clinical labs only and not for point-of-care or at-home use.

 

We are currently developing a unique, groundbreaking portable diagnostic device and test system designed for point-of-care and at-home use. The system is comprised of our PCR instrument that we refer to as the Co-Dx™ PCR Pro™ instrument, our proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device. We refer to the system as the “Co-Dx™ PCR platform that is being designed to bring affordable, reliable polymerase chain reaction (“PCR”) testing to patients in point-of-care and at-home settings. The Co-Dx PCR platform is subject to U.S. Food and Drug Administration (“FDA”) review and is not available for sale at the time of this filing. In December 2023, we submitted the Co-Dx PCR platform for review by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA). The submission included the PCR Pro instrument, Co-Dx PCR COVID-19 detection test cups, and mobile app, all designed for use in point-of-care and at-home settings. There is no guarantee that our Co-Dx PCR platform will receive the necessary regulatory approvals for commercialization, or that, if regulatory approval is received, we will be able to successfully commercialize this platform.

 

Technology

 

We believe our proprietary molecular diagnostics technology is paving the way for innovation in disease detection and life sciences research through our enhanced detection of genetic material. For various reasons, including owning our own platform, we believe we will be able to accomplish this faster and more economically than some competitors, allowing for significant margins while still positioning ourselves as a low-cost provider of molecular diagnostics and screening services. For example, we were the first US-based company to receive a CE-marking for a COVID-19 test in early 2020, as we worked to help slow the spread of the pandemic through our global network of distributors covering clinical labs in more than 50 countries. Our Logix Smart COVID-19 test was designed, developed, submitted for regulatory approval and ready to be used as an in vitro diagnostic or IVD in countries that accept a CE Mark as approval for use of the test in a period of just over 30 days. This is a real-world example of how the CODX technology can be used in an evolving epidemic or pandemic to get diagnostic tools in the hands of medical professionals in a timely manner. It can be similarly used to design a test for mutated strains of the virus should they not be detectable using currently available tests.

 

In addition, continued development has demonstrated the unique properties of our CoPrimer technology that we believe makes it ideally suited for a variety of applications where specificity is key to optimal results, including multiplexing several targets, enhanced Single Nucleotide Polymorphism (“SNP”) detection and enrichment for next generation sequencing.

 

Our scientists use the complex mathematics of DNA/RNA PCR test design to engineer and optimize PCR tests and to automate algorithms that rapidly screen millions of possible options to pinpoint the optimum design. The intellectual property we use in our business, consisting of the predictive mathematical algorithms and patented molecular structure used in the testing process, which together represents a major advance in PCR testing systems. CODX technologies are now protected by more than 20 granted or pending US and foreign patents, as well as certain trade secrets and copyrights. Ownership of our proprietary platform permits us the advantage of avoiding payment of patent royalties required by other PCR test systems, which may allow the sale of diagnostic PCR tests at a lower price than competitors, while enabling us to maintain profit margins.

 

28
 

 

Our proprietary test design process involves identifying the optimal locations on the target genes for amplification and pair the locations with the optimized primer and probe structure to achieve outputs that meet the design input requirements identified from market research. This is done by following planned and documented processes, procedures and testing. In other words, we use the data resulting from our tests to verify whether we succeeded in designing what we intended. Verification involves a series of testing that concludes that the product is ready to proceed to validation in an evaluation either in our laboratory or in an independent laboratory setting using initial production tests to confirm that the product as designed meets the user needs.

 

Using our proprietary test design system and proprietary reagents, we have designed and obtained regulatory approval in the European Community and in India to sell PCR diagnostic tests for the detection of COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the Zika virus. In the United States, we obtained Emergency Use Authorization (“EUA”) for our Logix Smart® COVID-19 detection test from the Food and Drug Administration, or FDA, and we sell that test to qualified labs. In addition, our COVID-19 detection test and certain of our other suite of COVID-19 products have been approved for sale in countries such as the United Kingdom, Australia and Mexico by the regulatory bodies in those countries and have been registered for sale in many more countries. In connection with the sale of our tests we may sell diagnostic equipment from other manufacturers as self-contained lab systems (which we refer to as the “MDx Device”).

 

In addition to testing for infectious disease, the technology lends itself to identifying any section of a DNA or RNA strand that describes any type of genetic trait, which creates several significant applications. We, in conjunction with our customers, have designed and licensed tests that identify genetic traits in plant and animal genomes. We also have three multiplexed tests developed to test mosquitos for the identification of diseases carried by the mosquitos to enable municipalities to concentrate their efforts in managing mosquito populations on the specific areas known to be breeding the mosquitos that carry deadly viruses.

 

RESULTS OF OPERATIONS

 

Results of Operations for the Years Ended December 31, 2023 and 2022

 

The table below provides a comparison of our operating results for the year ended December 31, 2023 as compared to the year ended December 31, 2022.

 

   Years Ended December 31,   Year Change 
   2023   2022   Change   % 
Product revenue  $991,473   $34,218,209   $(33,226,736)   -97%
Grant revenue   5,820,565    -    5,820,565    - 
Total revenue   6,812,038    34,218,209    (27,406,171)   -80%
Cost of revenue   4,184,949    5,481,093    (1,296,144)   -24%
Gross profit   2,627,089    28,737,116    (26,110,027)   -91%
Operating expenses                    
Sales and marketing   6,860,815    7,344,628    (483,813)   -7%
General and administrative   14,279,441    14,262,963    16,478    0%
Research and development   22,962,593    17,438,098    5,524,495    32%
Depreciation and amortization   1,230,474    1,282,718    (52,244)   -4%
Goodwill impairment charges   -    15,388,546    (15,388,546)   - 
Total operating expenses   45,333,323    55,716,953    (10,383,630)   -19%
Loss from operations   (42,706,234)   (26,979,837)   (15,726,397)   58%
Other income                    
Interest income   1,161,913    704,045    457,868    65%
Realized gain on investments   2,243,059    -    2,243,059    - 
Loss on disposition of assets   (2,578)   (138,117)   135,539    -98%
Gain on remeasurement of acquisition contingencies   1,092,581    7,899,644    (6,807,063)   -86%
Gain (loss) on equity method investment in joint venture   100,703    (332,969)   433,672    -130%
Total other income   4,595,678    8,132,603    (3,536,925)   -43%
Loss before income taxes   (38,110,556)   (18,847,234)   (19,263,322)   102%
Income tax benefit   (2,777,691)   (4,608,985)   1,831,294    -40%
Net loss  $(35,332,865)  $(14,238,249)  $(21,094,616)   148%

 

29
 

 

Revenues

 

For the year ended December 31, 2023, we generated $6.8 million of revenue compared to revenue of $34.2 million in the year ended December 31, 2022. The decrease in revenue of $27.4 million was primarily due to lower sales of our Logix Smart COVID-19 test throughout the world. As global attention and regulatory responses to the COVID-19 pandemic have eased, we have experienced significantly decreased demand for our COVID-19 test. This decrease was partially offset by the generation of $5.8 million of grant revenue during the year ended December 31, 2023.

 

Cost of Revenues and Gross Profit

 

Cost of revenues decreased by $1.3 million from $5.5 million for the year ended December 31, 2022 to $4.2 million for the year ended December 31, 2023. Included within cost of revenues for the year ended December 31, 2023 is an increase of approximately $2.8 million related to reserves against certain raw materials and finished goods inventories. The decrease in revenues combined with a larger percentage of fixed product manufacturing costs and reserves for obsolete inventory resulted in a lower gross margin percentage.

 

Operating Expenses

 

We incurred total operating expenses of $45.3 million for the year ended December 31, 2023 compared to total operating expenses of $55.7 million for the year ended December 31, 2022. The decrease in operating expenses was primarily due to the decreases related to the impairment of goodwill, bad debt expense, and third party sales commissions, partially offset by increased expenses related to personnel, including stock-based compensation, increased legal and professional services expenses, and increased investment in research and development.

 

Sales and marketing expenses for the year ended December 31, 2023 were $6.9 million compared to $7.3 million for the year ended December 31, 2022. The decrease of $0.4 million was primarily a result of decreased variable compensation, such as bonuses and commissions, and decreased third-party sales commissions, partially offset by increased professional services and stock-based compensation expense.

 

General and administrative expenses were flat at $14.3 million for the years ended December 31, 2023 and 2022, respectively. Increases in professional, legal, and advisory fees, personnel related expenses, and stock-based compensation expense were offset by decreases in bad debt expense and insurance expense.

 

Our research and development expenses increased by $5.6 million from $17.4 million for the year ended December 31, 2022, to $23.0 million for the year ended December 31, 2023. The primary increase in expenses related to increased personnel expenses, as well as increases in supplies expenses and professional and lab services utilized to further help us in our research and product development activities.

 

During the year ended December 31, 2022, the Company recognized charges of $15.4 million related to goodwill impairment.

 

Other Income

 

Other income was $4.6 million for the year ended December 31, 2023, compared to other income of $8.1 million for the year ended December 31, 2022. The decrease in other income of $3.5 million was primarily due to a change in the fair value of contingent consideration liabilities, driven by changes in the Company’s stock price, and partially offset by increased interest income and realized investment gains due to the Company’s investing activities.

 

30
 

 

Net Loss

 

We realized a net loss for the year ended December 31, 2023 of $35.3 million compared to $14.2 million for the year ended December 31, 2022. The decrease of $21.1 million was primarily the result of reduced sales of our Logix Smart COVID-19 test, increased operating expenses as discussed above, and a decrease in the gain related to the fair value of acquisition related contingent consideration liabilities, partially offset by a decrease in impairment charges related to the impairment of goodwill recorded in the prior year and increased interest income and realized investment gains. Additionally, we recorded an income tax benefit of $2.8 million during the year ended December 31, 2023, compared to an income tax benefit of $4.6 million for the year ended December 31, 2022.

 

LIQUIDITY AND CAPITAL RESOURCES

 

At December 31, 2023, we had cash and cash equivalents of $14.9 million and marketable investment securities of $43.6 million. We consider our marketable investment securities an important part of our liquidity and focus such investments in securities that can readily be converted into cash if needed. Additionally, our total current assets at December 31, 2023, were $62.1 million compared to total current liabilities of $5.7 million.

 

Net cash used in operating activities during the year ended December 31, 2023 was $22.1 million, compared to cash provided by operating activities of $6.6 million for the year ended December 31, 2022. The decrease in cash from operating activities was primarily due to decreases in revenue and increases in operating expenses.

 

Net cash provided by investing activities was $15.4 million for the year ended December 31, 2023, compared to net cash used in investing activities of $58.2 million during the year ended December 31, 2022. The increase in cash provided by investing activities is primarily due to interest and realized gains related to marketable investment securities, as well as the redemption of certain investments as they matured.

 

Net cash used in financing activities was $1.4 million for the year ended December 31, 2023, compared to $14.0 million of cash used in financing activities for the year ended December 31, 2022. The decrease in cash used in financing activities is primarily due to fewer repurchases of outstanding common shares during 2023 as compared to 2022.

 

Since commencing sales of our Logix Smart COVID-19 test in March 2020, we have used our cash generated from those sales to fund the purchase of inventories and the development of our Co-Dx PCR Platform, and to pay our operating expenses. We have increased our work force most significantly in research and development in order to continue development of the Co-Dx PCR platform and additional tests that will enable continued use of our distributor network to sell additional products throughout the world.

 

We believe that our existing capital resources and the cash generated from future sales will be sufficient to meet our projected operating requirements for the next 12 months. However, our available capital resources may be consumed more rapidly than currently expected and we may need or want to raise additional financing for strategic opportunities. It is anticipated that the Company will continue to generate operating losses and use cash in operations in the near term. If needed, we expect additional investment capital to come from additional issuances of our common stock or other equity based securities with existing and new investors similar to those that have provided funding in the past. On March 16, 2023, the Company entered into an Equity Distribution Agreement with Piper Sandler & Co. (“Piper”), pursuant to which we may sell from time to time, shares of our common stock, having an aggregate offering price of up to $50.0 million through Piper, as agent. No shares have been sold under the distribution agreement as of December 31, 2023. We may not be able to secure such financing in a timely manner or on favorable terms, if at all.

 

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

 

Our management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles (“GAAP”). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. While our significant accounting policies are described in Item 8 of this Annual Report on Form 10-K, within Note 2 of our consolidated financial statements in the section titled “Summary of Significant Accounting Policies”, we believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management’s judgments and estimates.

 

Accounts Receivable

 

Trade accounts receivable are recorded at the invoiced amount, net of any allowance. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. If actual accounts receivable collections are less favorable than those projected by management at the time of the assessment, however, additional accounts receivable write-downs may be required, which could reduce our earnings.

 

31
 

 

Goodwill and Intangible Assets

 

The useful lives of intangible assets with definite lives are based on the expected number of years the asset will generate revenue or otherwise be used by us and the related amortization is based on the straight-line method. Goodwill, which has an indefinite life, is not amortized but instead is tested at least annually for impairment, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include:

 

  ● the asset’s ability to continue to generate income from operations and positive cash flow in future periods;
     
  ● any volatility or significant decline in our stock price and market capitalization compared to our net book value;
     
  ● loss of legal ownership or title to an asset;
     
  ● significant changes in our strategic business objectives and utilization of our assets; and
     
  ● the impact of significant negative industry or economic trends.

 

If a change were to occur in any of the above-mentioned factors or estimates, the likelihood of a material change in our reported results would increase. For goodwill, the entity has the option to first assess qualitative factors to determine whether it is necessary to perform the quantitative goodwill impairment test. The quantitative impairment test compares the fair value of a reporting unit with the carrying amount, including goodwill. If the fair value of a reporting unit exceeds its carrying amount, goodwill is considered not impaired; otherwise, goodwill is impaired and the loss is recorded. Upon the completion of our annual evaluation for impairment of goodwill as of December 31, 2022, we recorded a goodwill impairment charge of $15.4 million.

 

Inventories

 

We periodically review inventory for both potential obsolescence and potential declines in anticipated selling prices. In this review, we make assumptions about the future demand for and market value of the inventory and based on these assumptions estimate the amount of any obsolete, unmarketable, slow moving or overvalued inventory. We write down the value of our inventories by an amount equal to the difference between the cost of the inventory and the net realizable value. If actual market conditions are less favorable than those projected by management at the time of the assessment, however, additional inventory write-downs may be required, which could reduce our earnings.

 

Income Taxes

 

Significant judgment is required in determining our provision for income taxes, current tax assets and liabilities, deferred tax assets and liabilities, and our future taxable income, both as a whole and in various tax jurisdictions, for purposes of assessing our ability to realize future benefit from our deferred tax assets. We recognize in the financial statements the impact of a tax position if that position is more likely than not to be sustained during an audit, including resolution of related appeals or litigation processes, if any. While we believe that we have appropriate support for the positions taken on our tax returns, we regularly assess the potential outcome of examinations by tax authorities in determining the adequacy of our provision for income taxes. See Note 11 to our Consolidated Financial Statements for more information on income taxes.

 

The foregoing estimates, expectations and forward-looking statements are subject to change as we make strategic operating decisions from time to time and as our revenue and expenses fluctuate from period to period.

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not required.

 

32
 

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

 

CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2023 AND 2022

 

Table of Contents

 

Reports of Independent Registered Public Accounting Firms (PCAOB ID No. 270 and ID No. 457) 34
Consolidated Balance Sheets 36
Consolidated Statements of Operations 37
Consolidated Statement of Changes in Stockholders’ Equity 38
Consolidated Statements of Cash Flows 39
Notes to Consolidated Financial Statements 40

 

33
 

 

Report of Independent Registered Public Accounting Firm

 

To the Board of Directors and Stockholders

Co-Diagnostics, Inc.

 

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated balance sheet of Co-Diagnostics Inc. and subsidiaries (the Company) as of December 31, 2023, the related consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for the year then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2023, and the consolidated results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.

 

Critical Audit Matters

 

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

Estimation of the Fair Value of Intangible Assets

 

As more fully described in Notes 2 and 6 to the consolidated financial statements, the Company acquired Idaho Molecular, Inc., and Advanced Conceptions, Inc. in December 2021. As part of the transaction, the Company acquired in-process research and development indefinite-lived intangible assets totaling $26,101,000. The Company assesses these assets for impairment at least annually or whenever events or changes in circumstances occur that may indicate impairment. The Company’s analysis for the year ended December 31, 2023, required significant judgment to assess qualitative factors in determining whether it is more likely than not that the indefinite-lived intangible asset is impaired. As a result of their analysis, the Company determined there was no impairment as of year-end.

 

Auditing the Company’s annual impairment assessment was complex and highly judgmental due to the significant judgement required in determining whether it is more likely than not that an indefinite-lived intangible asset is impaired. This required a high degree of auditor judgement, subjectivity and effort in performing procedures and evaluating audit evidence to evaluate management assessment in evaluating these indefinite-lived intangibles for impairment. These procedures included among others: (1) evaluating management’s process for evaluating for impairment, (2) evaluating the factors assessed by management (3) evaluating other relevant factors in making our own determination, and (4) evaluating and discussing considerations and conclusions made by management.

 

/s/ Tanner LLC

We have served as the Company’s auditor since 2023

Salt Lake City, Utah

March 14, 2024

 

34
 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 

 

To the Board of Directors and Stockholders of Co-Diagnostics, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheet of Co-Diagnostics, Inc (the Company) as of December 31, 2022, and the related consolidated statements of operations and comprehensive income (loss), changes in stockholders’ equity, and cash flows for the year ended December 31, 2022, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022, and the results of its operations and its cash flows for the year ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

 

/s/ Haynie & Company

Salt Lake City, Utah

March 16, 2023

 

We began serving as the Company’s auditor in 2016. In 2023, we became the predecessor auditor.

 

35
 

 

CO-DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

 

           
   December 31, 2023   December 31, 2022 
Assets          
Current assets          
Cash and cash equivalents  $14,916,878   $22,973,803 
Marketable investment securities   43,631,510    58,289,066 
Accounts receivable, net   303,926    3,453,723 
Inventory, net   1,664,725    5,310,473 
Income taxes receivable   26,955    1,870,419 
Prepaid expenses and other current assets   1,597,114    761,187 
Note receivable   -    75,000 
Total current assets   62,141,108    92,733,671 
Property and equipment, net   3,035,729    2,539,483 
Operating lease right-of-use asset   2,966,774    372,115 
Intangible assets, net   26,403,667    26,768,333 
Investment in joint venture   773,382    672,679 
Total assets  $95,320,660   $123,086,281 
Liabilities and stockholders’ equity          
Current liabilities          
Accounts payable  $1,482,109   $952,296 
Accrued expenses   2,172,959    934,447 
Operating lease liability, current   838,387    297,209 
Contingent consideration liabilities, current   891,666    1,689,471 
Deferred revenue   362,449    - 
Total current liabilities   5,747,570    3,873,423 
Long-term liabilities          
Income taxes payable   659,186    1,181,284 
Deferred tax liability   -    2,417,987 
Operating lease liability   2,152,180    50,708 
Contingent consideration liabilities   748,109    1,042,885 
Total long-term liabilities   3,559,475    4,692,864 
Total liabilities   9,307,045    8,566,287 
Commitments and contingencies (Note 12)          
Stockholders’ equity          
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively   -    - 
Common stock, $0.001 par value; 100,000,000 shares authorized; 36,108,346 shares issued and 31,259,668 shares outstanding as of December 31, 2023 and 34,754,265 shares issued and 30,872,607 shares outstanding as of December 31, 2022   36,108    34,754 
Treasury stock, at cost; 4,848,678 and 3,881,658 shares held as of December 31, 2023 and December 31, 2022, respectively   (15,575,795)   (14,211,866)
Additional paid-in capital   96,808,436    88,472,935 
Accumulated other comprehensive income   146,700    293,140 
Accumulated earnings   4,598,166    39,931,031 
Total stockholders’ equity   86,013,615    114,519,994 
Total liabilities and stockholders’ equity  $95,320,660   $123,086,281 

 

See accompanying notes to consolidated financial statements.

 

36
 

 

CO-DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

 

           
   Years Ended December 31, 
   2023   2022 
Product revenue  $991,473   $34,218,209 
Grant revenue   5,820,565    - 
Total revenue   6,812,038    34,218,209 
Cost of revenue   4,184,949    5,481,093 
Gross profit   2,627,089    28,737,116 
Operating expenses          
Sales and marketing   6,860,815    7,344,628 
General and administrative   14,279,441    14,262,963 
Research and development   22,962,593    17,438,098 
Depreciation and amortization   1,230,474    1,282,718 
Goodwill impairment charges   -    15,388,546 
Total operating expenses   45,333,323    55,716,953 
Loss from operations   (42,706,234)   (26,979,837)
Other income, net          
Interest income   1,161,913    704,045 
Realized gain on investments   2,243,059    - 
Loss on disposition of assets   (2,578)   (138,117)
Gain on remeasurement of acquisition contingencies   1,092,581    7,899,644 
Gain (loss) on equity method investment in joint venture   100,703    (332,969)
Total other income, net   4,595,678    8,132,603 
Loss before income taxes   (38,110,556)   (18,847,234)
Income tax benefit   (2,777,691)   (4,608,985)
Net loss  $(35,332,865)  $(14,238,249)
Other comprehensive loss          
Change in net unrealized gains on marketable securities, net of tax  $(146,440)  $293,140 
Total other comprehensive income (loss)  $(146,440)  $293,140 
Comprehensive loss  $(35,479,305)  $(13,945,109)
           
Loss per common share:          
Basic  $(1.20)  $(0.45)
Diluted  $(1.20)  $(0.45)
Weighted average shares outstanding:          
Basic   29,346,599    31,479,028 
Diluted   29,346,599    31,479,028 

 

See accompanying notes to consolidated financial statements.

 

37
 

 

CO-DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

 

   Shares   Amount   Shares   Amount   Stock   Capital   Income   Earnings   Equity 
  

Convertible

Preferred Stock

   Common Stock   Treasury  

Additional

Paid-in

  

Accumulated

Other

Comprehensive

   Accumulated  

Total

Stockholders’

 
   Shares   Amount   Shares   Amount   Stock   Capital   Income   Earnings   Equity 
Balance as of December 31, 2021   -   $     -    33,819,862   $33,820   $-   $80,271,999   $-   $54,169,280   $134,475,099 
Common stock issued for option exercises   -    -    70,791    70    -    77,800    -    -    77,870 
Common stock issued for warrant exercises   -    -    50,000    50    -    99,950    -    -    100,000 
Stock-based compensation expense   -    -    725,166    725    -    7,542,498    -    -    7,543,223 
Common stock issued for acquisitions   -    -    88,446    89    -    480,687    -    -    480,776 
Repurchases of common stock   -    -    -    -    (14,211,866)   -    -    -    (14,211,866)
Other comprehensive income, net of tax   -    -    -    -    -    -    293,140    -    293,140 
Net loss   -    -    -    -    -    -    -    (14,238,249)   (14,238,249)
Balance as of December 31, 2022   -   $-    34,754,265   $34,754   $(14,211,866)  $88,472,935   $293,140   $39,931,031   $114,519,994 
Stock-based compensation expense   -    -    1,354,081    1,354    -    8,335,501    -    -    8,336,855 
Repurchases of common stock   -    -    -    -    (1,363,929)   -    -    -    (1,363,929)
Other comprehensive loss, net of tax   -    -    -    -    -    -    (146,440)   -    (146,440)
Net loss   -    -    -    -    -    -    -    (35,332,865)   (35,332,865)
Balance as of December 31, 2023   -   $-    36,108,346   $36,108   $(15,575,795)  $96,808,436   $146,700   $4,598,166   $86,013,615 

 

See accompanying notes to consolidated financial statements.

 

38
 

 

CO-DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

           
   Years Ended December 31, 
   2023   2022 
Cash flows from operating activities          
Net loss  $(35,332,865)  $(14,238,249)
Adjustments to reconcile net loss to cash (used in) provided by operating activities:          
Depreciation and amortization   1,230,474    1,282,718 
Goodwill impairment charges   -    15,388,546 
Stock-based compensation expense   8,336,855    7,543,223 
Change in fair value of acquisition contingencies   (1,092,581)   (7,899,644)
Non-cash lease expense   47,992    30,430 
Realized gain on investments   (2,243,059)   - 
(Gain) loss from equity method investment   (100,703)   332,969 
Loss on disposition of assets   2,578    138,117 
Deferred income taxes   (2,417,987)   (4,810,457)
Provision for credit losses   612,809    2,461,032 
Inventory obsolescence expense   3,233,281    148,099 
Changes in assets and liabilities:          
Accounts receivable   2,536,988   14,924,427 
Prepaid expenses and other assets   1,082,536    (224,094)
Inventory   413,140    (3,673,309)
Deferred revenue   362,449    (150,000)
Income taxes payable   (522,098)   (2,201,250)
Accounts payable, accrued expenses and other liabilities   1,768,326    (2,483,821)
Net cash (used in) provided by operating activities   (22,081,865)   6,568,737 
Cash flows from investing activities          
Purchases of property and equipment   (1,365,306)   (1,427,512)
Proceeds from maturities of marketable investment securities   127,251,619    11,255,266 
Purchases of marketable securities   (110,497,444)   (67,995,926)
Net cash (used in) provided by investing activities   15,388,869    (58,168,172)
Cash flows from financing activities          
Proceeds from exercise of options and warrants   -    177,870 
Repurchases of common stock   (1,363,929)   (14,211,866)
Net cash (used in) financing activities   (1,363,929)   (14,033,996)
Net decrease in cash and cash equivalents   (8,056,925)   (65,633,431)
Cash and cash equivalents at beginning of period   22,973,803    88,607,234 
Cash and cash equivalents at end of period  $14,916,878   $22,973,803 
Supplemental disclosure of cash flow information          
Interest paid  $-   $- 
Income taxes paid  $55,975   $4,498,742 
Supplemental disclosure of non-cash investing and financing transactions          
Inventory moved to property, plant and equipment  $673   $218,906 
Right-of-use assets obtained in exchange for new operating lease liabilities  $3,203,146   $681,327 
Business acquisition measurement period adjustments  $-   $1,593 
Fair value of common stock issued as consideration for business acquisitions  $-   $480,776 
Fair value of contingent common stock issued as consideration for business acquisitions  $-   $199,359 

 

See accompanying notes to consolidated financial statements.

 

39
 

 

CO-DIAGNOSTICS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED DECEMBER 31, 2023 AND 2022

 

Note 1 – Overview and Basis of Presentation

 

Description of Business

 

Co-Diagnostics, Inc., a Utah corporation (the “Company” or “CODX”), is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. In connection with the sale of our tests we may sell diagnostic equipment from other manufacturers as self-contained lab systems.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Such estimates include inventories, receivables and other long-lived assets, legal and regulatory contingencies, income taxes, share based arrangements, and others. These estimates and assumptions are based on management’s best estimates and judgments. Actual amounts and results could differ from those estimates.

 

Basis of Presentation

 

The accompanying audited consolidated financial statements of Co-Diagnostics, Inc. and its wholly owned subsidiaries have been prepared to reflect the financial position, results of operations and cash flows of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). All intercompany balances and transactions have been eliminated.

 

Note 2 – Summary of Significant Accounting Policies

 

Reclassifications

 

Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.

 

Cash and Cash Equivalents

 

Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of December 31, 2023 and December 31, 2022. The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.

 

40
 

 

Marketable Investment Securities

 

The Company’s marketable investment securities are comprised of investments in certificates of deposit and U.S. Treasury bills and notes. The Company designates investments in debt securities as available-for-sale. Available-for-sale debt securities with original maturities of three months or less from the date of purchase are classified within cash and cash equivalents. Available-for-sale debt securities with original maturities longer than three months are available to fund current operations and are classified as marketable investment securities, within current assets on the consolidated balance sheets. The Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. Available-for-sale debt securities are reported at fair value with the related unrealized gains and losses included in accumulated other comprehensive income (loss), a component of stockholders’ equity, net of tax. Realized gains and losses on the sale of marketable securities are determined using the average cost method on a first-in, first-out basis and recorded in total other income (expense), net in the consolidated statements of operations and comprehensive loss.

 

The available-for-sale debt securities are subject to a periodic impairment review. For investments in an unrealized loss position, the Company writes down the amortized cost basis of the investment if it is more likely than not that the Company will be required or will intend to sell the investment before recovery of its amortized cost basis. For investments not likely to be sold before recovery of the amortized cost basis, the Company determines whether a credit loss exists by considering information about the collectability of the instrument, current market conditions, and reasonable and supportable forecasts of economic conditions. The Company recognizes an allowance for credit losses up to the amount of the unrealized loss when appropriate. Allowances for credit losses and write-downs are recognized in total other income (expense), net, and unrealized losses not related to credit losses are recognized in accumulated other comprehensive income (loss). There are no allowances for credit losses recorded for the periods presented.

 

Accounts Receivable

 

Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At December 31, 2023 total accounts receivable was $504,264 with an allowance for uncollectable accounts of $200,338 resulting in a net amount of $303,926. At December 31, 2022 total accounts receivable was $6,552,249 with an allowance for uncollectable accounts of $3,098,526 resulting in a net amount of $3,453,723.

 

Equity-Method Investments

 

Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying consolidated statements of operations.

 

Inventory

 

Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At December 31, 2023, the Company had $1,664,725 in inventory, of which $700,467 was finished goods and $964,258 was raw materials. At December 31, 2022, the Company had $5,310,473 in inventory, of which $1,327,264 was finished goods and $3,983,209 was raw materials. The Company establishes reserves to reduce low-moving, obsolete, or unusable inventories to their estimated useful or scrap values. The Company recognized $2,760,011 and $0 related to the change in inventory reserves during the years ended December 31, 2023 and 2022, respectively.

 

41
 

 

Goodwill and Intangible Assets

 

Goodwill represents the excess of the purchase price and related costs over the value assigned to net tangible and identifiable intangible assets acquired in business combinations. Goodwill and indefinite-lived intangible assets are not amortized, but rather tested for impairment at least annually on December 31, or more often if and when circumstances indicate that the carrying value may not be recoverable. Finite-lived intangible assets are amortized over their useful lives.

 

During the years ended December 31, 2023 and 2022, the Company recognized impairment charges related to goodwill of $0 and $15,388,546, respectively.

 

Long-lived Assets

 

Long-lived assets, such as property and equipment, are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from three to five years. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.

 

For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed. Once the development process has been completed the asset will be amortized over its remaining estimated useful life. The Company reviews its long-lived assets, including property and equipment, indefinite-lived and finite-lived intangible assets, and ROU assets, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.

 

Revenue Recognition

 

The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation. Based on the criteria above, the Company typically recognizes revenue upon delivery.

 

The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.

 

Grant Revenue

 

The Company may submit applications to receive grant funding from governmental and non-governmental entities. The Company accounts for grants by analogizing to the contribution accounting model under ASC 958-605, Not-for-Profit Entities (“ASC 958”). Revenues from grants, contracts, and awards provided by governmental and non-governmental agencies are recorded based upon the terms of the specific agreements. The Company recognizes grant funding without conditions or continuing performance obligations as revenue in the consolidated statements of operations and comprehensive income (loss). The Company recognizes grant funding with conditions or continuing performance obligations as deferred revenue in the consolidated balance sheets if the conditions or performance obligations have not yet been met. The Company recognized grant funding revenue of $5.8 million during the year ended December 31, 2023. At December 31, 2023, the Company has also recorded $0.3 million of deferred revenue related to grant funding for which the cash was received, but the underlying conditions or performance obligations have not yet been met. Cash received from federal grants, contracts, and awards can be subject to audit by the grantor and, if the examination results in a disallowance of any expenditure, repayment could be required.

 

Deferred Revenue

 

Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.

 

42
 

 

Research and Development

 

Research and development costs are expensed when incurred. The Company recorded $22,962,593 and $17,438,098 of research and development costs for the years ended December 31, 2023 and 2022, respectively.

 

Stock-based Compensation

 

The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.

 

Income Taxes

 

The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, deferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.

 

Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.

 

Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. The Company has uncertain income tax positions in the consolidated financial statements, and adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.

 

Net Income (Loss) per Share

 

Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.

 

Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive.

 

Comprehensive Income (Loss)

 

Comprehensive loss is comprised of net loss and unrealized gains and losses on marketable securities, net of income taxes.

 

Concentrations Risk and Significant Customers

 

The Company had certain customers which were each responsible for generating 10% or more of the total revenue for the years ended December 31, 2023 and 2022, respectively. Two customers accounted for approximately 28% of product revenue for the year ended December 31, 2023 and one customer accounted for approximately 37% of product revenue for the year ended December 31, 2022. One granting agency accounted for 100% of grant revenue for the year ended December 31, 2023.

 

43
 

 

Three customers accounted for more than 10% of accounts receivable at December 31, 2023 and 2022, respectively. These customers together accounted for approximately 97% and 61% of accounts receivable at December 31, 2023 and 2022, respectively.

 

Recently Issued Accounting Standards

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires an entity to disclose annually additional information related to the company’s income tax rate reconciliation and income taxes paid during the period. The guidance should be applied prospectively with the option to apply the standard retrospectively. The standard becomes effective for the Company for full year 2025 reporting. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.

 

Note 3 – Cash, Cash Equivalents, and Financial Instruments

 

The following table shows the Company’s cash, cash equivalents, and marketable investment securities by significant investment category:

 

   December 31, 2023 
   Adjusted Cost   Allowance for Credit Losses   Total Unrealized Gains / (Losses)   Fair Value   Cash and Cash Equivalents   Marketable Investment Securities 
Cash  $4,317,449   $-   $-   $4,317,449   $4,317,449   $- 
Level 1:                              
Money market funds   10,599,429    -    -    10,599,429    10,599,429    - 
Subtotal   10,599,429    -    -    10,599,429    10,599,429    - 
Level 2:                              
U.S. treasury securities   43,484,810    -    146,700    43,631,510    -    43,631,510 
Subtotal   43,484,810    -    146,700    43,631,510    -    43,631,510 
Total  $58,401,688   $       -   $146,700   $58,548,388   $14,916,878   $43,631,510 

 

   December 31, 2022 
   Adjusted Cost   Allowance for Credit Losses   Total Unrealized Gains / (Losses)   Fair Value   Cash and Cash Equivalents   Marketable Securities 
Cash  $12,834,444   $-   $-   $12,834,444   $12,834,444   $- 
Level 1:                              
Money market funds   146,359           -    -    146,359    146,359    - 
Subtotal   146,359    -    -    146,359    146,359    - 
Level 2:                              
U.S. treasury securities   67,892,825    -    389,241    68,282,066    9,993,000    58,289,066 
Subtotal   67,892,825    -    389,241    68,282,066    9,993,000    58,289,066 
Total  $80,873,628   $-   $389,241   $81,262,869   $22,973,803   $58,289,066 

 

Marketable investment securities held as of December 31, 2023 mature over the next 12 months.

 

Note 4 – Fair Value Measurements

 

The Company measures and records certain financial assets and liabilities at fair value on a recurring basis. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

The following three levels of inputs are used to measure the fair value of financial assets and liabilities:

 

Level 1: Quoted market prices in active markets for identical assets or liabilities.

 

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

 

Level 3: Unobservable inputs that are not corroborated by market data.

 

44
 

 

The following table summarizes the assets and liabilities measured at fair value on a recurring basis as of December 31, 2023 and December 31, 2022, by level within the fair value hierarchy:

 

   (Level 1)   (Level 2)   (Level 3)   Total 
   December 31, 2023 
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                    
Cash equivalents  $13,806,864   $-   $-   $13,806,864 
Marketable securities (U.S. treasury bills and notes)   -    43,631,510    -    43,631,510 
Total assets measured at fair value  $13,806,864   $43,631,510   $-   $57,438,374 
Liabilities:                    
Contingent consideration - common stock  $-   $-   $1,318,995   $1,318,995 
Contingent consideration - warrants   -    -    320,780    320,780 
Total liabilities measured at fair value  $-   $-   $1,639,775   $1,639,775 

 

   (Level 1)   (Level 2)   (Level 3)    Total 
   December 31, 2022 
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                    
Cash equivalents  $186,667   $9,993,000   $-   $10,179,667 
Marketable securities (U.S. treasury bills and notes)   -    58,289,066    -    58,289,066 
Total assets measured at fair value  $186,667   $68,282,066   $-   $68,468,733 
Liabilities:                    
Contingent consideration - common stock  $-   $-   $2,499,147   $2,499,147 
Contingent consideration - warrants   -    -    233,209    233,209 
Total liabilities measured at fair value  $-   $-   $2,732,356   $2,732,356 

 

The Company’s financial instruments that are measured at fair value on a recurring basis consist of certificates of deposit and U.S. treasury bills and notes as of December 31, 2023 and 2022, respectively.

 

In connection with prior year acquisitions, the Company recorded a liability for contingent consideration in the form of shares of common stock and warrants to purchase common stock, both to be issued when certain milestones are achieved. The fair value of contingent consideration is calculated using a discounted probability weighted valuation model. Discount rates used in such calculations are a significant assumption that are not observed in the market, and therefore, the resulting fair value represents a Level 3 measurement.

 

The changes for Level 3 items measured at fair value on a recurring basis are as follows:

 

      
Fair value as of December 31, 2022  $2,732,356 
Change in fair value of contingent consideration issued for business acquisitions   (1,092,581)
Fair value as of December 31, 2023  $1,639,775 

 

45
 

 

The fair value of the contingent consideration is based on the fair value of the contingent consideration-common stock and contingent consideration-warrants. The fair value of the contingent consideration-common stock is equal to the probability-adjusted value of the Company’s common stock as of the valuation date. The fair value of the contingent consideration-warrants is equal to the probability adjusted value of a call option with terms consistent with the terms of the warrants as of the valuation date. Prior to the probability adjustments, the warrants were valued based on the following inputs:

 

   December 31, 2023   December 31, 2022 
Stock price  $1.33   $2.52 
Strike price  $9.13   $9.13 
Volatility   187.5%   75.0%
Risk-free rate   4.0%   4.1%
Expected term (years)   3.0    4.0 

 

Fair Value of Other Financial Instruments

 

The carrying amounts of certain financial instruments, including cash held in banks, accounts receivable, notes receivable, accounts payable, accrued liabilities, and other liabilities approximate fair value due to their short-term maturities and are excluded from the fair value tables above.

 

Note 5 – Property and Equipment

 

Property and equipment, net consisted of the following:

 

   Estimated  December 31, 
   Useful Lives in years  2023   2022 
Lab equipment  3 - 5  $4,545,908   $3,574,730 
Leasehold improvements  0 - 5   548,648    224,957 
Office equipment, furniture and other  2 - 5   173,668    112,044 
Less accumulated depreciation and amortization      (2,232,495)   (1,372,248)
Fixed assets, net     $3,035,729   $2,539,483 

 

Note 6 – Goodwill and Intangible Assets

 

Goodwill

 

Goodwill represents the excess of purchase price and related costs over the value assigned to net tangible and identifiable intangible assets acquired in business combinations. The following table presents the changes in the carrying amount of goodwill:

 

Balance as of December 31, 2021  $14,706,818 
      
Measurement period adjustments   681,728 
Goodwill impairment charges   (15,388,546)
Balance as of December 31, 2022  $- 

 

46
 

 

The Company assesses goodwill for impairment at the reporting unit level on an annual basis, or whenever events or changes in circumstances occur that indicate that the fair value of a reporting unit is below its carrying amount. The Company estimates the fair value of its reporting unit by using forecasts of discounted future cash flows and peer market multiples. If the fair value is less than the carrying value, impairment will be recognized in the amount by which the carrying value exceeds the fair value. The Company performed a qualitative and quantitative goodwill impairment assessment as of December 31, 2022. Based on the impairment assessment performed the Company concluded that it was more likely than not that the fair value of the Company’s reporting unit was less than it’s carrying amount. Accordingly, the Company recorded an impairment charge to reduce the carrying value of goodwill to $0.

 

Intangible Assets, Net

 

Intangible assets, net consisted of the following:

 

   December 31, 2023
   Weighted-Average  Gross       Net 
   Useful Life (1)  Carrying   Accumulated   Carrying 
   (in Years)  Amount   Amortization   Amount 
In-process research and development  Indefinite  $ 26,101,000   $-   $26,101,000 
Non-competition agreements  2.7   1,094,000    (791,333)   302,667 
Total intangible assets     $27,195,000   $(791,333)  $26,403,667 

 

   December 31, 2022
   Weighted-Average  Gross       Net 
   Useful Life (1)  Carrying   Accumulated   Carrying 
   (in Years)  Amount   Amortization   Amount 
In-process research and development  Indefinite  $26,101,000   $-   $26,101,000 
Non-competition agreements  2.7   1,094,000    (426,667)   667,333 
Total intangible assets     $27,195,000   $(426,667)  $26,768,333 

 

(1)Based on weighted-average useful life established as of the acquisition date.

 

47
 

 

The expected future annual amortization expense of the Company’s intangible assets held as of December 31, 2023 is as follows:

 

Year Ending December 31,  Amortization Expense 
2024   302,667 
Total  $302,667 

 

Note 7 - Accrued Expenses

 

Accrued expenses consisted of the following:

 

 

   December 31, 2023   December 31, 2022 
Payroll liabilities  $1,643,186   $428,354 
Distributor commissions   9,958    159,725 
Other accrued liabilities   519,815    346,368 
Total accrued expenses  $2,172,959   $934,447 

 

Note 8 – Revenue

 

The following table sets forth revenue by geographic area:

 

   2023   2022 
   Years Ended December 31, 
   2023   2022 
United States          
Product revenue  $659,618   $24,671,554 
Grant revenue   5,820,565    - 
Total United States   6,480,183    24,671,554 
Rest of World          
Product revenue   331,855    9,546,655 
Grant revenue   -    - 
Total Rest of World   331,855    9,546,655 
Total  $6,812,038   $34,218,209 
Percentage of revenue by area:          
United States   95%   72%
Rest of World   5%   28%

 

Deferred Revenue

 

Changes in the Company’s deferred revenue balance for the year ended December 31, 2023 were as follows:

 

Balance as of December 31, 2022  $- 
Increase due to prepayments from customers   32,570 
Increase due to grant funding awarded   329,879 
 Balance as of December, 2023  $362,449 

 

Note 9 – Earnings per Share

 

The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for years ended December 31, 2023 and 2022:

 

   2023   2022 
   Years Ended December 31, 
   2023   2022 
Numerator          
Net loss, as reported  $(35,332,865)  $(14,238,249)
           
Denominator          
Weighted average shares, basic   29,346,599    31,479,028 
Dilutive effect of stock options, warrants and RSUs   -    - 
Shares used to compute diluted earnings per share   29,346,599    31,479,028 
           
Basic earnings per share  $(1.20)  $(0.45)
Diluted earnings per share  $(1.20)  $(0.45)

 

48
 

 

The computation of diluted earnings per share for the years ended December 31, 2023 and December 31, 2022 also excludes approximately 1.4 million shares of common stock and approximately 465,000 warrants to purchase shares of common stock that are contingent upon the achievement of certain milestones.

 

As a result of incurring a net loss for the years ended December 31, 2023 and 2022, respectively, no potentially dilutive securities are included in the calculation of diluted earnings per share because such effect would be anti-dilutive. The Company had potentially dilutive securities as of December 31, 2023, consisting of: (i) 2,618,362 restricted stock units and (ii) 512,112 options, and potentially dilutive securities as of December 31, 2022, consisting of: (i) 1,443,238 restricted stock units and (ii) 50,000 options.

 

Note 10 – Stock-Based Compensation

 

Stock Incentive Plans

 

The Company’s board of directors adopted, and shareholders approved, the Co-Diagnostics, Inc. Amended and Restated 2015 Long Term Incentive Plan (the “Incentive Plan”) providing for the issuance of stock-based incentive awards to employees, officers, consultants, directors and independent contractors. On August 31, 2022 the shareholders approved an increase in the number of awards available for issuance under the Incentive Plan to an aggregate of 12,000,000 shares of common stock. The number of awards available for issuance under the Incentive Plan was 4,357,937 at December 31, 2023.

 

Stock Options

 

The following table summarizes option activity during the years ended December 31, 2023 and 2022:

 

   Number of Options   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2021   1,111,363   $2.12   $1.31      
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   (70,791)   1.10    0.51      
Outstanding at December 31, 2022   1,040,572   $2.19   $1.37    5.88 
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   -    -    -      
Outstanding at December 31, 2023   1,040,572   $2.19   $1.37    4.89 
                     
Exercisable at December 31, 2023   1,040,572   $2.19   $1.37    4.89 

 

49
 

 

The total intrinsic value of options exercised during the years ended December 31, 2023 and 2022, respectively, was $0 and approximately $0.4 million. The aggregate intrinsic value of outstanding options at December 31, 2023 and 2022 was approximately $0.2 million and $0.8 million, respectively. As of December 31, 2023, there were no unvested options and no unrecognized stock-based compensation expense related to options.

 

Restricted Stock Units

 

The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the years ended December 31, 2023 and 2022:

 

   Number of RSUs  

Weighted

Average Grant Date Fair Value

 
Unvested at December 31, 2021   1,267,415   $9.94 
Granted   1,925,476    5.66 
Vested   (725,166)   8.66 
Forfeited/Cancelled   (41,000)   8.31 
Unvested at December 31, 2022   2,426,725   $6.95 
Granted   1,948,750    1.92 
Vested   (1,354,081)   6.17 
Forfeited/Cancelled   (95,897)   6.16 
Unvested at December 31, 2023   2,925,497   $3.99 

 

As of December 31, 2023, there was $9.5 million of unrecognized stock-based compensation expense related to outstanding RSUs which is expected to be recognized over a weighted-average period of 1.7 years.

 

Warrants

 

The Company has issued warrants related to financings, acquisitions and as compensation to third parties for services provided. The Company estimates the fair value of issued warrants on the date of issuance as determined using a Black-Scholes pricing model. The Company amortizes the fair value of issued warrants using a vesting schedule based on the terms and conditions of each warrant if granted for services.

 

50
 

 

The following table summarizes warrant activity during the years ended December 31, 2023 and 2022:

 

   Number of Warrants  

Weighted Average Exercise

Price

   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2021   526,281   $8.15   $4.01    4.7 
Issued for adjustments to contingent purchase consideration   8,719    9.13    1.88      
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   (50,000)   2.00    1.22      
Outstanding at December 31, 2022   485,000   $8.81   $2.43    4.0 
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   -    -    -      
Outstanding at December 31, 2023   485,000   $8.81   $1.29    3.0 

 

The intrinsic value of warrants exercised during the years ended December 31, 2023 and 2022, respectively, was $0 and approximately $0.3 million. The aggregate intrinsic value of outstanding warrants at December 31, 2023 was approximately $0.

 

The total number of warrants exercisable at December 31, 2023 is 20,000. The ability to exercise the approximately 465,000 warrants issued in connection with acquisitions in prior years is contingent upon the achievement of certain development and revenue milestones on or before January 1, 2027. There was no unrecognized stock-based compensation expense related to warrants.

 

Stock-Based Compensation Expense

 

The Company recognized stock-based compensation expense as follows:

 

   2023   2022 
   Years Ended December 31, 
   2023   2022 
Cost of sales  $46,586   $63,058 
Sales and marketing   2,153,974    1,866,116 
General and administrative   4,933,822    4,050,967 
Research and development   1,202,473    1,563,082 
Total stock-based compensation expense  $8,336,855   $7,543,223 

 

Note 11 – Income Taxes

 

The components of the provision (benefit) for income taxes consists of the following for the years ended December 31, 2023 and 2022:

 

   2023     2022 
   Year Ended December 31, 
   2023    2022 
Current:          
Federal  $84,435   $563,821 
State   (540,240)   (266,248)
Total current  $(455,805)  $297,573 
Deferred:          
Federal   (7,228,611)   (3,945,090)
State   (2,068,509)   (961,468)
Change in valuation allowance   6,975,234    - 
Total deferred   (2,321,886)   (4,906,558)
Total income tax benefit  $(2,777,691)  $(4,608,985)

 

51
 

 

A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:

 

   2023   2022 
   Year Ended December 31, 
   2023   2022 
Federal income tax expense at statutory rate   21.0%   21.0%
State income tax expense, net of federal tax benefit   1.6%   4.8%
Permanent differences:          
- Foreign derived intangible income deduction   0.0%   1.4%
- Stock based compensation   -3.5%   -3.6%
- Contingent consideration remeasurement   0.6%   8.8%
- Goodwill impairment   0.0%   -17.1%
- Other permanent differences   -0.2%   -0.6%
Research and development credits   4.6%   11.1%
Change in uncertain tax positions   1.2%   -2.1%
Change in valuation allowance   -18.3%   0.0%
Other   0.3%   0.8%
Effective income tax rate   7.3%   24.5%

 

Net deferred tax liabilities consist of the following components as of December 31, 2023 and 2022:

 

   2023   2022 
   December 31, 
   2023   2022 
Deferred tax assets:          
Accrued liabilities  $58,158   $98,141 
Reserves and allowances   734,631    765,004 
Deferred compensation   620,551    566,076 
Section 174 costs   7,337,629    3,460,159 
Lease liability   742,131    85,899 
UNICAP   43,943    168,936 
Net operating loss carryforwards   4,040,601    - 
Research and development credits   1,688,255    - 
Total gross deferred tax assets   15,265,899    5,144,215 
Less valuation allowance   (6,938,829)   - 
Total deferred tax assets   8,327,070    5,144,215 
Deferred tax liabilities:          
Property and equipment, net   (672,416)   (609,261)
Intangibles, net   (6,552,255)   (6,608,914)
Prepaids   (329,768)   (156,053)
Right of use asset   (736,226)   (91,873)
Other comprehensive income   (36,405)   (96,101)
Other   -    - 
Total deferred tax liabilities   (8,327,070)   (7,562,202)
           
Net deferred tax liability  $-   $(2,417,987)

 

At December 31, 2023, the Company had federal net operating loss carryforwards of $16.3 million and federal research and development credit carryforwards of $1.4 million. At December 31, 2023, the Company had state net operating loss carryforwards of $16.9 million and $0.8 million of state research and development credit carryforwards. If unused, the state research credit carryforward will expire in 2037.

 

52
 

 

ASC Topic 740-10-05 requires that the impact of a tax position be recognized in the financial statements if that position is more likely than not of being sustained on audit, based on the technical merits of the position. Our unrecognized tax benefit balances included $1,078,431 at December 31, 2023 and $1,469,577 at December 31, 2022 of tax positions that, if recognized, would impact our effective tax rate. The Company expects no material changes to the liability for unrecognized tax benefits in the next 12 months. Interest and penalties associated with uncertain tax positions are recorded as a component of income tax expense. A reconciliation of the beginning and ending amount of unrecognized benefits is as follows:

 

   December 31, 
   2023   2022 
Unrecognized tax benefits at the beginning of the year  $1,469,577   $1,067,853 
Gross increases - current year tax positions   273,569    1,045,590 
Gross increases - prior year tax positions   66,127    34,035 
Gross decreases - prior year tax positions   (730,842)   (677,901)
Unrecognized tax benefits at end of year  $1,078,431   $1,469,577 
           
Interest and penalties in year-end balance  $100,162   $34,035 

 

The Company is subject to taxation in the United States and other state jurisdictions. The tax years from December 31, 2020 through December 31, 2023 remain open to examination for federal income tax purposes and by the other major taxing jurisdictions to which the Company is subject. The Company is not currently under examination by any taxing authority.

 

Note 12 – Commitments and Contingencies

 

Lease Obligations

 

The Company leases administrative, R&D, sales and marketing and manufacturing facilities under non-cancellable operating leases and leases cancellable with one month notice. The Company expenses the cancelable leases in the period incurred in accordance with the practical expedient elected. During the year December 31, 2023, the Company amended two operating leases to extend the lease term and entered into two new operating leases. As a result, the Company recognized additional operating lease liabilities and corresponding operating right-of-use assets of $3,203,146.

 

For the year ended December 31, 2023, components of lease expense are summarized as follows:

 

  

Year Ended

December 31, 2023

 
Operating lease costs  $813,743 
Short-term lease costs   198,261 
Total lease costs  $1,012,004 

 

As of December 31, 2023, the maturities of the Company’s lease liabilities are as follows:

 

  

Year Ending

December 31,

 
2024  $996,676 
2025   1,018,383 
2026   714,630 
2027   300,591 
Thereafter   308,462 
Total lease payments   3,338,742 
Less: imputed interest   348,175 
Present value of operating lease liabilities   2,990,567 
Less: current portion   838,387 
Long-term portion  $2,152,180 

 

53
 

 

Other information related to operating leases was as follows:

 

  

Year Ended

December 31, 2023

 
Cash paid for operating leases included in operating cash flows  $954,013 
Remaining lease term of operating leases   3.7 years  
Discount rate of operating leases   6.2%

 

Litigation

 

Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.

 

The Company is a defendant in two class action claims and three derivative actions claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The plaintiffs demand compensatory damages sustained as a result of the Company’s alleged wrongdoing in an amount to be proven at trial. The Company is also a party to two civil actions, one in the US and the other in the United Kingdom. Each of the civil actions is based on breach of contract claims against the Company. The Company believes these lawsuits are without merit and intends to defend the cases vigorously. The Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in these cases. As of the date of this report, the Company does not believe it is probable that these cases will result in an unfavorable outcome; however, if an unfavorable outcome were to occur in these cases, it is possible that the impact could be material to the Company’s results of operations in the period(s) in which any such outcome becomes probable and estimable.

 

Note 13 – Share Repurchase Program

 

In March 2022, the Company’s board of directors authorized a share repurchase program that would allow the Company to repurchase up to $30.0 million of CODX common stock. The repurchase program does not obligate the Company to acquire any particular number of common shares, and the repurchase program may be suspended or discontinued at any time at the Company’s discretion. The timing and amount of any share repurchases under the share repurchase program will be determined by Co-Diagnostics’ management at its discretion based on ongoing assessments of the capital needs of the business, the market price of the Company’s common stock, corporate and regulatory requirements, and general market conditions.

 

For accounting purposes, common stock repurchased under the stock repurchase program is recorded based upon the transaction date of the applicable trade. Such repurchased shares are held in treasury and are presented using the cost method. These shares are not retired and are considered issued but not outstanding. The following table shows the changes in treasury stock for the periods presented:

 

   Year Ended 
   December 31, 2023 
Balance, beginning of period   3,881,658 
Repurchases of common stock   967,020 
Balance, end of period   4,848,678 

 

Note 14 – Related Party Transactions

 

The Company employs one person who is related to current or former executive officers. Seth Egan is the Company’s Director of Sales and Marketing, and is the son of Dwight Egan, the Company’s President and Chief Executive Officer and Chairman of the Board. During the year ended December 31, 2023, the total compensation paid to this person, including salaries, bonuses, and the grant date fair value of equity awards which vest over three years, was $0.6 million. The Company also uses the services of Winston Egan as an independent contractor for sales operations consulting. Winston Egan is also the son of Dwight Egan, the Company’s President and Chief Executive Officer and Chairman of the Board. During the year ended December 31, 2023, the total compensation paid to this contractor, comprised of consulting fees, was $0.1 million.

 

In August 2023, the Company entered into a services agreement with CoSara, the Company’s equity method investment, under which CoSara provides certain research and development consulting and support services. During the year ended December 31, 2023, the Company recognized $0.2 million of expense related to this agreement.

 

Note 15 – Subsequent Events

 

None.

 

54
 

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

 

None.

 

ITEM 9A. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We maintain a set of disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in rules and forms adopted by the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

 

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2023. Based on the evaluation, management has concluded that our disclosure controls and procedures are effective as of December 31, 2023 to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of our financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles.

 

Changes in Internal Control Over Financial Reporting

 

There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a- 15(f) and 15d-15(f) under the Exchange Act) during the fourth quarter of 2023 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

Management’s Annual Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Our management, including our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2023. In making its evaluation, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control – Integrated Framework (2013).

 

Based on this evaluation, management determined that our internal control over financial reporting was effective as of December 31, 2023.

 

This Annual Report does not include an attestation report by our independent registered public accounting firm regarding internal control over financial reporting since we are a non-accelerated filer. Management’s report was not subject to attestation by our registered public accounting firm pursuant to rules of the SEC that permit non-accelerated filers to provide only management’s report in the 10-K.

 

55
 

 

Inherent Limitations on Effectiveness of Controls

 

Our management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are intended to be designed to provide reasonable assurance of achieving their objectives. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost–effective control system, misstatements due to error or fraud may occur and not be detected.

 

ITEM 9B. OTHER INFORMATION

 

During the three months ended December 31, 2023, none of our directors or officers adopted or terminated a “Rule 10-b5-1 trading arrangement” or “non-Rule 10-b5-1 trading arrangement” as each term is identified in Item 408 of Regulation S-K.

 

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.

 

None.

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

 

The following table sets forth the names, ages and positions of our executive officers and directors as of March 12, 2024. The following is information on the business experience of each director and executive officer now serving and a discussion of the qualifications, attributes and skills that led to the board of directors’ conclusion that each one is qualified to serve as a director or as an executive officer as the case may be. Executive officers serve at the discretion of the board of directors.

 

Name   Age   Position
Dwight Egan   70   Chief Executive Officer, President and Chairman of the Board
Brian Brown   48   Chief Financial Officer and Secretary
Eugene Durenard   54   Director
James Nelson   71   Director
Richard Serbin   79   Director
Edward Murphy   59   Director

 

The following is a brief summary of the background of each of our executive officers.

 

Dwight Egan serves as our President and Chief Executive Officer and has been an officer and director of the Company since April 2013. Mr. Egan has been engaged in private investment business from February 1999 to the present. He was a senior executive at Data Broadcasting Corporation, a leading provider of wireless, real-time financial market data, news and sophisticated fixed- income portfolio analytics to 27,000 individual and professional investors from 1995 to 1999. He co-founded and served as CEO and Chairman of the Board of Broadcast International, Inc. from 1984 to 1995, when Data Broadcasting Corporation acquired Broadcast International and created CBS MarketWatch, a leading financial news site and participated in its initial public offering. Mr. Egan’s prior experience in executive leadership positions with public companies and working with capital markets qualifies him to serve as our Chairman, President and Chief Executive Officer.

 

Brian Brown became our Chief Financial Officer in February 2021. From July 2020 until February 2021, Mr. Brown served as the Chief Financial Officer of A-Core Concrete Cutting, Inc. where his duties included overseeing the company’s accounting and finance departments, mergers and acquisitions and responsibility for financial forecasting and budgeting. From January 2020 to July 2020, Mr. Brown was an independent consultant. From August 2019 to December 2019, Mr. Brown served as the Vice President of Accounting, Treasury and Investor Relations at Sportsman’s Warehouse Holdings, Inc., a public company reporting on Nasdaq Global Select under the symbol SPWH, where his duties included overseeing the company’s accounting, treasury and investor relations departments, preparing the company’s annual, quarterly and current reports with the SEC, overseeing all aspects of the company’s annual audit, including, but not limited to, the preparation and review of audit support schedules, preparation of financial statements and footnotes, and providing support to the company’s independent auditors. From October 2009 to August 2019, Mr. Brown served as the Director of Finance of Sportsman’s Warehouse Holdings, Inc. where he assisted with the company’s initial public offering in April 2014 as well as effecting private and secondary public offerings, acquisitions of a group of retail stores and preparing the company’s periodic and current reports with the SEC and complying with the Sarbanes Oxley Act. From May 2005 to October 2009, Mr. Brown served as the Corporate Controller of Franklin Covey Products where he developed and maintained the company’s internal controls over financial reporting structure in accordance with the control standards required under Section 404 of the Sarbanes Oxley Act. From July 2001 to May 2005, Mr. Brown served as an Assurance Senior at KPMG, LLP where he provided audit services to various clients in multiple industries. Mr. Brown holds a Bachelor of Arts in Accounting and Masters of Professional Accountancy from the University of Utah. Mr. Brown is a licensed CPA in Utah.

 

56
 

 

The following is a brief summary of the background of each of our directors:

 

Eugene Durenard has been a member of our board of directors since June 2019. Dr. Durenard is the Founder and CEO of Hyperbolic Holdings, a Swiss-based holding, management consulting and strategy advisory company specialized in healthcare. For the last 7 years he has been working with family offices on direct investments and philanthropy focused on life sciences. He serves on the advisory board of several private companies in the biotech and MedTech sectors. After an initial career in proprietary research and trading at Salomon Brothers and Credit Suisse in London, he co-founded Orion Investment Management in Bermuda specializing in quantitative asset and liability management for institutions and private clients. He subsequently sold it to Capital G Bank and co-headed their asset management. Dr. Durenard spent several years establishing personal connections with representatives of 40+ clusters of life science innovation, families operating healthcare businesses and industry leaders globally. He regularly visits labs and incubators, meets with leading scientists and innovators in order to keep abreast of current trends and developments. His advice is based on a thorough analysis that combines in-depth knowledge of science, competitive forces and financial expertise. He has published several articles in asset-liability management industry magazines as well as the book “Professional Automated Trading — Theory and Practice” (Wiley 2013). He has a PhD in Mathematics from Harvard University. Dr. Durenard brings a thorough multi-asset class investment and entrepreneurial experience spanning 25 years to the Company’s board of directors.

 

James Nelson has been a member of our board of directors since June 2019. Mr. Nelson is the retired Chairman and CEO of Sunworks, Inc., a NASDAQ traded commercial, agriculture, and residential solar Integrator which he helped found in October 2010. Mr. Nelson spent most of his career working in private equity as a general partner with Peterson Partners and with Millennial Capital Partners. In addition to his investment and financial responsibilities, he served as CEO of two of his firms’ portfolio companies. Prior to his years in private equity, Mr. Nelson served as Vice President of Marketing at Banana Republic, where he managed company-wide marketing, as well as the company’s international expansion initiative. He was also general manager for Banana Republic’s catalog division. He was Vice President of Marketing and Corporate Development at Saga Corporation, a multi-billion-dollar food service company. Mr. Nelson began his executive career over 35 years ago at Bain and Company, a business strategy consulting firm, where he managed teams of consultants on four continents. Mr. Nelson received his MBA from Brigham Young University, where he graduated summa cum laude and was named the Outstanding Master of Business Administration Graduate. Mr. Nelson’s advice to the board of directors from his experiences as a chief executive officer and strategic advisor is useful to the board of directors.

 

Richard Serbin has been a member of our board of directors since May 2017. Mr. Serbin currently serves as a consultant to many companies in the healthcare industry. He was the President of Corporate Development and In-House Legal Counsel at Life Science Institute, LLC, from June 1, 2013 to July 15, 2014. He was appointed to the Advisory Board of Cure Pharmaceutical in January 2017 and has been a Member of Advisory Board at Prime Access, Inc. since September 2015. Mr. Serbin has been a Director at Rapid Nutrition Plc since November 18, 2014. He served as Director at Viropro Inc. from May 2013 to June 2014. He was Head of Business Advisory Board at Mazal Plant Pharmaceuticals Inc. from October 2006 to September 2007 and also served as its Member of Business Advisory Board. He served as Chief Executive Officer of Optigenex Inc. from July 2002 to September 15, 2005 and a director from July 2004 to September 2005. From January 1999 until July 2002 Mr. Serbin served as a consultant to various pharmaceutical companies. He served as the President of Bradley Pharmaceuticals. He served as Vice President of Corporate Development at Ortho Pharmaceuticals, a Johnson & Johnson subsidiary, and practiced Patent and FDA law at Revlon Johnson & Johnson and Schering-Plough. He served as Patent Attorney for Schering Plough Corporation and Chief FDA Counsel for Revlon Corporation and Johnson and Johnson Corporation. Subsequently, he worked at Revlon Corporation, as its Chief Food, Drug and Cosmetic Counsel. He founded Radius Scientific Corporation. He was J&J’s Vice President of Corporate Development, and later led a successful public offering venture based on technology developed at Stanford Medical School. Mr. Serbin spent a large portion of his career focusing on international markets and clients. While at J&J, Mr. Serbin served on the board of directors of 16 US and international subsidiary companies, including Ethicon, Ortho, J&J Consumer Products, Pittman-Moore, Mc Neil, and J&J Development Corporation. He worked on multiple international acquisitions and strategic relationships, and sat on the board of directors of several of its international subsidiaries, including those in India, Hong Kong, Japan, Taiwan, Germany, and England. Mr. Serbin has a B.S. and a B. Pharmacy from Rutgers University and Rutgers University College of Pharmacy, a J.D. degree from Seton Hall Law School and a Master’s Degree in Trade Regulations and Law from NYU Law School. Mr. Serbin’s experience in business, law and medicine and knowledge gained as an advisor to the healthcare industry is critical to our board of directors as we continue to commercialize our products.

 

Edward Murphy has been a member of our board of directors since June 2019. Since December 1999, Mr. Murphy has served as a senior vice president and a partner of Dover Investments Ltd., a private investment firm. Throughout his career, Mr. Murphy’s duties have included investment analysis of various types of investment projects in real estate and financial services. Currently, Mr. Murphy serves on the board of directors of several Canadian publicly reporting companies that have interests in various industries. He has been a Director at Empire Minerals Corporation Inc. since January 2016, at Digicrypts Blockchain Solutions Inc. from June 2011 to November 2022, at Lakefield Marketing Corporation since February 2018, CEO/CFO and Director of Credo Resources Inc. since September 2019, at the Mosport Park Entertainment Corporation since April 30, 1997, at Essex Oil Ltd. Since July 2021, and at Darkhorse Technologies Ltd. Since November 2021. He served as a Director at Aurquest Resources from May 2003 to December 2017. Mr. Murphy’s experience in the capital markets outside the United States and his involvement in investment analysis is a benefit to the board of directors.

 

Dwight Egan – See narrative description above.

 

57
 

 

Involvement in Certain Legal Proceedings

 

To the best of our knowledge, none of our directors or executive officers has been involved in any bankruptcy or criminal proceedings (other than traffic and other minor offenses) or been subject to any of the items set forth under Item 401(f) of Regulation S-K, nor have there been any judgments or injunctions brought against any of our directors or executive officers during the last ten years that we consider material to the evaluation of the ability and integrity of any director or executive officer.

 

Board and Committee Matters

 

Our board of directors has five members. The Chairman of the Board and our Chief Executive Officer, Dwight Egan, is a member of the board and is a full-time employee of the Company. Eugene Durenard, Edward Murphy, James Nelson and Richard Serbin are non-employee directors, and the board has determined that these persons (who constitute a majority of the board) are “independent directors” under the criteria set forth in Rule 5605(a)(2) of the Nasdaq Listing Rules. The board met nine times during the year ended December 31, 2023. All directors attended more than seventy-five percent (75%) of the meetings of the board and committee meetings of which such director was a member held during 2023.

 

We maintain an audit committee of the board, a compensation committee of the board, a corporate governance committee of the board and a nominating committee of the board, each of which is discussed below. Our board of directors may from time to time establish other standing committees. In addition, from time to time, special committees may be established under the direction of our board of directors when necessary to address specific issues.

 

The following table sets forth a description of the four permanent board committees and the chairpersons and members of those committees, all of whom are independent directors:

 

Committee   Independent Chairperson   Independent Members
         
Audit Committee   Eugene Durenard   Edward Murphy   James Nelson   Richard S. Serbin
                 
Compensation Committee   Richard S. Serbin   Edward Murphy   Eugene Durenard   James Nelson
                 
Governance Committee   James Nelson   Edward Murphy   Eugene Durenard   Richard S. Serbin
                 
Nominating Committee   Edward Murphy   James Nelson   Eugene Durenard   Richard S. Serbin

 

Audit Committee and Financial Expert

 

Our audit committee currently is comprised of Messrs. Durenard, Nelson, Murphy and Serbin with Mr. Durenard serving as chairperson of the audit committee. The functions of the audit committee include engaging an independent registered public accounting firm to audit our annual financial statements, reviewing the independence of our auditors, the financial statements and the auditors’ report, and reviewing management’s administration of our system of internal control over financial reporting and disclosure controls and procedures. The board of directors has adopted a written audit committee charter. A current copy of the audit committee charter is available to security holders on our website at www.codiagnostics.com. Our board has determined that all our directors that are serving on the audit committee are “independent” under the definition of independence in the Marketplace rules of the NASDAQ listing standards. The Audit Committee met four times during the year ended December 31, 2023. All committee members attended more than seventy-five percent (75%) of the meetings of the Audit Committee held during 2023.

 

Our board of directors has determined that Mr. Durenard meets the requirements of an “audit committee financial expert” as defined in applicable SEC regulations.

 

58
 

 

Compensation Committee

 

Our compensation committee currently includes Messrs. Serbin, Nelson, Murphy and Durenard with Mr. Serbin serving as chairperson of the compensation committee. The functions of the compensation committee include reviewing and approving corporate goals relevant to compensation for executive officers, evaluating the effectiveness of our compensation practices, evaluating and approving the compensation of our chief executive officer and other executives, recommending compensation for board members, and reviewing and making recommendations regarding incentive compensation and other employee benefit plans. The board of directors has adopted a written compensation committee charter. A current copy of the compensation committee charter is available to shareholders on our website at www.codiagnostics.com. Our board has determined that all of our directors serving on the compensation committee are “independent” under the definition of independence in the Marketplace Rules of the NASDAQ listing standards. The Compensation Committee met two times as a separate committee in 2023.

 

Corporate Governance Committee

 

Our Corporate Governance Committee currently includes Messrs. Nelson, Murphy, Durenard and Serbin with Mr. Nelson serving as chairperson of the Corporate Governance Committee. Among other items, the committee is tasked by the board of directors to develop and recommend to the board the Corporate Governance Guidelines of the Company and oversee compliance therewith. A current copy of the Corporate Governance committee charter is available to shareholders on our website at www.codiagnostics.com. Our board has determined all directors serving on the Corporate Governance committee are “independent” under the definition of independence in the Marketplace Rules of the NASDAQ listing standards. The Corporate Governance Committee did not meet as a separate committee in 2023, but rather, because the committee is comprised of all four independent directors, committee matters were addressed as necessary in meetings of the board the year ended December 31, 2023.

 

Nominating Committee

 

Our Nominating Committee was split from the Corporate Governance Committee in 2022 and currently includes Messrs. Nelson, Murphy, Durenard and Serbin with Mr. Murphy serving as chairperson of the Nominating Committee. The Nominating Committee has been established by the board, among other things to: assist the board in effecting board organization, membership and function including identifying qualified board nominees; assist the board in effecting the organization, membership and function of board committees including the composition of board committees and recommending qualified candidates therefor; evaluate and provide successor planning for the Chief Executive Officer and other executive officers; and develop criteria for board membership, such as independence, term limits, age limits and ability of former employees to serve on the board and the evaluation of candidates’ qualifications for nominations to the board and its committees as well as removal therefrom. The Nominating Committee did not meet as a separate committee in 2023, but rather, because the committee is comprised of all four independent directors, committee matters were addressed as necessary in meetings of the board for the year ended December 31, 2023.

 

Board Nominations

 

In considering board candidates, the board seeks individuals of proven judgment and competence who have strong reputations in their respective fields. Although we do not have a formal diversity policy, the board considers such factors as experience, education, employment history, special talents or personal attributes, anticipated participation in board activities, and geographic and diversity factors. The process for identifying and evaluating nominees would include detailed consideration of the recommendations and opinions of members of our board, our executive officers, and our stockholders. There would be no difference in the process of evaluation of candidates recommended by a stockholder and those recommended by other sources.

 

59
 

 

Our Amended and Restated Bylaws (the “Bylaws”) set forth procedures for shareholders to recommend nominees to the Company’s board. Nominations of persons for election to the board of directors to be considered by the stockholders may be made at an annual meeting of stockholders (i) pursuant to the Company’s notice of meeting, (ii) by or at the direction of the board of directors, or (iii) by any stockholder of the Company who (A) was a stockholder of record at the time of giving of the notice, (B) is entitled to vote with respect to such matter at the meeting, and (C) complies with the notice procedures set forth in the Bylaws.

 

The following is a summary of key provisions from our Bylaws. For nominations to be properly brought before an annual meeting by a stockholder, the stockholder making such nominations must have given timely notice in writing to the secretary of the Company. To be timely, a stockholder’s notice shall be delivered to the secretary at the principal executive offices of the Company not later than the close of business on the 75th day nor earlier than the close of business on the 125th day prior to the first anniversary of the preceding year’s annual meeting; provided, however, that in the event that the date of the annual meeting is more than 30 days before or more than 60 days after such anniversary date, notice by the stockholder to be timely must be so delivered not later than the close of business on the later of (x) the 75th day prior to the scheduled date of such annual meeting or (y) the 15th day following the day on which public announcement of the date of such meeting is first made by the Company. To be in proper form, a stockholder’s notice to the secretary must: set forth, as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made (A) the name and address of such stockholder, as they appear on the Company’s books, and of such beneficial owner, if any, (B) the class or series and number of shares of the Company that are, directly or indirectly, owned beneficially and of record by such stockholder and such beneficial owner, if any, as of the date of such notice, and (C) any other information relating to such stockholder and beneficial owner, if any, that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for, as applicable, the proposal and/or for the election of directors in a contested election pursuant to Section 14 of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the “Exchange Act”). In addition, shareholders who intend to solicit proxies in support of director nominees other than the company’s nominees must also comply with the additional requirements of Rule 14a-19(b).

 

The notice shall set forth, as to each person, if any, whom the stockholder proposes to nominate for election or reelection as a director (A) all information relating to such person that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for election of directors in a contested election pursuant to Section 14 of the Exchange Act (including such person’s written consent to being named in the proxy statement as a nominee and to serving as a director if elected) and (B) a description of all direct and indirect compensation and other monetary agreements, arrangements and understandings during the past three years, and any other relationships, between or among such stockholder and beneficial owner, if any, and their respective affiliates and associates, or others acting in concert therewith, on the one hand, and each proposed nominee, and his or her respective affiliates and associates, or others acting in concert therewith, on the other hand, including, without limitation all information that would be required to be disclosed pursuant to Rule 404 promulgated under Regulation S-K if the stockholder making the nomination and any beneficial owner on whose behalf the nomination is made, if any, or any affiliate or associate thereof or person acting in concert therewith, were the “registrant” for purposes of such rule and the nominee were a director or executive officer of such registrant; and with respect to each nominee for election or reelection to the board of directors, include the completed and signed questionnaire, representation, and agreement required by the Bylaws. The Company may require any proposed nominee to furnish such other information as may reasonably be required by the Company to determine the eligibility of such proposed nominee to serve as an independent director of the Company or that could be material to a reasonable stockholder’s understanding of the independence, or lack thereof, of such nominee.

 

Communication with the Board

 

We have not, to date, developed a formal process for shareholder communications with the board of directors. We believe our current informal process, in which any communication sent to the board of directors, either generally or in care of the chief executive officer, secretary or other corporate officer or director, is forwarded to all members of the board of directors, has served the board’s and the shareholders’ needs.

 

Conflicts of Interests

 

On an annual basis, each director and executive officer is obligated to complete a director and officer questionnaire that requires disclosure of any transactions with our company, including related person transactions reportable under SEC rules, in which the director or executive officer, or any member of his or her immediate family, have a direct or indirect material interest. Under our company’s standards of conduct for employees, all employees, including the executive officers, are expected to avoid conflicts of interest. Pursuant to our code of ethics for the chief executive officer and senior finance officers (as discussed below), such officers are prohibited from engaging in any conflict of interest unless a specific exception has been granted by the board. All of our directors are subject to general fiduciary standards to act in the best interests of our company and our shareholders. Conflicts of interest involving an executive officer or a director are generally resolved by the board.

 

60
 

 

Role of the Board in Risk Oversight

 

Risk is inherent with every business, and how well a business manages risk can ultimately determine its success. Management is responsible for the day-to-day management of the risks that we face, while our board of directors, as a whole and through its committees, has responsibility for the oversight of risk management. In its risk oversight role, our board of directors is responsible for satisfying itself that the risk management processes designed and implemented by management are adequate and functioning as designed.

 

Our board of directors does not have a standing risk management committee, but rather administers this oversight function directly through our board of directors as a whole, as well as through various standing committees of the board of directors that address risks inherent in their respective areas of oversight. In particular, our board of directors is responsible for monitoring and assessing strategic risk exposure, including a determination of the nature and level of risk appropriate for us. Our Audit Committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The Audit Committee also monitors oversight of the performance of our internal audit function. Our Corporate Governance Committee monitors the effectiveness of our corporate governance guidelines, including whether they are successful in preventing illegal or improper liability-creating conduct. Our Compensation Committee assesses and monitors whether any of our compensation policies and programs have the potential to encourage excessive risk-taking or promote behaviors contra to our Code of Business Conduct. Our Nominating Committee assesses and monitors the effectiveness of the board and its committees and evaluates board members and nominees for election to the board and succession planning for the CEO and other executive officers.

 

Code of Ethics

 

We have adopted a code of ethics for our principal executive officer, principal financial officer, controller, or persons performing similar functions. A copy of the code of ethics is included on our website at www.codiagnostics.com.

 

Family Relationships

 

There are no family relationships among our directors and executive officers.

 

ITEM 11. EXECUTIVE COMPENSATION

 

We are a “smaller reporting company” as defined in the rules and regulations of the SEC. As a smaller reporting company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable, in general, to public companies that are not smaller reporting companies. Accordingly, this Report includes reduced disclosure about our executive compensation arrangements.

 

Summary Compensation Table

 

The table below summarizes the total compensation paid or earned by each of the named executive officers in their respective capacities for the fiscal years ended December 31, 2023 and 2022. We have omitted in this report certain columns otherwise required to be included because there was no compensation made with respect to such columns, as permitted by applicable SEC regulations.

 

Name and Principal Position  Year  Salary   Bonus (1)   Stock Awards (2)   All Other  Comp   Total Compensation 
Dwight Egan President & Chief Executive Officer  2023  $375,000   $40,750   $845,550   $-   $1,261,300 
   2022  $366,146   $146,245   $1,454,750   $-   $1,967,141 
                             
Brian Brown Chief Financial Officer and Secretary  2023  $306,923   $32,000   $701,550   $-   $1,040,473 
   2022  $280,875   $106,647   $1,190,250   $     -   $1,577,772 

 

(1) Bonuses for the year ended December 31, 2023 include accrued bonus payments of $20,750 to Mr. Egan and $17,000 to Mr. Brown that were paid in January 2024.
(2) The amounts reported in this column represent the aggregate grant date fair value of the restricted stock units, or RSUs, granted under our 2015 Plan as computed in accordance with FASB ASC Topic 718. Note that the amounts reported in this column reflect the accounting value for these equity awards and do not correspond to the actual economic value that may be received from the equity awards as the RSUs vest over three years.

 

Narrative Disclosure to Summary Compensation Table: We do not have written employment agreements with any of our executive officers. All of our executive officers serve on an at-will basis. The base salaries for our named executive officers were determined by our compensation committee after reviewing a number of factors, including: the responsibilities associated with the position, the seniority of the executive’s position, the base salary level in prior years, and our financial position; and for executive officers other than our Chief Executive Officer, recommendations made by our Chief Executive Officer. By utilizing a combination of objective and subjective performance factors critical to our success, the board will award cash bonuses intended to incentivize our executive officers to achieve results that benefit them and the Company. Performance factors include the achievement of predetermined financial performance objectives, adherence to financial discipline measures and achievement of business development, product development and long-term business stability. The board may modify or re-weight the objectives during the course of the fiscal year, if necessary, to reflect changes in our business plan.

 

61
 

 

Outstanding Equity Awards at Fiscal Year-End 2023

 

The following table contains certain information concerning outstanding equity awards for the Named Executive Officers as of December 31, 2023.

 

   Option Awards   Stock Awards 
   Number of Securities
Underlying Unexercised
Options (#)		   Option
Exercise		   Option
Expiration		   Number of Shares or Units of Stock That Have Not Vested   Market Value of Shares or Units of Stock That Have Not Vested   Number of Unearned Shares, Units or Other Rights That Have Not Vested   Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested 
Name  Exercisable   Unexercisable   Price   Date   (#)   ($) (1)   (#)   ($) 
Dwight Egan   50,000    -   $2.63    09/20/28    -    -    -    - 
    50,000    -   $1.10    09/02/29    -    -    -    - 
    -    -    -    -    20,833(2)  $27,708           -            - 
    -    -    -    -    137,500 (3)  $182,875    -    - 
    -    -    -    -    103,333 (4)  $137,433    -    - 
    -    -    -    -    229,167 (5)  $304,792    -    - 
                                         
Brian Brown   -    -    -    -    16,667(2)  $22,167    -    - 
    -    -    -    -    112,500(3)  $149,625    -    - 
         -    -    -    86,667(4)  $115,267    -    - 
         -    -    -    187,500(5)  $249,375    -    - 

 

(1) Based on $1.33 per share, which was the closing price of our common stock on December 31, 2023.

(2) Consists of restricted stock units granted on 8/12/2021, which vest in 6 installments commencing on 11/23/2021 and continuing every six months thereafter.

(3) Consists of restricted stock units granted on 6/6/2022, which vest in 6 installments commencing on 11/23/2022 and continuing every six months thereafter.

(4) Consists of restricted stock units granted on 1/13/2023, which vest in 6 installments commencing on 5/23/2023 and continuing every six months thereafter.

(5) Consists of restricted stock units granted on 5/15/2023, which vest in 6 installments commencing on 11/23/2023 and continuing every six months thereafter.

 

Potential Payments Upon Termination or Change of Control

 

At the recommendation of the compensation committee of the board of directors, the Board approved the Co-Diagnostics, Inc. Change in Control Severance Plan (the “Plan”). The Plan provides severance benefits to a select group of designated management or highly compensated participants in the event their employment or affiliation with the Company or an affiliate is terminated due to a change in control (as defined in the Plan). Participants entitled to benefits under the Plan are designated from time-to-time by the Compensation Committee pursuant to the terms of an “Award Notice,” the form of which is appended to the Plan. The Award Notice identifies the eligible participant and the Severance Multiplier (as defined in the Plan) to which the participant is entitled. The Compensation Committee approved participation in the Plan for certain executives of the Company, including the Company’s CEO, Dwight Egan, with a Severance Multiplier of three times his severance benefit and the Company’s CFO, Brian Brown, with a Severance Multiplier of two times his severance benefit.

 

Under the Plan, if a participant’s employment or affiliation is terminated without “cause” or by the participant for “good reason” (each, as defined in the Plan) during the two-year period following a change in control, a participant will be entitled to a severance benefit equal to the participant’s Severance Multiplier as set forth in the participant’s Award Notice, times the sum of: (i) the participant’s annual base salary; and (ii) the greater of the participant’s target bonus or the average of the three highest actual annual cash bonuses paid to participant over the five preceding completed years.

 

The participant’s receipt of any of the payments or benefits is subject to the participant’s delivery to the Company of a separation agreement of the type that are ordinarily entered into in similar situations, in a form acceptable to the Company, in its sole discretion, which separation agreement may include a requirement for the participant to remain in the employ or service of the Company for a reasonable period of time after completion of the Change in Control transaction to assist in any transition activities for which participant’s services would be required.

 

Director Compensation

 

We use a combination of cash and stock-based incentive compensation to attract and retain qualified candidates to serve on its board of directors. In setting director compensation, we consider the significant amount of time that directors expend in fulfilling their duties as well as the skill level required by our members of the board.

 

62
 

 

The table below summarizes the compensation paid or accrued by us to each of our non-employee directors for the fiscal year ended December 31, 2023.

 

Name  Fees Earned or Paid in Cash   Stock Awards:
Value of Restricted
 Stock Units (1)		   Total 
Richard Serbin (2)  $100,000   $198,000   $298,000 
James Nelson (3)  $100,000   $198,000   $298,000 
Edward Murphy (4)  $100,000   $198,000   $298,000 
Eugene Durenard (5)  $100,000   $198,000   $298,000 

 

(1) The amounts reported in this column represent the aggregate grant date fair value of the restricted stock units, or RSUs, granted under our 2015 Plan as computed in accordance with FASB ASC Topic 718. Note that the amounts reported in this column reflect the accounting value for these equity awards and do not correspond to the actual economic value that may be received from the equity awards. The RSUs vested immediately upon grant.
(2) As of December 31, 2023, Mr. Serbin had 120,000 RSU awards outstanding.
(3) As of December 31, 2023, Mr. Nelson had 120,000 RSU awards outstanding.
(4) As of December 31, 2023, Mr. Murphy had 120,000 RSU awards outstanding.
(5) As of December 31, 2023, Mr. Durenard had 120,000 RSU awards outstanding.

 

Our non-employee directors receive cash compensation of $100,000 per year, paid quarterly. In 2022, they also received 70,000 RSU’s vesting 1/6th equally in May 2023, 2024, and 2025 and November 2023, 2024 and 2025. In 2023, they also received 40,000 RSU’s vesting 1/6th equally in November 2022, 2023, and 2024 and May 2023, 2024, and 2025, as well as 70,000 RSU’s vesting 1/6th equally in November 2023, 2024 and 2025 and May 2024, 2025 and 2026. In addition, non-employee directors may be entitled to receive special awards of stock options or RSUs from time to time as determined by the board. The chairman of the board and the chairperson of each of the audit, corporate governance, nomination, and compensation committees receive no additional fees for serving in such capacities. There is no additional compensation for meeting attendance. Directors who are employees of the Company receive no additional compensation for serving as directors. All stock options granted to outside directors are immediately exercisable and expire ten years from the date of grant or 30 days after the date they cease to be directors. Directors are reimbursed for ordinary expenses incurred in connection with attending board and committee meetings.

 

63
 

 

Equity Incentive Plans

 

Under our Amended and Restated 2015 Long-term Incentive Plan (the “2015 Plan”), the board of directors may issue incentive stock-based awards to employees, directors and consultants of the company. Options awarded generally expire ten years after being granted. Any stock-based awards granted vest in accordance with the vesting schedule determined by the board of directors. Should an employee’s director’s or consultant’s relationship with the company terminate before the vesting period is completed, the unvested portion of each grant is forfeited. We continue to maintain and grant awards under the 2015 Plan which will remain in effect until its expiration by its terms.

 

The purpose of our incentive plan is to advance the interests of our stockholders by enhancing our ability to attract, retain and motivate persons who are expected to make important contributions to the company by providing them with both equity ownership opportunities and performance-based incentives intended to align their interests with those of our stockholders. These plans are designed to provide us with flexibility to select from among various equity-based compensation methods, and to be able to address changing accounting and tax rules and corporate governance practices by optimally utilizing stock-based awards.

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

The following table sets forth certain information, as of March 12, 2024, with respect to the holdings of (1) each person who is the beneficial owner of more than 5% of our Common Stock, (2) each of our directors, (3) each named executive officer, and (4) all of our current directors and executive officers as a group.

 

Beneficial ownership of the common stock is determined in accordance with the rules of the Securities and Exchange Commission and includes any shares of common stock over which a person exercises sole or shared voting or investment power, or of which a person has a right to acquire ownership at any time within 60 days of March 12, 2024. Applicable percentage ownership in the following table is based on 31,259,668 shares of common stock plus, for each individual, any securities that individual has the right to acquire within 60 days of March 12, 2024.

 

The information in the table below is based on information known to us or ascertained by us from public filings made by the stockholders. Except as otherwise indicated in the table below, addresses of the director, executive officers and named beneficial owners are in care of Co-Diagnostics, Inc., 2401 S. Foothill Drive, Suite D, Salt Lake City, Utah 84109.

 

   Number of Shares Beneficially Owned   Percentage
of Class (1)		 
5% Stockholders          
Vanguard Group (1)   1,781,283    5.7%
Named Executive Officers and Directors          
Dwight Egan (2)   370,881    * 
Brian Brown   213,220    * 
Edward Murphy (3)   147,500    * 
Eugene Durenard   85,000    * 
James Nelson (4)   135,000    * 
Richard Serbin (5)   107,945    * 
All Directors and Executive Officers as a Group (6 persons)   1,059,546    3.3%

 

*Represents beneficial ownership of less than 1%.

 

(1) Information obtained from Schedule 13G/A filed with the SEC on February 13, 2024. Vanguard Group has an address of 100 Vanguard Blvd, Malvern, PA, 19355.
(2) Includes exercisable options to acquire 100,000 shares of common stock.
(3) Includes exercisable options to acquire 50,000 shares of common stock.
(4) Includes exercisable options to acquire 50,000 shares of common stock.
(5) Includes exercisable options to acquire 20,445 shares of common stock.

 

Equity Compensation Plan Information

 

Plan Category  (a) Number of Shares to be Issued upon Exercise of Outstanding Options and Rights   (b) Weighted-average Exercise Price of Outstanding Options and Rights   (c) Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Referenced in Column (a)) 
Equity compensation plans approved by stockholders       3,966,069     (1)  $             2.19       (2)   4,357,937 
Equity compensation plans not approved by stockholders   -   $-    - 
Total       3,966,069     (1)  $             2.19       (2)   4,357,937 

 

(1) Includes options and restricted stock units outstanding under our 2015 Equity Incentive Plan.
   
(2) Represents weighted-average exercise price per share of common stock acquirable upon exercise of outstanding stock options.

 

64
 

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

The Company employs one person who is related to current or former executive officers. Seth Egan is the Company’s Director of Sales and Marketing, and is the son of Dwight Egan, the Company’s President and Chief Executive Officer and Chairman of the Board. During the year ended December 31, 2023, the total compensation paid to this person, including salaries, bonuses, and the grant date fair value of equity awards which vest over three years, was $648,201. The Company also uses the services of Winston Egan as an independent contractor for sales operations consulting. Winston Egan is also the son of Dwight Egan, the Company’s President and Chief Executive Officer and Chairman of the Board. During the year ended December 31, 2023, the total compensation paid to this contractor, comprised of consulting fees, was $120,000.

 

Policy for Review of Related Party Transactions

 

The review of transactions with related persons policy is set forth in our Corporate Governance Committee Charter. The Corporate Governance Committee is to oversee the administration of any related party transactions policy in effect with respect to transactions in which the Company is a participant and involving directors, nominees for director, executive officers of the Company or holders of more than 5% of the Company’s common stock or immediate family members of any such person.

 

Director Independence

 

For information regarding the independence of our directors, see “Directors, Executive Officers and Corporate Governance” in Part III, Item 10 of this Form 10-K.

 

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

The aggregate fees and expenses for professional services rendered by our principal accounting firm, Tanner LLC for 2023 and Haynie & Company for 2022, are separately presented and are as follows:

 

   Years Ended December 31, 
   2023   2022 
Audit fees  $154,811   $136,600 
Audit related fees   -    - 
Other consulting fees   287,838    - 
Tax fees   -    - 
Total fees  $442,649   $136,600 

 

Audit fees consist of fees for professional services provided in connection with the audit of our annual consolidated financial statements, review of our quarterly consolidated financial statements and our offerings.

 

Other consulting fees relate to fees for products and services other than the services reported above and consist of federal and state research tax credit consulting services (at a fixed fee).

 

The audit committee has adopted a policy that requires advance approval of all services performed by the independent auditor when fees are expected to exceed $15,000. The audit committee has delegated to the audit committee chairperson, Mr. Durenard, the authority to approve services, subject to ratification by the audit committee at its next committee meeting. All fees incurred were pre-approved by the audit committee.

 

65
 

 

PART IV

 

Item 15. Exhibits and Financial Statement Schedules.

 

(a) The following documents are filed as part of this Annual Report on Form 10-K:

 

  (1) Financial Statements. The Consolidated Financial Statements filed as part of this Annual Report on Form 10-K are included in Part II, Item 8 of this Annual Report on Form 10-K.
     
  (2) Financial statement schedules. There are no financial statements schedules included because they are either not applicable or the required information is shown in the consolidated financial statements or the notes thereto.
     
  (3) Exhibits. The exhibits required by Item 601 of Regulation S-K and Item 15(b) of this Annual Report are listed in the Exhibit Index below. The exhibits listed in the Exhibit Index are incorporated by reference herein.

 

Exhibit

Number

   Exhibit Description  

Filed with this

Report

  

Incorporated by

Reference herein from Form or Schedule

   Filing Date  

SEC File/Reg.

Number

2.1*+   Agreement and Plan of Merger by and between Co-Diagnostics, Inc, IDMO Acquisition Corp., Idaho Molecular Inc., and Company Representative dated as of December 21, 2021.       Form 8-K (Exhibit 2.1)   12/23/21   001-38148
                     
2.1.2   Amendment to Agreement and Plan of Merger by and among Co-Diagnostics, Inc., Idaho Molecular, Inc., and Kirk Ririe, as Company Representative       Form 8-K (Exhibit 2.2)   06/16/22   001-38148
                     
2.2*+   Agreement and Plan of Merger by and between Co-Diagnostics, Inc, ACI Acquisition Corp., Advanced Conceptions, Inc., and Company Representative dated as of December 21, 2021       Form 8-K (Exhibit 2.2)   12/23/21   001-38148
                     
2.2.1   Amendment to Agreement and Plan of Merger by and among Co-Diagnostics, Inc., Advanced Conceptions, Inc., and Richard Abbott, as Company Representative       Form 8-K (Exhibit 2.1)   06/16/22   001-38148
                     
 3.1    Articles of Incorporation       Draft Registration Statement (Exhibit 3.1)   01/12/17    377-01467
                     
3.1.1   Amendment to the Articles of Incorporation       Draft Registration Statement (Exhibit 3.1.1)   01/12/17   377-01467
                     
3.1.2   Articles of Amendment to Articles of Incorporation       Form 8-K (Exhibit 3.2)   01/03/19   001-38148
                     
3.1.3   Articles of Amendment       Form 10-K (Exhibit 3.1.3)   03/24/22   001-38148
                     
3.1.3   Articles of Amendment       Form 10-K (Exhibit 3.1.3)   03/16/2023   001-38148
                     
3.2   Amended and Restated Bylaws of Co-Diagnostics, Inc.       Form 8-K (Exhibit 3.1)   04/01/22   001-38148
                     
4.1   Description of Registrant’s securities   X            
                     
4.2   Form of Indenture       Registration Statement (Exhibit 4.1)   03/16/23   333-270628
                     
10.1   Exclusive Agreement between Co-Diagnostics, Inc. and DNA Logix, Inc., dated April 18, 2014       Draft Registration Statement (Exhibit 10.2)   01/12/17   377-01467
                     
10.2#   Co-Diagnostics, Inc. Amended and Restated 2015 Long Term Incentive Plan       Form S-8/A   11/20/20   333-237684
                     
10.3   Form of Indemnification Agreement       Form S-1/A (Exhibit 10.13.8)   05/24/17  

333-217542

                     
10.4   Shareholders’ Agreement between Co-Diagnostics and Synbiotics Limited, dated January 27, 2017       Form S-1 (Exhibit 10.16)   04/28/17   333-217542
                     
10.5   Amended Exclusive License Agreement between Co-Diagnostics, Brent Satterfield, and DNA Logix, Inc., dated January 1, 2017       Form S-1 (Exhibit 10.17)   04/28/17   333-217542
                     
10.6   Warrant Agreement between Co-Diagnostics, Inc and VStock Transfer, LLC. Dated December 31, 2021 (ACI Warrant)       Form 10-K (Exhibit 10.6)   03/24/22   001-38148

 

66
 

 

10.7   Warrant Agreement between Co-Diagnostics, Inc and VStock Transfer, LLC. Dated December 31, 2021 (IDMO Warrant)       Form 10-K (Exhibit 10.7)   03/24/22   001-38148
                     
10.8   Form of Securities Purchase Agreement, dated February 27, 2020       Form 8-K (Exhibit 10.1)   02/27/20   001-38148
                     
10.9   Lease Agreement 2401 Foothill Drive        Form 10-K (Exhibit 10.9)   03/24/22   001-38148
                     
10.9.1   Amendment #1 to Lease       Form 10-K (Exhibit 10.9.1)   03/24/22   001-38148
                     
10.9.2   Amendment #2 to Lease        Form 10-K (Exhibit 10.9.2)   03/24/22   001-38148
                     
10.10#   Co-Diagnostics, Inc. Change in Control Plan       Form 8-K (Exhibit 10.1)   05/16/23   001-38148
                     
10.11   Commercial Lease Agreement, dated June 1, 2023, between Ozone Biotech, LLC and Co-Diagnostics, Inc.       Form 10-Q (Exhibit 10.1)   08/10/23   001-38148
                     
10.12   Commercial Lease Agreement, dated September 18, 2023, between Ge Estate, LLC and Co-Diagnostics, Inc.       Form 10-Q (Exhibit 10.1)   11/09/23   001-38148
                     
10.13   Common Stock Purchase Warrant issued to Coltrin & Associates dated October 31, 2019       Registration Statement (Exhibit 4.9)   03/16/23   333-270628
                     
10.14   Common Stock Purchase Warrant issued to Coltrin & Associates dated February 6, 2020       Registration Statement (Exhibit 4.10)   03/16/23   333-270628
                     
10.15   Common Stock Purchase Warrant issued to Coltrin & Associates dated February 6, 2020       Registration Statement (Exhibit 4.11)   03/16/23   333-270628
                     
10.16   Amendment dated July 31, 2020 to Common Stock Purchase Warrant issued to Coltrin & Associates dated October 31, 2019       Registration Statement (Exhibit 4.12)   03/16/23   333-270628
                     
14.1   Code of Ethics for Senior Financial Officers       Form 10-K (Exhibit 14.1)   03/30/20   001-38148
                     
21.1   Subsidiaries of Registrant   X            
                     
23.1   Consent of Tanner LLC   X            
                     
23.2   Consent of Haynie & Company   X            
                     
31.1   Certification of Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002   X            
                     
31.2   Certification of Principal Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002   X            
                     
32.1   Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002   X            
                     
32.2   Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002   X            
                     
97   Co-Diagnostics, Inc. Clawback Policy   X            
                     
101 SCH   Inline XBRL Taxonomy Extension Schema Document (A)   X            
                     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document (A)   X            
                     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document (A)   X            
                     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document (A)   X            
                     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document (A)   X            
                     
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)   X            
                     
(A)   iXBRL (INline Extensible Business Reporting Language) information is furnished and not filed for purposes of Section 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934.   X            

 

#Management Contract or Compensatory Plan or Arrangement

 

*Schedules and exhibits to these Exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.

 

+ Portions of Exhibit 2.1 and Exhibit 2.2 have been omitted as they contain information that (i) is not material and (ii) is the type of information the issuer both customarily and actually treats as private and confidential.

 

Item 16. Form 10-K Summary.

 

None

 

67
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  CO-DIAGNOSTICS, INC.
     
Date: March 14, 2024 By: /s/ Dwight Egan
    Dwight Egan
   

Chief Executive Officer, President and Director

(Principal Executive Officer)

     
  By: /s/ Brian Brown
   

Brian Brown

Chief Financial Officer

(Principal Financial and Accounting Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.

 

Signature   Title   Date
         
/s/ Dwight Egan   Chief Executive Officer, President and Director   March 14, 2024
Dwight Egan   (Principal Executive Officer)    
         
/s/ Brian Brown   Chief Financial Officer   March 14, 2024
Brian Brown   (Principal Financial and Accounting Officer)    
         
/s/ Eugene Durenard   Director   March 14, 2024
Eugene Durenard        
         
/s/ Edward Murphy   Director   March 14, 2024
Edward Murphy        
         
/s/ James Nelson   Director   March 14, 2024
James Nelson        
         
/s/ Richard Serbin   Director   March 14, 2024
Richard Serbin        

 

68

 EX-4.1 2 ex4-1.htm

 

EXHIBIT 4.1

 

DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED UNDER SECTION 12

OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

 

The following description of our capital stock summarizes certain provisions of articles of incorporation, as amended (the “Articles of Incorporation”), our bylaws (the “Bylaws”), and applicable provisions of law. Such summaries do not purport to be complete and are subject to, and are qualified in their entirety by reference to, all of the provisions of our Articles of Incorporation and our Bylaws, including the definitions therein of certain terms, and all of the applicable provisions of law. Copies of our Articles of Incorporation and our Bylaws are filed or incorporated by reference as exhibits to our Annual Report on Form 10-K.

 

References in this Exhibit to the “Company,” “us,” “we,” and “our” are solely to Co-Diagnostics, Inc. and not to any of its subsidiaries, unless the context requires otherwise.

 

DESCRIPTION OF COMMON STOCK

 

Authorized Capital Stock

 

Pursuant to our Articles of Incorporation, our authorized capital stock presently consists of 100,000,000 shares of Common Stock, par value $0.001 per share, and 5,000,000 shares of “blank check” preferred stock, par value $0.001 per share.

 

Common Stock

 

Fully Paid and Non-Assessable Shares; No Liability for Corporate Obligations

 

All of the outstanding shares of Common Stock are fully paid and non-assessable. A share of Common Stock is fully paid and non-assessable if such share has been issued for consideration legally permissible under the Utah Revised Business Corporation Act with a value at least equal to the par value per share of Common Stock. Holders of fully paid and non-assessable shares of the Common Stock will not be liable for any obligations or liabilities of the Company that the Company may fail to discharge.

 

Voting Rights

 

Each holder of shares of Common Stock is entitled to one vote for each share owned of record on all matters submitted to a vote of shareholders. Except as noted below or as otherwise required by the Utah Revised Business Corporation Act, the vote of shareholders is required to decide any matter brought before a shareholder meeting at which a quorum is present. The holders of a majority of the outstanding shares of our stock must approve any amendments to our Articles of Incorporation, any merger or consolidation to which we are a party (other than parent-subsidiary mergers), any sale of all or substantially all of our assets or our dissolution as a corporation. Our shareholders do not have cumulative voting rights as to the election of directors.

 

Dividends

 

Subject to the preferential rights of any holders of any series of our preferred stock that may be issued in the future, the holders of shares of Common Stock are entitled to such dividends and distributions, whether payable in cash or otherwise, as may be declared from time to time by our board of directors from legally available funds.

 

We have never declared or paid any cash dividends on our capital stock. The payment of dividends on our Common Stock in the future will depend on our earnings, capital requirements, operating and financial condition, and such other factors as our board of directors may consider appropriate. We currently expect to use all available funds to finance the future development and expansion of our business and do not anticipate paying dividends on our Common Stock in the foreseeable future.

 

 
 

 

Liquidation Distributions

 

Subject to the preferential rights of any holders of any series of our preferred stock that may be issued in the future, upon our liquidation, dissolution, or winding-up, and after payment of all prior claims against our assets and our outstanding obligations, the holders’ shares of Common Stock will be entitled to receive, pro rata, all of our remaining assets.

 

Preemptive, Conversion, Redemption, or Similar Rights

 

The holders of shares of Common Stock are not entitled to any preemptive or other similar rights to subscribe for or acquire additional shares of Common Stock or any other securities of the Company. The shares of Common Stock are not subject to conversion or redemption by the Company and the holders of shares of Common Stock do not have any right or option to convert such shares into any other security or property of the Company or to cause the Company to redeem such shares of Common Stock. There are no sinking fund provisions applicable to the Common Stock.

 

Listing

 

Shares of the Common Stock are listed for trading on the NASDAQ Capital Markets under the symbol “CODX.”

 

Transfer Agent and Registrar

 

The transfer agent and registrar for the Common Stock is VStock Transfer Company, Inc. located at 18 Lafayette Pl, Woodmere, New York 11598. Its telephone number is (212) 828-8436.

 

Preferred Stock

 

Shares of our preferred stock are NOT listed for trading. The description herein is provided solely to show the potential effect on our Common Stock.

 

Our Articles of Incorporation authorizes 5,000,000 shares of “blank check” preferred stock, par value $0.001 per share, of which 30,000 have been designated as Series A Convertible Preferred Stock.

 

All 30,000 previously outstanding shares of Series A Preferred Stock were converted into Common Stock during 2020 and 2019. The board of directors of the Company may provide for the issue of any or all of the unissued and undesignated shares of the preferred stock in one or more series, and to fix the number of shares and to determine or alter for each such series, such voting powers, full or limited, or no voting powers, and such designation, preferences, and relative, participating, optional, or other rights and such qualifications, limitations, or restrictions thereof, as shall be stated and expressed in the resolution or resolutions adopted by the board of directors providing for the issuance of such shares and as may be permitted by law, without shareholder approval.

 

Our board of directors has the right to establish one or more series of preferred stock without shareholder approval. Unless required by law or by any stock exchange on which our Common Stock is listed, the authorized shares of preferred stock will be available for issuance at the discretion of our board of directors without further action by our shareholders. Our board of directors is able to determine, with respect to any series of preferred stock, the terms and rights of that series, including:

 

  ● the designation of the series;
     
  ● the number of shares of the series;
     
  ● whether dividends, if any, will be cumulative or non-cumulative and the dividend rate, if any, of the series;

 

 
 

 

  ● the dates at which dividends, if any, will be payable;
     
  ● the redemption rights and price or prices, if any, for shares of the series;
     
  ● the terms and amounts of any sinking fund provided for the purchase or redemption of shares of the series;
     
  ● the amounts payable on shares of the series in the event of any voluntary or involuntary liquidation, dissolution, or winding-up of the affairs of our company;
     
  ● whether the shares of the series will be convertible into shares of any other class or series, or any other security, of our company or any other entity, and, if so, the specification of the other class or series or other security, the conversion price or prices or rate or rates and provisions for any adjustments to such prices or rates, the date or dates as of which the shares will be convertible, and all other terms and conditions upon which the conversion may be made;
     
  ● the ranking of such series with respect to dividends and amounts payable on our liquidation, dissolution, or winding-up, which may include provisions that such series will rank senior to our Common Stock with respect to dividends and those distributions;
     
  ● restrictions on the issuance of shares of the same series or any other class or series; or
     
  ● voting rights, if any, of the holders of the series.

 

The issuance of preferred stock could adversely affect, among other things, the voting power of holders of Common Stock and the likelihood that shareholders will receive dividend payments and payments upon our liquidation, dissolution, or winding up. The issuance of preferred stock could also have the effect of delaying, deferring, or preventing a change in control of us.

 

If we issue shares of preferred stock, the shares will be fully paid and nonassessable and will not have, or be subject to, any preemptive or similar rights.

 

 

 

 EX-21.1 3 ex21-1.htm

 

Exhibit 21.1

 

List of Subsidiaries

 

LIST OF SUBSIDIARIES

 

Co-Diagnostics, Inc. (the “Company”) has the following direct and indirect subsidiaries:

 

Subsidiary Name  Jurisdiction of Formation  Percentage of Ownership 
        
DNA Logix, Inc.  Utah   100%
         
Idaho Molecular, Inc.  Idaho   100%
         
Advanced Conceptions, Inc.  Utah   100%

 

 

 

 EX-23.1 4 ex23-1.htm

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

The Board of Directors

Co-Diagnostics, Inc.:

 

We consent to the incorporation by reference in the registration statements (Nos. 333-270628, 333-226835, 333-237684 and 333-269350) on Forms S-3 and S-8 of Co-Diagnostics, Inc. of our report dated March 14, 2024 with respect to the consolidated balance sheets of Co-Diagnostics, Inc. as of December 31, 2023, and the related consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for the year then ended, and the related notes (collectively, the “consolidated financial statements”), which report appears in the December 31, 2023 annual report on Form 10-K of Co-Diagnostics, Inc.

 

/s/ Tanner LLC

Salt Lake City, Utah

March 14, 2024

 

 

 EX-23.2 5 ex23-2.htm

 

EXHIBIT 23.2

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 

 

We consent to the incorporation by reference in Registration Statements No. 333-270628 and No. 333-226835 on Form S-3 and 333-237684 and 333-269350 on Form S-8 of Co-Diagnostics, Inc. of our report dated March 16, 2023, relating to our audit of the consolidated financial statements for the year ended December 31, 2022 which appear in this Annual Report on Form 10-K of Co-Diagnostics, Inc.

 

/s/ Haynie & Company

Salt Lake City, Utah

March 14, 2024

 

 

 

 EX-31.1 6 ex31-1.htm

 

EXHIBIT 31.1

 

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13A-14 OF THE EXCHANGE ACT OF 1934

 

CERTIFICATION

 

I, Dwight Egan, certify that:

 

1. I have reviewed this annual report on Form 10-K of Co-Diagnostics, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 14, 2024 /s/ Dwight Egan
  Dwight Egan
  Chief Executive Officer, President and Principal Executive Officer

 

 

 

 EX-31.2 7 ex31-2.htm

 

EXHIBIT 31.2

 

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13A-14 OF THE EXCHANGE ACT OF 1934

 

CERTIFICATION

 

I, Brian Brown, certify that:

 

1. I have reviewed this annual report on Form 10-K of Co-Diagnostics, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 14, 2024 /s/ Brian Brown
  Brian Brown
  Chief Financial Officer and Principal Financial and Accounting Officer

 

 

 

 EX-32.1 8 ex32-1.htm

 

EXHIBIT 32.1

 

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S. C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Co-Diagnostics, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Dwight Egan, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

(1) The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 14, 2024 /s/ Dwight Egan
  Dwight Egan
  Chief Executive Officer, President and Principal Executive Officer

 

 

 

 EX-32.2 9 ex32-2.htm

 

EXHIBIT 32.2

 

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S. C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Co-Diagnostics, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Brian Brown, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

(1) The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 14, 2024 /s/ Brian Brown
  Brian Brown
  Chief Financial Officer and Principal Financial and Accounting Officer

 

 

 

 EX-97.1 10 ex97.htm

 

Exhibit 97

 

CO-DIAGNOSTICS, INC.

 

INCENTIVE COMPENSATION RECOVERY POLICY

 

1. Introduction.

 

The Board of Directors of Co-Diagnostics, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s compensation philosophy. The Board has therefore adopted this policy, which provides for the recovery of erroneously awarded incentive compensation in the event that the Company is required to prepare an accounting restatement due to material noncompliance of the Company with any financial reporting requirements under the federal securities laws (the “Policy”). This Policy is designed to comply with Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), related rules and the listing standards of Nasdaq Stock Market or any other securities exchange on which the Company’s shares are listed in the future.

 

2. Administration.

 

This Policy shall be administered by the Board or, if so designated by the Board, the Compensation Committee (the “Committee”), in which case, all references herein to the Board shall be deemed references to the Committee. Any determinations made by the Board shall be final and binding on all affected individuals.

 

3. Covered Executives.

 

Unless and until the Board determines otherwise, for purposes of this Policy, the term “Covered Executive” means a current or former employee who is or was identified by the Company as the Company’s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person (including any executive officer of the Company’s subsidiaries or affiliates) who performs similar policy-making functions for the Company. “Policy-making function” is not intended to include policy-making functions that are not significant. “Covered Executives” will include, at minimum, the executive officers identified by the Company pursuant to Item 401(b) of Regulation S-K of the Exchange Act.

 

This Policy covers Incentive Compensation received by a person after beginning service as a Covered Executive and who served as a Covered Executive at any time during the performance period for that Incentive Compensation.

 

 1 

 

 

4. Recovery: Accounting Restatement.

 

In the event the Company is required to prepare an Accounting Restatement, the Company will recover reasonably promptly any excess Incentive Compensation received by any Covered Executive during the three completed fiscal years immediately preceding the date on which the Company is required to prepare an Accounting Restatement, including transition periods resulting from a change in the Company’s fiscal year as provided in Rule 10D-1 of the Exchange Act. Incentive Compensation is deemed “received” in the Company’s fiscal period during which the financial reporting measure specified in the Incentive Compensation award is attained, even if the payment or grant of the Incentive Compensation occurs after the end of that period. The determination of the time when the Company is “required” to prepare an Accounting Restatement shall be made in accordance with applicable SEC and national securities exchange rules and regulations.

 

  (a) Definition of Accounting Restatement.

 

For the purposes of this Policy, an “Accounting Restatement” means the Company is required to prepare an accounting restatement of its financial statements filed with the Securities and Exchange Commission (the “SEC”) due to the Company’s material noncompliance with any financial reporting requirements under the federal securities laws (including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period).

 

The determination of the time when the Company is “required” to prepare an Accounting Restatement shall be made in accordance with applicable SEC and national securities exchange rules and regulations.

 

An Accounting Restatement does not include situations in which financial statement changes did not result from material non-compliance with financial reporting requirements, such as, but not limited to retrospective: (i) application of a change in accounting principles; (ii) revision to reportable segment information due to a change in the structure of the Company’s internal organization; (iii) reclassification due to a discontinued operation; (iv) application of a change in reporting entity, such as from a reorganization of entities under common control; (v) adjustment to provision amounts in connection with a prior business combination; and (vi) revision for stock splits, stock dividends, reverse stock splits or other changes in capital structure.

 

  (b) Definition of Incentive Compensation.

 

For purposes of this Policy, “Incentive Compensation” means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a “financial reporting measure” (as defined in paragraph (b) below), including, for example, bonuses or awards under the Company’s short and long-term incentive plans, grants and awards under the Company’s equity incentive plans, and contributions of such bonuses or awards to the Company’s deferred compensation plans or other employee benefit plans. Incentive Compensation does not include awards which are granted, earned and vested without regard to attainment of financial reporting measures, such as time-vesting awards, discretionary awards and awards based wholly on subjective standards, strategic measures or operational measures.

 

 2 

 

 

  (c) Financial Reporting Measures.

 

Financial reporting measures are those that are determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements (including non-GAAP financial measures) and any measures derived wholly or in part from such financial measures. For the avoidance of doubt, financial reporting measures include stock price and total shareholder return. A measure need not be presented within the financial statements or included in a filing with the SEC to constitute a financial reporting measure for purposes of this Policy.

 

  (d) Excess Incentive Compensation: Amount Subject to Recovery.

 

The amount(s) to be recovered from the Covered Executive will be the amount(s) by which the Covered Executive’s Incentive Compensation for the relevant period(s) exceeded the amount(s) that the Covered Executive otherwise would have received had such Incentive Compensation been determined based on the restated amounts contained in the Accounting Restatement. All amounts shall be computed without regard to taxes paid.

 

For Incentive Compensation based on financial reporting measures such as stock price or total shareholder return, where the amount of excess compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the Board will calculate the amount to be reimbursed based on a reasonable estimate of the effect of the Accounting Restatement on such financial reporting measure upon which the Incentive Compensation was received. The Company will maintain documentation of that reasonable estimate and will provide such documentation to the applicable national securities exchange.

 

  (e) Method of Recovery.

 

The Board will determine, in its sole discretion, the method(s) for recovering reasonably promptly excess Incentive Compensation hereunder. Such methods may include, without limitation:

 

  (i) requiring reimbursement of compensation previously paid;
     
  (ii) forfeiting any compensation contribution made under the Company’s deferred compensation plans, as well as any matching amounts and earnings thereon;
     
  (iii) offsetting the recovered amount from any compensation that the Covered Executive may earn or be awarded in the future (including, for the avoidance of doubt, recovering amounts earned or awarded in the future to such individual equal to compensation paid or deferred into tax–qualified plans or plans subject to the Employee Retirement Income Security Act of 1974 (collectively, “Exempt Plans”); provided that, no such recovery will be made from amounts held in any Exempt Plan of the Company);

 

 3 

 

 

  (iv) taking any other remedial and recovery action permitted by law, as determined by the Board; or
     
  (iv) some combination of the foregoing.

 

5. No Indemnification or Advance.

 

Subject to applicable law, the Company shall not indemnify, including by paying or reimbursing for premiums for any insurance policy covering any potential losses, any Covered Executives against the loss of any erroneously awarded Incentive Compensation, nor shall the Company advance any costs or expenses to any Covered Executives in connection with any action to recover excess Incentive Compensation.

 

6. Interpretation.

 

The Board is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate or advisable for the administration of this Policy. It is intended that this Policy be interpreted in a manner that is consistent with the requirements of Section 10D of the Exchange Act and any applicable rules or standards adopted by the SEC or any national securities exchange on which the Company’s securities are listed.

 

7. Effective Date.

 

The effective date of this Policy is October 2, 2023 (the “Effective Date”). This Policy applies to Incentive Compensation received by Covered Executives on or after the Effective Date that results from attainment of a financial reporting measure based on or derived from financial information for any fiscal period ending on or after the Effective Date. In addition, this Policy is intended to be and will be incorporated as an essential term and condition of any Incentive Compensation agreement, change-in-control plan, or any other plan or program that the Company establishes or maintains on or after the Effective Date.

 

8. Amendment and Termination.

 

The Board may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary to reflect changes in regulations adopted by the SEC under Section 10D of the Exchange Act and to comply with any rules or standards adopted by the Nasdaq Stock Market or any other securities exchange on which the Company’s shares are listed in the future.

 

 4 

 

 

9. Other Recovery Rights.

 

The Board intends that this Policy will be applied to the fullest extent of the law. Upon receipt of this Policy, each Covered Executive is required to complete the Receipt and Acknowledgement attached as Schedule A to this Policy. The Board may require that any employment agreement or similar agreement relating to Incentive Compensation entered into on or after the Effective Date shall, as a condition to the grant of any benefit thereunder, require a Covered Executive to agree to abide by the terms of this Policy. Any right of recovery under this Policy is in addition to, and not in lieu of, any (i) other remedies or rights of compensation recovery that may be available to the Company pursuant to the terms of any similar policy in any employment agreement, or similar agreement relating to Incentive Compensation, unless any such agreement expressly prohibits such right of recovery, and (ii) any other legal remedies available to the Company. The provisions of this Policy are in addition to (and not in lieu of) any rights to repayment the Company may have under Section 304 of the Sarbanes-Oxley Act of 2002 and other applicable laws.

 

10. Impracticability.

 

The Company shall recover any excess Incentive Compensation in accordance with this Policy, except to the extent that certain conditions are met and the Board has determined that such recovery would be impracticable, all in accordance with Rule 10D-1 of the Exchange Act and the Nasdaq Stock Market or any other securities exchange on which the Company’s shares are listed in the future.

 

11. Successors.

 

This Policy shall be binding upon and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives.

 

 5 

 

 

Schedule A

 

INCENTIVE-BASED COMPENSATION CLAWBACK POLICY

RECEIPT AND ACKNOWLEDGEMENT

 

I, __________________________________________, hereby acknowledge that I have received and read a copy of the Incentive Compensation Recovery Policy. As a condition of my receipt of any Incentive Compensation as defined in the Policy, I hereby agree to the terms of the Policy. I further agree that if recovery of excess Incentive Compensation is required pursuant to the Policy, the Company shall, to the fullest extent permitted by governing laws, require such recovery from me up to the amount by which the Incentive Compensation received by me, and amounts paid or payable pursuant or with respect thereto, constituted excess Incentive Compensation. If any such reimbursement, reduction, cancelation, forfeiture, repurchase, recoupment, offset against future grants or awards and/or other method of recovery does not fully satisfy the amount due, I agree to immediately pay the remaining unpaid balance to the Company.

 

     
Signature   Date

 

 6 

 

 EX-101.SCH 11 codx-20231231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statement of Changes in Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 995512 - Disclosure - Overview and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 995513 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995514 - Disclosure - Cash, Cash Equivalents, and Financial Instruments link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995516 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 995517 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 995518 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 995519 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 995520 - Disclosure - Earnings per Share link:presentationLink link:calculationLink link:definitionLink 995521 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995522 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995523 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995524 - Disclosure - Share Repurchase Program link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995526 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995527 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995528 - Disclosure - Cash, Cash Equivalents, and Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 995529 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995530 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 995531 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 995532 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 995533 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 995534 - Disclosure - Earnings per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995536 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 995537 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 995538 - Disclosure - Share Repurchase Program (Tables) link:presentationLink link:calculationLink link:definitionLink 995539 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995540 - Disclosure - Schedule of Cash, Cash Equivalents and Marketable Investment Securities (Details) link:presentationLink link:calculationLink link:definitionLink 995541 - Disclosure - Schedule of Fair Value Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995542 - Disclosure - Schedule of Changes in the Fair Value Measurement (Details) link:presentationLink link:calculationLink link:definitionLink 995543 - Disclosure - Schedule of Contingent Consideration Common Stock and Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 995544 - Disclosure - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Schedule of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 995546 - Disclosure - Schedule of Intangible Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 995547 - Disclosure - Schedule of Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995548 - Disclosure - Goodwill and Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995549 - Disclosure - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 995550 - Disclosure - Summary of Revenue by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 995551 - Disclosure - Schedule of Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 995552 - Disclosure - Schedule of Basis and Diluted Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 995553 - Disclosure - Earnings per Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995554 - Disclosure - Schedule of Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Schedule of Outstanding Restricted Stock Units and Related Party (Details) link:presentationLink link:calculationLink link:definitionLink 995556 - Disclosure - Schedule of Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995557 - Disclosure - Schedule of Recognized Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995558 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995559 - Disclosure - Schedule of Components Income Tax Provision (Details) link:presentationLink link:calculationLink link:definitionLink 995560 - Disclosure - Schedule of Benefit from Income Taxes and Effective Tax Rates (Details) link:presentationLink link:calculationLink link:definitionLink 995561 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995562 - Disclosure - Schedule of Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 995563 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995564 - Disclosure - Schedule of Lease Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Schedule of Maturities on Company Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995566 - Disclosure - Schedule of Other Information Related to Operating Lease (Details) link:presentationLink link:calculationLink link:definitionLink 995567 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995568 - Disclosure - Schedule of Treasury Stock (Details) link:presentationLink link:calculationLink link:definitionLink 995569 - Disclosure - Share Repurchase Program (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995570 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 codx-20231231_cal.xml XBRL CALCULATION FILE EX-101.DEF 13 codx-20231231_def.xml XBRL DEFINITION FILE EX-101.LAB 14 codx-20231231_lab.xml XBRL LABEL FILE Product and Service [Axis] Product Revenue [Member] Grant Revenue [Member] Class of Stock [Axis] Convertible Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Treasury Stock, Common [Member] Additional Paid-in Capital [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Customer [Axis] Customers [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Accounts Receivable [Member] Two Customers [Member] Revenue Benchmark [Member] One Customer [Member] One Granting Agency [Member] Customers Together [Member] Cash and Cash Equivalents [Axis] Cash [Member] Money Market Funds [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] US Treasury Securities [Member] Fair Value, Inputs, Level 2 [Member] Measurement Frequency [Axis] Fair Value, Recurring [Member] Fair Value, Inputs, Level 3 [Member] Measurement Input Type [Axis] Measurement Input, Share Price [Member] Measurement Input Strike Price [Member] Measurement Input, Price Volatility [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Expected Term [Member] Long-Lived Tangible Asset [Axis] Equipment [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Leaseholds and Leasehold Improvements [Member] Leasehold Improvements [Member] Office Equipment [Member] Finite-Lived Intangible Assets by Major Class [Axis] In Process Research and Development [Member] Noncompete Agreements [Member] Geographical [Axis] UNITED STATES Product [Member] Grant [Member] Rest of World [Member] Geographic Concentration Risk [Member] Warrant [Member] Antidilutive Securities [Axis] Restricted Stock Units (RSUs) [Member] Share-Based Payment Arrangement, Option [Member] Plan Name [Axis] 2015 Long Term Incentive Plan [Member] Award Type [Axis] Stock Options [Member] Income Statement Location [Axis] Cost of Sales [Member] Selling and Marketing Expense [Member] General and Administrative Expense [Member] Research and Development Expense [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Lease Amendment [Member] Related Party, Type [Axis] Seth Egan [Member] Winston Egan [Member] CoSara Diagnostics Pvt Ltd [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract] Assets Current assets Cash and cash equivalents Marketable investment securities Accounts receivable, net Inventory, net Income taxes receivable Prepaid expenses and other current assets Note receivable Total current assets Property and equipment, net Operating lease right-of-use asset Intangible assets, net Investment in joint venture Total assets Liabilities and stockholders’ equity Current liabilities Accounts payable Accrued expenses Operating lease liability, current Contingent consideration liabilities, current Deferred revenue Total current liabilities Long-term liabilities Income taxes payable Deferred tax liability Operating lease liability Contingent consideration liabilities Total long-term liabilities Total liabilities Commitments and contingencies (Note 12) Stockholders’ equity Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively Common stock, $0.001 par value; 100,000,000 shares authorized; 36,108,346 shares issued and 31,259,668 shares outstanding as of December 31, 2023 and 34,754,265 shares issued and 30,872,607 shares outstanding as of December 31, 2022 Treasury stock, at cost; 4,848,678 and 3,881,658 shares held as of December 31, 2023 and December 31, 2022, respectively Additional paid-in capital Accumulated other comprehensive income Accumulated earnings Total stockholders’ equity Total liabilities and stockholders’ equity Convertible preferred stock, par value Convertible preferred stock , shares authorized Convertible preferred stock, shares issued Convertible preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Treasury stock, shares Statement [Table] Statement [Line Items] Total revenue Cost of revenue Gross profit Operating expenses Sales and marketing General and administrative Research and development Depreciation and amortization Goodwill impairment charges Total operating expenses Loss from operations Other income, net Interest income Realized gain on investments Loss on disposition of assets Gain on remeasurement of acquisition contingencies Gain (loss) on equity method investment in joint venture Total other income, net Loss before income taxes Income tax benefit Net loss Other comprehensive loss Change in net unrealized gains on marketable securities, net of tax Total other comprehensive income (loss) Comprehensive loss Loss per common share: Basic Diluted Weighted average shares outstanding: Basic Diluted Balance Balance, shares Common stock issued for option exercises Common stock issued for option exercises, shares Common stock issued for warrant exercises Common stock issued for warrant exercises, shares Stock-based compensation expense Stock-based compensation expense, shares Common stock issued for acquisitions Common stock issued for acquisitions, shares Repurchases of common stock Other comprehensive loss, net of tax Net loss Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities Adjustments to reconcile net loss to cash (used in) provided by operating activities: Depreciation and amortization Stock-based compensation expense Change in fair value of acquisition contingencies Non-cash lease expense Realized gain on investments (Gain) loss from equity method investment Loss on disposition of assets Deferred income taxes Provision for credit losses Inventory obsolescence expense Changes in assets and liabilities: Accounts receivable Prepaid expenses and other assets Inventory Deferred revenue Income taxes payable Accounts payable, accrued expenses and other liabilities Net cash (used in) provided by operating activities Cash flows from investing activities Purchases of property and equipment Proceeds from maturities of marketable investment securities Purchases of marketable securities Net cash (used in) provided by investing activities Cash flows from financing activities Proceeds from exercise of options and warrants Repurchases of common stock Net cash (used in) financing activities Net decrease in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosure of cash flow information Interest paid Income taxes paid Supplemental disclosure of non-cash investing and financing transactions Inventory moved to property, plant and equipment Right-of-use assets obtained in exchange for new operating lease liabilities Business acquisition measurement period adjustments Fair value of common stock issued as consideration for business acquisitions Fair value of contingent common stock issued as consideration for business acquisitions Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance [Table Text Block] Company Selected Measure Name Named Executive Officers, Footnote [Text Block] Peer Group Issuers, Footnote [Text Block] Changed Peer Group, Footnote [Text Block] PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote [Text Block] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Equity Valuation Assumption Difference, Footnote [Text Block] Compensation Actually Paid vs. Total Shareholder Return [Text Block] Compensation Actually Paid vs. Net Income [Text Block] Compensation Actually Paid vs. Company Selected Measure [Text Block] Total Shareholder Return Vs Peer Group [Text Block] Compensation Actually Paid vs. Other Measure [Text Block] Tabular List [Table Text Block] Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Attributable to Parent Company Selected Measure Amount Other Performance Measure Amount Adjustment to Compensation Amount PEO Name Measure Name Non-GAAP Measure Description [Text Block] Additional 402(v) Disclosure [Text Block] Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis [Text Block] Stock Price or TSR Estimation Method [Text Block] Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined [Text Block] Forgone Recovery, Individual Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability [Text Block] Outstanding Recovery, Individual Name Outstanding Recovery Compensation Amount Restatement Does Not Require Recovery [Text Block] Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure [Text Block] Award Timing Method [Text Block] Award Timing Predetermined [Flag] Award Timing MNPI Considered [Flag] Award Timing, How MNPI Considered [Text Block] MNPI Disclosure Timed for Compensation Value [Flag] Awards Close in Time to MNPI Disclosures [Table Text Block] Awards Close in Time to MNPI Disclosures, Individual Name Award Underlying Securities Amount Award Exercise Price Award Grant Date Fair Value Underlying Security Market Price Change, Percent Trading Arrangements, by Individual [Table] Trading Arrangement [Axis] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Arrangement Duration Aggregate Available Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted [Flag] Insider Trading Policies and Procedures Not Adopted [Text Block] Accounting Policies [Abstract] Overview and Basis of Presentation Summary of Significant Accounting Policies Cash and Cash Equivalents [Abstract] Cash, Cash Equivalents, and Financial Instruments Fair Value Disclosures [Abstract] Fair Value Measurements Property, Plant and Equipment [Abstract] Property and Equipment Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Payables and Accruals [Abstract] Accrued Expenses Revenue from Contract with Customer [Abstract] Revenue Earnings Per Share [Abstract] Earnings per Share Share-Based Payment Arrangement [Abstract] Stock-Based Compensation Income Tax Disclosure [Abstract] Income Taxes Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Equity [Abstract] Share Repurchase Program Related Party Transactions [Abstract] Related Party Transactions Subsequent Events [Abstract] Subsequent Events Reclassifications Cash and Cash Equivalents Marketable Investment Securities Accounts Receivable Equity-Method Investments Inventory Goodwill and Intangible Assets Long-lived Assets Revenue Recognition Grant Revenue Deferred Revenue Research and Development Stock-based Compensation Income Taxes Net Income (Loss) per Share Comprehensive Income (Loss) Concentrations Risk and Significant Customers Recently Issued Accounting Standards Schedule of Cash, Cash Equivalents and Marketable Investment Securities Schedule of Fair Value Assets and Liabilities Schedule of Changes in the Fair Value Measurement Schedule of Contingent Consideration Common Stock and Warrants Schedule of Property and Equipment Schedule of Goodwill Schedule of Intangible Assets, Net Schedule of Future Amortization Expense Schedule of Accrued Expenses Summary of Revenue by Geographic Area Schedule of Deferred Revenue Schedule of Basis and Diluted Earnings Per Share Schedule of Option Activity Schedule of Outstanding Restricted Stock Units and Related Party Schedule of Warrant Activity Schedule of Recognized Stock-based Compensation Expense Schedule of Components Income Tax Provision Schedule of Benefit from Income Taxes and Effective Tax Rates Schedule of Deferred Tax Assets and Liabilities Schedule of Unrecognized Tax Benefits Schedule of Lease Expense Schedule of Maturities on Company Lease Liabilities Schedule of Other Information Related to Operating Lease Schedule of Treasury Stock Schedule of Product Information [Table] Product Information [Line Items] Accounts receivable Doubtful accounts Inventory Inventory, finished goods, gross Inventory, raw materials, gross Inventory reserves Impairment charges Grant funding revenue Deferred revenue Concentration risk percentage Schedule of Cash and Cash Equivalents [Table] Cash and Cash Equivalents [Line Items] Adjusted Cost Allowance for Credit Losses Total Unrealized Gains / (Losses) Fair Value Cash and Cash Equivalents Marketable Securities Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash equivalents Marketable securities (U.S. treasury bills and notes) Total assets measured at fair value Contingent consideration - common stock Contingent consideration - warrants Total liabilities measured at fair value Fair value as of December 31, 2022 Change in fair value of contingent consideration issued for business acquisitions Fair value as of December 31, 2023 Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Warrants measurement input Expected term Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property and equipment estimated useful lives Property and equipment, gross Less: accumulated depreciation Property and equipment, net Goodwil - beginning Measurement period adjustments Goodwill impairment charges Goodwill - ending Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Estimated useful lives in years, term Intangible assets, gross Less accumulated amortization Estimated useful lives in years 2024 Total Goodwill Payroll liabilities Distributor commissions Other accrued liabilities Total accrued expenses Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Revenue geographic area Percentage of revenue Deferred revenue, beginning balance Increase due to prepayments from customers Increase due to prepayments from grants received Deferred revenue, ending balance Net loss, as reported Weighted average shares, basic Dilutive effect of stock options, warrants and RSUs Shares used to compute diluted earnings per share Basic earnings per share Diluted earnings per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Securities excluded from computation of diluted earnings per share Number of Options Outstanding, Beginning Weighted Average Exercise Price Outstanding, Beginning Weighted Average Fair Value Outstanding, Ending Number of Options Outstanding, Granted Weighted Average Exercise Price Granted Weighted Average Fair Value Granted Number of Options Outstanding, Expired Weighted Average Exercise Price Expired Weighted Average Fair Value Expired Number of Options Outstanding, Forfeited/Cancelled Weighted Average Exercise Price Forfeited/Cancelled Weighted Average Fair Value Forfeited/Cancelled Number of Options Outstanding, Exercised Weighted Average Exercise Price Exercised Weighted Average Fair Value Exercised Weighted-average Remaining Contractual Life (years) Outstanding, Beginning Number of Options Outstanding, Ending Weighted Average Exercise Price Outstanding, Ending Weighted-average Remaining Contractual Life (years) Outstanding, Ending Number of Options Exercisable Ending Weighted Average Exercise Price, Exercisable Ending Weighted Average Fair Value, Exercisable Ending Weighted-average Remaining Contractual Life (years), Exercisable Ending Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number of Restricted Stock Units, Outstanding Beginning Weighted Average Grant Date Fair Value, Outstanding Beginning Number of Restricted Stock Units, Granted Weighted Average Grant Date Fair Value, Granted Number of Restricted Stock Units, Vested Weighted Average Grant Date Fair Value, Vested Number of Restricted Stock Units, Forfeited/Cancelled Weighted Average Grant Date Fair Value, Forfeited/Cancelled Number of Restricted Stock Units, Outstanding Ending Weighted Average Grant Date Fair Value, Outstanding Ending Number of Warrants Outstanding, Beginning Weighted Average Exercise Price, Beginning Weighted Average fair value, Beginning Weighted-average Remaining Contractual Life (Years) Outstanding Number of Warrants Outstanding, Issued Weighted Average Exercise Price, Issued Weighted Average Fair Value, Issued Number of Warrants Outstanding, Granted Weighted Average Exercise Price, Granted Weighted Average Fair Value, Granted Number of Warrants Outstanding, Expired Weighted Average Exercise Price, Expired Weighted Average Fair Value, Expired Number of Warrants Outstanding, Forfeited/Cancelled Weighted Average Exercise Price, Forfeited/Cancelled Weighted Average Fair Value, Forfeited/Cancelled Number of Warrants Outstanding, Exercised Weighted Average Exercise Price, Exercised Weighted Average Fair Value, Exercised Weighted-average Remaining Contractual Life (Years) Outstanding Number of Warrants Outstanding, Ending Weighted Average Exercise Price, Ending Weighted Average Fair Value, Ending Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Total stock-based compensation expense Number of common shares availalble for issuance Intrinsic value of options value exercised Aggregate intrinsic value of options outstanding Unrecognized stock-based compensation Weighted average period Intrinsic value of warrants exercised Warrants exercisable Warrants purchase Current: Federal State Total current Deferred: Federal State Change in valuation allowance Total deferred Total income tax benefit Federal income tax expense at statutory rate State income tax expense, net of federal tax benefit Permanent differences: - Foreign derived intangible income deduction - Stock based compensation - Contingent consideration remeasurement - Goodwill impairment - Other permanent differences Research and development credits Change in uncertain tax positions Change in valuation allowance Other Effective income tax rate Deferred tax assets: Accrued liabilities Reserves and allowances Deferred compensation Section 174 costs Lease liability UNICAP Net operating loss carryforwards Research and development credits Total gross deferred tax assets Less valuation allowance Total deferred tax assets Deferred tax liabilities: Property and equipment, net Intangibles, net Prepaids Right of use asset Other comprehensive income Other Total deferred tax liabilities Net deferred tax liability Unrecognized tax benefits at the beginning of the year Gross increases- current year tax positions Gross increases- prior year tax positions Gross decreases - prior year tax positions Unrecognized tax benefits at end of year Interest and penalties in year-end balance Net operating loss carry-forwards Research and development credit carry forwards State net operating loss carryforwards State research and development credit carryforwards Unrecognized tax benefits that would impact effective tax rate Operating lease costs Short-term lease costs Total lease costs 2024 2025 2026 2027 Thereafter Total lease payments Less: imputed interest Present value of operating lease liabilities Less: current portion Long-term portion Cash paid for operating leases included in operating cash flows Remaining lease term of operating leases Discount rate of operating leases Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Operating lease liabilities Treasury stock, Beginning Balance Repurchases of common stock Treasury stock, Ending Balance Stock repurchase program authorized amount Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Share based payment, vesting period Fair value of equity awards Research and development expenses Taxes payable non current. Gain on remeasurement of acquisition contingencies. Noncash lease expense. Noncash or part noncash inventory moved to property plant and equipment.. Business acquisition measurement period adjustments. Stock issued during period value acquisitions adjustments. Fair value of contingent common stock and warrants issued as consideration for business acquisitions. Grant Revenue [Policy Text Block] Grant Funding Revenue. Customers [Member] Two Customers [Member] One Customer [Member] One Granting Agency [Member] Customers Together [Member] Fair value of contingent consideration to common stock. Fair value of contigent consideration to warrants. Contingent considered issued for business acquisitions. Measurement Input Strike Price [Member] Indefinite lived intangible asset useful life. Rest of World [Member] Increase due to prepayments from customers. Increase due to prepayments from grants received. 2015 Long Term Incentive Plan [Member] Share based compensation arrangement by share based payment award options non vested weighted average grant date fair value exercised. Share based compensation arrangement by share based payment award options non vested weighted average grant date fair value exercisable. Sharebased compensation arrangement by sharebased payment award non options outstanding weighted average remaining contractual term. Stock Options [Member] Share based compensation issued for adjustments to contingent purchase consideration. Weighted average exercise price, beginning. Issued For Adjustments To Contingent Purchase Consideration Period Weighted Average Exercise Price. Weighted average exercise price granted. Weighted average price at which grantees could have acquired the underlying shares with respect to non-options of the plan that expired. Weighted average exercise price, forfeited/cancelled. Weighted average exercise price, forfeited/cancelled. Weighted average price at which grantees can acquire the shares reserved for issuance under the non-option plan. Share based compensation arrangement by share based payment award non options outstanding weighted average fair value. Issued for adjustments to contingent purchase consideration weighted average grant date fair value. Weighted average grant date fair value, granted Share based compensation arrangement by share based payment award options non vested weighted average grant date fair value exercised. Weighted average fair value, forfeited/cancelled. Weighted average fair value, exercised. Weighted average fair value, beginning. Weighted-average remaining contractual life (years) outstanding, beginning. Sharebased compensation arrangement by sharebased payment award non options outstanding weighted average remaining contractual term3. Intrinsic value of warrants exercised. Class of warrant exercisable. Change in valuation allowance. Effective income tax rate reconciliation contingent consideration remeasurement. Effective income tax rate reconciliation Goodwill impairment. Effective income tax rate reconciliation change in valuation allowance. Deferred tax assets costs. Deferred tax assets lease liability. Deferred tax assets uniform capitalization. Deferred tax liabilities right of use asset. Lease Amendment [Member] Lessee operating lease liability payments due after year four. Schedule of Operating Lease [Table Text Block] Schedule of Treasury Stock [Table Text Block] Repurchases of common stock. Seth Egan [Member] Winston Egan [Member] Payment to related party. CoSara Diagnostics Pvt Ltd [Member] Product Revenue [Member] Grant Revenue [Member] Assets, Current Assets [Default Label] Liabilities, Current Liabilities, Noncurrent Liabilities Treasury Stock, Value Equity, Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Other Comprehensive Income (Loss), before Tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding Stock Repurchased During Period, Value Depreciation, Depletion and Amortization Share-Based Payment Arrangement, Noncash Expense Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Expense Increase (Decrease) in Inventories Increase (Decrease) in Contract with Customer, Liability Increase (Decrease) in Income Taxes Payable Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Payments to Acquire Marketable Securities Net Cash Provided by (Used in) Investing Activities Payments for Repurchase of Common Stock Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Goodwill and Intangible Assets, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Deferred Revenue [Default Label] Business Combination, Contingent Consideration, Liability, Noncurrent Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Finite-Lived Intangible Assets, Net Contract with Customer, Liability Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageFairValue Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm3 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue Current Federal, State and Local, Tax Expense (Benefit) Deferred Federal Income Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) ChangeInValuationAllowance Deferred Federal, State and Local, Tax Expense (Benefit) Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent EffectiveIncomeTaxRateReconciliationChangeInValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent Deferred Tax Assets, Gross Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance Deferred Tax Liabilities, Property, Plant and Equipment Deferred Tax Liabilities, Intangible Assets Deferred Tax Liabilities, Prepaid Expenses DeferredTaxLiabilitiesRightOfUseAsset Deferred Tax Liabilities, Other Comprehensive Income Deferred Tax Liabilities, Other Deferred Tax Liabilities, Gross Deferred Tax Assets, Net Unrecognized Tax Benefits Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Unrecognized Tax Benefits, Income Tax Penalties Accrued Lease, Cost Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid EX-101.PRE 15 codx-20231231_pre.xml XBRL PRESENTATION FILE XML 16 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Mar. 12, 2024
Jun. 30, 2023
Cover [Abstract]        
Document Type 10-K      
Amendment Flag false      
Document Annual Report true      
Document Transition Report false      
Document Period End Date Dec. 31, 2023      
Document Fiscal Period Focus FY      
Document Fiscal Year Focus 2023      
Current Fiscal Year End Date --12-31      
Entity File Number 001-38148      
Entity Registrant Name CO-DIAGNOSTICS, INC.      
Entity Central Index Key 0001692415      
Entity Tax Identification Number 46-2609396      
Entity Incorporation, State or Country Code UT      
Entity Address, Address Line One 2401 S. Foothill Drive      
Entity Address, City or Town Salt Lake City      
Entity Address, State or Province UT      
Entity Address, Postal Zip Code 84109      
City Area Code (801)      
Local Phone Number 438-1036      
Title of 12(b) Security Common Stock      
Trading Symbol CODX      
Security Exchange Name NASDAQ      
Entity Well-known Seasoned Issuer No      
Entity Voluntary Filers No      
Entity Current Reporting Status Yes      
Entity Interactive Data Current Yes      
Entity Filer Category Non-accelerated Filer      
Entity Small Business true      
Entity Emerging Growth Company false      
Entity Shell Company false      
Entity Public Float       $ 33,000,000
Entity Common Stock, Shares Outstanding     31,259,668  
ICFR Auditor Attestation Flag false      
Document Financial Statement Error Correction [Flag] false      
Auditor Firm ID 270 457    
Auditor Name Tanner LLC Haynie & Company    
Auditor Location Salt Lake City, Utah Salt Lake City, Utah    
XML 17 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 14,916,878 $ 22,973,803
Marketable investment securities 43,631,510 58,289,066
Accounts receivable, net 303,926 3,453,723
Inventory, net 1,664,725 5,310,473
Income taxes receivable 26,955 1,870,419
Prepaid expenses and other current assets 1,597,114 761,187
Note receivable 75,000
Total current assets 62,141,108 92,733,671
Property and equipment, net 3,035,729 2,539,483
Operating lease right-of-use asset 2,966,774 372,115
Intangible assets, net 26,403,667 26,768,333
Investment in joint venture 773,382 672,679
Total assets 95,320,660 123,086,281
Current liabilities    
Accounts payable 1,482,109 952,296
Accrued expenses 2,172,959 934,447
Operating lease liability, current 838,387 297,209
Contingent consideration liabilities, current 891,666 1,689,471
Deferred revenue 362,449
Total current liabilities 5,747,570 3,873,423
Long-term liabilities    
Income taxes payable 659,186 1,181,284
Deferred tax liability 2,417,987
Operating lease liability 2,152,180 50,708
Contingent consideration liabilities 748,109 1,042,885
Total long-term liabilities 3,559,475 4,692,864
Total liabilities 9,307,045 8,566,287
Stockholders’ equity    
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively
Common stock, $0.001 par value; 100,000,000 shares authorized; 36,108,346 shares issued and 31,259,668 shares outstanding as of December 31, 2023 and 34,754,265 shares issued and 30,872,607 shares outstanding as of December 31, 2022 36,108 34,754
Treasury stock, at cost; 4,848,678 and 3,881,658 shares held as of December 31, 2023 and December 31, 2022, respectively (15,575,795) (14,211,866)
Additional paid-in capital 96,808,436 88,472,935
Accumulated other comprehensive income 146,700 293,140
Accumulated earnings 4,598,166 39,931,031
Total stockholders’ equity 86,013,615 114,519,994
Total liabilities and stockholders’ equity $ 95,320,660 $ 123,086,281
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Convertible preferred stock, par value $ 0.001 $ 0.001
Convertible preferred stock , shares authorized 5,000,000 5,000,000
Convertible preferred stock, shares issued 0 0
Convertible preferred stock, shares outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 36,108,346 34,754,265
Common stock, shares outstanding 31,259,668 30,872,607
Treasury stock, shares 4,848,678 3,881,658
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Total revenue $ 6,812,038 $ 34,218,209
Cost of revenue 4,184,949 5,481,093
Gross profit 2,627,089 28,737,116
Operating expenses    
Sales and marketing 6,860,815 7,344,628
General and administrative 14,279,441 14,262,963
Research and development 22,962,593 17,438,098
Depreciation and amortization 1,230,474 1,282,718
Goodwill impairment charges 15,388,546
Total operating expenses 45,333,323 55,716,953
Loss from operations (42,706,234) (26,979,837)
Other income, net    
Interest income 1,161,913 704,045
Realized gain on investments 2,243,059
Loss on disposition of assets (2,578) (138,117)
Gain on remeasurement of acquisition contingencies 1,092,581 7,899,644
Gain (loss) on equity method investment in joint venture 100,703 (332,969)
Total other income, net 4,595,678 8,132,603
Loss before income taxes (38,110,556) (18,847,234)
Income tax benefit (2,777,691) (4,608,985)
Net loss (35,332,865) (14,238,249)
Other comprehensive loss    
Change in net unrealized gains on marketable securities, net of tax (146,440) 293,140
Total other comprehensive income (loss) (146,440) 293,140
Comprehensive loss $ (35,479,305) $ (13,945,109)
Loss per common share:    
Basic $ (1.20) $ (0.45)
Diluted $ (1.20) $ (0.45)
Weighted average shares outstanding:    
Basic 29,346,599 31,479,028
Diluted 29,346,599 31,479,028
Product Revenue [Member]    
Total revenue $ 991,473 $ 34,218,209
Grant Revenue [Member]    
Total revenue $ 5,820,565
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statement of Changes in Stockholders' Equity - USD ($)
Convertible Preferred Stock [Member]
Preferred Stock [Member]
Common Stock [Member]
Treasury Stock, Common [Member]
Additional Paid-in Capital [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2021 $ 33,820 $ 80,271,999 $ 54,169,280 $ 134,475,099
Balance, shares at Dec. 31, 2021 33,819,862          
Common stock issued for option exercises $ 70 77,800 $ 77,870
Common stock issued for option exercises, shares   70,791         70,791
Common stock issued for warrant exercises $ 50 99,950 $ 100,000
Common stock issued for warrant exercises, shares   50,000          
Stock-based compensation expense $ 725 7,542,498 7,543,223
Stock-based compensation expense, shares   725,166          
Common stock issued for acquisitions $ 89 480,687 480,776
Common stock issued for acquisitions, shares   88,446          
Repurchases of common stock (14,211,866) (14,211,866)
Other comprehensive loss, net of tax 293,140 293,140
Net loss (14,238,249) (14,238,249)
Balance at Dec. 31, 2022 $ 34,754 (14,211,866) 88,472,935 293,140 39,931,031 $ 114,519,994
Balance, shares at Dec. 31, 2022 34,754,265          
Common stock issued for option exercises, shares            
Stock-based compensation expense $ 1,354 8,335,501 $ 8,336,855
Stock-based compensation expense, shares   1,354,081          
Repurchases of common stock (1,363,929) (1,363,929)
Other comprehensive loss, net of tax (146,440) (146,440)
Net loss (35,332,865) (35,332,865)
Balance at Dec. 31, 2023 $ 36,108 $ (15,575,795) $ 96,808,436 $ 146,700 $ 4,598,166 $ 86,013,615
Balance, shares at Dec. 31, 2023 36,108,346          
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities    
Net loss $ (35,332,865) $ (14,238,249)
Adjustments to reconcile net loss to cash (used in) provided by operating activities:    
Depreciation and amortization 1,230,474 1,282,718
Goodwill impairment charges 15,388,546
Stock-based compensation expense 8,336,855 7,543,223
Change in fair value of acquisition contingencies (1,092,581) (7,899,644)
Non-cash lease expense 47,992 30,430
Realized gain on investments (2,243,059)
(Gain) loss from equity method investment (100,703) 332,969
Loss on disposition of assets 2,578 138,117
Deferred income taxes (2,417,987) (4,810,457)
Provision for credit losses 612,809 2,461,032
Inventory obsolescence expense 3,233,281 148,099
Changes in assets and liabilities:    
Accounts receivable 2,536,988 14,924,427
Prepaid expenses and other assets 1,082,536 (224,094)
Inventory 413,140 (3,673,309)
Deferred revenue 362,449 (150,000)
Income taxes payable (522,098) (2,201,250)
Accounts payable, accrued expenses and other liabilities 1,768,326 (2,483,821)
Net cash (used in) provided by operating activities (22,081,865) 6,568,737
Cash flows from investing activities    
Purchases of property and equipment (1,365,306) (1,427,512)
Proceeds from maturities of marketable investment securities 127,251,619 11,255,266
Purchases of marketable securities (110,497,444) (67,995,926)
Net cash (used in) provided by investing activities 15,388,869 (58,168,172)
Cash flows from financing activities    
Proceeds from exercise of options and warrants 177,870
Repurchases of common stock (1,363,929) (14,211,866)
Net cash (used in) financing activities (1,363,929) (14,033,996)
Net decrease in cash and cash equivalents (8,056,925) (65,633,431)
Cash and cash equivalents at beginning of period 22,973,803 88,607,234
Cash and cash equivalents at end of period 14,916,878 22,973,803
Supplemental disclosure of cash flow information    
Interest paid
Income taxes paid 55,975 4,498,742
Supplemental disclosure of non-cash investing and financing transactions    
Inventory moved to property, plant and equipment 673 218,906
Right-of-use assets obtained in exchange for new operating lease liabilities 3,203,146 681,327
Business acquisition measurement period adjustments 1,593
Fair value of common stock issued as consideration for business acquisitions 480,776
Fair value of contingent common stock issued as consideration for business acquisitions $ 199,359
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Pay vs Performance Disclosure [Table]    
Net Income (Loss) Attributable to Parent $ (35,332,865) $ (14,238,249)
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
Insider Trading Arrangements
 3 Months Ended
Dec. 31, 2023
Trading Arrangements, by Individual [Table]  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
Overview and Basis of Presentation
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Overview and Basis of Presentation

Note 1 – Overview and Basis of Presentation

 

Description of Business

 

Co-Diagnostics, Inc., a Utah corporation (the “Company” or “CODX”), is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. In connection with the sale of our tests we may sell diagnostic equipment from other manufacturers as self-contained lab systems.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Such estimates include inventories, receivables and other long-lived assets, legal and regulatory contingencies, income taxes, share based arrangements, and others. These estimates and assumptions are based on management’s best estimates and judgments. Actual amounts and results could differ from those estimates.

 

Basis of Presentation

 

The accompanying audited consolidated financial statements of Co-Diagnostics, Inc. and its wholly owned subsidiaries have been prepared to reflect the financial position, results of operations and cash flows of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). All intercompany balances and transactions have been eliminated.

 
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

 

Reclassifications

 

Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.

 

Cash and Cash Equivalents

 

Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of December 31, 2023 and December 31, 2022. The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.

 

 

Marketable Investment Securities

 

The Company’s marketable investment securities are comprised of investments in certificates of deposit and U.S. Treasury bills and notes. The Company designates investments in debt securities as available-for-sale. Available-for-sale debt securities with original maturities of three months or less from the date of purchase are classified within cash and cash equivalents. Available-for-sale debt securities with original maturities longer than three months are available to fund current operations and are classified as marketable investment securities, within current assets on the consolidated balance sheets. The Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. Available-for-sale debt securities are reported at fair value with the related unrealized gains and losses included in accumulated other comprehensive income (loss), a component of stockholders’ equity, net of tax. Realized gains and losses on the sale of marketable securities are determined using the average cost method on a first-in, first-out basis and recorded in total other income (expense), net in the consolidated statements of operations and comprehensive loss.

 

The available-for-sale debt securities are subject to a periodic impairment review. For investments in an unrealized loss position, the Company writes down the amortized cost basis of the investment if it is more likely than not that the Company will be required or will intend to sell the investment before recovery of its amortized cost basis. For investments not likely to be sold before recovery of the amortized cost basis, the Company determines whether a credit loss exists by considering information about the collectability of the instrument, current market conditions, and reasonable and supportable forecasts of economic conditions. The Company recognizes an allowance for credit losses up to the amount of the unrealized loss when appropriate. Allowances for credit losses and write-downs are recognized in total other income (expense), net, and unrealized losses not related to credit losses are recognized in accumulated other comprehensive income (loss). There are no allowances for credit losses recorded for the periods presented.

 

Accounts Receivable

 

Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At December 31, 2023 total accounts receivable was $504,264 with an allowance for uncollectable accounts of $200,338 resulting in a net amount of $303,926. At December 31, 2022 total accounts receivable was $6,552,249 with an allowance for uncollectable accounts of $3,098,526 resulting in a net amount of $3,453,723.

 

Equity-Method Investments

 

Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying consolidated statements of operations.

 

Inventory

 

Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At December 31, 2023, the Company had $1,664,725 in inventory, of which $700,467 was finished goods and $964,258 was raw materials. At December 31, 2022, the Company had $5,310,473 in inventory, of which $1,327,264 was finished goods and $3,983,209 was raw materials. The Company establishes reserves to reduce low-moving, obsolete, or unusable inventories to their estimated useful or scrap values. The Company recognized $2,760,011 and $0 related to the change in inventory reserves during the years ended December 31, 2023 and 2022, respectively.

 

 

Goodwill and Intangible Assets

 

Goodwill represents the excess of the purchase price and related costs over the value assigned to net tangible and identifiable intangible assets acquired in business combinations. Goodwill and indefinite-lived intangible assets are not amortized, but rather tested for impairment at least annually on December 31, or more often if and when circumstances indicate that the carrying value may not be recoverable. Finite-lived intangible assets are amortized over their useful lives.

 

During the years ended December 31, 2023 and 2022, the Company recognized impairment charges related to goodwill of $0 and $15,388,546, respectively.

 

Long-lived Assets

 

Long-lived assets, such as property and equipment, are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from three to five years. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.

 

For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed. Once the development process has been completed the asset will be amortized over its remaining estimated useful life. The Company reviews its long-lived assets, including property and equipment, indefinite-lived and finite-lived intangible assets, and ROU assets, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.

 

Revenue Recognition

 

The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation. Based on the criteria above, the Company typically recognizes revenue upon delivery.

 

The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.

 

Grant Revenue

 

The Company may submit applications to receive grant funding from governmental and non-governmental entities. The Company accounts for grants by analogizing to the contribution accounting model under ASC 958-605, Not-for-Profit Entities (“ASC 958”). Revenues from grants, contracts, and awards provided by governmental and non-governmental agencies are recorded based upon the terms of the specific agreements. The Company recognizes grant funding without conditions or continuing performance obligations as revenue in the consolidated statements of operations and comprehensive income (loss). The Company recognizes grant funding with conditions or continuing performance obligations as deferred revenue in the consolidated balance sheets if the conditions or performance obligations have not yet been met. The Company recognized grant funding revenue of $5.8 million during the year ended December 31, 2023. At December 31, 2023, the Company has also recorded $0.3 million of deferred revenue related to grant funding for which the cash was received, but the underlying conditions or performance obligations have not yet been met. Cash received from federal grants, contracts, and awards can be subject to audit by the grantor and, if the examination results in a disallowance of any expenditure, repayment could be required.

 

Deferred Revenue

 

Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.

 

 

Research and Development

 

Research and development costs are expensed when incurred. The Company recorded $22,962,593 and $17,438,098 of research and development costs for the years ended December 31, 2023 and 2022, respectively.

 

Stock-based Compensation

 

The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.

 

Income Taxes

 

The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, deferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.

 

Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.

 

Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. The Company has uncertain income tax positions in the consolidated financial statements, and adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.

 

Net Income (Loss) per Share

 

Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.

 

Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive.

 

Comprehensive Income (Loss)

 

Comprehensive loss is comprised of net loss and unrealized gains and losses on marketable securities, net of income taxes.

 

Concentrations Risk and Significant Customers

 

The Company had certain customers which were each responsible for generating 10% or more of the total revenue for the years ended December 31, 2023 and 2022, respectively. Two customers accounted for approximately 28% of product revenue for the year ended December 31, 2023 and one customer accounted for approximately 37% of product revenue for the year ended December 31, 2022. One granting agency accounted for 100% of grant revenue for the year ended December 31, 2023.

 

 

Three customers accounted for more than 10% of accounts receivable at December 31, 2023 and 2022, respectively. These customers together accounted for approximately 97% and 61% of accounts receivable at December 31, 2023 and 2022, respectively.

 

Recently Issued Accounting Standards

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires an entity to disclose annually additional information related to the company’s income tax rate reconciliation and income taxes paid during the period. The guidance should be applied prospectively with the option to apply the standard retrospectively. The standard becomes effective for the Company for full year 2025 reporting. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.

 
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cash, Cash Equivalents, and Financial Instruments
 12 Months Ended
Dec. 31, 2023
Cash and Cash Equivalents [Abstract]  
Cash, Cash Equivalents, and Financial Instruments

Note 3 – Cash, Cash Equivalents, and Financial Instruments

 

The following table shows the Company’s cash, cash equivalents, and marketable investment securities by significant investment category:

 

   December 31, 2023 
   Adjusted Cost   Allowance for Credit Losses   Total Unrealized Gains / (Losses)   Fair Value   Cash and Cash Equivalents   Marketable Investment Securities 
Cash  $4,317,449   $-   $-   $4,317,449   $4,317,449   $- 
Level 1:                              
Money market funds   10,599,429    -    -    10,599,429    10,599,429    - 
Subtotal   10,599,429    -    -    10,599,429    10,599,429    - 
Level 2:                              
U.S. treasury securities   43,484,810    -    146,700    43,631,510    -    43,631,510 
Subtotal   43,484,810    -    146,700    43,631,510    -    43,631,510 
Total  $58,401,688   $       -   $146,700   $58,548,388   $14,916,878   $43,631,510 

 

   December 31, 2022 
   Adjusted Cost   Allowance for Credit Losses   Total Unrealized Gains / (Losses)   Fair Value   Cash and Cash Equivalents   Marketable Securities 
Cash  $12,834,444   $-   $-   $12,834,444   $12,834,444   $- 
Level 1:                              
Money market funds   146,359           -    -    146,359    146,359    - 
Subtotal   146,359    -    -    146,359    146,359    - 
Level 2:                              
U.S. treasury securities   67,892,825    -    389,241    68,282,066    9,993,000    58,289,066 
Subtotal   67,892,825    -    389,241    68,282,066    9,993,000    58,289,066 
Total  $80,873,628   $-   $389,241   $81,262,869   $22,973,803   $58,289,066 

 

Marketable investment securities held as of December 31, 2023 mature over the next 12 months.

 
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value Measurements
 12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements

Note 4 – Fair Value Measurements

 

The Company measures and records certain financial assets and liabilities at fair value on a recurring basis. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

The following three levels of inputs are used to measure the fair value of financial assets and liabilities:

 

Level 1: Quoted market prices in active markets for identical assets or liabilities.

 

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

 

Level 3: Unobservable inputs that are not corroborated by market data.

 

 

The following table summarizes the assets and liabilities measured at fair value on a recurring basis as of December 31, 2023 and December 31, 2022, by level within the fair value hierarchy:

 

   (Level 1)   (Level 2)   (Level 3)   Total 
   December 31, 2023 
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                    
Cash equivalents  $13,806,864   $-   $-   $13,806,864 
Marketable securities (U.S. treasury bills and notes)   -    43,631,510    -    43,631,510 
Total assets measured at fair value  $13,806,864   $43,631,510   $-   $57,438,374 
Liabilities:                    
Contingent consideration - common stock  $-   $-   $1,318,995   $1,318,995 
Contingent consideration - warrants   -    -    320,780    320,780 
Total liabilities measured at fair value  $-   $-   $1,639,775   $1,639,775 

 

   (Level 1)   (Level 2)   (Level 3)    Total 
   December 31, 2022 
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                    
Cash equivalents  $186,667   $9,993,000   $-   $10,179,667 
Marketable securities (U.S. treasury bills and notes)   -    58,289,066    -    58,289,066 
Total assets measured at fair value  $186,667   $68,282,066   $-   $68,468,733 
Liabilities:                    
Contingent consideration - common stock  $-   $-   $2,499,147   $2,499,147 
Contingent consideration - warrants   -    -    233,209    233,209 
Total liabilities measured at fair value  $-   $-   $2,732,356   $2,732,356 

 

The Company’s financial instruments that are measured at fair value on a recurring basis consist of certificates of deposit and U.S. treasury bills and notes as of December 31, 2023 and 2022, respectively.

 

In connection with prior year acquisitions, the Company recorded a liability for contingent consideration in the form of shares of common stock and warrants to purchase common stock, both to be issued when certain milestones are achieved. The fair value of contingent consideration is calculated using a discounted probability weighted valuation model. Discount rates used in such calculations are a significant assumption that are not observed in the market, and therefore, the resulting fair value represents a Level 3 measurement.

 

The changes for Level 3 items measured at fair value on a recurring basis are as follows:

 

      
Fair value as of December 31, 2022  $2,732,356 
Change in fair value of contingent consideration issued for business acquisitions   (1,092,581)
Fair value as of December 31, 2023  $1,639,775 

 

 

The fair value of the contingent consideration is based on the fair value of the contingent consideration-common stock and contingent consideration-warrants. The fair value of the contingent consideration-common stock is equal to the probability-adjusted value of the Company’s common stock as of the valuation date. The fair value of the contingent consideration-warrants is equal to the probability adjusted value of a call option with terms consistent with the terms of the warrants as of the valuation date. Prior to the probability adjustments, the warrants were valued based on the following inputs:

 

   December 31, 2023   December 31, 2022 
Stock price  $1.33   $2.52 
Strike price  $9.13   $9.13 
Volatility   187.5%   75.0%
Risk-free rate   4.0%   4.1%
Expected term (years)   3.0    4.0 

 

Fair Value of Other Financial Instruments

 

The carrying amounts of certain financial instruments, including cash held in banks, accounts receivable, notes receivable, accounts payable, accrued liabilities, and other liabilities approximate fair value due to their short-term maturities and are excluded from the fair value tables above.

 
XML 28 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
Property and Equipment
 12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Property and Equipment

Note 5 – Property and Equipment

 

Property and equipment, net consisted of the following:

 

   Estimated  December 31, 
   Useful Lives in years  2023   2022 
Lab equipment  3 - 5  $4,545,908   $3,574,730 
Leasehold improvements  0 - 5   548,648    224,957 
Office equipment, furniture and other  2 - 5   173,668    112,044 
Less accumulated depreciation and amortization      (2,232,495)   (1,372,248)
Fixed assets, net     $3,035,729   $2,539,483 

 
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Intangible Assets
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets

Note 6 – Goodwill and Intangible Assets

 

Goodwill

 

Goodwill represents the excess of purchase price and related costs over the value assigned to net tangible and identifiable intangible assets acquired in business combinations. The following table presents the changes in the carrying amount of goodwill:

 

Balance as of December 31, 2021  $14,706,818 
      
Measurement period adjustments   681,728 
Goodwill impairment charges   (15,388,546)
Balance as of December 31, 2022  $- 

 

 

The Company assesses goodwill for impairment at the reporting unit level on an annual basis, or whenever events or changes in circumstances occur that indicate that the fair value of a reporting unit is below its carrying amount. The Company estimates the fair value of its reporting unit by using forecasts of discounted future cash flows and peer market multiples. If the fair value is less than the carrying value, impairment will be recognized in the amount by which the carrying value exceeds the fair value. The Company performed a qualitative and quantitative goodwill impairment assessment as of December 31, 2022. Based on the impairment assessment performed the Company concluded that it was more likely than not that the fair value of the Company’s reporting unit was less than it’s carrying amount. Accordingly, the Company recorded an impairment charge to reduce the carrying value of goodwill to $0.

 

Intangible Assets, Net

 

Intangible assets, net consisted of the following:

 

   December 31, 2023
   Weighted-Average  Gross       Net 
   Useful Life (1)  Carrying   Accumulated   Carrying 
   (in Years)  Amount   Amortization   Amount 
In-process research and development  Indefinite  $ 26,101,000   $-   $26,101,000 
Non-competition agreements  2.7   1,094,000    (791,333)   302,667 
Total intangible assets     $27,195,000   $(791,333)  $26,403,667 

 

   December 31, 2022
   Weighted-Average  Gross       Net 
   Useful Life (1)  Carrying   Accumulated   Carrying 
   (in Years)  Amount   Amortization   Amount 
In-process research and development  Indefinite  $26,101,000   $-   $26,101,000 
Non-competition agreements  2.7   1,094,000    (426,667)   667,333 
Total intangible assets     $27,195,000   $(426,667)  $26,768,333 

 

(1)Based on weighted-average useful life established as of the acquisition date.

 

 

The expected future annual amortization expense of the Company’s intangible assets held as of December 31, 2023 is as follows:

 

Year Ending December 31,  Amortization Expense 
2024   302,667 
Total  $302,667 

 
XML 30 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
Accrued Expenses
 12 Months Ended
Dec. 31, 2023
Payables and Accruals [Abstract]  
Accrued Expenses

Note 7 - Accrued Expenses

 

Accrued expenses consisted of the following:

 

 

   December 31, 2023   December 31, 2022 
Payroll liabilities  $1,643,186   $428,354 
Distributor commissions   9,958    159,725 
Other accrued liabilities   519,815    346,368 
Total accrued expenses  $2,172,959   $934,447 

 
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Revenue

Note 8 – Revenue

 

The following table sets forth revenue by geographic area:

 

   2023   2022 
   Years Ended December 31, 
   2023   2022 
United States          
Product revenue  $659,618   $24,671,554 
Grant revenue   5,820,565    - 
Total United States   6,480,183    24,671,554 
Rest of World          
Product revenue   331,855    9,546,655 
Grant revenue   -    - 
Total Rest of World   331,855    9,546,655 
Total  $6,812,038   $34,218,209 
Percentage of revenue by area:          
United States   95%   72%
Rest of World   5%   28%

 

Deferred Revenue

 

Changes in the Company’s deferred revenue balance for the year ended December 31, 2023 were as follows:

 

Balance as of December 31, 2022  $- 
Increase due to prepayments from customers   32,570 
Increase due to grant funding awarded   329,879 
 Balance as of December, 2023  $362,449 

 
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
Earnings per Share
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Earnings per Share

Note 9 – Earnings per Share

 

The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for years ended December 31, 2023 and 2022:

 

   2023   2022 
   Years Ended December 31, 
   2023   2022 
Numerator          
Net loss, as reported  $(35,332,865)  $(14,238,249)
           
Denominator          
Weighted average shares, basic   29,346,599    31,479,028 
Dilutive effect of stock options, warrants and RSUs   -    - 
Shares used to compute diluted earnings per share   29,346,599    31,479,028 
           
Basic earnings per share  $(1.20)  $(0.45)
Diluted earnings per share  $(1.20)  $(0.45)

 

 

The computation of diluted earnings per share for the years ended December 31, 2023 and December 31, 2022 also excludes approximately 1.4 million shares of common stock and approximately 465,000 warrants to purchase shares of common stock that are contingent upon the achievement of certain milestones.

 

As a result of incurring a net loss for the years ended December 31, 2023 and 2022, respectively, no potentially dilutive securities are included in the calculation of diluted earnings per share because such effect would be anti-dilutive. The Company had potentially dilutive securities as of December 31, 2023, consisting of: (i) 2,618,362 restricted stock units and (ii) 512,112 options, and potentially dilutive securities as of December 31, 2022, consisting of: (i) 1,443,238 restricted stock units and (ii) 50,000 options.

 
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation

Note 10 – Stock-Based Compensation

 

Stock Incentive Plans

 

The Company’s board of directors adopted, and shareholders approved, the Co-Diagnostics, Inc. Amended and Restated 2015 Long Term Incentive Plan (the “Incentive Plan”) providing for the issuance of stock-based incentive awards to employees, officers, consultants, directors and independent contractors. On August 31, 2022 the shareholders approved an increase in the number of awards available for issuance under the Incentive Plan to an aggregate of 12,000,000 shares of common stock. The number of awards available for issuance under the Incentive Plan was 4,357,937 at December 31, 2023.

 

Stock Options

 

The following table summarizes option activity during the years ended December 31, 2023 and 2022:

 

   Number of Options   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2021   1,111,363   $2.12   $1.31      
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   (70,791)   1.10    0.51      
Outstanding at December 31, 2022   1,040,572   $2.19   $1.37    5.88 
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   -    -    -      
Outstanding at December 31, 2023   1,040,572   $2.19   $1.37    4.89 
                     
Exercisable at December 31, 2023   1,040,572   $2.19   $1.37    4.89 

 

 

The total intrinsic value of options exercised during the years ended December 31, 2023 and 2022, respectively, was $0 and approximately $0.4 million. The aggregate intrinsic value of outstanding options at December 31, 2023 and 2022 was approximately $0.2 million and $0.8 million, respectively. As of December 31, 2023, there were no unvested options and no unrecognized stock-based compensation expense related to options.

 

Restricted Stock Units

 

The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the years ended December 31, 2023 and 2022:

 

   Number of RSUs  

Weighted

Average Grant Date Fair Value

 
Unvested at December 31, 2021   1,267,415   $9.94 
Granted   1,925,476    5.66 
Vested   (725,166)   8.66 
Forfeited/Cancelled   (41,000)   8.31 
Unvested at December 31, 2022   2,426,725   $6.95 
Granted   1,948,750    1.92 
Vested   (1,354,081)   6.17 
Forfeited/Cancelled   (95,897)   6.16 
Unvested at December 31, 2023   2,925,497   $3.99 

 

As of December 31, 2023, there was $9.5 million of unrecognized stock-based compensation expense related to outstanding RSUs which is expected to be recognized over a weighted-average period of 1.7 years.

 

Warrants

 

The Company has issued warrants related to financings, acquisitions and as compensation to third parties for services provided. The Company estimates the fair value of issued warrants on the date of issuance as determined using a Black-Scholes pricing model. The Company amortizes the fair value of issued warrants using a vesting schedule based on the terms and conditions of each warrant if granted for services.

 

 

The following table summarizes warrant activity during the years ended December 31, 2023 and 2022:

 

   Number of Warrants  

Weighted Average Exercise

Price

   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2021   526,281   $8.15   $4.01    4.7 
Issued for adjustments to contingent purchase consideration   8,719    9.13    1.88      
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   (50,000)   2.00    1.22      
Outstanding at December 31, 2022   485,000   $8.81   $2.43    4.0 
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   -    -    -      
Outstanding at December 31, 2023   485,000   $8.81   $1.29    3.0 

 

The intrinsic value of warrants exercised during the years ended December 31, 2023 and 2022, respectively, was $0 and approximately $0.3 million. The aggregate intrinsic value of outstanding warrants at December 31, 2023 was approximately $0.

 

The total number of warrants exercisable at December 31, 2023 is 20,000. The ability to exercise the approximately 465,000 warrants issued in connection with acquisitions in prior years is contingent upon the achievement of certain development and revenue milestones on or before January 1, 2027. There was no unrecognized stock-based compensation expense related to warrants.

 

Stock-Based Compensation Expense

 

The Company recognized stock-based compensation expense as follows:

 

   2023   2022 
   Years Ended December 31, 
   2023   2022 
Cost of sales  $46,586   $63,058 
Sales and marketing   2,153,974    1,866,116 
General and administrative   4,933,822    4,050,967 
Research and development   1,202,473    1,563,082 
Total stock-based compensation expense  $8,336,855   $7,543,223 

 
XML 34 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes

Note 11 – Income Taxes

 

The components of the provision (benefit) for income taxes consists of the following for the years ended December 31, 2023 and 2022:

 

   2023     2022 
   Year Ended December 31, 
   2023    2022 
Current:          
Federal  $84,435   $563,821 
State   (540,240)   (266,248)
Total current  $(455,805)  $297,573 
Deferred:          
Federal   (7,228,611)   (3,945,090)
State   (2,068,509)   (961,468)
Change in valuation allowance   6,975,234    - 
Total deferred   (2,321,886)   (4,906,558)
Total income tax benefit  $(2,777,691)  $(4,608,985)

 

 

A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:

 

   2023   2022 
   Year Ended December 31, 
   2023   2022 
Federal income tax expense at statutory rate   21.0%   21.0%
State income tax expense, net of federal tax benefit   1.6%   4.8%
Permanent differences:          
- Foreign derived intangible income deduction   0.0%   1.4%
- Stock based compensation   -3.5%   -3.6%
- Contingent consideration remeasurement   0.6%   8.8%
- Goodwill impairment   0.0%   -17.1%
- Other permanent differences   -0.2%   -0.6%
Research and development credits   4.6%   11.1%
Change in uncertain tax positions   1.2%   -2.1%
Change in valuation allowance   -18.3%   0.0%
Other   0.3%   0.8%
Effective income tax rate   7.3%   24.5%

 

Net deferred tax liabilities consist of the following components as of December 31, 2023 and 2022:

 

   2023   2022 
   December 31, 
   2023   2022 
Deferred tax assets:          
Accrued liabilities  $58,158   $98,141 
Reserves and allowances   734,631    765,004 
Deferred compensation   620,551    566,076 
Section 174 costs   7,337,629    3,460,159 
Lease liability   742,131    85,899 
UNICAP   43,943    168,936 
Net operating loss carryforwards   4,040,601    - 
Research and development credits   1,688,255    - 
Total gross deferred tax assets   15,265,899    5,144,215 
Less valuation allowance   (6,938,829)   - 
Total deferred tax assets   8,327,070    5,144,215 
Deferred tax liabilities:          
Property and equipment, net   (672,416)   (609,261)
Intangibles, net   (6,552,255)   (6,608,914)
Prepaids   (329,768)   (156,053)
Right of use asset   (736,226)   (91,873)
Other comprehensive income   (36,405)   (96,101)
Other   -    - 
Total deferred tax liabilities   (8,327,070)   (7,562,202)
           
Net deferred tax liability  $-   $(2,417,987)

 

At December 31, 2023, the Company had federal net operating loss carryforwards of $16.3 million and federal research and development credit carryforwards of $1.4 million. At December 31, 2023, the Company had state net operating loss carryforwards of $16.9 million and $0.8 million of state research and development credit carryforwards. If unused, the state research credit carryforward will expire in 2037.

 

 

ASC Topic 740-10-05 requires that the impact of a tax position be recognized in the financial statements if that position is more likely than not of being sustained on audit, based on the technical merits of the position. Our unrecognized tax benefit balances included $1,078,431 at December 31, 2023 and $1,469,577 at December 31, 2022 of tax positions that, if recognized, would impact our effective tax rate. The Company expects no material changes to the liability for unrecognized tax benefits in the next 12 months. Interest and penalties associated with uncertain tax positions are recorded as a component of income tax expense. A reconciliation of the beginning and ending amount of unrecognized benefits is as follows:

 

   December 31, 
   2023   2022 
Unrecognized tax benefits at the beginning of the year  $1,469,577   $1,067,853 
Gross increases - current year tax positions   273,569    1,045,590 
Gross increases - prior year tax positions   66,127    34,035 
Gross decreases - prior year tax positions   (730,842)   (677,901)
Unrecognized tax benefits at end of year  $1,078,431   $1,469,577 
           
Interest and penalties in year-end balance  $100,162   $34,035 

 

The Company is subject to taxation in the United States and other state jurisdictions. The tax years from December 31, 2020 through December 31, 2023 remain open to examination for federal income tax purposes and by the other major taxing jurisdictions to which the Company is subject. The Company is not currently under examination by any taxing authority.

 
XML 35 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 12 – Commitments and Contingencies

 

Lease Obligations

 

The Company leases administrative, R&D, sales and marketing and manufacturing facilities under non-cancellable operating leases and leases cancellable with one month notice. The Company expenses the cancelable leases in the period incurred in accordance with the practical expedient elected. During the year December 31, 2023, the Company amended two operating leases to extend the lease term and entered into two new operating leases. As a result, the Company recognized additional operating lease liabilities and corresponding operating right-of-use assets of $3,203,146.

 

For the year ended December 31, 2023, components of lease expense are summarized as follows:

 

  

Year Ended

December 31, 2023

 
Operating lease costs  $813,743 
Short-term lease costs   198,261 
Total lease costs  $1,012,004 

 

As of December 31, 2023, the maturities of the Company’s lease liabilities are as follows:

 

  

Year Ending

December 31,

 
2024  $996,676 
2025   1,018,383 
2026   714,630 
2027   300,591 
Thereafter   308,462 
Total lease payments   3,338,742 
Less: imputed interest   348,175 
Present value of operating lease liabilities   2,990,567 
Less: current portion   838,387 
Long-term portion  $2,152,180 

 

 

Other information related to operating leases was as follows:

 

  

Year Ended

December 31, 2023

 
Cash paid for operating leases included in operating cash flows  $954,013 
Remaining lease term of operating leases   3.7 years  
Discount rate of operating leases   6.2%

 

Litigation

 

Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.

 

The Company is a defendant in two class action claims and three derivative actions claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The plaintiffs demand compensatory damages sustained as a result of the Company’s alleged wrongdoing in an amount to be proven at trial. The Company is also a party to two civil actions, one in the US and the other in the United Kingdom. Each of the civil actions is based on breach of contract claims against the Company. The Company believes these lawsuits are without merit and intends to defend the cases vigorously. The Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in these cases. As of the date of this report, the Company does not believe it is probable that these cases will result in an unfavorable outcome; however, if an unfavorable outcome were to occur in these cases, it is possible that the impact could be material to the Company’s results of operations in the period(s) in which any such outcome becomes probable and estimable.

 
XML 36 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
Share Repurchase Program
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Share Repurchase Program

Note 13 – Share Repurchase Program

 

In March 2022, the Company’s board of directors authorized a share repurchase program that would allow the Company to repurchase up to $30.0 million of CODX common stock. The repurchase program does not obligate the Company to acquire any particular number of common shares, and the repurchase program may be suspended or discontinued at any time at the Company’s discretion. The timing and amount of any share repurchases under the share repurchase program will be determined by Co-Diagnostics’ management at its discretion based on ongoing assessments of the capital needs of the business, the market price of the Company’s common stock, corporate and regulatory requirements, and general market conditions.

 

For accounting purposes, common stock repurchased under the stock repurchase program is recorded based upon the transaction date of the applicable trade. Such repurchased shares are held in treasury and are presented using the cost method. These shares are not retired and are considered issued but not outstanding. The following table shows the changes in treasury stock for the periods presented:

 

   Year Ended 
   December 31, 2023 
Balance, beginning of period   3,881,658 
Repurchases of common stock   967,020 
Balance, end of period   4,848,678 

 
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
Related Party Transactions
 12 Months Ended
Dec. 31, 2023
Related Party Transactions [Abstract]  
Related Party Transactions

Note 14 – Related Party Transactions

 

The Company employs one person who is related to current or former executive officers. Seth Egan is the Company’s Director of Sales and Marketing, and is the son of Dwight Egan, the Company’s President and Chief Executive Officer and Chairman of the Board. During the year ended December 31, 2023, the total compensation paid to this person, including salaries, bonuses, and the grant date fair value of equity awards which vest over three years, was $0.6 million. The Company also uses the services of Winston Egan as an independent contractor for sales operations consulting. Winston Egan is also the son of Dwight Egan, the Company’s President and Chief Executive Officer and Chairman of the Board. During the year ended December 31, 2023, the total compensation paid to this contractor, comprised of consulting fees, was $0.1 million.

 

In August 2023, the Company entered into a services agreement with CoSara, the Company’s equity method investment, under which CoSara provides certain research and development consulting and support services. During the year ended December 31, 2023, the Company recognized $0.2 million of expense related to this agreement.

 
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
Subsequent Events
 12 Months Ended
Dec. 31, 2023
Subsequent Events [Abstract]  
Subsequent Events

Note 15 – Subsequent Events

 

None.
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Reclassifications

Reclassifications

 

Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.

 
Cash and Cash Equivalents

Cash and Cash Equivalents

 

Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of December 31, 2023 and December 31, 2022. The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.

 

 
Marketable Investment Securities

Marketable Investment Securities

 

The Company’s marketable investment securities are comprised of investments in certificates of deposit and U.S. Treasury bills and notes. The Company designates investments in debt securities as available-for-sale. Available-for-sale debt securities with original maturities of three months or less from the date of purchase are classified within cash and cash equivalents. Available-for-sale debt securities with original maturities longer than three months are available to fund current operations and are classified as marketable investment securities, within current assets on the consolidated balance sheets. The Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. Available-for-sale debt securities are reported at fair value with the related unrealized gains and losses included in accumulated other comprehensive income (loss), a component of stockholders’ equity, net of tax. Realized gains and losses on the sale of marketable securities are determined using the average cost method on a first-in, first-out basis and recorded in total other income (expense), net in the consolidated statements of operations and comprehensive loss.

 

The available-for-sale debt securities are subject to a periodic impairment review. For investments in an unrealized loss position, the Company writes down the amortized cost basis of the investment if it is more likely than not that the Company will be required or will intend to sell the investment before recovery of its amortized cost basis. For investments not likely to be sold before recovery of the amortized cost basis, the Company determines whether a credit loss exists by considering information about the collectability of the instrument, current market conditions, and reasonable and supportable forecasts of economic conditions. The Company recognizes an allowance for credit losses up to the amount of the unrealized loss when appropriate. Allowances for credit losses and write-downs are recognized in total other income (expense), net, and unrealized losses not related to credit losses are recognized in accumulated other comprehensive income (loss). There are no allowances for credit losses recorded for the periods presented.

 
Accounts Receivable

Accounts Receivable

 

Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At December 31, 2023 total accounts receivable was $504,264 with an allowance for uncollectable accounts of $200,338 resulting in a net amount of $303,926. At December 31, 2022 total accounts receivable was $6,552,249 with an allowance for uncollectable accounts of $3,098,526 resulting in a net amount of $3,453,723.

 
Equity-Method Investments

Equity-Method Investments

 

Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying consolidated statements of operations.

 
Inventory

Inventory

 

Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At December 31, 2023, the Company had $1,664,725 in inventory, of which $700,467 was finished goods and $964,258 was raw materials. At December 31, 2022, the Company had $5,310,473 in inventory, of which $1,327,264 was finished goods and $3,983,209 was raw materials. The Company establishes reserves to reduce low-moving, obsolete, or unusable inventories to their estimated useful or scrap values. The Company recognized $2,760,011 and $0 related to the change in inventory reserves during the years ended December 31, 2023 and 2022, respectively.

 

 
Goodwill and Intangible Assets

Goodwill and Intangible Assets

 

Goodwill represents the excess of the purchase price and related costs over the value assigned to net tangible and identifiable intangible assets acquired in business combinations. Goodwill and indefinite-lived intangible assets are not amortized, but rather tested for impairment at least annually on December 31, or more often if and when circumstances indicate that the carrying value may not be recoverable. Finite-lived intangible assets are amortized over their useful lives.

 

During the years ended December 31, 2023 and 2022, the Company recognized impairment charges related to goodwill of $0 and $15,388,546, respectively.

 
Long-lived Assets

Long-lived Assets

 

Long-lived assets, such as property and equipment, are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from three to five years. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.

 

For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed. Once the development process has been completed the asset will be amortized over its remaining estimated useful life. The Company reviews its long-lived assets, including property and equipment, indefinite-lived and finite-lived intangible assets, and ROU assets, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.

 
Revenue Recognition

Revenue Recognition

 

The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation. Based on the criteria above, the Company typically recognizes revenue upon delivery.

 

The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.

 
Grant Revenue

Grant Revenue

 

The Company may submit applications to receive grant funding from governmental and non-governmental entities. The Company accounts for grants by analogizing to the contribution accounting model under ASC 958-605, Not-for-Profit Entities (“ASC 958”). Revenues from grants, contracts, and awards provided by governmental and non-governmental agencies are recorded based upon the terms of the specific agreements. The Company recognizes grant funding without conditions or continuing performance obligations as revenue in the consolidated statements of operations and comprehensive income (loss). The Company recognizes grant funding with conditions or continuing performance obligations as deferred revenue in the consolidated balance sheets if the conditions or performance obligations have not yet been met. The Company recognized grant funding revenue of $5.8 million during the year ended December 31, 2023. At December 31, 2023, the Company has also recorded $0.3 million of deferred revenue related to grant funding for which the cash was received, but the underlying conditions or performance obligations have not yet been met. Cash received from federal grants, contracts, and awards can be subject to audit by the grantor and, if the examination results in a disallowance of any expenditure, repayment could be required.

 
Deferred Revenue

Deferred Revenue

 

Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.

 

 
Research and Development

Research and Development

 

Research and development costs are expensed when incurred. The Company recorded $22,962,593 and $17,438,098 of research and development costs for the years ended December 31, 2023 and 2022, respectively.

 
Stock-based Compensation

Stock-based Compensation

 

The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.

 
Income Taxes

Income Taxes

 

The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, deferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.

 

Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.

 

Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. The Company has uncertain income tax positions in the consolidated financial statements, and adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.

 
Net Income (Loss) per Share

Net Income (Loss) per Share

 

Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.

 

Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive.

 
Comprehensive Income (Loss)

Comprehensive Income (Loss)

 

Comprehensive loss is comprised of net loss and unrealized gains and losses on marketable securities, net of income taxes.

 
Concentrations Risk and Significant Customers

Concentrations Risk and Significant Customers

 

The Company had certain customers which were each responsible for generating 10% or more of the total revenue for the years ended December 31, 2023 and 2022, respectively. Two customers accounted for approximately 28% of product revenue for the year ended December 31, 2023 and one customer accounted for approximately 37% of product revenue for the year ended December 31, 2022. One granting agency accounted for 100% of grant revenue for the year ended December 31, 2023.

 

 

Three customers accounted for more than 10% of accounts receivable at December 31, 2023 and 2022, respectively. These customers together accounted for approximately 97% and 61% of accounts receivable at December 31, 2023 and 2022, respectively.

 
Recently Issued Accounting Standards

Recently Issued Accounting Standards

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires an entity to disclose annually additional information related to the company’s income tax rate reconciliation and income taxes paid during the period. The guidance should be applied prospectively with the option to apply the standard retrospectively. The standard becomes effective for the Company for full year 2025 reporting. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cash, Cash Equivalents, and Financial Instruments (Tables)
 12 Months Ended
Dec. 31, 2023
Cash and Cash Equivalents [Abstract]  
Schedule of Cash, Cash Equivalents and Marketable Investment Securities

The following table shows the Company’s cash, cash equivalents, and marketable investment securities by significant investment category:

 

   December 31, 2023 
   Adjusted Cost   Allowance for Credit Losses   Total Unrealized Gains / (Losses)   Fair Value   Cash and Cash Equivalents   Marketable Investment Securities 
Cash  $4,317,449   $-   $-   $4,317,449   $4,317,449   $- 
Level 1:                              
Money market funds   10,599,429    -    -    10,599,429    10,599,429    - 
Subtotal   10,599,429    -    -    10,599,429    10,599,429    - 
Level 2:                              
U.S. treasury securities   43,484,810    -    146,700    43,631,510    -    43,631,510 
Subtotal   43,484,810    -    146,700    43,631,510    -    43,631,510 
Total  $58,401,688   $       -   $146,700   $58,548,388   $14,916,878   $43,631,510 

 

   December 31, 2022 
   Adjusted Cost   Allowance for Credit Losses   Total Unrealized Gains / (Losses)   Fair Value   Cash and Cash Equivalents   Marketable Securities 
Cash  $12,834,444   $-   $-   $12,834,444   $12,834,444   $- 
Level 1:                              
Money market funds   146,359           -    -    146,359    146,359    - 
Subtotal   146,359    -    -    146,359    146,359    - 
Level 2:                              
U.S. treasury securities   67,892,825    -    389,241    68,282,066    9,993,000    58,289,066 
Subtotal   67,892,825    -    389,241    68,282,066    9,993,000    58,289,066 
Total  $80,873,628   $-   $389,241   $81,262,869   $22,973,803   $58,289,066 
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
Schedule of Fair Value Assets and Liabilities

The following table summarizes the assets and liabilities measured at fair value on a recurring basis as of December 31, 2023 and December 31, 2022, by level within the fair value hierarchy:

 

   (Level 1)   (Level 2)   (Level 3)   Total 
   December 31, 2023 
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                    
Cash equivalents  $13,806,864   $-   $-   $13,806,864 
Marketable securities (U.S. treasury bills and notes)   -    43,631,510    -    43,631,510 
Total assets measured at fair value  $13,806,864   $43,631,510   $-   $57,438,374 
Liabilities:                    
Contingent consideration - common stock  $-   $-   $1,318,995   $1,318,995 
Contingent consideration - warrants   -    -    320,780    320,780 
Total liabilities measured at fair value  $-   $-   $1,639,775   $1,639,775 

 

   (Level 1)   (Level 2)   (Level 3)    Total 
   December 31, 2022 
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                    
Cash equivalents  $186,667   $9,993,000   $-   $10,179,667 
Marketable securities (U.S. treasury bills and notes)   -    58,289,066    -    58,289,066 
Total assets measured at fair value  $186,667   $68,282,066   $-   $68,468,733 
Liabilities:                    
Contingent consideration - common stock  $-   $-   $2,499,147   $2,499,147 
Contingent consideration - warrants   -    -    233,209    233,209 
Total liabilities measured at fair value  $-   $-   $2,732,356   $2,732,356 
Schedule of Changes in the Fair Value Measurement

The changes for Level 3 items measured at fair value on a recurring basis are as follows:

 

      
Fair value as of December 31, 2022  $2,732,356 
Change in fair value of contingent consideration issued for business acquisitions   (1,092,581)
Fair value as of December 31, 2023  $1,639,775 
Schedule of Contingent Consideration Common Stock and Warrants

 

   December 31, 2023   December 31, 2022 
Stock price  $1.33   $2.52 
Strike price  $9.13   $9.13 
Volatility   187.5%   75.0%
Risk-free rate   4.0%   4.1%
Expected term (years)   3.0    4.0 
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment

Property and equipment, net consisted of the following:

 

   Estimated  December 31, 
   Useful Lives in years  2023   2022 
Lab equipment  3 - 5  $4,545,908   $3,574,730 
Leasehold improvements  0 - 5   548,648    224,957 
Office equipment, furniture and other  2 - 5   173,668    112,044 
Less accumulated depreciation and amortization      (2,232,495)   (1,372,248)
Fixed assets, net     $3,035,729   $2,539,483 
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill

Balance as of December 31, 2021  $14,706,818 
      
Measurement period adjustments   681,728 
Goodwill impairment charges   (15,388,546)
Balance as of December 31, 2022  $- 
Schedule of Intangible Assets, Net

Intangible assets, net consisted of the following:

 

   December 31, 2023
   Weighted-Average  Gross       Net 
   Useful Life (1)  Carrying   Accumulated   Carrying 
   (in Years)  Amount   Amortization   Amount 
In-process research and development  Indefinite  $ 26,101,000   $-   $26,101,000 
Non-competition agreements  2.7   1,094,000    (791,333)   302,667 
Total intangible assets     $27,195,000   $(791,333)  $26,403,667 

 

   December 31, 2022
   Weighted-Average  Gross       Net 
   Useful Life (1)  Carrying   Accumulated   Carrying 
   (in Years)  Amount   Amortization   Amount 
In-process research and development  Indefinite  $26,101,000   $-   $26,101,000 
Non-competition agreements  2.7   1,094,000    (426,667)   667,333 
Total intangible assets     $27,195,000   $(426,667)  $26,768,333 

 

(1)Based on weighted-average useful life established as of the acquisition date.
Schedule of Future Amortization Expense

The expected future annual amortization expense of the Company’s intangible assets held as of December 31, 2023 is as follows:

 

Year Ending December 31,  Amortization Expense 
2024   302,667 
Total  $302,667 
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
Accrued Expenses (Tables)
 12 Months Ended
Dec. 31, 2023
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses

Accrued expenses consisted of the following:

 

 

   December 31, 2023   December 31, 2022 
Payroll liabilities  $1,643,186   $428,354 
Distributor commissions   9,958    159,725 
Other accrued liabilities   519,815    346,368 
Total accrued expenses  $2,172,959   $934,447 
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue (Tables)
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Summary of Revenue by Geographic Area

The following table sets forth revenue by geographic area:

 

   2023   2022 
   Years Ended December 31, 
   2023   2022 
United States          
Product revenue  $659,618   $24,671,554 
Grant revenue   5,820,565    - 
Total United States   6,480,183    24,671,554 
Rest of World          
Product revenue   331,855    9,546,655 
Grant revenue   -    - 
Total Rest of World   331,855    9,546,655 
Total  $6,812,038   $34,218,209 
Percentage of revenue by area:          
United States   95%   72%
Rest of World   5%   28%
Schedule of Deferred Revenue

Changes in the Company’s deferred revenue balance for the year ended December 31, 2023 were as follows:

 

Balance as of December 31, 2022  $- 
Increase due to prepayments from customers   32,570 
Increase due to grant funding awarded   329,879 
 Balance as of December, 2023  $362,449 
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
Earnings per Share (Tables)
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Schedule of Basis and Diluted Earnings Per Share

The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for years ended December 31, 2023 and 2022:

 

   2023   2022 
   Years Ended December 31, 
   2023   2022 
Numerator          
Net loss, as reported  $(35,332,865)  $(14,238,249)
           
Denominator          
Weighted average shares, basic   29,346,599    31,479,028 
Dilutive effect of stock options, warrants and RSUs   -    - 
Shares used to compute diluted earnings per share   29,346,599    31,479,028 
           
Basic earnings per share  $(1.20)  $(0.45)
Diluted earnings per share  $(1.20)  $(0.45)
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Option Activity

The following table summarizes option activity during the years ended December 31, 2023 and 2022:

 

   Number of Options   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2021   1,111,363   $2.12   $1.31      
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   (70,791)   1.10    0.51      
Outstanding at December 31, 2022   1,040,572   $2.19   $1.37    5.88 
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   -    -    -      
Outstanding at December 31, 2023   1,040,572   $2.19   $1.37    4.89 
                     
Exercisable at December 31, 2023   1,040,572   $2.19   $1.37    4.89 
Schedule of Outstanding Restricted Stock Units and Related Party

The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the years ended December 31, 2023 and 2022:

 

   Number of RSUs  

Weighted

Average Grant Date Fair Value

 
Unvested at December 31, 2021   1,267,415   $9.94 
Granted   1,925,476    5.66 
Vested   (725,166)   8.66 
Forfeited/Cancelled   (41,000)   8.31 
Unvested at December 31, 2022   2,426,725   $6.95 
Granted   1,948,750    1.92 
Vested   (1,354,081)   6.17 
Forfeited/Cancelled   (95,897)   6.16 
Unvested at December 31, 2023   2,925,497   $3.99 
Schedule of Warrant Activity

The following table summarizes warrant activity during the years ended December 31, 2023 and 2022:

 

   Number of Warrants  

Weighted Average Exercise

Price

   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2021   526,281   $8.15   $4.01    4.7 
Issued for adjustments to contingent purchase consideration   8,719    9.13    1.88      
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   (50,000)   2.00    1.22      
Outstanding at December 31, 2022   485,000   $8.81   $2.43    4.0 
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   -    -    -      
Outstanding at December 31, 2023   485,000   $8.81   $1.29    3.0 
Schedule of Recognized Stock-based Compensation Expense

The Company recognized stock-based compensation expense as follows:

 

   2023   2022 
   Years Ended December 31, 
   2023   2022 
Cost of sales  $46,586   $63,058 
Sales and marketing   2,153,974    1,866,116 
General and administrative   4,933,822    4,050,967 
Research and development   1,202,473    1,563,082 
Total stock-based compensation expense  $8,336,855   $7,543,223 
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of Components Income Tax Provision

The components of the provision (benefit) for income taxes consists of the following for the years ended December 31, 2023 and 2022:

 

   2023     2022 
   Year Ended December 31, 
   2023    2022 
Current:          
Federal  $84,435   $563,821 
State   (540,240)   (266,248)
Total current  $(455,805)  $297,573 
Deferred:          
Federal   (7,228,611)   (3,945,090)
State   (2,068,509)   (961,468)
Change in valuation allowance   6,975,234    - 
Total deferred   (2,321,886)   (4,906,558)
Total income tax benefit  $(2,777,691)  $(4,608,985)
Schedule of Benefit from Income Taxes and Effective Tax Rates

A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:

 

   2023   2022 
   Year Ended December 31, 
   2023   2022 
Federal income tax expense at statutory rate   21.0%   21.0%
State income tax expense, net of federal tax benefit   1.6%   4.8%
Permanent differences:          
- Foreign derived intangible income deduction   0.0%   1.4%
- Stock based compensation   -3.5%   -3.6%
- Contingent consideration remeasurement   0.6%   8.8%
- Goodwill impairment   0.0%   -17.1%
- Other permanent differences   -0.2%   -0.6%
Research and development credits   4.6%   11.1%
Change in uncertain tax positions   1.2%   -2.1%
Change in valuation allowance   -18.3%   0.0%
Other   0.3%   0.8%
Effective income tax rate   7.3%   24.5%
Schedule of Deferred Tax Assets and Liabilities

Net deferred tax liabilities consist of the following components as of December 31, 2023 and 2022:

 

   2023   2022 
   December 31, 
   2023   2022 
Deferred tax assets:          
Accrued liabilities  $58,158   $98,141 
Reserves and allowances   734,631    765,004 
Deferred compensation   620,551    566,076 
Section 174 costs   7,337,629    3,460,159 
Lease liability   742,131    85,899 
UNICAP   43,943    168,936 
Net operating loss carryforwards   4,040,601    - 
Research and development credits   1,688,255    - 
Total gross deferred tax assets   15,265,899    5,144,215 
Less valuation allowance   (6,938,829)   - 
Total deferred tax assets   8,327,070    5,144,215 
Deferred tax liabilities:          
Property and equipment, net   (672,416)   (609,261)
Intangibles, net   (6,552,255)   (6,608,914)
Prepaids   (329,768)   (156,053)
Right of use asset   (736,226)   (91,873)
Other comprehensive income   (36,405)   (96,101)
Other   -    - 
Total deferred tax liabilities   (8,327,070)   (7,562,202)
           
Net deferred tax liability  $-   $(2,417,987)
Schedule of Unrecognized Tax Benefits

   December 31, 
   2023   2022 
Unrecognized tax benefits at the beginning of the year  $1,469,577   $1,067,853 
Gross increases - current year tax positions   273,569    1,045,590 
Gross increases - prior year tax positions   66,127    34,035 
Gross decreases - prior year tax positions   (730,842)   (677,901)
Unrecognized tax benefits at end of year  $1,078,431   $1,469,577 
           
Interest and penalties in year-end balance  $100,162   $34,035 
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Lease Expense

For the year ended December 31, 2023, components of lease expense are summarized as follows:

 

  

Year Ended

December 31, 2023

 
Operating lease costs  $813,743 
Short-term lease costs   198,261 
Total lease costs  $1,012,004 
Schedule of Maturities on Company Lease Liabilities

As of December 31, 2023, the maturities of the Company’s lease liabilities are as follows:

 

  

Year Ending

December 31,

 
2024  $996,676 
2025   1,018,383 
2026   714,630 
2027   300,591 
Thereafter   308,462 
Total lease payments   3,338,742 
Less: imputed interest   348,175 
Present value of operating lease liabilities   2,990,567 
Less: current portion   838,387 
Long-term portion  $2,152,180 
Schedule of Other Information Related to Operating Lease

Other information related to operating leases was as follows:

 

  

Year Ended

December 31, 2023

 
Cash paid for operating leases included in operating cash flows  $954,013 
Remaining lease term of operating leases   3.7 years  
Discount rate of operating leases   6.2%
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
Share Repurchase Program (Tables)
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Schedule of Treasury Stock

 

   Year Ended 
   December 31, 2023 
Balance, beginning of period   3,881,658 
Repurchases of common stock   967,020 
Balance, end of period   4,848,678 
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Product Information [Line Items]    
Accounts receivable $ 504,264 $ 6,552,249
Doubtful accounts 200,338 3,098,526
Accounts receivable, net 303,926 3,453,723
Inventory 1,664,725 5,310,473
Inventory, finished goods, gross 700,467 1,327,264
Inventory, raw materials, gross 964,258 3,983,209
Inventory reserves 2,760,011 0
Impairment charges 0 15,388,546
Grant funding revenue 5,800,000  
Deferred revenue 300,000  
Research and development $ 22,962,593 $ 17,438,098
Customers [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]    
Product Information [Line Items]    
Concentration risk percentage 10.00% 10.00%
Two Customers [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]    
Product Information [Line Items]    
Concentration risk percentage 10.00% 10.00%
Two Customers [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]    
Product Information [Line Items]    
Concentration risk percentage 28.00%  
One Customer [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]    
Product Information [Line Items]    
Concentration risk percentage   37.00%
One Granting Agency [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]    
Product Information [Line Items]    
Concentration risk percentage 100.00%  
Customers Together [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]    
Product Information [Line Items]    
Concentration risk percentage 97.00% 61.00%
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Cash, Cash Equivalents and Marketable Investment Securities (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash and Cash Equivalents [Line Items]    
Adjusted Cost $ 58,401,688 $ 80,873,628
Allowance for Credit Losses
Total Unrealized Gains / (Losses) 146,700 389,241
Fair Value 58,548,388 81,262,869
Cash and Cash Equivalents 14,916,878 22,973,803
Marketable Securities 43,631,510 58,289,066
Fair Value, Inputs, Level 1 [Member]    
Cash and Cash Equivalents [Line Items]    
Adjusted Cost 10,599,429 146,359
Allowance for Credit Losses
Total Unrealized Gains / (Losses)
Fair Value 10,599,429 146,359
Cash and Cash Equivalents 10,599,429 146,359
Marketable Securities
Fair Value, Inputs, Level 2 [Member]    
Cash and Cash Equivalents [Line Items]    
Adjusted Cost 43,484,810 67,892,825
Allowance for Credit Losses
Total Unrealized Gains / (Losses) 146,700 389,241
Fair Value 43,631,510 68,282,066
Cash and Cash Equivalents 9,993,000
Marketable Securities 43,631,510 58,289,066
Cash [Member]    
Cash and Cash Equivalents [Line Items]    
Adjusted Cost 4,317,449 12,834,444
Allowance for Credit Losses
Total Unrealized Gains / (Losses)
Fair Value 4,317,449 12,834,444
Cash and Cash Equivalents 4,317,449 12,834,444
Marketable Securities
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]    
Cash and Cash Equivalents [Line Items]    
Adjusted Cost 10,599,429 146,359
Allowance for Credit Losses
Total Unrealized Gains / (Losses)
Fair Value 10,599,429 146,359
Cash and Cash Equivalents 10,599,429 146,359
Marketable Securities
US Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]    
Cash and Cash Equivalents [Line Items]    
Adjusted Cost 43,484,810 67,892,825
Allowance for Credit Losses
Total Unrealized Gains / (Losses) 146,700 389,241
Fair Value 43,631,510 68,282,066
Cash and Cash Equivalents 9,993,000
Marketable Securities $ 43,631,510 $ 58,289,066
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Fair Value Assets and Liabilities (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities (U.S. treasury bills and notes) $ 43,631,510 $ 58,289,066
Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities (U.S. treasury bills and notes)
Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities (U.S. treasury bills and notes) 43,631,510 58,289,066
Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 13,806,864 10,179,667
Marketable securities (U.S. treasury bills and notes) 43,631,510 58,289,066
Total assets measured at fair value 57,438,374 68,468,733
Contingent consideration - common stock 1,318,995 2,499,147
Contingent consideration - warrants 320,780 233,209
Total liabilities measured at fair value 1,639,775 2,732,356
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 13,806,864 186,667
Marketable securities (U.S. treasury bills and notes)
Total assets measured at fair value 13,806,864 186,667
Contingent consideration - common stock
Contingent consideration - warrants
Total liabilities measured at fair value
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 9,993,000
Marketable securities (U.S. treasury bills and notes) 43,631,510 58,289,066
Total assets measured at fair value 43,631,510 68,282,066
Contingent consideration - common stock
Contingent consideration - warrants
Total liabilities measured at fair value
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents
Marketable securities (U.S. treasury bills and notes)
Total assets measured at fair value
Contingent consideration - common stock 1,318,995 2,499,147
Contingent consideration - warrants 320,780 233,209
Total liabilities measured at fair value $ 1,639,775 $ 2,732,356
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Changes in the Fair Value Measurement (Details) - Fair Value, Recurring [Member]
 12 Months Ended
Dec. 31, 2023
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Fair value as of December 31, 2022 $ 2,732,356
Change in fair value of contingent consideration issued for business acquisitions (1,092,581)
Fair value as of December 31, 2023 $ 1,639,775
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Contingent Consideration Common Stock and Warrants (Details)
Dec. 31, 2023
Dec. 31, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Expected term   4 years
Measurement Input, Share Price [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants measurement input 1.33 2.52
Measurement Input Strike Price [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants measurement input 9.13 9.13
Measurement Input, Price Volatility [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants measurement input 1.875 0.750
Measurement Input, Risk Free Interest Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants measurement input 0.040 0.041
Measurement Input, Expected Term [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Expected term 3 years  
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Property and Equipment (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Less: accumulated depreciation $ (2,232,495) $ (1,372,248)
Property and equipment, net 3,035,729 2,539,483
Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 4,545,908 3,574,730
Equipment [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment estimated useful lives 3 years  
Equipment [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment estimated useful lives 5 years  
Leaseholds and Leasehold Improvements [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment estimated useful lives 0 years  
Leaseholds and Leasehold Improvements [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment estimated useful lives 5 years  
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 548,648 224,957
Office Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 173,668 $ 112,044
Office Equipment [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment estimated useful lives 2 years  
Office Equipment [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment estimated useful lives 5 years  
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Goodwill (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]    
Goodwil - beginning $ 14,706,818
Measurement period adjustments   681,728
Goodwill impairment charges (15,388,546)
Goodwill - ending
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Intangible Assets, Net (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross $ 27,195,000 $ 27,195,000
Less accumulated amortization (791,333) (426,667)
Intangible assets, net $ 26,403,667 $ 26,768,333
In Process Research and Development [Member]    
Finite-Lived Intangible Assets [Line Items]    
Estimated useful lives in years, term [1] Indefinite Indefinite
Intangible assets, gross $ 26,101,000 $ 26,101,000
Less accumulated amortization
Intangible assets, net 26,101,000 26,101,000
Noncompete Agreements [Member]    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross 1,094,000 1,094,000
Less accumulated amortization (791,333) (426,667)
Intangible assets, net $ 302,667 $ 667,333
Estimated useful lives in years [1] 2 years 8 months 12 days 2 years 8 months 12 days
[1] Based on weighted-average useful life established as of the acquisition date.
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Future Amortization Expense (Details)
Dec. 31, 2023
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
2024 $ 302,667
Total $ 302,667
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Intangible Assets (Details Narrative) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]      
Goodwill $ 14,706,818
XML 61 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Accrued Expenses (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Payroll liabilities $ 1,643,186 $ 428,354
Distributor commissions 9,958 159,725
Other accrued liabilities 519,815 346,368
Total accrued expenses $ 2,172,959 $ 934,447
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Revenue by Geographic Area (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Disaggregation of Revenue [Line Items]    
Revenue geographic area $ 6,812,038 $ 34,218,209
UNITED STATES    
Disaggregation of Revenue [Line Items]    
Revenue geographic area $ 6,480,183 $ 24,671,554
UNITED STATES | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]    
Disaggregation of Revenue [Line Items]    
Percentage of revenue 95.00% 72.00%
UNITED STATES | Product [Member]    
Disaggregation of Revenue [Line Items]    
Revenue geographic area $ 659,618 $ 24,671,554
UNITED STATES | Grant [Member]    
Disaggregation of Revenue [Line Items]    
Revenue geographic area 5,820,565
Rest of World [Member]    
Disaggregation of Revenue [Line Items]    
Revenue geographic area $ 331,855 $ 9,546,655
Rest of World [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]    
Disaggregation of Revenue [Line Items]    
Percentage of revenue 5.00% 28.00%
Rest of World [Member] | Product [Member]    
Disaggregation of Revenue [Line Items]    
Revenue geographic area $ 331,855 $ 9,546,655
Rest of World [Member] | Grant [Member]    
Disaggregation of Revenue [Line Items]    
Revenue geographic area
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Deferred Revenue (Details)
 12 Months Ended
Dec. 31, 2023
USD ($)
Revenue from Contract with Customer [Abstract]  
Deferred revenue, beginning balance
Increase due to prepayments from customers 32,570
Increase due to prepayments from grants received 329,879
Deferred revenue, ending balance $ 362,449
XML 64 R49.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Basis and Diluted Earnings Per Share (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Earnings Per Share [Abstract]    
Net loss, as reported $ (35,332,865) $ (14,238,249)
Weighted average shares, basic 29,346,599 31,479,028
Dilutive effect of stock options, warrants and RSUs
Shares used to compute diluted earnings per share 29,346,599 31,479,028
Basic earnings per share $ (1.20) $ (0.45)
Diluted earnings per share $ (1.20) $ (0.45)
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.24.0.1
Earnings per Share (Details Narrative) - shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Securities excluded from computation of diluted earnings per share 0 0
Restricted Stock Units (RSUs) [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Securities excluded from computation of diluted earnings per share 2,618,362 1,443,238
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Securities excluded from computation of diluted earnings per share 512,112 50,000
Common Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Securities excluded from computation of diluted earnings per share 1,400,000 1,400,000
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Securities excluded from computation of diluted earnings per share 465,000 465,000
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Option Activity (Details) - $ / shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]    
Number of Options Outstanding, Beginning 1,040,572 1,111,363
Weighted Average Exercise Price Outstanding, Beginning $ 2.19 $ 2.12
Weighted Average Fair Value Outstanding, Ending $ 1.37 $ 1.31
Number of Options Outstanding, Granted
Weighted Average Exercise Price Granted
Weighted Average Fair Value Granted
Number of Options Outstanding, Expired
Weighted Average Exercise Price Expired
Weighted Average Fair Value Expired
Number of Options Outstanding, Forfeited/Cancelled
Weighted Average Exercise Price Forfeited/Cancelled
Weighted Average Fair Value Forfeited/Cancelled
Number of Options Outstanding, Exercised (70,791)
Weighted Average Exercise Price Exercised $ 1.10
Weighted Average Fair Value Exercised $ 0.51
Weighted-average Remaining Contractual Life (years) Outstanding, Beginning 5 years 10 months 17 days  
Number of Options Outstanding, Ending 1,040,572 1,040,572
Weighted Average Exercise Price Outstanding, Ending $ 2.19 $ 2.19
Weighted-average Remaining Contractual Life (years) Outstanding, Ending 4 years 10 months 20 days  
Number of Options Exercisable Ending 1,040,572  
Weighted Average Exercise Price, Exercisable Ending $ 2.19  
Weighted Average Fair Value, Exercisable Ending $ 1.37  
Weighted-average Remaining Contractual Life (years), Exercisable Ending 4 years 10 months 20 days  
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Outstanding Restricted Stock Units and Related Party (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of Restricted Stock Units, Outstanding Beginning 2,426,725 1,267,415
Weighted Average Grant Date Fair Value, Outstanding Beginning $ 6.95 $ 9.94
Number of Restricted Stock Units, Granted 1,948,750 1,925,476
Weighted Average Grant Date Fair Value, Granted $ 1.92 $ 5.66
Number of Restricted Stock Units, Vested (1,354,081) (725,166)
Weighted Average Grant Date Fair Value, Vested $ 6.17 $ 8.66
Number of Restricted Stock Units, Forfeited/Cancelled (95,897) (41,000)
Weighted Average Grant Date Fair Value, Forfeited/Cancelled $ 6.16 $ 8.31
Number of Restricted Stock Units, Outstanding Ending 2,925,497 2,426,725
Weighted Average Grant Date Fair Value, Outstanding Ending $ 3.99 $ 6.95
XML 68 R53.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Warrant Activity (Details) - $ / shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]    
Number of Warrants Outstanding, Beginning 485,000 526,281
Weighted Average Exercise Price, Beginning $ 8.81 $ 8.15
Weighted Average fair value, Beginning $ 2.43 $ 4.01
Weighted-average Remaining Contractual Life (Years) Outstanding   4 years 8 months 12 days
Number of Warrants Outstanding, Issued   8,719
Weighted Average Exercise Price, Issued   $ 9.13
Weighted Average Fair Value, Issued   $ 1.88
Number of Warrants Outstanding, Granted
Weighted Average Exercise Price, Granted
Weighted Average Fair Value, Granted
Number of Warrants Outstanding, Expired
Weighted Average Exercise Price, Expired
Weighted Average Fair Value, Expired
Number of Warrants Outstanding, Forfeited/Cancelled
Weighted Average Exercise Price, Forfeited/Cancelled
Weighted Average Fair Value, Forfeited/Cancelled
Number of Warrants Outstanding, Exercised (50,000)
Weighted Average Exercise Price, Exercised $ 2.00
Weighted Average Fair Value, Exercised $ 1.22
Weighted-average Remaining Contractual Life (Years) Outstanding 3 years 4 years
Number of Warrants Outstanding, Ending 485,000 485,000
Weighted Average Exercise Price, Ending $ 8.81  
Weighted Average Fair Value, Ending $ 1.29  
XML 69 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Recognized Stock-based Compensation Expense (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense $ 8,336,855 $ 7,543,223
Cost of Sales [Member]    
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense 46,586 63,058
Selling and Marketing Expense [Member]    
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense 2,153,974 1,866,116
General and Administrative Expense [Member]    
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense 4,933,822 4,050,967
Research and Development Expense [Member]    
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense $ 1,202,473 $ 1,563,082
XML 70 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Aug. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Weighted average period 4 years 10 months 20 days    
Warrants purchase 465,000    
Warrant [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Aggregate intrinsic value of options outstanding $ 0    
Intrinsic value of warrants exercised $ 0 $ 300,000  
Warrants exercisable 20,000    
Stock Options [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Intrinsic value of options value exercised $ 0 400,000  
Aggregate intrinsic value of options outstanding 200,000 $ 800,000  
Restricted Stock Units (RSUs) [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Unrecognized stock-based compensation $ 9,500,000    
Weighted average period 1 year 8 months 12 days    
2015 Long Term Incentive Plan [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Number of common shares availalble for issuance 4,357,937   12,000,000
XML 71 R56.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Components Income Tax Provision (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Current:    
Federal $ 84,435 $ 563,821
State (540,240) (266,248)
Total current (455,805) 297,573
Deferred:    
Federal (7,228,611) (3,945,090)
State (2,068,509) (961,468)
Change in valuation allowance 6,975,234
Total deferred (2,321,886) (4,906,558)
Total income tax benefit $ (2,777,691) $ (4,608,985)
XML 72 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Benefit from Income Taxes and Effective Tax Rates (Details)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Federal income tax expense at statutory rate 21.00% 21.00%
State income tax expense, net of federal tax benefit 1.60% 4.80%
Permanent differences:    
- Foreign derived intangible income deduction 0.00% 1.40%
- Stock based compensation (3.50%) (3.60%)
- Contingent consideration remeasurement 0.60% 8.80%
- Goodwill impairment 0.00% (17.10%)
- Other permanent differences (0.20%) (0.60%)
Research and development credits 4.60% 11.10%
Change in uncertain tax positions 1.20% (2.10%)
Change in valuation allowance (18.30%) 0.00%
Other 0.30% 0.80%
Effective income tax rate 7.30% 24.50%
XML 73 R58.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Deferred tax assets:    
Accrued liabilities $ 58,158 $ 98,141
Reserves and allowances 734,631 765,004
Deferred compensation 620,551 566,076
Section 174 costs 7,337,629 3,460,159
Lease liability 742,131 85,899
UNICAP 43,943 168,936
Net operating loss carryforwards 4,040,601
Research and development credits 1,688,255
Total gross deferred tax assets 15,265,899 5,144,215
Less valuation allowance (6,938,829)
Total deferred tax assets 8,327,070 5,144,215
Deferred tax liabilities:    
Property and equipment, net (672,416) (609,261)
Intangibles, net (6,552,255) (6,608,914)
Prepaids (329,768) (156,053)
Right of use asset (736,226) (91,873)
Other comprehensive income (36,405) (96,101)
Other
Total deferred tax liabilities (8,327,070) (7,562,202)
Net deferred tax liability $ (2,417,987)
XML 74 R59.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Unrecognized Tax Benefits (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Unrecognized tax benefits at the beginning of the year $ 1,469,577 $ 1,067,853
Gross increases- current year tax positions 273,569 1,045,590
Gross increases- prior year tax positions 66,127 34,035
Gross decreases - prior year tax positions (730,842) (677,901)
Unrecognized tax benefits at end of year 1,078,431 1,469,577
Interest and penalties in year-end balance $ 100,162 $ 34,035
XML 75 R60.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes (Details Narrative) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Net operating loss carry-forwards $ 16,300,000  
Research and development credit carry forwards 1,400,000  
State net operating loss carryforwards 16,900,000  
State research and development credit carryforwards 800,000  
Unrecognized tax benefits that would impact effective tax rate $ 1,078,431 $ 1,469,577
XML 76 R61.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Lease Expense (Details)
 12 Months Ended
Dec. 31, 2023
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Operating lease costs $ 813,743
Short-term lease costs 198,261
Total lease costs $ 1,012,004
XML 77 R62.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Maturities on Company Lease Liabilities (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]    
2024 $ 996,676  
2025 1,018,383  
2026 714,630  
2027 300,591  
Thereafter 308,462  
Total lease payments 3,338,742  
Less: imputed interest 348,175  
Present value of operating lease liabilities 2,990,567  
Less: current portion 838,387 $ 297,209
Long-term portion $ 2,152,180 $ 50,708
XML 78 R63.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Other Information Related to Operating Lease (Details)
 12 Months Ended
Dec. 31, 2023
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Cash paid for operating leases included in operating cash flows $ 954,013
Remaining lease term of operating leases 3 years 8 months 12 days
Discount rate of operating leases 6.20%
XML 79 R64.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies (Details Narrative)
Dec. 31, 2023
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Operating lease liabilities $ 2,990,567
Lease Amendment [Member]  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Operating lease liabilities $ 3,203,146
XML 80 R65.htm IDEA: XBRL DOCUMENT v3.24.0.1
Schedule of Treasury Stock (Details)
 12 Months Ended
Dec. 31, 2023
shares
Equity [Abstract]  
Treasury stock, Beginning Balance 3,881,658
Repurchases of common stock 967,020
Treasury stock, Ending Balance 4,848,678
XML 81 R66.htm IDEA: XBRL DOCUMENT v3.24.0.1
Share Repurchase Program (Details Narrative)
$ in Millions
Mar. 31, 2022
USD ($)
Equity [Abstract]  
Stock repurchase program authorized amount $ 30.0
XML 82 R67.htm IDEA: XBRL DOCUMENT v3.24.0.1
Related Party Transactions (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Related Party Transaction [Line Items]    
Research and development expenses $ 22,962,593 $ 17,438,098
Seth Egan [Member]    
Related Party Transaction [Line Items]    
Share based payment, vesting period 3 years  
Fair value of equity awards $ 600,000  
Winston Egan [Member]    
Related Party Transaction [Line Items]    
Fair value of equity awards 100,000  
CoSara Diagnostics Pvt Ltd [Member]    
Related Party Transaction [Line Items]    
Research and development expenses $ 200,000  
EXCEL 84 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
  •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end XML 85 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 86 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 88 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 154 373 1 true 56 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://codiagnostics.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://codiagnostics.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://codiagnostics.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statement of Changes in Stockholders' Equity Sheet http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity Consolidated Statement of Changes in Stockholders' Equity Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows Sheet http://codiagnostics.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 7 false false R8.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 8 false false R9.htm 995512 - Disclosure - Overview and Basis of Presentation Sheet http://codiagnostics.com/role/OverviewAndBasisOfPresentation Overview and Basis of Presentation Notes 9 false false R10.htm 995513 - Disclosure - Summary of Significant Accounting Policies Sheet http://codiagnostics.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 995514 - Disclosure - Cash, Cash Equivalents, and Financial Instruments Sheet http://codiagnostics.com/role/CashCashEquivalentsAndFinancialInstruments Cash, Cash Equivalents, and Financial Instruments Notes 11 false false R12.htm 995515 - Disclosure - Fair Value Measurements Sheet http://codiagnostics.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 995516 - Disclosure - Property and Equipment Sheet http://codiagnostics.com/role/PropertyAndEquipment Property and Equipment Notes 13 false false R14.htm 995517 - Disclosure - Goodwill and Intangible Assets Sheet http://codiagnostics.com/role/GoodwillAndIntangibleAssets Goodwill and Intangible Assets Notes 14 false false R15.htm 995518 - Disclosure - Accrued Expenses Sheet http://codiagnostics.com/role/AccruedExpenses Accrued Expenses Notes 15 false false R16.htm 995519 - Disclosure - Revenue Sheet http://codiagnostics.com/role/Revenue Revenue Notes 16 false false R17.htm 995520 - Disclosure - Earnings per Share Sheet http://codiagnostics.com/role/EarningsPerShare Earnings per Share Notes 17 false false R18.htm 995521 - Disclosure - Stock-Based Compensation Sheet http://codiagnostics.com/role/Stock-basedCompensation Stock-Based Compensation Notes 18 false false R19.htm 995522 - Disclosure - Income Taxes Sheet http://codiagnostics.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 995523 - Disclosure - Commitments and Contingencies Sheet http://codiagnostics.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 20 false false R21.htm 995524 - Disclosure - Share Repurchase Program Sheet http://codiagnostics.com/role/ShareRepurchaseProgram Share Repurchase Program Notes 21 false false R22.htm 995525 - Disclosure - Related Party Transactions Sheet http://codiagnostics.com/role/RelatedPartyTransactions Related Party Transactions Notes 22 false false R23.htm 995526 - Disclosure - Subsequent Events Sheet http://codiagnostics.com/role/SubsequentEvents Subsequent Events Notes 23 false false R24.htm 995527 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://codiagnostics.com/role/SummaryOfSignificantAccountingPolicies 24 false false R25.htm 995528 - Disclosure - Cash, Cash Equivalents, and Financial Instruments (Tables) Sheet http://codiagnostics.com/role/CashCashEquivalentsAndFinancialInstrumentsTables Cash, Cash Equivalents, and Financial Instruments (Tables) Tables http://codiagnostics.com/role/CashCashEquivalentsAndFinancialInstruments 25 false false R26.htm 995529 - Disclosure - Fair Value Measurements (Tables) Sheet http://codiagnostics.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://codiagnostics.com/role/FairValueMeasurements 26 false false R27.htm 995530 - Disclosure - Property and Equipment (Tables) Sheet http://codiagnostics.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://codiagnostics.com/role/PropertyAndEquipment 27 false false R28.htm 995531 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://codiagnostics.com/role/GoodwillAndIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://codiagnostics.com/role/GoodwillAndIntangibleAssets 28 false false R29.htm 995532 - Disclosure - Accrued Expenses (Tables) Sheet http://codiagnostics.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://codiagnostics.com/role/AccruedExpenses 29 false false R30.htm 995533 - Disclosure - Revenue (Tables) Sheet http://codiagnostics.com/role/RevenueTables Revenue (Tables) Tables http://codiagnostics.com/role/Revenue 30 false false R31.htm 995534 - Disclosure - Earnings per Share (Tables) Sheet http://codiagnostics.com/role/EarningsPerShareTables Earnings per Share (Tables) Tables http://codiagnostics.com/role/EarningsPerShare 31 false false R32.htm 995535 - Disclosure - Stock-Based Compensation (Tables) Sheet http://codiagnostics.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://codiagnostics.com/role/Stock-basedCompensation 32 false false R33.htm 995536 - Disclosure - Income Taxes (Tables) Sheet http://codiagnostics.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://codiagnostics.com/role/IncomeTaxes 33 false false R34.htm 995537 - Disclosure - Commitments and Contingencies (Tables) Sheet http://codiagnostics.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://codiagnostics.com/role/CommitmentsAndContingencies 34 false false R35.htm 995538 - Disclosure - Share Repurchase Program (Tables) Sheet http://codiagnostics.com/role/ShareRepurchaseProgramTables Share Repurchase Program (Tables) Tables http://codiagnostics.com/role/ShareRepurchaseProgram 35 false false R36.htm 995539 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies 36 false false R37.htm 995540 - Disclosure - Schedule of Cash, Cash Equivalents and Marketable Investment Securities (Details) Sheet http://codiagnostics.com/role/ScheduleOfCashCashEquivalentsAndMarketableInvestmentSecuritiesDetails Schedule of Cash, Cash Equivalents and Marketable Investment Securities (Details) Details 37 false false R38.htm 995541 - Disclosure - Schedule of Fair Value Assets and Liabilities (Details) Sheet http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails Schedule of Fair Value Assets and Liabilities (Details) Details 38 false false R39.htm 995542 - Disclosure - Schedule of Changes in the Fair Value Measurement (Details) Sheet http://codiagnostics.com/role/ScheduleOfChangesInFairValueMeasurementDetails Schedule of Changes in the Fair Value Measurement (Details) Details 39 false false R40.htm 995543 - Disclosure - Schedule of Contingent Consideration Common Stock and Warrants (Details) Sheet http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails Schedule of Contingent Consideration Common Stock and Warrants (Details) Details 40 false false R41.htm 995544 - Disclosure - Schedule of Property and Equipment (Details) Sheet http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails Schedule of Property and Equipment (Details) Details 41 false false R42.htm 995545 - Disclosure - Schedule of Goodwill (Details) Sheet http://codiagnostics.com/role/ScheduleOfGoodwillDetails Schedule of Goodwill (Details) Details 42 false false R43.htm 995546 - Disclosure - Schedule of Intangible Assets, Net (Details) Sheet http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails Schedule of Intangible Assets, Net (Details) Details 43 false false R44.htm 995547 - Disclosure - Schedule of Future Amortization Expense (Details) Sheet http://codiagnostics.com/role/ScheduleOfFutureAmortizationExpenseDetails Schedule of Future Amortization Expense (Details) Details 44 false false R45.htm 995548 - Disclosure - Goodwill and Intangible Assets (Details Narrative) Sheet http://codiagnostics.com/role/GoodwillAndIntangibleAssetsDetailsNarrative Goodwill and Intangible Assets (Details Narrative) Details http://codiagnostics.com/role/GoodwillAndIntangibleAssetsTables 45 false false R46.htm 995549 - Disclosure - Schedule of Accrued Expenses (Details) Sheet http://codiagnostics.com/role/ScheduleOfAccruedExpensesDetails Schedule of Accrued Expenses (Details) Details 46 false false R47.htm 995550 - Disclosure - Summary of Revenue by Geographic Area (Details) Sheet http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails Summary of Revenue by Geographic Area (Details) Details 47 false false R48.htm 995551 - Disclosure - Schedule of Deferred Revenue (Details) Sheet http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails Schedule of Deferred Revenue (Details) Details 48 false false R49.htm 995552 - Disclosure - Schedule of Basis and Diluted Earnings Per Share (Details) Sheet http://codiagnostics.com/role/ScheduleOfBasisAndDilutedEarningsPerShareDetails Schedule of Basis and Diluted Earnings Per Share (Details) Details 49 false false R50.htm 995553 - Disclosure - Earnings per Share (Details Narrative) Sheet http://codiagnostics.com/role/EarningsPerShareDetailsNarrative Earnings per Share (Details Narrative) Details http://codiagnostics.com/role/EarningsPerShareTables 50 false false R51.htm 995554 - Disclosure - Schedule of Option Activity (Details) Sheet http://codiagnostics.com/role/ScheduleOfOptionActivityDetails Schedule of Option Activity (Details) Details 51 false false R52.htm 995555 - Disclosure - Schedule of Outstanding Restricted Stock Units and Related Party (Details) Sheet http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedPartyDetails Schedule of Outstanding Restricted Stock Units and Related Party (Details) Details 52 false false R53.htm 995556 - Disclosure - Schedule of Warrant Activity (Details) Sheet http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails Schedule of Warrant Activity (Details) Details 53 false false R54.htm 995557 - Disclosure - Schedule of Recognized Stock-based Compensation Expense (Details) Sheet http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails Schedule of Recognized Stock-based Compensation Expense (Details) Details 54 false false R55.htm 995558 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://codiagnostics.com/role/Stock-basedCompensationTables 55 false false R56.htm 995559 - Disclosure - Schedule of Components Income Tax Provision (Details) Sheet http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails Schedule of Components Income Tax Provision (Details) Details 56 false false R57.htm 995560 - Disclosure - Schedule of Benefit from Income Taxes and Effective Tax Rates (Details) Sheet http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails Schedule of Benefit from Income Taxes and Effective Tax Rates (Details) Details 57 false false R58.htm 995561 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details) Sheet http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails Schedule of Deferred Tax Assets and Liabilities (Details) Details 58 false false R59.htm 995562 - Disclosure - Schedule of Unrecognized Tax Benefits (Details) Sheet http://codiagnostics.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails Schedule of Unrecognized Tax Benefits (Details) Details 59 false false R60.htm 995563 - Disclosure - Income Taxes (Details Narrative) Sheet http://codiagnostics.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://codiagnostics.com/role/IncomeTaxesTables 60 false false R61.htm 995564 - Disclosure - Schedule of Lease Expense (Details) Sheet http://codiagnostics.com/role/ScheduleOfLeaseExpenseDetails Schedule of Lease Expense (Details) Details 61 false false R62.htm 995565 - Disclosure - Schedule of Maturities on Company Lease Liabilities (Details) Sheet http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails Schedule of Maturities on Company Lease Liabilities (Details) Details 62 false false R63.htm 995566 - Disclosure - Schedule of Other Information Related to Operating Lease (Details) Sheet http://codiagnostics.com/role/ScheduleOfOtherInformationRelatedToOperatingLeaseDetails Schedule of Other Information Related to Operating Lease (Details) Details 63 false false R64.htm 995567 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://codiagnostics.com/role/CommitmentsAndContingenciesTables 64 false false R65.htm 995568 - Disclosure - Schedule of Treasury Stock (Details) Sheet http://codiagnostics.com/role/ScheduleOfTreasuryStockDetails Schedule of Treasury Stock (Details) Details 65 false false R66.htm 995569 - Disclosure - Share Repurchase Program (Details Narrative) Sheet http://codiagnostics.com/role/ShareRepurchaseProgramDetailsNarrative Share Repurchase Program (Details Narrative) Details http://codiagnostics.com/role/ShareRepurchaseProgramTables 66 false false R67.htm 995570 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://codiagnostics.com/role/RelatedPartyTransactions 67 false false All Reports Book All Reports codx-20231231.xsd codx-20231231_cal.xml codx-20231231_def.xml codx-20231231_lab.xml codx-20231231_pre.xml form10-k.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 90 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-k.htm": { "nsprefix": "CODX", "nsuri": "http://codiagnostics.com/20231231", "dts": { "schema": { "local": [ "codx-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "codx-20231231_cal.xml" ] }, "definitionLink": { "local": [ "codx-20231231_def.xml" ] }, "labelLink": { "local": [ "codx-20231231_lab.xml" ] }, "presentationLink": { "local": [ "codx-20231231_pre.xml" ] }, "inline": { "local": [ "form10-k.htm" ] } }, "keyStandard": 323, "keyCustom": 50, "axisStandard": 20, "axisCustom": 0, "memberStandard": 40, "memberCustom": 15, "hidden": { "total": 187, "http://fasb.org/us-gaap/2023": 157, "http://codiagnostics.com/20231231": 27, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 154, "entityCount": 1, "segmentCount": 56, "elementCount": 644, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 801, "http://xbrl.sec.gov/dei/2023": 40, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://codiagnostics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R2": { "role": "http://codiagnostics.com/role/BalanceSheets", "longName": "00000002 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R3": { "role": "http://codiagnostics.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R4": { "role": "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss", "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R5": { "role": "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity", "longName": "00000005 - Statement - Consolidated Statement of Changes in Stockholders' Equity", "shortName": "Consolidated Statement of Changes in Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R6": { "role": "http://codiagnostics.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-10-012023-12-31", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-012023-12-31", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R9": { "role": "http://codiagnostics.com/role/OverviewAndBasisOfPresentation", "longName": "995512 - Disclosure - Overview and Basis of Presentation", "shortName": "Overview and Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R10": { "role": "http://codiagnostics.com/role/SummaryOfSignificantAccountingPolicies", "longName": "995513 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R11": { "role": "http://codiagnostics.com/role/CashCashEquivalentsAndFinancialInstruments", "longName": "995514 - Disclosure - Cash, Cash Equivalents, and Financial Instruments", "shortName": "Cash, Cash Equivalents, and Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R12": { "role": "http://codiagnostics.com/role/FairValueMeasurements", "longName": "995515 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R13": { "role": "http://codiagnostics.com/role/PropertyAndEquipment", "longName": "995516 - Disclosure - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R14": { "role": "http://codiagnostics.com/role/GoodwillAndIntangibleAssets", "longName": "995517 - Disclosure - Goodwill and Intangible Assets", "shortName": "Goodwill and Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R15": { "role": "http://codiagnostics.com/role/AccruedExpenses", "longName": "995518 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R16": { "role": "http://codiagnostics.com/role/Revenue", "longName": "995519 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R17": { "role": "http://codiagnostics.com/role/EarningsPerShare", "longName": "995520 - Disclosure - Earnings per Share", "shortName": "Earnings per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R18": { "role": "http://codiagnostics.com/role/Stock-basedCompensation", "longName": "995521 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R19": { "role": "http://codiagnostics.com/role/IncomeTaxes", "longName": "995522 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R20": { "role": "http://codiagnostics.com/role/CommitmentsAndContingencies", "longName": "995523 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R21": { "role": "http://codiagnostics.com/role/ShareRepurchaseProgram", "longName": "995524 - Disclosure - Share Repurchase Program", "shortName": "Share Repurchase Program", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R22": { "role": "http://codiagnostics.com/role/RelatedPartyTransactions", "longName": "995525 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R23": { "role": "http://codiagnostics.com/role/SubsequentEvents", "longName": "995526 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R24": { "role": "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "995527 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PriorPeriodReclassificationAdjustmentDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PriorPeriodReclassificationAdjustmentDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R25": { "role": "http://codiagnostics.com/role/CashCashEquivalentsAndFinancialInstrumentsTables", "longName": "995528 - Disclosure - Cash, Cash Equivalents, and Financial Instruments (Tables)", "shortName": "Cash, Cash Equivalents, and Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R26": { "role": "http://codiagnostics.com/role/FairValueMeasurementsTables", "longName": "995529 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R27": { "role": "http://codiagnostics.com/role/PropertyAndEquipmentTables", "longName": "995530 - Disclosure - Property and Equipment (Tables)", "shortName": "Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R28": { "role": "http://codiagnostics.com/role/GoodwillAndIntangibleAssetsTables", "longName": "995531 - Disclosure - Goodwill and Intangible Assets (Tables)", "shortName": "Goodwill and Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R29": { "role": "http://codiagnostics.com/role/AccruedExpensesTables", "longName": "995532 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R30": { "role": "http://codiagnostics.com/role/RevenueTables", "longName": "995533 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R31": { "role": "http://codiagnostics.com/role/EarningsPerShareTables", "longName": "995534 - Disclosure - Earnings per Share (Tables)", "shortName": "Earnings per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R32": { "role": "http://codiagnostics.com/role/Stock-basedCompensationTables", "longName": "995535 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R33": { "role": "http://codiagnostics.com/role/IncomeTaxesTables", "longName": "995536 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R34": { "role": "http://codiagnostics.com/role/CommitmentsAndContingenciesTables", "longName": "995537 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R35": { "role": "http://codiagnostics.com/role/ShareRepurchaseProgramTables", "longName": "995538 - Disclosure - Share Repurchase Program (Tables)", "shortName": "Share Repurchase Program (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "CODX:ScheduleOfTreasuryStockTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "CODX:ScheduleOfTreasuryStockTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R36": { "role": "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "995539 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AccountsReceivableGrossCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AccountsReceivableGrossCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R37": { "role": "http://codiagnostics.com/role/ScheduleOfCashCashEquivalentsAndMarketableInvestmentSecuritiesDetails", "longName": "995540 - Disclosure - Schedule of Cash, Cash Equivalents and Marketable Investment Securities (Details)", "shortName": "Schedule of Cash, Cash Equivalents and Marketable Investment Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:TradingSecuritiesDebtAmortizedCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:TradingSecuritiesDebtAmortizedCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R38": { "role": "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails", "longName": "995541 - Disclosure - Schedule of Fair Value Assets and Liabilities (Details)", "shortName": "Schedule of Fair Value Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:MarketableSecurities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R39": { "role": "http://codiagnostics.com/role/ScheduleOfChangesInFairValueMeasurementDetails", "longName": "995542 - Disclosure - Schedule of Changes in the Fair Value Measurement (Details)", "shortName": "Schedule of Changes in the Fair Value Measurement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R40": { "role": "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails", "longName": "995543 - Disclosure - Schedule of Contingent Consideration Common Stock and Warrants (Details)", "shortName": "Schedule of Contingent Consideration Common Stock and Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R41": { "role": "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails", "longName": "995544 - Disclosure - Schedule of Property and Equipment (Details)", "shortName": "Schedule of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R42": { "role": "http://codiagnostics.com/role/ScheduleOfGoodwillDetails", "longName": "995545 - Disclosure - Schedule of Goodwill (Details)", "shortName": "Schedule of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "AsOf2021-12-31", "name": "us-gaap:Goodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R43": { "role": "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails", "longName": "995546 - Disclosure - Schedule of Intangible Assets, Net (Details)", "shortName": "Schedule of Intangible Assets, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R44": { "role": "http://codiagnostics.com/role/ScheduleOfFutureAmortizationExpenseDetails", "longName": "995547 - Disclosure - Schedule of Future Amortization Expense (Details)", "shortName": "Schedule of Future Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R45": { "role": "http://codiagnostics.com/role/GoodwillAndIntangibleAssetsDetailsNarrative", "longName": "995548 - Disclosure - Goodwill and Intangible Assets (Details Narrative)", "shortName": "Goodwill and Intangible Assets (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "AsOf2021-12-31", "name": "us-gaap:Goodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": null }, "R46": { "role": "http://codiagnostics.com/role/ScheduleOfAccruedExpensesDetails", "longName": "995549 - Disclosure - Schedule of Accrued Expenses (Details)", "shortName": "Schedule of Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AccruedPayrollTaxesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AccruedPayrollTaxesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R47": { "role": "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "longName": "995550 - Disclosure - Summary of Revenue by Geographic Area (Details)", "shortName": "Summary of Revenue by Geographic Area (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R48": { "role": "http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails", "longName": "995551 - Disclosure - Schedule of Deferred Revenue (Details)", "shortName": "Schedule of Deferred Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "CODX:IncreaseDueToPrepaymentsFromCustomers", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "CODX:IncreaseDueToPrepaymentsFromCustomers", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R49": { "role": "http://codiagnostics.com/role/ScheduleOfBasisAndDilutedEarningsPerShareDetails", "longName": "995552 - Disclosure - Schedule of Basis and Diluted Earnings Per Share (Details)", "shortName": "Schedule of Basis and Diluted Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": null }, "R50": { "role": "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "longName": "995553 - Disclosure - Earnings per Share (Details Narrative)", "shortName": "Earnings per Share (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R51": { "role": "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails", "longName": "995554 - Disclosure - Schedule of Option Activity (Details)", "shortName": "Schedule of Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R52": { "role": "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedPartyDetails", "longName": "995555 - Disclosure - Schedule of Outstanding Restricted Stock Units and Related Party (Details)", "shortName": "Schedule of Outstanding Restricted Stock Units and Related Party (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R53": { "role": "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails", "longName": "995556 - Disclosure - Schedule of Warrant Activity (Details)", "shortName": "Schedule of Warrant Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R54": { "role": "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "longName": "995557 - Disclosure - Schedule of Recognized Stock-based Compensation Expense (Details)", "shortName": "Schedule of Recognized Stock-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R55": { "role": "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative", "longName": "995558 - Disclosure - Stock-Based Compensation (Details Narrative)", "shortName": "Stock-Based Compensation (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R56": { "role": "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails", "longName": "995559 - Disclosure - Schedule of Components Income Tax Provision (Details)", "shortName": "Schedule of Components Income Tax Provision (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R57": { "role": "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails", "longName": "995560 - Disclosure - Schedule of Benefit from Income Taxes and Effective Tax Rates (Details)", "shortName": "Schedule of Benefit from Income Taxes and Effective Tax Rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R58": { "role": "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails", "longName": "995561 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)", "shortName": "Schedule of Deferred Tax Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R59": { "role": "http://codiagnostics.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails", "longName": "995562 - Disclosure - Schedule of Unrecognized Tax Benefits (Details)", "shortName": "Schedule of Unrecognized Tax Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R60": { "role": "http://codiagnostics.com/role/IncomeTaxesDetailsNarrative", "longName": "995563 - Disclosure - Income Taxes (Details Narrative)", "shortName": "Income Taxes (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R61": { "role": "http://codiagnostics.com/role/ScheduleOfLeaseExpenseDetails", "longName": "995564 - Disclosure - Schedule of Lease Expense (Details)", "shortName": "Schedule of Lease Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R62": { "role": "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails", "longName": "995565 - Disclosure - Schedule of Maturities on Company Lease Liabilities (Details)", "shortName": "Schedule of Maturities on Company Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R63": { "role": "http://codiagnostics.com/role/ScheduleOfOtherInformationRelatedToOperatingLeaseDetails", "longName": "995566 - Disclosure - Schedule of Other Information Related to Operating Lease (Details)", "shortName": "Schedule of Other Information Related to Operating Lease (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "CODX:ScheduleOfOperatingLeaseTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "CODX:ScheduleOfOperatingLeaseTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R64": { "role": "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "995567 - Disclosure - Commitments and Contingencies (Details Narrative)", "shortName": "Commitments and Contingencies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_custom_LeaseAmendmentMember", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R65": { "role": "http://codiagnostics.com/role/ScheduleOfTreasuryStockDetails", "longName": "995568 - Disclosure - Schedule of Treasury Stock (Details)", "shortName": "Schedule of Treasury Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:TreasuryStockCommonShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "CODX:RepurchasesOfCommonStock", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "CODX:ScheduleOfTreasuryStockTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R66": { "role": "http://codiagnostics.com/role/ShareRepurchaseProgramDetailsNarrative", "longName": "995569 - Disclosure - Share Repurchase Program (Details Narrative)", "shortName": "Share Repurchase Program (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "AsOf2022-03-31", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-03-31", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R67": { "role": "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "995570 - Disclosure - Related Party Transactions (Details Narrative)", "shortName": "Related Party Transactions (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_custom_SethEganMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://codiagnostics.com/role/AccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r29" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r28", "r667" ] }, "us-gaap_AccountsReceivableGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableGrossCurrent", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts receivable", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r164", "r240", "r241", "r639" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r621" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r240", "r241" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://codiagnostics.com/role/ScheduleOfAccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued expenses", "totalLabel": "Total accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r31" ] }, "us-gaap_AccruedPayrollTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedPayrollTaxesCurrent", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/ScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Payroll liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r31" ] }, "us-gaap_AccruedSalesCommissionCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedSalesCommissionCurrent", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/ScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Distributor commissions", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r31", "r641" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r58", "r156", "r495" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r36", "r37", "r96", "r165", "r492", "r515", "r516" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r5", "r14", "r37", "r412", "r415", "r448", "r511", "r512", "r786", "r787", "r788", "r794", "r795", "r796" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r729" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r91", "r667", "r882" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r365", "r366", "r367", "r529", "r794", "r795", "r796", "r860", "r883" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r735" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r735" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r735" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r735" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to cash (used in) provided by operating activities:" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r699", "r711", "r721", "r747" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r702", "r714", "r724", "r750" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r735" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r742" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r706", "r715", "r725", "r742", "r751", "r755", "r763" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "auth_ref": [ "r761" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Total stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r363", "r372" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Doubtful accounts", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r166", "r244", "r251" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r707" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Securities excluded from computation of diluted earnings per share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r216" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r43" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r43" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r406" ] }, "us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionContingentConsiderationLiabilityCurrent", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Contingent consideration liabilities, current", "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as current." } } }, "auth_ref": [ "r859" ] }, "us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Contingent consideration liabilities", "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent." } } }, "auth_ref": [ "r859" ] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Impairment charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r9", "r56" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets [Default Label]", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r128", "r159", "r192", "r223", "r230", "r234", "r248", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r407", "r409", "r429", "r487", "r566", "r667", "r680", "r817", "r818", "r867" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r151", "r169", "r192", "r248", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r407", "r409", "r429", "r667", "r817", "r818", "r867" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Total assets measured at fair value", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r70" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r707" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r692", "r694", "r707" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r692", "r694", "r707" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r692", "r694", "r707" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price" } } }, "auth_ref": [ "r758" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r759" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "auth_ref": [ "r754" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r754" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r754" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r754" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r754" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r754" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedPartyDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r334", "r335", "r336", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r358", "r359", "r360", "r361", "r362" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r757" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r756" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r755" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r755" ] }, "CODX_BusinessAcquisitionMeasurementPeriodAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "BusinessAcquisitionMeasurementPeriodAdjustments", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Business acquisition measurement period adjustments", "documentation": "Business acquisition measurement period adjustments." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfChangesInFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Fair value as of December 31, 2022", "periodEndLabel": "Fair value as of December 31, 2023", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r69" ] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://codiagnostics.com/role/OverviewAndBasisOfPresentation" ], "lang": { "en-us": { "role": { "label": "Overview and Basis of Presentation", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r82", "r110", "r111" ] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/ScheduleOfCashCashEquivalentsAndMarketableInvestmentSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "verboseLabel": "Cash and Cash Equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r40", "r154", "r637" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashCashEquivalentsAndMarketableInvestmentSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r154" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Cash equivalents", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsLineItems", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashCashEquivalentsAndMarketableInvestmentSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r41" ] }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "presentation": [ "http://codiagnostics.com/role/CashCashEquivalentsAndFinancialInstruments" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, and Financial Instruments", "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)." } } }, "auth_ref": [ "r799" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r40", "r107", "r189" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r4", "r107" ] }, "us-gaap_CashMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashMember", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashCashEquivalentsAndMarketableInvestmentSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Cash [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits." } } }, "auth_ref": [ "r154" ] }, "CODX_ChangeInValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "ChangeInValuationAllowance", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails": { "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in valuation allowance", "documentation": "Change in valuation allowance.", "label": "ChangeInValuationAllowance" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r733" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r145", "r161", "r162", "r163", "r192", "r210", "r211", "r213", "r215", "r221", "r222", "r248", "r275", "r277", "r278", "r279", "r282", "r283", "r286", "r287", "r289", "r292", "r298", "r429", "r520", "r521", "r522", "r523", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r554", "r575", "r597", "r614", "r615", "r616", "r617", "r618", "r772", "r791", "r797" ] }, "CODX_ClassOfWarrantExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "ClassOfWarrantExercisable", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants exercisable", "documentation": "Class of warrant exercisable." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants purchase", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "CODX_CoSaraDiagnosticsPvtLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "CoSaraDiagnosticsPvtLtdMember", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "CoSara Diagnostics Pvt Ltd [Member]", "documentation": "CoSara Diagnostics Pvt Ltd [Member]" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r734" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r734" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r406" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (Note 12)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r33", "r77", "r489", "r553" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r119", "r269", "r270", "r622", "r814" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r670", "r671", "r672", "r674", "r675", "r676", "r677", "r794", "r795", "r860", "r881", "r883" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r90" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r90", "r554" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r90" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r15", "r90", "r554", "r572", "r883", "r884" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $0.001 par value; 100,000,000 shares authorized; 36,108,346 shares issued and 31,259,668 shares outstanding as of December 31, 2023 and 34,754,265 shares issued and 30,872,607 shares outstanding as of December 31, 2022", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r90", "r491", "r667" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r739" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r738" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r740" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r737" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r38", "r174", "r176", "r182", "r482", "r500" ] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss)", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r45", "r48", "r72", "r73", "r239", "r621" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r45", "r48", "r72", "r73", "r239", "r517", "r621" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r45", "r48", "r72", "r73", "r239", "r621", "r775" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentrations Risk and Significant Customers", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r80", "r138" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration risk percentage", "verboseLabel": "Percentage of revenue", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r45", "r48", "r72", "r73", "r239" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r45", "r48", "r72", "r73", "r239", "r621" ] }, "CODX_ContingentConsideredIssuedForBusinessAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "ContingentConsideredIssuedForBusinessAcquisitions", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfChangesInFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Change in fair value of contingent consideration issued for business acquisitions", "documentation": "Contingent considered issued for business acquisitions." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://codiagnostics.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Revenue", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r820" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Deferred revenue, beginning balance", "periodEndLabel": "Deferred revenue, ending balance", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r300", "r301", "r320" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred revenue", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r300", "r301", "r320" ] }, "us-gaap_ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockMember", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock [Member]", "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option." } } }, "auth_ref": [ "r286", "r287", "r289", "r674", "r675", "r676", "r677" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Cost of revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r103", "r192", "r248", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r429", "r817" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current", "label": "Current Federal, State and Local, Tax Expense (Benefit)", "documentation": "Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r777" ] }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract", "presentation": [ "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Current:" } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails": { "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Federal", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r777", "r793", "r857" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails": { "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails" ], "lang": { "en-us": { "role": { "label": "State", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r777", "r793", "r857" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r46", "r239" ] }, "CODX_CustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "CustomersMember", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customers [Member]", "documentation": "Customers [Member]" } } }, "auth_ref": [] }, "CODX_CustomersTogetherMember": { "xbrltype": "domainItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "CustomersTogetherMember", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customers Together [Member]", "documentation": "Customers Together [Member]" } } }, "auth_ref": [] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails": { "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Federal", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r793", "r856", "r857" ] }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred", "label": "Deferred Federal, State and Local, Tax Expense (Benefit)", "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r850" ] }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract", "presentation": [ "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Deferred:" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Deferred income taxes", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r9", "r126", "r142", "r400", "r401", "r793" ] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total deferred tax liabilities", "label": "Deferred Tax Liabilities, Gross", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r87", "r88", "r129", "r390" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred tax liability", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r379", "r380", "r488" ] }, "us-gaap_DeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenue", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue", "label": "Deferred Revenue [Default Label]", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r780" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails": { "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "State", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r793", "r856", "r857" ] }, "CODX_DeferredTaxAssetsCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "DeferredTaxAssetsCosts", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Section 174 costs", "documentation": "Deferred tax assets costs." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total gross deferred tax assets", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r391" ] }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGrossAbstract", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets:" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Research and development credit carry forwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination." } } }, "auth_ref": [ "r67", "r855" ] }, "CODX_DeferredTaxAssetsLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "DeferredTaxAssetsLeaseLiability", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lease liability", "documentation": "Deferred tax assets lease liability." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Net deferred tax liability", "label": "Deferred Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r854" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred tax assets", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r854" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r67", "r855" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "State net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards." } } }, "auth_ref": [ "r67", "r855" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "State research and development credit carryforwards", "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards." } } }, "auth_ref": [ "r66", "r67", "r855" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Research and development credits", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards." } } }, "auth_ref": [ "r66", "r67", "r855" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred compensation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs." } } }, "auth_ref": [ "r67", "r855" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued liabilities", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities." } } }, "auth_ref": [ "r67", "r855" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Reserves and allowances", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r67", "r855" ] }, "CODX_DeferredTaxAssetsUniformCapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "DeferredTaxAssetsUniformCapitalization", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "UNICAP", "documentation": "Deferred tax assets uniform capitalization." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r392" ] }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesAbstract", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax liabilities:" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Intangibles, net", "label": "Deferred Tax Liabilities, Intangible Assets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill." } } }, "auth_ref": [ "r67", "r855" ] }, "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other", "label": "Deferred Tax Liabilities, Other", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other." } } }, "auth_ref": [ "r67", "r855" ] }, "us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesOtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other comprehensive income", "label": "Deferred Tax Liabilities, Other Comprehensive Income", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains in other comprehensive income." } } }, "auth_ref": [ "r67", "r855" ] }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaids", "label": "Deferred Tax Liabilities, Prepaid Expenses", "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Property and equipment, net", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r67", "r855" ] }, "CODX_DeferredTaxLiabilitiesRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "DeferredTaxLiabilitiesRightOfUseAsset", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Right of use asset", "documentation": "Deferred tax liabilities right of use asset.", "label": "DeferredTaxLiabilitiesRightOfUseAsset" } } }, "auth_ref": [] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r9", "r57" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r9", "r226" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r319", "r653", "r654", "r655", "r656", "r657", "r658", "r659" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r319", "r653", "r654", "r655", "r656", "r657", "r658", "r659" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensation" ], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": [ "r11", "r62" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r694" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r692", "r694", "r707" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r692", "r694", "r707", "r743" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r693" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r681" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r694" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r694" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r728" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r684" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasisAndDilutedEarningsPerShareDetails", "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Basic", "verboseLabel": "Basic earnings per share", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r183", "r199", "r200", "r201", "r202", "r203", "r208", "r210", "r213", "r214", "r215", "r219", "r419", "r420", "r483", "r501", "r645" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Loss per common share:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasisAndDilutedEarningsPerShareDetails", "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Diluted", "verboseLabel": "Diluted earnings per share", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r183", "r199", "r200", "r201", "r202", "r203", "r210", "r213", "r214", "r215", "r219", "r419", "r420", "r483", "r501", "r645" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r43", "r44" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://codiagnostics.com/role/EarningsPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r207", "r216", "r217", "r218" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails" ], "lang": { "en-us": { "role": { "label": "Federal income tax expense at statutory rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r193", "r382", "r402" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in valuation allowance", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r851", "r858" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "calculation": { "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails" ], "lang": { "en-us": { "role": { "label": "- Other permanent differences", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates." } } }, "auth_ref": [ "r402", "r851" ] }, "CODX_EffectiveIncomeTaxRateReconciliationChangeInValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationChangeInValuationAllowance", "calculation": { "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in uncertain tax positions", "documentation": "Effective income tax rate reconciliation change in valuation allowance.", "label": "EffectiveIncomeTaxRateReconciliationChangeInValuationAllowance" } } }, "auth_ref": [] }, "CODX_EffectiveIncomeTaxRateReconciliationContingentConsiderationRemeasurement": { "xbrltype": "percentItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationContingentConsiderationRemeasurement", "calculation": { "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails" ], "lang": { "en-us": { "role": { "label": "- Contingent consideration remeasurement", "documentation": "Effective income tax rate reconciliation contingent consideration remeasurement." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationFdiiPercent", "calculation": { "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails" ], "lang": { "en-us": { "role": { "label": "- Foreign derived intangible income deduction", "documentation": "Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII)." } } }, "auth_ref": [ "r851" ] }, "CODX_EffectiveIncomeTaxRateReconciliationGoodwillImpairment": { "xbrltype": "percentItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationGoodwillImpairment", "calculation": { "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails" ], "lang": { "en-us": { "role": { "label": "- Goodwill impairment", "documentation": "Effective income tax rate reconciliation Goodwill impairment." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment", "calculation": { "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Research and development credits", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense." } } }, "auth_ref": [ "r851", "r858" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "calculation": { "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails" ], "lang": { "en-us": { "role": { "label": "Other", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r851", "r858" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "calculation": { "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Effective income tax rate", "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent", "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentAbstract", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails" ], "lang": { "en-us": { "role": { "label": "Permanent differences:" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "calculation": { "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "- Stock based compensation", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r773", "r851" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails" ], "lang": { "en-us": { "role": { "label": "State income tax expense, net of federal tax benefit", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r851", "r858" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unrecognized stock-based compensation", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r364" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r687" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r683" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r683" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r771" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r683" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r768" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r707" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r683" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r683" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r683" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r683" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r769" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquipmentMember", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r15", "r149", "r178", "r179", "r180", "r194", "r195", "r196", "r198", "r204", "r206", "r220", "r249", "r250", "r299", "r365", "r366", "r367", "r396", "r397", "r411", "r412", "r413", "r414", "r415", "r416", "r418", "r430", "r432", "r433", "r434", "r435", "r436", "r448", "r511", "r512", "r513", "r529", "r597" ] }, "us-gaap_EquityMethodInvestmentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsPolicy", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Equity-Method Investments", "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received." } } }, "auth_ref": [ "r7", "r74", "r247" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r736" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r699", "r711", "r721", "r747" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r696", "r708", "r718", "r744" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r742" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://codiagnostics.com/role/ScheduleOfChangesInFairValueMeasurementDetails", "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r422", "r423", "r427" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://codiagnostics.com/role/ScheduleOfChangesInFairValueMeasurementDetails", "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r422", "r423", "r427" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://codiagnostics.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Changes in the Fair Value Measurement", "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances." } } }, "auth_ref": [ "r25", "r70", "r71", "r127" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r16" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://codiagnostics.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Contingent Consideration Common Stock and Warrants", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r16" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://codiagnostics.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value Assets and Liabilities", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r70", "r127" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashCashEquivalentsAndMarketableInvestmentSecuritiesDetails", "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r284", "r323", "r324", "r325", "r326", "r327", "r328", "r423", "r457", "r458", "r459", "r650", "r651", "r660", "r661", "r662" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://codiagnostics.com/role/ScheduleOfChangesInFairValueMeasurementDetails", "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r422", "r423", "r425", "r426", "r428" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://codiagnostics.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r421" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashCashEquivalentsAndMarketableInvestmentSecuritiesDetails", "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r284", "r323", "r328", "r423", "r457", "r660", "r661", "r662" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashCashEquivalentsAndMarketableInvestmentSecuritiesDetails", "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r284", "r323", "r328", "r423", "r458", "r650", "r651", "r660", "r661", "r662" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r284", "r323", "r324", "r325", "r326", "r327", "r328", "r423", "r459", "r650", "r651", "r660", "r661", "r662" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://codiagnostics.com/role/ScheduleOfChangesInFairValueMeasurementDetails", "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashCashEquivalentsAndMarketableInvestmentSecuritiesDetails", "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r284", "r323", "r324", "r325", "r326", "r327", "r328", "r457", "r458", "r459", "r650", "r651", "r660", "r661", "r662" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://codiagnostics.com/role/ScheduleOfChangesInFairValueMeasurementDetails", "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r421", "r428" ] }, "CODX_FairValueOfContingentCommonStockAndWarrantsIssuedAsConsiderationForBusinessAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "FairValueOfContingentCommonStockAndWarrantsIssuedAsConsiderationForBusinessAcquisitions", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Fair value of contingent common stock issued as consideration for business acquisitions", "documentation": "Fair value of contingent common stock and warrants issued as consideration for business acquisitions." } } }, "auth_ref": [] }, "CODX_FairValueOfContingentConsiderationToCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "FairValueOfContingentConsiderationToCommonStock", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Contingent consideration - common stock", "documentation": "Fair value of contingent consideration to common stock." } } }, "auth_ref": [] }, "CODX_FairValueOfContingentConsiderationToWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "FairValueOfContingentConsiderationToWarrants", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Contingent consideration - warrants", "documentation": "Fair value of contigent consideration to warrants." } } }, "auth_ref": [] }, "us-gaap_FinancingReceivableAllowanceForCreditLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableAllowanceForCreditLosses", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashCashEquivalentsAndMarketableInvestmentSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Allowance for Credit Losses", "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement." } } }, "auth_ref": [ "r13", "r146", "r147", "r148", "r166", "r251", "r252", "r254", "r876" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Estimated useful lives in years", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Less accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r158", "r265" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/ScheduleOfFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "2024", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r115" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r263", "r264", "r265", "r266", "r465", "r466" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets, gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r114", "r466" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r465" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r53", "r55" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/ScheduleOfFutureAmortizationExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r114", "r465" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r703", "r715", "r725", "r751" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r703", "r715", "r725", "r751" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r703", "r715", "r725", "r751" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r703", "r715", "r725", "r751" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r703", "r715", "r725", "r751" ] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 }, "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows", "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Loss on disposition of assets", "negatedLabel": "Loss on disposition of assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": [ "r790" ] }, "us-gaap_GainLossOnSaleOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfInvestments", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 5.0 }, "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows", "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Gain (loss) on equity method investment in joint venture", "negatedLabel": "(Gain) loss from equity method investment", "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities." } } }, "auth_ref": [ "r9" ] }, "CODX_GainOnRemeasurementOfAcquisitionContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "GainOnRemeasurementOfAcquisitionContingencies", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 }, "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows", "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Gain on remeasurement of acquisition contingencies", "negatedLabel": "Change in fair value of acquisition contingencies", "documentation": "Gain on remeasurement of acquisition contingencies." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r104", "r577" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r99" ] }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeographicConcentrationRiskMember", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "label": "Geographic Concentration Risk [Member]", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": [ "r47", "r621" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/GoodwillAndIntangibleAssetsDetailsNarrative", "http://codiagnostics.com/role/ScheduleOfGoodwillDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Goodwil - beginning", "periodEndLabel": "Goodwill - ending", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r157", "r259", "r479", "r649", "r667", "r803", "r810" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://codiagnostics.com/role/GoodwillAndIntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r113" ] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Goodwill and Intangible Assets", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r12", "r51" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 }, "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfGoodwillDetails", "http://codiagnostics.com/role/StatementsOfCashFlows", "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Goodwill impairment charges", "negatedLabel": "Goodwill impairment charges", "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r9", "r260", "r261", "r262", "r649" ] }, "us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillTranslationAndPurchaseAccountingAdjustments", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Measurement period adjustments", "documentation": "Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r2", "r802" ] }, "CODX_GrantFundingRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "GrantFundingRevenue", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Grant funding revenue", "documentation": "Grant Funding Revenue." } } }, "auth_ref": [] }, "us-gaap_GrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrantMember", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "label": "Grant [Member]", "documentation": "Award of money not required to be repaid." } } }, "auth_ref": [ "r822" ] }, "CODX_GrantRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "GrantRevenueMember", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Grant Revenue [Member]", "documentation": "Grant Revenue [Member]" } } }, "auth_ref": [] }, "CODX_GrantRevenuePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "GrantRevenuePolicyTextBlock", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Grant Revenue", "documentation": "Grant Revenue [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r102", "r192", "r223", "r229", "r233", "r235", "r248", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r429", "r647", "r817" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r692", "r694", "r707" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Long-lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r118" ] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r1", "r97", "r131", "r223", "r229", "r233", "r235", "r484", "r497", "r647" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r267", "r268", "r582" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "auth_ref": [ "r268", "r582" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://codiagnostics.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r193", "r375", "r383", "r388", "r394", "r398", "r403", "r404", "r405", "r525" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails", "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Income tax benefit", "totalLabel": "Total income tax benefit", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r136", "r143", "r205", "r206", "r227", "r381", "r399", "r503" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r177", "r377", "r378", "r388", "r389", "r393", "r395", "r519" ] }, "us-gaap_IncomeTaxReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReceivable", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Income taxes receivable", "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable." } } }, "auth_ref": [ "r781" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income taxes paid", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r42" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accounts payable, accrued expenses and other liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Income taxes payable", "label": "Increase (Decrease) in Income Taxes Payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r462", "r789" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r8" ] }, "CODX_IncreaseDueToPrepaymentsFromCustomers": { "xbrltype": "monetaryItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "IncreaseDueToPrepaymentsFromCustomers", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Increase due to prepayments from customers", "documentation": "Increase due to prepayments from customers." } } }, "auth_ref": [] }, "CODX_IncreaseDueToPrepaymentsFromGrantsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "IncreaseDueToPrepaymentsFromGrantsReceived", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Increase due to prepayments from grants received", "documentation": "Increase due to prepayments from grants received." } } }, "auth_ref": [] }, "CODX_IndefiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "stringItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "IndefiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Estimated useful lives in years, term", "documentation": "Indefinite lived intangible asset useful life." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]" } } }, "auth_ref": [ "r706", "r715", "r725", "r742", "r751", "r755", "r763" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "auth_ref": [ "r761" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r695", "r767" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r695", "r767" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r695", "r767" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r52", "r54" ] }, "us-gaap_InterestIncomeOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeOther", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount of interest income earned from interest bearing assets classified as other." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest paid", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r185", "r187", "r188" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoods", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Inventory, finished goods, gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r782" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Inventory, net", "verboseLabel": "Inventory", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r168", "r638", "r667" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Inventory", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r137", "r153", "r167", "r255", "r256", "r258", "r463", "r642" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterials", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Inventory, raw materials, gross", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r783" ] }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryValuationReserves", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Inventory reserves", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": [ "r50", "r784" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWriteDown", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Inventory obsolescence expense", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r257" ] }, "CODX_IssuedForAdjustmentsToContingentPurchaseConsiderationPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "IssuedForAdjustmentsToContingentPurchaseConsiderationPeriodWeightedAverageExercisePrice", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Issued", "documentation": "Issued For Adjustments To Contingent Purchase Consideration Period Weighted Average Exercise Price." } } }, "auth_ref": [] }, "CODX_IssuedForAdjustmentsToContingentPurchaseConsiderationWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "IssuedForAdjustmentsToContingentPurchaseConsiderationWeightedAverageGrantDateFairValue", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Fair Value, Issued", "documentation": "Issued for adjustments to contingent purchase consideration weighted average grant date fair value." } } }, "auth_ref": [] }, "CODX_LeaseAmendmentMember": { "xbrltype": "domainItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "LeaseAmendmentMember", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lease Amendment [Member]", "documentation": "Lease Amendment [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/ScheduleOfLeaseExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease costs", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r440", "r666" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Lease Expense", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r864" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r117" ] }, "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdsAndLeaseholdImprovementsMember", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Leaseholds and Leasehold Improvements [Member]", "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement." } } }, "auth_ref": [ "r117" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Maturities on Company Lease Liabilities", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r865" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r447" ] }, "CODX_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Thereafter", "documentation": "Lessee operating lease liability payments due after year four." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r447" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r447" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r447" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r447" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Less: imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r447" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r30", "r192", "r248", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r408", "r409", "r410", "r429", "r552", "r646", "r680", "r817", "r867", "r868" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r95", "r130", "r494", "r667", "r792", "r801", "r863" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and stockholders\u2019 equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r32", "r152", "r192", "r248", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r408", "r409", "r410", "r429", "r667", "r817", "r867", "r868" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Total liabilities measured at fair value", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r70" ] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total long-term liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r27", "r83", "r84", "r85", "r86", "r192", "r248", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r408", "r409", "r410", "r429", "r817", "r867", "r868" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term liabilities" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r239", "r655", "r821", "r879", "r880" ] }, "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecurities", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashCashEquivalentsAndMarketableInvestmentSecuritiesDetails", "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Marketable Securities", "verboseLabel": "Marketable securities (U.S. treasury bills and notes)", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": [ "r78", "r779" ] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Marketable investment securities", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [ "r779" ] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesPolicy", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Marketable Investment Securities", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": [ "r79" ] }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashCashEquivalentsAndMarketableInvestmentSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Total Unrealized Gains / (Losses)", "documentation": "Amount of unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": [ "r100" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r271", "r272", "r273", "r274", "r330", "r461", "r510", "r544", "r545", "r605", "r607", "r609", "r610", "r612", "r632", "r633", "r648", "r652", "r663", "r669", "r819", "r869", "r870", "r871", "r872", "r873", "r874" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]" } } }, "auth_ref": [ "r734" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name" } } }, "auth_ref": [ "r734" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r861" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r861" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r861" ] }, "us-gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputSharePriceMember", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Share Price [Member]", "documentation": "Measurement input using share price of saleable stock." } } }, "auth_ref": [ "r861" ] }, "CODX_MeasurementInputStrikePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "MeasurementInputStrikePriceMember", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Strike Price [Member]", "documentation": "Measurement Input Strike Price [Member]" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r424" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r271", "r272", "r273", "r274", "r330", "r461", "r510", "r544", "r545", "r605", "r607", "r609", "r610", "r612", "r632", "r633", "r648", "r652", "r663", "r669", "r819", "r869", "r870", "r871", "r872", "r873", "r874" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r754" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashCashEquivalentsAndMarketableInvestmentSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r823" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r762" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "auth_ref": [ "r239", "r655", "r821", "r879", "r880" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r735" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r186" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r186" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r107", "r108", "r109" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasisAndDilutedEarningsPerShareDetails", "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity", "http://codiagnostics.com/role/StatementsOfCashFlows", "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "verboseLabel": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss, as reported", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r98", "r109", "r132", "r150", "r172", "r175", "r180", "r192", "r197", "r199", "r200", "r201", "r202", "r205", "r206", "r212", "r223", "r229", "r233", "r235", "r248", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r420", "r429", "r498", "r574", "r595", "r596", "r647", "r678", "r817" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recently Issued Accounting Standards", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r734" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r732" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r731" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r762" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r762" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash investing and financing transactions" } } }, "auth_ref": [] }, "CODX_NoncashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "NoncashLeaseExpense", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Non-cash lease expense", "documentation": "Noncash lease expense." } } }, "auth_ref": [] }, "CODX_NoncashOrPartNoncashInventoryMovedToPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "NoncashOrPartNoncashInventoryMovedToPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Inventory moved to property, plant and equipment", "documentation": "Noncash or part noncash inventory moved to property plant and equipment.." } } }, "auth_ref": [] }, "us-gaap_NoncompeteAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncompeteAgreementsMember", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Noncompete Agreements [Member]", "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party." } } }, "auth_ref": [ "r68" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r105" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other income, net" } } }, "auth_ref": [] }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesAndLoansReceivableNetCurrent", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Note receivable", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease." } } }, "auth_ref": [ "r240", "r241", "r480" ] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OfficeEquipmentMember", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "CODX_OneCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "OneCustomerMember", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "One Customer [Member]", "documentation": "One Customer [Member]" } } }, "auth_ref": [] }, "CODX_OneGrantingAgencyMember": { "xbrltype": "domainItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "OneGrantingAgencyMember", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "One Granting Agency [Member]", "documentation": "One Granting Agency [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r223", "r229", "r233", "r235", "r647" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/ScheduleOfLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease costs", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r441", "r666" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Present value of operating lease liabilities", "verboseLabel": "Operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r438" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease liability, current", "verboseLabel": "Less: current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r438" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/ScheduleOfMaturitiesOnCompanyLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease liability", "verboseLabel": "Long-term portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r438" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOtherInformationRelatedToOperatingLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Cash paid for operating leases included in operating cash flows", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r439", "r443" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r437" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOtherInformationRelatedToOperatingLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Discount rate of operating leases", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r446", "r666" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOtherInformationRelatedToOperatingLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Remaining lease term of operating leases", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r445", "r666" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net operating loss carry-forwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r66" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/ScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other accrued liabilities", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r31" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeTax", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), before Tax", "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r181", "r430", "r431", "r436", "r481", "r499", "r786", "r787" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Other comprehensive loss, net of tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r15", "r26", "r173", "r176", "r181", "r430", "r431", "r436", "r481", "r499", "r786", "r787" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive loss" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Change in net unrealized gains on marketable securities, net of tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r170", "r171", "r246" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure Amount" } } }, "auth_ref": [ "r734" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r694" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r701", "r713", "r723", "r749" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r704", "r716", "r726", "r752" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r704", "r716", "r726", "r752" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "auth_ref": [ "r730" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "CODX_PaymentToRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "PaymentToRelatedParty", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value of equity awards", "documentation": "Payment to related party." } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchases of common stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r39" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of marketable securities", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r800" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r106" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r733" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r733" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r732" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name" } } }, "auth_ref": [ "r735" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r731" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r688" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r689" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r670", "r671", "r674", "r675", "r676", "r677", "r881", "r883" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Convertible preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r89", "r286" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Convertible preferred stock , shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r89", "r554" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Convertible preferred stock, shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r89", "r286" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Convertible preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r89", "r554", "r572", "r883", "r884" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r89", "r490", "r667" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r785" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Reclassifications", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r778" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of options and warrants", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from maturities of marketable investment securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductInformationLineItems", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r653" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss", "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r236", "r464", "r504", "r505", "r506", "r507", "r508", "r509", "r635", "r653", "r668", "r776", "r815", "r816", "r821", "r879" ] }, "CODX_ProductRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "ProductRevenueMember", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Product Revenue [Member]", "documentation": "Product Revenue [Member]" } } }, "auth_ref": [] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss", "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "auth_ref": [ "r236", "r464", "r504", "r505", "r506", "r507", "r508", "r509", "r635", "r653", "r668", "r776", "r815", "r816", "r821", "r879" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r10" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://codiagnostics.com/role/PropertyAndEquipment" ], "lang": { "en-us": { "role": { "label": "Property and Equipment", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r116", "r139", "r140", "r141" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r117", "r155", "r496" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "totalLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r10", "r485", "r496", "r667" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://codiagnostics.com/role/PropertyAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Property and Equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r10" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r117" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property and equipment estimated useful lives", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Provision for credit losses", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r184", "r253" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r730" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r730" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r271", "r272", "r273", "r274", "r322", "r330", "r359", "r360", "r361", "r460", "r461", "r510", "r544", "r545", "r605", "r607", "r609", "r610", "r612", "r632", "r633", "r648", "r652", "r663", "r669", "r672", "r813", "r819", "r870", "r871", "r872", "r873", "r874" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "auth_ref": [ "r271", "r272", "r273", "r274", "r322", "r330", "r359", "r360", "r361", "r460", "r461", "r510", "r544", "r545", "r605", "r607", "r609", "r610", "r612", "r632", "r633", "r648", "r652", "r663", "r669", "r672", "r813", "r819", "r870", "r871", "r872", "r873", "r874" ] }, "us-gaap_RealEstateInvestmentsJointVentures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestmentsJointVentures", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Investment in joint venture", "documentation": "The book value of investments in real estate joint ventures including direct and indirect investments." } } }, "auth_ref": [ "r878" ] }, "us-gaap_RealizedInvestmentGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealizedInvestmentGainsLosses", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 }, "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows", "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Realized gain on investments", "negatedLabel": "Realized gain on investments", "documentation": "Amount of realized gain (loss) on investment." } } }, "auth_ref": [ "r502" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "auth_ref": [ "r696", "r708", "r718", "r744" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r329", "r452", "r453", "r547", "r548", "r549", "r550", "r551", "r571", "r573", "r604" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r578", "r579", "r582" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r329", "r452", "r453", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r547", "r548", "r549", "r550", "r551", "r571", "r573", "r604", "r866" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r449", "r450", "r451", "r453", "r454", "r526", "r527", "r528", "r580", "r581", "r582", "r601", "r603" ] }, "CODX_RepurchasesOfCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "RepurchasesOfCommonStock", "presentation": [ "http://codiagnostics.com/role/ScheduleOfTreasuryStockDetails" ], "lang": { "en-us": { "role": { "label": "Repurchases of common stock", "documentation": "Repurchases of common stock." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative", "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Research and development", "verboseLabel": "Research and development expenses", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r81", "r374", "r875" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r373" ] }, "CODX_RestOfWorldMember": { "xbrltype": "domainItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "RestOfWorldMember", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "label": "Rest of World [Member]", "documentation": "Rest of World [Member]" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r697", "r709", "r719", "r745" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date" } } }, "auth_ref": [ "r698", "r710", "r720", "r746" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r705", "r717", "r727", "r753" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashCashEquivalentsAndMarketableInvestmentSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r154" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedPartyDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated earnings", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r92", "r121", "r493", "r514", "r516", "r524", "r555", "r667" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r149", "r194", "r195", "r196", "r198", "r204", "r206", "r249", "r250", "r365", "r366", "r367", "r396", "r397", "r411", "r413", "r414", "r416", "r418", "r511", "r513", "r529", "r883" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Total revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r224", "r225", "r228", "r231", "r232", "r236", "r237", "r239", "r318", "r319", "r464" ] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "label": "Revenue geographic area", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r224", "r225", "r228", "r231", "r232", "r236", "r237", "r239", "r318", "r319", "r464" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Deferred Revenue", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r144", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r634" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://codiagnostics.com/role/Revenue" ], "lang": { "en-us": { "role": { "label": "Revenue", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r144", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r321" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r576", "r634", "r643" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Right-of-use assets obtained in exchange for new operating lease liabilities", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r444", "r666" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r762" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r762" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r239", "r774" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://codiagnostics.com/role/AccruedExpensesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r43" ] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashAndCashEquivalentsTable", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashCashEquivalentsAndMarketableInvestmentSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Cash and Cash Equivalents [Table]", "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "presentation": [ "http://codiagnostics.com/role/CashCashEquivalentsAndFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Cash, Cash Equivalents and Marketable Investment Securities", "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r406" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Components Income Tax Provision", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r125" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r124" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Basis and Diluted Earnings Per Share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r798" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Benefit from Income Taxes and Effective Tax Rates", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r123" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r65" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r53", "r55", "r465" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://codiagnostics.com/role/GoodwillAndIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Intangible Assets, Net", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r53", "r55" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://codiagnostics.com/role/GoodwillAndIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Goodwill", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r649", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812" ] }, "CODX_ScheduleOfOperatingLeaseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "ScheduleOfOperatingLeaseTableTextBlock", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Other Information Related to Operating Lease", "documentation": "Schedule of Operating Lease [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfProductInformationTable", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Product Information [Table]", "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r75", "r76", "r578", "r579", "r582" ] }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "presentation": [ "http://codiagnostics.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "label": "Summary of Revenue by Geographic Area", "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r49", "r101" ] }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Recognized Stock-based Compensation Expense", "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value." } } }, "auth_ref": [ "r23", "r24", "r64" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedPartyDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r332", "r333", "r334", "r335", "r336", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r358", "r359", "r360", "r361", "r362" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Outstanding Restricted Stock Units and Related Party", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r63" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Option Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r23", "r24", "r63" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Warrant Activity", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r61" ] }, "CODX_ScheduleOfTreasuryStockTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "ScheduleOfTreasuryStockTableTextBlock", "presentation": [ "http://codiagnostics.com/role/ShareRepurchaseProgramTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Treasury Stock", "documentation": "Schedule of Treasury Stock [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Unrecognized Tax Benefits", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": [ "r665", "r853" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://codiagnostics.com/role/GoodwillAndIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Future Amortization Expense", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r55" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r682" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r686" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r685" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r690" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "auth_ref": [ "r237", "r238", "r541", "r542", "r543", "r606", "r608", "r611", "r613", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r636", "r654", "r672", "r821", "r879" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Sales and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpenseMember", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": [ "r99" ] }, "CODX_SethEganMember": { "xbrltype": "domainItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "SethEganMember", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Seth Egan [Member]", "documentation": "Seth Egan [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share based payment, vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r664" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedPartyDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Restricted Stock Units, Forfeited/Cancelled", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r351" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Grant Date Fair Value, Forfeited/Cancelled", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r351" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Number of Restricted Stock Units, Granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r349" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Grant Date Fair Value, Granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r349" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedPartyDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Restricted Stock Units, Outstanding Beginning", "periodEndLabel": "Number of Restricted Stock Units, Outstanding Ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r346", "r347" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedPartyDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Grant Date Fair Value, Outstanding Beginning", "periodEndLabel": "Weighted Average Grant Date Fair Value, Outstanding Ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r346", "r347" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedPartyDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Restricted Stock Units, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r350" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Grant Date Fair Value, Vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r350" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedPartyDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r332", "r333", "r334", "r335", "r336", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r358", "r359", "r360", "r361", "r362" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Warrants Outstanding, Exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised", "documentation": "Number of non-option equity instruments exercised by participants." } } }, "auth_ref": [ "r20" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Warrants Outstanding, Expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations", "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of Warrants Outstanding, Forfeited/Cancelled", "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event." } } }, "auth_ref": [ "r21" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of Warrants Outstanding, Granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": [ "r19" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Warrants Outstanding, Beginning", "periodEndLabel": "Number of Warrants Outstanding, Ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r17", "r18" ] }, "CODX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Fair Value, Exercised", "documentation": "Weighted average fair value, exercised." } } }, "auth_ref": [] }, "CODX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price, Beginning", "documentation": "Weighted average exercise price, beginning.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" } } }, "auth_ref": [] }, "CODX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageFairValue", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average fair value, Beginning", "documentation": "Share based compensation arrangement by share based payment award non options outstanding weighted average fair value.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageFairValue" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of common shares availalble for issuance", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r62" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Number of Options Exercisable Ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r340" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average Exercise Price, Exercisable Ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r340" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Intrinsic value of options value exercised", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r353" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of Options Outstanding, Expired", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r345" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of Options Outstanding, Forfeited/Cancelled", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r344" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of Options Outstanding, Granted", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r831" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Fair Value Granted", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r352" ] }, "CODX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average Exercise Price, Ending", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the non-option plan.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value of options outstanding", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r62" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Options Outstanding, Beginning", "periodEndLabel": "Number of Options Outstanding, Ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r338", "r339" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning", "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r338", "r339" ] }, "CODX_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Intrinsic value of warrants exercised", "documentation": "Intrinsic value of warrants exercised." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedPartyDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r334", "r335", "r336", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r358", "r359", "r360", "r361", "r362" ] }, "CODX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Exercised", "documentation": "Weighted average exercise price, forfeited/cancelled." } } }, "auth_ref": [] }, "CODX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Expired", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to non-options of the plan that expired." } } }, "auth_ref": [] }, "CODX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Forfeited/Cancelled", "documentation": "Weighted average exercise price, forfeited/cancelled." } } }, "auth_ref": [] }, "CODX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Granted", "documentation": "Weighted average exercise price granted." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price Exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r343" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price Expired", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r345" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price Forfeited/Cancelled", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r344" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r342" ] }, "CODX_ShareBasedCompensationIssuedForAdjustmentsToContingentPurchaseConsideration": { "xbrltype": "sharesItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "ShareBasedCompensationIssuedForAdjustmentsToContingentPurchaseConsideration", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of Warrants Outstanding, Issued", "documentation": "Share based compensation issued for adjustments to contingent purchase consideration." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Stock-based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r331", "r337", "r356", "r357", "r358", "r359", "r362", "r368", "r369", "r370", "r371" ] }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-average Remaining Contractual Life (Years) Outstanding", "documentation": "Weighted-average remaining contractual life (years) outstanding, beginning." } } }, "auth_ref": [] }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm3": { "xbrltype": "durationItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm3", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average Remaining Contractual Life (Years) Outstanding", "documentation": "Sharebased compensation arrangement by sharebased payment award non options outstanding weighted average remaining contractual term3.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm3" } } }, "auth_ref": [] }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average Fair Value, Ending", "documentation": "Weighted average fair value, beginning.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted-average Remaining Contractual Life (years), Exercisable Ending", "verboseLabel": "Weighted average period", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r62" ] }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Fair Value, Expired", "documentation": "Share based compensation arrangement by share based payment award options non vested weighted average grant date fair value exercised." } } }, "auth_ref": [] }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Fair Value, Forfeited/Cancelled", "documentation": "Weighted average fair value, forfeited/cancelled." } } }, "auth_ref": [] }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsGrantedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsGrantedWeightedAverageGrantDateFairValue", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Fair Value, Granted", "documentation": "Weighted average grant date fair value, granted" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Fair Value Forfeited/Cancelled", "documentation": "Weighted average grant-date fair value of non-vested options forfeited." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Fair Value Outstanding, Ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable": { "xbrltype": "perShareItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average Fair Value, Exercisable Ending", "documentation": "Share based compensation arrangement by share based payment award options non vested weighted average grant date fair value exercisable.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable" } } }, "auth_ref": [] }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised": { "xbrltype": "perShareItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Fair Value Exercised", "documentation": "Share based compensation arrangement by share based payment award options non vested weighted average grant date fair value exercised." } } }, "auth_ref": [] }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-average Remaining Contractual Life (years) Outstanding, Ending", "documentation": "Sharebased compensation arrangement by sharebased payment award non options outstanding weighted average remaining contractual term." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-average Remaining Contractual Life (years) Outstanding, Beginning", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r122" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Fair Value Expired", "documentation": "Weighted average grant-date fair value of options vested." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/ScheduleOfLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://codiagnostics.com/role/ScheduleOfLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Short-term lease costs", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r442", "r666" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r110", "r190" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r691" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r145", "r161", "r162", "r163", "r192", "r210", "r211", "r213", "r215", "r221", "r222", "r248", "r275", "r277", "r278", "r279", "r282", "r283", "r286", "r287", "r289", "r292", "r298", "r429", "r520", "r521", "r522", "r523", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r554", "r575", "r597", "r614", "r615", "r616", "r617", "r618", "r772", "r791", "r797" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r15", "r35", "r149", "r178", "r179", "r180", "r194", "r195", "r196", "r198", "r204", "r206", "r220", "r249", "r250", "r299", "r365", "r366", "r367", "r396", "r397", "r411", "r412", "r413", "r414", "r415", "r416", "r418", "r430", "r432", "r433", "r434", "r435", "r436", "r448", "r511", "r512", "r513", "r529", "r597" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r237", "r238", "r541", "r542", "r543", "r606", "r608", "r611", "r613", "r620", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r636", "r654", "r672", "r821", "r879" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity", "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r194", "r195", "r196", "r220", "r464", "r518", "r540", "r546", "r547", "r548", "r549", "r550", "r551", "r554", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r567", "r568", "r569", "r570", "r571", "r573", "r576", "r577", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r597", "r673" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity", "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r194", "r195", "r196", "r220", "r464", "r518", "r540", "r546", "r547", "r548", "r549", "r550", "r551", "r554", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r567", "r568", "r569", "r570", "r571", "r573", "r576", "r577", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r597", "r673" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r700", "r712", "r722", "r748" ] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common stock issued for acquisitions, shares", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r89", "r90", "r121" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common stock issued for warrant exercises, shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r15", "r89", "r90", "r121", "r520", "r597", "r615" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation expense, shares", "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails", "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common stock issued for option exercises, shares", "negatedLabel": "Number of Options Outstanding, Exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r15", "r89", "r90", "r121", "r343" ] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common stock issued for acquisitions", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r15", "r35", "r121" ] }, "CODX_StockIssuedDuringPeriodValueAcquisitionsAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "StockIssuedDuringPeriodValueAcquisitionsAdjustments", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Fair value of common stock issued as consideration for business acquisitions", "documentation": "Stock issued during period value acquisitions adjustments." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common stock issued for warrant exercises", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r15", "r89", "r90", "r121", "r529", "r597", "r615", "r679" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation expense", "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common stock issued for option exercises", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r15", "r35", "r121" ] }, "CODX_StockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "StockOptionsMember", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock Options [Member]", "documentation": "Stock Options [Member]" } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/ShareRepurchaseProgramDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock repurchase program authorized amount", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchases of common stock", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r15", "r89", "r90", "r121", "r529", "r597", "r617", "r679" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r90", "r93", "r94", "r112", "r556", "r572", "r598", "r599", "r667", "r680", "r792", "r801", "r863", "r883" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://codiagnostics.com/role/ShareRepurchaseProgram" ], "lang": { "en-us": { "role": { "label": "Share Repurchase Program", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r120", "r191", "r285", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r299", "r417", "r600", "r602", "r619" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://codiagnostics.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r455", "r456" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r741" ] }, "CODX_TaxesPayableNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "TaxesPayableNoncurrent", "crdr": "credit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Income taxes payable", "documentation": "Taxes payable non current." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r733" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r740" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r133", "r134", "r135", "r242", "r243", "r245" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r761" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r763" ] }, "us-gaap_TradingSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradingSecurities", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashCashEquivalentsAndMarketableInvestmentSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r78", "r160", "r640" ] }, "us-gaap_TradingSecuritiesDebtAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradingSecuritiesDebtAmortizedCost", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashCashEquivalentsAndMarketableInvestmentSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Adjusted Cost", "documentation": "Amortized cost of investments in debt securities classified as trading." } } }, "auth_ref": [ "r486", "r779" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Adoption Date" } } }, "auth_ref": [ "r764" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Arrangement Duration" } } }, "auth_ref": [ "r765" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Name" } } }, "auth_ref": [ "r763" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Title" } } }, "auth_ref": [ "r763" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Aggregate Available" } } }, "auth_ref": [ "r766" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Termination Date" } } }, "auth_ref": [ "r764" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r59" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical", "http://codiagnostics.com/role/ScheduleOfTreasuryStockDetails" ], "lang": { "en-us": { "role": { "label": "Treasury stock, shares", "periodStartLabel": "Treasury stock, Beginning Balance", "periodEndLabel": "Treasury stock, Ending Balance", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r59" ] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock, at cost; 4,848,678 and 3,881,658 shares held as of December 31, 2023 and December 31, 2022, respectively", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r34", "r59", "r60" ] }, "CODX_TwoCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "TwoCustomersMember", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Two Customers [Member]", "documentation": "Two Customers [Member]" } } }, "auth_ref": [] }, "CODX_TwoThousandFifteenLongTermIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "TwoThousandFifteenLongTermIncentivePlanMember", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2015 Long Term Incentive Plan [Member]", "documentation": "2015 Long Term Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r406" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://codiagnostics.com/role/ScheduleOfCashCashEquivalentsAndMarketableInvestmentSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r644", "r660", "r662", "r877" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r760" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Unrecognized tax benefits at the beginning of the year", "periodEndLabel": "Unrecognized tax benefits at end of year", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r376", "r384" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Gross decreases - prior year tax positions", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r385" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Interest and penalties in year-end balance", "label": "Unrecognized Tax Benefits, Income Tax Penalties Accrued", "documentation": "Amount of statutory penalties accrued for a tax position claimed or expected to be claimed by the entity, in its tax return." } } }, "auth_ref": [ "r852" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Gross increases- current year tax positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r386" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Gross increases- prior year tax positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r385" ] }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unrecognized tax benefits that would impact effective tax rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": [ "r387" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r670", "r671", "r674", "r675", "r676", "r677" ] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants measurement input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r426" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Expected term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r862" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasisAndDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Dilutive effect of stock options, warrants and RSUs", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r798" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasisAndDilutedEarningsPerShareDetails", "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted", "label": "Shares used to compute diluted earnings per share", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r209", "r215" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasisAndDilutedEarningsPerShareDetails", "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic", "label": "Weighted average shares, basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r208", "r215" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding:" } } }, "auth_ref": [] }, "CODX_WinstonEganMember": { "xbrltype": "domainItemType", "nsuri": "http://codiagnostics.com/20231231", "localname": "WinstonEganMember", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Winston Egan [Member]", "documentation": "Winston Egan [Member]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://codiagnostics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r770" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-16" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "b", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(c)(1)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(1)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(2)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(3)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(4)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2C", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29,30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "330", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(a)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(a)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(c)", "Publisher": "SEC" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r772": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "SubTopic": "740", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 91 0001493152-24-009955-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-009955-xbrl.zip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

      [NR-&G9'2L*'A>R)>9SO50S1)B-('EE$ 8;@[MCGSYHU*5]"N8 S+\ M_)&^*,[TL<,H"Y(8[@_@!NR+@: M&>N&?/ILY*)@C(D'P90PLRJKU,W0(G__C>"0JT]V=$K Y^@Y9;RSO(3SW MQ W<%S6$.#6(U]'%"MD?P"L941UC71) N?[^&(<"ZUZFNV8W$NX:>OJZWZNL7JNT?W_5RZ,P MICM?6C_JKJP*S7C]\I?1A:5^N\?/_K&ZKG-D9,X<[>?*T?;299_,EC^-L=SV MRGA0)/ 33$Q2U?MGF-@+1O @:7C;][HR_@\AV9O7.;QZZ.,J)V?Q/S=%R1<8 MCSF#29'0O]S1)EI2)?HO11+CZF57^Y%V9/&!9^.]*L4PY8XJ&U GF]0@UR5K M]:T#=9!1ACB_]G+83WGK. >NK+83'>@[,#K488US7D7"ZUVNN_D'_1+LON6T ME7/ SQQQSSK "W=3=2J(FRCU50=_@>_V@T>^83*HN -OD]1?"]XOO9GHZE1. M=&5G;.A4F2=IMS2M$8YX6S ,!#C!U,-4KGU4==KO!^_# 8UV]F8]=.LQ 2?A MO-*P3D;YO$'AP ^T3E?IT^?S=<<":!@(6@%.?OC17\Q5NS^7K^ND6L%,GB;0 M\J-'[I!+*O# 3GGGBU_,]187:UU]=%X":!^]8V-(/]T9QE'YZB,K>5)_W1$# MH,DZB.$C'N X>%>?UFOIU L4W]T-TC'[[V,J_Y ^O L>0$-#\$IP?)YCDB$" MHB_?N9#GSS_K??3(?7E)!1[8E^]\,7B/]FJFJQ-_@$OI!W3H._:&=.B=81R5 M0S^RDB=UZ!TQ!._C@0UW=N@]=_MI79D6/!37W@70,3OV[A5_2+?>'@V@X2%P M%3BY]%]4PAI=)+0:&SV>FNE\\LA=>Z'R#AZDK[_WAPC1]VUU#]#7^H ]^@9C MX "]$XBC\N9'5?#$P7D'!("FZ@!FCWT9.UP7W[\>'+QV_T#@=/5#5O24-Y+= M41Q)ES^@Z6/>P8:W8-_GVN8[,!=(WQW#$GV2J@Y[2?F=UVY/L3SE!=;G) A5 M!1[O*A_7XA).%JLO*;7=&+N=EY[^;\U;6+X+I(5(8C7BZ_#=S]%5NK_/Z?QI M.'TXC.'NJ\N#]^+]IER_^S].WSTF']+C;H[#1R'V5C\FNRT'@22$G2UQO$GQ M[?QRM4[S+<8/F#S3440QRJ4S_)%EOR+5AMOA?.\*(O'Z"E5O@MP MF&]YW8DY9'7UO.-#?"AXQ,:'=<->R(L\Y66BNG^C3O?G)R#IA^BO=$)&Y]$Z M*:.4E7^"SE;YADK_PHO_[^!]=9JZNDDR?%WBE>I,Y.1?\=D_#U1%W9XY\2? M],G#V'6 WL@^@?@WPG?)NCYP+*^NVAA%C=LJ^^Q ;@9U^X6=)ABZ.\$=LO@Q MIZQ$!7OJXI0[CFC6T46X4@[.SO&A)AXFNIWS7XNSYRA)V11XE1/N_$X>V3)] M[C@.V]A5VC0Q4/VWP/2R QNH#F_2_KBB/;'@ZBCB^E0'HWE.4%(4&W8R[G@[ MJ&KGD@],UUE)DJQ(9@=YI,WITT?1<4=4YB2=V.&[Q]^AW8T==NY6J$K[S7IY M7A5:_P.>:H<]>+_NQ(>]=&;-]XZI!QNK;VL)A-_V1AEC[LVM7O!E@ICWGX(",/S417-P2H(E:#< M2FN.5E4;?] .JC2':D:LRWQ^&/[QE#$5N?_)%)>O!I\^O)MJL1Y[:0Z53;84 M4_30\S0JBMMY;45GI)%5DD;86T\P F[9JY2$P3@3/&'D'E""B09W_/M&W))[ M-KMTECN*&=&LYM,-MS6BZ]B8=()SS!&HDFWK^E&"\%3;$$('W2O,7D9('TJZ M/#[+XAOZK?0Q>JVWF=[C#,^3\NRIX.Z0JDY&%>65DGL8VZ/IB'+@4'<\^"&= MZZ)^!,9BP0RKFI!HA>.FT@0U#045H(Q3X1R2JQ:'PBU]1]%;;M(-P#,[#]R8-5U-LM7V':TM54. MR%:#01IZ*C2A;0HXH8;J<39&]#K5."[:%1&"D2[&R7AIHP^5G0[8#^*;JJ+6 M2Q:6O\Y85+T]3O_"3B)*(ZT::7]Q:R/D7>!:*0HEYYL=3"$(PQ50DO%]CNJ$ M=]3H@!G+]EG&.)8!UAONQMNFJHG> ;?]BP2Q*I[-%L33H=I'Z%A6*2E0T12$"(7)H4PUR%U3Y M$LE^14+K)B;C7?N'JKRCZA@&(Z0+$4E_.$$9+MEAFWG=98YM.KDMEYBT_Y0M M^%7>.TQ;(S.%+ZL5 MX>.B-E9?Q4E2&[E'W?5*@=8+)":ZDKU3Q%%Q6L0]I.XI>]@!)XN,+N<(+2QF MUVRH0,*NM=;S1(SCSQ3$_Y1G]:*&+G/JW99[7&#:0LNS M++[ SSC-UY(1_E ?@=9!W"O(M=/8?^$8UP7.U@W[6"/,,Q;&.W$T(SA.RKV[ MV3Y+ Z<#)_N6",HM"BLV& \T+XE4&H;*F'*K6A8 M)_PFLF;8!]IBNR<[0!QJ$J:L#R0O"LO[9"JE$$>%]0;(S@;+-< ,P58P57>^ M.,$BKA;^F(-@"?U#\V^=I3=YQ@5=>I_-9F03I07_+_7-DNB)=K,R41ZBFZ[X MH+S=LU*T#!]9-MR^L)]!0@K32A"E.\EC[33-FN$J)Q?YYJF<;U+Z&WM"8^+N MH_W0$70DBXJ:H$MIOG+LGW0I98' MNH[!<,O9D=?'BA-I""'?.%" MK3NZ]<66SUDRS\FJ?7^-CU965BDTPW%':XJ:0E(UH$S2816ROW^Z/C^[@^=I MW:[Y&<)L<9,7Q7E$R)::Q'/=V\[0NA*"^E)FT[3.DUH].!W'8Q9>[F)WVAHE ME%(M-.NJP2,L_<,Y/^#1,Z\Y#.+@5FI+";T(L##1Y/EKBH!+8"O\I4J!^*0Q M0,$LB09$ATP-4[OGW=G" [7QW3'GCK E3[F]HU:49UE\^?LFT5UE<"XE/!6- M)IJYJ2P"\.3J %_(4%'+\T4$;H1YUA>@-&[NU%'CKMN,!-6D,/R[4\TYE1N> MZB.JP4Q^AT*/HSNX&R1Y=ZP6*R#WBCN"UU'2;!:Z,5_0#<]NA3DVPW=/\3A8 M*@7@=:]1+6_'-1]1+#!H%.,<2>C-D0V9:,6@L*G9P1"[%#)L72 MNFU8RD,F"'1>V=D'@I>T<[0GI)WZE[J0\".=R4#SD*ZFQ6Z M8"G4Z1Q*_[Y(LHP=L*'K#/8/6QR%GU@51M*1G+##C^S0Q29EQX*N:(O7K_O5 M;]5'KW=-#@JW&G0N' "71U:(!?4=2P:S232I.Q,]FL)5,5=9I\QXD[S3 M\I\X5<0=K0!RF ZD+!IL]S%4QNC.HRCW.+N.WAACQUDS]2/J-A?X8-W&L6@ MW69495AT&Z=RH<4P)K1)WGOBIB0TKOO ]K3]/N95^=J7V9@653[HI?6U<18S M#QNX=UW%2>YP%J7\;$UU]=UYOE 5 V#L,AII-[W+RS@:#ILLD.RO8XJQY =0 MUHT.RTC&"'W*R/T4I2#.?CI?&H)R1\CM2M 1W ":[,+/*=P;/]?9'^ZEXC>#R6MUW>T_6V5:B=7% +V5*C1YY M0[-7%ES>NQD@?ZDP^T)N<-K6F4H;X(U-*Q++5>%R5HM73E%B,U"#X:O"G7]< M1N7/^2:-V6LGL[)-*/FH?1)D;&$ 5G&6!ENLY0PE@>'Z7O#M(Q4E+0^]L +Y M:SBS$N$V.VD))2WI;FIB\3"66L>X MD)AEG2#8'*EW*-%!C6*:$)Y[%VLSS/ M3C-)'J.]B?*PS$GYB,G*1!29H$^BJ(%VB2)*@2&*$IHPZS+!TY)*@F**B2"! M>*&E0Q@6&&\!FQA0G;&#U?C4>\3]L:Y-PG47;7D"^XL-_H1?R\<7G#[CCWE6 M+E7+@O'%^:76?D;WF3BN+*_$?<;D*:>XM-3=RXXATRG1?C@:7_(] M:Z8M!2*5!R:.87!=!)AY=QQN"5'_=%Q$I=]4+6M'E .6K%TS1].5%7*;@SO96A[@WA4*<'IN#=T81&VQ 1'3/!H!M$]>RC,07.?P1+:LM\)M2XJ ML*ZE85/S_9M;8NN,SVMFB!;['JRC) MFA_9'N\;JSJS*28<->V-5)/67 90.EL#%X\UUY*UZ\$'2]$E <[HB]J#9R>D M]"]XNQ<#AM$:(ZT9+2GC.!BM!B[DAZXE^$4#LPGY;.LIBY-XJ?'^F?BHB_,5<\1D^I*I)VB ]Y/41UL(KJ'<*:_"M@ MNM3!3!/\I:X^ZA3 3V%W_UYE$BR748;Z2K_P\O\[>.^;Y:Y=G#,B+RG))*X2#Y((RYU\QPA6VM6@,53.4$O6_3K;V? MYKZ\XE3 /5[3.E@R!Y;-YAPI0R#;5U;+>MO;-\%MM^]5@L%';QMTXFJZ%6I-B*M.EI7^BAJ"T 1+R$\3=LUY3U. M60ZM.SK';KO.ZOMM[Q>K (5366%B$"/,E8<9' J"0^\]T MDK\MB4V2M@[@2 MZI9W@IZV@Y^AA @456!:]IO5?!+;UH@NATTZ8.AJ"53TWQ1LM%X=>[H%2_V< M]W2:B-D+'IB"Y(^[[E;Y[[<[D7JG\XSE.^#_[R=ELT:X&V*V:I5' F&:$-^7 5)61W!(Z]@PS1F93GHC"C+!U8_#R>?#C4* M\$*1=G"M$Y_A^MT\SZW%B?88O>*"LHWY@_+S;AJQ7^-\YJU=Z+RQ#IEL*&PFA7#IIU"PK2QHR24;'DNQ>2 MH5 E ZN]U "%C*659+WY4@]Q(2O^EK!)M/[+=?9,S__2 M0#;F7J:HFCTG=' E)1M9^=^3IERT8@6C,F>1N>KI[C4KN_^ ][=!F/)^4]#% M:5%T!J"/NR&E\LK/XG]NBE(XNSM&'Q8;QH$?MG]32F_P[8[+U0(%1;N2@C0U MCQ-?%\4&QQ<;TJZY?F)N=*<&"EUSCR@#5I./-T >=D]X42CF934M7:U,.G0H M@C<^6S%Q(]E69.T7E)U-23K._1RQ)7M95+5S5E"Y(HGYB8(\N\J)I+>(!#G0 M=V"1Z+!&ZA>[K5=7]K:(^5SR4G^T8654,/'==_F%A"?)8WXD%;0N'!=WSEQUQW\M11'U;+C0/OL"SI+CG*O+=.@;3X[1G<+-A& M-76C?'SM/$!NT2&5;,JD8-6&UJ"W?8AAT]Q!51I8FX:M!9]SJ+ M\3S)DA+?),^4H=3Z;)$\I9@_V/.YP/-->I/,Q4B#K2*L%G1$+3ZSV:BCE.FS MA&%U 2AB): -+X+^.@\3J[C'17D[_SDG::SHJ MWGV^V&"V4XF;[(CL'>G6QY;T'PLM6$WC EGL.94NBJG?PK==6W7$ZA+-F@*" M=!N=:7RY6MSC&69=WJDA^ZK'TYI2W,Y-NJAV/DA=3)"&?7S)'Y?YIHBR^"J9 MEQAG+(D82Z%#X5.H%!@[5*".-MIKPVK>,=#%K-AO_H28&F)ZJ%5$3#/HF,M/ M'S^9#S@_#0\XWZZY?_PIS]A991P/\M)PXE]$)6X7:I>OF,R20M+Q V" 1;%P M%: [C#[K8$%1)U7"TQ85XJ'UZHPRRBM(_ QF!0J]U*A05,&JQC,4LSQ$\]TB M'#?8PIP@\=T&P_MPX5#\P3M#IPH =@>&[B@[Q.VF+.B:CFTZJ[+PL9 ,B6;E M)DK9O#AY;W"'\&5UA='V2_N!93>0]0+&_J8GY#M08E<@;=K%V0X83[X8[EAA M79D*SU84 <8A%3[YF;]:,KQ/*ERZ:V.^G>.+;"^GB>K>U2D">IL \B%EFK*! MM?/DAEE/AIT8>NV5<#/;F$N=U+4PCJR-A\TCTI;T.\2G MCX&=![1[2-Z?AS--L]I :Z9U@IZ:?%5APF9C^FEUO-N)?P?Z#BRR'=9((7I7 MC7[T[ Q(N<1HD]%!.=VRE2=?Q1;H)2F7=#U:K/&L9+XL M7<.>MFO8.5=B-QU9REA^YY\5=;1=@1>3SQ-..&\33A-.-G8#'VH#8J@FECMA(L]]6/T2,J ^ AJF,_ M4RC$B( ,_/9HOOB.XEP5QL&_.^(??03$/F)DRV3?* R.% 5.#'W2$?@735Y M'&@=/@J0C7XL=B)?V$,]$]2*^PG>-X>@XP@87QQ!Q]>!BK*G^E//[.HS^GJ+ M(U)\TPVV_2%I_0X&K=_]_[1NZP#@)8%WQ^44-PEJ!$_L,2^C])K:EF1%,IO8 M"7;Y*D"Z>S)9O*1="^U2!K4I:U"I22L9C;!%#+[,/E. M@P2_.G>^9(2\SAB?*HJF:?["%NYBDRA%@;6)":?0*%P!)1GO+_5,T.@$:97+ M^1S/V*W[ZXS.3_@Q>KVGZXM[S/22-.$0%;G$>B^:"&TX5<&P6GQBJX;\:(NG M%&'EHS)Z182%;TGO$^KL>[T'8L RZD.>QR])FEZOUG1A.IH_8C''QQ:E#:.Y MT92(DK9(L$1PF!3V*^[XB.$\N=@/'N!FH0L\QX3@F%8$3Y56G.>%)#.G7 Q6 MTVHQ#INL$>9-Q5.\LI(WI8TR -O%RE8FP:J7OM* M&TT83?4Y2^8Y69U'ZX0NWI)_R2]ZVZD!;S@=9IOVVU3Z:-8K('0S-DQ,<''/ M0CNW\\]%E3=2UXIJ+;"-:(2L;<-TIXT(4V=+W$U1)\@,THA\(#FCYL>L"A09 M,61"L)I(@W#8(EP4M;)!\V+<8-KP^';-%T#9HC^JU^&NXF*#S^8E)O_ $;FB M52=IGA&E0&N_\2:(#Q@,NEY<+92+:_L^P:EZ*3>@.5 @QJ:"NR,])1ILXTU2T( &KKE7PA+,: ME5SX&J_=FL?\'J=1R;8WB21.(96"5?,ZB,/:KV79_1]22?-GJ,,$(L[SAXA$ M%TFTR/*B3&;%W7-Y4ZI>!]!*PVH1&ZCB:RI,!W64$-5"5"UL+R%YO)DU;Y0J MFD8F!*M%- B%+E*)[MY8#5C[W?=A%74OBL"J>24^P\NV86I]4YPNHFC]:QU^ MWQ RV%^4"OSZ]M?T*?56YSW<=5WK<0WKNI(Z0;5Z$FX0RM6@I016O "<]@]T)C)XA+!ZIY#F&9IS$FQ>7O MF\&&NEKJUQ_ U+P&G' 8A?]\@L[*DB1/FY+').F*E2YL08PK9UELUR F'4 = MPQJJ9EA"41:C2CQ0(WT@>5'0!=P\D6C3;C@SASK# M.SG37QR1,H@7\O1MY8G/]9Z^%- /K[U"@+ZS&5LO%;P\W!)%?7]S?M?OECC! MX%=OBD'\[AITYB_/"Z,S6OR3I\]/)K-9&WSM#SH2C(4!47$88Y<054)R4@OY MHJ7Q(Y;?DUUGKPB^VGFRM+C SUG>7)#%Q?6^S,,LW\5IF']L2OS*%C;TL5N6 M).QCE)A\;.VH,:,Y0*ZQ1"TU>3J;-LXSQT\E48M\797'PBRB19/ M5&HJ=X?+^V<#@0/% =%F@[)_)C5 $Y%F-TC"/;"5&GNQJC[#UJZ5NX7^^0*& M*C,V[0MQTA4J97WN4#175W9754[ \#?!QJVB@T* VH\]5GT>.$44<=DZ68W? MG:4K3%IXQ!_WD/].,'LME.[.7[.\U#P%<)$#Q)X3W/XE\D8X0%*<;7>H"GSV M=[U'_,9.KU<2$$T' &J[O\^L/!(W6Y3@!7R*&!8O8AGO;[W"\]EC_NS%&!"Z$R(?Z*/#(4&U*@ 0^(VQV]AO!O8$C@D YH\ M U1+XFII<"UOD[Z3GB'+#<>#@P*@Z=+AM.1*$07#DPB1]&=E(%:"YM$-NR:Y0QO-O"74!D@K!<$XZ^[RB"?;D#A,9U)T&1[TX:*X/H[9N MQ/@M90;NZ?TU #QBL:]M* B!T!NK?5 MCDM$=2"AA 9W.Z-Z"+V?E!=7C2Y/_(H7@8_9.<_/0Q 3=.7'EE2H),LJ>@C\ MU@W-XBX-B-\1H UW[UGRC5H)$EH"Q/0$\@B=J8)"[[SS;WO.*IR8\NU M$H1,ZB!>&SX;!:C1 *L7WK!(ZV-[88TT($)'@';LA:4J.+WP398WFXO&!Y/V M4H#X= !K;)TT]5$C3(\LN#B_UP>K;=[$:9A&8]NF1AH0ER- .[9-JE)#\7Z"\5HJ3:L>M+/ @7#?O%XW9I M3R4710#(SSQ5O'=V2A0'W%L5_0%J3"->A,[X.C^V)3@FI%GV!4@B0P(:HM@0 M![=&YYSZW;UQ; M0$(,$Y-442D7A7Q=.ZZC9I+/M4E+\CEBL@#@;\*V61)'']K8(^[2@'K9$:![ M=YI%K%%*:*,$B<>)7 _ZN_[37U"2]A6YQW!O0:JI+" *#T(T7-=C-W[ D2,B MO=4/B/5W%EI% %%A0F8,9R>?28-X<7I1%7&*BX(LK)[(''P@D+4\=!A^('F4 M0D!#\C3UZ'J!T(H4M0%J%*.69N6D!\#SS/,HJEXK%GG$YDZ.T\;R5+H!=0R3 M5ZGW7T94R?IK-:U7@Q M%Y8I36LX2.!!#)!/WYXB9[930MWEK0.:1WFH]&Q.SA9S' UH#S^B0U$RU@9@>:OL]1MSKY7L;KRZ8-2DZ6G#Y:F3]-9K6J\F O#ZER/RU/L/) -I3_U M@@+ A!E YG<>FVJ1%F;.@M06+1O#X$J;=KS##=,/5. _]U?G M&?IVC@4I8! /1E$2.$W/KTRJUSEUL?_FX]>-GG']7DW#_G. :#6]V1(/[$T1 M(PK9;R#-V>CZ@U5_D_+;>LNVG+;M4U@2C*VROQ; ;&GSPS2R3GX398_X]B; MC_?,_Q9N;JZU/T^7F-;K[&2XXM7I$S#KB:6#W5.8XXRI[@Q^36!\YC@T+@[A MM+/93SCJ*X\Y[5S8- "O]E5CK6,O N'DO%F[0%W0[&_AQ9;+R]G-G\[&>10,4#,(?[6?[!3S*#BKFA\WIP.+K_:<38/R M\F5K/-E>X%3;,@HYB(/:#X["G;OT1)7@FHM 6)ZV%- IBF@+\5% &!T M5JOSE31(/)VNTB2P*CLV6ZX[@U$8>(+-.L(W\ M=MHK))[9H'?) AIM4CI \"$G2;)?8:J9TYJ+0AG!+1#V.EBC"(P^U'VX=%( ML-T=-V!V.U;@(R:/(2:S11%H-+38 Z:B<<+#!.B7-=?["!<%$:AKL"7+$ZR/ MV3"Y$4!>,U_=>AF3A26U#V>!X-K6# X6Z/<0U4PJ-0+ KD@6&SN\JTBQIT2D MM7S !29F:.2S*_R.D\P8.V1:"RMSPA$5&^^!+6/"%UF .&:/AW=K+/IR/39H MVWP\AUG*<>J@S&0FJH71@T:I!=PQ"=!B^">%> "688^9R<3*NJ8Q-1O?-W%K M]%ZCG*O1LMPBDB:1M+F&@9'=X90_I3]9IMXCIV1#.E?F8595&>]2_ :MHA\Q M [X=I]>>ON:&Y/+ZDH!(/@#0N IK6G: F @4*NS&A77U]9TY2 S-!193DM)G1$:)#,BDEJ,"Z>8DHXJ8/+IA'R0:D53+PHDB""0^EH/ M1*ON_K^]$S@H!>\68^IB[RB]T).@G*.=Z-3! 3J"X$DVX75I\:VLKDOSR+8? M]'5[H/<+[I]_%-Q+>ULO5E)0=EC9;1& /!U":KOT],31CS3'4?8SC?]C5:F/5+4-R% 4P*S#%F&7"[4\ MXT-(P")#)$RC^;"JA&;)N"%BVSS.I-6Q]HG:$J) M.H6=-( H?XB9$'GNJ(BT LN/FHQ). T3VE'5V=L=?,:H [Y_'(;NX O*N8E4 MAVI]GEB_I;YYF17:@57^)2">^IBZ!+ 2-#=0X6M\O,5DB,8R>3T#)--:B"2] M5Q6^P_OR\1=.WO&W+"U?M-WP6%V@*#NR"GV&J<( 296HYES)^E1FZ FC;1CO M O07#G-TG_I:$]K6_QCZ5TCW1/1J2%5_NB7_17X6/Y%_T2<[Y)?_ 5!+ P04 M " "Z@&Y8A!>E !M5 #&P04 %0 &-O9'@M,C R,S$R,S%?<')E+GAM M;.U];7/C.)+F]XNX_Z#KB[C8C=CJ[JKJGIF>G;D-^:W&MR[;9[NZ=NY+!TU" M$JG]Z>?G=),V\./"B)"9__2Y.OON/__W? M_]N$_=]?_L>[=Y.+D$3!GR=GB?_N,IXE_SZY]I;DSY-/)";4RQ+Z[Y-?O2CG MOTDNPHC0R6FR7$4D(^P/Q8?_//GY^P_OOQM_TJ M-S9O'B=I%OJ"M1]XB1].$V:53%Q1=T')[*_?L9(O[!,?/K[_4'S@?^X5RM8K M9IUIR(WKN\D/73Y^XD4"AA;CU*XFQ!6!$OLI),6K-',7DW M(DOVB?1F=K/B79_95CJ- ][=*5F0. V?R%62&@&U;VD(-6YFIPLOGI/T,K[/ M$O_;(HD"-ER=_YZ'V1JL JB5@5@X]=+%190\6P'>J-2C<#>LMSZ%Y)E1>>*E M(?O:+24I^ZY@V"0EK':?6.;+I4?7-[/[9VQZO$VBT ^) M&5RK5GH4GS/)_Y_;VI,7<7H9=!=AS,:$T(LNV91 <\&Z<9BU;JE'-2Z\D(JI M^3/QTIP2D,3:2CT*=TL3-D!E:P8'!V?%OV.235>G1]$^)4GP'$81^\PEZR/Q M/'R,R#1- 3,:H&J/@K+.0',2G+^LV,!N[D^*XCT*=$>>2)P3DR"U8CT*<.[1 MF(T-Z2VA]PLV;9LD497O=5YAD]<[OL@3LS"#'C1F&ZKU*. EV[4LR8/W8K8@ M2=$^A]UDN0RS93E(GB9BF&=[*L!4 :C:)Z7<5.[(*J?^@A'$AJ4Y]99&1K6U M>NV%$5N5!&S9FJT?J,5S+[[0V]GH%)#Z@Z\-H&)J>YYCCK')BTX :&6_/ !-56ZG_] M Q-*6GC M1!,*GVMX==%,"E!E8=9(\$$5%889[T$'-.A#0R^=@*R#J@[^HK@ MC&1>&*77'N7NMB?CEJ-;JWVJYR](D$>D\%PUY_;/'OW&I&#@7L9/)!5VB=@AAM@=6QC3T&=DBS7)ES@4*\NJO]9>H2[-#Z)PNG9-WO9F=NU-XA* M7V*Z[==,C!)O>U5@[0SC_K0= !5!\'ZBK QI^WPJZD\B+"?O:ST>-UPY\/* MB]="A"[V;M_F,,N8;$$H#QJF2S'REZN*AZ2,3XSG0BK[]4NK=L?QOMOVD19- M#<+5 Q7.O;68M*T9T=4>_ #!>EUBU$O_[>?+T _&# M\G3[:746IGZ4<#_POIB;^P2-BEQT_H/0H3CIEK72GY#GE/)!KP=!E2WU)^ST MV:/!0[ADO;X'@;6M]2?T9>$P9[;']Y!3OO>:RT),+20W-SF4^-N ')KX/8DO M:U(G_JH2DGW%?K%7A;QD) Y(L&F(JV!U#R0+,UZCO)_S?O*.7^81\3KLQZ)D M*(XE$^[^Q M,K4B/XP@U0:)!]:B7*C]$G69JLQ-J3])*+,"AO6F+8_Z>WPU[P*5)7Y8B9LF M[_Q%&&VIGK'MF J=$HE$(6@5*/:)<="+Y'@-0J398 MB)Z1U*?AJAH'K !VKR00WP^H^$IT&QGF3=^Y(_.0R\M%V=[OT8\+BBI X#]B MCA1:;9$8F,9Q[D5L=9Y0 _#[)8%X_X2)MTPW))C_;\XV#X1&:PC2C<) L'_& M!%NA(1+>8IL6%LX*,^#-TD#$_X"Z\%#HB 3Y_8)$4>G]@H N*P^$_8^8L*OU M= !X<67CC$TM<.PK58#P_\D5^!O:(C%P2VB8!&Q*IP#L&X6!J/^"B;I"0U2\ MS^, BO:V*'C_@P]V33TDJ"_"U/>B0J(+]KM4#[>D.!1RE#VG44U4V/]./ H& MO5(8"CG*-M2@XLB G^:4[@FC'574I:&0HVQ 34J.C/EYG(79FJ=9NLZ7CSO' MZ3[6S5)0C%$VG2JE4+#=>!KBC&>/TN%;+PG%&&6OJ5,.!>=3I@_E-W(#\O*? M9*T#NE$4BC3*'E.K'@K4MS3D$='WH6\>-)IEH6"C["SU"J*@_>"]7 9,*W%I MCH-D!EU9!8H]RK82I"X*!3R:BZZ2BKOXE%]_<::$*):H5@>*+LE>5JC,VI)QA2CRU^>Z7@ **L@&5*3,RGE<)/_M8 M)+'6']LL!<4592>I4FKL@9='$Z?*KE_Y,SB"#658K:LQ,HQ?:9@Q"?CMG3PN M?32*4S%%42B\*-L_K7HC0WTO@NGYM:C/;(5(PUT>_GV<9>6@(*-L]M2*C8SP M+26<:<*6W2*.BU\WH#>SF6KDU96'(HZRUS,KBHO\99KFA-KB+ZD%90%EVP=5 M>NQQID@]MW[_X?&!WYA1C#*-4E"L4;9\*J5&QO8Z*6]&W:^7CTFDOAXB+0A% M&&6#IU%M9)#WY)##6RL"!19E9R=5!VE,.'_Q139$=?2"O"048)2=GDXYM+%W M#AI[YY9C+\J.3Z44$K9%;#CK43>/43C?>U%"#K.T OB>#2;B&E7'OK\GKOQ4 M2-4AKJH!!1[Q$%&O+%)\6D:XS.$3.?,RKY10 MA[^J!A1_Q -%O;)H\?/TE$T\\T1_9EXK"$4;,116JAH*R/=++XI.\C2,2:H= M6VH%H2 CQKQ*54,!^7Q)Z)P-:I]H\IPMRKN=.K 5%:"@(T:V:E7% ?]E=X^\ MN/^F15Y2&IR= !%VI9)8:3>VK]#E!O,2)T!QI%50NKOH18*3]1U/&\_#%![(2W;" M/O1-OR@"5(?R@YI1" S#R#1=^C,J'-X)G68920O8U,$$NO)0(E VQ&9%T=* ML(Z[S,XI3>AIP@917\\ I!Z4"=1\0V;%,4Z[$GH1TN6E8J]6*P).(8=VCE57 M!P=2=8S'7@$HG#CGLDU5<,"\2GQ-I$&C$!14O+/6IDH28/_R0T/Z*_:+S5^E M?]QKK4W.[Q,O\M@DS39[I'+NNY?[^\/DW61[-BR2?\=I$H4!G^YA]FQ1^,DWN\+(ZK'9W MZV^C6?GND%&'>CFLA.-6D.YW%84F PQ#[8DH=X!0/AK%T?*6Z\&5,:!0%9T( M_B X?_*F]BYX=NI1NF9[0?'DM)H88'6T!.@@#I(V*CG"W^[Y]MVC[6H?4UE+ M6PDM9WH+K@#:HS-4GG6D=\0GS)J8K-5?;T&"3#\'0"]?)MR9A@Y[26&TA.RM*%!JB\[$+24K+]P\A,YF M/W%$N*>=FAE09;0<[BV8LD #G;GK)!,OQ%XE7FPYQ0"JHJ5^;\$:& ETSH#] MJET/ZM]!VV;.-_05)GOQ%O!5H;520B%>EF1>)$KBC8_)BM!L?1OQ]\WC@&\, M5GQ#KETNZ&OA)9VWV;U"-$?O4/LOSMZ%\T5V,_O"AFZNH9H?0S6\%/4V!(%T M1V?HDN$6ST,V'A=*,>LY?_&CG!\W?TJ2X#F,9)=EMTLG2&V\_/8V?-D@@4[; M'?&B2/X_21AGO[*?<@:PFC1(7;S\^#:4P5% )ZS0Q[2FP$R: M;^\Z/8+U0^7)=S:'BJB;11(QB%,^GV9KLP<KO[NIQ6V.*'WMXK X,,, M71V\]/]M&5 2Z.J)Q\8?>>NM^?X0[(FME\=[/ ".M=P3*]?-VC=';MAA\X]EY>K]S7,%J=YFB5+0N%$PVKC MO9[0EE4;5- IM)D*.\R! [RRT)8>T.1WP+N_ZR3V6^P39-7PWG/H?:N@1J5K M%_23X$40\I[]1Y!R>G/V7[\]>"]DLPS>?5Q"!2^M*HSWJH,5@HE9$T>&N[.R M6V]/RJL*ZASYQHIX#T*TH0JJE2.T*=;"VGZE7T:WZ65C>$3 U($A02?/=I4+ M8;5+FWC/7'2@NSN(Z'8@5=MR;8+YID8']K2J'\>R$T0DYM,=O2\ICX _?D4[ M+ X;>3SZ9DSQM7QJ*^$])M(/OP!$T ?2-H=[/1SG#?!"23^<'< AWNUF8!"R M&FZ\2 OCO7 "1[D1XZK2&9V/2FX*T_6C1DF\ET_:,J'2%IV&!\HV+SE=0XB0 ME<5[_J0M%6J-[9<1OQ3+B)C,^;U>U(7$- C$ML2+;KTPN(Q/O56821]PVNQG M5!7P7EEI2ZE!=_1.-O7]?)E'W$;$+0.>((R2!7]6[8D4GI^K).7^GIO9@_>B M/0JW:PCO/9?67+;#"IWC.Y)Y84R"T"F+9-P M1-#):^IFLX['?'RF+3EJC0]X,VW:Q8 \)(J:>._?].XVT6+3*_WXV5EN!;0+ MPHI4%@1[J5H^PE.U3/YEK[U_?4O=,N0FG6%]0X6X@5BGWQ(JTAA"]^WJ^H>; MZL4.(?2)=5_<(@GE-,\6"0W_N>O5)B*;];"3PO3&H H2)YD3K^Q8LK:I@YT= MIF?&]J%PDBU]EEN-;FW2W [H:NN5MZ$SX'9TA=I/>:#*V*ED.I!H 8Y+1,*G M.FTE[/0S_1#G["37D-$TPRDK8">IZ9,HQ^8VR_3M*JW:S&H#.M/ZH\O%*6WO MD*646 @+/%W:KX*=H:8#6T8@7,EINWO(]&961C8F<1&!47' <]>[W(ORD\Z+ MLFM\DLPFN^8GS&PG>Q^8B"\@9BK;BFKVI"@K8#FQ2T$>]$G6ZN5,O:MAIX/T M,0/Z#??UO@[5/#K(Z+/>2/@S2YJA3E;6#1;D-J0"OR)^]6I?CP2D-*N S_ZU M Y[]@Z=L"G(_8[L"0I]"GTQ?0AGLK*B\Y"& KA2^XN,:'7%QAE (DYXE2R^4 MI9W?22XKCHR]$E85^C(==G[B/B\NE1^\(T\DSLEGHGBCCI>5%T7SCNK1VD=6 M+7X_:U@%N)^H%X.@E15$SF-'6P#U[,B"=@71RAZ!.)F4X1$W$:+,,XY/IDX1,Q\F2LB'W88DL6 M$ ETQNX8C.SS_,&5,S9C1HG(+6SDRU -^\3%EBT0"NAEBNK*6MA'W48LL3 %TEC8YA"^7*R^D8NJM..8E0Y^B//;!BO6(I]4; MG9:&.A;+.?S<_[9D*+4]AH7Y[J8)@,-J8?2,__:K\::N!\S@=1(G^XIMGG@Q M;K$ 5=&?"P"S"\8!?=2\C#/"8,P**<6E+]V9JZ0P^J, <+ ;[P2H5$>GA2?$ MY\%:NW3XG[PP3ODP87H10%,-_3& ME2!X$ GCQ$G.79MH#\,8$U4 M"R6=ZVSW7D1N9I6'0R ]35()_66 [MU,"04Z74K=6JP('7@9H"U51A@.>/&_ MV\EL#DW#.&=Z[B(.3\@LH62;;9.DYR\,+$96&'MT+1;4/#\6K% MT!\Y@+L 9/H=GY2OC#\B28/A'JSV64.PC MCTE*4!=1"HU+]"Q2?%@WA/XT!H8EF7#MV99PDU?.)+EH0\!IY*5I:5.*K!=U19I5#I&.IA;#Y,&P\?=51%(FP]CXQR1E':-! M95IU3Y]$D\I='BS7:\R6)5G(#&D_^Z.[E"Z$.= MW?CF^*!FP8?3HUDE.:=YQFD4=28;AP4=2HW1N9"DWC1QHJGB3)(-"VZ,"*!S MI'BYS<23H1IVUHTV7(&0P.?+_#J;D3MX$]@).5KQ:(L0.J?U=]I,!*K*8R?D M:,.67G=T:D9ZEPX_#'6 ]\A6(BB024 SU.,NBP.M]D=6^ G:^C]?>O49]9U:PG3KB MP?!73 UE]"01#XVP;9) 6Z1[;3F/ZAK$3D;7SVQJALQ5RLNIHD?. 2UB9[GK M:7X]7-:%U5;2>;3LV?LM8*?+ZZ4KRT!QE<7R%;\N-,J:.)R$>=:XN,'D'5GE MU%_PD:-A?P8&]54/)QD>& =[9\4OA;,B)G/N\G7^?KR:<%AM]%1[O=YL=Z:C M#IJ*8KAD>KVEHCA$]_IO'QS(B]?!P\[E[\5%>Q[CCGM=/.PV)#K@MI&)/Q"' MZ*^0GGKIXB)*GA4/COX!_N H;VE2-(5]/6.KE-6M#$DMM'F*RW)+DZ>047NR M_I+RE*C;5-)3/PN?B@0=YG3++=IRY>DN#9'-F:\E8NC3X["+DL'R(K8'_!#6 M+-/@'WF96?,AN2-^$OMA1/9D?4AZZZ/#? W[4+LW$QF2#'1+JSZ$PGZ.2.LW M8=2UL4^W!R50_:Z,"=;L_V5ET6,51B14C94#-/K\4C@Y(\7_ M5M0K;QR;#P5LVD /D!B5=EML'32'S<##H"+ADS[E'JPV>GA%"UY,Q*I1.NAU M6U/16TI67A@87\HSUT1_VW ,Y"C*4S:)LOJ17H?<81MI02>N&T!\Y', Z0-@=]#FO=%:D>66_2M); M;]UB":%J!/WIPV%6$GK,CL]&Q,JIU)('0!0(;#J'Y30#:P_]T<8!UZ 0)-$W M&O"0JSX"1AUX@;'/,$1+Y [X@2V%LL4Q2C_QQ=JVT)]<["_"&( 9^JC AJ[2 M,R/"(2AA2C"[SM:WD1=G;$3C-U56O(C&CVS1!OI;B1VX2EIK?01[$Z:=3T@@ MGA;G)ZM,P<]>QM\"7=_,/GOT&Q$OC^[>!]6>.]@VA?[\8G]FTQ9']X8*2]9A MU=&?8AQN@ "R>WAC QRR/M8*#CP,V9N-V"-W?$O+BS#V8K^?I:6V+?0G*_M; M6@(PPY\O*C,=S]G!!"9,\5VVTBX3N4GE M*07417]GLC].P4@=X\0OP:N/D=R!YR-[,Q![Y YXXN>:\O_G.^(GMN<1Q_8, MGM!G!LS_P#9!^[^HE"QR!#6=KWZ4\_P+YR^^>!3RCG6&\]F,Z!8-8\L!-=?A MTS/!%QPX7+U6X]Y"4P0B>]$GFN0K5H,_/"LN)>4D*!W-VG1OXTH!-6R7G+08 M/!U\YO779]P6Z8@^#I_5RTWS/IZ\5?EJ%0F@O6@#]&4\2^BRX-J<(0C: -2D MAD]3!C7<488K!E_OHFMKW4Q#+6"4':&RS]F"74],D&JN .$5$)J MC)PTRT)I&2X=?$=:5.JC,U/>D-[YF>-@N_44Z>\ 'EAX$U >G7*\VB+4E5/] ME?\;>LO6@A6AQ.V6S\D3"1X2FS/[ROWXMFU"Z1S.]6K-33,Y0#= T3OP73A? M,&O^DA)Q:_7FL7A%[3+>[+$O$KH-4!*)$ !APYT:A5K%<,[;ME;1A_:#C@$G M>Z@K'*ZP]3[ZE'J\;VUD'N:\NRX85!NH=E0(K%/ M%>6#?0UJ%L/E@>QB%@.3(#&=83,R"QQ3XG\_3YY^('Y0>$INGU;<"Q,E?.C: MRE8D8O[EEY]9EYV\F^Q*L'_<>NO)4SIAG43L5&*?5/[>/?]R5<)BI>('NP4* M^P<_)_XUK7Q^]_6K>GKMBJ6SFJ"*W1=< V>5@^*:S-9LR5U]&W@?9D51!S"O64<%6(7,E93+ M8X \C:*Z("%1/RO-JNAKX$.N-9L*_GH]=LG)QV#A,@["IS#(O4AMX_4R^$AK MC+LN;"5+]$A6O9/ 9,V2DOC8RBUBWWPE@H]KMFP5_9#PG*EJJZT5P0=68[0U M62OYK$>RV:T !HMME,.'56H*^^;:D'I<8RVW]&I3W2N CZC&4/1/)"S(GVE&/Q>;^][R,ZKWX:VO;IUS:B?)OA$;K!Y0#+%@ :#SZ'TA M>> QK6+5M92=X KCJ14"H]U_!(N5S4MU&Q_AJ9^Q_56TYF$9)J"E9<%X]Q^: M8H>W1M.181<;!281E\(XM"@+@X'O/Y;$ GB#KF,O>Y*8R7+-C.%I;AY;U*7! MV/2%+IC"#\I97 -/0?:=&"!HW>& /05C3X,*2N D]Q- 03 M4)03J#HHK!0O(?-CW (VMAI>KL0+;>%L1A@$/C'29-L&F+=!=LWVO+7#:'1G MQKXJOZ9B!!;/*!3U5BA6E.F:P%,W2";^CZH,^,S,H62 8![M$M_A($]<&4P<8/X!^R) MLT0%O=O=9 M"V_8X164P9X/X&/KH;%I4QNYGWF,>>?0J3#/(29>F.)B705P0 M+?J227/\$4^Y&5:5!7,PB"NBE_$,TP&Z&4 MRI%PLTLH4RT&3Z.+XB22"]U '#?=>HL#?&7WD9<$LS1DDFP) YKC>[QA2ZPF M>*R'"6MI03#4P]UU,$"MT0_#4ZH])-@O <9VR*S.6FQE&HU_[*@.[]G^$0SE MD)F.M5#6]!@916.@5*OPJ &R"9.VP6D.A$DE\2=F"*4@9R3U:2C)(E3(>48=_HV M\MS,&OHTR-HW0UC-4H H56?LJW\\_5B9A^6, M_:\Z9E]:$!]\G?E4P)9*/_(%P,.\>@8$^.T:VFNXAE;M1B0C=!G& B+>I\S# M1K,&[D65E@,W!(2Q%Z/S>5;JH'8/U,K@7E,!@9@HA4=!>2, 6^6NTS U!4 I M2^->3%% V5B8*-4<&?7[[-LM]6_H0TK/TRPLLOQ])MDB"0P,P&KB7DTQLF&C M_MC.WSQCG3CF.6HA Y"F..[%%",'1D7QAOOK)/L[V0ZAQ-0E8#5Q;ZX8Z;!1 M?V1F+IBZ24PV*PNV8%-[155E<>^Q&-'7JXB+]UE.'I+S%^Z$(6Q5Q[/"^F*- MH1R4K!K O>ABRPP$# ?H^C5,(H'@S>QOR9*<\M>;Z?K*>[;B3-\*[BT9R[5N M6Y RPF)R2S,4BL^S2WA7KGI@5,H6+B\L@$D\N)2 MP,OEBB?^8P(7.58-JXV63>%>X>E$E9)Q.QCQ%O*@E8NN/.X]GI[(,P."SQ!T MK]4HCWM!9SB&UNF)07O '#D[%J>] M#^&R>)I'C^);O>C&[W&<>"D)J@%24YX%?B[F__1DO2M3/M,LE-AI M$@?\W1>^ C]+EEX8J_D;YFO(9B!G5LK^,/J/G.ZVG#FWUFXXU5 7QXTPL%H! MZ/0=^X!I(P_DF%59&#?"P!I[)\Y4-]+<4A)D=!D'%Y$WU^->*XH<76")NE1/ M+&MGO>\T3@,* +U>%CF*H,4XT]04"?:_)<\[>8!CC:H.^Q;.9 M>\(EX3X>OGKXU8O474%; 3F$ $@$0&>,3B%=[$-ZAJDB8YHZ'N%L3?3?KL*>_CG MRP!W64:C!T*7ZP;5#N(]]<8.'LTC\O['QY_?\^D[2%89T1Q!*0OCGD%9 MH6Y0>/SD6E8,Z,KCGD!9D6!6&V6H$7)HDTK(RN$>.+48XC49<1!)V&SA 4DLE$4Q3T^:C'L*)1% ?XL MIT6N/ WBNS*XYT6&D3NROJX![F-0"?:WB3AYCW"91 MZ#-Y;VFR=:M4CS'^:#K&V#0P\>)@PELA 2N(<*)1U:3!E.YH0U%Q')]D*4A0 M%<*X%P!4 W:=X?N-EI8]#R80BI%'-+EH&V<:;$8? M OTD"+UYG*19Z*??^\FR& -OG@A]"LGS- Y.O#1,;V:WE4\TQ\&?WW^HCX.; M)L2X)QKA&7KWFL&Y<>3[/%%'A<7I8YKQJ_\2 ]U<\=#4P;F^QN-,=9TT89%VS<>6Y M;(KWQTICDUUKVT7+6Q?M<,-.QQ.@6T+K'UI7M,/%E>YWZJ4+_O_\B>$G+^+' M]&P N6"[]M@/O8C-]!G-%<%./[__J=X%>5/_)OY[4FGQW\1DN6UT4FT5Q8:Y M@$S-NN+&WFBJA],CY1Q^]N@WDO&X@=WN%- ]6S6&W%=A=-;Z:P?47.F\VP#6 M\LD293]M!"7RFA-1=;)7%\5^MVKL1 3T17TMG)XHDPG0YPS5D'L7A)Y:WP+A MX$HO8GO7%:'9FO5^/A:L>$^0=:(_U#O1IJ*8W79542QO(PN_2Y]5-3%W)$!5 MG-ZD% SV I))O2X/(@W5U\ TUCI<&ZAFB_Q^8)?".1%@ 6GMA)2FJG" MT9"6HFTD(\%56*1[9;L7JS[8ND'L>=-,:#UQ53?H7.F#=^2)Q+DD)>3/[W]I M/BE8E$4QU?+C%XRYTR06S'P-L\5IGF;)DE!S]P,W@-,5#>(!^AZ\!>3.9DEE MK>/9 N5*3SOW:!S&<_Y>J4AI)NER'QJO>&XJ3=CJ?%)40['.NO#F[J:N@=._ MZO( .I2F"G(/,M%1ZS)&W5WI(_<9$^K=8STAH*RKO&^0.WH_9E0; M#@9BPY5!Y#)F/Y('[T6ZI?S0B,@IRD^*"BC=8RNQC6]'6PFGFTM$ O19?2WD M#@B@IM:[(""XTE58GU^&V;(\N^3+:;9,(+$B8N9#(V*F4E]X3_=;P#G,5JMD MT[LLFT$ZN(<("3FSMVP'^[B^#<7UT_M6T+G2;\6,?$=6.?47;%Z^IDM9 MEVU$V(BJDUW=R:8RSJ[L]SS,UH#=9*T<4N@:WV(LDHA9=UI(=)UDQ*JK632! MO<>44E,/6K-%Q)4>5"Z@;SV:K1_88C?E;YPEL73::T2_E)4GHO9DKSJ2[U"N M#,0I:JJ)Y0V5RV75UZP:0?>)PBAL.$.M<7*E!][GCRGY/6=MGC\IXLX^-$)F M=I4F92V2!3E[H*!W'";_LOGI7]^N.W0)0@L3>DO8?P=WQ(^\--T^/#@-_I&G6?$L[_;ZC2X0 MS;:E0[L"T1:K7J]V]G[Z-F63RM8T$F4A>X7LJJ9T]4! MYX!PA2XS .@<\8O&/-;F)EL0N@G!86,%8<;%Y#;1!:P.9*[_U&1MF;."!9W$ MPE%0O&%U&3^18EPW]C5#-2!I_:1&\KV?:LD]:*;V542SZ_")Q)86D:[UH VTG^&M]:]O -HZ"- M&0[)'Z)GVWF.,9A>0%4@E_TGC&O+)1B.KL3Y2? BV'C/_B,8.;TY^Z_?Q.,P MI1!F(G@5;0T@_OUGD;/&WZB*6_U%%3YLVWG [8 W[_A4MM30&8)3PC[/'0]G M3(,H$?<8R_M"ICT&J#*42G<<,1:8H/,GCTB\V>0FNHQ])CJ;E_E55>.>L55C M4'[=\=QTP R=[VV\G,4&4U4#RIP[GAN3]@>]&ZG?.P S;*P()=HA;P\,"_3N MR <02A9L#&'C16&=A:CPTPQP"U 6W7$(V:+C )UB["^2.]^%Z;=3-H"$&?]) MQZ"F$I0T=WQ S0>;HFSQ6]:!*S'WU2<0B#NY]]2U!&W?'8M$7+E< .>-8\ M\7";-+2CD1K!.G?>Y%^*UI'B.XXKB=Z]OR!!'O%[6E)R[Q<)S?B#!I6C'OD[ M\9)=3 ]M8\?LMTFQUQ^FKG1\:<8]=1]OI&!0Y-U#[LE'F("O_YV14 P-\'CN<#B=39#J<),5+WNT;Z>64N3^]YK2D>XVG1MQ MK7;HDDI'D&@4 KZ,FPGXT48AQD1P5O2'FE%J$5CV,OR?IFV1M$9"TATLE_D M&4=AF= L_*>@IHR#L#6-?KZ"O:SNTV;ZQ-V5V;V6I%@]HS?R2M53%6.OH8\D M9_%N@&HFW+4?W M,X)I[$4;(=-IEM'P,>?O=R87"27A/#[E1[24V=W)^A/A:896B]"?4N)9]=$! M/HJ>[:-+!N01Z$!?RDEAX>N(BA-O#1WN6S6&O9CO9B,=\'-E-FAD+59."XTD M9\VTV<@SQ.'GS]X-.G7)N)O\E\NO% @2BWL%Z=3/PB>+6;B/MH\Q'7=_F*.OVDRJ MW!&&1.@SJ(127^*0H<.3B?=M2]8?PE[MH5A62SI<,C-I_M&O'L]?GZ4W]"Z< M+V#)[=HWB>W!'=ITVD'LDI'(WSCH>&(2J W,Z(DYA9X,]L*6IZ@G)"8S,*L1=2\?:,']^Q$#Q Z-&2? MSV:$#R%DJ\ =&ZQX5H_8#Z-PM_>TRNP;!![>=?% %IAYQ#W7W@P+D_D\T^A0SEZI7=)%%TD5+Q"94V_?9O8*[@N M%M 605>6:)IW6M1+MD;6:^T[1=C7(%_1@T57A&T4^(X#VFV5%;"O,_;P!)$! M#/1A^(JP*8/AX,^_Q\S'?"C/WF@8J[8VOA M&K7L-MJZV$?;VB>_+/1PK%. GE$Y(YD71NDU=VSS/;.LNS3NX]L\IU)^8++] MPMN[*KUL$MD(%>1^=AG/$KK<^30@>T%E55-';!CX(/W1/@^@6;-JGE&TBX\U MT5@O)Y<96:9JSK25W& +;)'-&X]JU;;KI'[I2FE6H8K]:T<3^\=OG[U_)'07 M2?H2RIAA!67E#I0,A3:5+<9X\%][2R;XGCAGR=(+98]#L?*:XLAD*$!M(*_1 M8+?DZ7,MMQ7H,UD^$JI8M35*H3U@H<>HN4Y3Z#?0CO+A.8$!*BN(]ER +:9J M+0>"]28FFP]J49640\O;;PNJ4L?A,!59ZGFV#^X/6)N0E9=&R\O? E^=O@.A MO.TG#\F<\#>I8,-LO31>(N[6XZU<871?;B,%ZLGZ@7U.L;+;W2%15SK091Y$ MM8IOTA&VN&S*%:!*I6HE-]@"6*&)IZI2'9>&W6DJ.WU#2.5HM]'*5!'[H32 M =:)@F'AXD!XPJ;%Q=*CWZQ'PUI--SI9CT-B3;]*G(,KY&T$M!X<&S7=( ]J MGD;NZNIACY7-1TE-@Z2ZAG.CH\(,:R29($ ?&^^]B*3EM>-KDID(4A3'?OZO M)3M:Y=&I:=K.)YJDZ6E..2(VG6B_'G9R$_-1@+$3R8# YRN*DF>/&>)%PG:- M^6,VRZ.FZ&;Z[)K!CI=I06<;G/#9;4C(1HP6?;%:"SM@IH^NV$0!G:KM"\Y, M-C4U^Z6PXWWMJ9!I>= OAVT5X@GE4K:AX6GJ-)LS57GL1^$[4"G5W)W^=.<] M?_8R0D,O@O"R7QQ[!=^!%IG>[K"RS5;.7_RD3P1"C:0.]C/O'?A1(H!.DKB! MLWMK_'3AT;F.(%5Y[ U6BY6"5O.!SJ#$L==%'@=A/"_W=8KS)VE)[)?/+5!6 MZN"(X6]NH:E9*$LV"F(_?VYOZ@I=#WHQIGT]6LVFH1KZ@^CVY(* 0.]N#0?8 M+:'\%]ZZ3VVCVM[W\[LBD?.)Y= M6]V1$Z[N#T$J-<2/;9>+UQBJH(9YY6Z,.\!2ZP.R2<6!8MV[#ROZN !-G6,E M;+N%:9F_3BZF_+>F<\UNK;I!N=F0FTO;#DIC1Q=PL8Q!5Y4RV =E?1BN MI*,Z=FC].8G)NEA).IRF.?QPS EAX:=.:^W&^O]VZ7_";V='6P798# M,&B&")W%[?.G)^OMCW\+">4NC/45=V#H5S;0^FY,>5U6.5!-T2/#I>_'-T4V MA4-:-N,&P7;FK&(8IC'V@F8KV66\RMDFB6OWWC0":RMA3Z*M+%=%HAH5=P;= MBHP?VC#WP97)?O(HR]V!?GGYN M&IXX2DE09A=)6FJ.W2W:@1[&]F.TA8XH7.[.X_862)/ M;>E%W P_L8&'"ZS96@+K8T=AMF/4#AUT,AMCBL6XBK^0Z6D<=88-A:LP._4H M73.1Q;1M[?ZN5\<.Q&S'FA4V!QWC(1M"[(93_*C._@9/=^,#M@MI63YO32# M>UT@ &]T(EJ=%,V*&(!*P]C'_5NM=RH #OOUM9"WAS+^R@U6?I@\ G!NK*K\PP=%"@1U#(?'M;&=N<(C0J.\:V MV:H!!P<-)9TY+JBZ:+>F"_8^:VMC.[LL3!5R]J- !WT[_KH.;4<PPX;78QS>R52!F56?UU1Q9LX=T!2, MB V4<6'[1?X&=?G@6L9^2L. %-=P'Q+^+EL2BT>C)/SQ9JQ;<68R'H+25HB@ ML_R5/W'%)I8.%.^:P X=<(+?.J+H\W(% ZNQV50/.XA@C $:AIU[P0>G"X_9 M9GH9R_8?FN"##]HL!$6CDS">9 M2C46H-/X6@.#28?); ,); ,); ()C)QQO M 0AO 0AO 0AO 0C.T/@6@'"0 0@G>Q*-^/5FHU+OBG[ M><=F7X%OOA?@6[MZ5X2&27"?>33KXNY5/0C84(0$EVF:D^ BH1O%I_[O>9B& M7$.5YZA%.\X,&T.YCUIC^S;42)K][1MT]5Q@V.3U0+X<<6A5I?M?L$ N*6A;WPWU5P3>T=L M-CX#42HP!HIX:7P^H^$W QF\(J >=NP2G J@0HYX%NJ2"AE_32(&+-_)VO8A M177L6)7.'4D+BW,D\D<\+B@AEW%&&-+9G9=9CX:Z-K 3[76FTPR0V7,KJ8K\8U9E#-2#HW&V<46QI?!?.%UEZDV=IYHDWQ^IJJ%FT:^4( MSGT@&_B:4;1!VFGSX-;Z&BMS19$9JMF>3\HM'*$"'Z MD\Y=OFE+>,2WK6&[Q#=2W4:,H:J:9K\XH"KV0U1*$<%O49E:<,-E &91^2*5 M24]\+[120H ?&5+7#29M;;=&*$11?+^L4LJ3M=E%"ZI\W&16-45WPJI5 WAC M097=(-/":*$\NN2JW0IEVK\V"F*O:BT,L$:,0F?T/<@56XJ311(%8HF^^T"<%^78=*Z0:!6 MFOQ&0$?>"]W'2X[EH*]\&L#\',;A,E4S/+H*IQIG&B@RL@G(W"G$G1/UT3&718_4>US M0Z9ZSF[\6I.W!P@Z;U/?SY=YY&4D.",,7#\4T+*?(R(PCH/R#3/Q>Z56:H;[ M^P+V99/6MM WR/9727XI3IUB,N="H&8I4VIW3=HQ[PKWQ]T"].(V\LZ]"P=:%F[?0'W=IIUU3Y=N&_35AK;RNI\72M M/$X9QF%&KL(GTA 7'#9F;L.- XH^.KJ-UOAA9!H9&QM"Z3:>0\67_V_I'0T\A+4T/./9M&CI_@IL[H@68::7>R7GM+8]"9=4-N MT-W"S.%\RQ7'#DJ[Y/Y6GZ3I'0.<@<5?_3CC3[PDH(@,8'7L+7!+PZZ1:X45 M^K:79V%*EBN2D>F<$E@HE*X.]HZI'P[-J QT.?R2[8)F2A6TI[V\/KPZ]DTX MB]5?])3.7_PHYS!"G1., _J/. 5PT.*FV."F;?/,"N]!I4PG9U\R('IY)]$0^ M)W&V:+>H K5[!&?W_4#K\+">:H.D3/6P%]4#4WQ4,5,ZK(JA^IJGO,@8$+*) MX$_UB6 ;.<530S2. K?C_V3;ZMM,,)JN;Y%5CBRYV-Z-YB0HYP==UO)?= NM MLIG-X@H])_FMM^8G-/P.JQ#-BP IR;65T(+5.:Y,,L9;]."]D/34],2!K@[V MQ1 S+!W2V;K(%H:6H ME3Q=1KI,];!=>_9\P9! )ZP%5]UI&N[>1-MN!6+H0%?^]_ERZ='US>R./)&8 MOX/WB21SZJT6H3^EQ%.O2G[^L;$J*=KBBY*RMK)K;\(;Q%Z>E))=,.O@ M[[UP]K^&V>(T3[-DR3JE<:D";@"GSS)&O/F<\@AA9B-;7@V!?OI:;H2+6#)7 MZ\MZ#?'#^!3R-;S.8.ZN7 O?@U@FC+2KP8/U#!?U[QEV(IAA-[AYD3J-AZ;X MX5&CUV>8H#H3'61>ET89,L?%5Q?'3_MA-*TJ#VI%^@QT2XG__3QY^D'<.J+K M@HGR'SLBRE_\]N5>@GKY1_XWS$0@1D/9@%N1MY^UN"),Z8ZDV*XM#)9K"$OE +K-\B MU6GOXG!HSE2OK>1&9^IG$&QDH__)G?$/DH5>6\D-H@ &:.+)I6SSNZUP0TSC M,L]XC,N ?!Z Q/X3/'@OK4^'Y(TAAX9 CQYJ#'? M#9WSADW>$LI_XXMA=:\6=MA(2QHA4+0^YWXB]#%)B1,GW=O N[-2@Q(@ MS1'W>UW@W::9[6'WV\GVT'VV(=,F-&.M[;2Z:LAC;[=#;1 DV#D%E3>T?QE4%WM$;DFNA8:#'D[I9! N/K:]]0F_ M'-&"IGH#V$%\ W$EQ\F%]4_O8ZD+>?X&'$Z/-^V?> :7)U<)HSPCP;E'8[9L M3]DZ\'[!0->LCS[HUD>B67$#J&QXLFEYPIJ>B+:QUTQU7SV+C$S']K&W;.:L[TC&Y>PKX:]&DV#*MD=LFW6=)OYFI-+#NU>J&L-=<_?1K$U#H!-?5- S.BN+8"4XLR=(JW;-7$)?.TO[@ MA&XK8#\XVY'2FN+'X.I5[&!T.0Q^_EC?RFPW*ZO&9@4];\'A;ULJU^#C+ RX M#3(X[XF?4W'1KDB#18)B)[]J^ON"&R8S3(>K7YCM#33\).S;BSC\F;1LS05/8N[6U<=(&:J](F,P((&> M?KTFEBFF2E'<$4(AQEI?",H5PHZDXODKDO@^2WQCY)2D*+J32V=4C>,&A:;H M>]VO?'UKOJ!0*X;NB+# 7JHA.NX=1^.3M;P!_8PUZ$<=&1X/8/&CQW&8NWJ= M31/R.HFYIAM&,D+G UF,2^^5\+N[-/2Y8Y9/4U_B,$OO[K^8)@9#-;2KRV#< MI72!P$"?0\Z7JRA9$R)DO%EQ3$UT::H J?J38U0904"GJ>-H,UWR# 6#3>J; MYI'C!/IV\_0[8^]SX%Z"T<+NISY3CZV+-6$\/^G">(I6)IMFL"-V=G+>S#@[ M)$Z+R'4B7L$X97"D@IU'+Q7)*T4HGME!WK5=)"=5>2C'!=S)/.5[F[GP!YRL M=T5*H:?/'@T*5JL'K<5!K,:QU?^G\.^]]&!*=:_74(Q@AW&[9*NU&(+S%T+] M,"6W;'6F.PL:2P!L)Y3KA@VA[SC,_=&,UZ,"K^LD?F(;#A+4T!(1Y6>,QPLO MI+]Z46ZR^)%DP(XW&\[H1R7Q..R^PSA1W)BXC&^%/L.-YO7O8'NOG1RTY62@ M;YZ-:J56>@VTG.A3".RX01SK[)]&]TVWB\K6:X,Q!<&.DSR ;;-*N$PS?C\ M9146*0=&F.JE'P.:XQ]>E3EJ:''?Y$RSA40YI)G?6A+L$S,WI_^6A+IAR1UV ME;]B^P7 F ?'SKI%+"DSPUS[3"I7"1T1D+^'/ (<[WT8T S_.7PS' 86MPW M.=/4(%$.::ZWE@1\>G!Q M5I=IFI/@+*=A/"\Z:7&CNQ*(E6[ZJ6X5T*(MJ&$=V E4:U3M3Y)^*4Z28IY" MDM23%!W8 F #!_;T;RD'U(B/[!AJ$#8'2HLWWIFP;J#DHJ!( K70 SF*0L/1 ME5F[H^[JL)X[P@.TV>\W:?5R+WH@=/EAN'5I*V'0DZL[N2#MP*L;-GV@4;$6 M633?OZZS*2E4O01--3-R'JR].AT9:V/;1W:4U1^ +EC\0"MC^SEGH(5Q&T&@ MAGT@9UU8,![)$J+LMORZ^-!+",FGH+;XN@Z\E)R\\N5#!1>KPZF*-CM$&395:9Q4&)]ZU%M"H.?M2D,=E^9[#XS$=^9B ^)9TK* M3TW$M][R',C;Q4X7W/XH$9PIN/,GW,AG-WD1=#\A\.\S4W+$=J M];T%_^CT?]69$0=S 0S9,PXRFV+KR:E(1GP9,R5S =Q-MB#T8>'%==_&8.<# M]B(@)^3J;SW6UQ*C+8NO-XL+'#&,W 6]2N?\8.UP=WG+A]0=S,$S)5E+@)T# M[ ![Q*%F6.I)82/@[?Z ;KD-ADB1%@!S.*]+@)UT[ #-6D[B M<5_%ZPDL)Z<":Q&QLYP=?)]YFPHJM[\Q9P.)$-@YTP[0N)54OLT).KQXF@\G M)P0[^;#SMAUNA[$R@".>"MP[)K"XQ37879<#M&L)BL<3I^J(L]C-DP*+#C/8 MA9Q#[C @@ ?J2\CQL>4SM8 WO/Z@"X MFWE[Q,O-X-:V78CUD**O-/O2"!D, MK+[^]M17-]ZPCT%UU[8Z0= A><'VAM%( F"?]P]T/VM4^EZC'>N6J8.S<+0O M=(V)G/NV^V@&X;$-"#9W!3O=^.PH#/8)O$-W9WNA=$B\8D9/^XS:F_8)78;]*0\2@J60VF+;^ ?0 ^UHC9B8"!3*653*U2 MO?+/#?8U[//@_DUH8&)<,J0&'1.K0SX74+@*AK39W^H#? MQ#[//!0_3HVD45=3D-M:NS5B*6G++.F@35C?4F ?/B+L8X5OC[5"UN8(7T#+A&ZOYO:UQPWU+NI MA_+8%!J.A[9>J"CHT)K!3JHC>\_*"4R/=_%0"9L==?&P]]U7^GI5+VPY["/H M_IAJ7Q/78(^I'OP1SBB,'LX"H-,KJ0--54.\DGI YT9.L'R,4S_D/=5!O_KV M7E5;IH[68]#M\=7^]KF#/+YZ(,=;2"CB+F>[JV.W1!A?EF-]: J+5=<6M5WB M]SZZ%);Y\>@>HL*$LF,,,FO_,4G)85X5/9B+3A97/5_+(U66Z/42:C_@&U5M M(-AM8)$N.[40X%A?HQJ5/W?-N-L$-KI3S>K31_9NU'C #62TR'?H[XB?S./P MGV6B^7<-&,]?^(]$<[G^C[K+];OV)Y4/3*I?F)2?>+MW+V\7^U&I\^4J2M:$ MW!/ZQ(9OQ401"3'83U6;*C:;0D/P U.]?LZ-AT &?FRJ5\3P'Y[J1YTK\RM4 MO7_(#6L;M.?6C+!W"/'?JKJ,V31)[AEK8NUP58JN?[E*6^GUF846#O07KA32 MF9ZJ,E1S@V6 ]<*X1*RY M^30./GOT&^&W$,NUNXD:S;W&THM$(&G<<[!BC[_(*)>T:>2)2LN*) %D&5L>^PMN'0 A5T!LME M%0GDJZY2:#6)T/K(*>4&VL/5GTZU M.9!][ECK;2^77-LU'R$4CF:OM3P]4F MVCII^M0VOK3)MKTWKYI37K7VL4=O3[7WZCWKC!*^QZSUV1W 2=9'VV[8T=M3 M[1!;VCQ/K/=W[9=Z'?SNZXSNQ8*^L.[FV^@R,U/@W9,G2G'@__"N M6C$W^L/0@U=-Z4HV6T>7+$HM=YK$ 70,'.9K;EB.U.IMER:M]!]F0!9;VC(L M1SOJR@IB>Y&'-.N]D"&LG7T,U-X;4P7>*>A J@Q12!,Z^6*;955'<$2XA M=EJ/:I$KA'T47CY49!I):\6P,^QIC:D&O%1#_*&N]>T.<7&C'$72Z9,71GQ4 MN$BH"# >P.EF_"+RN5!_GLK>;N# .#I<(U1= 7U(,B^ZC-E2(TY#?ZB7 JV^ MCNT8<<\Z6Y!W\)9:N48TEGEJ/HG]+I"S-FFD"=T004$(V\0Y0K=4=*SJW_GQ MXG62_9UDNQ %S5)XN$\Z[]IH:XB#TX1NB*TOJ.T/_WQ=TN$%JBJ/8PN#_5;0 ML*,H#K68V0[ZO@1>;OS:KE([76"V^S9VD&O_ECPB>/V,QPKC.XV\--V^"EWI M6 J#T93'?DIH&)*- *%/E/L2WM [/B)6%IKJ6[-B=%HQ/6ZF3;+/8E\ZVB.P7,L:[: M2D@]-:?:'D2BIBN_TZT:)C6 F2*V3J=352:JJ.[3OKGU@88*[0"U*\GU$9 MWS\U6"^VYMQN-Y[QC1)JYL&S4MR>)O.6S6&[B.RG\TZXH8\1->FWZD-'!VA] M;(=)-Y:TC!LP.^ATI!M5]_!J;22P5K#=+D.8B@U^#GIT3Q?]M+N MLQ[M@W 5!3PL!!UXN'FZB./HEI/7$T'4.&"Q< MT7X9.-2@+F,5V6%;JG;!0-MJ35)FV.>S&?'YM3#VBSMFZZG:??N''W7NV_(+ M$\Y+Q8%+THD7!Y/M9X135WSHS:';4[#,!MJM;!Q>'DP1^V$4%OVONB7.F0SK MO<*:L)@^&C\X=V^/D*+O%B&ZR)>ZNBQB),*!Z$*=QD"T*WOXKG MXOSREE!^>=@\//;W!6P/]# F8H/N09C+11"&I?S=K&*O(6R/=.]4VEN*!-B# M, A50B^?I"FK4*X2>S$9RT]ANZD=,*I6Y#CXF"-$5QY\R1!DBK"?TI OU8K< M4TOB\=%\*;<_WGY_S6.[T(>RN7Y1ZF=XZV KGY(D> ZCZ'*Y\D+:T3)DC6'[ MQ['M0 WP04QJ&Z_Q>>SQV_V][)I5;6*[VAV8IO1P'X3%7"?<5Y>S8H_1)B6Q M/-MM-RNR^0ZVFWZ8+94]TH>ZH+$]T.O:Z $Y]/M0%]\X1IW+-@==K- T34F6 M@NRJQ2@.^A#8(^B L0V%P2LQ0+%XF ;_R--,Y.'IP9NXUQK4E [,NZR"[2"6 M0[H%XW#>9+@M')$;^1A/KQO#)S]E";U'IGP6:H^LW^N.K#?-BC/IHF%Q6%UI M^NV0NM_ I"V#GVB20AX+,-0[N*-E&!#H@WI#3*YC^;O*)HL^B2"2J>_3W(M2 M\;^DVC4MF&W]!>S39""E!COH"/"A6LQF^7N1T+,D?\QF><3^EN3:A>$0W\(^ MS0+96U=$/C'8_V0MJ?\ =]C MZG2<=1A'5/T0?J0G3PT]KXF-6U&41C\YZH?ABN;'T:$K[BXKC[&TW@$>"<&@ M<&EBK8AY2Q.V],O6_ 6=C%\X_#T/#8%/U@U!.1W#.:-C"$*K$:]C&:8K.F_" M0YFZEXRV>,YCN8K!K/YO6ZNQ:AIJ1V-XE+K:40M,C]"R;BE9>>'&UVEM/8WJ M4 L9P^O5?:218N-@>*1<_B)=ZNQ+6IBQV7.FJPLE=@S/&8!8"\WP61VH;XLH M&'Y\06*WT]+.P5.O" [W<))U QY#$(\< OHE MIMOG@1ZV5Y5UH9\?=*&?U>9$^.>FP;> SW[T4/"EUD%9X>!"/ VJM_;)KL3S M+/>91S/405FA'P.*\G@*?N*71_RHEV<;*S,RET_+>"^W21IRYNPMP;I][+C0 MWBRG);+H#F$K=6Z9&G0P,U&VCAWV.;"1&%!UU43.R) F8MDZ=N1G;R;2"M6# MWB_VM0KY[0-^M&EO9L"5Z64I[N22H2>Y'85177)MK,):J6L*-?^YPW M]&CU;B0H.\E*/L9R@W?-GUWC%RUEF\>/] M>_3+H[HMV%8U<'C;*DMLT+E4K/@>%E[V-T>S*B6QGHHSDR^4EW9"+:F)2-8!^3G";+95@DPF%#Z#;-J,^S@5@LA2V; MP5X<O]RYQZ[-!_:R;WW9-3Y)X M4C9>SGH.981Z33/?%=LN$[(_^&^OZ]]Z:R'^64ZNF5$]/)/HB7QFBBPTNY/V M+1[!+-H5SH-^%A6J_-^)1Q^>D^XFM&WH&&;XEN@Y,/U;R,V^J=G]MFCJ.)83 M+1$\*.XODEP3*6[?$K9S:VSFJ_@-E#\'*LYTEA&JX90WUK(M;$=6)U8[Z'U@ M';I[1\8_WQ^S P^R473(-+[$ 8.,IS?D6>_X&=QTR?_5TD[4S6%GWQK<:$Q( MH@\1"KFA#E/[]':#7?WKWVW:>Z*[H=@J(YNM2=O6P\ZG-2!W-6P.>DNN4/$Z MB?V6%E"MBIV?:T C:"+4LQT@>WG%A=7+F*>!](KW J/B6MH^'AI/[Q]TGE[1 M_*32_J3\P"1+)MM/E*[?-WJA<&SB_DIXS@D23-E@ MXLW)'5EZ8;SY(S\6? _E$-+2,;A3V^+G-O%GY=Z Q\(8'_>Q;^D8O*EM\7,E MI$B' 2"L_H_U:;G2GGAZ9Z]%=^+L7],LO%N&G281TR$ID)\R!IBP&^'Y$E3Q MYP?V4\H4X+?('KS'2../&^);IF&BT:&<'2R&0*>:I1;'OGK0A0UE1+QYINMJ M?7[%#9L:KF?6#*]?\*JI5'!,[H&U?3.K2#I]"36VHRC^RHQ @4)E>8U#9E-3 M3Z[<9[)\U.7_LF[(#0/0&G.-0VL5=UOC?H]NV6)WRKX9\.\J>2E.*&5%L?=\ M+6UN_^A5C8%CV[H1CDV&VZ/UO[AH?:AR!)[8!YXP(J?K^RSQOVG\K7_2^5LW MC4Q$*]@>59Y0.UN;-VOU3>*8>^ONXP:8R= M0$LQR=V154[]!<^OPM=F0FZN@F*B4Q?'GNST+.EE=V0^Z[/76.1^&;9( M*+],6X0+:NB>W$5TEXLM[["]1/;]6<&PX3*+M*[[N5SO@.=H6X *>YN:8; MC':R[AK-9IWQ_=X<-0U.I MX$" GB;W'O7.=HOTVZ?L*@NTX!KJ8-],A $-4AS=S22\!R=L9Q?P=!&$#7$% MBMMSA9/UKD@9Q#GE.<+$?_U*4GZ,4*1>UFV)>_T*\KX9NCAM9)CI'^F!^FSY M]8>DJJJBKRK*NC2U0$C2J.)(3Y4GW2R3F>E65]IJ+DU:%IT)!,9HYYCE7_A_ M/;+>RW[S_P%02P,$% @ NH!N6&V&6%M0 P 5Q0 H !E>#(Q+3$N M:'1M[5AA;]HP$/U>B?]PB]2JE:!0ME83I)& T#53"@C23?UH$I-X2^+4,:7= MKY]-$@9M*+2%J4Q#@F"2>[Y[]WP^K%Y:5Z96V%,OVPU=7$&^5,NPS+:FEI.K MN%M.;ZO-KGX# ^O&;)\K(QKR&IQ4(@X6"7 ,'3R!/@U06$Q^*,( ,S)2A*$P M[65V 6(N"6M04;2#_3(NM!UF(%%O X]>3X1"TW!4427MM* #8. M.68;CB C?-=<-TDL:*2_14LZ06Y(!;(=%PM[1F@?PR'W,!SXSNV8 MUELTB%#X<,"FHR/P4 SR]HCZ/IV0T 6',&QS0*$#)$P'\=PRJNT8)_F)M!I- MLPVMMFGV&KIN=+Z<*Q5E.A[T&JULG,X_I,S!K&0+CE 4"^3L6QTFQ.&>G*JR MG\R][A8G]\U^-L$=9B)AR,]H&%+.::"D.ZQJZ0M,3+#(HVJPR/D '!5CLWKKV_$013 MJKF.MU_'C,0.L3FA(8BZ?D%9@.1@PWZWNC+_G7.EJFP\AAYF\F'D8AE!=Q)B M%GLD>AQ!KKNIKN?=6(A ?/1?+:K%AM?*I6/WXN5@]/3W*829=W6?5_25E2N\TP*0NN2^"++6/ M?7R99$3E;-LTU1]X;L1]!^WCTA-I5[J3Y$+5NF47N)/L;R-5WCW#\ MGJ2;8_\2X?A((_"%?6Q/?816U3ZR]F=PFV;W!R-_A?FOR;, MAG.'0AL[T*+B$LEV('ZK.NYNQRW<_E JP07!OE.#GNB"Z@+@ M=HQ%ZH1A';I) FM@HIA#J911KAO?%H^"9IW1F8QE==^UO5Y_\;_O#(S+3$N:'1MU5??;]HZ%'Y' MXG\X%^E6FT3*C[2L%S(D(&%#2P%!NFF/)G&(;X.=VF8=^^MWG)!=VF[:'KKI MA@?BV.<1M<^\-ZS7GKC5Q\@ODYP2SPO:'3*IXXVCH..^.%^Q'6 MP4??>]V(!==]Z+0S#0';405S>@\KL2.\670T84TEBQOHB*[+TD_3S]HB*=OR M/H24:RH'\*NQ!K CYX1MF*[7NO9Y MQVF-A\],K$QG59-4P#QB?DKLF;,Q66]FZ\!; M>2XL;\;^; *CR61Q,P]F\SOG Y9/*+C"U01:@$XH M,!X*F0E)-!,<-@>0-*:2\M ,Y1:2;IG21P.EB:8[]%?P8B[4.=BV;75?M7O= MJV;1[O:N[,MCVW[5N[H PJ/BM?>/?=E^"8+7:U,A=PK6EIV/KJTK4]"/"@-, M79A^L9>( D%JB'#Z"*Z)#!/H7#2AV^Y>P#W3"1JH#)=#RW%H%ZC=WNF#\6L(5$)Q*FX M5YA.F8,X4)(W.% >T>@I.BXT1G\1BC1%17#>%(,9@[,T,C,\0!\SCMHPDI[P M.).YW4O4Y3YA85*J3[(,YU9E93P1"I'P/48ZFF.]F#QC\5GO?I3?BJV@2B[[ MEFK5:P'F!E/E^Y.*H5^3%,^'/KFE,,F7Q8TF2<4XY!M6O5;N6!5#_]VB1]A_ M619,&4VC/BS)E@XPP-W>?#K0<0"++-\%^^ 3I<&RCI,WT; M(7%W_-8W3DEX"YWS2]0HW\60:3 :^QY,/-]?CEP7#Z6O&^U&_KY>CB;E^W'2 M8SRS.Y),(=:R-< /2:03P[K]]_<.R,&JC/&)2MS"2%J*C@P>9B&E<>[AEAXG MH?\3-'#-G79E_@P#?*(XI4XGZK:,O(6$__]J>5S<+7-%+^[LYFK_%5!+ P04 M " "Z@&Y8?P7WD?(" "L"P "@ &5X,C,M,BYH=&W55EMOVC 4?H^4 M_W"&M#Z1W-SF#BWL$\O N\RTHL MN.I HYXI"%E*T@\(?0'PXGM^/0'U_!R)_=Z,!C MI/[ZF#]OA*/HVZ]?Y/ MA(ZL<(ZRVFMYS32NR98S"B$;RP+1HPFRPY,R8IV,<&7C3XF,; +DTR?D'D' M I(KL*Q]L^:X_H?GC96U$$J)M ,M+?I"R"65CVN#A$3WT#@]1_;%887$POX@ M\&#H!<&T[[KXU[RLU"O%?#[M#\OY?H]]OD@D"&!+=5:DZR__=V/ M/)R5.;Y2B<<42VY)=.LH!:T]WVKOW67?H/4$L#!!0 ( +J ;E@7L)9I4P@ M I' * 97@S,2TQ+FAT;>U>^WM(HVS MWM_GS)IY7T<>/XLOV9W?0^GW?^W I4%!^Q M6G4B.N!C(Y8=:OY(>J;<;U1 MN5HI\MRFZVS6V#BNLUA\C:C=/+B]YBL^6 CV0X/7JJ85O6 MR'^$PX&6CIN=3V?=XVYO][FGWI-7K7EYL;ES=7M_'_T,"]!K';&\T M97>1FH3"'XB2L\_4,'V%9B,5,P\M_@5>1 ML.F >[BEF1K)&.OERCTH$ E/&,/UU*% N1&_$^A\H6&#>SX0H=_0>DIT1 4\ MJ;UDA&(1V@ <7V@V&4IOR$Q"O^;U)T*+M!$:Q4B:4'!?1@,0=CS$*,U8>(0R M18'&QP"I? P86P]LU9\N3LBON[,+$LK-4NW_%"0D6" C6#@QQMRB2V @GRD\ MU@O/911 /O!8HAT9>6'BPW+!&@N66P+M2!U.V1A&3Z1%9!:&,U9R.%)","O] M@_U\2:V7J$02H@"H2($J;)_&@O*X&;(@5!.3\906 VEBS=$;IYL./*"6%IC& M9(@LY(R'"L8I&"<_2W60$\;I#45FYYEE?M#F2Z+J)N64- HGA:""0.)RV^Q8 ML^TRKH4E"!B\[(>"#)D)4%,_E&9(-:C8""J)E!)=^])XH3()ZI%^TBIT3#'6 MRA,^;AN'9AOLX O0C6.MSE=OR*.!8"U(D^LDQ!!K^[Q<.]P6#DKMT'=7[E)2 M/!\YFJ).&$F7!?9R1$* 'NG(H5CJC7V(?/!9'7UM![->E^_NV!E8)3J4I'CO M:+TQ5&Q6H/G^\S-%3N,'YS1>E>Y_+'2^DP_Z:PN#IC/-96.EIRFJ1+&=6H6BN+\ TKKLT0E.)1@,0/??2D)2:!7XBLHU1XG,>)"Y*.BU";OD+A9?I MII3*/7HHH+:X?. GGB]+'W,7&8RYSZ"B\#/WTBR9&YYVOF;I:+SW(.#8U7_UW1HXT2/X2R, MS29XGM*^16&3BP,1"+.]!LCK*\Q)-?+J0/7G8JH,S M4B;&0SJEA@8-MBK[DG"-_MCV(V@"N @([I72*7H/G)VQ^]*IHQV';/%OUQUU(D3@O$N?K)_SPEWCY M9L\0^AESE>92C.3A(F?,51E9_5K32P/Y=3F,!QGF&42>^#)6VLPR!O8&VAV- M9!P+\0T%W%=<6X7I2X"TC6RK% 4$IR%5BT]*>&?L*+XD$@.Q))A$GCUEL%.\ M4RNHH7BG]KY8K16F1X2E!6O02G-ZQ>U* 7=+@=O9::R+X'06J+F5H0U6; M]K0')K/S1(\2UUJ%Y5X^<3UCUS5:A?NH;<1,JCQ*E*X%-AU2@8 MV9X93ZF[Y,)%&=VK\%Y0S!CQ07K^7:<"5HS&H9H*/)T,E9.L?,DQ@,B_$59G M\?@SF7^WD(,_5@Z^B!G6,,T,U6'UM[?/^F ?'SG\?W,-Q5 [*+&]ZM[!-ZVT M#PT@=+FOXEB-CE@_Y-X=J^T>8KSVH(WKZ-_-@&OTATY"H]NLF(H;Y<)_7S8J MW>9K^937WR1Y\BF/K?%;;VZ[E@ZW6]!B,1];S#4(7F[%KSF&DZ$40;J67X67 MT,L]=ND20B5VI1$P^2(]:GSECE' +3XH^C-Z1\#^3[G,3J4(_2-V!0%21P-? M$H2:5+'.+L\G'9_.7K7ZV\HT*YB*; MEH7)K-!LNAE[\>9XY:]IR(;RX(L9+-0*?9>-^W(;^@Z<_P-02P,$% @ MNH!N6*;;E7Y!" G$8 H !E>#,Q+3(N:'1M[5QK3^-(%OV.Q'^H19H6 M2 E)>*RT)!,I(6&(A@$$8=7]L6*7DUH<5[K*3CK[Z_?<*CLO0C>]#2/<;3X0 M;-?CU..>>^YUD<9E_Z^KYNY.X[+;ZN"3T4^CW^M?=9N-BOO$TTKZN-&^Z7QB M]_U/5]W?]P(5Q6>L5IW$K"_'PK!K,6-W:LRCDKM18O="RV /%5'U-JLWYGHH MHS-6W6M^B 9F4F]4;C>*O+3I.ELT-HGK+!9?XC(/Y1 WM!R.XKUFX^+FNK_: M;#G@8QG.S[[5L"UKY'^%PX&6VLWNQ\M>N]??W3FN'1XU*FU,$37??),!>"** MA7[-$62SG2?,F/7S[EV_=]$[;_5[-]>[.[9T1S8>UC=EH_+0+";_*>;_)":6P?PU0?=* MNSMM+7G$VEK-4-X3FOI@\8C'9S_# O1;;5C[>??JZOZV==Z[_N/WO>J>O;YM M=3K9]7>/:R;]>$1%J[_M64??Z-]]?RM3FFV/A]FDQ&JRE\J&1K_S?Z.J'AZ= MRNC--T_M<#'9_Z@C?A4,"VF4LR$CPTN#>-1E/ 0-R=*QTQ%[$+I M,6J5_V0J8.>JW)%\&"D@\M!^+_(.ZZM#QJ^[][/X;SR+&^;UKE?\*=9?:JF. M!4)FPZXAUN:J;&,L5ZNW),"D?"$,5S/'0J4&_-'@,42Q"&X#C"\UF(^F-F$GHU[+^3&B1-D*C&$L3"N[+ M: C"CD<8I9D(CU"F*-#X!""5CP%CZX&M!O/5"?EU=W9!0KE9JN.?@H0$"V0$ M"R?&6%IT"0SD,X7'>N6YC +(!QY+M",C+TQ\6"Y88\5R2Z =J<,YF\#HB;2( MS,)PP4H.1TH(9J-_L)\OJ?42E4A"% 5*5"%[=-84!XW(Q:$:F8RGM)B*$VL M.7KC=-.!!]32"M.8#)&%G/%0P3@%X^1GJ4YRPCC]D<+';>/0[(,=? &Z<:S5_>*->#04K 5I$&&+MF)=K MI_O"0:F=^N[*74J*YR-'4]0)(^FRPEZ.2 C0,QTY%&N]L0^1#SZKHZ_]8-'K M^MT#.P.;1(>2%.^=;3>&BLT*--]_?J;(:?S-.8U7I?N_%SH_R ?]=81!TYGF MLK'2MRFJ1+&ES[F+#,;29U!1^)FI],D+ M<*,B3DJ<&W@0R@:2:^#:SQ@:CD/R@0QE/*>8?%O?Y+DLF5N>=OYFK>@R]^#@ M6-7_)1W:)-$3. MCLPF>I[1O4=CDXE!$0O,0/@-/Q(0\$A5)HMCY!7@N.8'< M+DPX#Z:1;ZS%MGJG6+V<>(;NE(<)J>KEBQ(1!,*+Y10T9[:D/!>)E1?$"^YR MF05=D](4-Z B9+YQN=:!2N)OP'A)6,,7I06EE(-OO_UA \I84[+:.CCAY@2@ MZ@X.>BB,+@>;.=]8BVWU3K'Z.>'RCB/'C,LWZ);>\*?Y9_MD*Z=_A[:GK([R MO$03GZYD3YZVZN",E8GQD$ZIH4&#KZ-TBMX#9V?L MOG;JZ,!A&W&SR#J15K?N1/AI>@IBWTY-&FK,62@?!3[L>86-2J4?GJWZ\RZD M2)P7B?/M$W[Z2[Q\LV<(_8RY2DLI1O)PE3.6JHRL?JOII8'\MAS&DPSS B)/ M?!DK;189 WL#[8[',HZ%^(H"'BBNK<+T)4#:1O95B@*"TY"JQ2J1744+Q3>U^LU@K3HT.4O)0@+7H)3N_8/2G +FEPNWBM M-1/\D0)5ES*TH:I->]H#D]EYHF>):ZO">P2K"X5S%+?G&6FRK=XHU+R^]6E%Z M!CW0D'0E\*FP:A2,;,^,I]1=/NN#?7SFH/[%-11#[:3$CJI' M)U^UT@$T@-#E@8IC-3YC@Y![CZQV>(JAV8,VKJ/O'>RK_AMKKUDQ%0=\Y1\J M&Y5>LW 3/TZ_KWK@GY8G6RF[1L7Z/+<^6Q"\W-9>$^OY2(K P;M8^* ;EYZQ MD<"M.\F N\OG=+^U/.R0%O\9_15@_Z-^8L3LJ$\^:H$"[5"WR[COFZ&OI7F?U!+ P04 " "Z@&Y8WKX- M]HD$ !Z&0 "@ &5X,S(M,2YH=&WM66MOVD@4_8[$?[B+U"B1S#-)M047 MR6"SL99B!$Z5?)S88YBM/7;&0Q/VU^\=&Q.2L-MM@%59%440>V:NSWV<>\:V M?N5^&G;+)?W*,DS\!?717=L=6EV]GO_B:'TUK/<<\Q:F[NW0^E@)8B[;T&PD M$EP6T11&] $F<42XEI_08$H%"RJX$)>.BW41$3/&V]"H=$_X79IT]/KXQ91_ M:[H#:V.)[("DC[)*0C;#$X+-YK+2U0?.R-TT6PU(Q,)E^UN&L[DI^Y/F.-!2 MKVO=7-D]VRV7SENUIE[O88B4^>Y!'/ HEU3LTX,BVL>$&:/>MR:N/;#[AFL[ MHW+)&8![94'_RK8&8-U8_6O7_FR!,\ IUN3XLH(>CJ\GTVMCA(7E.M#\%:YK MTQKT:S"U^LIG:)Y?-H[2,6-:+AFF,W8M$PHGP76.TI=5,LJE#XWWL"K"J3'I M&2-K6G5NAM8M&'U7C;0:C=:A7?QCD4H6+(^K/1P M,W+)2_FG'J2Q1P>F)R# MG%,P.%^0$"8TB86$.(!^7#49F?$8(7AHT.9>#4[5U)/0OU_$G7X<)80O3T1V M= 9H;1"+"*]3_1VO*S*S2TH$4.Y3'TSJT>B."CAO:ICRUKE6+I$4 A;BX!K' ME'H+P21#IPCWP7KTYH3/*,*)(I:F"C/^J9D^D13F5% $NXDK=Z& A< U,!^4 MN($U4P'JSQD-T#!>2+*O%)P@8!X5Y1+:4696?FG("J&BKT&R$.F"< DR+KJ- M:C:K$*IFHP%Z0OPXD>C+YO1BDN+ ROZ4B#O":5IU'D.Z!,/+PJTXH.$XD1@6 M7!@MX0N/'S V,]H^LAK;3@S7Z U1AJSA<#HV^O;HMX^51B4['ANF61Q_MV,/ MS)=S-;7QKI)MR'1W\OU6OJI<>R0LHB+CI++:WNFN^694K8OD\>#A/FV>K6/M MFKN@/C!0=TYS<*LN$RS"< D>\BU4?%_W $'O%TS0"%4I5=QX8AJ<$FPT IJ7 M<.J?K1GUU#/6_6)%J^:'\XN.ZB2;$<*OR5M+9:>J^&]Y]T/7PFNLNV1E_P0^ M-&=;Q\99QE'3(Y(1$3<0DC".6L=R+2X(39A 1B>"IHJ[FAHF88CB@]M+AML+ M'$B0S*F6K0H8)]Q3Y]&@SS+32O1QUB+,J1\G5&373',4SS6ZMKU^ZIG4='\* MY=Z%.H M#7SN_6TGCNTL0/6ZW;WAU##K?5P M3!*Y/9U[+=DL;3G$/'<_\_9W>=N"8'=N[M.'[,9SEQ?JE48,!KZ;1B3&>V@@?L%Y9Y:V $GR38!;1B25$*U M6J3?M#\_?TR^;M3OE2\OFG?O9?-&QY[4=E-=7ZKOR>NV M7OS$T6_2)Z1!MF)=V<^4NXA?D?TB\WH=8U&$92.8=17-/&([%\>>GQ 6KKQZ M\I=!K:MW)_G+%/7.Y2]02P,$% @ NH!N6)5$U@R$! )AH H !E M>#,R+3(N:'1M[5EK;^)&%/V.Q'^X1=I5(O$FV7;!BV2P::RR&(%3;3Y.[#%, MUYYQQD,3^NM[Q\:$9&FWFT"U2)M$8'MFKL]]G'O&L7'E?1SWRR7CRC8M_ ;] M8WB.-[;[1B/_QM'&9M@8N-8-S+V;L?VA$@JNNM!J)@H\%M,4)O0>9B(FO)I? MJ,*<2A96<"$NG1;K8B(7C'>A6>F_Y;=ITC,:TV=3_JOI'FR-):H'BCZH&HG8 M B](MEBJ2M\8N1-OUVPM)#&+UMVO&<[FINPOFN- 2X.^_>G*&3A>N=1IU]M& M8X ATN;[1W' IUQ1>6 /BH"?(/2A/?.=E$ON"+PK&Z8S9S)TIN88 M1L[$Q$,\Q?0/FT-,C[6;S M!!M%T26.A_F/5:I8N#XD:(>72[[@G/J*"0[W3"U!+2F8G*](!#.:"*E A# 4 M-8N1!1<(P4>##O?K<*:GOHV"NY7H#46<$+Y^*[.S4 #L*A/XULJH=.J8L;;G7*)I!"R",>V,.;47TFF&/I$> #V@[\D?$$1 M31RS--60\4_/#(BBL*22(M9=6+D'!2K$786!9(3CI[C'^ R7C(8P8IQPGZ'' M;A@RG\IR">UH,QNWJE@P4@>_"LE*IBO"%2A1]!K=:C81U*VF"N@)"42BT)?= MZ<4DS8"-_3F1MX33M.8^1'0-II]%6S.@BN-$5V>6(GM MYX5G#L8V#.WQ>#XUA\[DUP^59B4[GYJ659Q_LV/W+%!+/;7YII+MS QO]NU6 M_M2Y]DE41$6)I++9YQF>]6)4[8ODX>CA/FN=;V/M6:]!?62@WI+FX#9-)EQ% MT1I\Y%ND^;[M 9+>K9BD,3;L5'/CD6EP1K#/2&A=PEEPOF748\_8]HL-K5KO M.Q<]W4EV(X0?LY>6RJNJXO_EW7=="U]B?4U6#D_@8W.V?6J<91PE/289$7'_ MH CCJ'4LU^*"T(1)9'0B::JY6]7#)(I0?'#GI;46!Q(D8HGFIT?7_]-#*IZ?\0RH,+Y:LHM8>B6U27S3='C[:% M5=C-\7\DTE]"ZR+;AU[\*Q-OA0RHK-T*I43Y'WOXI M;WL0O)Z;A_0A>_#,87_Q])GIWE0RO)C@U<=Q?=WT?;'BBO%%,?VXNG=TB4.$ M/]5JZ"6-@BY,R8+VT,#=BG(?%_[G_Q_?-N9W M6J^?->O!\V:-GCVJZZZ:/E?;I\W?%U%$DA2Q%4=/Y'1?[WWDY%?I$M$P6[&M MY"=*702PR'219:.!L2C"LA/-A@YG'K%3*(13_C4:^CU/_N)'OQ_Z&U!+ P04 M " "Z@&Y8577S!1D0 "KAP "0 &5X-"TQ+FAT;>U=;6_;.!+^;L#_ M@=>[*W8!)TW2;:]ML@&8UDDA\.9X;P\I _>#=^?'K9;!^_ZW1[\R_!_!\.3X6G_\."9_1>^ M?>:^/C@Z[_W)!L,_3_L_/QFKU+QANSN984,Y%9J=B1F[5%.>=NR##AN(7(Z? M0$-H>O&E[?;9E.=7,GW#X-5]9L0GL\43>04/GPW#;K?&?"J3 M^9N_ZYC>U?)_PM+QY/!I.M+9_L$S[! F?O$(2#XX.NS_\>[DZ&38;OVTO7OP M[.CPWNC?,BIS#X67W;/@TUQ\+M3]@@_[QA\N3X4E_X+[M7_9[[,-9KW^)WV%3MKNW M.2L,7#E_VVX-W_7#J??_.'[7/?NES[K'0P:,VGW]_*<.ZPY8]WT?6-';G/E_ M?6OS5Z&-',_=0YG& KOJ9QC M?QW&->-3 3.)V0]F(MC3)$;M 5GJND;M%K0Z"5NAR#S-Z;T?.T3/:)[PF5[L MX8B>UM_F:,8B/!(C7- M$F&$[2\7T&#TEX@,,ZI3/OM8P+J-)4P-. *DR9S!@LEG6YB)0M\@;K>.G=&Y[1>,_A3V;EK\#LMXSFYX4@CVKYWMG9W==BL3N7W;^B,O5G3A[/\H MX>DUBR8BNO;[0$8.1 X$ZM7]L[+[QF=X.&M@9:#=:BS M^7[P92K>Z6H/70X[^@)1L'QZS4\E',I$0I(S!4S_V?CH['P&)9!4@ICHY M;);OX?2_FR04<*&_J@JC#:PHAGRKK:T-O7#]P2RZY4]A^7FY_-NL:]LN-04? M_LZ6X.J/P9?&D)G:3R!^&PF10D-=@#E&$:*](18N+$S$%:<.(?:$ER1*7P&, MRFDV'PR?0*0'02WS=ZI!$8FCMTYS8"SV'>-13,)H3,&&"/!$FF9@M.F8*/2&0Q[$Z=: MLM85QD+P-\PC?##EH(!Q&P7Z&.BIX:;G4+,7AUZ==6X.,.R2Z/:K5A$8&^9M2)(/AOEJ@"1!7I@UO!-V)Y-A4"Q M1D,ZF\@(+2LXU7DQQ8Z=B[_-AC#ZI#*7'+K^"X(",V>W;D2T1V$ 8:.%*8@% M)A=S=6.)H\PO_!>D^FX/1&@V FQ@SMR>HA(96_9 :TOY3-!FQ]'Z V4_$,\A MS)GP%!\)E""?^/'=Z1]MYYHGQ%K*A.:4((+I&$F[E4N/4C0$NX(A&H8.2!ZFYT7>6VI8&UL/GG"@0=1,2T2>/.&UA7Y1O5$C1VY74PD(O*9 M]Q@6.#(*!&T#E/<1[P(]>0/JE<;-!O# ,C2P11=*8]C"B4U!H\YZ54*%!N4. M+1?JNLB#(L9"]L#Z8NA_@4?G_%A;P0$GT128H3!U8QB8NR7'.]Q[R%&.O?B0 MGPGVP^1R1 8$ICJ;"#198*SFY'?"N!'7$[(V?O^@JIDC#TQ]PI'R<:ZFS "_ M+#?@#]Q=J#BF>![7[(=]V3OB_ :\3!IL#'YX8US6:2*_PW+25I&*&Y"*.A70:"Q3GD:HE+!MQ]+OY['5!Y)K"'6L:**CM%IH0>+; M+1]+6C\BRR4W$+W^CGMIGMM4I/B4V4HL*\#7PHU[0<+Q*TN2".<9 XL3E1&+ MD#CHAZ*O2KA",*Q_\6>O?5=0S( M_L?6%GLK11*_81?\2NQ#!Q\++ M"0[:UY>!H![V3WSP9?U=>>8G/1N"3B[Q\ M=I1P8.;N]@M@"CF",+5A]^BTSX[[IZ<7W5[OY.R7GY_L/*'/@XONL?_L!G7] M12I)>*:!./_7/@A\;"8XS9U_K_(!AI>^#U!)6'R>>"[##.IL3\286O1\BZ#K MBH/#'J+R+O'_< ;P+S!G!9]&N>#76]:%?P/2ALP->?=R=6EJ4SD3"-HSE#0K M7(]4<=:=:.OYGDHP\K%#GO1"SZ5QA;]75[C(W#:75,+1 7^ABHL[Z*[,)&4& MMHK,X8W&QKJYWB7!C1KV"0-_\&Z (G)JB)S&4WY08W21"S'-,'L" MXG:L4MAS-$G;I8CI"R=Y PFC\)PU2=MU$#@"ERZ%SBM+5NA>A]J)UBHK%[T, MB9EV"^S,',79(\2LCFR2%].O$44GC,KUEC/!W;S*J.U5(=&_4I@F5S5 MW>3<^D?673OK#GK=_S*/P7O/\VOTJ*K*NYY/1RHI(;KGO3^V';IJ _CVB#5O MF/-4C[&*U;WRJ:E+<87!%\\;?5P#;\:X%8*(Q2]0[A?(JN*BJDK-?K-_^=7U M6VJ'$68]41$=C8#@:_<5.^5C/A?&"':1=-CO2L53@:$7TOFGRJ_9[NZ+UZ^V MVZT3=']$(K()5KG38CJ"GF&P'_9V]WYDK_9>;;WZZ?G+9BM].(6^\/%U X)\ M(SQ@4V@-/[NVD[D'%?G5FQ*A8_77P^VWL&>".32;CVW(U#D1V!+D$%@ MA]TQ-,T"1NXRFQ0Q!+$L#4\C7FLW$8+SND4%D;B1JM#)_!9D;[FZ"RO*9AAD MNXB?TK1T(BY,&$"@#UWM[>SMD).RM[/[VMHP7VW%M*TOMRZD # '[(Q:Z=-0 M0MCGD3%O4ITA+5*7+<:!,,@H!;2.I%TTNG@^-06?"GJ;(E+-9J=MRIC*MI^H MF7-MJN2(^SX6>*15IL*2@RGF"N9'*0K7'WUPH*M, >O@&2* +4IW*H'2#E&1 MJL77RL*UGQ0E&K/R"*M[)1<6VD5*[6K$T$W'I6=XTJDR6![VY7MV)XB-+\)5*%\-[&=9[P68=0W"#C-2RBA0?R MI+%/:S01VOY6(#(0[$_R1)E'4#^02CX"1VE"*-NZ#F/316V_4P+8!WLH-T#+ M@B)P@M..YK9V1;V(3]&$IU<"_2@+ UU&76CGO]D247"@K3)'R\1930K0(WAR MW0E[N^7P^HC-ST5X.\(*3OF)CHN<%)Y'/OFK%A"B%C.ZH@N8@D^.EE8.+ ,= MA8 9>,Q+O:2WY& @Q73JW]JHLC!(=3YO',L[!-YL@/"NUL(*$1$B(!81$E\\ MV1I XE8@Q1.", 1PB<\?8 6PXHD'1%1@BB\G^*OR?-B[!Q+O7S#^^?KE?U[? M%Y5?.>BF>@@2%S@=WH>R:EN;"*%FUD3(UE2PUI2L;YV^:83EFY/U*.W.4L35 M&)]UD:?&^#3"LI'&QQV&<8Z/A]5#?$(9ITX9H07GZ"ACDVX%3SR@QK='7)^H M^O@<,^;0QX^T-',W)G^OP>0WF/QUQ^0W^8 F']#D U;G V WT]71_3MV27>D MM/&^-H*LQE5?QU5I[%$ ;0^JFEDN(V$AYI(JI-XX84FE22BLF> U5JH1ELVV M4E4)E$]5D5:'(Y=/I\0>](=HE2*/)ER+A3,\35)T_<2RL6&-L&RV#?.6RU\5 M!(9HE17RH"]QXP]:@YF[40FTQ3O0Z,<8JH_A(6YV^QEN-X0C9#SF,B^/D$<6 M,=@(]$:0U5B_=5R5[];ZU4I"9K)X,:\S>65A* # $QZZ>KLZ 1TE7--UCA[^ MMNH$N*T4!>;-O64)L:_26?4YH7\IP-7*XNT0FU>B>-'9QI+X=UOTGB M3X\O1-+DB7+C++'[X&/N\FRUOXZ8Q[@DY8V;!-:M]Z/M@)A5Q$-V!/^#0C27RMDNK__2]MJ0JLM@A@XO/.5QDZO<#+*:/60=5^6[W4.J M7"6WP7YY;L'O'G5(=?W"SA5N]^+M1W--OJR$60UQG4=5^6[-:[AR33GE*;+I\3J3CN? MBL !OM4SWX<_&S' M^<;^@N6OW[GEP,6)O!:)G"@5TX^-F/KOLUC_W=XM6N&0W=VG+EGC/ZR\3O6V M@ +>M@?X5\Z]W:I-/M'*7AE!U0!W\\B8Q2*A>\L[^&/1T,Z>4:?K4+!B0->= M,G? %G^- 'B?*SKG7S0WH*[31$[&[=;,7\IPZ['FSJH,WO)OGP4_?89/RM\X M0P$B\1@M_N9Y>#^Q-]@V?OAN]/#_\/4$L#!!0 ( +J ;EB9#7MRP1< )^U ( M97@Y-RYH=&WM7>MO&[>R_RY _P-O@!8V(#G.J[V-?0PHMM(*Q[$-6^U!/EUP M=RF))ZM==1]V=/[Z.P^2RY562GKJMU2TM2TMR>&0._.;!X>'OPT_G1ZU6X>_ M]7LG\%/@/X?#P?"T?W3XDG_"MR_-UXO] %.IKT96Q'B?O1:B20F4OC@X_GI\-?2*Z(SG5\?S] MMRB@9W/]'\6S?7'T8Q+DLX/#E]@AL.FB<8+W,K=,CR?%;4[M\,-1_^M$![IH MMW[Y^?#EAZ-O3//9K^-3GN#Q>?=DT/OU[/QJ.#B^ZK1;@[/CO6<\WV>_H+!^ M_;/AX(]^NW5\_NFB?W;5&P[.S\1E__C\C_[E9W%Q?CHX_OR,.?#@2[SW^IU. MZK/\=YD7>C0W'^HD4DC$ODYN<^*O]F">OQ\-DB)+HS(L=)H\)X)A@AL& V#93T ]0%Z6S M0F'O,-]9&NMPWA$W$QU.Q"Q+KW4$(\&#-!IP.;U6V1PYH+(L351:YC%0=P/] M0A\Z09FGK]4"'8:-P-VDX&EXM".?,_5G"6L8(==FF9I))"RQ3-#)6"#G@9E3 M["$J%3XXA;\S+6-XV1,<+M82QE]:G1M=3 2.,]()/( -8(0T,]W2P-AM+DIX M$7FB(P6_P8.Y"DM8$@T\B.5-OKB-+HA=_BY"/L-\^ N<&; /W@$5M5NX(9#* MN2"*KA2),=C/)Y;DJVJT_M=P(I.Q$KVPP*]?_?+F;4? PDD@%5F]0(G_O$]/ M!V882US?K(Q5SGL5F\8Z)P8 5Y,(5H]V]9G,(_FGN"K2\(OX)+,O"@;/B'DI M[AB?'\J."'/@[=*P'_F5 *HS'I'V"#[8;HU*? N^!JGS:6$W]FC5U+YKJ M!!8\DUM=O=75&@2/$8D@$.(8%"KH'=XA"L5^,"?I811ZUA%Z)/+4"$\27_X3 M'2=JG(:!/Z:Z*)1JT/3\14TJMEO:2JU0Y@HD:XQ:803$)*A:43NBH$H]LASE MD0)]$?F/F^?<6'NB!R(S4C YF"11F /7(U6?*/78;D&7J)IB4O(![#"4RS G M'$Z.1J G2&Q&&I1Q*>-\*S.?V=O_AF7F,6(K6.K^5]"RB*+RK=S<9+GY>P*( MS4 V1,&Q)SJL;($."9G=:)1BB--G939+%X,-M.Y4 M?L%IV4&P%]PGMC$TR'%HH#0N29W@=\JNLNN\/M,*M)>B5HQ?V.S MHY6!#1$TP#8,95* 9#5#+DM7.]R-!D5K!H E* 0NT+2<\FY9XMJZ?0XO7UY* M-')3,0!K5;S=?[43[$+3=NM2C8\5],H70+N(P&2'CG&WF3>7_"3PNTXC\XK"\\U$;]2>A.G]3[#/ZP9"Q,YB><3)!FD :]R MV"D1S&38^W#:%\?]T].+WLG)X.S7?[S8?T%_7UWTCNW?9@S37PA:2\YRH,7^ MAM(K*B8XJ_T?FD*:PTO;!^R1 F1B;)D*RU'G,K(>6YS8%J;K-V]^J/@U//&? M6 YW.(+>O(56/CLM(P_$<#X# GN9#'1X(,[D5#&SSU+D\"N_T4O;"K]9''T5 M?2^'E_@_9##\A*5J6+4@4_)+-R ?Z'LQHZ7V]^E/Q+V+^B+35JW&NJCW[I.- MT^'M9]U*FU)CQJ0BWP4P)*D$$\QW#,=%9@N(7 ? BF1Z6TVZW54 ,>7P82 M'BHH)IE2')Q0Z&L:Z1STA)@KB6!W.E41@G^B +J-;+,(@UM-WO]VZZ\SH#)5 MP#)*QM1F!#Q FY0QLXDK+=HO3'^[A1- A&3B6!1[N"QCA3&7 M[JM&!+X*NE$DA]Q^*!K9HK \MG8$RLIFBL D8I8:S&5X7S&N*30%]G>.<<)\ MID(V-DSG*TBD(!P2*@N,-*JH0SO3F,:@XN93:\:/,UG9N2NZ2T,P_',#3VF; M)Q$W :S(\^"@8LW-:3LEX'DS4^%XQ[O#\(ZB8]_<)94+EGRIF@.$641P MEL-\LQG@<'A;E+CJ'Q-89KKJL3P7NZ*@&#V6.>MLP_RK%0[U<>TH@C5N2\W&J.2]UK[#CEN][];!S*:\DP 0LYB&E!&:IFX.JU MYO0@F'9)L+*!>YQLE5?)/&;FW]>\0W"&^KA)RS@R2)&@0=4E\MV1:^ 0TWF# M(0-#?06P3,3#HC5X#K<_L&[5D^T6/[K[,-#A/E[+9RYU*)_PKR%9WQ"H@5E\ MF;_+ZEF'9VW>VM,%M-M=^;>GUP.(LV+K1*FR43*.C(')7)I,$Y?;TB RC>D, MYJR.J+V1F&18^]JENZ!>T(9=KULZ)NP*OP1E09W'>JH+UK*9*K(4;5DT-=^# MEMFUF]N^;;Y9[REB$W"%?7T K?0N:A\.M'*W2 J](+D:LX1/*,9!W1I=NN@Q MR(NL#"D+=T4(E))]\25+L[%,]'^H-QH?Z 8=$$M0Y2-#/$@..TP$=GZ*=*/& M2D$KN(;7:^=;<11M\6+N>&D]'IGR*:$$7'P07WY6Z;!<4R3%1+=A2!PQPEUI MU33Y08AQ6_SL MD;A+MQ;ZLO%[WYKE]LSV.Z=\)WC2MGRS.Q)-^;U'8T0BK4TR?E-WG&9D9<<%-&UHK,)@)F L)O M+HP=*S,P_68I P?VK4]-FIBT=*WQWUNJ=B2&$$;HF#?=2J!D-A&8'Q2H.+W9 M]:(@8-BB8E5?)09E %"E29F;;*P;.JY1&?++9RZ M+4<9J,NY3SYT[FB%D, MW.DP%]A2^%:'[1:"O&*^W FV)KRA ? 1] 2F$'!9IK?9HX$L 5-<1?6UHOXK MA&#S#3%7.@$>%OS RFC-$C@V-# J1IML81/03,PF0!24E@B,QQA005A76W2W MU@A$%Q:[PL!D-W:Q2W*DT/@=@H< A-%^R^:6*F\-: ,*N_\2S,3[-R/FZJ . M BR E6JL0S1P/-ZF\#S2(,$#VY)K-_- M#=9!/>#E[1&V2AKWL0-D=Q8M"Y<0]GI2;ADU?W1HX](IH$]&X*\"RA5,?G@U ML(7*?Q,JKT,@!&\ P>2J2HIWIT48Z.!1!Y3U45,*!:'<)N^;*',#7N_71 M'#V0UZF.[,'P*"V#HK,NW2:O'*KDK(+YAYQU7:3DF:K.^*-+L\R2/=%SN3J) M4NQ5#53%97;E&\]C(W=H5C0J+PG&%"E!R 45^\<<9TM@,Q4E%A58FS/4=!#( M)JEO&"3<*KU;4GK1PRJ]_D+"8\WB S!*'FUQQ083OBPV>7>K$9^_1J3P+0;N*#K75!O2*HBQ2Z,YWFA2'B;Q657[O1$:L!%?1$BB5^ " 70S& MG67R."(7$$)OCK0^*GQB16J5Z.'A=-/(A;'1AU,V^E#:K4)^A26=21UMF@)Z M-M,C%^T*EYO;5FNQE3L+ZV$K?%=60"LL1*0R_^6DP"=I@L420^SPRROY/Y70 M#,/ (=$"_P_M^)"51M0?[UXK(/[D%:ZC7,;K=L@"0'-:5"%NQ:'AHVTH2 M3N:NG4%P1:NB-"QQ;"\QADI1+4^$CB<27TS2/=-:[\"X@KWNW6%LI?[Q@S;>57EP (T2M!B$^K9KLDC M%;-WFE5CR6@0R(_MZ(E^(NDJG.I(* M)=.#.QH7K >PJ?1U-GH/FU)7;7_]; M6>Q'FT=U[SE?&[54F%S[-!8*E.1(Z<*]BTNY/GY2"B?7KTZ769.!0A57;Q2Z M.CBA"&R<<$()'<;U@?8.II# 9SG30F6HTF1SM]'VC7\R2T7I[$]CI=+1*%=% M]76L.59')8J]V&7'%31S4467MVI" MBQYVMS+"I)C95+BE_@M3KZXJ\2D :O!1N+I, B2!W3B)I1-TI%'9+V:X >@ MKS<6CFXMAR>S5$_GA*$?R=FR1X8>-Z%$X3LN]0A( M;0 #3!-WJALMIUYTC4;>ML[CXXWJW7W=-)-32#7JO)P%TN1^31!.@^)C9[R3 MYGY=PP!# 7.J1I^YZ '5-$03'1"$+J=<,9VKSN=EQG6:O=+2!#VHT'A:8/ / M$$>!XY*;R7O M)DM>+YL"ZYJ6Q23-X&MS(X39)_84,M8,4?ZI<7-J XC^HN@RI84+F4 "@7B1 M&9:4F\VR=)9IRL4# 1Q=ZYR$O/'WHK#SK^U8.)^^)P;FNDA[8P6[G"M2 E41 M; ]Y <2E;ESZ3@%O \K*:IS'[72;7B)1,.M@;6K NWY&4]/<4DHJM)BK_JS M=SX:RQ-/EQBUL[:XE$TIY/I\2\?.O<)W[KJ_K91^9O+F9Y;2?5BD 8B[UQWQ>O_UFZ4+3!+! MKWW> #_9LJOJ6M='MJG-6!3-%M]:J/FQ[N"=S?.F@@SV["+U4K7R<\TMW*_7 M!U?N#L UE&+U"Y#DD;9IA#5V6U5$5DM0)6:S)@K3#"CGDQ\YE>W,F=3\7W.7+%YY3*\?;LMA!>&V:F?CU0X;!YC&01=CUZ0@ M'^Z!3BCE 7^:%.PJ^YIV%+LVEMOCC88%7?O@V0KLGQAA)H0M7$B7R7KE5IO@ M-:>??0]Z7[@FG$HP?Q/!G]'%W6 >W/W-W6(#+^Y>GT7Q=IM%<1]9%&^W610/ MGD6QZ?>"_<*(Y)Q$JCW7)2X1<&PO:]ZB$>.J)-,K7W8"6ON+;=C(9F*.RACT M>P%ZN?"N'X[ES9[X?6;O\IH52S4QE035O63@+EV^9>_UHEXO35^(-'KAER2] MB54TYNQ/M'/#"9N$5_@+7I758RH]5^?0'8!&V&5&,K6&T'BCO%*^-L.9A@1> MS&7!U8>90L2$=816&?."=(?-=/V&Y4XXKL-7HE;&*]4>F*CJSBLDTI:1+-QI MN8Z;2=.MJQC,0K+IEP"/-1O@A=;R8K72/=%#T(;O/7YCTX'PFF@^@[!@J#LC M'GKGFIH<0P3)'#S#P\QN(!WUB-R5-C>.:8L%"0E/:U.;6>VU*F-6L@4PMK)7:6UXI' M-JO"Y>GYWK4:OW%!J(Q'W2QXL__6O/V Y&46R$3EW?.OL7*9V*_W]U_3)'EN M]6CTAEU=V(R)IIM!%RZR;*KX MYX,*:#USBL! $M(B(=B)DG,W6 3FH. S.KO.C@N'"R;U_%9JO7#:@RH9H2NZ MVME8YAKGTD#A^DL[T;<<>6X0L?6";"7N?RMQ7['$O2I#?(O2;&O6;;BLK0IG M5G7. LT!.JJR1$> ,:07*D)B-N,.GVU*R&-9I3-CA(1:9AI)P,]R%,#X:(J_ M>CDG\#?7>*]A6E-B5%+/&R6+UGMDWVT]LO?AD7VW]<@^N$?V\4A?WE6W[&VV M?JAVJ_<=+N>G.\_O]JH_W2D.SH[[9\/!'_WNA]Y5_P1,F/-/%_VSJ]YP<'XF MCD][__K0._ZGN#@_'1Q_?M:_8Y8WP]S:W5O * M&__2>9R=0[KN$X?FT[D?5UB7WE6[M@I'M:Z"@2/?NL87/.+V43"I!F P9^RS MY(,1Z-V)G>,)& )'_*B5I& MNL^";TC%TJJN@"E7':D5BUY!O9^3.%4==EG8"A>VKL=,SLF"<-/#&ZK1_P$P M?T:E.Y#A&"2H+@*(OG%*1@Q&E5.]5K,,YQF5H?&_A^AMX006JG*"]97*3.%# M0$XXD;GBXB;ES+CZJ2"+LW9,+1-SK5AU[1?,\Z6S6Z:N)J;CJKNJ"U<(=BR2 MG8_F/G^C4N%F<[M,3^FP=:&HN-K<),ICEB#99 FQ,Y Q^8\6O/P/(UKO38P^ M[WH&W[+5_HJB,%-Z^\L/C_8$NR'Q]7U3^!39?)>'[Q_RG/T5T"-1LM[*GGJD M6_TVR>+3 X_@+/_=6_GK?6 _'8CS&85IWHM3"1IZZQ*[!Y?83W?G$GOV3JN7 M'\Y//E,]]-^>Z/_A]02P,$% @ NH!N6+$8[%KH= ( LR09 P !F M;W)M,3 M:RYH=&WL?7ESVTB2[__X%%COS*X=04HD==L>OZ!UN#5M2QI1;O?, MBQ>.(E DJPT";!R4V)_^968= 'A(E Q2)(7=GFZ1Q)%5E965YR_?_Y^[OF1B)P/_'_]:W:O]K<]\)7.%W__&_S=;Q^?G__I\/UOM>#)?!I7[TCU>].!Z\ MW=Z^O;W=NMW9"L+N=OWHZ&C[#J]Y)2]Z>S?UND:M5M_^_:&NUG7UI%F&"'__>/UY_3R>/KUZ:7;<).[D'P>:L;#!]\SF%UIZZ?,[$X^9'BSVT6F1EW^=AT MZW?"#W!'8T=?&/+.S,?N;\.O^L(DJG89&YB+.RQJTX7JA]Q3X;LP\'@T]6KZ M)7>Y&X?5>#3@T712X.=M_!GO:51K.YEIX8X[?9SP0^X53I#X<3B:?K'Z,7=# M%,:3U,.7N8N.+T]^-U?AOF5=/XABX41;3M"G2^OPSRO_SF-GXE"K_,Q'#?[PZ#OR8^W'U!D;]RG;DIW^\BOE=O$T;?1ON MVI:/?/]?U:I])KCGOK5;/'YG7[ ^?VO?N7?O[/,3^N-[K7'Z_6OK[XV33\WF M%?P'"8/_O+X5<0_^>WI\\L:N5N=\UL[)=QSW]XGQ?M?CG?]9NTVZJ5:OU9]P M]][1=PX,#2. ?YI][KOPO_C,8]WO'>9%_!%/:F:>=!(X"3U(1 [SKG@H O<, MOHN^G_W[$8\\R3SRU(>U'AW#0T/FG?LNO_N5C[[70"+O'S5VZWOS/_9@__OO M,/DH*^HU>/*/+?AZ_MOW/P(CG'RO?U>R49('7SWB$8WOK1X+>?2]\9U. OF, MB+Y[Q&-.D)(K]:B="8)^ZME'WZ^2D'_?S3YD -_(1[0#=V1'\97Y!<5>$TH.KB'73'4M[DB&GAL]-;V Y_C;^+N M+>Y''L(FIP_"=;F/.QX_P547P%.A<.1NOHNO4?">A4$?V;Y:J\,_<4!_UQLD MX'P8%[R'B[\>U/9??2!.?[^=>TDAKYVY#?(D'+SZ^\$!LAPFP MB"9/$_,P?7@*X"_?0$H?)U$M MM<]OV)VF3_ (YO$Q$UAO[!9-W56HR&O%@?/C-^8E_%$4[>X]%T6S5G!WOVB* MKOF0^PG'+3F-WT[O'"]!>Z0911S^<6&-7TW;S VYF5/:OSOTB.^?0+6-U5N^ M\'Z;A^.C:M2.BA[5IR!P;X7GG?<'3(0HQ3X'4325\*E2:(S G<(9X9HS3_R% M&V?(HQ@)_,3 ;$(J^70Z)R9X@LJ]>M%4$I?V @^.M>@45--X-)5;ZVK%U6W? M@9' J(T%"-,\P\OU-]=-^W%\5#NUPL7"$T=U$W(6)>&(;C\.^OW GT5RX;OT MB20W'3C"$X_%W+V,>SP$J@<4GXN9@<5PY@*' M/_^NJQ?/L@L>V].W9Z.V;F.]YC$<<-P]9:$/3X]F#6PQ9]B,@8&M1[_,>>(N M9D\VEKHGGSKD^?=A8ZG[\*GC>?K>VUGJWGOJ^.;<;SM+W6]TYGYD(#UPNF&N MR=W]*9REFR]I!^XL]U0L;!+FWY,[RST;"QOATW?I[G)/R,)&/.>^W5WJOFTZ M8'-$@A2 Y]RHQ;L_%C3J^7?F[E)WYD\,Z>E;<6^I6_$GACCGWEN0G^6:#Y+0 MZ:$0F1C44 M-['P$3[YT-A=0)K%4D8\GVJ[6WQBU]-,^27MT/IB=FBAPWU !=ZM%ZZ.%3V& M1ZF7N_45\?PM0GHL*..EP+'-*2?JA&]M#&+SYOZ&?H MG7^'[SR#1[*HK;SS#-[)1:@M.\^5T;_8'?Q,&?,+'50NX6;)GK*%#FP!.2G/ MOUI[B_!K%EM*M5M\J&(!I52[AX5K&E=AX'#N1D@"NF<0'^.RDSEHGSJC>\4G MQ9T#'< [,1Y*$U6/LQB4!YC:),YMD7TD)+I"2"_,"B'2ST 2$9VX@_P8: ?J,GNI MZ;O?6(B%IY$<8#."ZR(!)PZY/,^"<,JB_<3P"C_[SX0/$@(&EM:E-STON$6Q M =0?PTD@XFDB;M8YPZ+>]%-C_ZAP"_$+"W^ 10 M?=9@E[(D/\U418ZX23V>Y1 M9!"<+&^K*K^UC1K-;/*Y/80OWJ'$4+OL*6I4)2O=6[LR9R&^:K>45;_/^Q!%S M3R[L/2-X/D7F$506GS9:-),4J(4=K)+>,INI"ASQX?.I-8L<-K-C =V8-_/DD8N%C MG"$^#XN/H#W?&&>N8^$A"D0$74&&W2N,8>\+-66"23?!S"CNLAFY.*B&U1W[ M+ E=',3#W&/7,<;G7?3B8 96=."S5GR_\#,Y@U[];')MYC(7?DBMPFAGKNV* M*9HSU?NBCZ_B2]!_W@(MFI6++Y5^OC'.7,=GUK>6-M##U=.WEL;(AZNG;Q4^ M]ED2NCA?9C%JQ](6O3BWYXH.?-:*%X\N\ 0-9'G+O KZUO+6MG!]2^>-/\:_ M>'2P7#)F1*"/BH^WG0EX'/\LAIBG'C._BQG_\D3/%-(T^T$8B[]HU\^E?Y_[ ME%<> 0]$G(4.:K@GN,[! %EC^F(?+20,5<3PQMG]*<.KUXK/Q'N@2O+3-H:I@S8VA[A6N510UM,IM-]?^!I8LO.]^"T'/'Y--] RW>VEW@ M&O[40(LW=*>,SK0->X0TKM>*3VO_QD6WAY)@"+I-EU\D."4BH^C])(K-L*OFK0MKQ/#2RZ%%#&UMKW?WD*A3.G*BQD\,>JX"[6LU%'1LY M_7@"I[C1*I\Z_/T5'?[IW4!(@^NG&7LA^'(_R]A3QK< [AY';RYV>=L/+V][ MQO!_@^.9+XRKQV,1*\/59T'8X2(&6_%GN3H'[KPR7#UE?(O@ZH4*K9_@ZHN MJI[YV'0LD-$/5Y31YU!)YM$8#U>2RW]2*9EKX*MZ+A>AELPU :O*V?,J)O,, M\F@A8*JKH)K,-?J%GM+/I)S,-?!5M3GF54_F&N1"P&I604&9:_0+%5^KHZ+, M,1>-VL*,D.F8&?+Q\[=)G6L,*^D=T>-:*"\WQJ&N?WK]).!)48S\(.,6L/HK MIXW!Z.4\2,BN&&FA&DFZSD]B^TB;'+X&+WF:Z;%;/!SMB<+COV%W,L_]\6WW!U@E+X0P+ Y*C4*?:/H[;P:M4):A_B@8J \HLBDOEC M 0PQ$OV!QU]MF]?DGBQ?%05)J-X$%^$PQ%LU8AK=/0)7WF/N F$/1[C^TGPM M7/RA(WAHTR" KEX<#]YN;]_>WFY%W-GJ!L/MX_-?7WVHU6KU_:/&;GWO_?;X MS>9EV]/>IMXUH"-E@H0H9B$=*A_2D>CGI+^-W\5]-[V'1IR^V\W>H;_.OEU_ MIZ9RYO0:AJKM5\%,6YLI%3Y6$<0?4MK-\]4OQ4W.;K6&"["6DZ-H7\#DS%0P MUF::!4&;N+$JN1/ M5=X]RQ2F^Y!WT5)+OU>_N$#)W< 3CE 5@K8K^MA$+_!!MPCCMVHLEV&+AT,P M5YMW(GKU@\?9CCT4P-;(''_%1!I3@ MOJEYD*^>1(Z,=Z ;/? Q<) GZ4ET%,C?&4VYOF@S8I)3QQM\;P+[W;_>$V-^ M*8L]NSOZYB_ZS+&_E,6_O\7\YC/ O>-_,4R08G!1- @G*^0]G-(A/_>=H+_& M2NQC&6+>N7@IS''-8R9\[IZRT!=^-WHQG#!]X!N^[&OI25[XY$PTGBLMN=*2 M6ZV8QTQ.+2VY%[/8I26W.I;_M.16SY);/A.4EMS:6')+9X[2DEL%2V[A M:2_W=/4NS9;2;-F$ .L*N3 M!KGTQ2Y-M-5)@USZXI#$.'E"_LC",VD M9/!=QB:J4)ME8I(_CFY& SZFP=Z_(HLFZ"/WG5Z?A3\F!.K4]2]]!7-!(Y7; MK]Q^&[7]UB2O0VV_F]M@U@YL,8]'"L_K@L>/VY\;M_TF)^J9&'[JLJR?-"A/ M/]Q^ES[7$UGNOGMVW\0\E9MO%3??>IU]P%2$60G&;[,+ZSTJM^#]6W#:;)4; M<14WXDJ>@D]10DLS\-GUT-(2W*1-.%,5+3=AN0DW_67P4'39Z;00\W,[L>1^?,7&"PV_1[17.=)NF;R@KKRG_K(8$+'EBE7AB]67*!%I[Z0E^"=TGRE5^X7&^<8XHO::E MUW0]95G)N27G;KY\WE V7E/^60W)5_+$*O'$^LF4TEM:>DO76P*6'%QR\,N1 MUQO*RFO*/ZLA 4N>6"6>6'V9,C->](5."H(NQ!*)) R%WWT9OI0,LV5FX2SD M?R:(M3"#T^Z9L)4[7C7Z.2 M81_#L&O*&#/MFE(OW6!IMZFAFT4Q=:F7K@%3;ZHO:E%,7>JE:\#4SZN7KB13 MEPS[_'KIPCWOBRR^HGW$[ %Z<21V&WU6,BO0N&L,5R5240<&]LD M9-1#HW\I9F_)!2O(!0O7/L: *">F(0[%C\WG @*Q>W#LFRX)2AY861Y8FAR8 M=1K0%/P6>"P6'@Q@DQEAUA53IV#394+)#VO!#\\N'Q#_% PT?@YWACR*K\%D M>8E,,7L>7JJD*#EC13GCV67&Z=V .S%W;WC8?XD<,3G^3941XYR =0,#'("* MT41A_/V+\$4_V0!&N H#F*IX=.7!)#9]UPQV&F#YV$P4$GQ!J/9KYG?5JPBY M/3NY+YK+V%W)90OCLNSDOE N*WEJLY9[7+TME_M%Z:R?06?CO6U,V&->22C98 M1398NO9TV>D(AY?>'GWQU/DH]:+E<-R+5(*6RW$O4>.9.L,E?VWBTH]K.>72 MK\K2/V,R_KD/L^;P*+KF$<>Z%IBW$ZQ;"3:$*1; GLL6@, &RN65DFLZQ?6G[)6&O!6,^I>UP$OA/T!SSFS6[(-\7* M?A)?S)Z*C6.&!Y'92LFQ%I)C]2';2L9:2\9ZSO+E\DA:W2/I&:PD)TC\.!Q] M_]HR' *;Q4V<-186Z.IJQ2!I\=9//.B&;- 3#E-8!FK(;[^V"O.SJ2F[#%L\ M'(+1G>>SW(26-M7].E+)D"^%(5=+HWJ,A/P4LG56IE:-'3/364K'1TO'DADW MCAG73C*^;,8K95+)!J4T4.@4USR*+SO? I@JE=SQ4M1X JB8&/Z+4NG716*5 MK/KB6753I.IFJ__/RJBK8 ILBD0MV72CV73-I6G)DJ4<*QFDE"!/B@:TF,>C M:S[D?L(O>#Q^\)F)/PY\!Z8G9#$L#Z(-;2QK%>RTU0?=Q 1^''WDOM/KL_!' M_DB5N*W?;NNVV=3G;'C+BRKVW1,.OW(:@WU#<6KK?WTC"FWD!8%!J/CH/^(/#AXUA>=&Z\I;">KZ:G M9))2DCPH2?"$"@5B"K?BP/GQU1=Q=-WZNOY,TX2GNL)+8C'D+>SM)6+!H],[ MQTM<[N*\(!\E,9U EYU3%OK"[T97/*1&/A]'TQ^09[E[9Z^44_.QX&E_X 4C MSFD*+P>X'B7[S<5^,V>N9+WYCLA2^FV>]%O) W@V"Y;2;W.DWVJQGBFWK1UF M?#@WM\%-+T@BYKMGHA-S[G\._"XVE#@GDQPF'+%\UI\'<107K)_MU?:HL2^3 MBW(5M[1<9G86W;^QY(?5YH>%@X+,C+IDY.H&U.,W;UGHCO5NG!QAJ3C/%0@H M6>.E:Q6EK-B\ V%Z<]]R:3< ;64&&MSF^C_RR[QR'HOG5?#F6O[=@_W]VD[C ML&2#%ZD"SI 895!QDR2$6N1Z>2RLACS(+'K]^C> -> OA',>FH!2YLPG MS&/3[0M?1%3!,.0OBYOFFH52-LTGFTJ66GV66C,I-;VIQ,MBJ#GFH)10<[L# M2W9:879:+>DT/3^$.ELW8=@N#GW]F08]@I>=)L:&NL0VF72":6/=U,@1\-X. MO.!YEO*G_:5$^S+]I3JEAL>]T^XF)-5>P7/QRS?DS+IKU?#5XNN:)+P#2KJ:_Q!5#6+B)"<4[+Y(^ M#UD<3(+)S#_V^S^.9]Y5"_ZF?5:;:_X9]8?/7;Y910DH<,C^(:^Z''FHCQZOPT+ M_<&RK/<#.XI''@BV#NSVMW:]-HCM&SB=(ON"W]K709_Y%?E%Q6Z!D.B\L_LL M[ K_K8V7UM[9*".JS!-=^ KKR_ 8?A\-F)]]KUZQ+K>KU0_O80GT MZVZ%&_?P]MK?7^5^: 7/:>K_= M_K!V(VB='G^]/K\Y/VU9S8L3^_3WXU^:%Y].[>/++U_.6ZWSRXNU&E9##>L; M _'I=\$NJU@G6\=;=J.VMWNTM59C6>>-<1:$?4L^$=6+._?N^U'MY#MWN:A6 M3P(G05,%O93?'=1L\5S\_AW_JL,_W__:O[S;]_[E['7_^@&/@^/.#WQ2L(1C M*V463M!Q&S,.,G:![3/4\N&%;[/O>T7TB+MAM;Y?KQV]^@!Z^*]THJ:O2%FD MY);%T_P:SNOYNQ>^$\N_C: M_&Q?GUY=7M_85U^O6U^;%S?VS:4-A]X-G&QV?<>^O+;K>Z_=-_;EF7WSRZF= MGH?I6=@\OL&?ZT<[N^NUW.O(HG!R6'&/VQT1. M/%1C.DY">%A\1O/P;WCROR#X>!S\)%?MOS] K6%L5?GAP>3C'?/ M5!Q*?>+9:+Z\7B]ZUW&.Q[?M_KAFCV$/0>#9]^@2!PW^!SLY^#4\GPP(T@?%WYN7%+H8*Z]6=P_KN87G@/Z^[:9QK]G)<<\V[E+'MQPBP M-YUSDI8S^GJ>W/6ONH5Q3OZ]>>[9P]A_]>2\^>GBLG5S?MRJ6.<7QUMS,U+! ML8A,;&$\&K%)L0;#+VNW,5^?WC$GMI"1[*!CIZQEL\AN#;B#^0FN+7S[/([L MXQX+@8 -\*C%K WG@\,]#[YUA-_]QZO:*_H\8*ZK/S]Q7%6/=^ &EL3!.UOM MEL/:W\W/H>CVU.\4''\?AX]_U9"',?;=T?,&NTY%VM_'[MB.U &_]O1-.=\+ MU4!VC_Z^<#-@4O)^S$E>3%X/0=6F@#;EL!_+WGO'@3M#$#>2_QS[IQ?!C_CI MKO^,45"-N(/I-3$?A,$0)73>FS$'G7G!O?_JP]>8]>81U+$[L#5 MA]W]:F._=K1SM#\GU\&_PL7*JWD?!W.UZJ?.:]KO-, @M ,P$T/[CR04D2LH M;Q..V^R11!.QZF,267EFAA9VF2_^HN^RFL%/"JKGEDZ;Q(KG6]=;K2T:H6H? M$*X=[^5%&M$LY=H$SQDQM4U:WH?UU%!7G69S#JJ'T=M<[BCI\-9.?#C=/>'S M2;_N0>[ ;+INR*-(_>?A;G[N]NLQD6YX:9\O+\00FO:NS6ZE9K MR\:\RI[P//LD%$,^=_#I9-IHC^'/R_ FN/6GC]7]<_";[_%O9W>=HL>:OCH_ MTJ-7'UK,B^W/[ >W\:*Y1W@V;81T_EV&5Z ?P[DQ0RW_K?'G/YO[X>4G5E^> M6CZ=P-QD-&KWZN,3,]"8-@-7 9#B_4<,9ILE?YX<77?[OP?7;:?H9MZ9NQM=JZ%;0L0CC;_[UC]'EU4$!6RG[OOSF 4/M]6&M_F96 M.&^6:, 2>^^J%_CWAAJ<>O?SY;?FR>>O!0QB_)7Y@>R ";AS6*W7=F8;@.LJ M"%)'YO_\]V&C?O NLF+N\0'.A>W+L!#(!R]!7Y_-8*%+83"-YC^2")3N49%$ MIXW-K)!6B8?@&_2\V1U7=?/E4.GCMU1O=$F63==_?PC//[MY&CW\\XO12C1 MX^_,ZY^[,F%'.?,(4?PA/?1%>)27S2':Q%("4\K*Z>SQ[]_BCPW>#?>2IY=I MI.R1>V&>-_8DAD7)#TN@]*8GY>JL'#F]BT^5O)V=[12?^!]_JWO'?SW=/SON MS$,A/^G'FT92GH'V7\&!$;GLSUD>O&,V$#'S; D-//6L6%#\8$F6QLH3_2A# ML)LS!.T+L./7;+AKN4;GOHL1-VZU1[;3XZ!"POM_V$(N19BFBXG(9O8MF+'5 M'WYP"R_G+((U[>VIQHBF"6* M3,'A6K'&QO.S'\3PS9^)0+$$TJB#*>4AE7A$T\74#N9#R!*-5%C=S\S[.6;^ M+? 2/V8A98>',^K2[K[B:/=L @E;.J+\\Q[6#+O2A ]@WEO>YRRB\8X M^'7]C=T#J8MLZ]K,\PSO9IFZS=4%\,Q[^%@K6LC0^!W6%UDNB&R_2[\/0NYP M\J77&S85>$;V:W@(J'-VE(!I'O4"3!W6]3%QC\7C!-^R:'*_T*A DW89HL^%Y].:A M[9R9%YP6M;MF.#EB/OK$.S\27@1*S'WOSVWGG5JYG5>.Z,=M9S*"/""0V\QQ M8#OC7G6)1=$"\J=^"WJF7YWZ0]0'.0!O"?4A8#E!'T8VPN,9G@;'&\Y%U^Z& MP6WS>+./JY_DY?]N %BC3+D*9?;B[$7:HN MGD&GOE*;@_5&N]J8IG!LK1G3/$___=5=9WJ(/+>WQ>^[)]Q;Q&E M$]NGT+'4:XL?R_@1LRYKT$QGGNC=F-G_B0#F3Y79K.2F7O#TW^]P) _),7!8 M-PA'TS7(5G]_U+C\XX_/S:>[&2<"(?1RXF='O7Q:;G..NKQ^64#M5I*;T+Z)G2GM1C!_;4<-+Z/221\'LWPEGSZJW6P[_QU\T?M MZ9 ()WC:A:ME*_RJ2>*GN+",S;7&M!_[B(.O[.D(?O,@@=U#6%[F/ @&5N8A/(./IV/-=J94 M;*%<0/9#(4-TYI(+%ZP^C!W&@9U$G*Z" 4BPT2E(84%([_)&N&-O!;P:/3P^ MD!^@ZV8[@GEH6R*&!%**G=M<%KJ1C=5NPIV5/;'SFDT-Y&R5GL15 M]21F G=*3\08 /K46!QSK'#$E85%QK O)[)?HRZV,5F400*#WZE%YYW.IS\ MS[XJD,,[!;JE?> JE(9AX-G!$&A)F2U54:E$R[#4;FTW4YK18F&;P6.KEW<> M'U&(\'5]S_ZZU4*(_(/&/M9QO,']DXX2KO!;NY^ M.5KH03&;KOPYL3OW.;$>S+^>.[9C16E:$O"B_ZEH0B2R!OIK33MK9/; MZ6 "-MEOQ?WX%)][;-XV>UL%W>-_=OY@8G#=7@H2ZVSZ\MMKK]Q>ST_T PDZ7E$>1MFP=PA*X!!%@R%!J7I9F2'#Z(W= MVE:]=E*M@^ HM;'58;YI<=VHQSU/FP7VZRGYK+D )LC_-_G4OXO@ 6B0%KY! M&[1N^VRZ4.5)?_"CV3\5SM-+=.8W:K,TY87H_MS^L_5@B;7D8ZS=8-TN\"IJ M&7VJ9;"'S$NXYL-A0(HUF@Z8:* ^.E1X9:.XC$3 M6 I$4#1 [P'QB<)+)O> X -K1);>65(!H8=&6,E%R3L>)MQ% 3R<&9V&OFLK MCRRFXMTC9_N8Y8-BV8]!=2$KF2,]H)8%OJM[>?R9$"HIOM%B S"%[P0P-X<[ M_G:_L_J*S(\S+V#Q=W&N=MO^3@T4E]NSG6$W\@Z^I1E]9Z%LN#NQ13*/>97; M@4W9+1YVX'YUIY;?=7[2=X/8Y0[0ZKVRU1\190%@RTMZ /90S>TYV/$[.Y5: MK8;_T]M.$Z8WW":D2ZP\T4VRH;^PT.F!W*_8L,Z[%>1CT$MN\5_WLYXL?*2: M1]EF]C*)R9T#FQ-Y<2!P/:;Z0I=,TW=K!.#QK"-Y+ACQ&4U-31/4 MY<&,KQHCY58!!_@.[OXSP3,<[J+14@!H=&-D^+7V:VY;-91O/=X4YE-CU9.L:B RRJZ?'$K(2<_:BV.4A' M(&9 ,YE=CG9H_=!J-2V#O:$OZH!_*F((!N*[E+;@H58PM9%05@@;$M1""TKG4KR$JGZ M*2B?-NR3;A@DOHL:2!"^M<-N^W6CMEMI[!R"R;+W)L,W< 6^]A^O&D^0K0_J M*"EC,;L7HBWUW__Y#O9.T=NJ>7UCG^,J<%XJ&C\N3S3N%CF" MKW[(H\##;*Y6S#KH#^[+),=UEY.-G5).EG*RE).KP'FIG#Q>GIS<*W($QZ,V M#U66^VCM16-I79>BL12-*\%Y1C0VEB<9]XL%CD +X( M'P$1.CP>V2TE4E9K4 M=$UJ;VF:5+W0"B39F(_PT2:[N=NRR-4^I0+V"ESA$=HV5;WV @_!JKX@5%88 M4>F[[,EE7R6ATV,1I[)3>:^=MAY;?R7M8)6E9ZFDE4K:"Y2_^\N3OX76COS? M:Q[Q<,C=K?^W]G+QL)2+I5PLY>(J<)Z1BP?+DXN%UJ)\F41;14=?$D5"0;0V M,XAS9P9H\3CP78G\B]> <$T\B?1X.:'W+OQ L4R!&\I"3T(0O//TY$URQF^T@B6WE,,"JF+47I#ME-4PI2$M! MNA*<9P3IX?+D:*'%,*D.VDKQDE&>MI+!P*//+!Q1O^#U%YQE>4PI.$O!N1*< M9P3GT?($9['5,=0J!]NDD+@$E9-U0ZX$*+7J:WV_],0A&Y0C63H]YQ5R$?8K_4PF M2]E-D:C/4;537U#53EFV4Y;MO"2J2KUK!J18;6EZ5Z/0NIT3@4UZ@Q N.35] M0T/&H46WZ22 M\SC3HGSMA>1^O122I9 LA>0J<%XJ))<'T=@HM!)'56Z/[,M;'W3+GAA@.E$[-OY.^D>WXQU3NJ#&=FW?CZ"]L2#K<4MJ6P70G.2X7M\G ? M&X46XVBQ2A(3@R,@;J.<#+T)&>BI,G)240F3TA5@G_LN!RW6Y9M@Z>^7J3VE M7"WEZDIP7BI7EP<8V2BT..4H- MM-UR>MQ-O$W0KJ8'G[=CUO;X!^O]X/$#Z;.P*X!8O+2VY'3A+=VXYU].2!'PUM\2TOF:[ZS?V->@C_;U:I:0U<, M-87M('1Y6)4K\M;^Z,&>M>M;>S# */"$J\=-Z MN9A5^H]7M5?T&&P0 6WZKW?VK7#C'LY [>_3SN%4##VX_3W> MH3L,O^8>/77I,I.KI_6=?3,:P/N;(6L+YYU]P?I<3OU%@!/:R-ZTK>_"7U*N MTRSW?ALF?LH2A)S]J+9Y)PCAT0-:U>RD[T^9]-H:3GK*T?=-3'8Z<9J):W]^ MLQ:L#>J19)3!01%D+EJFR"<)]Q^O$&,=H_.*?*G@6N?K-Z0I8K)@FA>@2,!\ MGP7A+0O=ZN<@^ %;U4IA2!:]!HO7LM>#Z)N>B*RF[R>@ %WS01#&"%< Z]*' M"ZJ_@H#TT;L?V8AIV*B]ZZ@5\^2* 0UZQ>B"^CM9,R'\(399MD,1_9!Z5@)' M @4*"%#;;GI>YEX[P#HV"V[U<]]V;" O#D*4MW:'.;&FA[N(O1##KW:>>'P5 M/,MV R>1#Q&^H],*7;L]LD&IY"$=4/!*+F"*X HO7X)F!+SO;[% :8;_RI Y(N$3WZ? M>.[XEQQ8O)]]H?GA#JMO)N@ AN*^.W%UGXW&OZ+YG_@RB'&:F#?Q0\BQ#&CB MAJB7I=J"!5,_W K/T]?"M\B$/O 0Y6K!*L/GB--L1_@S,3QPDV;(?XH M\ID;T!.""EX(JX8OZ28,P?0Y1W)%:#/'24+F $4W1'Z&=9 G ]\;V6JBD%,M M9&Z]]7_XP:VOMK[\FX1!)2\)Y'Z@R<#]'80PA)YP>C#>DW#WAQ(UM0+*UY![D043C@''(?4 R&Q.? YS>C@_^2:,7^D;JG@)3#@-DA(@K:%!^I76[BT M#DM@?O&A^17$A[D"UCVT40J$L#-AAN30>P'A('KQ.:UGW"\(S)20F7QS2;@U%.XE):$4)" GY8E3 (DLJ'*0RQ31.%&.> MZ NIPU04.:Z$T9ZE]"DYZ-MPEH*^ D(WK!#50WF![HR[7K% M^J@6:_RLE[\W*P0=J\=I+L*79B\\J&22")\( 6[-A #7KT7#2&FY$U,CS]%4 M];U%%17. T(DPPE)6]K0(T[OZ.BA7/*^D$2^ANNT;M4Z/59O?;-EG_NP,MU> MG"HS,\]S%D5)?Z!VS33VR6Q81X1 +O 3,D1N.-84]1YW+_)(@(H)O,=V>>0 M@\$-].+\62*9<9+3Z5(7#N6(Y_D^U7>S^H#UT"8H#YIG.FC.^\@5L&I69Y80 M>J1Z\:"\LXW,PEV%AQ#)*]JD;XN=/OEO7.AG\5VDGM6L)W7:\H4\- MJTT-&3T].*-H6O2F^JD DJ&QL1R&.-H_."J(] 73BB<6TI91VQQ/^.0TXD/F M)1D=DM0":9@%8).Q 2B50W3@(,)<%!45^'TZ,ZXJ^ZU-BL(SD/I3&0*%BK(7 MNR3K(ZWZU(V"R&..PP>Q]$MUR)D!8LA-G%CI,:CMMKD24J"2=J13I<]#M!K$ M7R372I&U,G)@C4@M1=:S+\GZB*P@":6\:@L/RRK)L1S$VH>&(1@/_46)5*0& MP!XC.T1G0:E0KQ.*'Q=T:VB!B;P"F), M=&5DJAUBI!6NZ6*>0VPGIF;H@%50J7Y5>2Z!95DUB! M3]FR_2#D8^F5^'4^P5+GK<%3*,M>%J00=U%^JS>B+K-I"B9Y%+BL@T+8M,=R9=3B'6 B7(-[!^F&F+L3Z/.<1< M">9.>4(F+#Q8?6&?S?S->JB,+QIP]D/6%[%(;0G;Q0H;^GO\>BJ!(^Z/L4S* M!QG8]K2#'T:0#.C>*01;V43[B&JE<%/@:]#N%6EGO8K.6L8DC%S2LHDJZ+. MP3SC@&6Z1D8J8X&>3T2Q#NQB,RH+2Q&#SL;NDGLQ&W9*> 9]QT+@&79*>(87 M!\^PEB=5,[*2>XI\4%C*^EE=<_PL8)8]6Q==:XK?P05I/@D MLJC )$K:D7 %'!8P2UAV,YW -Q5=VTN'S*V@*@47>#Q>CEZUUGRI83X:*G7ZPZ'$I?6^<7IZU6"5NQ'*)AZB^'&'G@M^64+X?HN87=;%$&"K$U M*6W?5'3P"9X*E"2H1B>@AZOX$J@*:)]T2?FF X+@"PPM,/!(9TQWP*XA(H:" M2>V:Q\KE @_;QNI_58")$ %^XG@<'@"*B O&M\<=!'VS7Y]<-%%WO[YHOLFB M@X1!&Z95%9OZP9 1MH.ZCX$V'P2>PE8P;X6W@ U!'Q(J;^0LPEGVQ)\)O+0M M8-0CJR.+\<$DLR,GY-R'U\FJ5M8-L:(5Y@-.0C88>"CWR5UC7R;968CL:!2! M)1/97"(]2&!U_!/>%MR"5A7!(9JA%FUWA#=!\R7L,E]$?8G@ #/-<5XUM8B' M #9AT)<>)O0Y4&5DASP-*4*+)S$./'XGRVE<6D0XS4$E[*G5H'4V73:8"]:1 MH')J-5FTEEN69@\JH86Y[,EJ'N8.R?A4&!-HK\$Z<*]BHV?"QU.5DN69TT.3 MZ^KXFAZ(5:*P+?#Y@Q"X/-2I%6V$M @38C?[M>'9*[H(#_O=P\8[S::RE)QC MN9^/ "4V>6VD:?J#C^PAO\/Y$%&4<+)9\?6,)DHMVEN%FC" .PETQ.Z&P2W, MC2&LZA)Y R;0I=AA'ASV@R 2$BR&ZL?Q.TLCBT1O-/2"*6=%[TN(%=:1=!,J M'!A%@B8XQIK[V 9.WP8VW[*_2H,UH?P3H(7#!:/]V">H@J8TL +,&&1_5$V%:S8O03$"DSJ0'@>N)' MXG<3?\10%,%?"EH#7_\?\8/9=(.I;6;H/B6H_?$XRSDKB4Q.*B@U!2C M>:P=*:>&+[TK>-4@@"6K!IVJ0Y@JZ"6H]H(^Q]M+_6XYF T81&@JO;Y/R0L\Y0 M'*<#EL1;&<,K-X8!B _TQBF$,3B6."Z$F5TD)*0UZ\!EZN0C?R4NTR#P1B!: M&4+(] @_@\NL8"/WX1VIJ%>'(WH_89BJ\'OVXH$)!GHS(!Y? MMUKH'PVDD#P)DZ[=S)V%EJ;J[*2IJ0*24>&5"HB$_&%#)CRF,7\BAFL32P$/ M/&^Y#LC.&.XW4SB'F@+?ZFK3K\VWRBF1RHD!(6JL'?1::VY-\>V MZ?3J\R!S2FC&C:0,3SFV0I!&N-+;4N/J<&EM9.RTV M#(![=P#JJ,H9N&44GC+&)8E";87E+5FP'SL@,QU!.$H8M *MT^F!Q*1J%J*$ M^STTEMR\!JV-.QU&IC"=/01-& U4B1089:W>X-;7I@&"^&EQ41F#&LR*'<27 M8@[9@B+JJ2.(1;$RO"C,S9W #_K*;)3 GWB.ZL1XPJB#WX);;:-F0M-JA0DJ MT$,3#M\MS:1 $PN&!9A'%L7TM/EKI* XS5:C,.WN7R/JIKF87O>D&;\,5B? A>ZN+! MC#!<,*V6@WES2$O>+@$J:&%H+?9J-O4<"@FL%3T-GX.NN+-;,(YXC/Q;"<-$ MIZIQY>"?J6(A-8B)L\N2R2C,'2DMDKP[N&3$^4,1AT%6O\:&<;^=D$FEB9,G ML"RDQXD]M;_ 3-,S] &I#WIM^:HI9X@+*0(7'4$H%FR<%GNG9KML1.<],*V0 M$6'F56$F/5=S '3JO5 3T5V2R.FHAX)(13:''T5A'HU$'*QT PP"P?J!(]S MFC>YD53"$"R&*U%B$ MQ%#\@8Z]&'U+)+^C!!'[+"G<\"SA\8@*,3,.2Q#6*#.C 7=0C&/9 6PO=)QA M1?HT@UB(,RZ0HLO M" >PD?O&R&M=7!ES*G^B!'2-IW23BU;[PU,U)_5TIU%V;L( M"@"KHOS)<0#["W.:0HX R3(_"M[X1Q!:J1?>S"/M31E_V!H[$@D4DJ ];S5J MA(183K6-1LWNDD$M4P:Y3QO_:TLZO.$R7$LYHDCI1YZ'JIW&0@7!YE)R;<@U MK&0P&$D$BJU\%_!Q'=V8ZP,$X"96HWFA0<:8W8%R;!@(HFG 1B0AD RD7;U*20,A BKG9,GBP6AZZ]\7%R)CK*0,W'B0& MG8KS6$5H:!0@^9)8[P*%E:EB3V@"8"ZQQ+XRYNJ6I;5L%V-I;31_M) M(IT +VL/<:IPIC,Q1NUQUTY.N?U 9W=E7$H?'RZ+=88G&6-4=0T+HR+( =9R M8,L$4%7D$[ATGW%7"DPY4KSU5JE$.M=YR_X-;]43GPE0@@VIU"OC5)88I=++ MJ283'=^JKE)Z])111(.4NCO8,I@YI-P"9%AH;$.;"Z)7G1^@A&,P'DTMTIWVHZSORL'I]+E56A+4Z+=J30U0##8NGU#KBX#M3/F'_%$9/S_"N)Z0V7. MO4FMNV52ZT*36G?+I-8RJ74=SGU*K+ >GUAA_TQBA=+M3Q.T+V @B.\.%G\\ M4AU:X(QT,4%J ?D7]KSY%];C\R_.Y;"^^M0?@)J%R>DQDW%OL%&Y $Z_IA%5 M&"2M3<:[.;GTZ-!@R%T1D.Q5'=B\Q(P'NYH99\8A5045OS=8BF5BKI9E(W3[DMIE! -E"RDI2UH]4CLAEDUU2 ^N@ M>G>@M9M#'B4[)>=[I7X.*N5 +9#(@)Y,T=<&!\8)ZV$\&T_AAX;,-UBCEQ!^9 MVE[T%]AI"BEYUDF8L=BTJT#VAKT *DXV)H_$M/+9CH1*"X<_0239P@\@_L4&4@S:$W;N!Q1,OO%8SIOTR=S M%"Z!9\L&=,R+ OF*N!=RGKIMS>--9,A2])U2$W0 M^+"(,8KI7 *Y3 HS*@V%EO&PB"BY5/^!^&"0QSSXM"7U&&:VFI:")O9&$SZ9>B#Y&GU&& MNB ,,?9<[5,6+(4T++V,*N5=KYUV$U$X!'MRX.+">4,>.Y.7F3,OP'+H!7"J M8'8V*,A]\9?T2JD1:1))Q:/6:V,L./9ZRLR4Z7Q32>G)^FV5X4G?5NQ!TH9S M47$8OG$ IX$R2# 50Z)Z ".2SRY-QYC":#@],E7UMD3[!NEV MQ#:8Y.Q!&(N,)'I:GF_JDGULGF^N:[#3PY2-BJ7C=CQ*[5>P:@9 .+&G!F4A MA2F=>A&93@\F:8IF0Z;TC!?.D'Z9#[JEB>+4^51F(2'2AX2%&:+T,DE0^E:9 MC5T9F_7Q7%L3""25,NN@F)(LKF*FE'9D["[U[-QS9Z:35TQV-S 8><"14]NC ML;P763_A5W/?5K3JY5LJT2N-P&E)C,YP*?9V:BAC0"I&8\O!R*5-_NO48IC!X:9V![I]'-U* M#^_]1KE'O\A?+ZE4ZR^3>X_R$SL'')MX^%G3MJPB@CKHR71Y2GZ0 M1W2/]V6\)Y96-:BTS@]5KP*:LZ"(O/J,*6E5%]5A"MJ&/0;KCQ@9&*-&J RK MDX32UT!"W&^G'?5-1WK \=-+, MVE2Z6W!$58H,W4IA/.AA" QV@MPX5&''JW%0E3^($-]8I<94AF[*B#(1?*[#SJ[YKN416@BH).?"M/ M49W&KSULLCZGF@R4,8D%%]IVTZ4U5AI81U:7.:+VZTF8+II]ZDJJRW\R%9]2 MVJ53AX+OC9P+#-1+&]4D8$@NR)WBC9VC=_FC>\WWQHR2N,EBBT!".UAI%C'8 M1;-5%J.%Z'6K4+8INA8P6<<;910#F7>!-;'C9V4$) \9\I?/(O2D .O+=%W# M#\H[$W!95J."V.B^V49/#HP[E%J$3.+!)KXZ64U6(DE +*T!H=OT3I.(SQHR M3W7*EF[.=--@;:U48E5N$RH*VL(S+G.8,]"W^%^\ZH;HZ'J3=:!*"T<5 M9N.I08**;)E8(PO#K(8![E#>)_$AK:3[ZY FHB53ZGU2C6-Z]>^U7.<5HPI00K/#Z+!H;MU" U]W92KJ-XC>71-ZZ@Z+*HUEH3F1;ELL@6TEPT30=. M57V6^C73%.I,*.RZ]9L,>BD^!7$12-G"J>=X6CO \'@%OOM;?:NALPJQT7 G MD=EOYER[H(4!67 .%(F8#D/8A$H=?'UQ_LL;U%>Q][5.<;\F-TC3<;C'T]+Z M#'J#_?JZB<65&,)Z8V-%$NXWX! J]K-2+59O]V0PH%Q L&54XLB ^7Q2X.?D M//65UO /=-I/&G?$Z%0[(JU>5521H*L=IX!J )%8227-FG3L$HD3EA'U=/<2 MN[G]L9*)5E);;5B;_.I5U,Z2(^JH2CL3=&OS;J9ZVXJQ7"9*AS9=VL@# E8% M9'?B.SUEUM(0E*6+.@0\I0GRS;,;0)VL^S LV U@M6$L)+&E R13$&2-V8.5 M*46#&J_=HSPLPP&YG,R<7V*-K0U=X).(ZDG,(QR,:UC0W60 M\KE@TU+)B9R#=-4T;Y&ABQW2C1=_DKF1SH\BT.4.YWU)# X(OM;9O/@5L/[' M\X]O*A85.0X(-Y .0,WW8WGPVB#3D78R$#.AR&XB7,IK=9/0>&=,<%37:^#- M;3X*?&7/K+[+^(5[N)]ACN_)"]LK\\(6FA>V5^:%K45>6"GU-D#J*> 4LE$R M88U\L;/.);N1Z6"_7/UFM$23I3!#+\PD(BEM&=0+:56JVF]8V/J&G^#^O#-OD"-KOO,OL3>>+.T'EDG*I9=6(< MLRJ3"(0J1698-%8J@ILUIG.L=:GO2M-394Q=J'R#+](*=S6<"]FYB"WE M2CV.D"@[=OH"58LGE3X@RH""1Q(QB_R0WLC>30T=VR%7M)R^6YS9Q,_4"@B< MID8]&R;6>#B94Q7Q10FF-LDW4B@\YI<%C'2"/E#>IC;1*:56KH^]V!PHD,"W,;,-DYPG]*XT$KSL82,2W5G,_/J#3@V(& M#6PZ2R_'GIP\SU/(Z&Y<,^ AC%'+;"M?U>!5CR?U,MF#%4M%N?( J?5-L MK)QZD:ZFUMQ#%:\42%?N.\)7(6]#%A]Q"-]CG%\0G@)E#(PA_)45TDM*_3DW M83#K1.W *U6\ITS/QWG,)=>C[>F*?65,*S Q$ M2);@-/N<27D7OG5,":4>7=""!_3L9I\C .IX M7 /I4/R8(54EWX?F=N45S7USCEI'5^:C'5XHG7&VV&"&U&Y,/FT1=$:\6P( M&1GC5L>I;Y]^;6J%'8,8POA*X25;=A/,C4K^RXJ5JX$PL#2Y^H6)V58U!')B MU/MHB'KM\U4+YQ>B>]9$>0K-,[8& 0+TV:/FF-BEF701>V;* M]!GX&KUBIJ("F0S=_=JKJ:P#1*AC YZ &+(^!8$;P0N'0@>(B+6T^2 WX%%2.D&($*'O/+ YG@ZOI(]&U_)>B\^:(BE]]OBP\)AENRI,$O6 MDHIN46=!E+R*UU"%D^J/H_&06DT0RJBG*19RGR="I5]AE37*=(;:3@AG7B F7YH&N4(WU0Z'$6B MZ)+M3 >RC!VP;LAY7V729NWYZ2''B*H1IMEN#WHL[#.';&;F67F?GX;R M-2X")<;ZW+@9)50M_>KG?8@R4I/2:\Y 7>GL!&E"OQ0VN;=;:;$U51?G@XZI M2\MG?6U'FHLE(5+N2%<0HFXIH9:5B'IDJ0HQZ:>R-,&2(+CEFH$-)BHIADC. ML:(]+FFJE<@T:S#MFTR57BZBJFA4CF!"H] 39JE9EH,I!>@S^B_ZLH=MZK]( M'6<8T^QBPV$#HYAU#TSUP"EVKN\IEB'(C%#:T>KY1N7.IY-:N1TWJW58AN%U MQTD$2.CTJ(5#^.1&Z573* M81\HWZ4NP CF,@T(!-D[10"11%&/99.FF'N5(0,G-UOOD $U(<:DL4]@65S$_0Y6U1 M9:T*[.>" 2I7@[P[6T1&[F?LP2RD\$8V49[J()3$=@E$/1,X1O4*LP4<+,3H M*I'8V#I,\ZBG4Y$^&]W^)'-5%D/Z0 E:G*G>J->V:OJYFRIU[LU8W"\S%A>: ML;A?9BRN1<;BBS_Y+WWK"V7YU].2!13,/IP*#E< 1Q/QSEQUT:R89R[@D3^U M)K55RCEL(Z:2#&:88V_L*112#E6\E]\Y7A+)2OCV2)$I3T6E6*:EV/(PIJXJ M<2B<'!R0 6&.+4=#G( B$':57CM&@SS_M<=/8I^!?I!D H\I#/:8'T%H'%M4 M*TS$0)VAS;3+EZ6[?(6J4;9: U07S#I(]8R:$Y*S#6F]OJFFF@)^\67DP''H MH&,DZ8^Y8DRRP?2(M'5LOT[+I(8B)+1BYF:>3EU )](8WDQ/6[!?_W+UVYM* M-H22RV:K4"IHBE(116P45:SI4(+JK^UL\H";9,J R&6C$B_LYG;Z]\=M\PH= M!&]^/#;P$>/E1#)N;,'FV,W..)\TX@SKMYK7S:O/I[]K<(]S\^XOYN&OS\^^ M8)D63,2O@FS?R0)1 @S(=4[)]A29!',D=YD@?YY/14G2#$U?WZ1+TL\?GT'[ M(3_0J@O>9?NL9*Y*Z;1ZQJ/PBVZJ8.52/G4ZEXFN5"1H")TL4J++Q=,I)1TP M,SFAI71DT-VT". ^N9\02R8;LS)>$?TJDP!GI26(ROI58)0:H3Q;X9Q#R%). M,7D89H)2*N6.'&D8U4+RZ%#)=7QFRHM/02=+@F*BCFX7.56H9S=EP MI*&5A*H4#_P\QN:6?4%M5]('R@QT.7ZJH!P< Z;:9*=66JA8%73R'5<]#Z2AU0!>VHQ>?0?E5EN"L0-PLT@"WK M5"95T)TJF< .VK!%5/V!@A-!/Z#*>"0U""B1"?%,]1S)^NI,TQ!"RYF$*&&Z M(;+TG8K8DF!0X2#0D%H$"&90\35&:GW_W: WBI#'U!S9'2[1 XAER7,2J4,L M=?VZ 05X\.D$R>DROTNY&IW,A'82KR,\+$[@$<_@6Q%6$G<-O%=VN@FY32'G MF-6MF /7-&95 M[HWR<(N[/*1MJH-EM=&T%-I^W2!D3[H<]"O09NS7S)I(O#S#&NH*_>=CKJ*= M=+*3EOWZA%@+0VUB",I6"I%11<2(-WE->!PD6L;O='@OF^69T^%R":'*?3>- MS:6J.Z1.R0A3:-A>R5Y3SGM:M?5F1&4G(W!-T]D0MR(\5B:/RA])]*GES\N4 M2L;-AQ< ^X%R+IV*A ZBE7,P$H 7I?#5Q*D@O7R=@:4 <81"# %5O)&E$G2G M5=,;<:;;ZSQ.D)E..K8N1$& P6X08J3$*)AIDPG+[/;'2, U.]G74AU1=7CG MK4N[OK-[N/>V4:OOVQD>E3!P:?U,)HE]++*$VU'GP*EVYIK-E+4,+\D?\,9C M;.D^<:8SC#F,T^9(B+27A%'"[;&NF&,HY2ESHQG?Z8"@8^.W1#K,G[W!RN4M MRI1%O"%S[VL\),04,/D2AOL9[!FY I9<@=*L>49N0H0T3+BG*)YJR$9MT>0I M*PT(RIB[HUB1.IMP]V'"<%Y0J,;U\J1*'Y+>?9MY2^)C5]Z6\DTZ,NP2 CMA*%:I7J*A2GZA/".5-Q-7!,ZPO#9W76HMLU-Z=G1SC[VG10OX= M^FC%4<-E-O7&3?O**4EH:7U3U6VJ/*(1S]:T9+HE7('6*#M=-<!, M<4;1Q_63*1(R(&CP[5D^#JL7-A[C!RQ/ "TV:TI9(7:@P$2HKCO<'L$OA#@6Y MBAT0A2H+-N>VYA#U(JP[NT4\;?P!!S7@OL)M,V4%H9Q_Z33('-9X#?$WT(HE MP3B8\<=BC;,YMN7"YW"*4MLD2^U,,LNS>!F5E[A,5#T%O%71&-7,4:#!.G7Z M_@H58)/CS^?-5./,NZ6G;3^5BH%WT18EI#V%$D_)H\JBK=C2TM ;JH)'I\L M98H(K5!N5/I,L&B?TU9W)[IRACSIP>(\)F.@:J ( ()6UI!RF=YT42B?)[\;H^=?4STV!% M5**O6WV@5\>4HV2RR^9BDAQKC)5A?FUMP*:_-YOBH,RF6&@VQ4&935%F4ZR# MX'C?_O"%)*=U25A#5'1>-J19GJ&KE,X@G7UC8TAU0GIL71MU51GK,J:51M U MV:L3.$JY+ALRU*2T&QGV9G(;7)^T7 M5 E^"=58(XL R(!#I 6 MJ:A?SAU@=/^Q4UVFK.A6B8@4H9\GHX^F@LPX$"4-0+XJ%R8%B)$FAKW%$!1( M]A[![LI#3H5EZ,@VY38R,)09++HIIB, ZR $M@7K@8V-R?=CE8(&P*OT3#WG MAM5!]US(3VUC"JUV@$6JL#]D W'T42C<6V"?\7KWUU(I3=I<0L%7=-P/0<^X M/Q1A0,E@;Z:\#5657)/, -NT4]=)(EHG 54DETL&1493 MS"TAX1G1M:!BK:C9:^,AGP24PH] ME[G4A 5=A#4'":9K-@.BU\(0P%"XB>P)N)Q.=R]^3Z &H9H.6K]Q)\9XKPI= MMY2Y5NH32RMBTXW"9(XK;6]9^4I0-?],?$Z(0++A52S/>W7P4&GM9 5;!K(C MF[V:W8ZF<248$SY/@:4L"5PTT=1RR_Z2;Y&I73,M'0L<3;@ZL[4;TO3'GIJA M*O]11_RT+IVF(V;%TB'V#D6GL7!$IGP:R@@G7[4-RK4P@FMBKF+A-E;K8>Q]B<_#3 DF6L#'[LJ%U)W MNY$:CF[:)Q,YI_4+I8Z?^F5I!SBM!LHJN#@@;0FE\E "6DT;GXK29DXA0O 9 MA(SRK3++KCN04G/2ROBP3"]7.?^81RSD"8K7DR)G%LE*$W:R QF;(QM9R\AQ1^BS MB9JQ$LD$T(4@G]3C!*9('Y3J@)9X,P0T:>:-M8$*"=8I9([WN-)J308+F$>O M2A,R^H9O,FWDL$4@;*0?3KJ!*\4 M'BP/.&>:/\A@BY$FZ!;'WN,^@7WY,F^G%6_9GX,$&]6!.!ST:,_I5G*$.M(3 M ]WET3(5#.8@D)Y4EVH8L'4TFH3C5.3[(T]@'F0@#Q1"468T6_89-BGR1G3^ M7, NH!(]B4IWRTT##3>;8I\9,NRO^89<,4HGR; QG[A^3-[Y;V4RI"KW;TO$ M6#+T2?-/ @X;N8*1+)70AH3C::5,WVBUR#B3"#^&T%9)=B&&[,D5\:$WAG#1#&EF'C?1; 'Z[U M402#2(I7!?O=TCC2)7;Q<[NF5"MI-^=_,7G9!K00$RXB.QG(>@K963+;DDZ> M\QXMN-VF!<>TZ#Y!A<@$3LQNSCAF9#T7=M'T/.S#K9',$,DP4=L7B^,"1W98 M)N5GJ^ZL0)^X6/@V;-/+IHJ9Q@S[(5*>$\!%5!\@>)K M42LR#7BDBT4D GH/FPKX7=5^V/15P([N9!&J%KC4V+UDZ<<-93(X\-]GI_C_ M!0ND9C=$*S).0!&QFAGN+>70<\JAUL65E99WHC\<:YN23&->EEDXTXL<=ZWQ M$PRQQ%>7 ]E.& S0GQOTI8[+P/; %MFBK_(<(^PH.A2FUZM MOG"KDW!>:'-+BYQ2"1EU1Z3"%'7D=#%>!R:9ZJ>A:D]DLE?FU$LC%CI15YF$ MBEEU*2.983J-.'O>P,NI4$9J[PDU\.@D:+ZFIZWRSF9>BSF_E+V5B9CT^-B[ M)9Z@_ X-WHLK U>DDT8EX(\B@?H98Q(>'IV^!,'T_TA\N8V-,RU;-:@UB^- MM93.ED=IXU.-6K\&ZTEAWW^[;&:"ZH[$W46Z>1YE]QKF?K0.DDLZ4R\WDP&*3:2ZP3*!;: +=89E 5R;0K8/@0$O$U54$ MUN?T@ (%L8EP,#KA&X^JYS--2LM$ K%3+S4ZP93? VM)E%9Q9?<;X3'0H MK8]6"IVP42)4.)"1P<*EKR7G1Y'1R4SV"QA$U@].:EPPB 6Z,Y2FE#5*C&)' M".0JLT?U-ZS8QLL#2MT8D@[WX4SO&:7(APFE3!A52A1),8J120O#"5FU06J9 M69U ^X"Q9E:&/M%')J].!I1/,P;45!*UM%+!"Q9P@[" MG8KD4[V/J\!^,#Z%5/.?'ZT$?9# ]OBS(<>6QJEJ(F\:IW/2BV7<+>VV0G$9 M2C3$"'-&-TYO->3)NGX,@2&-"8V;^3\BI(/ M"Q5]%JK)([&W*H_3[*'3)M44C+6IE#%W^1!MZ"<(+P.6CL2"4.RIW@3<+?G" MH::3F8AHQMI);Y%1+KUQJ-N Q(' \8LHNR^GN$0E."@N$/4Z(*2&B%+;R)"R M;KF=R@Z%K:%-',,+PA?$OF;J=$DZAE9A1B@XB=&3F ]P(-A,EN(JO",,-H3# M!M+6RTBDE%"=PY*A1W5_ 5O1CU1@.3#P;E)QQV=/-9V .7X);E' $(^%YFE^ M8'<31E6QW*PK,6!;IA!;L>FU:T!A)!=D!R#+IJ;<+KO;9@S>W!Z0+MM[5VP# M[(O5)QIT&_297FLUR=&18DIP>DTE4)R2O0'=N<=*% MRR3JOMV05,S40LM:9.,6VZ,'EC/89AIVK]"DREAO\S]_BIWW2MEGJ6GW:'(7 M#4\(9F4!-#8*)_)H_^"H("H7+TC?BP]-U>*;/+EO);&$,]+^\!E.862U2&8$ MV3\$H?91WVCZ]LO)7546U*LFI7ZF8_B4)N]2$8ZK/0SQ2NTZVT5I1:X1'D\NFMO7%\TI MA4]P@]/#L*!J-&VL$:)"*"]$ZABB0 D,+N."H5*"J9)8!5.N+H]OTJ;@9'P[ ML9+@H51["%H!45,5.:&,)W70NULA4@QL'L7".QW$8Q"$FK)-. M*5/,*0(=5+*RFF<9IP4$EEYA"'J1U/ M5+V*#:Y3[+G'=)2G=F-$1[Z=CVX\76ZO=:>JE,,KMR0O6PXW'2<)F3/22K$4 MQV.B.!/Z8!*T4'5Z)JP.5?BK*S$QSY% V&084W4-42GF,@$)NZ"TN>_T^@83 MG"DZ,,)Q=7Q-5&@ @9*;2ZI*";\VF@E$ M1 ^5RB95DJN.)VU"0A S"F0*[X75:E0IFE/(E0:^LL(S M4WCQK ^9P7#C=2&;-6MJNRY@G]+N.F$QLX\E#!@P(>TJW%3V-UT,F>X.-!L' M7C#"G%HBQK1*F\C+R>66P[PAVHI ;2F.:A6S $XQO:]1 E8S1644)*$QR4= M^JJ?'M&"N+E4FJ]KSJ3)EJU 13=8<.MCVKEJGQOF5_C*5M !45K %'M49RH(P1):!8%DV+6 EM@Z]R>4NRO/56EV%^Y)7G98O]+IG(_GYN.8M[TX\S6 M*>M:;Y/ *-7=+!)!>@(H"9KIXY."\*MG:J 535/1$2(U@/_PI\Q.S*#EQ^K M_B0$#T\P6!WF11@[003Z(=<=2O$[";*93@+SH'-R6>;,,^ZDA@S95^]I1!] M#R+FE\3I62K*WTDP[U^C4- IASB/F. TX+X;H:==H9"-(ADGJDJW,$=5GRS[6+6WE,SL>ZV(/A^FP M1"*2O>)5;]_;P/ZZU=I2A,"5(L8^8JJT[#A0W62&F!TG),X+T-;6>6@063&',X6*C4X#YCU0$$]'F*21*:+.O-53V1J@)"C4B+6 M<((_Q"%S%H(!&=K4FP\4"TFKI#!3/ (//Z/F0Z'LT8XI<7!'5#&("!WA<;D4 MH33%545S:P(V4%=S7B-,RQ_D" 98^I59XRP LV:\O/K7> MV)]%.T3&N0HYS ==5-$SJE[0!#;Q>+6E4P1/9.Y(T+&RZZ77'M]ZKH%O+Q+' MXW!+TQ$NJ!ZA0'09("? W!:_._ZFF4.YY@8X9LH["83G&D%B0 6\09@9X-M! M;BAXA7I)2V8_5FSU-LE9S0$-/Y$#:"9PL-(;6]SK5+%=&!.HWGX4R-:T)9JJ MR%&]0O=NDN[>-L/R1[619U>YH[]"9F..=9/'()E ?!S*=S=]"B1'X%;L@#X6 M4//I#%RKODO.2,@CN(G0BE =UU7Q)3#-6FB+*AA3<";ET%544=!M5;0T0C5HF1& .F.I2(2BJ2G?*HHX.>NCVPJ? M4((I4#S$IW(_X1B$;U&=<4KHY!T*NRQ*VI%P!4, 6V8 F-K8AT=W:$/)J9J' MC'5HV[);@<=5ZQT@8E-><.KB")#W# M6'F]5OTU9Z_J9B;P!N#;@]UWL+W[[<"+)-PQ-6*CUR@8L9!3%HK<^"3@+(W) M14.2:- $UYO!J"*4BRB"$[NBJ[@1I H-;6!K$A$\[(LXEJ>NQV[E41UBXQS9 MAB?)RJ[)@YB0MN34'<:&5!V99;[_0340NHWME.OV(U: M8X?D)OS1J-"[9(V%-]JR;T!U3NEBCE1B71ELR97N-@[_3B@.IB!Y\O5C;[?U MVTEOP"9A^DWWOFCGX*DO:FS9E_ 64M()\0^;A(_2EUGX#'03X//IJD<-0_?_ MSV^_\_>MS6W;67ION-7H/K,.>54P1I)=BYNSYDJ178Z[G9BCY5TU\S+*9#< M%-$& 38N4MB__JSKWFN#H&2G+45T\-#5CD@"^[JNW_K6JV6B7=*)89-5P4HZ M*H(6BN8L&I%'E6%CS>NZ+Q?B[6"N#E[#'9G)Z+5+!IW:-V4^=SL#H#)W4L*3AKEO-D3$ T[:Y;=MN1XRORW:98U;.R82 M5=Y#VWYUC4IH65!]!MIZ0C0A#D)CVJD&2_W:\U&00:__ID<-4$1M3,6X=4(= M3,[C4?J#, !S1MS4EW W6DS8$$]J15TB*A$BAC.VQ) +TN!B+U&5'-X##>U] MI4;/Q$3@ES ^D"5%NT(JX;4,95#HHF)KE#9295V8=.+Q5[H),QD!4163#T9/ M9">A1-(D?*MOJR)/W&!W7A!NO<3!]&D$0V7K@!XH),RB#20G!<:>^0K.FR)4 MZ-A5XJ61B@^MA]98*,H!N:4C1@\*#$3,RAA.F^.ID 196 41"3%UWHG913D1QK>ZQ8#4S_ $73]+R"I"N1.AI_] M5X&F3I:>@WWR/4&FL_1UORZ:/&783'+N-BM7<)@T/'EPZ*,7GWNX/B\*.;OBZH5_/:?Z]7PW]S,%^^>G4X27D '\*PMVT9DYXNULK4D"&(A79!BYFB[9< M30+/C 7C*C6N;6@2#@*,1HSS?(V^0'H&9P96[C,P>FY,)Y\<3_GD.\TGGQQ/ M">4IH7P(HN-O+I&BH7GP0*)$!C?=:+@I1BO*W2I;:@\"@O-2R<%9(]#UB4"@ M>6A2H971A/1,$9!YY3)N\MP2 %5-Y2QT]V"31G1V(4'8T(T,H\0A).\!4=2L MY#HR2#%ZP&8P=H>^3*A7-2J'5;$1YW?.J=)T;_>0 &B]1&N!6LNBV14*FS*. M]N=1(_A\:_L4<%!JP>P:L![S]R7WX8,!8ZA;C3'N7 UCWT;KEND7_>K;Y).>/'GZS9=_/#T^^8H,;'!)<258D&I0T[?KP1'8$6E33G95$T;K!\H? M<$KP&?@:_VR.46 *$ R8LN EHA3]L+GX^*/!,\#VD97C#^]5:""-HP@P(X M\I$GD>8\KZ [8.[H81XE?W.J>DK143).I$P"![WM):!_HQN>I5T_ Q>V+VM$ M,_"?\!?_4[S/X4 UO?XQ3V&RW.B5#@%U(,)#28%\_#K.LKKLG:J3XGT/_UEM ML?$0XG+SRM5]BYBB\"S%GWQ[KC".\'2I\->N3PM6TSV:$DALU5TCZ>IW99^> M9?A_R;<"*KDJ%H^Q*2E.X^+LW<7C\_JOCT_3T\?4X,DTK.5YR?U]<9$^>D'0 MF_0"Y,L53 <#>MR_Z?&R<>Z+>.FH#6HN;?>RL,S)8)F1'Q;#8!2KT39%1/6B MW;+V74,X5Z_@T.3L,M,__:$X?W%Q_H9'C_?[1X46O=S LJT+9@1_)8VR*'CV M Q@Z\]!(>+'_8-"Q_?;JX40%@=3"F-U[4 1%!T+VYRY?D9J@ M>PF2&3M>8\B15)%BR5# H:?#P*%UW4ECRM8KWP@TI.W60,V53F)QT1=X^)QB M57>L7B;VM2@Z4"1B! Y](:[FH"BBZ@-R[=S"+50K$-AN\D#NQ\V?(_P!FVS3 M]KMZ4SI%&B-2B3!*"(NE_GD;0DL1A@E-O #TZU,UB['(*UD"Z@E4*C]N4:H +R ^4A0A^:7BJ/T29X<8V+K MO" X&D7?Q9EG*P5#6!3FQ@LV%Z (-^XD>)82;B;XT$6!:72Z7>35M\IC,H-+ M00YXAI>4BUJ7>='(.T(ZB_Y=M7D7?EFY9<&M5Z]\/LNN>MU*29))':<.*R(3QRDN^"O,K]$@E :7NB'VU MV[WC,([U0=Y%T-UOXMW_GHKEMF+I-IN:BO5>54CK,P4*[E=,$D &Y(!N T4D M8U!K!ELS/R*8)ZIC%%1GFZ8HTY-OT"0X><)-?) R#4FC"S6OV1/^8]J#.&\RJ_^$_KZ^O MC^:UC3J M) =9=&.M@9%<,$8J/E-($B=@<>:=9QM X)V')[[&8B?F_-N)U/> M[6[S;B=3WFW*N]VUZ"@6__W7Q ME_2[L_.?WKR[F"R >S/.WA7M^S8QE6NH0[_UG@?8:,HM-FW*O6T*DM*ZA((> MV.6 VL'[QN[I2@SH?@.VF"#W:@9_2;"#W!\)>XIQHLB@J$('^QXZJF*MP8&3 MCKHQ(OM(B3<.;!4/->/N 41>%3Z&>:""C7*@T&.[2S6 MDNMKG!2RN;RI*+E"AO^_/3WZ*ETC3$T\^7][\NSHF?XER0EJNA,"W%O[\:+W M3%B@IAWB#D,5"7ZR_U%*Y]I0J=L"R98=-I)S"?$8KP6G>G.\GV,W8Q!-6BAV M/Y#QJP-_!(3;(HS7%T/ XBYJNC""M*3"-BZMP P>;<4U%2."![*\Y2;EE[#L M1^E;CZG@ D&*]L553E@DI4Z]@EH>E&@S]0SM7Z%'C$RZR/#-!6#NT4RVPIK M&5F.L.FM"VADR0$V>$2VM:2%*$9:EQ;&@16*7+ P$NL'@P@<9I=YJ?&K6!#$I4#PF6^;3T3013L M)4?$1<8W=Q]NV7V\8AZ1\ M13[PMRD1&(KGBW)7!IN;23C,%P<9H(U4>[DDQD\3Y!ON;%[@FR7IAS@?CE/B MKLFL_"DNMP'7;2%2_CR:PQ.=W&5#SDA7;A-[K>'L.D*B&FW6$B;<(ZFB4PIB M!/^_W]"R%-6RR9$Q+^085RY?T% R.47FKH!SC[O1.E?.9]:ZJ MA!R:2X)Z+)Y"BM5!FM2 G/3:$G3],8RSRFW27S]O MI,YNL-7^2:;"K^UQAH4+F][R5Z\0RO8+)?$[NE_)6;45D:0'7,L94)X4;3C3 MOGG=ABI(?/NZ.4DQ60P1&R1<807RZ.F?0;CCX0^:;4=0_\F EJ5HTY"]DMHY MR\D@!W:$:)US(7/6E0:;IWEQ7X[H?^$O,.&0=LDNI::$39-A 5!FU?TN0WM4 MN81?(ZE*V!C1N:%>R"B61(OL5>R45,;I-F-#\):&78?)#K['08\<8-)!?(0I M%HW9YNR!G^0;CF7+'>Z]I/Y'C[*?E=)2+%E[U/F)B2)]S%.#35!NE11#E+>M M8MI=CZ/TK&-PD)AI<1TR8I6H 0(J1+"9B1-(@3]M8O65AP"(NH(G8Y5@7I0] MUP#7,ZU*&5USDZ)'RMY%L6!0()/,>#PV)]UE?X4C1UM4 MY<[$C $PU:*2HB:A(Q(^>%J_G&CZ'DZ28%)"DQ2X%"D0+TK M!9#3K\ K3S=\M]Q28XJ>,$."\_"[&MM/,KNN)V-$ X)">Q*V'A1&BB_GG25J M9H<_FLR)29!,@N1@!(FVH$# U@*S$^'^IVM7]5*.>*66A-9_3]=\NN;3-3^8 M:RX,!MIS=E.7&-!L,Y,6)[($7S;KLQC4/WI#\=PYI_ 10$%U*KO\39-4F*3" M)!4.1BJH\A?:;,,AY^D%/'Z&/J1,B<..@6#HXY^F^S[=]^F^'\I]'XD:K V[ M NAVR6]N%;"CJ8+1[.':N4YA%3;IN[DUE5*=3&=7= MEE&=3F54!U%&-0F2_9 _I/\N8%J;8 MSIC0..(@5OQN0BCF1;W&KMU"M:PP),/=1U8JM=4NJJJ^R@UW 6%V\"$XOM:Y M]R9U1IA @0,QGVZ[,NAY?M$$U;MO7GEA/D8<@SF$@52ED:9AK1L[BNL]5.K$ MP$XDR4SL'@C= _8,H5L(3_9L[@218P*.T%E,"987M8"VN+2J]F4UFB@16HW& M;7HD=<$* <2""[!96;6ERY\/N2(NFLZR5*;72\,5;:X"UB/(6DUHZ/LYFT*C MKB2M?Z^W$:O\*$V_Y-/Z"6[WL7"[Y^E>"^77(O%^EZ"[41MM0N+M&^NLJ?,% MC4X!,\I@U'I:3&$$03&.M%P4.!-B(>IQ*5U)N"%1CHOMT@9C\03/-;R;GRIT M_CN)ZMSJ;CSP\=_[4*]-L'*?=RY9FV2 MA'F73P?Q [B)-L>_#P/[4@=CFS3[FV<#=7*_#P/[4@=IKR+?&=!5Z@[;#M-^/9P(A%W*Y=M=Z6\'&FGHH+3 M52O\/C5B'#W9R4,XVI\$(?SA)_$> PQ=\?RS$DI1;_3.V MS04!B>48F"'XA,59DS0\B/'_7J3A 6W)9 !^G $8&7/,ELU8N@&4CMN";N&? M4XW9;S!HI""+7'&$OH\0K6I/$"RX*+!7 'R!$/NU)3+5 MK]T.<;Y%4R\3QKX3CI_CI@2*%P V@;,''.M(7"[]%2*"VS \P[$X,J7!X#-? M>9+<4GEBBTX&I2:R#EQQ(LT"MLPY#Z/%G%F)R;*V1:#I^%H('%7)8CW/; &O MG\?D_]S%P]9#X)NH-[4TJ-TTQ5P@"C#G2U\W,WRXX:35GW"UA3\<4S7"??;U M819KZA;L^[SXRA&LF&H6CY'>>DN8O;) 28I1-6PMV^383@-[:V"LK6^I';(< M],@ICQL?A^860LXO-W+\94R#76"M540T#9]O\=Z3P <+]A_8A'TP)#Y\<$76 M\6F>:K+NM8U0@Q?_HT\8'I!X.X7O>Q&XT?E$H6^S2U@]%O=-@E1FD:9]") ! M[V,&6%17=8F-DUL0MXTVKK%8K= KBQK>_C@#91TI?YW,GE"!5M80+P)EP,*;F, M&G)QFVGB]#$_V.F[(I:5OX.X(3%S?+Q[JMAE%_EBYUV"S9O;)9,'X*^Q<2LN M'';W(,L92$WKJ'>QW C$B7-KUFHXQW8/4@\+>IV?0(= M4D-$FX\\UCQIY_IQ!QH::0N[@Y9;#A<+KY.EOL]+EP7L><='@A&ZNX614Z%]BMR_VR M\2TL6!R7_OBFV.^MQ>H$>_ZT.<78T9OUW4@=.W986H"(KL>X3M@-ZJ09$^D* M;M714'.XLIP,E7L<]%G9K>K^N*>!C/\AW6\#>0A-WQ8U*:S:G!"0)-I!+S10R[D9 M7\4&1!*=)9A$AR,RB5 T?C"(8((4@C##IFYY@WJ<60GHD%U32[Y@B$U*ZS[] M<90\.\W16E<5-<9\JOR2K%X83K[.P$,HV)2NCA M3^M]/G*6!%L*NWP. CAZT(UYS!*%O/"H;Z2(BNVDS.Z;"87ZV[9#\39^F,8( M>.)@YWI3\M?I1.JFQI'2:^^5=MQUE=J@=AHE9(42_%3KGE+8*![Q^$BUS2DW MDPZR7CQ,ZH#I&FI1%<[C(&WT:NN70OBP)E.;=5P\^X M\3(+^<1[G3B[MB;O$2J\,O<;-^Q&+LY.J[;$S4>#0N2:3KK]Z\%* MH$!'PL;5OH!#AOT+L%V[UAZ$X[7LJSD3+@V"0=0) 9/LSZF[>(5AC^?69K,Q M;Q-62D0F7A5-CXWD82 K^!!_G6SJ:_BDK'DQI3LM?SW(A0;<#31[,8K2 MN=)AH*NO?(X(*1_S+E?* ^WZV[+)[M,9RQM6+S%'1W(A&&^YMB$1-;1-4V$; M3@N>$D7*Y'F2)V%A2#_'(X+#\5?#][!/0@_[A6/8A_#H9QX'LJ",XLKE/FSL M?N'NZGH.H[/7KNI&4!\(-X$U^ #C.(GM_,!$F?U:\?P9&,H/?]"LE,^WZ%Y2 MB_%NFU!^V@>"S,G5 BLA%457EJC\QEF*H=O+<+3+0A/>21!Y>J)">C0"-%-@:M+<]XW8X'-B@ \<4#%H2C3Z M432P2TP'B!%U5W79KSGT@D?!YF39>Z?DL^; 23-92=RXR[RA;VM"-J&$+.49 M2/Y6G=%#J)IJ8TUL^@;/8I0*)O2$3TID^_5LW!)=4R?^D?[4DL,#;A ^K_T_ M_^N;TY.OGZ=7>4.-E6]1RN0C9FHW9*#-U["[V&.55Q+Y+4C%T^J1O4,P.[VF MR8; M_9U@?G7L"N#O523)$(JK?+Z%LW,=I=S9VB'.7/LGU*TH:NQ#+1@$PSBK^IH3 ML;Q@&0+3,CM?7EZS7LC#'*I,<0U 5%4*G^'(H4.\#]>.A='P@,/K17O/L*TV MFKZHP]G$W ;\)FT+N$I5NP,TS>&*@.W2Y()9P:& 15:@MN>UHU,DF#BFL>:, M#IYW4MJ=9+ J=PD" BU-,)?YO9@^;.<@FL4(,A(\V!OPW"485QRD!!.GR7O$ M(/%#^PKV"4.>?>OV:XCHM!@K(_%)!FM(6(LHV \9!RQU5+B^BY@008R>)>7I MXEX7Q#@V*Y!V"[SGS^"[D?<\DT8MG!%%V;RT"Z UMWY_0>JU( M[+X+-VI2\?L'_3R=@:]TV8"'NL#H6]W\$6]7Y^XD#]FXN0-W9I&^1*RZJT!& M_PR7_JSOP)'P2*PF??GS&2E8O+[G;_[ZZL7CDV?4[0>O[<\7K!$(@<6PS9L> MI\]Y>_X.$]P="NB$!8C (-AZQ<_A2*78":+IO>K&CV@(*0QAT'L([-8-B^(: M;% :$FM$Y!30'(2@JO41Z$#"?Q.Z 8>:\,NNZO>. M/J5#6QKSIY/0G2Z[QIR,@B M-9G;'=**@>O]%0,17I([;8R=#!S8SQ5A,R\Z@N/>HX5_+S?I\Y(+&,W#J[+* MF;9Z;N"D8#K;.C46!.PYEFE!88=V?K<83.&QF<)1^J8"C=T4 M9?HD2T^/3X\SAFF+ I!]I="@SE8E]>OZLO@EO5@C,OB\;L 2I=!>\H*W IX& M+WJDK_P" 7/T6YI?%:?C5[6X#JV@(6$!_&!G6ZD"&2GM.TJC<[[W-H!6$\0[ MG"98H(YZK,O?._D2 MEH!)[KHCC4%H<"X$1[ACE\!ZH&Q%@H759Q-P(:$*0%(CN9'P( MO'21-PO3R-C) D([12M$NOFRJ-(A\GTX, 5B@9Q ;3Z.Q2*K@02%OYDD MAW VN&;T_@!,A>7[=_S+&@&0"Q8SU"ETR2VS: U%->TJT6'F.#3B\O; C?D* M1OW"8;T&80RR@311&T+3ID"(#(:Q#/,]W"CZ8T$(T3^"BD58QR0R/G(VKY:) M*\@5D]"G];]0_XC:6J2C_IGIP9,R9+*'65P\0J$AV]& M]4UNQ/@(R@B)6GR5.5SQZWR;[6F=Z*'X4C!I@/AXNSP_GBE*P>1XA:%I7WW" M0=.ZHJ@>-;8;Z8N'+Y>W<3LC+;+:]\JE+^CUW@!#EJ0G7C($E%[K[?.S09B[ M#Z7>5.M 4:&7L@ Y"$@&3SF*)Y(_ PPQ#RB==8@,W;RKONN1;8) MJ12*<@?J@6)*6(P[\FW!XFK[-2,[]>2.>:M\&LF\VS<9.:<)^>U.^'+DA,[R MMHBJMM7I%VA(NQ-&4OB'U';BI<2874O&-F$F?@&#N^I6;5BF!0$/E^SVMRU: MQT+>0[5X%0;$R)_)N7(IIWH>ZS/(*#:-DWW!T)\2;%!D?^9<)7$%F"37M.-Z M<4 QPF5Q4 XY(Q(;>F#";7V!KA\MSML?SC*N/9ZY\))4J+'P%!1+98# B*01 M&KAN%)<)(;SADH9CVG 1,);5NS7<$EK!,"8PX LX_QQ0QM?R=L'H_*[DY;I& M%&MYC86YXG:TD2+H9U)4-/G=F6N1 MB"YON:7[NN=I@\C\S<,:7% /FKSO\/KO_FX&WU') 4P:9(17UT+"F4J7KZ3Y M\:8F3"K&.Z52H!W%^S!51=DZSI+C!0/S6G##B J%HX1V)AU#_:^,T"7^$E%) MSN/WQ?P]!@6SHNK I4Y_)D);+1714_0V375 MZB0!*0M_)?QLOH!'%53CCC=MUH.0D_S5HJ"/5I2(J)=%%Z6UP Y%UVUBO[QO MUN.1NT5(CDO+@O'KKE9471$S7:^V;0%6%!XUY!2,SN.LJ?-%:?71\.Y\S+'W M0\@45,+L>Y*2I7HCMT _-SG#"_L7N; D"?K.TQ?KM]+OZ-J>T[5-SU <\,U: MDRF*"7E--WD=4EL+.5I='JX191[>(>DA1RV7,V,DA/[),='C+MD)BRU;[F"% M3%BO#;R>.Y)RN8-9OP3L C*"=/8D?5!&II<>(\U/@6_:/Q7D;CLXNG!RFZ)% ME(Y66?NY8=:IWV%S1H_7;CZ_.DOXO710Y'@^$&?J#8..J\[BL)<>RW$1&ZE+RQ_!S]NN=+.2F$M DO^C+](.*?K4 MQ\\O<\0/1W4.-1-_$$<^-=+PRG&#A>G$/I.IZD/*6YH'UVI$Z' TV=)R^Y]#R MJTKQ)6^1>TF"(BB'SYAG3/]T-J>^&B?/GGU%3L7WK]Z>G<7JJ0T*,>@F3ZA# MXMO]XN9]IWY33NUCU@RJBL!-%9$Y@GKO"/J MK^DZ/?SK-$GH!S_/0SM2AR.A6:*R8&Q]=9E@P+RX#IG GP)Q$Q44@OU:KX7- M\5RA7_([D=ZGQ\?/1'K_]/+\>P\Y+(C'9L/L@($;4.7T2 )1'))@*+?YOZ;":VA6CYU>9[!)*#%Z[JGJBQB,\0*_):'B -Q*=2/'Q).SA2A;W& MY5P6&.,87UBU6(887)PA,=5(HI5@"=21:N96>;FD^!H[@#)+)G@,0/9,V>_#S/+0C=3C:3/V-MYKC M3]]RZ*9-+WI,LA!UDGS)^:HH%XVK/#Q^UU]BCT3$OS:")(+;C:C* MKE:RQ+RJ2*[30.#/YS]<#!@E/4695I_@FT^/GV]TU5 7<>(']<925N8**_3H MJR?/.2&# 2N#JQ!UC74V2Z;VJ'DUI&?7HIYWU)B#% ZW=ML@<*-K^+\V]0(4 M+?T'NW6KHJDW" (*;7M=N1M=1UK*^QM=>J8.XL9!9N.PKS$330X;A7KB02'\I"^<@F MF%9AI7Q(51KYKHG,KT,:6KP V@E%MEMH"8E>M" 3X;*H*BER..LO$0]Z@D0U M)T]H*78.-76N(6X$GE4KLV$SAVV^9\?_ 4<:;A)<>/A_>"E!O7&Q4SCOF+EK M"+K/N_"HN/IBP)XX))'$)].2(31YTX/Q-L>$I[\5UV[6%IU[KHLQJ82'KQ(F M*^-C?_DP5W_D]/Q>;8>\RD&](X4:CG 7[S4.\5.(@7[?P&[YU\,DG87LY=2B MF)RWDH'EGI6)A>$0KB?/X1[;@1Z+?-F"6)0#A@)CD\5ZUC:4.&BZN,:%E^CP'W-HN\B$J7M MFJTW@) SN\)$IOC OD3BLB^P'7CE G4[TOE>(7G0X&M:5[CNR\N\"]&-W82: M-W>HTR-J\0;YO;PU1 1E.!"+18D#OS[R\*O6:D==B_4Q8K6I4><'%W"IN[9: M;)^-0U@#2C9B!R-"YD6!0Y+N$SOSHJ'0W'@I!Q&(-$*-PY!&XAZ(3!(3-&(_ MPY@*UYKQK4'V:$3^--2- _[ TT K*Q2-T7BH0I$FNNR0#ZWAWGL;;+&WD5,@ MZ81NU;=R:.8/+B8GC;IDXOIR8. Z"B>-W M7ZKQDD4@%BHZL@18AT6E:GOJ-K@YA9-:4ZO]C1-^&Y*>FP2@R>,L84="1<5' MZ2OB$=W4;5M0I2R.+3)T3!FACD/B$+OSH!@#64]*'F8'O=L(NV7P+Q4DA1$3 M0*FEZ1AC[8:B$A]GN64M?*6A)>AKD*RPKRC*,D,C*KTJ:OY!W-.XE8=*'U=^ M8[14XP4,:J;V[9[:#MMU@C+P61)EY0>E66/0L?$2&2WWXFX&&6: FJ*M!=#E M?H$?4R:#J0RT$8J:%&%JRY#U:U*,MK'?:MF3F0!$O)R'LF/4R*E V MQYD=&QC>=N1PZ$G0RC[BM;3G(3'%?V%@?G/;6W=W'/T=,0=PIYA011MJ:*W.>HF9_I;2R$JPD)=(PR6VC5LA@3ERHMYAMCQA=*:Y>M&)XZ7WCT%TL]F]'V33,;9BZ#CSQ>E*I? MNP;;;(U=#6L4B6M.S":BP/:# *+>61X[8?^*CNE'=?0S\?7 M[Z_*E+)(*B@EUQ]AXA(*8 MF].HGP^932F3>BO6"FHQX*JB+@J8K6@97&T.5 MJ9U(76C-JD92HI2&ZZZ1$HH8F;'(J^?T$B]$,'H[4TQ+ID @<8EK;UFV&$X( ML!#7CGMU:O-.C^C8[19&?_&C3>!WY>(:Z2N07B;?%%C3[!MU$:-];DE<*6FU MP6YU?J<]'H?_9-83Z0EP*>:,:P\6,QFMQ7O'J\ST]TE?:6!'*;S166V=8SN8 MK&CM9S9Z=,6@\$/4GA1":\X1(4?46UY2B%Z$L,16?JB9KTPXIODQ7J5#2YT8JIO !!/>I0.T?";],/@'\TF(NX[16W7B@ ?& <\TO+Z0T.J)A M)^]ZZKW,5Q$<8Y#J18ND;JVCMWL.JM&E#UK%(A@1Y=*QE-A= F9,_/Y5AJO$ MYD@BX,Z]P$[V'40-C<-$!Q.,T)9D%F@P8 P-ZE<4:7J4K08M^^"*,X?FX*F> MV8:DI,_;D4+1@!<%(!!H*BT:P./8= (U=942T5I89P++#@LTCB4=X$@Y%,16 MR^[,CGB3 TYJ9P)$OC&&CZVS9*SZ79K*"DN8H&4C=RTTGMF!N.*D>&U:[I 5 M&G<2>5Y4WIO%$.Y] !RC_,]/5'% )(X*/&(+-EF MSMG)BEO)"LZ%KCZ.!7NS=TT-;\3Y4-]Z6)Q6K IZ<\R3/\+(Z%=NY"(M);CG M%^O:[0"5DS&@,C?<<[_D*!3HM7BM:#R4/9SDN/"8E<<'J97>=-Y(# M+3<<3/+L5L0'ZLA(8/NL;P>T,0D:O?XI8D/MS,ULBQ1@PCE"7Y=78\9\MK"_ M:)_XU#(?79%/:-0'NN68/BYAV\F\A@:"7T2_GL%YD5$H[*L+A\U7J;\LMTU3 M]T:MVB$I3NCD'?PV4#U%#09IDL/9[7C_1AKMRG3>&BEZH0MTX3=?% =IR.^_ MOY ^%793V,_0+Z1O<'>XU\TY!N>2=\7EJI.0^VY'81^X1:GBA8"9#8^2SJ!M MI1X9K):.4 .=9K,P!IKLD%_"D=E@3S!_+6]2Y\3?">=?NW($4BB["1HS9]L1 M4VES) CC@"C+93BA+Z0_&=B>!DS7?$S-670 M-,*+[>J1?TT '7,8/8<8:!X/B<"E.%3(D)OHT3(N)J+BD\MSM (=6.Y@<8C,8DPM@R];562H<(JY=%WS2<=D)"#\ N/ ;T,<^+5! M?7@E#]J;_%;6NZ3! E:%P+E%2\S48"+(2G H5M4C6.>^IVPB*)9!*8A7Q$QU MXQWEX0*S74WITXS;2;#I/IHWU8!%2-QL,^'*-JWKQF+N']=TSH84T(%$PYO M*60Y_U&J?I2SA]!(64!ZA 2L]YJ>: )&[^ M'-ZJKWE.OB[O&JT'G!@I^F7/>M>:2WR&YGG$!._# [*X*3<\Q@.*C8T[I!_" M5H;X;!^;PGWD3Q$&4S>2'3(?\]YX,+9^A,>4^P#&P?_G/E2?ZV657 3.!ZPG M6"X.BQ@ RW.INOI[7W'U.+RN<,O?F4EUP,+\!Y!$23CH<8,",!Y6^ZG1^WH :^6QCFK%E$('B]+=)$'P:)KY)%409-;+_]4$DL9L";:O% M1Z!!*/:6^-@;N1C8U0'<^"^/.5K3=C;4G+XHI#@!>\'79;^>%3ZPXJ^)TT"F MN=XRB\?+1QGRC@C%.64\5,[# WN4_LTIP$Q&XR,ZY38* MW,IQ]$E0$YGR#P_REXL_T+W.L6EW8>7K6!Z5]V%PN(_2"_1:;4LY#8 ML*@(S=0/(WA) "C%5Y9O1(G[U=7[LK"10AU#>ZKVEEPR1=-SG__5Q4K4D."3 M8\P$*7^2^:]=[F2UY)RX?ST#:VZ?=37C)$&X@%5B;S>APM#2UZ)MI'C M0X!'B1!CD3A])^"P-!K3"]!1'R_[KG8XDM,F'',\,MV_OK&$JCH MB2IA\U9MH]!PM+IF!^C(W+[2B5UI-L9UH6V; M[+;7= T-5$ZM";OK(?5SL*=5T1J:+PU8<0[DG M[<;I=$F9ABKX?<$#?YUV /FX#A(!1K-!/*>:!\1?9B,<=,LQ( /FDXK%9=G_DNT#X'$"0&9JO-:XE.46 M=""UPUMSHUR%#L"2>E,T\8K*P!@E,2=Q^K&R90^E' +N&LQ@!J$G[8:7?4F5 M'6V=<;)_ ,E+0BG#8PXS+02_31 .\?/5./59?8&GV\$/JAYN07A/ O90!*S( M.K)-7;JM^U"Z%I?Q-UVEC8YV8V<<'^0.V)KZ;>(4N53>9\IKY/]"$#@'UZ#> M.N?_J-[B$#<^!@J_(03(-I*4K,'(? *3D2]H/+%P0+62D*W"IM^^Y+G>(N^" MRPEKQEE8>M+$80J?.Z,=;?.!PUXEWH.W))>XH M!+^%-LO,D+BD2+*/3\D.!?UK[.1Q,R!Y/ C*H>;=L"EYO7PLD[%C:7?&>V(J M6NMKWU/N<:3]M4-O'R.;H3/L*/^K=N,%"=W:NQ!8>AM&) 1K7V@T;?Q;._#^/-D3?KDM^D(V M5--OU)+-C/.KQ7"$[-Q3,9U)& G?B:&SX!9KB,F'U?"^P<[F7# >?%@KB_QD M:WH@P=+(M".<7$;Q*O8O. &W-+U5PQIGB4E)(-N*XFLGV^A#L1E?3]B,N\5F M?#UA,R9LQD%K8 -&]*4VY,]+$'6II63HL_5&N)U@9?%D493?+(^R$2D823AME)W(V^(N"XXS:)0_#-D!/C MMO!?8GTZVTSDAOCGCL471P?CHG_E;;DY$9+([> O[+0W#S4=5 0^K+4,%\6? MH=^\WE+;F$[>U,=Z4ZNB= FE;J02Y])55&L9SE3A:QVI(@Q.#IS*[8S0V<-/ M3"S(?YB9^+T$#T@8A2HY_"$%>V8N2I[N3YN:+"LR)S-BRNW+I@YKRUB[9(KB M8N =:2P/O8' M;RNQT,5F-T*EV;<0Q0IQKMUU'N9J CTSRHDYTHMS*8YKF&447:BRE HN'^;& MW43[CET\ O(U#/,OX71[(M10;L[C0?YR!V*1>F3[-X^=,N9?HC!54:E6U<+Q M\ .O01]91E.W+OHU:B=JO^=A#A0L+'30/%"0[STLM*3OY_7C\&R;C?@B,]&^ M)*]NJSO?+0F+ZWE\^,Q#4T8NU(W[E>S9+_]D)7,-<4X0F%MS75O-44ONC/;L M?B3X)*Q_+6T2<^2-FEUJ<^[)9_ET-":R6$\&5PYO:/-DU+1R16<#&N/0<2'#"N;,(.4RS[DS:+,4 M\2L%3"6N2: ='-2C<5*77Y;F,[0$9/*MY5X:,/]1V2DX0KS(;*TK$42'I@8J MG8C+)_FU7#[IAW#Y6'YSKCL//R/+,;K=SQ,3?95TF<@@T>CA8V&-SKV MC=4UH]7DQ(_9+:I$)[MJ1:LI^Y/@_CPWGI6W>)^+BUT3;YIQMT(!B(:96>;" M7O3B@XZ)R/0F$9G$!YJ,GHA"G,R]G;Q+1'Q^KVP'69SO"]!9BG8@E2GXQ0NNN+@P] MXI$[NCS*#+--\C&4.1]-D/-!_0GQ;B41TPTQ$7RANL2"SRV$6J([_*5;)B[5 M6COKJBA\HR03NU 7(M._5$J#[^01/S78=^"\7FOV&B;R1;;#\7>#WE(=Y3DQ MA^@OP^HW6A @^"(E!AXP$HMRL']9[A+-[CI#J#/JF6'IB?*IDO>WK-+&NT,] ME#>4PH>[U/52$(*_">7P_.Q8/](>?Q&H12PW!^]B$GG@$1B-.WHQ>X77 -9Q MCZGZ<'N/TA=N(P4(M?"%Y*KC!\T/3&0Z&6'4-7PX7OP#E(=53!> _ L!)_9%-$D!AH>>;/.%!*-4$$G MK>ZH[]Z>%XGV3>P3T'V0LXGG<1.LZ)L)5G2WL*)O)EC10<"*)M'S MB3D%G&U&]]&\O\%M0Q(R[K#L=CRSF]O2)6-MZ0ATP]U5N"9*^M$]WFE(I]Z' M BUJCOBNBAE74DARD3C,/J"'7>)[V$4,G[@PY[!/\%E5Y.FYAB.48]+S!Y]\ MDS["+PM:^?S\[9EBDS/O7+/Y5.O88.I_SJL>P;BGQZ?'!(Z6@&Y+A8 1OH6) MW(2^0;D)K2"PQADDZ@T&NSND@KV):H(BTSXQHM!V\)O! MT(\)]B15($R0>]ZKE+EFDKH;1"3-QFD()RQ]R=^6$=54"DNGY MVW=PI:\I/37G<<#.Z *"C^6J2WA4A63"MBB2!TBH+C<'E/B/W:[\#*';16.9%\K-W8&<-4Y.[: "X7S-<=BN/;$_K$=.)5% MV_:F'=Z5VZ%&&]R[X%3K#5Q$>G&T=,6XST?I&68)$.2%YST09+:>"@*%))P* M\*E!@^]AC)S:O8CARG>0B]PAFN^">)U T+9]_YWV7IHY<_?X&F[U?_ M_M77SWRAWI]>O'VGIN^H:/D!AGSZ949&I:%*?I"7^SN M042&PVX.&N;%(<-*V-:8,I'!-6&[F<@?R!H7$8JY-?OFL.3=3K^U@9TN6S52 M,R\F#B?SV*D3\D*J.CXR&R&X;^WKG-WO6D^^HRV8YAA4J27V+G M]+WM?5>U?GG/?8XID,S %=U#_&QM)R1+V".M54]*;,>":DH)L;V[B(.7"7/: M""PZ4/W%JR2[30R=U$G"\X$/[+%$^PE+B=!H1RNP*NN"&^OLF-+4OJA[Q7=A[EIM)J% M:3ZCX3!'O>-Z)WV_D9>4L,)<'X4LU#=.AKZQ9P:SB#[O'"F'@29#RGIQ*=8C M9N1;1$ES1HO'= M6?AC/A1LI7(?'-])C.HGX<\OP#\DG_,)>VO'?/I>_LP'T.-"?/DCDS[MSB%] M)'W+?OX+_?0+Z83#_P5.'M[)LJXNO34 'Z&%F!@+$3U*BH=Z2G -P*C4@O-> M7\9FMHZ5PJ/P4#!2CV!P"]?8\63&DB+R&>VE1A-*Y)O4QVA,UVK VK+H$ 8+ M ]-B=F #10&/:J>Q>L0@A/=H::,P0(NNQ39B(!^:1/O+#"P^74LZ+B?/V<$= M4'?QPJ$K\8C2R"!N$73Z!9?=8)"OY,9.8F0P/:VNE2XE1I/SEHRYC-P$91Y5 M7WW@:ML0,N-SZ?$A"FR4&2N5DZ^>/#_Y^NA+4#QE*7@/UB<";U?=<92\(N?_ ME ^FH0N1HSXXAIX CYV#62Y!CQUOA/C7BLL"-9=%.'Z+BT]F1-M#ZF7H1H9XPK[R*?EWQHGB#+Z#[;*%Y9-%$YDYB^E>0,71-*4.*\)AX2[$G M,B4%9\/>FI25P*1LB0A'D\E:.X3_%JUPD 2".F8U)EC]6./&81PL;R-C=6:[ M$Z14]=!0XO!\S[-P0CF&1&JJUZ"5A?TB*EKJ%9/H>D@?V2@7WI)=LJBYIXER MQGX4+X?&-=M-0;GNNO4]S3*?MDURSFWH'NV&E4?ZHT35]N,XS[%Z-QRF]T)L M[G7 3'P]4CI-.%9;H)9+D(1!Z3?4S1( 9$C(&,9A0]+&8%9Z;>*#E>,7^&\4 M=S^,;@>C4$-//D!.$PAKJ2%U1=I2!9H$/0W+#@9)8),;ZRK+GC:%BOY?+37%/"LJ#U_8(!ZR$XSC;;2K63)X';#F-88 MP(MF@[6"'-*+ M&H6&([&;\#1HW%MR$4-528D I9UT$G=Z-/[=6)0MUA:LEP:GXR6U/X MQO1I>L!'^FN01,*@VU@O2^8P,#W)]24NI3R)9O;"ZPXJC?">\@5O,0/'QS4 !)%T[H:+)\J3$-GOL.R;WYTTW1(FX6> M#I2?-V=$]XGX^"3Y@.NY?SFYRS22,QD'S0+*J[QI*&=#Z#)>1964/-!D9*"Z MUZTNP:"5FV2,]\V32@YA23(OQK3!7*]Y2C/$8 J8_E!"S"VOIWIB#.-ZR*X7 M9G7OU^OMGK-[RQ(..VTH/]?"S<7^R;WZ =%=-_:"55=,5QT8K,V*T^=X2;W> M"3LP/%NXVQP9P%Y8"P)7SI/C"T\2#GLSFE9R.X(K"BU5VR!F\"X1 M7A2_GD@P+N;HXVB[H29P72Q]V9^@GG]C/VF[>I/:F5.VF!]$ M4DF?8UD7#&@%91VLA;0A@X!BV<-GR.%4:+76?FF;B0VF/1]$!LO1"XVY$PK%,JZ';^0B-/$6!Y>N#3$P M=89[R6,L0I,$N33P#7UMX)'\Z<:NE8F&.F<1.:X$69O!/DW!%6/[Y#Q M(4C>>=R@=I -E26=;0 2A%=>W&--V5!JI5TU[^3?H4/N#<>;X-GS&T2W.]ND/+!$R>8KVL]I0_CRXF*2R(Y9!FUI@.RL!+E6C')9;H^.Z12 M5Z2^;_3H-CI;%W%MO=$YJ MX1X&?58AIUA]HVRBR(#@ \ %]'ZS=(_L>Q0B0- C#%A7%4 /E MC[I\H02O7 M;U67"ZVUSSE.(^W9)F M-J8I0*K:YN1Y%4DCE)_^]3,V1\$&E;1^O96"A.!(SIQJ>Z1'QC?6-II^ J'3&(H M\_G $_@E>CQA$G,$J7CV]2S0Y7M==P\79$;Y\),?-?Y5GY'/\(9^-UF M<(8/0[V*N,)T* 33N\'M9!A\W6/]^E2D1R#8V#?G'[%&>^\]#>Q@C"[C MA9?53G9N8;ZN,>7LB[*B;O:A!=W^RWJ4GG$/@S;.$'FW+"Y:ARDG^0*Y@ZQL MJ2/)HP5EDH82@/.,:%B<;P%M4E]\DNB<""V!M@2AAI@EUZI)&3S/(4'@4=^2 M4WK&_;/0IXQ;91&&=V?\[#5Y9KAR&[(-NS6[C7'WPBJ'N2=VZI%_)!3B9<_D M[SPRXQ"3?]L&7B![)'P8 :[-E=3Q89TE.4?*7QQ8F@E-K[6/NY*:N95N52([ M2L">:RGQ#\P=&,0>RGD- NQV .7K;U#A_G(T4?9^!.=F6'3"V =83;CW-75; MH8DDMZ2G9)0P9)W,;G_(W8Y0!."WMF*@!WN_*$WKX@QX#:+\. M"1MRA]_PEL"5PX/[K>SFE*VXYZP;7]5ASLVH.PD%ANHG;4H9]\8:1NHT!F- M)7\CB#1)W:07<-(QEH?'%JW=2Y?X3%A()=%$6L_@1'C ? Y#%1@41A Q@4?- MOG;;+U KV"63HG*!("$)\U86"M7UWW0,;3UHI!*6'2E17-/49%]F&!TL6LK2 M4?,#@5C2<*@<'10[4^Q+A1Y:MIFX#&&0U[Z)F>Y>C9108!!@"AY#CA_,'#I: M0K?W] Q(77 N'!^OE\O'93YS);)C)L/HJG0%&FP\UY#M>==(FC&3JKQFF"[: MZ5L=J"@'0QEM-=S0*:0]$/EF$6?$7A6ZF$9X-^$I"UB!W1 ] 2,3!$;&ZU[< M/B[<8HZ)DR'FNQ6+>,ZU\SPF@Q=^)S6$O@H0Y,,WQ>,1:V;\Y9MZ"[(G?.EO(:RH^H#-76 MK/(YL24*H_U@[S?B%K64/Z5DQ><4A/O$L3;N6.20+MNP=@MM*"-*Q5N-1!,61*5'^_S6O>!"CBZ% ,+.MO/;JBV&:+3;3?, M(;0SA^06,E,MA-%J"W\GQGU^=0OV.PS*/>W_T&$WSSH4LOD/M(E/W?BN09[_ M-[ZJOL,MU8*7N5@KOAOTGEN<#1Y#HZ"7#SB=Q;(TA3L2YD*S\KK>]W8?)Z/$ M>N/00B8./BJ^FDO%BW&)_5B3W;-F#6Z,5U8;\+.*.2?%*#+"7."BP%AG$_4K M O4QQ((0*C2LX63A#SW:4!L\7;'1Z)9BX5/4)D'R_FLW6N7*A4ET_!E>\_=^ M<;E6Y#+E&9E9K'6(!_%$6[(L3&%8<11*/44NETD-I:?G?" \)$(*]@R'(H$S M6+\!&,[8:L>C$,MO8#8103\'B-=$_4N. M!H;SQ4V32+ ,H(LI MVO9."+M&5(3B80P4!E(5-I'L\$KSA3;[&7&R@LNH'41>=6Z=/H%;2>\RE5U' M0JY\8*KOHS$4)Q.&XFXQ%"<3AF+"4!R"Z #O2>CH$XSCI]^!Y*V;*3A_K\%Y M+.??-,7C?!N4*@X!=3OF71!R@YNWJPX2$J$W[I_ M$K6*FJKFS.V]Y)N7>3*[0%4[<]O:]H^NRZ,$H]OZFU!LRVCX$ 6_8:1(/J:G M*J-PJ&G80>YFIYV.VG3-WJF2&X-=)J84"HU$A(883^@I>3O3E:UC7CS](7/C M4Q^Z/Q[8"1@[MD'96N4Z5+X?/;%(08(*--KVPQ\RHI?_(/HTJ.*/'M/QT9=% M=8?+"F; )QCCZ288^1(+RN0X4F+3M=ONGYWS5VXA03#JP)D?VF"/46",0HIK6Q9Q_(B'P-DY'$/D?0STPZ=<>=W2-L MP@C* :R@IM%$R>&^OF(J1C%JPOF#$'F6(K1SE=NT9=NDB>3/)GDR9W($[KT%1-5 M9C1*5S5U6:Z%N];"N%!&#.ZV_'GW(C-H2B"IPU]YKC\2&-/MGF[W=+OOYG8S MLQ2-SU>Z!2\ LM66QK9P9;YE;>D[*/CKJ;UJYJ[ M,H[1;U!-(.)N!);3N*L"1C'CZK?O7IP%G+)R;FB3A)" 8X?"]*13K'.95PB. M&:CO22Y,>2"HKZ1<'E)AU1:8E7'8D1DUWW/5DL MT2C6=J-E3B*#!,Q80EXS#O/2Y5R5N\]SGV3")!,FF7"W$;^JJGOQU+G\B&-V MRL>E=4WQ]^!6YPU=>4S52Z3.5:MF>V.["G?L;N@[5U9=]L< K M/MW-Z6Y.=_,^8FO,)K,I.KB8H"K[.5/DH*F,5$5$55D6\VW462YN$2G1<4-] M-[ [>T/,-N1X*_XG]8VZ@CQ8N!GSE" 78;4]7>KK2TY6^)VT,%K.-9V6>!7]5 M; BZ5I;YK/88VK_7!3C1J+W1^\[H@@_O<^;-?;2[BTZB:3[?)LH?['!,L7,, M;Q"RFT3 ) (F$7 ?WODEL\&D;EY7];J89^2-T^8+C2+Q2G@*,]_'N?9L7OI7 MWWQ#\:Z6#VVZT=.-GF[T?=QHI4>V=U;Q,AOZS^DN3G=QNHOW<1>O\E(K4#%D M+4 S;M\K4!7D=MXPA:K^>;J?T_V<[N<=."T+] M[!?>[EVF[YVI\ISNX70/IWMX-_>P:#=]9VYA:,@2-:(;$G8:>6^Q8P:8R7WIR%JFN@@VA;'$8CZO M^XJ2PQN\L(52+G#:9[&M8#SSZ>).%W>ZN'=4$4%]AG!TDF/%SCO*,[Z6K VG M:;0_E.GX5S/5^.CUE!8-!TK:_> '_:I*HAZ0AM&=*]L(S>H;44J O_;_QEBB ML;'LMS+I@)0J83T]-63^B#P+AH5<%VV2IV7=2I-[K&/A'E[2#H@[CF+W<);Q M^ZCFI1F1P_)8KHSC!IC8W64.^)*7R,L4/ E")]!^\B;NPV=3MV&]!=WTVWH=.HV-'4; M.@31P>UNSL G>-SE[QT&PQ/J4-U:4E9P-Y")-5W4\YYK,U&"_MSE*Y3$JDV* M%GM84_\Z*@(GO;9IR- !<^7G=; 1VZ&G[^ MJH:+\.T639,/F(->![EAP?A(ZR9<$%S%7N#7MAQ*.-71=^*ND-4_G$'8&FYC^_W^8_]R!4#R<0 M()Q%_W1<'[T*M9-X&Z67UZS,*W#65F[^7EMY@0!9NH881KEI6&B&/>-GP$=2 M0#FK\V:!C_/M@H:MSO+4:WU*"G2=6V\>+JOA0SSD#W-4]VW 3 ?E(6S)X8@_ M,@T7*OQ A%WEK4*8>D'6RV6!H31LYKY!4XW'MN7(%9'6P^,X8!9 M]FNBA\9B'?]8PAIA_)8C7&# E:49V"P,A*)_MMR=-VZZ70<^JDD,/[@M^;U* MW*IF2"5ZQ$2EWZ\I-WRESO+#;4+W^1^C2=Y\M@=E,OO,6"E&1Z.[7M72'QML M(N0 QKPBNP_^:2 M14T;A3$:V-=R2T#VBH!,&\K',9FACS!->>3?+H\L>\4TL+I#\[Q=W;)-Z5EH MS138*?.MH!+@KQASDWXQ^:RMR[YSE(IM'&4V!4- @CN)4B-<' C6Z,)M\*F8 M\,WWI%-'(6\@,NKF/I7_CSEBXK0QXRE%IC6IH$005E8,6WL(QLZO*C)^$4]J+-^ MD!?4BU2&>T@VLEV#K^8:*<:E<\[(',[MR<,>D'L> MB[D /%#K_+U+=A"L);5M[1C >>6X;HGQL.TDS.\?%!2T[D><%[2G0.8Q# =/ MSD6@#'[YB]AD9VRZG3Q[\O0HO=A_6/BPRJ$2HQT)'>"L+0N'[4+AX716B,:L M:DD&F4.JXJAH,$/#PAZ/--F1<_#ZL!&H5,HX3#VU\1DWI6^)?]+%R_/P--.O M>%2S4*;*$7#)"3[)S*6[KM.MRQN6WO OB"$0$4]E%/I'">I/,< MN>4ZM'L7H$*\?>NO#6L_>.!B%S ^O&XS)ZCMI>C#LF#L@J6>@L]AT==,:7.4 MO%JF;;UVYH4?]BY#-4WX]L9IAB^7[XH($+"@@>7O/!OV,QDBS>5AZ[K!4#C& MQ$MW'VI&_@AKX/"A=PWD.0QQXE4/W!5N( 3G&NP9LHF0BG1 /,[7)4\W/=R^ MN4J8U/0:5UP=VYHMEP%0XM4^O(-AT66+GI/@_\O1AFMXV>3K2;OSD=)CV+Z6[Q%*9H@)9G%,IC*EV##6.9'RW+@(3Z,%J:Q"D*%2I-=W@ M)'B-0[(TN)8LS4P+:VI3#:=FRX^!HU9>X5ND,C.49#(K/AS !9C7HFM %;2F M00V+9#GM18670O2.L@(RF\*ZJ*B8A>2@3M$#JL&@!NUE[H+TVVGYU-,CN@YC M(=BG"TUT..O$#V@[;G*EM_;9+OZ9P6WK67'9\Z]-49-6OF;V M,;:%X)KZE\&_T8.A8X7K,0D8VB,>7T.L)K=*D M(*6DK[J_ DEH>6:=7/F%#/_:*T!K<\#=0>R+6O+*DL,%;0/!#!N\*B[Q],V5T^ #F5EZ](/1R+2YG:-3;Q'BQ1(7%"W1OE);U#>M MERXX5-D@XLH>02^C(F?)G-QQ79?I%J)Q-PLF\!J6BI:+7B>SBQ=E_I><2I?B!K*A,.4-IQ\KBO7/R0GWQZE/__X[N7%F]=_??DB MO?CI[+OOTO,W/_SP\L>?+B8KYWX&_6-=W8O'\9L6G3Z9BD[U%W=3=/ID*CK] MW16=@AC7F=RKJ%;5].5=JJ;SH_3\O[]]^>[BY?G/[U[]]-^3.KJWD&Y?8?ZZ MTXA^L4;G5ZN30N8<#%X,7L'[.:C9@MO9JL--_B8'Y,10;(KV_:ZC/=^BB1SRTOUC>%U3MY!'N3H@]EZG3G"^FO-(U9&8EP) M?0$U5+?F,,)J-(Q'O3M8!S+HEF3QPU7N.TT:!,.@ZL6 M&VHN QX<]H"A*S\OZU[/B?F E]E?&FSSR-=A3K,(18@T^05F7X[2[_H&_5]R M:/F$(R]H42_ V1V_(>"1NTYJEK&SC=3FY,2Q3VE\2CU'!U6GR;>%TQ>XQ[*\ ML&:^!#J:0#ION.M&1N&.#'SY1='S25@7%36QE4T8EV@'I@4.4G7]5"=R(SCZ M'RF>&Y1"7FFJC>2KQ/BP\)8N'6E1K+ E"3-S M97U-D1B2QAK9_,05]K_)N3CXLONXF/Z34 1.M>_[QOH#JPFAP9/T2'R/6JO3 MN>L@=1G-NUPO*0II'UGW>M>SP8ONC>Q&3D?<$Q3\?H@F#Y'"\D['+]?@(9]_ MU$;,M^#MBW;7C5!S;Y]9P3I-CKG:)FJQ9]89R#2?A\:Y:Z[0 B>51H.@_%53 MYPO,CJ*5M8$GN_353_!?5T535SB^ZIZ<]I LQB8J#5J_# MFRWXR5:2[0T1+2\XZ=XUX.A1IP>C.Z+LR]50QD=ZC .K<:/A*[6JA MB ^!P1!V^IB W72IITO]FU[JEW1O:'CKOH2GYXR ZI&UI].@75WM"12*63R9 ML=,Q_DV/\3DW7F8J%E9'Z695M%@! +H!;$ L6? @0=5*7FM0D MXKQI6!3O1B0"^I2]%6]\F:B=(FC1;MG4!#P&$8UM#2@S6% &F8+U^9[P^M0" MXS<8])N^2482>&6.>-@:#60P1MLA;IM.P;7S4.G]^4>,X,+KL2,LL>=0677_X=2;(>ZSB0OZ_%@0 _0L=<#BR MF8"0,?$'?T\HS*;@E9;HK&))/(KT]G32Z=*F 1^DXS MWXM\C8#J SLZ8V#! QCV@:WR69LH@(7+W^&66(\NP #H7+;][.^."->[3BIC MFHY8Q<' SBM&\C?NJH !4(QY>%NQ'&HW7)UCA0J5'BCP?0%#G6.Y1+'&.TYY M&NT!"'57ZA\#-"ML;C#'N06G@JI K5B77,,1J(755IA M" *K^'IX.E(O^*(9>(0MQ^I6V.A'B/';?H."=+ZBXMN&>,.X_H#A3,09T!5: MH*2&,F<*I?S%H)C"(&E&280$$NH(CP@QJ!\%?6&Y;]\B;HENUZ#ZXUK7<3> M2TS]><1ZT+J2#2)"<:%&:XF<4?!G-Z^H73"L=UH4<&JYALW2EQRE MW]?7:%YE>\84&KY$A71'L#1.B02X)ICPH,D@_:D U25XSD(A$M4]833HDKY/ MU$Y2,.6E!%8/]EB^2>*"R]*B1F/T=_1,,M,M-^'FN5)O%ZH @Z$6&/E-@H0J MIZ@N4"N(E0@!!BM3?84PNI.SH_0="J#ON%Y.O\9BMDW/N+;_'56DXGW_#H%L M)\>/_S)=SONA&TO.J"[P7,L U>3Z5NL+7X2."ZWZ2@5:_522.13U(VYTR+YE M0V64>:\C&8%1LETU@A00Q"I[X_UFPG1]N!'^3$?I6\%DTFB MZ) M60:7PW>0G()3CZXHH&1T\BFY+)@&#Z?\4"P;4<7 MRM@F9GD2+BEF:67-WZ P0] !+-*<2Q;1/A6R.*I>AC<:_>_[ S+!#4,O5)PJ M7A8\W37&5S[?> M3#/QMDS+^/&B#F%VJM0C$-VN&^#)+[@28,]$T^N\I;M.R@Y^LZX[N10@!GVN MM:L3(F\YQR K79M79G(7^LX?:'>:]-'YJXL?OLA28D; [['UW?.F">:^J<-X: N1[M@/(2$\J7N+U=1E4Q'JW1:Q/IR+6@RAB_?P$B9:T?G6'):VG8#V_ M>_/VY;N?7KV^QE34.=E:V+R4#3V)OJ0F8L:QM0UH^U\*C*2 _?/ET^SX^#AM M\;W@^"'S"Y@/)2C_AL!G9+WU"&3IN98.2?&H2,^3]*0H=Z2."&1!WFIL#HS' M@D*7Z>GQZ5?>4H'_^(:*$4/8R-E17CM^"L4]#3FK,--(_:=;,/) ^[:WSI%@ M9)K6R2+Y0$'R]1T*DB='Z>N7?SI[C>+D_.7+%Z]^_-,D3^YIT*\J8G#BC'>S ME8Q&:C(:F9) 8ZZ;LX7,&>3?A>:XI[DY"1H/I" MNOV2A,#;K&%*6U ,#W'<:X\XNJI*,:,B:D$#D#$=DPEQ@'6T$-ZC:Q]ZFG11W/8N5D4 MML8L/8K9!2TU @*:!3Y(@[*)=BX'1ZI6K/P85ZKG:*.IHJQK,$XEE&B!;Z^V MI*^4%UV65"E:;3T'MJ7+0_KR)$]%YR"O:]X6K2Z*3!D6AAE997%$YH85L-_B M*-0Z(_/6^$I+;+)3FVZB# MR3GH)G.5M/^O@/U1YK=LP,*9B&(2-59T5(U@2_U)AVX:0[X7IH7D[[0E^"B$ M#-G#;7%#1+ ^>H#Q5L+").04XB]\2!5U?^9;@OANFGYU6C-EA M?*+II&8Z!R;4)X3*/;'[GI>@G9*S>8 \782.*>D+AW%,*HBXZ(NNG6R:_8.^ M:_[H_RC^\T^N[!)#RDZ;E_+FI8]>%-R- J4".D=?<%YSVJT[]VBKY,]]Y=*3 M+S-T^8ZS%#]0RG"3_N2(J^8N.4H)^ M5\]!373>$1QNMG^#?I#(!_JV+,+YGAMB;L^EO[R1G;9&HV^5ETO\(L@"!_\B M>R/E-#NR\N-YQ*)F]UX2"XH-99RD1]"[2YC@55$KL!YI@YS(H)/C1S/F!3H] M?I1_H9;G+;T(HA5.7_MD@TZ?.&\9X(: !!F$V#WG]>,717Y9U7 TYL'TA:N, MO4^PT\O"+<&&(10>I5X[)H$E;"V,"U,],LYAY=?K^K+X!1LEP.:=O_GKJQ>/ M3YXE8J<;PQ>7]PSLK#)]%R(XJ8Y%,LE!0VH]9G M:^Q M:?;8,"S#_@(LN@V8&?D2@89"7RNM"I6^J M],\]6*7A-H3ARHFOP*9F]FB_(4?)&WQ0,U_! : ?GG ">$[''LQ0Y#J"7]#^ M@I'Z&K/2;_7)@OK0-?Q:GQ!_R]^XULT)O3P<1:*GZ.+L/%P?H&P^;P_&JK;N2Z M9@*G.I$W8&NC+@7GNJFO]4MS[)[N*KS'YA!323+-J28;>.%4J)F#C&G!EIB4 MT7T;[-S)$SOV,.TD')VJO7:-0B5TXF] 9"$]V\G7^GLZ*+KA?DXD[1 72U[\ M0'#I2/I+4!+IR3?TJ"=F&0G0RZ"L2_"L6 ;DG3P^TX=+$SO2SM@C7:XRZ M_+U?7%*VE9="T//R;RS#_86!K?)<8@=;U]66.?O 9Y;MY[O_]#EXA:&4WY%; MNG4=$P6VKN/$MSD>-L*J]T_:CV%J>HT5!9SY]JT"^->@AB[KINY;=*3#C5WS MH6>(GP0\*B)C8Y>ZE@0AM-'-MH&FZHWTFUD1'2PD)=%,O.QLZVZ>L>89F7/7RO MR3,U..&"1S9L+'ZSY%4U/\I8GL?M%#;%Y>5VEL_?MXKF'AB9&'[$L-T\ -%_ M6H4Q!\M!(D=&FR-25AMA$%B&@MEJ(AN5@$T!C<6LU@,_.RS'8&2D&T'C\SJ? MFF5F"^CFU4X^:+5_<.75MDK_4KJBDO%0^2S\2U?0VS@LFC]T2TC&(KQ3MG+? MM_SYYCIRQ(*R!.>4L>#'W U &I\-L5* M-#GI \X3DD;*J>M6"I+J%9Z6G8GBV;/1EK"#*)#$M-NF3TCUGQJ3NKW!IC:; M(2H1W2_$8R""%*WA13\O4'LO>LRH]A5>=# 58:%6MBJH@J6;<8"3YI2,F;XG M+S[05<.)^O//UIPZ&SLSJ-&9 -?ZE-V+4W8O\JJ'42>G;"(_50/-;*C?H9U3 M0A+DJB[[JLOAF&S5C):"$S06X":".5-\%E50AS#L UME4%T_8MD<2=2GP3GW ME4>8T?H$6NR'O(./KM._@;#,J8/6KM!,1H2FT6-44_9KU-,6(^^1?$O*P#=]S968T;Y7Z[._XD2(GTU#O2><6/_Q2;\V?,?:;O'+@, M53:N]8;+8:8I6ZJO-*Z[.&%1\&-45NB8-/)G6@4 M[T\9/XT42OAIP95XVIW(BO?T]*M8O.-2$,A/5D&*Z23$A6G%#7FT6"/;.M'! M[7SE%CTFWL!KI($CPB<9=7$7L$ E(@84P(/* $? 'C%UI(+__/(YP0(H,W?E M@L,KCBR'@FGH7TKD9*\KFZ K>V#B[R#=C0^'%'\Y08KO%E+\Y00IGB#%D[5Z MC]8J6Q;!'_[73%6JVA^F)0ONT( JW>!T$3<%?B7%UY)AHG(8>O-I4;"NON]S M> /UL/DP"_*C;=YDK\W;WF+SMC=%-L3&^U _/XG]? ^4VF=X[@[:AG=.3C7W M\8'QG;"Y"- ;;@ANQ%]R,(6V:)QVO<^!?=KH#FVT'6BR&]DYL#MWD"82UE&; M S^64#&Q1LQI2;CGYC.VZYW=EIA)IL3,9Y28Z7)LRY-H']N]Z*6+&KE#FRH2 M>OBJ_ZZ;]U-:YOZL!F/51PBDRF1C>= -4B%;S%I.+ M(WH\[&>4(WIR4P"QE6Q7.)>,5=%X*K7*HY,K5U]2)W1G/!++?]AR:-&O0KQ@ MR>F)XFCT%[HTT;AV@HT>CZ/8GM-C?= -<"AZ^7=NUE ,43-$"9\<7 P%[L N M$#T?E?FXJC!_BG.T&F ,&*+15\GHGNX MFR**_F0*9O@IA1(7 M3( W1!RR' M()A1FVW,UDHF$,Q!:VG$[==KV$X4>,:'3"=\_F]J[(XA2M*KH_3[_GU?&((6 M-5HG)DQ/5 M/S48= R'8"E\\L51.AG3]^=1J[425)ZWDD3.&C#$OG,2_F[-7?[KMT6-%099 M^KI;I(\P0LT=3$KXM1CI]$4UT1,U<1$; 4J"B]\#?M.#E'3D4N\HS,BL:_'O M;-RN.?2WE2I):XA(;OQ$Q\]+ +\IFN2,0;PX#3K3(,I07WG[6XUN-#K2JB?# MBU]8-T5ACA82T9"N,?!B^#UBZ,4KT"N/[:8<-QA%9B1GUGFD&B.AI=1Z4^Y0 MA51)V!**N1$HC3BP1T^/]RXS^%TP%TJ*_L#&"Z[,:Y=3@YOT#,V/]"S"4Y][ M4R0Y6V)O7G:/Z)#Z/C1VRR@TFEDS[63_OO,KG7_I[L,&!R"!YXX=TXC@^\83 MP ALZ;N=,TQ[[T%(;S@(R:\["*\J=C6L4>?$"]15*< ]IOPPNS3(&YB9+UTW M2-MG#+]$SE7K 5K8Q8).6;@K"Z?%HW2-:,:8;->:[X8@4Z'KMD^[@X4M51P^ MD?TDD@@BRQ)SIA0&_F=_O-OWOE3 >_GM$"R.)X)!^[N3U7-"&/VOG: OLE@0$V+:X#M7Z4 @E\:8#YA_GO MF4;R8=.HJQL'&<":ISI*>XUR%,;H&..IAN.9^S L>L"E'Q/*$IP,>HR-Z[8! M)<)A_GZ#9=L\^:B??&I*PC\(2M_>Z$8DDQOQN5BQ;^$F@/ZM0*11&R?)'YXM MKHH6RP7! +D#6_:KXV=BRR9QJ=EDR3XT2_:V Z)!8_V>CQKO* N2*"@]W8X] M2NR=%=:97=:$0Q.5CZ%0SX[M]>^JV+#DTW=F^%LDJ43C\II2S!7*ZAK^VX^? M&2B(W0*KYEHB_;U3&%.6 I*F2VC90%$@Q?5V"'X%!0:"-! M>%'Y=+I\SUPO3,H2Q8;0^N?ID^/'+^#@HY(5;1ZB:Y+5QZ%(BY7.%!5(GY9, MPMT@IO,>+B!J"1>9H;?M'0Y*:PC]#'OFNU:]FIP*>)$52E>LR8A<>W3O0?XT9O,.>XF+3!?;0KP0A[4KJ\85;8H1^XRA=BJ*(]I-D= M%MITNBA"[W]/^?XXKD_V EUN.MYX4KDCCW1S($.&JF\*<#]$V@E=OX>#1.:6G_QE7#6RG/X&-LLG2_^H=.#7IMV# KT!179'5EV%> M$AZ+&NB_OGU\>O+X&,SWIU]F":9$1E>FOK;"X]].LV^^.LZ^.7YV]/6S*&NT MQT_!VRHYIS4JQDV^E3:_?8,UV02D0&0IUU[DX=C&WGR36SB M%1@JQE/+].+LNY<__7?ZXO^S]Z;=:6/-HO!W?H6N3_=YD[5DMP;&I(_7PA@G)#8X MQL[07[P$"%L)2$02GG[]6U5[:P(!PI88'.YZ[FG'!JEV[9K'1KMVVFI?760_ MS=,O@=W>"TH#Z*;EYH(E:IGRQ$HP/K\VO+BK#<^V-KRXJPW?BMKP[9)[Z4L. M7($447(57\F=5R\N3Y/:;-,KS5HEEM'U>_('!P42&'S'D<=JR!EY6NM8Z_>ZO4' /5/!L; M1FD/N;0*_VHBF*ZJ!Z4"4=F??<_ 9!^IG-]A6_&V\ A;"735P8IGW@>NA*L) M!YKC\@E]&'O3<"D5JX_U?XEQ6,9W?;YG-<*J&+_]2SZ0R\+(ZX _$*H4%9M\ MX;V>PUA?='N"7,A[<[U9JX?C+X$+O89%?X(<],0W$(A008,?$68?\Y_HVIKI M]#'4=>/M;Z+X/):A> MR.[JI]UF*B877^4;)T(EIXAJ=E"4P;\$,]J);K-$+ MON*-?_>W1W5LZQ<5C?=T0#/\D&,KJFX,AX78NACBI (:/K:=1[LYT (#.O82 M#$?XVJ:?+KU/8S%]:/D%W,^IUM<>L71!.!^(PC?+Z@WAO6+.JX079+E0*>_" M3ZL1A!@6[F$,=S'^0'C> MGA(21#R23M4P4Q^/,*;)P\RX487"S[F>CLV8WJ=Y5@/@]EZ#)3B&[966\2GL M*!7,7MSF7;:%CE9WT@R2OL9G[+*]$!UOXVH/>:\3=7A,?RT4B(8Q<@F MYV-P&M=#8V5)L "@/^;!=P:0'CYD:#F"-_ 11!*?81_>_9MC\I?M-S!=D+DC M3-4!;JE.*Q%>=UMKU@'T^=AVQAJ.E+.\'B5!+N[+DK9?S$M>W1!E/R[XS)0C M+X->LS#W1.X5]BI1VKQ'M1Q\$)B_QP!GO.+\74K_W1@T"LUP^;:&=UN&LKA[ M#N*"X3C@9)QPZ8-%PH0SPXE[&,@+Q0R3/S\FNKC'HX)!0'%I<*4#I6"8J[X' MMY<&Y*L _(WV-AVH,X83>Y$0MFZ(S^]I2SI;T#@7DC\>\0KRN.67]B>$ZDL"[[OL-GX!,>(C^Z@Y@2OOF9DF?RQ_LJKT 00A\== MXK[*MESBFG6+]YO@)W%!.;,:)V$ZB&5RGN7<4F-RXX'^MW,8S"O(>8TS.FN_ MP!)71*H%UT^%D/ W<@N#)?\&D>ZM@[T1WOC8P28-BEG,NATT MV1JN/A1D!;GW'%O>&XT&$PLX.=TTT9:[H- R^O4G\'1XU?YGMJ+0DS5 %%@P M!T_K/ 93?K;-M=_FBP?8+W0L!O>=^W,.>,55.JD95>@F9@# MM<)Q+YS;UHVM#;=0-LU1&DN5$28_7[*"P\EPX:1WRRH>0PXN/ 6!_[\]N319 MVSBGC)7P<:^C68_/'/3B29ZSGL=K0AR;SO+@%T*>-K#GZ)?T&#A1-W7BR_Q: M_5?2RR+EF-/85=)';JK$C-/*+LE[#9+W/'4>["O[%YRWPSTCMOA2I;S,VK.2C%Z1=H[!">-L*[0@(RI[9#F[+&;#SJN^I>DKB84WW5OJO17.M =C.!YZU_3&LL/U2$(/=9\M MW&$SQMO0)?)&M$>^8"%TJ4$5XLHO,*EN QT/^+^Q@=!ZJ.*%)> M5-2RJ!0*;Z?U'U?^2GE&'X8L_2/)_R@JE5W*\GO \S\J_F+R<-Z#_HXGGXD. MA(FWL4Z%>++UOI*?^ Y%!?<.2R6Q6"K.^M+R[WG) ?Y:$G;Y0"IO!N1_'NKS M8D&21$E2G@W_2QCSVZWAZM/<&,N!\B0'RO^H4H@#Y^$LZ0W$8&A_WF?BGK4< M'%,7MGH0M@D5L^DU.R)=K#UBZ569I%S"M 1U)A=<2;6,(FL8(7&7%S]=9R9O*\*U[N21SY2QPC.20[+.RPL,/" MZM7KM+!2&+8I++'H2,KS;H:^!D[SN#/07W@ULQ_EJPI)E M37E'L29Y/HADA M8DH7/A,'!W)^.Q&PHX24*6&FX?0L-$S60&U!IFP]%?6;63:_J96@F0$Y&5G= M@G+0ADF@\9V)M.?%Y=MM:,RYGPB@6#-6?<;T;H7*YEA_ZRB4 AV/L/CQ+U4Z MD 2 <<"+*$-O\>I/63'HV'5T%G.ZUY4/1_.F/85B#USILS#(%R8,=(ZXQ MY)/ZJ#$M]'&1C6!C/7 $!95]:M0NB].$<=,Q(-R#9=PQRS@E=$ A:\ MAM:J\"_X_<3>6/L(XG!H99<@9.,]1WK7Z!M=GHU@M^+G''CM;^1J5EFXNHWU M)1ED]Q(O>"[MAGA-1LK3'>)5V@WQVHHA7MLO1K(H[(J,II(#P<('2A4/A(MZ MNW[QM7Z\*QQ,/.)+R7#$5PE'?#6K'^IG]=!<+QP%>M5N-UI-FML%'SC]T6ZT MA=:)<-)H5INU1O54J+6:QXU+[S-PKU>GE_B)UGG]HHJ_WXT170W7X7SY/LA> MFL@.[S8U-I[<;\1"RV[L^%LYX .#1\<@XVO6L 5O#R2.,V#3&="N[.E.US8Z MNL/-03!>C1%.)V=69DZCMG6O&RG\#-PHZC]'C'LMW\9"6UNHR2+F,VBU&Y'S M.+=>2Q=.)L:OP8=_@H]![1S^V@ZMRZU3&C(!]C96,0@HL4ISI$T.;& M4<[8(G0/OM#^P+)HH']HB2CSELP[;$83;,/Y16UQ?&.K:WAN"4Y<'H[XZIP6 MH)Q/]O?3A.$^ K9 M&.<&!T2CQS KXFOP:)7YAR=QOW /05%1EV-#N'-.F/=-E70'7!RX80]W!M^ MYEW$[+:;-MK@6]$;?N-@B,(<([./:4H8SNA!5P%%\0W)A['#6Q][ M/BRT(YE+M#Z7T\*=H?&]KZ[N+\O]!\L6N:K"'A5SW!WH\ !P1'K"T!KHW3%V M;;TY;E:Q(/&B67T;ECBVU<$%=&S5DFG=:;2*C7]/PQ9::^#P55/>6ZFMF%08 M3C4#-:.S>,[ ^#V&EW8,./5C#K_3Q49.<&.ZMJZ;M B%!/ -R'P0AF-:C,8F M>X?$<8 %1W >'1!KN!:$?"X6+,(?X6W6/7A5N#)* MLN@N#W(>>;"N;US 2)I/Z]U1NRM77 ZMW[K#G7"H86AM M I6EXEH'T ?GM0MZ(%H9P!9406P#E;/N(_@<*'EX^9C(S5^'4[/.Z4.H$/)E MY;V_J9$H3$=]8]+>=,OT6[=_Z8_"G?Y LW:PR8),%'R]1HCBE_:./JL_C."; MK!/[QK;NW=L L/T>@3?2#-S/T]<&&%2CM7%WG!_H=SE3OR'J<][R."-@!B#6 M!X_!&CR';?/ <5"N#X('L NR _0D4/H_0.8'PI5#5SNF,MP1!A5QHUH8>8R\ M/,QY'\EYG(ES"MFB'O9YO J,&7I['6S]!LB.EC_0%=W!Z6GSR&! B)KB9V]? M>(27O+WHR);]P5@WGS11<,<=W0:B!CPY8NY6!UH A#G"$=MG* JW8Q K@-21 M 2;M4+LS[#&)&F # [[?O35^CZN)H1=XCY8(8;%U-L*^O8!%$-!,%J#2@2AG] HY#)V8 ,X'O8-4*D M@YS#6<9GB.G;)B'(KCN'UTT!=?XU@X+8P&BH\KC'@YR"2UKL<; <]EYGS=X4 M)G?X)IS]XP-C%P%A@T#[ M\#&N^7#1(UW3R!H\@FC%+ 5XA,"5N/R'V2O>&K3:12#JN7*D@4O@#J'I@=OH M9UT>R#$7O^!X^W8 ]BC0 *\S[OSDLP&O#MH'X$]83$@>V^,;H1K1A3D/JI/C MJK^7S=;1X&4&"$N7A&8+HEK6\&XF!XO 1_NTT8A\RF"?)>VRO,<1()TA+C3M M!:2#H.=\T/'1_-6\AW\MQO#M5LQH'-E@GOO-21*'GA44]6? ?^R S MNX9.V]!PG"L62(#$!"OEYI;-FS%O-:J,B%C0GG/GA>M0CMO^V&U0B@Z%4P.O MU[HW/=< ?O3%!"TUY$L%@/!5>[]#?8VA MD@5/]&NY6GT?2R^\DVB!VB)E9> V<'M J[XEODE=N+?L7\RHN=4'P 1P!F8K MC2@LS=TX>%=/QPWGX8N_&5@=;*G577P(JX3A4[PPI$X[RZEZ)>*7 !1T,707 M!8FMPK9IGCI&&DZM&^-!: ^Q$S<*/ILBS[2J'\K!'P/#@ED04[J+CW+'_7_, MBASS?E^-*/_.<&TK;%_#4QI?CUE(G@/'-# 0FP[,#HBM8Z70+WJ&IR ]1>]Y MOASEFD"3SWH8"$*Q("!:!%42>MJCP],"!HM&:X-]P.2@YU$ /NJ6WP=&*L(L MS;<5TDGP+7"W&*M ?.LC@UT6#<_V+@[,"=V-6-X41N)C/.$RV"#^H=ZCNX)# M]76RDS3V*8U,/: >$%8F+GQLN!X0C@$BC2B+P*$MON3+:PP+B)GAV&4+1,%R M Y;*<2R1Q^OE0FC$*)]#RH0)&1=CBAD$;E-@C+(HSDZWK6+46,[+$HE"4&P5 M#K3=$G_BIF*7#0DC]XR\6M)66#"A^SDU+_H5IFG/S?3$/:Y%Q1(VC"V1_,8- ML3SF$:E)"P^.Q75J+II&]W;H;F#E!I-M33IXZI'@66_HL>G6K M%O 7EGOZ*XE1%0ZUGY:="Z+P/AZ)-UG^X6!"):)L0;?:!(4)+T&68SO+ VM# MD80;M5G &SZ&=\E.Y'#[:#! T\Y+#V.A*\9@X([XE7:MT2,; M.T31F,>M(BIL;'P;+W?I? M#NKF/!.L-R\53_&C6QY3WML^,]+UZ$ M["#G.?8]3-]W,.+F19EP$I67M^Y974HV$)R$*L1TJ*S!2_)Y>16F\>]Q;Y[H MF7,$J>9Z!6T4_T&8P ;)\:(5"QO< .WH';$GZ"QBC]/D*?Q')\6OWG,O#"U( M(/3>@? 5O^HA/E03X>@V]^C\/!9^%XQ)2JQP9&*N#0[4 YRS) */P] A6;C@ M#HBSYTUH-E4&XB)"TWR2U?;M)@Q[HRJ;ZUC7$Z MAAX?&7-SJSSB4;\*$LAP2+J;4#!W^NHQ?J,A=3D \F"_"Z8%$6,I[Q'CS+2K MOT%T7FY8Q#+ D^,J.S3*.[P4QN/X$+BFW^ <,QF.H>E(+30K6I@% +E^W"GT MBL1)3%&$*GREGBQQV'I#6IO,"(K'J\DMBX2:J2N35UCP2_D,U-ZSAB+@'H\W M "I#$,[T!Z-K>=GR$,EVK)ZA\^ NED?[#R=*#2 )S8P/PS+$U +YS:'H?(,J MU$V.!E_1>FXE;7#E]4GD>1*Z0_2/VI-%"IER(GR%ZC#95D3X5G^?5Y;KO1S< MBU]P^(9YM3%U*)P$SXX?A&.J_? H<1=#6VULF"IM0@6?TS6I(H\&^4'? 6V1 M-%R\>/QZV$"D+MQ 3&I"4#%+B023MV/[W1TYRHF!!Q9.06+&P?5B(EU0 %A4 MZ45XP^F^:-WK-UV!8[!7NK:WK093:?[R?",MQW /C.CAMVPJ4S71MIE]S MV]5LVV#!)/QD\%V*:9*_B#J.NF78?'UF,*$3;/,&:K#"=:R%HO/DJ(V'(NK\ M6<+(&J%@"EOW?F^UAJE@X9>).5^6G /W5N]Y[D$('C(M 5JLF],P5$KJ2]_E M?U:U<83ZY-JYE3;*[? ?VOA".2L,T+>"QC:/Q7^ V^D(=738@MH[5:;E[BI) M%QQJL;NNU34VLF!;1Q^PA 06A*#33)4;MN$$&Y>#)=)>NYMWJ8]PJ8(^ZTX= M_BRO*2WV\SG^>>4UB,FMVK&1[33W8OHS]V>)D V=9Y\1!H0:-?*N=@;\JJ@F M@TT-*(LVE$*R.>W47-[7>]HT66$;SOOW:KG^19L?\I-I299*.^>A:QO<0G,\ M=7=93NR?_#B?A5BIR&*^-&OOQ*:L&Y@!O HW(<--2)7MA/^-JHJ*4A1+ZG+[ M'MYF /O\714S#K!?*2T%^-\KF4".[YHIM3Y@C=$L!MRZHTZQS^P'(<7S&_]52EB$=265/[C)9A2!B>[),KRE*/]IV'BC0+R2Y9$ M29ERW?\D&5:9LN)6*<,2!C'V#EM^]E%_&&'=BI.Q9;GX@RNTN7? I G,^I7N MWF%;&_"R>5:2#]_(WK$M2N#<+KDD,3-X2J*:SX-:WA1'^TV^K )ZIDS[-3BU M4PII'3[M?/K]0+W@@ZFYE7=9QV=DX+U21:!95175 MQ/6WKY9]"P6P0(IBI?#'8^*-+($@4\6B.N4?_DF"3'Y^.FH--IFZG$ [Q?0A MZZ'V^\"V_LK>Y,&+D(J LS\Y\8VILTJI(I;5/SEUAM98"3"A3M?^_D%8*$RY MU)N9/^3C>;K6,.L(]=;GQW; ;'+FL(%-0&QJ]PJ(61;EHBQ6DJ3%5I,U! Q* M^4T) ^<+);%MPGA^3W?Y@3EY5Q6(IZ>B05TL)^_(+\A*K4N7/RR_&A,&V]IKR8J%2 'I] M?@3RE= KV-T@NHH[$?Y&!<._*%:4YS?_;[\0W\\_GPY68J7-\)_9JA NG 17 M>\C>R6,Z7XE*+ZP"F(BI%K-I(4.B:N3\OK;7:-K&* M;?B4"[1LZJ^A;_:-(I9*);'X@B[![1>H;_*@6\MBI?PG:Q59+*O8]/_\NH=7 M8F/LY]?J&RRO7J?EE<)PW-1= <,=BXZC/.]*Z&M"SQIW!GH<,J:&Q"WY%%^) M8X&A(I873WQ2GLV>&XX"F=/#X@DMKQ8%"D:,05 O'FRP<2A80C@MQ(.<7^@- MSSS_A'3B6^RV= KW_ 62E=T"2>\;V2R0K.P62";%^G0Z.PXQ&2V03'G[@W>2 MK=O?0)LK:%J;LX70Q\B_S0?ZQ+)SB]9'T((WOG<>_OY7\:#L+1T/#=B+;)CP M?@=__DO-'RC^Y_E>O+G;)V@I>0\W9VML 7GX:4KI(.\_[5YS:&>G9L/AA=Z8 MUG2RU=0.S?;@:S-"R^6";6MLL]LM&/8WM]:8;7.\M^Q![R!7=82;@=7!T0HN MKM3VFG=#:]-LW1E9V!OD+=0(MKC!)_6AT66[F/ ,O6"#('84V0:*X5YXGQ1" MSP^,/>]P<[T<;O:(+)9#@!$YN"G4PPYA (YE: -XAM7O.^!/\ 5-_,KX-?U5 MB%[;37CT,.#.-O@>I3EWHZYABZ5T4##,/YY/033B0$O["V]M+5[ ;]K@XQB1-O'236W6']J63U:^ R<;K'5D3-D/RTP MZM"&4=JLIPD#["RW!1"G:".#,897TC<>V'ID6FP0;(Q$V8;H<+@8YZ"2B.V M,Z&[N@_&(]^MQ)8=:UR?W!"C,4(+O?0UK$K:>*!!^/FCYW)UOR=W)^U6 ?0W M/0?"8&PSRRZ^/YKLBWPA+/B2B)K(3K)YCRX4#DJY923HM!R)>7*L]>B&ON=X M\LW[0S#9 H7-#1]X(0H=#:VVCNL]VUN>;-@]LLX>N3D*!QX:CH-=F&*LV>:) MW5X 90@$.(*#:W4'N&T493WR@^-:7?#0Z4N(4/@6WVD3H7PWC(O-),ATWCFI:VS/HV%"W[IMA1A)J]5=<=R\15 MKFRO=IB?&%7RI^2(^?:?R7SQ7((OF,5M'M9WO+ V7N#3$'/3TQ!#(A^IO0\" M%1Q[L-3S,ZC;F;U)DV]'%2D @/NF00P^DNW-50::AR'R$7,D?$4^I/'.<-#" M[.MX$E^>^T(^*H@7$1L[3D# @=X"("9U4HZ)=F<,?G]7W]'KVNFU-;9SLU1J M0+&!4$+?LG!0G/ MY7 \+(EI)))S/5L,-M,U*CL68[W,"YM_O=_RHI<>N\P"PQA MZ'*??K[?8$3'0O!@H\845,B9I@AI+A1QF'PO^RQZWJ&TQT[^'>M M8]UQ(T"+F#!4:D&)SFBR(&J8A&!],9JS$F1Q1"*8';L].7 BAQ 4Y57:/ M)3I=YM[#_=#=3"8"F&&32V+8' A5$/ N.>R#1ZI]\5_$4LL3'3KLBD-IY835 M*%'K=/:CE[1ZE5=@:6T^T"#C3QM?KAK'C!X@T'!3&PB_Y4.(H2$.1J1<2"X[> M!8Y&<<;X40T8\D#XIOO2+X?2>N$C-))XENUB 1M*1T_.#PP KX<#0ZC*Q +) MS=)&H?EF*.I"SW)O-1":&LIDK8?JI*/G !JT'9G8L]C!C3[H1!VDQ:1PP_>R MW#7ER#&:2 .G,,$0BU5*MRDA=3:=!>=/RH74 *_@*_EHVP6SUL4N:)D238R9 M9@Q9#H&SOD"%A?*O&)910O0056KTHI%MW1D]E@*(>QD6(_Q57%;)3<5BZ%WA M8='1$\5&8\(IIYQ73!JV'9SXXHN=BETEI88)*"ZTQ*@P$DM?/CJ(/D.$+_PW MY4)O(CE6#GD$R1B%DVLX[Y3L9$:(:+V(FQ^FBYBQ9+N&#>=%BBB2R&)N2$\? MCKR":Z_^,:Q\V \ M0%#//8T1(ZK[.M:QVOIH;(.7Z#"U88U=!^RH'BN0'0X!< =U"^$6_9OY!/NKHPQ,+[:-?,G+)$,CPPC$QV%(5:QE/@LN2+ M!^Z(@\N+=3P[GY#*?06*F^@F:H6<]] >8M8[? _+CHS.&-"$*I' !P YU@PO$% M&0PE /P6V..C=0^PVJ(00<'T<(I[-D$'WZ7=:<: Y5VFSC/4T-DEUWL\!&B& MEJWG;/A8CX*J\ ;NAL(_D4<)9$0"2!/\+KK#P%^@.-D!;*"8\$14 MBZ??&%TX-OKN8Y,E-05.-0V7=9ZX@+(1ZRG!2PF7@!!B?4;&(@]^"R%I@D%K M?EG(D\QW-T/;;[Q0IXD:%\S X4%"?#;Z.18!('G*,!(^;LA$])!-H,QH) M?]1QQEB$YTMR3_-2MAE[4B@KSH>?LOJ_P.S,40.,3ZEX5!.(GKW?LAW!,8 A M-)O%?E&H$R9)M/KF,HIW_+87^-6PM;#EJ0VYZ-DW8?Q3ZI%'17* L3J#[]@3 M>&CU5&]LGD]_9U^EM^_%5'7 M(&:(G@#M DG-I*>3$T90Y8UA_^*.6ZKQ*!1Q ,S_ C:#4!U0X32[^MDUE!* M'[\W'I'I5I!"IAL7R0QZLO(U#-(?"$W+LXX(FQU=-S'UW,L!-G7&M;TP-C0? M&QH!&5-5]XUSD^4B-Q*ODK;HDD#!X%7 1]2.A <'E@0)!\1/Q (VH'9GV:22 MD*)!YAE]C#]I@T&@2;9*-B=CR0FULUTG[!S6+AJ7C5KU-%>MU5I7S5C_.%RB6R876B95KS!KPGM4#KPREQD$(A>%@<@9@1.G MV;P_L8N9-2KI)HE[!7H5_M+&KSM<0V+N$#ZGCTB%PQ?&E'=$(0@O&Z'1X@GD M#]7JN2>/61Z6O4SSHAH@XT"C!$<.X!2X%>-@Z2V%3WZ!GH0[&A(HA#E0?"Q MPJUI#>1QU^7!$S0+=-J0/>;Y!19*I\KU<"S<=SW@7D#AC^W)TB\O!#_Y/?:F M'M,$+$D;'6Z_#)=JL/2X4RF)?(20#K5D],'1::%\&Z "@(W1P M:Z#VQH*5T) >A%\ 'MB+$ K&08Y[&E%1<\<$B0*9L;B,]%SLL@]$0*EU#7L M[GB(CGX73:YJUQTS6Y#H$_5/ST#-Z'F">,4!J.PY[!,#$>)^2F14@.2+UK\//W=*<+NI(1<@.P+Y39O0"/5$T38;P@/"(*3M ODZ7] MSZ+7W]RTX!X5^$9N-A^%Z9/;.@YV;:"6-]P!?)03?GL\I,IV>'\[!'HU /V< M@\[90PQC'F^""IKCCAK4$,#'K7LZ>A=MN2ZS$0F_?A1F@A8HD\7<"R *=$[Q M$D5.FG!/_FM8Y#+',_YHSD[=\#@ETK=' "OR1EF% MX!9HB:U4;6!O_&L<H[+".18[Q*X MZ/:*9)B>0EXUNKY&%"G#@EH1?#'0Z=8]2@(6'?9\ M4 Q)%S^Y[X3%&O/313_5S7(M@2[!O\"'A_ U+I[BS"SFGV+A)95^>=CD[7-> M0GZD/0[9?UUPCZ@^B:$ %/" ^>&(_GL0R:YNYL!']&=8T.-]-%KX?]B)_8NC M83PZ!E#&)L>2 ;\'3&'-%^G9N/OV/HJ6$+X<@'8"-X[B+SGFO ?QHLYC&*V< M2,@?YL8,FCV.@W\%[]>+%H7B#G& X*GU_9YU;_HA(>\^N>&9@R\->KRRCD7) M--N$R]\E<5*OGQHZ.-MG N&-A;".X$1[$H*A.3\>96>#NL@]&@@>H M^?T$C3FF^#(\B;+@W'$R'L10Q&!KC(,KB5<2 J0@" MX8E%@L)1+'*J75O#XW;))PQ=W5_JX/- M>L=*5NUPPU\D*H) @;1S>;8$SI1C>!OBL= L8N_!"M#Z@S8<\40\A>A#CY]X M)DUD>[=EA!G'38'Z":N;276T],$B*B,ZCC_Y0V(TU?1$?OXF/DYRSOCPI8&7 M#I341U16BJ7*>P:9=PTO #5-V) S$ SB#C]TQ(*LCY%2BW"&EG=FA*M+R?7! MEEI:UGO'D[5]C)!A69,?\\+HZ?LP%F)6-Z1$*VF012JTM6B[\D:=-W6ZWS22 MU\S'W)T%6I#1N!6-;O?T+BD]/FTDU#(>ZHCP:@(\_1EIJQ]3I9#0L:Q?K&%L M1^X;?-X_0\QC@([@ !N'C0^T[D&6.[?&"!F DB>\ZXXTP8YD-_B\?P;)AH0R M@1,R]9E@]BK0.F,'!+8#!GOG)QOAQBO&:):4G^JF"CIRPM[CGW<$OKGG_3,( MW#.]T1/M4BHH;(>86.)F4/UT#WQ"FPP5':QQ"Y<1N+9N]D(1^[@E0]OIF6X\ MT(U^SA]:1/V?:/-UNV.;ZG?,1S]]@Q,&]H=LWP06,? R#RM4-\(R7@/CESXP M;BVK1_E ?[QZ:#02&WS'2VIXI4?NGC(Y7GW] =94A*884R )7@XF[BVO?+%8 M-Q/V QBVX_(,D_![#-AR&;7YQ2C8#(CEAV@+W]_J;+ 35?6:>A>^A=45;(@Q M5C%0M<1O+/;T'A0SLLU?>3'QT8E/>-:T$S=W(52*@S7'+)[&"KEM^Y'Z<7AZ MU9^I[(-"6;P$S]0?NKJ.D^Q=QW^LG[4-SN7XN5",U%FN'U)Z'P3AQ%SX\]X' M_& <#>4P'#]7?"!%ED%D2T0C473.&+C&^( MO24V=&)J'M\N/;BRJ'XC:,S)[4+X*^TA81$JM&\&.*7RSN"U^&R5!#)(2OE#C%2<<;OQ$.,#O1!_NZ2.FMTC081T>*3.^3T,$ MT1ATT(J"@X&]H46U9YAU *N0WMT+WDK5\%20(&!! CW2LP!;KIM>$BCLD"E9EE&ZSG M(I=BV48 [.)B#2%H09R MU3-2O5I;:HER?./(GR 5JDZC@5+Q->4BIF9UMAQE]HF4+9&#[> M@+\YYXW%8HD8;%>=!I_$L#]OV9^S&E=2[G12,?E4A;. '*- M&V;LPLVBWZ'S?BCST:M/#PJW>]V8WB'P-GZ! M1N%5^WA@6P?4XJ60I8P; FULN&"N$ONNK_O'KC?I5G\ (C=9'BR'&_L0_V-0 M'GPRT02IDJ+HH9[K/GKJ<#;I'@"+Z*Q 7I:]'$,M7"%_XE]GV[].J@BE_+EA M4J4YP[,9??26R82M%&18&H(E8C<6M<@'WC\K] AE3^%3]YK=VQ]8UB^:$! P MIT8=A!3BI+PLBPU0;PMKS@GWY'H-M&""$DDY)")R9*?P=DO>PL-#"\&HGV#A MS&",QI++\[S,,N8^/_RTHYP%0!N]_]O[[UJ2U:#J,TW+I'%9/\N5J@?"EZMJ M\[)Q6;UL?*U3HR'\XM3[]W&C73MMM:\NL GQJ'5U*9Q5+S[7+X6+1OOSSI!9 M#= @N;VA *^!;>;7+2N[NN5LZY:57=WR5M0MI^R);O,>^*A"S/L*D718^4 X M:32KS5JC>BJT06_5S^K-2]8SW[XZ/S^E?UL<:J#%P#HX334$!_QB<772Z'?^HKT(&9%^%_5Z8J8-3+="&]TR-=?F? M6JU>/SF9KMU>1['%OYIP:^O]_]O[GX_:M23)>X=L%@&%VQI <2.=!B,+%^!! M.VPRTOFX,P!O.C0TX,2PAT"#VJ'PYKQ6;1T)C6.A:7DSIU"_/?0>KBN28(*)^'][\,9WD1?N$43& MP]V^7)35RMZA4I+^_2?R"H^+R/.?<9C\S,,H_F$4=IC3^V^EJ_-/5N>DF.0P M"CL,_;3$4?)@6N4+I1E'>9M&G4^H&Z!@F%F+1#6?935:'&_RD4LOX$R?GWXB M/REIHB,2V3QB3=U"^U;70_)?>^G]9GRCQ57?:!K2-GJG:F9W&L2H4?JV_ :2 MK;G=TK;S:S[[N\6KK04UNVULI+BU!KW0# @^VF*G_NY:44LHA:YVJ0!>F&;?E?O/2ZZN6GA^)5W>1^&PC\>HN$K^I MD?CI.UY,S5+6ZY"> M#B;A,;*H1K&H6^/(TFQJ.#DV;)TU?6 0*&RG;_$A<0N$H=V8%CRYZXBXJO[E MF??U'2>E0/_Z#@#,TQH9)GCY.<71=[J1'S/B8DD"*JMW^JF@\UFV'(EAIN)G9C !-O5( :;,G&.B;_+ M(T?[G5R:1&32"HG)X4HF>4]OO+&0=SKNEF1="PO&&K^E=A"V4X?89=[W=ES=)XZ@%.E MW(&VS;KAM0@:.,>1YABL;IDKBYT.V(BKN<26L=SBF>Q8H\PWN(^P-Y8W+D1E MAS]E*NBC8N/T)[YE4/Q)?T Y1H/FK$D#(OJXQ>!%)O23/J/F"(1:$T;,90E) ME#ZX+-@"X#DU?J\Q\VYRGBP,>3DM<)(=&C''S.LW$8'SEJ>-W[+::SLT;)DU M31@A;XK>QF6TM_C=>V-D4T3.A^OJH'T@]'5:/?! $!M- +@*7A@ MCW'L'5MN@8T.3"3SVVJ'5S3WA/H#KS@'&(9&L#Z#\(&'VF81NO7F]3?B3EQ! MQ_?L$77';11AXQWAYH \_;MF%RAXQLM2'K>1T3_@7PG)AA %BU1 MZML %5MXXK,,&TH99C@T:T7XK,/,&)%(O--A ]/N6/..%ULV:;&ZY M:UL#ZGT-G< ?)G @5!U::)[S&OA9^].]/L7Z#'7XJHGM$?WDKQ,%'+.)9_2; MG%A'&6M/(BE*\Q%\0>J/&Z6U+6"ELBDZ\<)ZF6,3R<&/:'6R[6HDPDV+S=?D MK]\)C#4> '3*"IIKZ3,UL::NK]\8V2P&%>M]LP_GES&1(CW86\G:$S1+3Y([EMT-4Y(P? -A X-4?'E/B&6 MQ%#(D=VQ^WI]JQK?492CPCKAC-9G[()LFW$_V"'J+Y%BK#5D%T1K,,?^@0;8?R._Y<$Q4BC>YA++CHA6MD3.QO$G7+OP!R3(H$ 3.RV YAVI -Y&:Z#Y1RO/<-320[ PBV94Y8(3>@O@XR_(7["C#5S= MGP)V[Z_&CMA:"50CZT@/Y@>P>0/<:H3WB"CW0\!Q&3\#.J(8D0MJ:BEF"P!U M#S+'!RW^ 6PG*4U0GW5MWGI7^- CO^:=M%^OM/_7.*PS8X$B)HS]3W#NV5=O M!,_4NH@L9INL7A_ R;T+3.DXZ[O(JI-C"Q#&*,,B"Q99@99"@J^86$Y&5T!K M72[2&SWMUA+.0-AT<=Z%2&D:9H57>W?HP?=R-=R7->(#2RB- U#X21I%4F3? MX?74C0O.OZ-U@]U>4R\VS'T^UP-M>IW659/!#;;FP!JQB2_^?HE]W)?1RTUO MU7 M',8-PNTOI2C*DBQ*DA1=I<9\&-U;L\B_-S% ;WHC!<8&;L$O1E]W:NM$ M;FKK!)L#26H,!SKY2RB"=T2@"N;M>SMH([D/2GO$Y,$"51R>D>M/R D\MKC! MCA.#2**C'8G8IN:YW/H;[*(7,;7>!!Z1"_9J5)E7@)D?3A"&[9\T2@_^J$F* M)V(L1J-P0?AN'&\-RC[@9:=>UBF5T#[ 4%)B^11E#+D^.(G6(AAQO"G7%)"CBRLF4W'H?TPE[?AF5,: 0VO MON&A28WU*04@BCG?OL0T!LU4Z?=Q^A" '!_4H,\$+CLSP+RX!$4VV1_UR.RY M *^&.>'Q.WINSBDG!1\));:<<"IRH@TM#$0B;AUFQX?>-)S>.NN)A.*B>G+4WALU\@V""(U-^!TEN7WQ-M1^>9.S<.R@1R1D"3%; M^DT^\B@OPC-F([>\J:Z1$@)$!QND,QUYV0FC-1[@'^>?W&3'8B':L8AUN_'- MET[IHO_[T]>OW\^4])HO\771?D49.YE-$^CU]+0VHVUQBZ_ JQ!R=!OEC!;9 M/QLH!BXG@<= IB$&M_C("QI^3RT6-8BG.DEMEFI'W9%TF6++K_?**.4!6;>U M@9L[Q0%A-:IING*UV]='@V?H.N3D/)G(J9<\YU>.&4\NK\P%7[R0-O]>:#'_ M[QV^M\T6'OL])FI^UV2219-)?M=DLJE-)G%,/;>]9#NKC,M4Z$ M1O.X?EZ'_].\%"[J'QKMR_I%_5@XOSHZ;=2$:JW6NFI>-IH?A)/&Q1D&][;Q MQ%LYPS!YU\ATU3>+%V[9@;?REJ;;+%;16;&[C16T3A 3)>J44"ARGTJW!!\5 M_0:[)MX^LVTBER"HK23JH8@V.3C10>:YA4T4L8GCY;HD%C9&Y.9=B5<;_ M"$)=+N;121LCA'4T1NSDQ$9T/NQP/Z^U87W=#$)\-T,\1.DV, B+&QARJVA@ M$!8U,.2VI($AL_&_6\E9V]>3D$T;0CCCGUMC&X(0:4/(K;<-(::?:VO;$'9L MO[+.@H7-!#[_Y=;;3"#XS02Y!,T$Z?T_C9)4B M7;%G.8'ZRIP\]13ZOVI&_^KQ>_G\>R\M],=GJ?.KS5*O]@IX9KHHIE/S\'HE M6IJ.1P>TKTD%*61KSJ]( 24,M%^DH"$KL*65@EUMR/Q_T'H]VGENV=YW7H%F MFI_L+^SR^AGG]0N[O/ZFYO6W?XU3AFM;4''[,__9$6JM_>-&]4.SU;YLU-IB MKM&L'?#U34?M!OSIHE'?SF5!D15(1]73:K-6%]H?Z_5M7'XT?P7-/$'@&9"J MI%S+,IB&W\KMUI>;XHT]*(&8& _A'(_TD7>A ?#[T1E_T4T.S]AKDTP.3>ZU M 7=[-- 76!)ZM.SN9E\JDVIQC M(<6\,DX"3'6 38(>"V?,XV?A=WN.KJ1S]-!P?Y]M>&T?73U<_OY_5ZS_R1_K>?$J+DR7V3>>-(N5%12V+2J'P-D2-H&6\ M]MO.82HG[RXTM3%U=@,A.#^)!EN4"V=WU_\.+):#\^XP9=H PX. M[SK=0+1N%#"Q=YP/W3'N%JF:/?P/;I"YTP88X_D[X2['O^FO&,^5)T/B]\6C?B)$5:=5C_Y:+J^J'VF!/X#\X9'F.X=;H 5?MXVC0L+!W*.?%BEP4RZ6R M%RKT #Z<==Y8[,13Z2M"NY(>VHM[AXHB5DJJ6);4]- >R_1'(:8_T^Q?.GDK M05T'EZN3K*ZXCQ^NZL63?+.?E:"79TCZ $J<1*,[+CE"025+QN)V/OW,06'6 MS%K:.\RK8A&LN((L+:2:-2FK=+&7(L^5]PX+H'?*%5$J%E^(O5A&4\,6%)_R MP6J%$*LU3!PI8]F/<+Q) MUOI\IJN]IFO\+&BK5F(^6.OGHC"&,N::@@P&I5@LYN'F"]O)-PNQE2*?**"3 M1%66Q'PI$SZ1(WR"72B7VD,@$";9Q6F=N\?'_4].K[Q&3<0 %5SM00]KHS43 MQ13RLN8D%7R$HE@I;"T;)<-8BMR41]E3+@$WR94LN$D)<=.YK8\THU=_&.FF MHX-#V<+BR4C@;,K.ZW7,_F]E,"P\)WCR(F7$H<7J7027E5"RX3_=58;5YI-, M IQFS708#Q$+E9(HR_GMY+OG(C%%/BSN'9:*LBB72UEP82W$A32_$W"S-W+#:X@Q24C)<[DD>H8:3[ON. MWMTW'O9OC5Y/A\_ 92K&0\<>2%()5-U^9*_PPM144KBW#V=SF7LAO6?-VB5@ M[0(.!EW(V<^ZN(5&[)2"O03N=CEW YL_M0K*]5/]]^/Y_=WQJ'KY'"Y/I&F5 M&9KV$H>H;I)27:GZ+.\=%A51SH/PEQ:G$S92?ZY44U;V#BN*6%)5L5B2LXY) MGMO8)N\^G@\TTP4A@ND/&@[, B=R(V"@LO%XW)+OG=Z7SAH=00]@-MG3@W;] M\91YB,R8PXH469/4@EA27NKC; OVTN.WH@P^M5A0*V*^G$F\)9QK:[&9%.;- MJ:XY^@6BIM6_ I,JEU#'TR:VJVS.]RW^OMC;\+W M6JEE+A:S9C8%R:52+(JETI9Z@\NC+T5N [->+8$Y(+\TA+6PTBS8PL#4-XB2 M^@,V>L+)/UA6[]X8#"98[OCV06T]WH^=F^?DM].+=4Y,X5^_=DN"RZP9+T^Q M3S!?Q&+QI4&$;4-CB@Q8(#26BF5153/1=Y40#U[HVJ!.WK:Q6Z/^CY8FFQ1Y)>5"@_%15"\<+"04R^/'WI%4]/VU=Z M?A4:/CX@-"UJ%$9M+$X4C0_-0I+R/ *EKPD]:PPZ*%%=Y9)/62*)C]>Z?6D*" J>X>RHHI2N2@JY<5QKF?=S\)I32<\ZX]8DYL(@%\6GLJGM:OGQY^ M/!JGUOB#T?RUZDB;7V$[8A ^#\E3:N'9A:%11&6LHDL25E;DRXHH2ZL.7*\4 M9>FIS9*,5HTB*I5,RM6/H[QCC_7>M*2<9)^?]>JGYH?OI[:\SL00!]:!/-/D4?2J&38HD3&)QZQ9+;]W6 :9I;ZXHFU[L)*:$V1G4O4XE.NB/EL:I;* MX2D%.* :'OW-<&]K8PO M/9F4Y-*RYOWRWJ%:5,#"RR@GLG_[ZJJS"$4U6[;NZ:-Y\_EN]*UK!/L92OB062ELZF&#E/FB9 M*CG+)57,9],C/8.QFI;9C8V"UW]?Y;7NCW/=?LYLKL3YCU,+N J7R>^"WR\O MONF2=MW?O\1>61Z<#"[8-XR:3Q^-V^NGNV/;U<;]'X/JQK3WOB@4_D+6K[6. MO[^+QUS&\K(L[QT6"Q51+F^99[(LRE(4EPIZ'8 Y42F_M!9W83CIG\_2_V[Q]^FVPZJB=[UD .P4ANZQI(Z$!J>1G&Y ;1=:>$;#@WK,F M<>SX%_-R2:QDTSE;7AR7GJT\'KY_-FO=S\Y(65_G[)PH]2:&5U>G3_*4"BK M_R]OJ?W]/!2FR'P%<&$DL?3BML7%=0I+1O5FLV3ULJ?WCWW%V:*9@:XD M(>OMCY^D&K1=G9# "NM\.5']Q1\7$EOEE:8HM"@4+^45L5Q>W&.53>UU;&@A M"-LQ4>6'[6K-HT]'O\\&I_WG#&3+JB9;#M=D#^8%*%XIA<=>8M;R"$/T8J& M>:2,B'=W7VD*F\K>85XL5D#8%!=[X)DG"/QN#R990,)4V_4GUP(ATSNY/?[O M9[WQ<)1?[?B/19+E3Y0G&4N1BK1W6!%5J01J<"=%TKVE]&1'1=X[+(N%(O9_ M+ YMI"<[*I%2@N'08-UQ./_=L^&Z1M"8&HB0DZ]&M__K]%O76%%' *[)"@!D M&PW"( IO:#J8K+S=]80\TPD/CV^M!0J.T"MPV,/( U&@YB]1^&MRR?#)S .= M:W;+I@5Q/3K;N6ZW;S4;SMB@%<1\N5G_XON'OE7XK3Z!%>0:+H(U%X219@MW MM/UB:N-Q\=G \,UEO4KI9M!J'DOWE>6!633O,@$X*5@AC>9)5,.=TY.=J*)3 M,H1W.7V<#%YU[U ZD*2X0KZI7X071P<7]%Z8I!9E)K4P"*IC]]:RC2>]-T&R M;JMP\?'8*/S^822A$D$4''J@H/E/G*;=V8PT"QI.L_W?U4[]Z.OM)YP0\VQH MEB"&27A2)]HX LAG .-+"#4.1HS-X]#)&8,GYQ/JU*5,$VQ^ 8DT'&<\1:P_ M.[T[]?2B?V(FDV@<#H.>-4VFU04PM,:NXX)9"%IE A#M]J-^?B,]?/I=6@H2 M*WCB-#C'2Z&$:AU+VIV'F=]IX"3VO(X\2"1F^/6S:A1J!=?@).E^8)A M925\6WP.?"&$K03(4LI(3%NPE+- 8MI 5D!%)Y%ZR\G%>"G).)&-AP^.*6C M&7UA:H4J?6YJNZ@HP)-&.KST3A]L2BT*;KK;M%J4I* 7GPOZPG@JAAPL<[:; M=/1%:59^U0H?[S*-I.X=,D!F.D.3<1P./6"KHJ%+U^1EZ-(4E; IN_B*)*<@8N3CZ>*!?[- MX.*_O-K\3RM?]F=00P)_1EGNU9P0.U_=P8=:27$'W25>G?2.U^"YP /3!C!= MQ:U(X%O+S&G)RG$YFD<+L5Z+??[MOQO[13I[QJJDU;*( QI^;%4B$O*L6X MA&52JIV+Q-F.\7U[^.,_]5?GY^,:J39MG)9P5:=8QAF44EQZ<4FJ5=9:"3MI MDV>;0%>DLB=&M[-P.!&Z4LMD*U+%X]^L]P=*M)1%NRQ3EVQ9%HN%A?;(K3[H;7"HZLT2>%Z%Y)>QI:X@%DH%L51YSHJ& MMUN!L/1D/PY$D$%8RK)8?M9,F;=S1']XI7459"X^4AN<:T:O8=:TD>%J@\GH MW$G'O'LLE[\ZM\^9@?"R698^A )NF]PW3*'+@%RK,3 #<5DS$GBBE:)8!D\T MKVY91^]S,)T^:8X^]([A+?!-WP,P:!SK)>6 MEL-SUMQ91*E=%$L)EE9N)FNF@,X46;:$T_Q44)8[QM=PYUDT8^_\^[QI^)%3>2'9%A=M7Y.5YY6?GB:\N:X\OH M:14J95%.8*;M>@)2N+P4Y0L&6"I@#LBBI"Z_*^+YO0+JW/)PWM$X&DDCZ7KH MB 7[KZ9C^!M7KNTZ%I7)YV4W>:L%5YA)H)*7>%VK7]< MG/IVF,O]._*>UX=C,K=(N#2&P-9-_5ZXL(::*;)?B$);MXW^>V&HV3<&/!X_ M*D7?V-4!5_9$320^>;^O#8W!X[M%SZ;/.L:3SD )H.^=<*[= %.V01/H9A>^I1;?"Q3BAQ_SPOX^%Q0]XRZY]<$.N.]:(SJD_POO M*T4$[%\B<#CQ8, 9A;@/_PVP=KU_1U\*6G.@C1P SOOIO7!O]-Q;/*[T=\SY M4>//T,H 7QPWAC@X\NC8>PIATL/A>^'R<03OK]H@M[KOA29(,X;GIH4(58OA M;_WC?0W_%(@ C____0LN.7&LUVZW3QG'ULGZ<:U_"?\[JSAI3V%?J(45K/\'JB7@HPGA ^2Q1,+O D;>]Y;' M9C(1MNG]H?-4JPY^EM"$G^WGA3L(!WYGT)L9\(O#$] & M,M3_[14G5>DHFST]6F:3,$PR]9:9<9*-0*"2/@*1@=)! MUI:<5DF=-.(G'5^PG3LGMC6,6TQ3?^@.QOA>G/((_^MAYO_6L5UL.;9ZXZ[; MLD%HWQE=O?I@.-?7WLQ]_E?^^#.B^.NG2O7G1U/6ZX]N-F.2N78HYO^.,U_3DP ES#8M?3?1N I^DT)CD@S_"X)D_):N MXRXIA2053C:O5&0Q7UJ\NF,N.N/Y]M7>D^+?D[*:>RI0M;8BEQ-M'TQ\50L7 M$68E=#[8FCDI.=-$X>>IF-[=JIN8@B/Z0Q6:9BZOIZTV#"8HX/J6L M2&(AMN/H#T] )NO"I\:/[+>AO=1P&6H?SI^^W=>NGXS>V:C]Z=>U4BU94DI[AT6Q+"NBI&YI(U9F-D(:Z"TO90>\L&ZQ M9CENJ\_Q<3UT/);\/OYQ=W9B_;CI%=//R4]M8G!<#%[]&8HY@O%5LBW-Q);+ M>;&R6S2:^IUE(0E4"8VA?%D6INF$L_D2E47^J M&N/K)\50Y%OET]U=;16C &9Y?&UMP$L[AQZX:W5+9J-OE0)=)?>N*(&+]](V MQ^W 8R9B-K]W6!+5?!Y48R9K^L+1EP^Z":)L .>M]H:&:: LQ3$!\;PW_OI3 M[>PK&/P4\<6",LRHGGP&:W8]JGW6^=RBK:KV8Q MHP"YQE6_?J*P 3%AXEB= M,WE^%[J+&+FQY+XZUI9I'II:+HN%V('"647Q3N9%\:C#]WKH.GGI^DFI]K]^SO<_ M7_YXCFV_K*&A+B=Y$':A#_?E21_+W'ZILV#^9R MEUWYRY%\>=QHJ$JFV4N:I\@F*(J"J6<=MGN=R@>\^Z;V&>0>'17_Y@V:8#BH2W9ED,_NK:GZJ-"Z+ MSQE>^Z+(K >F< /0"7!9A@]OUM4ABV+Y<_"W2HXK8[D7^ 2B5'AI<7)VJ$P8 M[BK(J6XK#"L3O!V\G)9Y;#@CRZ&!U:T^%I2[CCQ)\-^>NA]KM4]W1\_IBDI+ MK9!? H37"P#&JFR-0,[XQA:8G_.QN19/HH)\4(C=CK&(D-:\B^ 9R,S4K"]@ MF@)H5Y87V_1+&^]^,R(Z$/:PT #,^#(W=]C@YT?VT" 172S:TSKHQ^G MM6KY2"L=/2N<\+**&:Z'[##DQ)8!['1C/O!K45.UUO'W=TOA>(4Z"\4\UM # MOR:8.;=15F)*>,W">"PH6.%6KE3$8CZ3!5.E6'6*-9NM?F &,6;E0T4#ECUO M?K1[^9^UA_$F-B4@4[\9P'G>(F^S&:+"4'=OK5[(XH0?A9^6 3_FE33WA%4AE7\M61:UQ]N"L5-BMS.BO^N+4D/9^B9][>*@V9 EL649BQ MEN_/%DEIWE\F!E-Q[Q"\'!4WOZXRC9J/Q+B]](W7^VZ88WA-,#?PB":BLL]= M:@^Z4W]P;0WNPS U^['AZD,'4(DHLRWJLO "F"P=&T@N-,9.GS[^^G3]=/GA MZ]67LU_W0TG+Q!B;$\,L;^.&$@!=QFCWRZ)A<(+=@S^ M*=>1;10%RZS+8CE?2I3:7LZ,4:9$"&"#R\\CW=2Q.QQ0X?'[?Y_/[%_EF^'5 MYPQ3H#/MDX;/[R !"+:M5VV)"'GJ2M8B$R@N6BJ5Q&(EQ8U(K[[ 8IDKS%2. M%&GU6!EJM4:S=?E4.OUX_638M4\MN_-I M?)I?B4DQD(5R MY95?6[:B1&$-F,ADSQ@YM.C2%@9^',NLNJYM=,8TM_W2.M=LW70C M55WJ1_W[Q\I=YRB?XHZJ655=T2VY8>FR0?54&P7,XHDC,VCARK1Y9<5':X#D M%XIOGYYO'ZZ;;H:G<_D;=/=9A!>+^>3+KM,++AXGU+K=?,WJ=[3ZQ65G#8&#<&(C;E$]3]EN,P\\4P!&;G MTJRPDV9I M2+/%%YF):"JN0S25(V-NIU 16' HD,*AAS MWBA@%H[_J6NV"5?H@ W>OM5L_4ASC&XDD..6NT_6J/;4:Z?;&LQ2SB-F.@Z! M+QQ\_[L-1.)& ;.P\C/V1BGJ\E3[7+VH-;_7M:]95F7O'=(KGX>[*:&[O$2- M14#*"K'1/)DA3\_IG4Y4K.)XI@-EL2V76L9_I6A\KDI:#HDE:>]0.GA6X]V\ M^'=M#NL<&X.QJ_<8\W0?BJ/QXX>6]M^JPI1[AQR C:$!#L]:F:DDOP)FFH?( M%;&3D@D[A2>? MW?^..KUF^^SK*J;0O-A62:E3>2E$92%Z?5$1)R94C$2):KXH%BJ;V[^<,8)? M))+GHA?[*V2*F4C9C#VO+&9)+G^G\,&8LF?66G>_OOZT3E/<0)FZL9,MJ0!NU^]K0&#R^6_1L^JQC/.D>"WK0 M\P$/HVV N:WK.:V+Z4?-?,3!E*;EP@-<"PF'TD$:FGI]P]3,KJ$-X*7P"^JL M.]BND\;<3N[?_[>_+YP8^J#W3C@'=GH/W_X]ULTN?$LMO1>^:H,Q_I@7]O,N^2)-'; ?=<:T2']7WA?*2)@_[+REZX^&'#!3O%F_#? VO7^'7TI*(B! M-G( ..^G]X*WHUF2_HXY_YRX,< 7%W<.L6KDT;'W%,*DA\/WPN7C"-Y?M;6. MT7TO-$&2,3PW+42H6@I_ZQ_O:_BG0 1X_/_O/X#YF#NP=>W7/FN]>2>,Z [# M6"_&8%W:0JQ/R\8XQ(31B7@FLGTY:Z;)AO]V_)-T#K=+@@#H[&&H\GYJUY($ M]B<_0JVU?]RH?FBVVI>-6EO,-9JU Z':/!;:5T?M!OSIHE%O;^61:ZUFNW7: M.*Y>UH]S[4OXSUF]>2FT3H3:QVKS0[TM-)I"^[)5^_RQ=7I/RQ_:=.4Z-)Q,6GM^@2N5K6ZO6VL )W!KV9M5%QIC4 BE?R?WO*I%B>HX%C M7AE'/N?U/=(C]3I8?^=12FV@.0ZXY$@AU0?#N0X5HIAT M5T"]Y[;>UVT;G 3\V)F.CD/,LQAA85X=;AJLO.CS8A_R5/TY;/:_775K@Y_I M7TUU"!YQLIZZM5S-GTN*\M+D4Z-<=81V:K4OCF%\5K_?_WFD$Z#R9&E47MHT MGNF1D,GPZJ'TVZ_^L7+SZ_/5EYL,R!/?MPTHK2R-TBJ\$0,5VN!<,WH-LZ:- M#%<;>&AUSM36Z<.7:D'II8]6_JYM0&QY><1VN^/A>(#FS:Q*40_)MY7OK:.B MH]+U?J(=1MMH9GW_XK/PW+Z2/4>]DV MH%2^?E(+7]J?Q]_;YN<,.)A=3SJ8H-CGPD*_5=G;Q?21%3B!D1#9=*@&RY)] M$Y:<,2'E_[<$*+[U*W M.$I:3[YJRL_@RIB-(6RX_E\2H/BC>K;5*S_F$I0? MF$9KYT$PS?8-1([WU;_C;VNBNN?ON"J@"2KQL%4I MAR>.Q=0/N5O]@37ZHZ:?U#VFEG_-RD:L&YI%AJXW+ 9"\>( MC?7@:=W\$).Y/BITNP\7Q8*IE5]*OG-+OA<4=5>!_5 (L5)N#^+K*8!3*_+& M016J6)8K8KFH+"SRW@JV6G !4PHHTQN8-]JF5&;(3]# N1V(3RJQBELNN#.A ML+D%"VE06V7OL"R)2DD6*PD:9K;C(I)27'E'<=,4%U]ED *IE:6]PT)>E(L5 M$7Y^):26X@VD@6)L_5?S8KY4$*4TV7GA9 @Z:L-QQGHO/+.2NFOH;ZT1[;^H M/^AVUW!P9@1;L9?E[&.>SW;P_8)!P"&.!8M@$70.2]:SD/?G?6;SEABK\AQ- MO-!WR/1L@4]07$Q[S+"-)[[,/(:S\Q/WZ^7MS>E_>=]C2$J&4R[%\P3.4IA( MUCV:O+PH7CS.?AH*G?TU^' MX?GE4?GJ_O)I-9N(9AO*]YIM:Z:[LY1G<>$66,J%I)9R0(&96<>C[M7HK/_M M9Z&@++2.IV@O8_/8/_[&F,1 7 5)E#98SSY;XJ\:V7/E?PGQO+$X3BJ*7I,9 M_%SRR-ST!217*F)E^\E%W5[35WU-IN^2E)X&#>.L92D-O?*RH# ?F:SWT(#0 M38?V(W^P<4GGT]=ZV;[I7GV]<5,#PJP.6AEZL[:C3+> M:[)VY]%?9O:O-?KRJW?UZ;/3#\JA%A%AUE'AV7C8%$.X KJJI!1$N?B4*)G7$0EX1\Y67S@I=.PWEM]=B MSK\FB_G%Y)\&8:N,L%514=0LK.@$Z6U"1K4+-HA#3 QF\_>KYEFO5KJ5O\AK M#AQK(;AV5G24&;? BI[JS9AE/4;H+S.SV2Y_[+N.+;NMGPO#QF'*R]AT#A]^ M8VSE_-YAN2SF\Z_05%X#ONG-GS"<51Z_)-'X!A61N"X/8SY6I/@XY+C(Y+I9=JF%C#5YJT/"[TT=CNWJ*]/X6 :Z-Y MW3.NGSI/^7CM*? M3JM?OG=^-+*+9\R_V[>Y:7^!2)+@W M-=-[BYW"6Z0*+=6OT%*33>$M%"3UJ'K7^FT])[NZ. Z>3:%4=;\@;S*(@PI MSZ-/^IK0L\:=@;[4D%(UR9#22=QOYM#>8_/CAU;][O,GJ[MPZNF22%Q2397G M%"?%7OCSU51&]#(U3RYCA,U)F2WMR6TF1F=R8'$U'!A3G_KCZ;0]&IZ[=W9F M#)/"^.!5U:#2[&DU+Y8*(/6+BWN'MH/LTF+D- 9&KJ"Z594*WB7N+G#9-/KR M-YA"*4L"F[.X5&(]\;4N]!4V^T8SN=",RXE5J<3J_$N*6%%W,G8%%[K*#&0Y M>>)I=[,OO=FL!EZK4@54: 7X4Q8E=?%%Y21'KYT/KBMVEE>]5V+GN&,!MKC.P$@!ZRO+D:S:9[@R>N)Q?SW MV/O0N#*N?MN=]<9B\M*+>56Q&%G=Q6)>2RQ&SN]B,:\V%B,7=K&85Q"+ MP9U&NUC,=L1B2JN*Q43K\=4T)M=>_2<7*J<7'RVKMYMNS/O&*0*B"LZW5'Z-B\W6?@-S]4B% M(W]C$9]4>FU@[^H&T$S6;AUN!RN+JEH0"]+F,F]2&MK ,6])0=^V)M8,R-^U M @9(@[1E1MI%L5QXZ7#O],9X.3^_M>2'=NWXZCFV\W,F;>PF>B5E0GEC+>A7 MA./-&Z^1R="@V2H]PXE>JJ*0.5A4Q8KRG*FM&S+0*R]OX#B0I*!OKQ$B;YX1 MDB5OIFUOJ*GP7DH3O<[:O=))_\R6FH,L8W1Q8[QPKL9NB-=,+E->4C*SLS*2 MX7C.6(9-!WV.$;KIH&^=;??L44QS(C;IYVT75UH@T9( GHH9 "/2P[T.M\=';:M,;W96DU0T1WP[U>_=B2I))CWJ;?W7"O M'54]DZKF#+C>X6P&SN9X-SN?Z45# MGS732UV$EE5WL4GSN]CJ6]1'6OU:'DG&52?_6%IS'^F\_:=_5MEU4G4^)VOV MVOM(CU?#@3$%K]]*'YV/'XVOO\WR!O>1KJR250$B5(NB+)5%-<%NV>T@NTWJ MGUA%1:Q2\2YQ=X'+9M*7O\&5])%B=$\NB(5202Q54NP]W/61KK[@&&-JE:)8 M!AF;5W2M.LCS?YF,^LCQ7AD7BQ4RJ*<9MO^[B*C%YG& M3>7W#LM%49)5L2AGU)4?&X>1GA>'Z17K]UW9L8NWA9=/]'I>6&;3O+_:ZXF_ MG'_Y7?U^80__,PIKCK\4=C/5ET38'SQ3O;*V^(L\_'+3N:K_ -FVB[^ -BOL MXB];'W]1B[OXRVN+OY1V\9=7$W\I[^(OKS?^4MG%7UY!_"4O[>(OVQ%_RYW+\C[VE].-D[098 8Y?&4'>$IGXO7%A#S139+T2AK=M&_[TP MU.P; QZ.'Y6B[^N"IP)$&W44\ZR#%_I.4,OO!>JDA1_SPOX^EP8]XRYY;1L[ MX+YKC>B0_B^\KQ01L'^)P.'$@P%G$V(]_#? VO7^'7UIUQH,M)$#P'D_O1?N MC9Y[B\>5_HXY/X8Q9Q2 7QQO!CBW\BC8^\IA$D/A^^%R\<1O+]J:QVC^UYH M@LAB>&Y:B%"U'/[6/][7\$^! /#X_]]_ /,Q=P!NP*_]C@X"#9X]HCL,8[T8 M@W5I"[$^+1GC$!-&)^*9R/;EK)DF&_[;\4_2.=PN"0*@LX>A'ORI74NX18T? MH=;:/VY4/S1;[Y]B7\YZS>O&P+K1.A5FU_%$Y.6]^V\&1QRCJ92/#BIZI4O)9EY?K)O1Q) MUDBO'95PLM%X".=XI(^ */2TI; OU,(*U?\#U0JG[Y6'B[(YO/C^Z7;>A,K%_; 9 M0JXBO(H/N<(@?QP.\XT?CW?-BV[:D/MS<>=6@@>7.^,E,7>]1(\!T!$RW?_M M%>>'^".6U +R\N3##UVS':%N]H#%P@7H"4ORI]XR,R&\$0A4TD=@DD+]9,C: MDM,N7#6^-&D$+>.5:,LX2OESV[HS@#J/'J\20*ISIPI8(!.&&K-VOG1U=/QF7O]=':DFM_T>OMC24NOD8?; M!\7RWW'7/FN: /^6\O?<8)EG>\0^>BHHYGU:^?LY.:2U=X3EE:4ZPN;B9BHY MM(WX5OS&RJ57!R3 -E^O@U(MOWCB6!)LQ[)G/L2>U=[/\?_/WI,V):ZT^YU? MD>N][ZUSJN(*ZFUZI$$Q2@0\?O[0 MGL. JT^SCT-ZEP')$P<@[]3?6M@-K-212B@ M/KX)F?0,QG]6$/PAUY-R714CPX1\CE&&G18,S:RBRL9[;<@VPZ_PA%.85J@? M[7@W3(D]B1(].XWX!I8SJ""@W&&'1)Z'#HG82*7Y].$VK(\&HEM(@L7P% @\ M,RR=9E9GVVQ EM[:XU4:_C![%KL['D\4H#,TCGX[5+6I,/K_G_X,(R$X#(G9VE, M:QS-@C,L?'ICZZB)]6^UBX6+*/6:GP-9)]EP>7QD3!$( MJ^>(R!PR3*&K>R@QW[Q*WG4>6K\EM$>YD^^(>)O84J!:F$E20XB<0VA#=,]" M[L\Y3,08ML""S5<*OW^N!?1=DBZ9:93,LK2PT4"IJ-N91@O3*$@9JCO2=":; MI5/\)HKW,N\ XU+Q'3:?L;5\@\^.BJ80FI>8R8MAT*XF)]W=* MS'D%=KA7.4F0Q0=>.R0S@3DYX]-T-LO&2SRN!;I(J F\G-B&Y3;IK;M2*GJ] M;8\(_W8"[K,A,AU5P%]TT+L7B<&+Y$NK4GK[N+]*[U$,VANGVGB_%+XZV3G! MGB2>K50M!>DNJ8\[.6-I%FM722'.DUHR&_?L]L5^;R\DN!BXETJO*BJHTG*O M; 'N5_JY ?LL/!3T$(-#P1#^+]CLWZ;3F 0'$4D_IKK(Z*B2!_WWB_U+0+I+ MW <_8#))IY.;V!618WZH$(PT B1 P23'TMG4)BPDB('F0XP%6>^KIC:+55O, M-@V=\:?'WP7C_N&2NRAJ_!YE$>P:1)#D[IM89&3G!X)+?C#=1P!72(%4$M+; M>I/C ]!HZ1,*)S'Z,DPZ"OH4IJ)F9D,&,PY;$[\LK?@<]5!+-N;M,/9&;#PK MI>KOS,?N V;F7K%8A,W"C*A].4+]?*5O M10.-^N^;D&%8,M+9,\";:N)KD\T,B.C#94N1:!DL=ZBPII(G9RF&I3/);?6L MN, Q"K])BB$,+<7026Y;G]/**8F@E_<,51N_:%A2%=213_!.'X_?VR\7;(W? M1#_=2@0ZVZ/4AJXJ2&^2FJ]#"-W-0VZ7E :^--+[V//ZY"KW?BN^?QJ=RB8M^#=) M[S-C<3H$XTQCCR1G*;+8D)5CKEXH5L<\%MA2Y1$UD3R$2C)\_]R\;Z!6+LF3 MYSMT?Y/:->^UMP@)G]8>]\PP5@-Q'P9(BB?. "Z%#9 -' +_Q ^@D=H?*3*3 MDI-)D-.U>BN)1 ;<71 M3''RHFQ3@Z,T#P0V@N594[.>(:CF8VFZAXFC:T":20$ M!B,ZZ%2:H[F-'"I!YQ//GQ;2K^ ]+[+1R9.L):3=6 ;!&(ANVD'P';:0J;)J!'/PD MG0S07W#M+,+E1J4V\(02D'XOCFW;?V)3-ZW;E=6?9$LZB^N<%# M0ZB%D-R'/$VS)V<"RV)%:Y-X\Y[C6]O"-EI"-;/+D@P6/&&3*A?(_V,='4KC M3+#]^(LF&,W M@'93+\NRN]^E0D#*3=.I#,VQZ[=1_<.'1H=XN]%R.H$$%3,6CL.NQ_:@[\F: MS0^^.U$$O^V]J%.0O(>UJ0QSG*2^CB#;\E:C\)"DTR=G*5K HBO-K0X5;"2Z M5IIA"\!B)CPO;M55RW>?+XJUFR=UDR3\B%IUR?:FCZVZM@LQ>3W86!&P&@&1 M D<-853!-&.,[Q6Q9V#] %JP]^$1D'U3[NSDC5"?2%S[4R]7W_.I33("%H@\ MGVC20&MV1-#2U19(,+)%HK$C>W_[M22#PW&7RG,&E&@7F]\TB9"D@Y'@1H5?-A;T1AHLC&NM&Y%[0.1!K]5 MU(3/+,W4,<<)9;;8D73^<#49-G;5BLO>M,FNN^9^99-FN\Z>/754E.[L?]^9 ME>M!>XL5W > H"#H#WG#PL DT&V!.2]C2=A$ISPO: MEP_4NKGFN8M*B#[QP';DE/SUT/(\ 'D3(!9>/C?]&K+ M:5<^_I(Y#&RA(ZPL7[7Z3.M3_]JD$\LV\T5FO5\M>Z='[]=V^GAV@9E=UO4! M#.VNM#P3E:?,ZIJ:K4_>4\:HU!JF'@K1]$-895:C+Z0U99TTI%/[0#QFY'HD M:IH8?6>>@"UE!.CT&:O.J"M187<:(>2!I]-T)AU);ZJ4CSU:4K5'U+=LO#D" MF#)&"1$HD[NKB\]6NW,5H==WH3+G;I68HTVR6[P*WNYW%_&K+VR7VEK:="]S MV'()45G[8PS0-2\Q$EZ3,<=/,!!NWI'UR6ZDEDU;G\"%IJS/=_6U*[?/"^U> M/*S/9>K<=\7[X)>]C\R+3/;(S?9PJY%:G=DD86])#E]J=D?LS>OO!\# OQ"H M'(H*(M6KV+R4FP:2X(M<3YK^P//D/=)D59K/X6LJ ]AE\:M):N,?10,56RT$ M%BLP2 ]3E/ETZ_JCUN]V-QGC$#@X#^Q-LK8'A?J$U8%-0OZ W!/M-YR\V\O8 M!PO+PB1[.BFD, O;I%_^GN/]!W!!T7(C]N0L)= IS(UX;HNFZ"O=&EL!T@&9 MV7Y/5"XP5^CC7^"_FUWO!TBR\NK4'M;+JO7)\$I]*=W5JFDIFM3_P)I6?A'K MH42#:J"VW.N!S@5)1 1?8B^<(Z2H-1%AFIYR>J45JJ62Y4AB;#;-T9D +6?_ MM-# @>,!$QX>\%C&9>A4,HWY18AA[Y5^L_S>&&RQ/KE^8P8?STJJ.-YI]@<; M@*LB*)L*RD_9S>B(_(R2U$%#08%F@JZY2CR(*#S/7=9J8\.DZ$R /L&^M[@Y M,STBP6%(U-16$C40$OARTJ1W1MN@WU?(B!U1 6B5%'54[IEG@ZF,WF!L.I_2 M1E^M2FF/\\.]^X5NY$U%A1E!) YA1VRQ#>PUF0 ]L RD88*Z%V7I M#I$JA/KD7DX-KUYNWCN=/30(,/=#05>CS0 ZQZBVB+.F-A[=L===9T(=.%*: MKF9W*_<]*,.)GV^ISXDT+'3VV 9FIKU$I!BTJC1X!DP[#!QF,=(* I8\NQ[J MN#.X11&KRT+G*IK/9N@T'TGKY:FT4',VEYL[UI,L&'W^5L*ML? MWH=RS)\5YLCNQK>)&WO#^>[H)OF,JU8:E#3-C RO:O:@9'N0A'>AN MU2&2:NK2TL+Z9%@>?+%,]Z96WD4(=W53[R[LFC)4I]Z0IOJP\S#*#C=G1-[) M>9M!>Y>,/@O)[=L.GHT]<".0!MB*PM8;DZ&S&U5VKB3M<^\$0P!9I?6D(S*$ MI](P1+D',5X[J%)2-:?0GDQS]+;CPY0]8;XFY]E&U6CN7%TG>S]56Z<#'=D= MQ%7K !"K1-81R,R,'AIY6F*8 T9]>@'M6N?8 OZ[HW4^R9"N_TEHK;GK]K6' M!^-(2![BAQF&YJ+I/%UPI?GY0,>GUW7/T.-;=QBR&6K-2>\#=Y(CR._:[][# MVT=;>-QGHTU[ZU/3NCV3G"U'-26ZV]^_/0S%? =DQ2^6C6LBQNY( X9FT$(V MDAGW69F.ASQ%'F>WJIRW]^BCL?:UJ:&F+O MS9:F9'(2+!?AGG19LCS/1!@V? CI$$A%B FI;( JNR,7_N2,SR3I=#H2Y=$S M3AZ0CQP9\ILAPM'&!_5D.F/=^<6J7#%AE=/S7E3$8M>'YUA$U4@]W3Z6LUWE MD]VCQ)FE+_N4\2>UC;VT.R:UB)!L=^0(X=ALEN8VFB+N1X[_D'+VLT3BW[[7 MG68B,563NTBG[K"U\ZAVQ1YM?D!35ZXBE!";F+SQ@F,P%7NJ@1]_G9Y2)1DITD_J7FRC7_C7GP.8 M?/>3XK*_*$*(^(\\=7IJD;XD#X,G-YD'/#74/CFD\X']DQ1L[%^S_4@3*8K% MI F%P=_Q7IOVWZ=?BOF^(O9UO#G[3[^HD2P9'3AN\C\^YP>QMD"NX/WY"0,/ MI4XM[7M/'DC:,/Q%U<9]_/ZC"'4YUFC'V"\X 0X$[3=GC3# M),-PN>-Q9^ON+&HV^V_#P=1&W#9N+@;*S%L]R:8=P.+>.O'LO%:@S/>U>I%:N)6H7*5^ZJE9MR(5+M>?&1XAB: D\QN3W0>^-V M,#\5T]2R[P9=_)MF8"35TX(LMGLJ7KFI8^';:_Z@*9%Z,L0.9G9:7[6\3W\9'43(CDW^ MRIOV+/D;)D)5<[ZH%'Y;G_Y-4YC81*JK*J@Y4$2-DMSW4)9%3!D=$2I"ATA1 M^WB7>,>#EM@T!IA $T"R9@-)W32+(3B+=W$J:L;48@9J=GJJHK9EI/^@:GB? MG@TRZ5_33U"BAJB!(2L8"A)QJF&+'+^"; 6^DQ 4Z.'O #G;"3BWA/ *! QX M4__@GX@]41E;W*0W:"H(BP9LUDCVYOZ=V18F*KN+%858U MC)G1U+XF(T/4QNX^Q^ B,#="Z7W4E%MR,V'N$W8,OX.;^Z+N\X^0:V* 9XDP M.?P[S-8QM*@VZB$,'Q.&FOG#@5EW*_;["C:6S)Y YB0;?/P>I".3SSC^2C0X!B2XJ9F>A@0W $<*O&E,ZMO$\U^/FOYA=B2X: M[TS4X5>M4Q"N9KQ=$1N4/M8A?>Q'K.@IABP L^4G'0$[+N*UNQAU=L./_W"P M8XZ0Z,/(6XO!8OC[N0%)F;Q*R@1D8TSHCU"V)BK*&$93H3YX$$5S7 ^X&#$W MP8OT@0=IB+0MU8'>Q+89U<8,HBM^( K9ETT8K:CK@Z[5),SDA*3TF0)2%[OV M '4L#0PS&P8^]]TNX4'PHSFOYP^J.FAVW/?B9:#(Q6SS;0TEI1/NE/:I.5LJ M!%?D(8F+0&H.32FHC=\,CVBHC04,R<1S8BI-6 S>X"11TY3> ?;>$*&S"G'R MFQ#!WS@O,N4'I@9WE[/0<=> = $'KHZL:4#*__3/WP=2V_3I4CG,\V#;%DC- M[>L#Q0"9.% DS#DQX#7"*S&?577/11TY8?297)B MDL6+65!+L7F?^\*^:@;[:(=@25]%NP3/K7HU6W'B+PVOSH>_]7D;Z&+XT)H$ M301-YNYR\H2'D_NP?(L+/_4(F*H&83?XM3GBJ1"IORRE_"*7N[>5-&.F)7\(NQ\G:GWO Q\>VPRWP[ M]SEFTAY\7 DU!0HZNETPFC#*>\!!N?"@;(#$U<>SQ-L?/H;>:[*JF9E'CZBI M8)6'0)2X$)W$(X__QHNKT'+#BZL\,]4Z=[V%ZY-VZ[GYVAI\BL_H\+%V!DU3 MY_7)V^WYY;OZ>=D>,-"#=/K,L<7&&"H5>:2!0P$$J:I18R1JCN;M"F/-N2"S MB,>RMDQI#!*V.= TL)S@]XZ:W_?HAY;1X%G)]JV0M_142L:RMFDD5%-DX]\. MPM#O>9-_!7*L< MDO:I&TZG",PU.OA!FNJJ/32V?.)4:]"33*6]([<[F)4H,EY#\@Q-TRV#HD>I MFHS/A8T8:]3:F )S"EZ03>(_CK'%JU$*Y)42'RUQ>5L/V%V'31=V:SJ#=:[) M3[^OJ5_$6T&\0/CAIJAIQ)XS?R42$Z6 FJC;0)H;,89SV)\FK$_9']04N.<3 MZ1PTV#T9ILOX!"+00'*[ MB1'M^&8;8D&#KP8\BF?+,@_YY#'S,-K,0SYYS#R,/O.0*%HVPL>29'>@*OH- M;#-5.Z]^2)+1O/IASJ,?+EZB/E&*][T>_WZ>NVK'3RDLU"?N8V'G7#'3K#9W,85LW%)8$I<.IBD8](HT6O)@A11.!3Q#0U M_<02(BYMHA4\_:ABK44C!9ICJB%C9@F?)ZS G5>?,;,2K #>U LDU)C>$/YG M*,H*[/D4,_)3R!GX0>7F/IO[)5'1;*4U,3T?V.AH"($J;'1T:J7::D+%M>]A MY66-QQ=N+[%H>][QQ1"FM',IIO8)NW!@ >H::.^.8V$FBC"S9=%[]PG?NZ>= M_X4 M^%H@V\2,W>*K "T5;Q*KL1#[ %\,B4*;MD@@C "8.+X2O!DP1!*F2>'X:32D MD!,.>AB1S?2>MBA;0'74;2(P[L/ND6D"4 DZ/[20^010_SZ03TNW(MU.W8FC>^P7"LC M">MB7=G)23(#[%CO %6@J6)3L8N,CDHBTF*B)6LZQ$]HROR3.C @8"W;T68( M-UGA(Q5Z(9E'MP\+9DI/1W^;AY!]$&@Z\C:-NXEI",)!X^_1.O MD\AI, K2 M!XUW$MG$]J+5W@ K6N"/CEP!$I4%'5$! Y(!/-T"8L!#OH M1S?%R-[U+)YAZ/1,WQ(6'ICYD"BVN:KN6=;FJV3((2#A*>"@+3NL3;F,+[&$ M\9D@F=D',C' %C,0*IA^[]Q[@DF8A"EA"!0U4V/IJ2[@_([H<'&2OPHA!4+, M3EAB%X'Z^%N'-4V44*XG5>!JK+BQ_N@DH,T;BCR[),X9:+7ZY+U53NM)]-IGM7Y:6ZC":OPG3DU3"Y1H0+)6M%L:S5H),\K2G^7L"6!%T2S=: \5Q M9Q,&9<=^\D/9ZR6T!J2FIIHRPU^Z;HQKQ_PT,,RP3 M$Q9M>!*L\*6 7,+Z"5X* YY8!%:.K2,F5?B/>6+G.K%6)"%\4!!)%I3D!MC2 MCZ;289O&@ _>+7HBS8FI-WO1@TA7:U4L-ZB OX YUY*7.:FE%95S@%X89:*5X)[G0U$#?WTR1F;3-(NPH2^F6QA M*M-8YP9&Z&J@F9,S M+@FS+OTZ0!%X^O(,=EV>(:S-,U@3T&UF],!]HMNO+MHQSPBQL0_TOZ4%@:59 MWJ^USP*ND9CC&M12KI':EFM8(%?YK\\*5_F=5\5]5#! 9,PY9)(^Y;54B;/4CH)Y MHS6>0D!PF]HA+BM",54ZY U7)*;B73^H%V0U]#6]IM/9:58]L]=?;%?ZP>=F M :'EI,3V,4P(-6.03BZ7UQ:$_C&8]FM:^$@MAM#"D:1E''KRS+3LP3\A6"PW'&8@U;\PI2!=: MR#2&B0;&J1GM(%8$X8?@B;-GG)#GB!_*B45#_(FRH\USP6:SBMQ-"-834Q%K MG\K'7#5/<5SRE$F>PG]9?U?4= RM(TKSBO>Y'W61^5Y3!GKJ/C\>=0M/A8NL MHV@[CZ_2K+WK1FR!,RRT+$^E>*Q)^\W!,FT3R,:P]T3#S9KB9PXX.3_@E+ P MQ@)2NE"QX)H!4Y8OI\;MM\DH_S$/)G"8DE]2;?AI8*A-O3!J^'$G9^EDDN93 M?M,0+,M:U!/31R%*R%*WFW.81W%TBS%UZ2Q&/%98[$P#9\[40?S=00'HMK2";BT#^1F=7Q3%K*)\ M^B#DUG0;H@4LG)P)-,=@S/.=;+0>W28#TZT%IO=QZ^*Y55'%#W$>3/0,X=)4 M&YQ=(=)OB'!, ?_CV/1RCWI "F:"4K %QO[D7G[IUIX^Z8; 8&[RQQ,,[3LC?RYT3E2 J"CC1LP4#D3D/2H$F4BM.N.L3F!4;D M!C8OL*Y 4\1#.="=S%6KU4O"3/V0-:?!"62W(7 @XE_H34WLFUK(HO02G[O- M^]TM%'L0<^;1VO$,BTY?HG$EF^PR0Q\Z<8X9^$[G7A7I]DQ!0F8CG-[@Y<(=)!]N0LN<3!Z^3V$'O>OA03L[L@Y,29/?HE'GVHR-M9UMV+D)#5H*MF"ZD\SNU!SU,3$A*ZG:U"? Y86?&R(S6]>NA;<:S6)M T+)SOV2QF70_DIN MR9;:['Y'[CY!YC]9'<2&4#FP-F?UB(59CYQFZ]0$(TR/!3B-CT!B26@S6]*0T(/T\2^M46))_) M+3,[FZ28A5,;%J;6**.TMZV<=XO'R/CS<< M["@[:^7-I4RS,,DDF7K=-1 ?*Y>BD.QF"D\>?]/<-E:F8OB^<8=C=]GD,LO' MUT!D@T&,=2!FV8BET><#\WG5J[ZV=@.Q*&:MLDOMX.XJ7.Q%:T@ZWU5%Y5*ZT;MM6^ E:]4&<'OL; 68Y/%ZY/W\X_D[U9U MG(',JT._N5GED:U/KL_5YN@._?Y46B=G-T[+Y,117]SQECVPM]M5FTU^S';_ MV'PU.\(ZO?%ILSS3"=&2$*EB#OIT2\@DT#Z;LFA/(K 5&]%L0E?P?BV35PUE M:6J0@6YH(IESKV"-T:D:MM72.4UI1FO5W4.E.Q2U0TT;D>]0 MF0 4J%O=C$A1)DE8-35A.*V5GD(*W.4>J:.0B$:-[Y(HB 1DFK6.I[<1-,&5 M'!^=L]46 F43[U(:$&Z,%4AP/[C%D.0JH"EXP@RQ-$%7-RLMK+UJY$>R81;] M?<]>MP=..B55PUK\*;Y&8EJ!M25J3;-9@S4HQ*RST50H9;8FX2ZSA&@KVRKP MFD ['C0@UC<:$C_UG 7D2=Z:68F\"II_D2:3D'D%X1#I!U6Q"WR"_7+^/@-(('D$Q\&(!(TB2%:*ZX"':2%6DVVOW9BP[4;=,1R]3>?LRK-% MQN.C_1=OU;3N&(]0C6X.K9?,*FR\7 -@,8=N+M M$&X6OIEV2P-93)5@2+GEFPUH-I[3K1)IS]KNHG3"P9:YUA'F:TR(6U<&"L2L M6@Z']MA;HNXMT,9 <+(:%^[/[E0Y MO LX![D34S&T=#'2X<;J?",W0>Q.S[8'ISR# &%2J&2/8RM'?0 M9!%X7$+'"Z6&@2]P.IYVW@*[ U$5>T>E8;FYQ:QE?4:WI[ M[L -VON?VAW>GB67NLAMF^$9WI @+FCO^^PV/F P$]ZU!"+,C-RYYUP#^L/ M_R859M, ]*QN.;@M@;?@L+](/Z"_\%J:2Y]F";5[N\0_+$Y7AMO7B26DB"6- M__(_8)JCF8-*3N;@0P/+\VGGH3'N0[!0&2=\4&S05Z%Q&2@MV@Z\-T>%?RD? M<1#4O2"L<;3EH5VQX* I,3PY*: M+BH>))QB00FS#D4GGGZ[X@XT.&!I3L, MX^9%]>POMW"2CJI$(39?KZX M^Y?^-^ \5J$1L7GMO<3JVG:K+,%@R9\7F ,9EM!?HB/QLX[!8AV9UW9ZNF2) M^F0\R3_=#?1[6?N(GW)4J$_$IX?'0O-*?7_G3\[(21/646TG_U$OVBT_(_T4 M!XVN;$R/W"0IDX2M4&VX)](.$I@&X3%M,$E[P'VL 7>8B$ZG/@0%QYB==CK= MII$!3 M=ZI!.LO=:VH+'Z9HO=^9,64][(Z9LA#/[,R9,#=#.TJ,Y0T01Z(F>?R4P.M7 MGEVTIOM--S$QZ_2(-"?*"E;=',>E,T!5;&L(68/X%JB>T]*V.B-. M"16@-2 .$G_=!]B[+<#6;:&XK GE&MM>N.?$DCW/BB3?S4\W$(60OO6(YW4+ MWI&PYJ' +!7#]'-UD;$POW?Z5/:>%G1#F6+Q)?,W%A;6^SVAE_(/[C[5WKD, MND_EE(X3JKSP>^^B:*4KFJ9?&G)D]Q2ZA6$U%K\QM2QHR9Z<"3\6%VMT03L! ME7?@^+'(6)P%\?BI4H[$HA(LW1QI[!#CTH*L@H5C]MW(9>_U6)59Y0+??;_7 M,C5/>XD9W%P5/9YY3PA9V$&O@#LY2_Y87/!A7P%IP3Q#;]Y4AFG! .TM/9XW MO6/FZEO**4G525B.0:0I=HGO:I*D%I DF0PSK?M:\RZHI=P\T<0WWYAN-0J3 M'.VJ9_)C,D$;;]KB'>A+= QM>[@B:;"!;6)/8ZP64DT"CNJTX%]C_#SO'69+UAVY"TC9XF2G6)FE&QVWA$9<-GZY.*\^Y2M M,)_7'S%,VBS6)Y>2HC#L]>/@53PYL_G.C.Y]5+UWD&5F@]YFI]A&Q^_':]DS ME8B^%:%I3Y8GZJP=<;=\H#^H%W!F&AWH?=QL#C1]/L.-N!XG<(>JU,BKDYAC]4IQ^J4 U%X MS-2/7$\JN-D713,3::ZC%I>9#;?FIK2!R">OCH1/[2>+OZD>&,/] MW2D?%73[FBJ_YDLIQW)_7)!OMBVN1"8)$2W($V/H'K"GGSP M1]9>[T!45J'9'0FR ]/ .$+,A H9T4XJ,4$EQ-"\5\3>?#-*+IN:$9W>UK,; MK%V?5)BK5.IAQ.0S3/Q$::$^^3V46:74>O\J-$_.JC ]ZI1$+1)>&!Q%Z5X" M=>##)IY)$IQQKL;R:7KS:& < B8QYT':_!^E]JT4'_.O^'?$2VI5@4[_AG!' M-WCV6'W2[<@9#6FD\"7J]A5UC,CX G.*/?%A#!3#6;9+>)UNSS!JJ'BOQ*LL M8_$.F1%^,E^?.E_3@WINKTMH%FFZG\DXO>FASR0;U S0\&C0H=3$WP.]NF&/X)S! JN%9.*!\?J7H DHO!TV MN:#JT1RT0;J6DJI;9^B/,]W!Z_FQ@3S5C=1-H2.;&&AH9X.?]Y'SM(NVGQ"7 MK8E?BYWDI'7^PFS=10O4)U\7UQ=#*2 M24*SV%>SUUYFWJ0# 0 MJW=3\/W(R:*VJ1HKJX(21GG!U[I3@=I#5@V=2 WM77IG>LUFEMA9O_!*_!+O M="]P"9C:+]D+;5&&%<["GULU5WB/5A<5(HN *ZB]MDI4/B &;&22RCG010W4 MEH_]0'80J27N'$^0=(CU?(P)LS)DMH3!Y):0&&\0MJ'V53D[9S7\AH M5,C>FY(GXDB'%=M0I^WD\;GH-'N(N=*2&:I*S,@PK[PR3SOVE!GZD)$S+JZ' MH*H4)!AFU*;QLYB"?U!7UOEU1Y"YAY@;(&QS>*@CP48(-1*=)J?.0K;D7[H+ M9[>TE:LTG<))*EK<@LSX4=-+ABG?HDVWK+ MJ0^Y%H?B9U?E\/;?M)+T?']3F*1.SNZ0D2A;N<$WD!L,ACY%SGVTLW:VY7-1 MEYL):-YF\3-K-@NY#/Q!%_,2][Y21\V!):7M M3@I?AFF7$R>R9.8RD\F\WK>/[!=+ &RL&9I:A_TWCSGO*(;*V/DZX7DM2:!K MF6-P0161S-OSNPCW]J# QBWM<8MEB=D_MD!K.C]^4&8;/,^ *&0ZVVT52=;= MP8+F>RQE@YCH6-RZ7WC1ASC2L4@EB8*>3<\\:>4!F@#1@T"$_ H_<.K -E;D MMQ]U)N^MWS%%M*F)+-%K^-E$(V\SLZ +UB=))7WSE*LV>"D;/PV'JT\JS1M& MZWRJF7[ZY&SJV-.ZSE'#V;\G>?IZ"*NQ))E&.B-@]N+P(+#6!CW;*T2UK>'Q MDCW'#C-.#2 J%:9,^ROI''EO\L@%_\K(= M@5]B3BU9HS[A!J(T9H=OS&4,DS&2]4G_J\8^7Y1KY7(*4-ES4CT!)R38675= M0Y1=O'*,8AT [YE.W9#<# FGA,,,GXP0Q$M$TD90[X,G&?@+*8\V.]: -K8L M W*.!NZQ"@MUR&W$U/NR5)?Z]<']0///AJSKFG%Z>BN^JYJ#/KDO6:_7[6)5 MY^-;DLM1KR]^\_D8LNS-G[M/6;^?>SK(>N>HU^P WYU9='YHM+7:!+UTJFUE M<%7BW+K,J84I#6BG[P#IY&P6NLS&T)U-COQVT'V_O[JKU*IR_D(.#-VE&9_+ MX+LL?]:5,A8HZ[.0M-Y07P4A^[E%APZ84%J^*SFEMZ>L)[L4D&,ZO305.E#F MLF#C!Q2L33-^K;_]DV^M__W'T[O?-&I5@P2[K0Y?2_)O$ZOR;ZG:2/5P:RN) MP(X,ND-#L5TZRT#X';)GO,NU>,@BFJ]"NS.K'O0.&1&QH\E0O'W7N/'CS7/V MT!B(#R1M,O '3D!B"I]68)S:PKST_U@%GJ2MG1\E+$I$MZ+.R$'Z'>'\^D*S MTD/V-S% ^:^OY,?O$KK\NDSO">47BH=Y0!XHQF=/SKB%DW$WQ7@6&AU;";@D M"@MM>\8NUI,DUF7S&Z/F[7AW%];F.1?/'HOEO[KCTPIV<99*'HOS)68I9ZFK8EG7'R"+85T8,WE_.*56]U]2> M"K4HI)ID979>)CN3)E/P<)!U%ZY/M%%29YY>95'@XI<[DZU/,E_EJZ&F=S\^ MF]"0"JA,&2?*9MZO"PNJ"JF]T/KAF#*SN_&)F#P2AMPUI_/(4!79PS_V5&GW MIU"4,E.(R=59F>,EI]3)[RZI<])FQ.Y=4LI5S^W>)68B.,D9EM0^J(O6BD[! M^6Q+?NA6X13T0:$5F7T'1:0PW6Z@Z]#9&A\;2PE2EM= BHR&R)WUYZEKUBQ$ MM$^CVSNFK7&?]GQ[Z'/MO)6FR%!%^'RV*LQ>NN<] YR52?_2*;^R-*OZ63+; MAL2?*Q_XELN]A",AW;;T@)$V#N2J3Y0I++(T9640DU84U%\UM8\E2YI/_OV3 M*G>A -6Z0TPW[I-4 >.A0@I(\49,/'(J1V%0)0S"&$//'LE\$/+E>P.24.^I M6)![IDYA-CAW6KR;58;3>.6IBR35K5#,C_%,\4S]G6K5T!=ER2K72+CE&F8- M1'L@2]:H!KM(@M0JD!8TJJL_N!T>3,PEY9WXP;'5HLVN J8W$4/"]"&Z?A.E244@DAJZ%A)ZMT:MV/8JGDP'T ME0#NYNP!YAX;^NKZT1_+M0^/J!<*]4E*NY0N#'D6#S:L>NLZ5% MO0/_%C%A8V0##,GUI%LG([WJ)*3[J8="L3(W\A%[K5D=J0 M#E]#O%,-E. HPL&87S/6=H;-U2>U:N:BQ&319;MQ<@; H,WQ$AZ8F!7=KNI1 MAD%P T*LWTE[C*!-8[.#I(&"*BU_3*MV,(.M(:U;[D&G,0+1&B">+RHS,W5( M66_FT?:OJD]:;/6EUU$:F8?#'D"[(OG9:YZ7Z)-=/E[Y2.GO_ MT'!0%6MY?47$;\%4C%'!I@BHJO7G:^2>76Y/N:1!N9Q_MA.?3U^^M0+RP2\_ M6.C^!"+H2X+U9N[ B15G=T/T?KD0WDC]LB>MFS++F.$5BO2+LL[N)"N0?)*I M-9TMX(, _/[OA&5G$Q66Y*0$V@>TKYEQS 4YC^_F?9>?S6:(,_3#!WZ.-,+$ M-DQ>U8WH !];\#@#L\#>,FOVJ!M29WD$UNP9:J2DX / I7/*_TDT6J=:-\2U<\$T-J-O]@D M3[-]YJ6NI33QH38 %L^>POF?_XP_RF>3&__@E0?Z/LZ83T\YX8]HU M302PN+ LH(:1ZX*C;0(=]W4#AFZZXS;K4\X*;,C-FG8SH6C\K1TG'E]W2KT; MM9.!NG(K3CPEGT]F3I2:.9$&M[0J>+SZ0,NF>[J186?C(NO]]^I-S1(CBG=-HN5M@9*T==G:TAY*JF;J#*0A#PYA.Y7Y0JZ;? M,P]NC=H2E24H_GC-P5-L09_*7Z<=69(0?@8?G)6_&IJ23&7QK9TZEM6AWI'7 MZ>+G*73U%5!7 %#^"52;WQ+3R#UG;_6KYQN(A8-D]T#3TW%DZ?F9OS]/E=KY$5-@ZG,Y,)"PXN4?G_7 MS+8[;R5/^>,B)304- ETOCV@3CJ>J,.M8/6A80K?%#_[M8JB2V[2J4<']Y)] MF%P\G>1"X.+;J.POIM=^F7?,?.$-]*2FF)_V+I?=7/@]PN?PV-\WN-7>$I M6 ^@NW0@+ "9_?62\X>AX62@,H@6LEF:9U>K. M\8T'I?L]T(.S!2[%C@B@- M:VV-:_4?^O):CI#-R".HMK;$YHXW1F7WXE/9,4ZAQR\VFV(N"T]H [=-M)B5 M_:Z8E8K, [1C[&%SH[[2$+X&&K_,R;0+^1P#<9S]@\1Q=J<.KAVC_?T%.YBD M/Z^?6'D-'UH$5!">:VVOE,$G_U#*"-U_MVO^GR]>_LZ^/-?.Y8 NPD@U!F9) MK&XCI(G BVCO UYF)Y16!PW2*344-XR+:>>AN ;"Q9C,K7Z9+EV=\R5FA5&_ M+Y,]8E;'K,7J(G78N9C"A&L\AXLRA?RX,;Q_:UR_M=[=A)$M,CQU=R7G8 MUF>XEU).?3R^9-KB.+.!V;C%S;#,WF^&W<1Z"Q?ZU3=4U-\*EX]&=IG=M2.K M*F*.R1XBQRR%9=^$BQCRL_JJO/:,MS=A#\.IAWAL&0!VYE\BD[[#@CY3I2S M--TP;ESW\[;Y_,YF/Y^TI6ZT@TE?V#^>IXCJD>(86OCVJH>PTQ2&/:"_\7G^ M>J.Q3[<,&WD:0U"5X]MF$PI1AOWW@#S=FZ_'6BT_?K_+1AKZ7UN;B DG34?/ M2:-UGD@BIIS,'^3^R!U@ M8H:#JT+VOM=*38;BRP'5(_!+JD>_#RX<3D:(BPW:3:OW]/'V56U\8U=#Q+PM M^Z?X$?B])=$X"%LJ5U_++-_FRR@6UG^TJ"V;VKD:\C$THR-F2W&A7Y;M*[4:M2)N8KHOWNP/;-0QL94_. MA S-)QDZE$2Y#_!A6, MPAJU1O&YVU7-I0+:F),J]YY)7]TV^&XZ+&-P2_ZPO34X/6%C>W[!;6[KQ0>A MUFAV."D+E>'=;?%VZ,D."VJ0A2T]HA86/!$6 I^AN6\M++CM+*W);]F0:I/B MRQ!M':/<$D6VKGD( VU(G@F=95)T)OV=T::XEG$VJ?Z6):Y=N[VX:V]C144@ M8J)&B.T2,@(AA&TB_4..%H.90?;FXS3F*+ZC>Q8PCWW,X@DX2&!V%@\;T),0 M^MR=B$$7/N26#M+9=AK% 1\[^("<[PN$M0???%]0+!YH\WW/''A0S?<%@:]& MN5O9$:L),\6-O,GLMGW+R[R4KV:YKGC[?G@39M@H6]H+:6P>LG2&XVF>YV/4 MT[ZPG4MY:Y3)7^7&V8ODI,6N5WX53L/[5"S&EJR*ERYP#;..:WCK6V+S;*51 M&@R&2G8#IW)(=[4D'GXX=Q6H1:E9EV6OO[E32 M3&/AA._>N'O+"3-QH(;^\/EQG!=&]R]2]!5=X>?DI;]MLOJJEI'1.%]VC'V% M]TY^6'A(5>]V5T$6$+,RW[854J!"K#A@3X<[-QJM2^U&X ZRG.NPI#;SITAM M9J=>L!WC?._C]?[U-X<^2^W("\9VY'_;+UFP?PI9!$VPC ,55(S6^:=02*NY MCTAKZ(+J"F'W, K1S1C5J)G-"L=FD2M6^VRM,.WW9;A'S,RX MX,PL4I^=BR;I<$WH4K_4>6'1MH+>-W"U:1W?\TDPWGS"RV+,.]E-RP MIU9;20%-E ULPFVN9DD?F1U=#;>):18N^(MZ"G4N6E4D,.Q=='KK]*G8HU$1,>((!X%E$ M ?7R;?CUQB/;CA-F#C,X>]S,<3.[#.C_(1-FEE;DAQO+WT-;XG&^AIYOSU^> MT+W47NP!\)0^/LKJ?91R'T>3K/6 M3/+;-FM=E4 ;3F3,RZ3I5F> M^>;\N!190L(>J.->R5:T-I?J/XNQ2$K8/YYGL.J!;>D,2R=3J6^.ZNQ.S')W\]EW"(RU#V@,]7)8+['VY69X( M<1B:U,\P(P2!U>KPN@B4^J^WXGMP_&Y,<+HX7+FPX("?B5!9WW.+U M;;7R^7%?J&Z2RA(73TG$O(W]4]P@^TO^<1!V(-P^O>9*'\_!^.\B!CU MN#_(,Y$^J,0C=V33A=S_Z#Q]?#[SW\6?$#'2\G^.LV!5C>1N4/2CI#\_WI6$ M=JH30Q,_8FP4#MM^7S'09Z8/^J$-[UD:.%EAK4^$^SPK?61[XVJ,AO>PH?51 M3Z=.SC)).I/FZ!3[G1OK;SF\Q\(6)EV:R%?]Z^(HN[UANQIW EJV[!J%5_&Y ML565>@&MVLE%]^ZJ7"I?B/Y%GSOP,@P5L$6&/#S85@IN5$ZDAYQ]'W5YI MH*QM_^UD'D^(EY_!_)^AV11+9U+KU_[&\_XW,.PFE>L;-E]ZN?I08SN.)T2L MR9ZXAK_5&5YDXC.,)#R$RVP4H-QS'8[WF M;M!%FMP\^[?OW%PFQV-EK9VY9&]+NB)\;# TYCBX9\F6_8S(D6E$NMB7D'M# MI!M=S)\\50%4!RD2)>J4VJ)F!])P^ C&0$.4BFU7RN@@JH=/03$LU<7O[^@_ M8@0B_UN=1=FIOP:>P8CTIMB'$@T-6/TT]3N>C(*L-Q55Q^#4:WC11TD1P7TUM8&K0,GK7\;9W>J@1(\];__G6$9YA=E MKNTRP\\"W7.BB15[MX MN3'5-:] )XJ6AII87NI4$VD&-I.HEFG(8UM.Q&:;83ZDR&)#5DQ>(QI4"ZYS M2*X32TH1UAAH&I8^F(7ILOZ#*KD/R#I\B.U!_"3F/HD^)DJ$_X27&:D#S+8: M"'Z/Y"%^IH4)%/,U18&U\,G)%BA5H_JB+%&&2AF:V--;F)&)SI[&%-XU?I9( M?65L/F()\08R1@CU[':H?1&\=S(&@J$G\ : &W9=?*0DT4#1\T/K0[DG(5@R M^4.0>T?L3+14.!=6OD!KW8V%J) MOS]W?[]L/"\X\G.0B$""^4D]#%1P#=M4"AQ")U2-J7B(K,]UX@N483/@@;>O M%W_FN=T]4._Q=I?=+ON3JC1TI!&/L'63IZ9 L,@:7^"@I[K/6!\3"0$DC\63 MIF*;3@04:3BMK3&O%H^W?3#G,&^;^TD]+;O+GFKL]SXCOKH$&!_HJZD,)'3V M[W^=GE(E&9MF/ZE[L8U^X94^!ZC7Q"OP_"]3'_Y)<3QU>FJY6R1Y&#R2:Y[U MU%#[UGFM#^R?I(BNOM;\UV!37?U,@L4A4KP_/S>$QW4QM;3W27M8GA>2-@Q_ M4;5Q'[\_IV'FW_Q%W6&+S83SG0H Y7GOK_ZQ?P9?N;X/V_'Q[S\8\CYWH"'Q MX[2!L.#!:_?)'7JAGO*!>C*&4)]W"OD!Q@M.@+,)2@_"QY)DHW07Y(B*8EF\ M4J7W:-M)YV F^7H0H-&>UX.0+?AY$ (N7)_<"$_,JW+^.VF(!^Y4F#$!"/WH M@R[> GY()XK^ H/4L@6D );I0A\9K&E_FK!'.=,@GH@9@NG0Z,B]67.C8V?V M1&]4A.J_"9N>IKT_Y^?U2:JKON3:A4O^J>'@G23K?47$;\'DAD[.JLT.D@8* M2N +\?B'#*>-^YD2_YNW.2-XF?SY5J.[,;9;W7C7#QO MG'.:==\*\H-4>GLHK3.A>[T;Y[[5C?,[NO%)C[]\DG\_Y!O-=OC#TWVS9<.[ MEJ!IOP%+V"478H'3 1R<$Z1CNP\6US*H>A61R5DUZ#Y#M+Z*-:V M!TV\Q,IZW2#.3(/YV 'XN)GM^]PZBF(RM3*WUR>="5(W^_UD/UF?*,,OX[TK ME,14ZF1]=%]1/ 5GL)/F+%\,/QL[,,])THB1N^E9R(0Z\GSFZ=G'MTA%]H&U M;_8IMZ@$;YFN'FIC>QW?+UJ1V KSXB#+.45G4H<_R#[@K0:L*^+9$&;%Q^.D M2_JQQN2D!T:IX5(A&PT5^DH3(4#.OR4XQ.[59_FNV'I0.QL(CN!=L[PR9/9$ MBX>KNX4'GNSKOZ:[M3=D13$#&#W50/JW:&V GY9([DG2;=AO#T9S?#LM=5RU=O^PL[O\,_GV'L%XV:K!,+GA1<48R-/6$N] MC%LYZ_=%AD@4A-167/![(T- [4!88[S)]P;8GJDG7,I(GYP):9K'YBJ7CHA- M[J4+]4Q MI\7K8^:)_Z3+F,F+P,YJ:E[M=M5>U8#<=-?VD#6N]/G<+;Y^1APK\HD/.3L% M\>!NE3K%?X>]XN7P9C>+VLT)O&W$_Q+?6KBQQE!WO:2+VAYV[:LYY"N%WS_7 M1-[=J.)<% I'!MME-,=DZ&QV=3__XQV%#O]L>/#WY7+&L4DZG3E&K0X=.<*]>";BB_<5S;PG)N/QCRP/S%STQG=J:_3[LK") M- XG,+.ZVC;F+L6@PF.-!(?O[8,-"K!OU$4[0J?U M=IZ$%^98*1CHQE/QO'&G74%3NK^N=)NO_&7Z6 9O$%%_&[<:5?PKT=*^'6ET"6;R_XZD/+28]>"V:X%;&3G MV>)2#D7%.NHBNP;-=Q#:1^FV/6B.70N")2$LR2:(?6W^<3-K15BV[5K0E9-R MT:AU7XUCTX(UW)7;E4(OG!M\2/4L6?[DC,FDZ%0J_5TZ%L3I2J.H2LD*Z\PS MC\FE!@S,I8_-&4)&WW!1,X6Y39)FTMEP&-PTL-/#9G M6$KQQ^8,$\S*.A1,B$ [$)+)D[,4L$ VNB'CL46&@*I!YMB9 MX3"H)US*8 AE\/C?-,?%J3.#;^^% _+<'S<3B\U$5^_?YI1L!@U>Q\S'L=Y_ MD5")9;U_YD^J]P]=P8N@!$-(LB=G+(TU?IKA5RO[QSL*'?Y<>/"/J-[_8:A< M/_7+;]<&=WA._6.]O\M=L\=Z__5A=JSWWTE)=SR$(8^9,_%"Q!=CORRY^O]K=?<#;I(DYMG__8=<9O)E>J3NZ=^K38I]RK" M^P8E]/ON#'#@S0QJ'93(JUV\W!@J&IGT+YUJR3VQUY2QSB#W=$,;$*RCC Y6 M%D0-+5 >*(S_(J79N(G5&%W63?->-RBU135!WVEAC :&C\6KV/,(YB%CC^$3G\K0_E'I:4>,GD#T'N_>%H M5.XE\%7WD,D'1[+1H?J:K&K4&(D:)38_!S*^:_P=7L/H(,I".< 7X+P8EQS] M= S\C#!'7Q>1W",+ ,\#K- [&"4)?IBN_@1Q]1/4L%U)E*%2_8'6[(@ZF@H( MT*!S=^#K!J)D71_@?8PZJ$=05<0OPK! ^,D>X"!&?+'9D;&4E7Y0-=B!!_5; M2_:+B4!4F@,%X[U$#72@#9&2L!S *CY\U-?4AG7RA%FQA3^$=(%)6*9_-'(!E?$]" MG))54S*\I*E=TK,GR>!_#-7MWW-"(2Q[^V"S:0,L^:?U!$?(F\'T7$_R: Z6 MX)+*(HZ@OA\C%AW MO#8;-FV3]1SB.#^O3_17\?ZZ/RH(0[>%RU1'I9.S:K.#I(&"$ICQYRT$LI@H M4!1%2(KRZ.P.C*?_%]/646MFKH28#.$V$6&@B0B79)),G?QI!^U$-.'J_2&3 MZEDZUIL:6#L'8;[ :VLS\#%FU' _'U=KMJ.R#?F MH_K13\KEEA))6-!"K0R/,:OD,DU_#7ZN14>4%6?L)A5G6X']0"W\S#H6_G9% M:(P;QIX'&Y+*1.4NJ9H-YIS'3JA/VNS3%Y_/]F^5'4\061RW)KP>6'U@Y9\8 M%:!<-*PS3AE#L0\P_;4DPK3VE9\L4:>C;X:)C_5_)Z?+*(=,>4AF65K(,.%% MG/Y>0D"I\$1 L3X9?0S59B[SRK.92'-"9IRW*^4 ]YV]P.&+D&CI8"'Z,\D] MM()=YAK&&(V^SI_OA:_.Q_V!FYH^G@3B2D!?364@H;-__^OTE"K)2)%^4O=B M&R-:U515\0J\\,NT*'Y2'$^=GEK(+\G#X*S;/.NIH?:M\UH?V#])$>-J+5,D MF('A9\,MSHS'^_/#$1^%)#G;9<7NG.2%I W#7U1MW,?OSVF8PIJ_J#M,H2:< M[U0 *"]X?_6/_3/XRD5,&RO__0=#WN<.-"1^G#:(T^PG5B#@#KU03_E /1E# MJ,]3K!]@O. $.)N@]"#\UJZ&/]SA#KZK:244O _+O- -$7S&JN4^#_S34Z_' MG/C5%SYI.]Q_).;]X\%?@;>*Z4]4P"\/O_+XQT]%"4!I^<>==6?C5].1 -U^ MS/6I2Z*!_)SX2S?IA!.6;)":VV!"!/>\0JE]-S*"^537"8W!B\Q/\5+F-]9. MG!_][,-D!IJ M=GHRYMN+7>'$])URA9^'[ I?N9OZY*/"/J0JHU?ADSMPE25J5VNJ/KF\^*R^ M/SP+G]E,(%>K2YI3BC-E%@Q058=%O3A9Y#'QNZYJ(+O 9C_2\_.&0TO!8Y;DX[ZF,_/I82&ZJ&U>4$VD_8P8IMV,8-]!%CH%2R, M#$S5Q)AU+%R2]492;&6I/KB'?-NF3R!@]A=@",QX_V MJFI9SFEM&5Q$<$Q$W!)CVL;,0AWU5D@M]<-5+C MK'^!ZZM8 MZ^*CA(_PZ9,S/@1\WQG:;:NAALU=EZ&=EAJU!)$OM[OM0T"[52QVEVB7 ;3S MRY_:'9M=[0Z=?VWQ"RK,D$1B=-1?4-?D-IH_, JHX2T"UDO&:U@\UCX^+&TC M^>MML:'(#=1/RPZ23X')P6N_L&% CCC_XBF4A+KUG]) @_N8#3"N M$T7F9/ MSCB7'3H91[OH>[8Q0G ;(H3)_2;7??6Y$U%:W MLEYV6:H^>;OXN/JL=JX&N<:!QVICF,#R;X,DAB:>[>2+"M0<4B6G]KCLUA[_ M^T\C^C*EN6)"]EC62RKD,+V.2=5J%PI0=;N6&PID?2O%:?P72/*"WS1AZED' M*:3(M"'V/O"W8K-I+J2A)I*'0(RT5>GM_<1YK"^.R2<)_(D&:2N>3C8T"?>K M!'6\#6[$?E]3O[!R8DSE^$CX7S-;!G^D=U3-."7B'#]GCY:!]:"XUM8]19GRO8,Z/&3^,;^H#LKC] M,'PS=C(SQ:M3 F^=1>N34EJ^+73?WS_50R]+Q9SQ#E-#0J!(1AOSBYI)G6$+ M]4EC4M/ZW?-!LH9.SFQ($.1UP.!<\@Z89_RJKA=BCR\B0M.HJ=0Q/@@B>M#O M]^OHLHB$Q^=J\\#1SSX-Z0. [*-@#HT,)V=1LA,2G:3!>-4\QU 4A[V2FXA7 MK$_&(RP[E9M*[R)('MX*=A/W7#L_:V+YL/;M**$\N M%6V>W&Y3Y/9^UZ'!\$E'K8%"WB-YNZ8=A(\%K@!1H33K-^:4C[#]W>W%\Z0:).NJHX-_N M]C5UB*QXQ7I1P$5Z3W)?LM(Y%JF#M/]2]AQQ'85H/.CIN=MWUOC=V)T0#7R$ M'6I*PLG9HE"FCZ94C.OM3ZM05USM52[W\OW+':K#Z]W^;G2KU&K=*I3F>-D, MNQ<=:AF8)]E)NB]?K'47R4_]H$[LZK2SG '&OFQ/)T50AQ!MY-4NDJK)3>1]]9: M PT?]WA]I1%N-S<.WH/!;W M.JT*_6[EI8O!1T8;9@_B7G>B]W#)G>D]@7R+H>L]_@">J,V[0?F\G;V]1@;%2>VMGC/=QZ@#Q95;+V0&^L!A? M&)9.\OP>]9N-9^]9,<8;L^5O<]"U)H!(,#6C*9N-BTBR85?%FYF0#P)%!]?/ M(CBH>98N^7G#>CD71 4/A/"?%01_P%B:\P!J(0;7Y3N;4B79P]PG#)LNW]0N M;FL/;B0'+N?GPMM9(P A&^/DWYE(EOC) \MB;DTQLL #I0M.G)'8!9OUHC> M;JDM?\%@&M*ID&1FKCKKZ@[:JW^QSP;=+H&6@NAL=P@376U>Q9\8\C#?^OR< MM ;R2B4+@W4YN6W9&7S9[G?'U@4(OB4Y@4ZSZX]1/O3IGB[:!'(7S*.-Q:AO MSW,OS^(%\_B^RG _0+2)A/.2H; "EZ7YS.JF,^$T@U]>KR?4)^B5OWW)-+2K MY_2!Y]C',?]\QR5#%ZHJC61%P1A>[AEBKRUC+#![\RXO&DIEN9FB(>\@I?66 MK4]4O= J%E/CUL?!]^NURH92"\N&V/I$EF^'M\;HL?*:/CFS84$XF L-R@1' M7,N',!QL\HK?SNTKB=W>8\C1;%@G/(-,H:8)?37!::.VW*FQI&DC(1,-F499 M4]6A%!9;!$YC=AAO U.$H'9>)>52#D7!+V6H*Y9;,BF%D5UJ,[7X!!D+I9G3 M6)U944UW:(QN-:QWNK2;-353.V].SR*_7"M\B6.7.%5:-F;X MB9<3+DC6P%EG]W7LQGLX?;PY=/XFNV(RO3\0/:=A^2%W=?0I! MJLU7,TS.(PK:QK$K> 2@A!PV3/A10T\2> M;DY@QX;%O:4VY,P.%C LQ-V-/Z5,.KF*TGJJ7 EN9OCR4VT>_=M@T[Z3&5EG M,N/:'H;%U)4Y.4ME&#K-;ALDWF?0SS&LY&Y?E#5R@QBX&M;-#BS=$+6:QMGKS7.8;325Y*<[R=[^S1QJ\\-_][A 7AH,*-)?)T *_>J[N M8<8B9ORRRS6.E:6L._3N^J$QC#SUQ=HGAND9HPS3[+/S6'M*(=*);%L7KE>! MAFRJ4_GKM"-+V ;\2>$]L_)70U.2V336)DX7%-CM8(1FKCY1\@_-5^[FZO%* M/G"C)(8NACF3-="\S]1QWF?$\SY3QWF?0:%^*/,^C^QE%7LY\,U"+T%K4B?Q M><(_CC\2%#"OQB@:Q(.IH3[DF_3:1/'">#I$"D7RYO _/9C!V8"YBS2%?SWJ MH!X"?RS^#VE3J'G]H4U9:PZZT&>TB?2$VFP.P'$K0@-F"=.&@:+P(&.I-E33\,& M&[2@1W09Y #SX/\LJ3UUU MNER7OFZ\R32-JC36C[&J[5FF)L] M!D2MG;MAZ43.2G>[@W2WF)UDUQ&LDHRY#(*V8'-I#@OG(Z?3L_.1_2-;@=>N M3\2!:&0^7Y*IKG#@QJ4'SSQIE<>&E]\B!FD=>R84F:]/?K]Q#X+VUGEY[JP* M10("S.7(6,SHD"*2<>AXZ3398[@U?,+;39[>2V_(I=[/@.=Y(4\@Z32'-XQ- MZPU?ZM/8,. &2%'8>F]=%&WSV<1JZ&X'[,W/?3>?5G^(_4?#P#&GC6@+47\Q MIV:X!2R8(N@>VR.. 0" M!A*_0;?2@EP=GZL@>,UWN2:BUT'CU] IQ&H4XH>/9#A%+;.#S\:WXKFIY!=N1,Y7_9:B9 M!)@\6B#)]:2""Q"K$T#KNE#LURX5R^74&@U*8M-()I/9#&<[(O*5PN^?0<$,2&(_N=^>LUF/GV/)S0;H'!(E M7DR>\\+-]44_-RZX,]#+LXGD:W8.!<OKZ6,9SO$6O6_4J M#@*.0V4W;#3L9I^9K'=J#R_5[2-\]:1A35M#TSV.-T]DG=?>%FYC5JEC C'( M8-W?-B,?#!@3+BCG@&1:?VN?/Y]W+N3A[]>/H/K;)NW=%F]D24V1":[2;90^O0,-+R J;LUG M2=>79)8/Q&8#9UH?9(LL_N TP678G'JO=1XRY[^+3&--]2^*BH#UX;4'+(>" M8:S1+D-WX>0LG65HCEN_T49LVFX=@D:\#+-KO]G)=>MWY?T9!56#(^#2H2G' MN^+4J9,S+LG2J=3J%M4;\>D#;M%54PTR%GL&1[8OF@FB-A]J\RYA2U5L,FA< M/&:?GAI#+;VEOK1E%Z9M%*9P:2R-5?$TS62%C=2A^'3P8D-7A299IM8>W3<+ M[4[TE(V%76K MN&WUA7 959:XQ_@DMY$^L&G/N //4+,:-X#IM\+^%=F/ M>T'^1:E\(>/_#DZR)'/R@ ZS989EG$DHFDS,@!!9G(D9H9JP3MY>4"SWS=L+ M'.(,&^\/"2X+LSB_,72VRO8,#R[?,@/4#SQN5NA\LD!N@PQ0O\9!.\W^?+W_ M/19JW;>O;"/\[,^Y!EB;9W]BDU&(>?9G0,=B@#E@D69B,9]BJM\LZ7PVO.S/ M"'S<&V)4B(XF(:YIGP$350)YN'>*FATAJVO*19-MM/:1]HEY4#8.:9_%K5S+ M.[U1_;:4$N2O"R6WE-GL/^WS -C-,>US5VF?P;*A_-,^PR&?U6F?D\_4I3"Y M?QQ\,F&F?<[B^99IGQA;N6/:9Z1JW;)T(C:GH_ORJ_"D->*7]KDA*F[-9_^@ MM,_BP6F"2Y/C]$RW\%Z\OJ@VOT_:9[18OCK10A!.SGBL5X2:.W=H:9^Y ]"( MEV$V]]J\O7CLWCZU E<_'5+:Y[XX=>KD#*-MN!G+Q[3/^*9]IK94Q28C-?O0 M>'R^4O5F#-,^HQC *?PI:9]AUD);V-0Z%VJCXD!];##?*.US"RP+H(UD-M=& M_H"T3PNQOIIIY;XYNC]'[[%,^XR$49EIG^E4)MR5#+XY9G]/'LB9!^,V! MF,G^7&=N@ .9A(^#<^[>IGSZ-N65DIGZY)(_+W6&+]GB8^!=;")K/8X22]0[(,MUN7TNFC.JF M4U?"8N4'(4C[_5.>O,2_WF$/JP?)/!4*VLU;\85[9PZ\UZ\/]04?SI(^#F>9 M(_5PA[.DC\-9@D+]4(:SQ+=5NKJLG7F)#-SP:M[%KS[JZ6A1#_4,9MHS/=23 M/CW4PWAI?2(6,VC8+!5RC\J!,UP8_8+P(9J>*2;6_!:OF44A\Z"+9FC,>56H M#D;J!2- .)AW@K\R&[;KQW;M$6\YNI'16$%\/6\6U0OIO)];V:<=1D:;)$1Y M:8BRB"C>4Z3GG94;I**>G$'"-54D:VH$?>#];S^0]SEX5JUSKF30Y*UYOGZ'-U\;(66(;O%[.\0#VA5+-^7< MW>1-OJU/.L6!6GM]1]T+U^:(VN%M869F5K-;FC:";Y9?F$L539G!!ME=P1>= M36S>UD4/U>' -$L$H MM6WMYVBADW(K-B=WC6+C_#9[];L;0?'N@L8PD7@72M.J$E DUI0TC+F+ 8U#ZE,&9H3^$B* MM5RB3<\3;554\#G5;E?6=?Q"?[H=M?./8[;4OLR$Z.>8WS\VIPQ-;@P,5<,0 MM[?D$&G09-1E6+LM&(@$#>\;)KB&_E.C22T3B7@HRHBM= M6'Y;41,T-N8%)DMGF-58&<=ZL8.ZMA"92>;DC.-3-)=:S8G#"TSDYX6U'WLA M,0F'OSP6GN[3;/]&F$0GJ%>4FM@\!3GV^?>-6>R-D4 .,\VD6:P=9+]=K<7! M7%AX+"2=Q*H8#=84WX09M'-$2] 8*?Y_%R0+(OLM')D_9M2/,+V3!)?B:LZ.T2$G3! M^B2=_W@O/]\51^1:#QX+"+H.( M<0X8>I"F^&4@K2$SYR%PK6'9=CZ^0&I;$_L=N9G3 MD.B+KLQL@G#.-\(8^A[JDT$_GW[O_T:93OK ,1SRA9V@(V5&@4B^+U8,C ZE MF;"A&F.J[1R6$O%IXQ6@#)U"9H)]J?ID\O)U=S>\ORU=91<&^P9=?.@QY,T^ MNH!UL8@"-#K(M%F?*-W4V7Y1<>BH[!_%RM5]YL]/QC*?OINDG^27=:)]@?9, MLC?G GR!FW4=3(O>V4#@3!/7B713&;[??WY=9-KAAP3]HH#A@3">'<.=RTF% MC[*DGI4[5>)P_?:ZHT:!H5#2M:0[F)9OIA65_;+;!0=_SU-+H^[\E, M^$GW/A4GB[))S%W9NO_!IS=L<*$G2\Q8SPQ7ZT+K^#[MOEY35Q:&^Q3;J"DA M2Z>8U1&8[Y"+$M9ES??5W\5E0?]AGDZE&5J(/*6%/4R>=:&);N_JZ\_/UV=& M+/+-QL[*Y0(G I"=+N)BWRR*O%,>Z$&!,(B*.SD3Z R;I(74,7E@T[;\T#5L M45O^\"+WW,YYTJ3"M+C6RT6MJ;U'JQ3-@\.,^N]2^]X_D8=!T#Q6:6@^DZ29 MS.HN9 >9X+<++24,2 MKZ2.!"7X7ABZ$RG0#REY>5$V1(K[N[VG6%G?#CJV) M7G!?E1:Y+4O_V\3(G=Q\&?G+U^S=M;AK?K[ L(TUA_'AY62)^OQM_3][7]J< M.M*D^YU?H?'B.B_U*[/3IZP@,V,8KQ^#U"R&0 -E"PEK \.MO994VT(( M"82/)V+Z];%!JLJM,K,RGXPM*BHOM%KZB5&3$:Q #T.DP$"U-C:0<[T]^EVK3^:U$K\SG^1/1=^*V)HM5KEN+<UJDBKUZ9EPJ>%>R^E5[ MQFZLS*K9I5KD'SG?F_G*_)BO[V>^LCLR7W$.7#XZ;?(*E/X!"C\*W!R=#$;[ M0N)R_(E:S/X'_\51^&A/H7)F.I &@J0H&"WX05 _;-%A.MRXHS=UA&(53Z6\F=4,?!0,_5C.B%H+S+Q< MMKM*=ESCM7G>FJCEJ4)' 9(6;/2"Z+QY.8HWA:QBE54[#VDP&W?GUA"NXXS# M>H)L+)K/' I--TF^_T_$(E[82,27VSB^D8@K7P+W);SQEQ]B8D0\5"%CXD0\ M?W1:S&PNXML<+J%SO'%4&'C/#8_S_/"_"4NTJETQ7'8\SSY*Q5QB5&V#N_+$ M*5[AZ/1/.EH.5/K/ZFJF?'6C-95B8J1_@^J$Q$D_3&+>!#-PZ=@)-ZJ [LR? M&M?9'O-:U?-)AQ8_1 3N[FF-[_.*PG,I"S;C!R_# R_#*T.$YX=4) OP:>:+ MM)\I+4V#*)<6K?>ZS^[,'XO7U]V2>GW[F?1Y>-4A*PUX-25(GG/N.$, [?00 M*[(P A-9+OR%&FH?R6TG>$EF?,,A^UY%Z^ MUM=9O6]Y-[4E14I371Z)L@2H,H9.!?HZ(:N@2@%M+O'E,]=OK2UYM]8VI)[" MLRI/<UU[^";7V7=Z-0452)ITO MTK%TBB:ME'69UP-Q+=LHBTYJ,RCE;\G/A)!]7Z:) J,?###=O\>\U MNQ-6''/W-Q_AQ1_32$4VDSQY0\20[51C<7.[U(\RZ$X;@%7U";? M\PK:^P@/-\XE]KML6^CSX1V NK>L,\VGR;#&=9\&8H #P!/-7S[]X[A-#]Q& MS(C%911=90N9="X7*K)#:3/J?O$+,6A[O8^$%EZZP" M'K_:Y)76D/4>3IEER@$HLKY/Z,R50;97S$@/74Y(N%B;L+%E7]C86F=^\Z"V MNE_OC4DE+K ;),Q4J,M%G.4(=BG?*M0KTPYFU&0837$RK MI:RT&CP ;]2EYBP/[M.@)'_O1OE!^2Z.K42,?"^+A0.UAM231_R-K*J=^;K4L4W\=LEW];#T=SC0?Z0&W^%9P56V!6](E=%2WE_QT=!Z7&H \NG\YF M,^E2"&P_!_E")\K^_N'Q"AYOT2$4@L.9HU/&L,8A\I];<#B>0R.YICA1BXGA M)L7CF*[9R84$TB!1BUD)WO*,*=:)(KX^,0UKY95 M):]<-*Q9Y'&7TS"<-5]>;5CW)+IQ$WC3LVLU>7/(,V'2N6(Y36]44;Q2&7.K ME-'(R;FH4>$@.0G7\YVY\)3IEKD;=?AZ[HP"L4)CS%]_M\#W?2J)J, M'!AY#%1"2CQE%5+! $G&A];C-YBQ':X0C:%_(,S6I]E.(,R8U:>@G^IUYMG) MV>_7VO2I4HX'T#YT/$O69M^QR*,Q6G+ O"DS6$*,M:SS6Y.7.#^S\6@?V M84!A'!9WX_,6"FMY"]OB^6Q[T"O,*_."F'T:O"EZ MM.$2?D6 ==^T_-^?N::FE[*B+P(YB2SNJ@Z(%F88#)N9<3" M$[%T=$J?Y#9I)7;GXVSMJ09HCV'*B?YT6Y7J;^[E[K&0V3ZP.:VM](KVSG!C MB?O5G/(WT)P@0NY$=PHT'97NV!6]2:]M.JA"K,"B5V>M=*XS5[N/DU+UIE J M)[V3U:.P$E=6\E\ %<>?_OM?Q\?4N<"+W#]4$[G0O]"3/G5>ZJ$GY$J_J"=6 MU-&/V1QU?&RH+B=,P@?^9*_'FCPV]FO\POQ* =-^K9JQ<.V67BSV]Y+1^KQ< M;8]+*/QHKTH')R5-&OZB GB'ZJBL%VA]XNZ0T:*T/E.!H+F2LYO_%"=/D"JN]UP+\(XR0ET)J1T M"/S6EN@/[V2 F"25\*X'9#>75&V:S;$+Y?N4@NENZ[>90H=LC)EL$VEV/%8 MD;_0T:OQXFRI,KZ\,/:R(FD"9R2A6WQ/5P1-X-4Z>1!'L#.M];M+M2LC0-+J MC*6\5/!&7[+KO4T,FOJG+F@S>*PL08?<$O8+^L-(EEJ0!3>Q7AZ9_KPZF]1_ M-^R^5WNQYK8YH]\U++U-1MN$R<=(&!R_F1&*OQ.8^% M'-N;G25R?&0_Y3)7OGAZ>__F)F=AXQ'EN0MT-HE6)IZMYHY. W/%X0W M#8\;\SW0$'&6=ATLA>C=.('K<')')U+NW;'_>%-X?YZ_G#_62K&>$\5=[,[5 M433[/7B^Z&?YVFO_.YE]WX0PU%B [9NB2%[EI?4,7SY!-CZZ716.3B5Y;4L^ MEC5D>P561!Z@N65*M24'O2@#_U!_"7_OP 0% M^[9;ON-LYOV )5<08$P5H0?5 G#RPNP ]:'U:+J&\OS^]],P7^<_OI6-\' - M PD1F?\$4*SI E-*9PM>0.!$OQ1K*88[!(\DU8)_"1Z2&7V.(PF261^-17G& M\Y@=][AVTI3*7KZ7J15_%Z^'WSU'XDN$R"2R='2:9S)IAO&71ZMP%21P,Q.; M"65BZSN.EQ-A8C]^3YJ?K]/WZC3B9$12W)4=FUBXKD_G/M4TX:?2=\ MKH0O&7$-%;ZGR0IR-SAD^'F. M.-;X@!S*(L1^6$'DHP6VD.O11P]H2HCDE3%363(G6'AR$4> M19ZZD9&/W>:5$66Q/@6LI_Z"A\&",O2O1:G OV1^_4W!:P6,0&HF< 55U3% MJ]G(=MS%:BU8#\ HQ3BOSQMG*5JCW.\+/;05XOCKH@:Y_W3*L7D)GL'Q8]B& MI.'# -*( DMD8@8;Z28)=T+ DHW%L1-6$'&] M#]I7RMJ3CMY-MKE(#]@,^B\[&"C\ $#:T).6?<(S)_+=JA/![T!8;.^LF*L\ MEQ6,,-P1&H:G6%KP#V&-4$RU./"G/97;0UE7$6G/A;[&\Q*( DB"M3OXHNGC M78SO1Z6KUH5:[UD^WIU%./-"AMS0$/J)!@$MH5CET,5%%T]T6N3CE1P3>M:B M1F3.'H/"CPPX>X$.G_>]%TEH!LLNM2B[*0_9G:(8?%E8JSL4UN5\423"^C;[ M_/A\_M*FMYEO(:Q+P]3V(ZS(XK<#M$Q MGQ?.K:J/T!+0AU0C84&QQCXI3L?W_^$O_']0:I>F/HD]:2#R_./M92$,2BT1 M-,H4M$0"TH:?^G3 <):V#V)9ZC\%V])"*3+:SZGZ%Z_T!!2%-9%]7XFM\(T) M<BL2-T(?9[Z"Z/HNE (DPB,:MBR; &9,@>4 M@I=7S/BB*L8P?JP414!GF"S'OH@Y,X?8N6K&^H^/W<9;MU!]XSVB,.-QE.-Y M:>K,G&BWW;"RK8,TO[UZ1F=,I% 8!28+EY(,PZ2SA6QT<\TBE32OH4>%>(1L M";;$/#;PJ0&B!]6+GN(WD7)*KUNZN[ZU"S)7G$*'(HQ!-(E<1'UZM)G13Q8X@5.XM18C8=C'9_J@4+Z^?OI,?-X M=:M/A_Y":GL(\0OH3DBR,QG-0V]3EDFHC 8^V(^'P5^*=;QEZ"&M1Z>8YS8\ M^%:81+8"TQ$>,60H8T-JH@A5]M/.9E-ZO:JW?G.YL!Z,L?$()O$R^V9&-3?Y7GV+>;2&U M9B_W?G7]6!1"'5]1LB, 'O0P(=)B"$B]3'/]:RPHD9OF?(2BB5>(O[/"/E_< M*^.[095K/9;#VF=C]Y%(X,:3TB.C>BU*^^Q!]O6-=/=C+M=_T\7[7(!%6#+2 M$?*D0.^=)RY-V,*E?@H98GBRHG(MU>GY]+TQ"3@O'<8Y2C;LRW5)CG%>PUD^ MEY4^CS[-_:<*I0>BF&C'V5BMCH*M8.O\_CG\^KAY[_,U,:QU]J!$).*X?]>M M&*6E]F#!^I8Z6Q_Q^?KL\ZO<"VVIX^+/OGRY@!1Y%(F0179M;,CU5J-]F:5Y_#W1FXQ M#4&;:&Z-(J5*C&+MEZ+'6./,:L3DG8]\V5ZZ,QW>+&#>W=V*;8E])5SFBK+V M4.[39_V0@6'4TEV]K[WL\+YI%V;;3[XQ#'P^0L.];_E>6P0V_GZ\(SQ6%.AD M(@XPHLS=^];@N%"IQB.E-\X^?T@S=O,:G(36W43M9&$P #I'I_/%U54-T48\ M":RG<8G2Y6?[.MNOE)]O DZ-]>II#JJ&)H;#(4/C&II=#Y_TDK8HL]:;U<:X M!*Y^>3-[IXN]+R8;16W,H=7#Q"%O#*Z'\6K?2D0^)PCK<%MN^*N^57OL*#V& M9KI,A]->O47SJW8E9KCW9OO.?=U@]E#;5-K_ MC3T'36J6/&Q8TN5W>L]G'E)Y5GYX*>RAH*N^_>";2@M-- M"II<+)F/5/;AOB;.]( H)+Z"IO+^BX#K>RIHWG5\XUQ<=<%3>5] M^2O)L+TK"HVWVXD_7W?M4WE W/=XJAM@B&7$'R\ M-E]T[HNOC_OX52N&/G/Q_P8?N/Y42%#)B]=-WQ8E+YGL.B4OGN*VN1ZOEM;0+_0J:%BK M-3*J\IFZ_S'1J&F9N_;5XYD4/B0-$N(0Q$E\2 M?WF.,/U]=G\F#2^O,^N7Y\0IS-^K9"OGONAG+:N";(T).8"H(B*<-?GX:+ HY"E=Q)J1RR&&@CJ8NR M;#RQN;^?Q1S$8O8261JN& 9W/H3(,LIB.,?>5T26SU_M6FM!Z4%D]UY="EPZF@X0X*8%E2-KL++ L M?2H3'LMDS',^_?>_CH^IN@)N?(O8I/_H;(YZOC84&E.F(2O>B#;.M;DL3&XQ_B%^94" MWNY:$VO"S:'Q&NKC'ZZA]7F)@T.$%A[M_*0Y#L-)29.&OZCV;(S>7U'8KM#[ M1<%0/$+G.QD(FBL[O_4?\VOP)UL&30'\]S^(\AX\4'CVX[C+(\U%SQYC'CJI M7O"@.GV 5'<3Z<\+2%')IQCR,N>+%61K/MOP_*X_T[4,4NX"H#;MKF)OS M+WNTYUV22=](TQ<'7CHKT@@E M/V,I+Q4\@7PVDJ*G\R);>1EH^5KI.TF1"\1G:RDZSJ,##)TX:'>%(('* ,!/ MSE>DD*D4T;_)N%Y[1K27!724_YCD]TK66O8.&[@%<76;NYA01)9D5&@XQ'0+ M$]>^KD$8N02U:B;'D, M*2M;&+*;^VZI4;N\S?6_BZSLVG+E0%9*?K*2,F1ET:LZH2IX%+G+*J7!45-X M:@K_D63T6I+ILDT9$CG\>X7OR0,)^87@JJ,M'N-('\9R6Q1&!P[\S*-7BXB; M''(;S>?\3)..>$QT)(/2(9^ADKO=E8:9N8F):8E-A&K)PQ M70*\GH49T[DU9DRO^=[._'.8I_N<]E ;Y@Y@X/0 4N84![:^#S< EIE_:#VJ MU(" ,5""BNRBQBLC04+_TE4SH.R),OX9K?J#UZ@Q+K=$7X:_ 1%9:?:__XWH M7_RE@F$:R1*Q513Z 3YCOSTU%;0A_AVKJG)/ '/E;M#['A^=BR(NK'_JZ"AJ2,@>ZK@Y\Q[BA?:0E9;OQH/'2OO& MBM;OO1P?I+UFW#CDBH7;VL5E2^IZ5'EY&^ST@E'WG[N:V^E@X'5)&C1VU21? M)Y!Z4=6'9:&J/9TI%-,Y)I_0Z:Q>U3*19$C"LVVKV<);*\I-^ZIP_OQQI[ZS M_M4WGM;VT-5EJP'&,6J23^%.MG!T6CXI>^6@-U2D@YX2'$G*>Z6PA)@?O+4& M]CYGM-3*-AN/7G!P?D=5&"#"/6G8(M%"7N2$TJ=N;:V#US?C.[95> MVZW!VF?/:NE/AO ?_-&3HX].2_L]>K9'S0M 2-T<=R-F^QS5Q:ZS2"LTDZ&V=L,]S0HUM=)0 8G_Q.DF6'NQ]92N8KKWBESHJ^6:HC\U^/M6/N)[KR2*_E9(9[N_ MZ\KECDX+)^5ME>*@+[AVHXTAALAMK6J9ZB.CJK?S%EOZ8RZXW/UNX;VY;":Z MH J78)1SI70QOSJNVM$%UVZRYYM><$4N_I=B^^'R;3Z(V"RX1]YQ96DPZ<$\0ZS[R0W;6AH?U8&;9^"& M#=?W;W#F)@?QUNNV;C<-,.O8:^RB45@ M0"14&R&T48#0Y@2^ 3"BZ5#H#0&#"3Z,X<30I[KP'>OY& J)I:;+V/4V(M)* ME,*$8/)O+>0?K:Q:IF\JDO[N]F06Z;(&1G\D(762\?SS.;B>+?K ^1/,JQ_0 MP/A! Y]9!=_[?PN8P(0O&0#P#)@Z:HB.>D%5=60DI@8+G$:Y+TBL!"AAZ'%L M#P45JF#C<;+JHE%'G]>&@L)18U;1!!XCS5$J.1M5:JS($X'C.8),9[P_A8P) M1A]6,<3<(A;?\KH,]#R,VF?\&;*=L X73!]+0VBIQQQ@IA+81$R+)R!L70TW@6'6C&LRBA;^$,.NET M\,8F])2///TSY2/>*1]Y^F?*Q\^4CQU"V()#B.PMXJ1*,E HL.'-H_U>>0 ' M3?4"JRT7EL%J&6^PVO7>T)E?C K".7O1''_V$YZ@@5/9A=>JC] 2X&RRC@T+ MEG7M 2<_R*Q.9-9*9]X;,[FG]Q;'_6;#(+,:4D:9",@_J*O)1!^U+\CLH.(' M>=47>=4UY77?4*QX,&MTD*N'P+: L:1_,!&")E"^X@F4!P3*FP.[[+PRW#R<:'HOG"TMQH,R3O7U-+;!U-HZ_R[1Y&#:<.=UZWI %3092K$>\^Z MQOZ#4#\CJTO('YWF,X5T)D1%?')P<<^6IDAOQ0@GX8.GHON#W\[;5T+N1>9S M124 O'9Y*GI$,FF/BMX)'2(72[^+^P)@/QP47C.]([D,!<@\[_8'O=OB.-?+ M!HPSM[.7!R2/H8"1(Y7%(@QQII-J(P,?[,N\I8O.VI+P;G+'%H9YJZ\Z79+< M^KRYDN6WR<67&QTOU/AQXOPY/8(P5YHN()R5EY2VZ.^<>HOR6@)Y];ND3#9. MM]:%NN6LML&JNL.A?I+?93\6+V^M(^N^T.0_NYY/7K=\H%&.V-=A0. M62HR-[:,?(5TD5E=Y;@ MB.#M(A4@!JJ#2EY33G!G+%>><%#NFQ\'4\%#B.1Y]!N\X(7UU%9#)E9->.?;R_'9FRE8Z3 M@_CJZN#0((Y/XWW(DW*0>1KF!P^9LPP?_J2,DBV9O;.%B2#JY)CO]< GZM_C04E?QS\;]+ MH_O+0EU^KH4W\7%Q:5\NX0(B8HSFWJ+;%L:^K-[(P](%J_9SX8Q]7,S:E]N4 M',._/9B:J5A)@U"+9/)!4&!@;#LH+#@[OYU.<\5AO>>%MN(7%A@/3B;.60B* M[/9JIX#.Q3S]#:?QY**.J A[MCQKV7]=RJ\SW5DB^C:,P'+Y?W+_KOZW>.W:*6 M_'#JQZ/VSO)'I[E2/I1[%FW(Y8-$M]^Z<)=XO8FWV<&[^L&^!XS<6%T7GJ#: MV]6UX'$<(;@6?"/4_JAE;/G"=* JV8 MN\*]"[1< ID;JG>YWLU+_3*[AP(MP*_4X&6VU2,*VSW<3)22P%] M!/$5:&6S^R]]CO?&?J,"+1>;JE/Y7OUZ' U4;N<%6ME]N4')L>AK..'Q5V5% M,I@P?%662Q:;CV^L_/[[\JH?ON\QIA*2[/Y]P8149;FX5.2K5PU9SI2'>Z_* MRNZ_/CIQ55DN?GU\J8TJT[L=G(>T\'$Q:U^^4G*L_2;^^\$5:$4RBF^] BUW M6'"M/=,WE?/^I==0RE@+M,*J0R[ /SV8"_'83JO-JII<LJ:PW ]P?0^0^^MT"<5:\^.2@$+OJU1\J2F?C?P.:G["-Z*^IC$C;6,N3S:H\#&>Z+EO*?WF]JD_G+Q.Q/^"$[P#,IM"W"R M$1?@E,,7X!S66,EE/+)-F&5'5*&+>?QG1\Z5E[>,>BN>WW;7Z36-=M#C=D48 M:],C.K$3;#&Y?DQDR%G

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end XML 92 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001692415 2023-01-01 2023-12-31 0001692415 2023-06-30 0001692415 2024-03-12 0001692415 2022-01-01 2022-12-31 0001692415 2023-12-31 0001692415 2022-12-31 0001692415 CODX:ProductRevenueMember 2023-01-01 2023-12-31 0001692415 CODX:ProductRevenueMember 2022-01-01 2022-12-31 0001692415 CODX:GrantRevenueMember 2023-01-01 2023-12-31 0001692415 CODX:GrantRevenueMember 2022-01-01 2022-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001692415 us-gaap:CommonStockMember 2021-12-31 0001692415 us-gaap:TreasuryStockCommonMember 2021-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001692415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001692415 us-gaap:RetainedEarningsMember 2021-12-31 0001692415 2021-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001692415 us-gaap:CommonStockMember 2022-12-31 0001692415 us-gaap:TreasuryStockCommonMember 2022-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001692415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001692415 us-gaap:RetainedEarningsMember 2022-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001692415 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001692415 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001692415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001692415 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001692415 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001692415 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001692415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001692415 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001692415 us-gaap:CommonStockMember 2023-12-31 0001692415 us-gaap:TreasuryStockCommonMember 2023-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001692415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001692415 us-gaap:RetainedEarningsMember 2023-12-31 0001692415 CODX:CustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001692415 CODX:CustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001692415 CODX:TwoCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001692415 CODX:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001692415 CODX:OneGrantingAgencyMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001692415 CODX:TwoCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001692415 CODX:TwoCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001692415 CODX:CustomersTogetherMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001692415 CODX:CustomersTogetherMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001692415 us-gaap:CashMember 2023-12-31 0001692415 us-gaap:CashMember 2023-01-01 2023-12-31 0001692415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001692415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2023-01-01 2023-12-31 0001692415 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001692415 us-gaap:FairValueInputsLevel1Member 2023-01-01 2023-12-31 0001692415 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001692415 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2023-01-01 2023-12-31 0001692415 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001692415 us-gaap:FairValueInputsLevel2Member 2023-01-01 2023-12-31 0001692415 us-gaap:CashMember 2022-12-31 0001692415 us-gaap:CashMember 2022-01-01 2022-12-31 0001692415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001692415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-01-01 2022-12-31 0001692415 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001692415 us-gaap:FairValueInputsLevel1Member 2022-01-01 2022-12-31 0001692415 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001692415 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2022-01-01 2022-12-31 0001692415 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001692415 us-gaap:FairValueInputsLevel2Member 2022-01-01 2022-12-31 0001692415 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001692415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001692415 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001692415 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001692415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001692415 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 2023-12-31 0001692415 us-gaap:MeasurementInputSharePriceMember 2023-12-31 0001692415 us-gaap:MeasurementInputSharePriceMember 2022-12-31 0001692415 CODX:MeasurementInputStrikePriceMember 2023-12-31 0001692415 CODX:MeasurementInputStrikePriceMember 2022-12-31 0001692415 us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001692415 us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001692415 us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001692415 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001692415 us-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001692415 srt:MinimumMember us-gaap:EquipmentMember 2023-12-31 0001692415 srt:MaximumMember us-gaap:EquipmentMember 2023-12-31 0001692415 us-gaap:EquipmentMember 2023-12-31 0001692415 us-gaap:EquipmentMember 2022-12-31 0001692415 srt:MinimumMember us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2023-12-31 0001692415 srt:MaximumMember us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2023-12-31 0001692415 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001692415 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001692415 srt:MinimumMember us-gaap:OfficeEquipmentMember 2023-12-31 0001692415 srt:MaximumMember us-gaap:OfficeEquipmentMember 2023-12-31 0001692415 us-gaap:OfficeEquipmentMember 2023-12-31 0001692415 us-gaap:OfficeEquipmentMember 2022-12-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2023-01-01 2023-12-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2023-12-31 0001692415 us-gaap:NoncompeteAgreementsMember 2023-12-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2022-01-01 2022-12-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2022-12-31 0001692415 us-gaap:NoncompeteAgreementsMember 2022-12-31 0001692415 us-gaap:ProductMember country:US 2023-01-01 2023-12-31 0001692415 us-gaap:ProductMember country:US 2022-01-01 2022-12-31 0001692415 us-gaap:GrantMember country:US 2023-01-01 2023-12-31 0001692415 us-gaap:GrantMember country:US 2022-01-01 2022-12-31 0001692415 country:US 2023-01-01 2023-12-31 0001692415 country:US 2022-01-01 2022-12-31 0001692415 us-gaap:ProductMember CODX:RestOfWorldMember 2023-01-01 2023-12-31 0001692415 us-gaap:ProductMember CODX:RestOfWorldMember 2022-01-01 2022-12-31 0001692415 us-gaap:GrantMember CODX:RestOfWorldMember 2023-01-01 2023-12-31 0001692415 us-gaap:GrantMember CODX:RestOfWorldMember 2022-01-01 2022-12-31 0001692415 CODX:RestOfWorldMember 2023-01-01 2023-12-31 0001692415 CODX:RestOfWorldMember 2022-01-01 2022-12-31 0001692415 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0001692415 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0001692415 CODX:RestOfWorldMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0001692415 CODX:RestOfWorldMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0001692415 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001692415 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001692415 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001692415 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001692415 CODX:TwoThousandFifteenLongTermIncentivePlanMember 2022-08-31 0001692415 CODX:TwoThousandFifteenLongTermIncentivePlanMember 2023-12-31 0001692415 CODX:StockOptionsMember 2023-01-01 2023-12-31 0001692415 CODX:StockOptionsMember 2022-01-01 2022-12-31 0001692415 CODX:StockOptionsMember 2023-12-31 0001692415 CODX:StockOptionsMember 2022-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001692415 us-gaap:WarrantMember 2023-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001692415 us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0001692415 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0001692415 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-12-31 0001692415 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-12-31 0001692415 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001692415 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001692415 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001692415 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001692415 CODX:LeaseAmendmentMember 2023-12-31 0001692415 2022-03-31 0001692415 CODX:SethEganMember 2023-01-01 2023-12-31 0001692415 CODX:WinstonEganMember 2023-01-01 2023-12-31 0001692415 CODX:CoSaraDiagnosticsPvtLtdMember 2023-01-01 2023-12-31 0001692415 2023-10-01 2023-12-31 iso4217:USD shares iso4217:USD shares pure false FY 0001692415 10-K true 2023-12-31 --12-31 2023 false 001-38148 CO-DIAGNOSTICS, INC. UT 46-2609396 2401 S. Foothill Drive Salt Lake City UT 84109 (801) 438-1036 Common Stock CODX NASDAQ No No Yes Yes Non-accelerated Filer true false false false false 33000000 31259668 270 457 Tanner LLC Salt Lake City, Utah Haynie & Company Salt Lake City, Utah 14916878 22973803 43631510 58289066 303926 3453723 1664725 5310473 26955 1870419 1597114 761187 75000 62141108 92733671 3035729 2539483 2966774 372115 26403667 26768333 773382 672679 95320660 123086281 1482109 952296 2172959 934447 838387 297209 891666 1689471 362449 5747570 3873423 659186 1181284 2417987 2152180 50708 748109 1042885 3559475 4692864 9307045 8566287 0.001 0.001 5000000 5000000 0 0 0 0 0.001 0.001 100000000 100000000 36108346 31259668 34754265 30872607 36108 34754 4848678 3881658 15575795 14211866 96808436 88472935 146700 293140 4598166 39931031 86013615 114519994 95320660 123086281 991473 34218209 5820565 6812038 34218209 4184949 5481093 2627089 28737116 6860815 7344628 14279441 14262963 22962593 17438098 1230474 1282718 15388546 45333323 55716953 -42706234 -26979837 1161913 704045 2243059 -2578 -138117 1092581 7899644 100703 -332969 4595678 8132603 -38110556 -18847234 -2777691 -4608985 -35332865 -14238249 -146440 293140 -146440 293140 -35479305 -13945109 -1.20 -0.45 -1.20 -0.45 29346599 31479028 29346599 31479028 33819862 33820 80271999 54169280 134475099 70791 70 77800 77870 50000 50 99950 100000 725166 725 7542498 7543223 88446 89 480687 480776 14211866 14211866 293140 293140 -14238249 -14238249 34754265 34754 -14211866 88472935 293140 39931031 114519994 34754265 34754 -14211866 88472935 293140 39931031 114519994 1354081 1354 8335501 8336855 1363929 1363929 -146440 -146440 -35332865 -35332865 36108346 36108 -15575795 96808436 146700 4598166 86013615 36108346 36108 -15575795 96808436 146700 4598166 86013615 -35332865 -14238249 1230474 1282718 15388546 8336855 7543223 1092581 7899644 47992 30430 2243059 100703 -332969 -2578 -138117 -2417987 -4810457 612809 2461032 3233281 148099 -2536988 -14924427 -1082536 224094 -413140 3673309 362449 -150000 -522098 -2201250 1768326 -2483821 -22081865 6568737 1365306 1427512 127251619 11255266 110497444 67995926 15388869 -58168172 177870 1363929 14211866 -1363929 -14033996 -8056925 -65633431 22973803 88607234 14916878 22973803 55975 4498742 673 218906 3203146 681327 1593 480776 199359 <p id="xdx_80F_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zK17KQjiKMW3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_822_zyY9s81ohGz4">Overview and Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description of Business</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-Diagnostics, Inc., a Utah corporation (the “Company” or “CODX”), is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. In connection with the sale of our tests we may sell diagnostic equipment from other manufacturers as self-contained lab systems.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Such estimates include inventories, receivables and other long-lived assets, legal and regulatory contingencies, income taxes, share based arrangements, and others. These estimates and assumptions are based on management’s best estimates and judgments. Actual amounts and results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of Presentation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying audited consolidated financial statements of Co-Diagnostics, Inc. and its wholly owned subsidiaries have been prepared to reflect the financial position, results of operations and cash flows of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). All intercompany balances and transactions have been eliminated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_80F_eus-gaap--SignificantAccountingPoliciesTextBlock_zS9IKylZNoL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 – <span id="xdx_822_zPA1zgukJ5Tl">Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_841_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zgfVcYfuqaVe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zZMBHjoqHgu1">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zo0xPam83Tq3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zf8QIN6BmfMj">Cash and Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of December 31, 2023 and December 31, 2022. <span style="background-color: white">The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--MarketableSecuritiesPolicy_zlEPnn4jBAJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z3qanzkPGLB3">Marketable Investment Securities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s marketable investment securities are comprised of investments in certificates of deposit and U.S. Treasury bills and notes. The Company designates investments in debt securities as available-for-sale. Available-for-sale debt securities with original maturities of three months or less from the date of purchase are classified within cash and cash equivalents. Available-for-sale debt securities with original maturities longer than three months are available to fund current operations and are classified as marketable investment securities, within current assets on the consolidated balance sheets. The Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. Available-for-sale debt securities are reported at fair value with the related unrealized gains and losses included in accumulated other comprehensive income (loss), a component of stockholders’ equity, net of tax. Realized gains and losses on the sale of marketable securities are determined using the average cost method on a first-in, first-out basis and recorded in total other income (expense), net in the consolidated statements of operations and comprehensive loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The available-for-sale debt securities are subject to a periodic impairment review. For investments in an unrealized loss position, the Company writes down the amortized cost basis of the investment if it is more likely than not that the Company will be required or will intend to sell the investment before recovery of its amortized cost basis. For investments not likely to be sold before recovery of the amortized cost basis, the Company determines whether a credit loss exists by considering information about the collectability of the instrument, current market conditions, and reasonable and supportable forecasts of economic conditions. The Company recognizes an allowance for credit losses up to the amount of the unrealized loss when appropriate. Allowances for credit losses and write-downs are recognized in total other income (expense), net, and unrealized losses not related to credit losses are recognized in accumulated other comprehensive income (loss). There are no allowances for credit losses recorded for the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zjfI7s38hG05" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zKSsan0x0tQ3">Accounts Receivable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At December 31, 2023 total accounts receivable was $<span id="xdx_907_eus-gaap--AccountsReceivableGrossCurrent_iI_c20231231_zd5G7Uv4KiLf" title="Accounts receivable">504,264</span> with an allowance for uncollectable accounts of $<span id="xdx_90E_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_z3WF38LF7oo3" title="Doubtful accounts">200,338</span> resulting in a net amount of $<span id="xdx_90F_eus-gaap--AccountsReceivableNetCurrent_iI_c20231231_zsOBKSr949Yc" title="Accounts receivable, net">303,926</span>. At December 31, 2022 total accounts receivable was $<span id="xdx_905_eus-gaap--AccountsReceivableGrossCurrent_iI_c20221231_zg1wQ3qeMxme" title="Accounts receivable">6,552,249</span> with an allowance for uncollectable accounts of $<span id="xdx_906_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_zo4xqO3OXCoa" title="Doubtful accounts">3,098,526</span> resulting in a net amount of $<span id="xdx_909_eus-gaap--AccountsReceivableNetCurrent_iI_c20221231_zoKjKV2z9B38" title="Accounts receivable, net">3,453,723</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--EquityMethodInvestmentsPolicy_zjyDSkjQltQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zzFO0EyklNR4">Equity-Method Investments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--InventoryPolicyTextBlock_zSp7OhUdQxgl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zl4ZF9vYbOg">Inventory</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At December 31, 2023, the Company had $<span id="xdx_90B_eus-gaap--InventoryNet_iI_c20231231_z6PCywmDUDG9" title="Inventory">1,664,725</span> in inventory, of which $<span id="xdx_90A_eus-gaap--InventoryFinishedGoods_iI_c20231231_z94I6ygZzwCk" title="Inventory finished goods">700,467</span> was finished goods and $<span id="xdx_90E_eus-gaap--InventoryRawMaterials_iI_c20231231_zJMptRxe6gUe" title="Inventory raw materials">964,258</span> was raw materials. At December 31, 2022, the Company had $<span id="xdx_90F_eus-gaap--InventoryNet_iI_c20221231_zVeBGEa9llqk" title="Inventory">5,310,473</span> in inventory, of which $<span id="xdx_900_eus-gaap--InventoryFinishedGoods_iI_c20221231_zjyfGVfOoaka" title="Inventory, finished goods, gross">1,327,264</span> was finished goods and $<span id="xdx_901_eus-gaap--InventoryRawMaterials_iI_c20221231_zpzPiWmTUqAf" title="Inventory, raw materials, gross">3,983,209</span> was raw materials. The Company establishes reserves to reduce low-moving, obsolete, or unusable inventories to their estimated useful or scrap values. The Company recognized $<span id="xdx_90C_eus-gaap--InventoryValuationReserves_iI_c20231231_z7HeyO90m1va" title="Inventory reserves">2,760,011</span> and $<span id="xdx_90A_eus-gaap--InventoryValuationReserves_iI_c20221231_zYUie1DzaI72" title="Inventory reserves">0</span> related to the change in inventory reserves during the years ended December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zxLil2YaJv0a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_z0gbqRq4dQkl">Goodwill and Intangible Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill represents the excess of the purchase price and related costs over the value assigned to net tangible and identifiable intangible assets acquired in business combinations. Goodwill and indefinite-lived intangible assets are not amortized, but rather tested for impairment at least annually on December 31, or more often if and when circumstances indicate that the carrying value may not be recoverable. Finite-lived intangible assets are amortized over their useful lives.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2023 and 2022, the Company recognized impairment charges related to goodwill of $<span id="xdx_908_eus-gaap--AssetImpairmentCharges_c20230101__20231231_zROHa50m8DUk" title="Impairment charges">0</span> and $<span id="xdx_902_eus-gaap--AssetImpairmentCharges_c20220101__20221231_zFwqQ1qJnSYf" title="Impairment charges">15,388,546</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zjBk0XfSy838" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zKBocwNeXqlf">Long-lived Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived assets, such as property and equipment, are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from three to five years. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed. Once the development process has been completed the asset will be amortized over its remaining estimated useful life. The Company reviews its long-lived assets, including property and equipment, indefinite-lived and finite-lived intangible assets, and ROU assets, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--RevenueRecognitionPolicyTextBlock_zkXlqbLi9CK2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zgp2Yuq1aaf8">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation. Based on the criteria above, the Company typically recognizes revenue upon delivery.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_ecustom--GrantRevenuePolicyTextBlock_zyzCUNusPirk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zaUQRDcJojj4">Grant Revenue</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may submit applications to receive grant funding from governmental and non-governmental entities. The Company accounts for grants by analogizing to the contribution accounting model under ASC 958-605, Not-for-Profit Entities (“ASC 958”). Revenues from grants, contracts, and awards provided by governmental and non-governmental agencies are recorded based upon the terms of the specific agreements. The Company recognizes grant funding without conditions or continuing performance obligations as revenue in the consolidated statements of operations and comprehensive income (loss). The Company recognizes grant funding with conditions or continuing performance obligations as deferred revenue in the consolidated balance sheets if the conditions or performance obligations have not yet been met. The Company recognized grant funding revenue of $<span id="xdx_90E_ecustom--GrantFundingRevenue_pn5n6_c20230101__20231231_zUTj38eP6Alh" title="Grant funding revenue">5.8</span> million during the year ended December 31, 2023. At December 31, 2023, the Company has also recorded $<span id="xdx_90B_eus-gaap--DeferredRevenue_iI_pn5n6_c20231231_z6ID4mjPr8Ta" title="Deferred revenue">0.3</span> million of deferred revenue related to grant funding for which the cash was received, but the underlying conditions or performance obligations have not yet been met. Cash received from federal grants, contracts, and awards can be subject to audit by the grantor and, if the examination results in a disallowance of any expenditure, repayment could be required.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zGBmU9O1qKka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zHdll12KRuYa">Deferred Revenue</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zGnsfG3qBV8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_z721q2mfbAs1">Research and Development</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs are expensed when incurred. The Company recorded $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231_zkOeMY6IYCF6" title="Research and development">22,962,593</span> and $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231_zq70NmF6GRO1" title="Research and development">17,438,098</span> of research and development costs for the years ended December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zO1J66Qw1C81" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zXvi2lFfjxDc">Stock-based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. <span style="background-color: white">When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zxGKGvd04jLc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zEM3A1mvmcL">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, d</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">eferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. The Company has uncertain income tax positions in the consolidated financial statements, and adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_z9fZAoQAf3e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_z9ZrFdVPLDz6">Net Income (Loss) per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_z0l7LUASb4d9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zOcL1rhqo8p7">Comprehensive Income (Loss)</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Comprehensive loss is comprised of net loss and unrealized gains and losses on marketable securities, net of income taxes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_z3uady2vZ1H1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zpxT2VGITII6">Concentrations Risk and Significant Customers</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company had certain customers which were each responsible for generating <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zeWhSgluJF3a" title="Concentration risk percentage"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zjPJNOTSiCGi" title="Concentration risk percentage">10</span></span>% or more of the total revenue for the years ended December 31, 2023 and 2022, respectively. Two customers accounted for approximately <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvaMjr3yRLV9" title="Concentration risk percentage">28</span>% of product revenue for the year ended December 31, 2023 and one customer accounted for approximately <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zxx0kXFeHxH7" title="Concentration risk percentage">37</span>% of product revenue for the year ended December 31, 2022. One granting agency accounted for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--OneGrantingAgencyMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z0UiTEgdSQP8" title="Concentration risk percentage">100</span>% of grant revenue for the year ended December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Three customers accounted for more than <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_z5HhCKDJFR9h" title="Concentration risk percentage"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zB4AiwtztUO5" title="Concentration risk percentage">10</span></span>% of accounts receivable at December 31, 2023 and 2022, respectively. These customers together accounted for approximately <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zcVLqDdo9Oll" title="Concentration risk percentage">97</span>% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zkFZiWlLg7dj" title="Concentration risk percentage">61</span>% of accounts receivable at December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zrw0s1UYia53" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_z8xIJvrsmkqc">Recently Issued Accounting Standards</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires an entity to disclose annually additional information related to the company’s income tax rate reconciliation and income taxes paid during the period. The guidance should be applied prospectively with the option to apply the standard retrospectively. The standard becomes effective for the Company for full year 2025 reporting. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.</span></p> <p id="xdx_85D_z6rHdGAdpqK8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_841_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zgfVcYfuqaVe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zZMBHjoqHgu1">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zo0xPam83Tq3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zf8QIN6BmfMj">Cash and Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of December 31, 2023 and December 31, 2022. <span style="background-color: white">The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--MarketableSecuritiesPolicy_zlEPnn4jBAJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z3qanzkPGLB3">Marketable Investment Securities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s marketable investment securities are comprised of investments in certificates of deposit and U.S. Treasury bills and notes. The Company designates investments in debt securities as available-for-sale. Available-for-sale debt securities with original maturities of three months or less from the date of purchase are classified within cash and cash equivalents. Available-for-sale debt securities with original maturities longer than three months are available to fund current operations and are classified as marketable investment securities, within current assets on the consolidated balance sheets. The Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. Available-for-sale debt securities are reported at fair value with the related unrealized gains and losses included in accumulated other comprehensive income (loss), a component of stockholders’ equity, net of tax. Realized gains and losses on the sale of marketable securities are determined using the average cost method on a first-in, first-out basis and recorded in total other income (expense), net in the consolidated statements of operations and comprehensive loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The available-for-sale debt securities are subject to a periodic impairment review. For investments in an unrealized loss position, the Company writes down the amortized cost basis of the investment if it is more likely than not that the Company will be required or will intend to sell the investment before recovery of its amortized cost basis. For investments not likely to be sold before recovery of the amortized cost basis, the Company determines whether a credit loss exists by considering information about the collectability of the instrument, current market conditions, and reasonable and supportable forecasts of economic conditions. The Company recognizes an allowance for credit losses up to the amount of the unrealized loss when appropriate. Allowances for credit losses and write-downs are recognized in total other income (expense), net, and unrealized losses not related to credit losses are recognized in accumulated other comprehensive income (loss). There are no allowances for credit losses recorded for the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zjfI7s38hG05" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zKSsan0x0tQ3">Accounts Receivable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At December 31, 2023 total accounts receivable was $<span id="xdx_907_eus-gaap--AccountsReceivableGrossCurrent_iI_c20231231_zd5G7Uv4KiLf" title="Accounts receivable">504,264</span> with an allowance for uncollectable accounts of $<span id="xdx_90E_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_z3WF38LF7oo3" title="Doubtful accounts">200,338</span> resulting in a net amount of $<span id="xdx_90F_eus-gaap--AccountsReceivableNetCurrent_iI_c20231231_zsOBKSr949Yc" title="Accounts receivable, net">303,926</span>. At December 31, 2022 total accounts receivable was $<span id="xdx_905_eus-gaap--AccountsReceivableGrossCurrent_iI_c20221231_zg1wQ3qeMxme" title="Accounts receivable">6,552,249</span> with an allowance for uncollectable accounts of $<span id="xdx_906_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_zo4xqO3OXCoa" title="Doubtful accounts">3,098,526</span> resulting in a net amount of $<span id="xdx_909_eus-gaap--AccountsReceivableNetCurrent_iI_c20221231_zoKjKV2z9B38" title="Accounts receivable, net">3,453,723</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 504264 200338 303926 6552249 3098526 3453723 <p id="xdx_840_eus-gaap--EquityMethodInvestmentsPolicy_zjyDSkjQltQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zzFO0EyklNR4">Equity-Method Investments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--InventoryPolicyTextBlock_zSp7OhUdQxgl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zl4ZF9vYbOg">Inventory</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At December 31, 2023, the Company had $<span id="xdx_90B_eus-gaap--InventoryNet_iI_c20231231_z6PCywmDUDG9" title="Inventory">1,664,725</span> in inventory, of which $<span id="xdx_90A_eus-gaap--InventoryFinishedGoods_iI_c20231231_z94I6ygZzwCk" title="Inventory finished goods">700,467</span> was finished goods and $<span id="xdx_90E_eus-gaap--InventoryRawMaterials_iI_c20231231_zJMptRxe6gUe" title="Inventory raw materials">964,258</span> was raw materials. At December 31, 2022, the Company had $<span id="xdx_90F_eus-gaap--InventoryNet_iI_c20221231_zVeBGEa9llqk" title="Inventory">5,310,473</span> in inventory, of which $<span id="xdx_900_eus-gaap--InventoryFinishedGoods_iI_c20221231_zjyfGVfOoaka" title="Inventory, finished goods, gross">1,327,264</span> was finished goods and $<span id="xdx_901_eus-gaap--InventoryRawMaterials_iI_c20221231_zpzPiWmTUqAf" title="Inventory, raw materials, gross">3,983,209</span> was raw materials. The Company establishes reserves to reduce low-moving, obsolete, or unusable inventories to their estimated useful or scrap values. The Company recognized $<span id="xdx_90C_eus-gaap--InventoryValuationReserves_iI_c20231231_z7HeyO90m1va" title="Inventory reserves">2,760,011</span> and $<span id="xdx_90A_eus-gaap--InventoryValuationReserves_iI_c20221231_zYUie1DzaI72" title="Inventory reserves">0</span> related to the change in inventory reserves during the years ended December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1664725 700467 964258 5310473 1327264 3983209 2760011 0 <p id="xdx_84B_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zxLil2YaJv0a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_z0gbqRq4dQkl">Goodwill and Intangible Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill represents the excess of the purchase price and related costs over the value assigned to net tangible and identifiable intangible assets acquired in business combinations. Goodwill and indefinite-lived intangible assets are not amortized, but rather tested for impairment at least annually on December 31, or more often if and when circumstances indicate that the carrying value may not be recoverable. Finite-lived intangible assets are amortized over their useful lives.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2023 and 2022, the Company recognized impairment charges related to goodwill of $<span id="xdx_908_eus-gaap--AssetImpairmentCharges_c20230101__20231231_zROHa50m8DUk" title="Impairment charges">0</span> and $<span id="xdx_902_eus-gaap--AssetImpairmentCharges_c20220101__20221231_zFwqQ1qJnSYf" title="Impairment charges">15,388,546</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 0 15388546 <p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zjBk0XfSy838" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zKBocwNeXqlf">Long-lived Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived assets, such as property and equipment, are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from three to five years. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed. Once the development process has been completed the asset will be amortized over its remaining estimated useful life. The Company reviews its long-lived assets, including property and equipment, indefinite-lived and finite-lived intangible assets, and ROU assets, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--RevenueRecognitionPolicyTextBlock_zkXlqbLi9CK2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zgp2Yuq1aaf8">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation. Based on the criteria above, the Company typically recognizes revenue upon delivery.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_ecustom--GrantRevenuePolicyTextBlock_zyzCUNusPirk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zaUQRDcJojj4">Grant Revenue</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may submit applications to receive grant funding from governmental and non-governmental entities. The Company accounts for grants by analogizing to the contribution accounting model under ASC 958-605, Not-for-Profit Entities (“ASC 958”). Revenues from grants, contracts, and awards provided by governmental and non-governmental agencies are recorded based upon the terms of the specific agreements. The Company recognizes grant funding without conditions or continuing performance obligations as revenue in the consolidated statements of operations and comprehensive income (loss). The Company recognizes grant funding with conditions or continuing performance obligations as deferred revenue in the consolidated balance sheets if the conditions or performance obligations have not yet been met. The Company recognized grant funding revenue of $<span id="xdx_90E_ecustom--GrantFundingRevenue_pn5n6_c20230101__20231231_zUTj38eP6Alh" title="Grant funding revenue">5.8</span> million during the year ended December 31, 2023. At December 31, 2023, the Company has also recorded $<span id="xdx_90B_eus-gaap--DeferredRevenue_iI_pn5n6_c20231231_z6ID4mjPr8Ta" title="Deferred revenue">0.3</span> million of deferred revenue related to grant funding for which the cash was received, but the underlying conditions or performance obligations have not yet been met. Cash received from federal grants, contracts, and awards can be subject to audit by the grantor and, if the examination results in a disallowance of any expenditure, repayment could be required.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 5800000 300000 <p id="xdx_842_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zGBmU9O1qKka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zHdll12KRuYa">Deferred Revenue</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zGnsfG3qBV8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_z721q2mfbAs1">Research and Development</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs are expensed when incurred. The Company recorded $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231_zkOeMY6IYCF6" title="Research and development">22,962,593</span> and $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231_zq70NmF6GRO1" title="Research and development">17,438,098</span> of research and development costs for the years ended December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 22962593 17438098 <p id="xdx_846_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zO1J66Qw1C81" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zXvi2lFfjxDc">Stock-based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. <span style="background-color: white">When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zxGKGvd04jLc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zEM3A1mvmcL">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, d</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">eferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. The Company has uncertain income tax positions in the consolidated financial statements, and adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_z9fZAoQAf3e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_z9ZrFdVPLDz6">Net Income (Loss) per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_z0l7LUASb4d9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zOcL1rhqo8p7">Comprehensive Income (Loss)</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Comprehensive loss is comprised of net loss and unrealized gains and losses on marketable securities, net of income taxes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_z3uady2vZ1H1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zpxT2VGITII6">Concentrations Risk and Significant Customers</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company had certain customers which were each responsible for generating <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zeWhSgluJF3a" title="Concentration risk percentage"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zjPJNOTSiCGi" title="Concentration risk percentage">10</span></span>% or more of the total revenue for the years ended December 31, 2023 and 2022, respectively. Two customers accounted for approximately <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvaMjr3yRLV9" title="Concentration risk percentage">28</span>% of product revenue for the year ended December 31, 2023 and one customer accounted for approximately <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zxx0kXFeHxH7" title="Concentration risk percentage">37</span>% of product revenue for the year ended December 31, 2022. One granting agency accounted for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--OneGrantingAgencyMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z0UiTEgdSQP8" title="Concentration risk percentage">100</span>% of grant revenue for the year ended December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Three customers accounted for more than <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_z5HhCKDJFR9h" title="Concentration risk percentage"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zB4AiwtztUO5" title="Concentration risk percentage">10</span></span>% of accounts receivable at December 31, 2023 and 2022, respectively. These customers together accounted for approximately <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zcVLqDdo9Oll" title="Concentration risk percentage">97</span>% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zkFZiWlLg7dj" title="Concentration risk percentage">61</span>% of accounts receivable at December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.10 0.10 0.28 0.37 1 0.10 0.10 0.97 0.61 <p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zrw0s1UYia53" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_z8xIJvrsmkqc">Recently Issued Accounting Standards</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires an entity to disclose annually additional information related to the company’s income tax rate reconciliation and income taxes paid during the period. The guidance should be applied prospectively with the option to apply the standard retrospectively. The standard becomes effective for the Company for full year 2025 reporting. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.</span></p> <p id="xdx_807_eus-gaap--CashCashEquivalentsAndMarketableSecuritiesTextBlock_ztCGiDmSwobd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3 – <span id="xdx_82A_zTS8GF19eHgb">Cash, Cash Equivalents, and Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_zf2SWnhlb8Q2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The following table shows the Company’s cash, cash equivalents, and marketable investment securities by significant investment category:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zAp7Fx6s2PQb" style="display: none">Schedule of Cash, Cash Equivalents and Marketable Investment Securities</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="22" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Adjusted Cost</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Allowance for Credit Losses</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total Unrealized Gains / (Losses)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Fair Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Cash and Cash Equivalents</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Marketable Investment Securities</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zyKhFnLoh8sk" style="width: 6%; text-align: right" title="Adjusted Cost">4,317,449</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zhOPuTS7j8Q9" style="width: 6%; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0695">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_z1bAV9MsJVW5" style="width: 6%; text-align: right" title="Total Unrealized Gains / (Losses)"><span style="-sec-ix-hidden: xdx2ixbrl0697">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--TradingSecurities_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zFUlnlSVvyHa" style="width: 6%; text-align: right" title="Fair Value">4,317,449</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_z6sPNc9ghZF7" style="width: 6%; text-align: right" title="Cash and Cash Equivalents">4,317,449</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecurities_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_z4caqpTOlsdl" style="width: 6%; text-align: right" title="Marketable Securities"><span style="-sec-ix-hidden: xdx2ixbrl0703">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Level 1:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Money market funds</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zQigIxvtBPr2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjusted Cost">10,599,429</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zFvTgr3fpQpi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0707">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zeRx2961HDUe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Unrealized Gains / (Losses)"><span style="-sec-ix-hidden: xdx2ixbrl0709">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--TradingSecurities_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z2Awplb5xur4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">10,599,429</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zPG2uz7qKU2i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cash and Cash Equivalents">10,599,429</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--MarketableSecurities_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z2CEHX9WVTBi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable Securities"><span style="-sec-ix-hidden: xdx2ixbrl0715">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Subtotal</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z8MsH7FJB4F1" style="text-align: right" title="Adjusted Cost">10,599,429</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zDCybvPZbKZg" style="text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0719">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zI6kRW8gay8" style="text-align: right" title="Total Unrealized Gains / (Losses)"><span style="-sec-ix-hidden: xdx2ixbrl0721">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--TradingSecurities_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zSZeEsZDHRt9" style="text-align: right" title="Fair Value">10,599,429</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_ziVoYlYntZZ5" style="text-align: right" title="Cash and Cash Equivalents">10,599,429</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--MarketableSecurities_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_znhvsDsPJRIa" style="text-align: right" title="Marketable Securities"><span style="-sec-ix-hidden: xdx2ixbrl0727">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Level 2:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">U.S. treasury securities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z6wSL9Oi8tDk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjusted Cost">43,484,810</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zY2HPb3OtQVl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0731">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zQzPfEJSVL45" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Unrealized Gains / (Losses)">146,700</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--TradingSecurities_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zqMcVj29qUr9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">43,631,510</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ztqBYLr2UM12" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cash and Cash Equivalents"><span style="-sec-ix-hidden: xdx2ixbrl0737">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--MarketableSecurities_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zmLxRTTCyjN9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable Securities">43,631,510</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Subtotal</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z3wvWUnhWs49" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjusted Cost">43,484,810</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z59Pnf6zvaWi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0743">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z5rLfnUkZxSb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Unrealized Gains / (Losses)">146,700</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--TradingSecurities_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFISYI24g4Ie" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">43,631,510</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zEixkv8r9Ycd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cash and Cash Equivalents"><span style="-sec-ix-hidden: xdx2ixbrl0749">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--MarketableSecurities_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zD9LwMZohJv4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable Securities">43,631,510</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20231231_zLrJINOTLoOd" style="border-bottom: Black 2.5pt double; text-align: right" title="Adjusted Cost">58,401,688</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20231231_zGzTF26z7AU6" style="border-bottom: Black 2.5pt double; text-align: right" title="Allowance for Credit Losses">       <span style="-sec-ix-hidden: xdx2ixbrl0755">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20231231_zS3j87JMb4m7" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Unrealized Gains / (Losses)">146,700</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--TradingSecurities_iI_c20231231_zI5OvNMEMvDk" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value">58,548,388</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20231231_zXitdTzEWve2" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash and Cash Equivalents">14,916,878</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--MarketableSecurities_iI_c20231231_zSXid3gTMGNg" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable Securities">43,631,510</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Adjusted Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Allowance for Credit Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Unrealized Gains / (Losses)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cash and Cash Equivalents</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Marketable Securities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zI4dCS93maMj" style="width: 6%; text-align: right" title="Adjusted Cost">12,834,444</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zCJAy9G0zf2l" style="width: 6%; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0767">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_z2C2ObFuuvl9" style="width: 6%; text-align: right" title="Total Unrealized Gains / (Losses)"><span style="-sec-ix-hidden: xdx2ixbrl0769">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--TradingSecurities_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zNpYN8nn1m5c" style="width: 6%; text-align: right" title="Fair Value">12,834,444</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zii0bK5QlNt7" style="width: 6%; text-align: right" title="Cash and Cash Equivalents">12,834,444</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zvkySZu6vrhf" style="width: 6%; text-align: right" title="Marketable Securities"><span style="-sec-ix-hidden: xdx2ixbrl0775">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Level 1:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Money market funds</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zQvVNtk3OBf6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjusted Cost">146,359</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpvVRyC5wPWd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for Credit Losses">       <span style="-sec-ix-hidden: xdx2ixbrl0779">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zDjhCvDQ6SNb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Unrealized Gains / (Losses)"><span style="-sec-ix-hidden: xdx2ixbrl0781">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--TradingSecurities_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zh3BtbfHrL53" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">146,359</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_znkYPYX3eqFg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cash and Cash Equivalents">146,359</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--MarketableSecurities_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zOtfBq5D7oAk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable Securities"><span style="-sec-ix-hidden: xdx2ixbrl0787">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Subtotal</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zj4OchRmM3qf" style="text-align: right" title="Adjusted Cost">146,359</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z6rCOpR22yte" style="text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0791">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAvnoSf05ezl" style="text-align: right" title="Total Unrealized Gains / (Losses)"><span style="-sec-ix-hidden: xdx2ixbrl0793">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--TradingSecurities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEs6ehGfSed1" style="text-align: right" title="Fair Value">146,359</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zZlw9kRnGhnd" style="text-align: right" title="Cash and Cash Equivalents">146,359</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--MarketableSecurities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zPAygaqEHEe" style="text-align: right" title="Marketable Securities"><span style="-sec-ix-hidden: xdx2ixbrl0799">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Level 2:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">U.S. treasury securities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zyCTeVMBWVAf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjusted Cost">67,892,825</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zl4PJdTkDAqi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0803">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zKVc2ulO4CX7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Unrealized Gains / (Losses)">389,241</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--TradingSecurities_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPl9Org36pVa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">68,282,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z4SFbt6W5bsb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cash and Cash Equivalents">9,993,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zHID2PIcIz59" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable Securities">58,289,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Subtotal</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zb75OImgHOTc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjusted Cost">67,892,825</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zS5wG8FmjNag" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0815">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ztKMSOqkPDSl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Unrealized Gains / (Losses)">389,241</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--TradingSecurities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zu5MUYAFkV3c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">68,282,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFGipkhUkqV4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cash and Cash Equivalents">9,993,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--MarketableSecurities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zkFsVRNF5g6h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable Securities">58,289,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20221231_z5PC2dk9nySd" style="border-bottom: Black 2.5pt double; text-align: right" title="Adjusted Cost">80,873,628</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20221231_z17FziJpKEw9" style="border-bottom: Black 2.5pt double; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0827">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231_zGmNJIFDJBA" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Unrealized Gains / (Losses)">389,241</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--TradingSecurities_iI_c20221231_zdbiCRwmnFul" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value">81,262,869</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231_zOKL2CFWJko" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash and Cash Equivalents">22,973,803</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--MarketableSecurities_iI_c20221231_zwIKAQCrnwJ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable Securities">58,289,066</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_z1g8H2MFsl5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Marketable investment securities held as of December 31, 2023 mature over the next 12 months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_zf2SWnhlb8Q2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The following table shows the Company’s cash, cash equivalents, and marketable investment securities by significant investment category:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zAp7Fx6s2PQb" style="display: none">Schedule of Cash, Cash Equivalents and Marketable Investment Securities</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="22" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Adjusted Cost</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Allowance for Credit Losses</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total Unrealized Gains / (Losses)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Fair Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Cash and Cash Equivalents</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Marketable Investment Securities</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zyKhFnLoh8sk" style="width: 6%; text-align: right" title="Adjusted Cost">4,317,449</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zhOPuTS7j8Q9" style="width: 6%; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0695">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_z1bAV9MsJVW5" style="width: 6%; text-align: right" title="Total Unrealized Gains / (Losses)"><span style="-sec-ix-hidden: xdx2ixbrl0697">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--TradingSecurities_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zFUlnlSVvyHa" style="width: 6%; text-align: right" title="Fair Value">4,317,449</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_z6sPNc9ghZF7" style="width: 6%; text-align: right" title="Cash and Cash Equivalents">4,317,449</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecurities_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_z4caqpTOlsdl" style="width: 6%; text-align: right" title="Marketable Securities"><span style="-sec-ix-hidden: xdx2ixbrl0703">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Level 1:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Money market funds</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zQigIxvtBPr2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjusted Cost">10,599,429</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zFvTgr3fpQpi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0707">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zeRx2961HDUe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Unrealized Gains / (Losses)"><span style="-sec-ix-hidden: xdx2ixbrl0709">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--TradingSecurities_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z2Awplb5xur4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">10,599,429</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zPG2uz7qKU2i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cash and Cash Equivalents">10,599,429</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--MarketableSecurities_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z2CEHX9WVTBi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable Securities"><span style="-sec-ix-hidden: xdx2ixbrl0715">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Subtotal</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z8MsH7FJB4F1" style="text-align: right" title="Adjusted Cost">10,599,429</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zDCybvPZbKZg" style="text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0719">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zI6kRW8gay8" style="text-align: right" title="Total Unrealized Gains / (Losses)"><span style="-sec-ix-hidden: xdx2ixbrl0721">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--TradingSecurities_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zSZeEsZDHRt9" style="text-align: right" title="Fair Value">10,599,429</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_ziVoYlYntZZ5" style="text-align: right" title="Cash and Cash Equivalents">10,599,429</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--MarketableSecurities_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_znhvsDsPJRIa" style="text-align: right" title="Marketable Securities"><span style="-sec-ix-hidden: xdx2ixbrl0727">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Level 2:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">U.S. treasury securities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z6wSL9Oi8tDk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjusted Cost">43,484,810</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zY2HPb3OtQVl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0731">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zQzPfEJSVL45" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Unrealized Gains / (Losses)">146,700</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--TradingSecurities_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zqMcVj29qUr9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">43,631,510</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ztqBYLr2UM12" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cash and Cash Equivalents"><span style="-sec-ix-hidden: xdx2ixbrl0737">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--MarketableSecurities_iI_c20231231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zmLxRTTCyjN9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable Securities">43,631,510</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Subtotal</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z3wvWUnhWs49" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjusted Cost">43,484,810</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z59Pnf6zvaWi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0743">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z5rLfnUkZxSb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Unrealized Gains / (Losses)">146,700</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--TradingSecurities_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFISYI24g4Ie" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">43,631,510</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zEixkv8r9Ycd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cash and Cash Equivalents"><span style="-sec-ix-hidden: xdx2ixbrl0749">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--MarketableSecurities_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zD9LwMZohJv4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable Securities">43,631,510</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20231231_zLrJINOTLoOd" style="border-bottom: Black 2.5pt double; text-align: right" title="Adjusted Cost">58,401,688</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20231231_zGzTF26z7AU6" style="border-bottom: Black 2.5pt double; text-align: right" title="Allowance for Credit Losses">       <span style="-sec-ix-hidden: xdx2ixbrl0755">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20231231_zS3j87JMb4m7" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Unrealized Gains / (Losses)">146,700</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--TradingSecurities_iI_c20231231_zI5OvNMEMvDk" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value">58,548,388</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20231231_zXitdTzEWve2" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash and Cash Equivalents">14,916,878</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--MarketableSecurities_iI_c20231231_zSXid3gTMGNg" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable Securities">43,631,510</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Adjusted Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Allowance for Credit Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Unrealized Gains / (Losses)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cash and Cash Equivalents</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Marketable Securities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zI4dCS93maMj" style="width: 6%; text-align: right" title="Adjusted Cost">12,834,444</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zCJAy9G0zf2l" style="width: 6%; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0767">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_z2C2ObFuuvl9" style="width: 6%; text-align: right" title="Total Unrealized Gains / (Losses)"><span style="-sec-ix-hidden: xdx2ixbrl0769">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--TradingSecurities_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zNpYN8nn1m5c" style="width: 6%; text-align: right" title="Fair Value">12,834,444</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zii0bK5QlNt7" style="width: 6%; text-align: right" title="Cash and Cash Equivalents">12,834,444</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zvkySZu6vrhf" style="width: 6%; text-align: right" title="Marketable Securities"><span style="-sec-ix-hidden: xdx2ixbrl0775">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Level 1:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Money market funds</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zQvVNtk3OBf6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjusted Cost">146,359</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpvVRyC5wPWd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for Credit Losses">       <span style="-sec-ix-hidden: xdx2ixbrl0779">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zDjhCvDQ6SNb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Unrealized Gains / (Losses)"><span style="-sec-ix-hidden: xdx2ixbrl0781">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--TradingSecurities_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zh3BtbfHrL53" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">146,359</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_znkYPYX3eqFg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cash and Cash Equivalents">146,359</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--MarketableSecurities_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zOtfBq5D7oAk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable Securities"><span style="-sec-ix-hidden: xdx2ixbrl0787">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Subtotal</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zj4OchRmM3qf" style="text-align: right" title="Adjusted Cost">146,359</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z6rCOpR22yte" style="text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0791">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAvnoSf05ezl" style="text-align: right" title="Total Unrealized Gains / (Losses)"><span style="-sec-ix-hidden: xdx2ixbrl0793">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--TradingSecurities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEs6ehGfSed1" style="text-align: right" title="Fair Value">146,359</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zZlw9kRnGhnd" style="text-align: right" title="Cash and Cash Equivalents">146,359</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--MarketableSecurities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zPAygaqEHEe" style="text-align: right" title="Marketable Securities"><span style="-sec-ix-hidden: xdx2ixbrl0799">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Level 2:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">U.S. treasury securities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zyCTeVMBWVAf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjusted Cost">67,892,825</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zl4PJdTkDAqi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0803">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zKVc2ulO4CX7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Unrealized Gains / (Losses)">389,241</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--TradingSecurities_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPl9Org36pVa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">68,282,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z4SFbt6W5bsb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cash and Cash Equivalents">9,993,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--USTreasurySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zHID2PIcIz59" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable Securities">58,289,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Subtotal</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zb75OImgHOTc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Adjusted Cost">67,892,825</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zS5wG8FmjNag" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0815">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ztKMSOqkPDSl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Unrealized Gains / (Losses)">389,241</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--TradingSecurities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zu5MUYAFkV3c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value">68,282,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFGipkhUkqV4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cash and Cash Equivalents">9,993,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--MarketableSecurities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zkFsVRNF5g6h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Marketable Securities">58,289,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--TradingSecuritiesDebtAmortizedCost_iI_c20221231_z5PC2dk9nySd" style="border-bottom: Black 2.5pt double; text-align: right" title="Adjusted Cost">80,873,628</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20221231_z17FziJpKEw9" style="border-bottom: Black 2.5pt double; text-align: right" title="Allowance for Credit Losses"><span style="-sec-ix-hidden: xdx2ixbrl0827">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231_zGmNJIFDJBA" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Unrealized Gains / (Losses)">389,241</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--TradingSecurities_iI_c20221231_zdbiCRwmnFul" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value">81,262,869</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231_zOKL2CFWJko" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash and Cash Equivalents">22,973,803</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--MarketableSecurities_iI_c20221231_zwIKAQCrnwJ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable Securities">58,289,066</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 4317449 4317449 4317449 10599429 10599429 10599429 10599429 10599429 10599429 43484810 146700 43631510 43631510 43484810 146700 43631510 43631510 58401688 146700 58548388 14916878 43631510 12834444 12834444 12834444 146359 146359 146359 146359 146359 146359 67892825 389241 68282066 9993000 58289066 67892825 389241 68282066 9993000 58289066 80873628 389241 81262869 22973803 58289066 <p id="xdx_805_eus-gaap--FairValueDisclosuresTextBlock_zYu0wDeZgruf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4 – <span id="xdx_82A_ztvwdchIOVP8">Fair Value Measurements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures and records certain financial assets and liabilities at fair value on a recurring basis. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following three levels of inputs are used to measure the fair value of financial assets and liabilities:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1: Quoted market prices in active markets for identical assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3: Unobservable inputs that are not corroborated by market data.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zL5U1YlBX0ta" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the assets and liabilities measured at fair value on a recurring basis as of December 31, 2023 and December 31, 2022, by level within the fair value hierarchy:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_z6moWAgDH4Ub" style="display: none">Schedule of Fair Value Assets and Liabilities</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAD4Mk0LEej4" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 1)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zXbLCtEqcWKi" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 2)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zOM5iQdFZQF2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zn4HUiXQCbcg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 1)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 2)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pp0p0_zlvxtjm5Fa66" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left">Cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">13,806,864</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0842">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0843">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">13,806,864</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--MarketableSecurities_iI_pp0p0_zamJqINEfQoh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Marketable securities (U.S. treasury bills and notes)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0846">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,631,510</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0848">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,631,510</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_zMRUzmbtZUtc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,806,864</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">43,631,510</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0853">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">57,438,374</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Liabilities:</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--FairValueOfContingentConsiderationToCommonStock_iI_pp0p0_zir3FqVmEYq6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Contingent consideration - common stock</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0856">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,318,995</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,318,995</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--FairValueOfContingentConsiderationToWarrants_iI_pp0p0_zrbcMERjNEKi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Contingent consideration - warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0862">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">320,780</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">320,780</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_zGnyNofwXHDi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0866">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0867">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,639,775</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,639,775</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zbEAdaHhU5W1" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 1)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zcdPKOmcY4H7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 2)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWGVdzflhLGh" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zsWk8KpZjKwl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Total</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 1)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 2)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pp0p0_zmi0iEtTmYt" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left">Cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">186,667</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">9,993,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0873">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">10,179,667</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--MarketableSecurities_iI_pp0p0_zw3vz65zPQLb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Marketable securities (U.S. treasury bills and notes)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0876">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,289,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0878">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,289,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_zAWuhb3z8p0i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">186,667</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">68,282,066</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0883">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">68,468,733</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--FairValueOfContingentConsiderationToCommonStock_iI_pp0p0_zg3l98euYy1k" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Contingent consideration - common stock</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0886">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0887">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,499,147</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,499,147</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--FairValueOfContingentConsiderationToWarrants_iI_pp0p0_zQvlKUpIZKt3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Contingent consideration - warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0891">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0892">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">233,209</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">233,209</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_zwLBc57WrGh9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0896">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0897">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,732,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,732,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zNUpTTzInO5j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s financial instruments that are measured at fair value on a recurring basis consist of certificates of deposit and U.S. treasury bills and notes as of December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with prior year acquisitions, the Company recorded a liability for contingent consideration in the form of shares of common stock and warrants to purchase common stock, both to be issued when certain milestones are achieved. The fair value of contingent consideration is calculated using a discounted probability weighted valuation model. Discount rates used in such calculations are a significant assumption that are not observed in the market, and therefore, the resulting fair value represents a Level 3 measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zpdn14zW2MP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The changes for Level 3 items measured at fair value on a recurring basis are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zsYaPKpwD5v7" style="display: none">Schedule of Changes in the Fair Value Measurement</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20230101__20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zr5JjQ86pSRk" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_iS_pp0p0_zZ1kSkp0iIfl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 84%">Fair value as of December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,732,356</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ContingentConsideredIssuedForBusinessAcquisitions_zg2Ux4C9pMl6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in fair value of contingent consideration issued for business acquisitions</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,092,581</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_iE_zwkvocA8Y428" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Fair value as of December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,639,775</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zexBVP5xhkP" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the contingent consideration is based on the fair value of the contingent consideration-common stock and contingent consideration-warrants. The fair value of the contingent consideration-common stock is equal to the probability-adjusted value of the Company’s common stock as of the valuation date. The fair value of the contingent consideration-warrants is equal to the probability adjusted value of a call option with terms consistent with the terms of the warrants as of the valuation date. Prior to the probability adjustments, the warrants were valued based on the following inputs:</span></p> <p id="xdx_89B_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zkO2Q6OwY5q3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zHGqSjQV5q98" style="display: none">Schedule of Contingent Consideration Common Stock and Warrants</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zStncyLg47yj" style="width: 14%; text-align: right" title="Warrants measurement input">1.33</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z0swE95w1H9" style="width: 14%; text-align: right" title="Warrants measurement input">2.52</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Strike price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputStrikePriceMember_zTFnRs86Dhhj" style="text-align: right" title="Warrants measurement input">9.13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputStrikePriceMember_zRCvyZlMmmjl" style="text-align: right" title="Warrants measurement input">9.13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zhPuszBpWHDj" title="Warrants measurement input">187.5</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zfX1ZfnF5Ckj" title="Warrants measurement input">75.0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zEctuVJ1CmXj" title="Warrants measurement input">4.0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zr6wf5a4Igmg" title="Warrants measurement input">4.1</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zYMEblibep7i" title="Expected term">3.0</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231_zKpoVOMyV30e" title="Expected term">4.0</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A6_zZGkJqShJuAb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value of Other Financial Instruments</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amounts of certain financial instruments, including cash held in banks, accounts receivable, notes receivable, accounts payable, accrued liabilities, and other liabilities approximate fair value due to their short-term maturities and are excluded from the fair value tables above.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zL5U1YlBX0ta" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the assets and liabilities measured at fair value on a recurring basis as of December 31, 2023 and December 31, 2022, by level within the fair value hierarchy:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_z6moWAgDH4Ub" style="display: none">Schedule of Fair Value Assets and Liabilities</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAD4Mk0LEej4" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 1)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zXbLCtEqcWKi" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 2)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zOM5iQdFZQF2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zn4HUiXQCbcg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 1)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 2)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pp0p0_zlvxtjm5Fa66" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left">Cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">13,806,864</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0842">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0843">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">13,806,864</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--MarketableSecurities_iI_pp0p0_zamJqINEfQoh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Marketable securities (U.S. treasury bills and notes)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0846">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,631,510</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0848">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,631,510</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_zMRUzmbtZUtc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,806,864</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">43,631,510</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0853">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">57,438,374</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Liabilities:</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--FairValueOfContingentConsiderationToCommonStock_iI_pp0p0_zir3FqVmEYq6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Contingent consideration - common stock</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0856">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,318,995</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,318,995</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--FairValueOfContingentConsiderationToWarrants_iI_pp0p0_zrbcMERjNEKi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Contingent consideration - warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0862">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">320,780</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">320,780</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_zGnyNofwXHDi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0866">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0867">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,639,775</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,639,775</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zbEAdaHhU5W1" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 1)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zcdPKOmcY4H7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 2)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWGVdzflhLGh" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zsWk8KpZjKwl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Total</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 1)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 2)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pp0p0_zmi0iEtTmYt" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left">Cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">186,667</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">9,993,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0873">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">10,179,667</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--MarketableSecurities_iI_pp0p0_zw3vz65zPQLb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Marketable securities (U.S. treasury bills and notes)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0876">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,289,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0878">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,289,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_zAWuhb3z8p0i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">186,667</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">68,282,066</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0883">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">68,468,733</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--FairValueOfContingentConsiderationToCommonStock_iI_pp0p0_zg3l98euYy1k" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Contingent consideration - common stock</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0886">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0887">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,499,147</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,499,147</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--FairValueOfContingentConsiderationToWarrants_iI_pp0p0_zQvlKUpIZKt3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Contingent consideration - warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0891">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0892">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">233,209</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">233,209</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_zwLBc57WrGh9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0896">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0897">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,732,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,732,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 13806864 13806864 43631510 43631510 13806864 43631510 57438374 1318995 1318995 320780 320780 1639775 1639775 186667 9993000 10179667 58289066 58289066 186667 68282066 68468733 2499147 2499147 233209 233209 2732356 2732356 <p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zpdn14zW2MP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The changes for Level 3 items measured at fair value on a recurring basis are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zsYaPKpwD5v7" style="display: none">Schedule of Changes in the Fair Value Measurement</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20230101__20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zr5JjQ86pSRk" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_iS_pp0p0_zZ1kSkp0iIfl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 84%">Fair value as of December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,732,356</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ContingentConsideredIssuedForBusinessAcquisitions_zg2Ux4C9pMl6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in fair value of contingent consideration issued for business acquisitions</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,092,581</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_iE_zwkvocA8Y428" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Fair value as of December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,639,775</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2732356 -1092581 1639775 <p id="xdx_89B_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zkO2Q6OwY5q3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zHGqSjQV5q98" style="display: none">Schedule of Contingent Consideration Common Stock and Warrants</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zStncyLg47yj" style="width: 14%; text-align: right" title="Warrants measurement input">1.33</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z0swE95w1H9" style="width: 14%; text-align: right" title="Warrants measurement input">2.52</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Strike price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputStrikePriceMember_zTFnRs86Dhhj" style="text-align: right" title="Warrants measurement input">9.13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputStrikePriceMember_zRCvyZlMmmjl" style="text-align: right" title="Warrants measurement input">9.13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zhPuszBpWHDj" title="Warrants measurement input">187.5</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zfX1ZfnF5Ckj" title="Warrants measurement input">75.0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zEctuVJ1CmXj" title="Warrants measurement input">4.0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zr6wf5a4Igmg" title="Warrants measurement input">4.1</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zYMEblibep7i" title="Expected term">3.0</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231_zKpoVOMyV30e" title="Expected term">4.0</span></td><td style="text-align: left"> </td></tr> </table> 1.33 2.52 9.13 9.13 1.875 0.750 0.040 0.041 P3Y P4Y <p id="xdx_803_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zF7iMDmjjqo2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5 – <span id="xdx_82D_zbzTrpmBu0Te">Property and Equipment</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--PropertyPlantAndEquipmentTextBlock_zXYwHEe5RVSc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zywiablLOnG" style="display: none">Schedule of Property and Equipment</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Estimated</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful Lives in years</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Lab equipment</td><td style="width: 2%"> </td> <td style="width: 14%; text-align: center"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zGxqoLjW4VI3" title="Property and equipment estimated useful lives">3</span> - <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zLNxxFhxOGq1" title="Property and equipment estimated useful lives">5</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zUPXOFw2QSwj" style="width: 12%; text-align: right" title="Property and equipment, gross">4,545,908</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zAwUJlF0H237" style="width: 12%; text-align: right" title="Property and equipment, gross">3,574,730</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: center"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdsAndLeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zyunsAMj2tXb" title="Property and equipment estimated useful lives">0</span> - <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdsAndLeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zJ3TYiInCpH3" title="Property and equipment estimated useful lives">5</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z9zIE4oehgsf" style="text-align: right" title="Property and equipment, gross">548,648</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zSamhsnpEFpb" style="text-align: right" title="Property and equipment, gross">224,957</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office equipment, furniture and other</td><td> </td> <td style="text-align: center"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zWFcdeJkHZmb" title="Property and equipment estimated useful lives">2</span> - <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zXfCdGuk8rv9" title="Property and equipment estimated useful lives">5</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zocNuIBg9MKe" style="text-align: right" title="Property and equipment, gross">173,668</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zCaOTZg8tjy6" style="text-align: right" title="Property and equipment, gross">112,044</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20231231_z127ILTGMTQ1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: accumulated depreciation">(2,232,495</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20221231_zQZlDOWvZdU5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: accumulated depreciation">(1,372,248</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Fixed assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_c20231231_ztivCfqqzfui" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">3,035,729</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_c20221231_zMBAWVaG1Rj9" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">2,539,483</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zeY4MW8brJV7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_894_eus-gaap--PropertyPlantAndEquipmentTextBlock_zXYwHEe5RVSc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zywiablLOnG" style="display: none">Schedule of Property and Equipment</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Estimated</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful Lives in years</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Lab equipment</td><td style="width: 2%"> </td> <td style="width: 14%; text-align: center"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zGxqoLjW4VI3" title="Property and equipment estimated useful lives">3</span> - <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zLNxxFhxOGq1" title="Property and equipment estimated useful lives">5</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zUPXOFw2QSwj" style="width: 12%; text-align: right" title="Property and equipment, gross">4,545,908</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zAwUJlF0H237" style="width: 12%; text-align: right" title="Property and equipment, gross">3,574,730</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: center"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdsAndLeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zyunsAMj2tXb" title="Property and equipment estimated useful lives">0</span> - <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdsAndLeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zJ3TYiInCpH3" title="Property and equipment estimated useful lives">5</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z9zIE4oehgsf" style="text-align: right" title="Property and equipment, gross">548,648</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zSamhsnpEFpb" style="text-align: right" title="Property and equipment, gross">224,957</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office equipment, furniture and other</td><td> </td> <td style="text-align: center"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zWFcdeJkHZmb" title="Property and equipment estimated useful lives">2</span> - <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zXfCdGuk8rv9" title="Property and equipment estimated useful lives">5</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zocNuIBg9MKe" style="text-align: right" title="Property and equipment, gross">173,668</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zCaOTZg8tjy6" style="text-align: right" title="Property and equipment, gross">112,044</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20231231_z127ILTGMTQ1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: accumulated depreciation">(2,232,495</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20221231_zQZlDOWvZdU5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: accumulated depreciation">(1,372,248</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Fixed assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_c20231231_ztivCfqqzfui" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">3,035,729</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_c20221231_zMBAWVaG1Rj9" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">2,539,483</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> P3Y P5Y 4545908 3574730 P0Y P5Y 548648 224957 P2Y P5Y 173668 112044 2232495 1372248 3035729 2539483 <p id="xdx_801_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zosDfEE6yfk3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6 – <span id="xdx_822_ziiMvMtwROY7">Goodwill and Intangible Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Goodwill</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill represents the excess of purchase price and related costs over the value assigned to net tangible and identifiable intangible assets acquired in business combinations. The following table presents the changes in the carrying amount of goodwill:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfGoodwillTextBlock_zMSXnWtUBRL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zakdvgQ6JNq5" style="display: none">Schedule of Goodwill</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Balance as of December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--Goodwill_iS_c20220101__20221231_zLshZkDAeIl3" style="width: 18%; text-align: right" title="Goodwil - beginning">14,706,818</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Measurement period adjustments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--GoodwillTranslationAndPurchaseAccountingAdjustments_c20220101__20221231_zzhAOlfUOJ57" style="text-align: right" title="Measurement period adjustments">681,728</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Goodwill impairment charges</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--GoodwillImpairmentLoss_iN_di_c20220101__20221231_zSLVI4bcl0Ha" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill impairment charges">(15,388,546</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--Goodwill_iE_c20220101__20221231_zU11ntw81cp2" style="border-bottom: Black 2.5pt double; text-align: right" title="Goodwill - ending"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zlCQcY3LJRJi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company assesses goodwill for impairment at the reporting unit level on an annual basis, or whenever events or changes in circumstances occur that indicate that the fair value of a reporting unit is below its carrying amount. The Company estimates the fair value of its reporting unit by using forecasts of discounted future cash flows and peer market multiples. If the fair value is less than the carrying value, impairment will be recognized in the amount by which the carrying value exceeds the fair value. The Company performed a qualitative and quantitative goodwill impairment assessment as of December 31, 2022. Based on the impairment assessment performed the Company concluded that it was more likely than not that the fair value of the Company’s reporting unit was less than it’s carrying amount. Accordingly, the Company recorded an impairment charge to reduce the carrying value of goodwill to $<span id="xdx_90E_eus-gaap--Goodwill_iI_dxL_c20231231_zbSdystRBq6h" title="Goodwill::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0979">0</span></span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intangible Assets, Net</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zauat8qW06m5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8BC_zXZ3Q5rZhWVh" style="display: none">Schedule of Intangible Assets, Net</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="13" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Weighted-Average</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Net</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Useful Life (1)</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Carrying</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Carrying</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in Years)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">In-process research and development</td><td style="width: 2%"> </td> <td style="width: 14%; text-align: center"><span id="xdx_908_ecustom--IndefiniteLivedIntangibleAssetUsefulLife_dtY_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_fKDEp_zLheGfNdHHge" title="Estimated useful lives in years, term">Indefinite</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zVC5LKGpAyDl" style="width: 12%; text-align: right" title="Intangible assets, gross"> 26,101,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_ziLm5n7gDTwe" style="width: 12%; text-align: right" title="Less accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl0987">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zCx8GwOGFUxk" style="width: 12%; text-align: right" title="Intangible assets, net">26,101,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non-competition agreements</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_fKDEp_zgBVBhGivXYk" title="Estimated useful lives in years">2.7</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zDuuiueC5rR1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intangible assets, gross">1,094,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_z6jThQ8BXE1b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less accumulated amortization">(791,333</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zTX2zKfXOjVe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intangible assets, net">302,667</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231_zubGR9UUbvr7" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, gross">27,195,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231_z91TgwPcDgR3" style="border-bottom: Black 2.5pt double; text-align: right" title="Less accumulated amortization">(791,333</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231_zrw4HFsg7md7" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">26,403,667</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="13" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2022</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="text-align: center; font-weight: bold">Weighted-Average</td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Gross</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Net</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="text-align: center; font-weight: bold">Useful Life (1)</td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Carrying</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Accumulated</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Carrying</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(in Years)</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Amount</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Amortization</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">In-process research and development</td><td style="width: 2%"> </td> <td style="text-align: center; width: 14%"><span id="xdx_90A_ecustom--IndefiniteLivedIntangibleAssetUsefulLife_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_fKDEp_zYPXy5TmZx9b" title="Estimated useful lives in years, term">Indefinite</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_z1qa6pcFs49l" style="width: 12%; text-align: right" title="Intangible assets, gross">26,101,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zh59srlGc2bf" style="width: 12%; text-align: right" title="Less accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl1009">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zsMF65ixGlAl" style="width: 12%; text-align: right" title="Intangible assets, net">26,101,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non-competition agreements</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_fKDEp_zzq6H5zPRuq1" title="Estimated useful lives in years">2.7</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_z2AsePIY5Urb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intangible assets, gross">1,094,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zTs8mDjEKGSc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less accumulated amortization">(426,667</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_z3YcMGRmMUfk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intangible assets, net">667,333</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231_zwo9QbRVJosc" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, gross">27,195,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231_zfB5TwEuoRb1" style="border-bottom: Black 2.5pt double; text-align: right" title="Less accumulated amortization">(426,667</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20221231_zxc7lPcwPBej" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">26,768,333</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span id="xdx_F08_zH4BFhvW9ERh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F14_z4dE0MofHWg6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on weighted-average useful life established as of the acquisition date.</span></td> </tr></table> <p id="xdx_8AA_zUDDrLZEW3j1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zaE8evcFDARl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expected future annual amortization expense of the Company’s intangible assets held as of December 31, 2023 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zYBcEoGdBpAh" style="display: none">Schedule of Future Amortization Expense</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Year Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20231231_zXPLBhQLYTo3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortization Expense</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzZiM_zhEuoTYjemG6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 80%; text-align: left; padding-bottom: 1.5pt">2024</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">302,667</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzZiM_zFaPLziAkOY3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">302,667</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zwVTupyjbpV9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfGoodwillTextBlock_zMSXnWtUBRL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zakdvgQ6JNq5" style="display: none">Schedule of Goodwill</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Balance as of December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--Goodwill_iS_c20220101__20221231_zLshZkDAeIl3" style="width: 18%; text-align: right" title="Goodwil - beginning">14,706,818</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Measurement period adjustments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--GoodwillTranslationAndPurchaseAccountingAdjustments_c20220101__20221231_zzhAOlfUOJ57" style="text-align: right" title="Measurement period adjustments">681,728</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Goodwill impairment charges</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--GoodwillImpairmentLoss_iN_di_c20220101__20221231_zSLVI4bcl0Ha" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill impairment charges">(15,388,546</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--Goodwill_iE_c20220101__20221231_zU11ntw81cp2" style="border-bottom: Black 2.5pt double; text-align: right" title="Goodwill - ending"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 14706818 681728 15388546 <p id="xdx_89A_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zauat8qW06m5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8BC_zXZ3Q5rZhWVh" style="display: none">Schedule of Intangible Assets, Net</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="13" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Weighted-Average</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Net</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Useful Life (1)</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Carrying</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Carrying</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in Years)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">In-process research and development</td><td style="width: 2%"> </td> <td style="width: 14%; text-align: center"><span id="xdx_908_ecustom--IndefiniteLivedIntangibleAssetUsefulLife_dtY_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_fKDEp_zLheGfNdHHge" title="Estimated useful lives in years, term">Indefinite</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zVC5LKGpAyDl" style="width: 12%; text-align: right" title="Intangible assets, gross"> 26,101,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_ziLm5n7gDTwe" style="width: 12%; text-align: right" title="Less accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl0987">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zCx8GwOGFUxk" style="width: 12%; text-align: right" title="Intangible assets, net">26,101,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non-competition agreements</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_fKDEp_zgBVBhGivXYk" title="Estimated useful lives in years">2.7</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zDuuiueC5rR1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intangible assets, gross">1,094,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_z6jThQ8BXE1b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less accumulated amortization">(791,333</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zTX2zKfXOjVe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intangible assets, net">302,667</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231_zubGR9UUbvr7" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, gross">27,195,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231_z91TgwPcDgR3" style="border-bottom: Black 2.5pt double; text-align: right" title="Less accumulated amortization">(791,333</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231_zrw4HFsg7md7" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">26,403,667</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="13" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2022</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="text-align: center; font-weight: bold">Weighted-Average</td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Gross</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Net</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="text-align: center; font-weight: bold">Useful Life (1)</td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Carrying</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Accumulated</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Carrying</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(in Years)</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Amount</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Amortization</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">In-process research and development</td><td style="width: 2%"> </td> <td style="text-align: center; width: 14%"><span id="xdx_90A_ecustom--IndefiniteLivedIntangibleAssetUsefulLife_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_fKDEp_zYPXy5TmZx9b" title="Estimated useful lives in years, term">Indefinite</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_z1qa6pcFs49l" style="width: 12%; text-align: right" title="Intangible assets, gross">26,101,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zh59srlGc2bf" style="width: 12%; text-align: right" title="Less accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl1009">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zsMF65ixGlAl" style="width: 12%; text-align: right" title="Intangible assets, net">26,101,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non-competition agreements</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_fKDEp_zzq6H5zPRuq1" title="Estimated useful lives in years">2.7</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_z2AsePIY5Urb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intangible assets, gross">1,094,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zTs8mDjEKGSc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less accumulated amortization">(426,667</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_z3YcMGRmMUfk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intangible assets, net">667,333</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20221231_zwo9QbRVJosc" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, gross">27,195,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20221231_zfB5TwEuoRb1" style="border-bottom: Black 2.5pt double; text-align: right" title="Less accumulated amortization">(426,667</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20221231_zxc7lPcwPBej" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">26,768,333</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span id="xdx_F08_zH4BFhvW9ERh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F14_z4dE0MofHWg6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on weighted-average useful life established as of the acquisition date.</span></td> </tr></table> Indefinite 26101000 26101000 P2Y8M12D 1094000 -791333 302667 27195000 -791333 26403667 Indefinite 26101000 26101000 P2Y8M12D 1094000 -426667 667333 27195000 -426667 26768333 <p id="xdx_890_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zaE8evcFDARl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expected future annual amortization expense of the Company’s intangible assets held as of December 31, 2023 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zYBcEoGdBpAh" style="display: none">Schedule of Future Amortization Expense</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Year Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20231231_zXPLBhQLYTo3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortization Expense</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzZiM_zhEuoTYjemG6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 80%; text-align: left; padding-bottom: 1.5pt">2024</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">302,667</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzZiM_zFaPLziAkOY3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">302,667</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 302667 302667 <p id="xdx_802_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zrHeIEJpoYN6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7 - <span id="xdx_82D_zcEN2OAm9sHg">Accrued Expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zZ4zZBkEIdya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8BC_zTi4zaMNbugi" style="display: none">Schedule of Accrued Expenses</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20231231_zPOtjbCLt9d9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20221231_zNbEbBM9JXm2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--AccruedPayrollTaxesCurrent_iI_maALCzYz0_zECg7VTTj1K2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Payroll liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,643,186</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">428,354</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccruedSalesCommissionCurrent_iI_maALCzYz0_zwgCRy2FgH83" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Distributor commissions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,958</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">159,725</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzYz0_zfMF5tuApwZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Other accrued liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">519,815</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">346,368</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzYz0_zRDUP72pL5z" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,172,959</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">934,447</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_8AD_z5Mk8VYTbNf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_895_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zZ4zZBkEIdya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8BC_zTi4zaMNbugi" style="display: none">Schedule of Accrued Expenses</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20231231_zPOtjbCLt9d9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20221231_zNbEbBM9JXm2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--AccruedPayrollTaxesCurrent_iI_maALCzYz0_zECg7VTTj1K2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Payroll liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,643,186</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">428,354</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccruedSalesCommissionCurrent_iI_maALCzYz0_zwgCRy2FgH83" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Distributor commissions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,958</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">159,725</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzYz0_zfMF5tuApwZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Other accrued liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">519,815</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">346,368</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzYz0_zRDUP72pL5z" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,172,959</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">934,447</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> 1643186 428354 9958 159725 519815 346368 2172959 934447 <p id="xdx_804_eus-gaap--RevenueFromContractWithCustomerTextBlock_z7CkjE3SZt6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8 – <span id="xdx_824_zcTrMRPEwIM4">Revenue</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_zupC7jpXe8h7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth revenue by geographic area:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zzWxNNvPMFJ9" style="display: none">Summary of Revenue by Geographic Area</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20230101__20231231_zyi47Nz7UiW9" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220101__20221231_zdLOvjPqxG8g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Years Ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">United States</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0d_hsrt--StatementGeographicalAxis__country--US__srt--ProductOrServiceAxis__us-gaap--ProductMember_zemyxUwKBni1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: left">Product revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">659,618</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">24,671,554</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0d_hsrt--StatementGeographicalAxis__country--US__srt--ProductOrServiceAxis__us-gaap--GrantMember_zKqqYV1aE4cb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Grant revenue</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,820,565</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1058">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0d_hsrt--StatementGeographicalAxis__country--US_zO1f3fWGTcrj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Total United States</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,480,183</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,671,554</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Rest of World</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0d_hsrt--StatementGeographicalAxis__custom--RestOfWorldMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zzLxtCHY9NKa" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Product revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">331,855</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,546,655</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0d_hsrt--StatementGeographicalAxis__custom--RestOfWorldMember__srt--ProductOrServiceAxis__us-gaap--GrantMember_zTvW3CEGY0s8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Grant revenue</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1067">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0d_hsrt--StatementGeographicalAxis__custom--RestOfWorldMember_z8HAUzRQGQO5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total Rest of World</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">331,855</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,546,655</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0d_zuTmQDEvzD8e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,812,038</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">34,218,209</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0d_zGggZ7cE2p86" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Revenue geographic area</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,812,038</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">34,218,209</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Percentage of revenue by area:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">United States</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20231231__srt--StatementGeographicalAxis__country--US__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zHTbr3pDetz5" style="text-align: right" title="Percentage of revenue">95</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__srt--StatementGeographicalAxis__country--US__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zrxidxiZeHkl" style="text-align: right" title="Percentage of revenue">72</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Rest of World</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20231231__srt--StatementGeographicalAxis__custom--RestOfWorldMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zJ1d3pz3Un74" style="text-align: right" title="Percentage of revenue">5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__srt--StatementGeographicalAxis__custom--RestOfWorldMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zBEs29JLtPr7" style="text-align: right" title="Percentage of revenue">28</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A0_zVIK3c1YCu5a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deferred Revenue</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zU7KKb8sKMql" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in the Company’s deferred revenue balance for the year ended December 31, 2023 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zovZkE3c1Fw" style="display: none">Schedule of Deferred Revenue</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ContractWithCustomerLiability_iS_c20230101__20231231_zmSoc5Dfuauf" style="text-align: right" title="Deferred revenue, beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1088">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 84%; text-align: left">Increase due to prepayments from customers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_ecustom--IncreaseDueToPrepaymentsFromCustomers_c20230101__20231231_zOs8v2Hdimai" style="width: 12%; text-align: right" title="Increase due to prepayments from customers">32,570</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Increase due to grant funding awarded</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--IncreaseDueToPrepaymentsFromGrantsReceived_c20230101__20231231_zcPbvalpdOLk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Increase due to prepayments from grants received">329,879</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> Balance as of December, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ContractWithCustomerLiability_iE_c20230101__20231231_z1PVvhDdbVgl" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred revenue, ending balance">362,449</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zwiLZD7YnlP6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_89A_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_zupC7jpXe8h7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth revenue by geographic area:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zzWxNNvPMFJ9" style="display: none">Summary of Revenue by Geographic Area</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20230101__20231231_zyi47Nz7UiW9" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220101__20221231_zdLOvjPqxG8g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Years Ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">United States</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0d_hsrt--StatementGeographicalAxis__country--US__srt--ProductOrServiceAxis__us-gaap--ProductMember_zemyxUwKBni1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: left">Product revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">659,618</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">24,671,554</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0d_hsrt--StatementGeographicalAxis__country--US__srt--ProductOrServiceAxis__us-gaap--GrantMember_zKqqYV1aE4cb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Grant revenue</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,820,565</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1058">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0d_hsrt--StatementGeographicalAxis__country--US_zO1f3fWGTcrj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Total United States</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,480,183</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,671,554</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Rest of World</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0d_hsrt--StatementGeographicalAxis__custom--RestOfWorldMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zzLxtCHY9NKa" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Product revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">331,855</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,546,655</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0d_hsrt--StatementGeographicalAxis__custom--RestOfWorldMember__srt--ProductOrServiceAxis__us-gaap--GrantMember_zTvW3CEGY0s8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Grant revenue</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1067">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0d_hsrt--StatementGeographicalAxis__custom--RestOfWorldMember_z8HAUzRQGQO5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total Rest of World</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">331,855</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,546,655</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0d_zuTmQDEvzD8e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,812,038</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">34,218,209</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0d_zGggZ7cE2p86" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Revenue geographic area</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,812,038</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">34,218,209</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Percentage of revenue by area:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">United States</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20231231__srt--StatementGeographicalAxis__country--US__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zHTbr3pDetz5" style="text-align: right" title="Percentage of revenue">95</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__srt--StatementGeographicalAxis__country--US__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zrxidxiZeHkl" style="text-align: right" title="Percentage of revenue">72</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Rest of World</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20231231__srt--StatementGeographicalAxis__custom--RestOfWorldMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zJ1d3pz3Un74" style="text-align: right" title="Percentage of revenue">5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__srt--StatementGeographicalAxis__custom--RestOfWorldMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zBEs29JLtPr7" style="text-align: right" title="Percentage of revenue">28</td><td style="text-align: left">%</td></tr> </table> 659618 24671554 5820565 6480183 24671554 331855 9546655 331855 9546655 6812038 34218209 6812038 34218209 0.95 0.72 0.05 0.28 <p id="xdx_898_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zU7KKb8sKMql" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in the Company’s deferred revenue balance for the year ended December 31, 2023 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zovZkE3c1Fw" style="display: none">Schedule of Deferred Revenue</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ContractWithCustomerLiability_iS_c20230101__20231231_zmSoc5Dfuauf" style="text-align: right" title="Deferred revenue, beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1088">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 84%; text-align: left">Increase due to prepayments from customers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_ecustom--IncreaseDueToPrepaymentsFromCustomers_c20230101__20231231_zOs8v2Hdimai" style="width: 12%; text-align: right" title="Increase due to prepayments from customers">32,570</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Increase due to grant funding awarded</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--IncreaseDueToPrepaymentsFromGrantsReceived_c20230101__20231231_zcPbvalpdOLk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Increase due to prepayments from grants received">329,879</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> Balance as of December, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ContractWithCustomerLiability_iE_c20230101__20231231_z1PVvhDdbVgl" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred revenue, ending balance">362,449</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 32570 329879 362449 <p id="xdx_804_eus-gaap--EarningsPerShareTextBlock_zrg3c72nRbdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9 – <span id="xdx_82D_zLRsSbxjIvA2">Earnings per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zBnAhYFvRwW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for years ended December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zRxOEGhS7lJc" style="display: none">Schedule of Basis and Diluted Earnings Per Share</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zkTGrQnmJmI5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20220101__20221231_zW3rcj1aiZk6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--NetIncomeLoss_zXyfgH1ZGbFi" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left; padding-bottom: 2.5pt">Net loss, as reported</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(35,332,865</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(14,238,249</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Denominator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zEKiuQc8iNdf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average shares, basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,346,599</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,479,028</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_ziV2b9dLlmRd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive effect of stock options, warrants and RSUs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1106">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1107">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_z3vBQYDwVA9b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Shares used to compute diluted earnings per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">29,346,599</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">31,479,028</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--EarningsPerShareBasic_pid_zAz6l3VgZru" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Basic earnings per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1.20</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.45</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--EarningsPerShareDiluted_pid_zbSACQdXNU62" style="vertical-align: bottom; background-color: White"> <td>Diluted earnings per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1.20</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.45</td><td style="text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_8A4_zsbUv8CL689l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The computation of diluted earnings per share for the years ended December 31, 2023 and December 31, 2022 also excludes approximately <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn5n6_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zU1fzCyvEQIi" title="Securities excluded from computation of diluted earnings per share"><span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn5n6_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwdPyphmTuEk" title="Securities excluded from computation of diluted earnings per share">1.4</span></span> million shares of common stock and approximately <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIMzMwTpo5ml" title="Securities excluded from computation of diluted earnings per share"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zk3qo9d9GVZj" title="Securities excluded from computation of diluted earnings per share">465,000</span></span> warrants to purchase shares of common stock that are contingent upon the achievement of certain milestones.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of incurring a net loss for the years ended December 31, 2023 and 2022, respectively, <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_do_uShares_c20230101__20231231_zUL6jWzXFUD8" title="Securities excluded from computation of diluted earnings per share"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_do_uShares_c20220101__20221231_zyQgWGf3eDYf" title="Securities excluded from computation of diluted earnings per share">no</span></span> potentially dilutive securities are included in the calculation of diluted earnings per share because such effect would be anti-dilutive. The Company had potentially dilutive securities as of December 31, 2023, consisting of: (i) <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zozOQVh5Eekf" title="Securities excluded from computation of diluted earnings per share">2,618,362</span> restricted stock units and (ii) <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zc5c2D7Q7Khk" title="Securities excluded from computation of diluted earnings per share">512,112</span> options, and potentially dilutive securities as of December 31, 2022, consisting of: (i) <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zkQvPqYwjCwl" title="Securities excluded from computation of diluted earnings per share">1,443,238</span> restricted stock units and (ii) <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zXjnYuQuefcg" title="Securities excluded from computation of diluted earnings per share">50,000</span> options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zBnAhYFvRwW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for years ended December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zRxOEGhS7lJc" style="display: none">Schedule of Basis and Diluted Earnings Per Share</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zkTGrQnmJmI5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20220101__20221231_zW3rcj1aiZk6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--NetIncomeLoss_zXyfgH1ZGbFi" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left; padding-bottom: 2.5pt">Net loss, as reported</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(35,332,865</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(14,238,249</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Denominator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zEKiuQc8iNdf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average shares, basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,346,599</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,479,028</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_ziV2b9dLlmRd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive effect of stock options, warrants and RSUs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1106">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1107">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_z3vBQYDwVA9b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Shares used to compute diluted earnings per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">29,346,599</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">31,479,028</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--EarningsPerShareBasic_pid_zAz6l3VgZru" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Basic earnings per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1.20</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.45</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--EarningsPerShareDiluted_pid_zbSACQdXNU62" style="vertical-align: bottom; background-color: White"> <td>Diluted earnings per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1.20</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.45</td><td style="text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> -35332865 -14238249 29346599 31479028 29346599 31479028 -1.20 -0.45 -1.20 -0.45 1400000 1400000 465000 465000 0 0 2618362 512112 1443238 50000 <p id="xdx_80C_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zddNEZSoTIYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10 – <span id="xdx_821_zA1Er1L9tLPh">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Incentive Plans</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s board of directors adopted, and shareholders approved, the Co-Diagnostics, Inc. Amended and Restated 2015 Long Term Incentive Plan (the “Incentive Plan”) providing for the issuance of stock-based incentive awards to employees, officers, consultants, directors and independent contractors. On August 31, 2022 the shareholders approved an increase in the number of awards available for issuance under the Incentive Plan to an aggregate of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20220831__us-gaap--PlanNameAxis__custom--TwoThousandFifteenLongTermIncentivePlanMember_zGpOm8JSGsEc" title="Number of common shares availalble for issuance">12,000,000</span> shares of common stock. The number of awards available for issuance under the Incentive Plan was <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenLongTermIncentivePlanMember_zZyqkqWxtwM2" title="Number of common shares availalble for issuance">4,357,937</span> at December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuL9fFVIgKtj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes option activity during the years ended December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zlcngleeUMH6" style="display: none">Schedule of Option Activity</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zfUUbIZb6CZe" style="width: 12%; text-align: right" title="Number of Options Outstanding, Beginning">1,111,363</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zvn4rcb8NKM8" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning">2.12</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231_zqQVU2UJMuwh" style="width: 12%; text-align: right" title="Weighted Average Fair Value Outstanding, Beginning">1.31</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220101__20221231_zqPPnYJESQd4" style="text-align: right" title="Number of Options Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1152">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zPdmlbpnJWHb" style="text-align: right" title="Weighted Average Exercise Price Granted"><span style="-sec-ix-hidden: xdx2ixbrl1154">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zyDPc4jJKU7i" style="text-align: right" title="Weighted Average Fair Value Granted"><span style="-sec-ix-hidden: xdx2ixbrl1156">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20221231_zGOrpNgCdSU9" style="text-align: right" title="Number of Options Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1158">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zbkzoEQ07O4i" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="-sec-ix-hidden: xdx2ixbrl1160">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20220101__20221231_zAKnE0zwjIvb" style="text-align: right" title="Weighted Average Fair Value Expired"><span style="-sec-ix-hidden: xdx2ixbrl1162">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited/Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220101__20221231_zjqhxkLjfeDl" style="text-align: right" title="Number of Options Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1164">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231_z3Eme5Eyqx9c" style="text-align: right" title="Weighted Average Exercise Price Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1166">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20220101__20221231_zuSITH25j44" style="text-align: right" title="Weighted Average Fair Value Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1168">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_zzmeq1JkAWSl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding, Exercised">(70,791</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zCystanSzAW8" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price Exercised">1.10</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised_pid_c20220101__20221231_zod7otR9f0Bf" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value Exercised">0.51</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_zpmrcp3Wknya" style="text-align: right" title="Number of Options Outstanding, Beginning">1,040,572</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zHqTK3fA9WLf" style="text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning">2.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231_zEHLyj07cx13" style="text-align: right" title="Weighted Average Fair Value Outstanding, Beginning">1.37</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zxDJl2djPTNi" title="Weighted-average Remaining Contractual Life (years) Outstanding, Beginning">5.88</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230101__20231231_z7jBRtM9qKI1" style="text-align: right" title="Number of Options Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1184">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231_z5JrsANdXSyf" style="text-align: right" title="Weighted Average Exercise Price Granted"><span style="-sec-ix-hidden: xdx2ixbrl1186">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231_z0k4KdxUauCl" style="text-align: right" title="Weighted Average Fair Value Granted"><span style="-sec-ix-hidden: xdx2ixbrl1188">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20230101__20231231_zEBykw0yCVV6" style="text-align: right" title="Number of Options Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1190">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zzmsaRODlyu3" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="-sec-ix-hidden: xdx2ixbrl1192">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20230101__20231231_zFXvDXYu5Ip7" style="text-align: right" title="Weighted Average Fair Value Expired"><span style="-sec-ix-hidden: xdx2ixbrl1194">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Forfeited/Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20230101__20231231_zwBClPZLnujl" style="text-align: right" title="Number of Options Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1196">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20231231_zd1Ng1zEiwe7" style="text-align: right" title="Weighted Average Exercise Price Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1198">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20230101__20231231_zTFUmkXTtr18" style="text-align: right" title="Weighted Average Fair Value Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1200">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20230101__20231231_zuMbactPfx61" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1202">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zkYPXudxeDm9" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1204">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_984_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised_pid_c20230101__20231231_zdupCWD85E8i" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1206">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231_zYM2YU3MUxD7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending">1,040,572</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zIDt2NTJUBn7" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Outstanding, Ending">2.19</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231_ziwQBOBnhHK2" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value Outstanding, Ending">1.37</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231_zH2CZFgc5bFh" title="Weighted-average Remaining Contractual Life (years) Outstanding, Ending">4.89</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20231231_zWxTFnPWLR9a" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable Ending">1,040,572</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231_ztiSRsau4fnf" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Exercisable Ending">2.19</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable_iE_pid_c20230101__20231231_zGg4yFlGWn5b" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value, Exercisable Ending">1.37</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_zDZT3VkMjSG3" title="Weighted-average Remaining Contractual Life (years), Exercisable Ending">4.89</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zVxZ0eHsNUU" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total intrinsic value of options exercised during the years ended December 31, 2023 and 2022, respectively, was $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zswDQsbb6x6k" title="Intrinsic value of options value exercised">0</span> and approximately $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn5n6_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zVF7aAXgt5D8" title="Intrinsic value of options value exercised">0.4</span> million. The aggregate intrinsic value of outstanding options at December 31, 2023 and 2022 was approximately $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn5n6_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zTMCy2Bvy5xb" title="Aggregate intrinsic value of outstanding options">0.2</span> million and $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn5n6_c20221231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zLOb8IDHM4fb" title="Aggregate intrinsic value of outstanding options">0.8</span> million, respectively. As of December 31, 2023, there were no unvested options and no unrecognized stock-based compensation expense related to options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restricted Stock Units</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zqh50fdtRDh4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the years ended December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_znMvlWauzPkb" style="display: none">Schedule of Outstanding Restricted Stock Units and Related Party</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p> <p style="margin-top: 0; margin-bottom: 0">Average Grant Date Fair Value</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Unvested at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhd76MDGHSnb" style="width: 14%; text-align: right" title="Number of Restricted Stock Units, Outstanding Beginning">1,267,415</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLTJ6FWkNsja" style="width: 14%; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding Beginning">9.94</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zcqy0nS3PIU6" style="text-align: right" title="Number of Restricted Stock Units, Granted">1,925,476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhGsGOt2miVh" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">5.66</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKLpNaSAY3e7" style="text-align: right" title="Number of Restricted Stock Units, Vested">(725,166</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zT4XLEetUTSg" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">8.66</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Forfeited/Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zp8kIohbFj32" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Restricted Stock Units, Forfeited/Cancelled">(41,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXAaNI3RYfy9" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited/Cancelled">8.31</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Unvested at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvh3M2dVg7E6" style="text-align: right" title="Number of Restricted Stock Units, Outstanding Beginning">2,426,725</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zC9DruVIeOS5" style="text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding Beginning">6.95</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2CU1ssMzSa8" style="text-align: right" title="Number of Restricted Stock Units, Granted">1,948,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHlTRHZzhzof" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">1.92</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxmXkor33Gc1" style="text-align: right" title="Number of Restricted Stock Units, Vested">(1,354,081</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3EKlGRt0cI3" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">6.17</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Forfeited/Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDBdSdiacP7b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Restricted Stock Units, Forfeited/Cancelled">(95,897</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztIe6HJpuF21" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited/Cancelled">6.16</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Unvested at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9SK3v3Suf97" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Restricted Stock Units, Outstanding Ending">2,925,497</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zY7bM55B1Gc3" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding Ending">3.99</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zcUf8RHC0Ah6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, there was $<span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIvtFoGByBmh" title="Unrecognized stock-based compensation">9.5</span> million of unrecognized stock-based compensation expense related to outstanding RSUs which is expected to be recognized over a weighted-average period of <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkS3s90LAnuj" title="Weighted average period">1.7</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has issued warrants related to financings, acquisitions and as compensation to third parties for services provided. The Company estimates the fair value of issued warrants on the date of issuance as determined using a Black-Scholes pricing model. The Company amortizes the fair value of issued warrants using a vesting schedule based on the terms and conditions of each warrant if granted for services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zGm6iFaGPpqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes warrant activity during the years ended December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zcp14VjSddQa" style="display: none">Schedule of Warrant Activity</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted Average Exercise</p> <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231_zts8Zk16Tuej" style="width: 11%; text-align: right" title="Number of Warrants Outstanding, Beginning">526,281</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zTJi4Xoe47ra" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, Beginning">8.15</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageFairValue_iS_pid_c20220101__20221231_zbfgcM7p4c3b" style="width: 11%; text-align: right" title="Weighted Average fair value, Beginning">4.01</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zSqLJooZvGxg" title="Weighted-average Remaining Contractual Life (Years) Outstanding">4.7</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Issued for adjustments to contingent purchase consideration</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationIssuedForAdjustmentsToContingentPurchaseConsideration_c20220101__20221231_zwlGyYXTBMbh" style="text-align: right" title="Number of Warrants Outstanding, Issued">8,719</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--IssuedForAdjustmentsToContingentPurchaseConsiderationPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zCVjHaZyPha8" style="text-align: right" title="Weighted Average Exercise Price, Issued">9.13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--IssuedForAdjustmentsToContingentPurchaseConsiderationWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zuN0HNtpr0bi" style="text-align: right" title="Weighted Average Fair Value, Issued">1.88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231_zuToqGPFDhKk" style="text-align: right" title="Number of Warrants Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1290">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zg2Vh5gR2B2e" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1292">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsGrantedWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zc4J1e9iuEe7" style="text-align: right" title="Weighted Average Fair Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1294">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231_zur5hyRwHMPi" style="text-align: right" title="Number of Warrants Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1296">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_znOf6WpWCH0b" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1298">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zkmI5Punj23k" style="text-align: right" title="Weighted Average Fair Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1300">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Forfeited/Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231_zntU1523wll8" style="text-align: right" title="Number of Warrants Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1302">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zQ8mOH6EoWD" style="text-align: right" title="Weighted Average Exercise Price, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1304">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20220101__20221231_z9sLoh8Gasf4" style="text-align: right" title="Weighted Average Fair Value, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1306">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231_zBFMww47hEc7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Exercised">(50,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zajl4XfThVN" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, Exercised">2.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zV6Mtk1w38e3" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value, Exercised">1.22</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231_zgXHOXuQKjda" style="text-align: right" title="Number of Warrants Outstanding, Beginning">485,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zZlM3gjskajf" style="text-align: right" title="Weighted Average Exercise Price, Beginning">8.81</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageFairValue_iS_pid_c20230101__20231231_zgqbwohPfy2b" style="text-align: right" title="Weighted Average fair value, Beginning">2.43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm3_dtY_c20220101__20221231_z0l309U0q73e" title="Weighted-average Remaining Contractual Life (Years) Outstanding">4.0</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231_zYE7CYTTKCs" style="text-align: right" title="Number of Warrants Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1322">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_z09dle1R83N" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1324">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsGrantedWeightedAverageGrantDateFairValue_pid_c20230101__20231231_z54PFd9khL2c" style="text-align: right" title="Weighted Average Fair Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1326">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20230101__20231231_z4hsN4cLXEH3" style="text-align: right" title="Number of Warrants Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1328">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_z5pAabUvms8i" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1330">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zCwoOsxUmgsd" style="text-align: right" title="Weighted Average Fair Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1332">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited/Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20230101__20231231_zPUZaojQHJfh" style="text-align: right" title="Number of Warrants Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1334">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_z7eCJIoo29h" style="text-align: right" title="Weighted Average Exercise Price, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1336">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zkxsIC1cMgFd" style="text-align: right" title="Weighted Average Fair Value, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1338">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20231231_z4KtW0LAFfHb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1340">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zz8fLqqFJv1g" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1342">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_z6cx87XDrqI5" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1344">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231_zcufPtvEXGQ2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Ending">485,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zrXZ2sMlFMbb" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Ending">8.81</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zEdQaU1OIxId" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value, Ending">1.29</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm3_dtY_c20230101__20231231_zi3KSB7ddt5k" title="Weighted-average Remaining Contractual Life (Years) Outstanding">3.0</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zsT5RqzWIUhe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The intrinsic value of warrants exercised during the years ended December 31, 2023 and 2022, respectively, was $<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriodTotalIntrinsicValue_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zL7V1tWcWh1h" title="Intrinsic value of warrants exercised">0</span> and approximately $<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriodTotalIntrinsicValue_pn5n6_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7DysL26ij1l" title="Intrinsic value of warrants exercised">0.3</span> million. The aggregate intrinsic value of outstanding warrants at December 31, 2023 was approximately $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmrzBGwUlqf1" title="Aggregate intrinsic value of options outstanding">0</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total number of warrants exercisable at December 31, 2023 is <span id="xdx_909_ecustom--ClassOfWarrantExercisable_iI_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBSJjAJbzirl" title="Warrants exercisable">20,000</span>. The ability to exercise the approximately <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231_z4iqe068wFnc" title="Warrants purchase">465,000</span> warrants issued in connection with acquisitions in prior years is contingent upon the achievement of certain development and revenue milestones on or before January 1, 2027. There was no unrecognized stock-based compensation expense related to warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based Compensation Expense</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zG1ZO3xHtDAk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized stock-based compensation expense as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zqqGf0Cvi5Ak" style="display: none">Schedule of Recognized Stock-based Compensation Expense</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20230101__20231231_zUyU6PXatIVi" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20220101__20221231_zVwz74A60Wr7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zsZdlhB6NyQj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Cost of sales</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">46,586</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">63,058</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zB8zZJvF8PU7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Sales and marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,153,974</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,866,116</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zDaT9YBOZd1e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,933,822</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,050,967</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zlSekZuMCO85" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,202,473</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,563,082</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_ze6lQOV68Zvl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,336,855</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,543,223</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zmRCb7DZKnml" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 12000000 4357937 <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuL9fFVIgKtj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes option activity during the years ended December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zlcngleeUMH6" style="display: none">Schedule of Option Activity</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zfUUbIZb6CZe" style="width: 12%; text-align: right" title="Number of Options Outstanding, Beginning">1,111,363</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zvn4rcb8NKM8" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning">2.12</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231_zqQVU2UJMuwh" style="width: 12%; text-align: right" title="Weighted Average Fair Value Outstanding, Beginning">1.31</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220101__20221231_zqPPnYJESQd4" style="text-align: right" title="Number of Options Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1152">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zPdmlbpnJWHb" style="text-align: right" title="Weighted Average Exercise Price Granted"><span style="-sec-ix-hidden: xdx2ixbrl1154">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zyDPc4jJKU7i" style="text-align: right" title="Weighted Average Fair Value Granted"><span style="-sec-ix-hidden: xdx2ixbrl1156">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20221231_zGOrpNgCdSU9" style="text-align: right" title="Number of Options Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1158">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zbkzoEQ07O4i" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="-sec-ix-hidden: xdx2ixbrl1160">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20220101__20221231_zAKnE0zwjIvb" style="text-align: right" title="Weighted Average Fair Value Expired"><span style="-sec-ix-hidden: xdx2ixbrl1162">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited/Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220101__20221231_zjqhxkLjfeDl" style="text-align: right" title="Number of Options Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1164">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231_z3Eme5Eyqx9c" style="text-align: right" title="Weighted Average Exercise Price Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1166">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20220101__20221231_zuSITH25j44" style="text-align: right" title="Weighted Average Fair Value Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1168">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_zzmeq1JkAWSl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding, Exercised">(70,791</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zCystanSzAW8" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price Exercised">1.10</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised_pid_c20220101__20221231_zod7otR9f0Bf" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value Exercised">0.51</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_zpmrcp3Wknya" style="text-align: right" title="Number of Options Outstanding, Beginning">1,040,572</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zHqTK3fA9WLf" style="text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning">2.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231_zEHLyj07cx13" style="text-align: right" title="Weighted Average Fair Value Outstanding, Beginning">1.37</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zxDJl2djPTNi" title="Weighted-average Remaining Contractual Life (years) Outstanding, Beginning">5.88</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230101__20231231_z7jBRtM9qKI1" style="text-align: right" title="Number of Options Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1184">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231_z5JrsANdXSyf" style="text-align: right" title="Weighted Average Exercise Price Granted"><span style="-sec-ix-hidden: xdx2ixbrl1186">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231_z0k4KdxUauCl" style="text-align: right" title="Weighted Average Fair Value Granted"><span style="-sec-ix-hidden: xdx2ixbrl1188">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20230101__20231231_zEBykw0yCVV6" style="text-align: right" title="Number of Options Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1190">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zzmsaRODlyu3" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="-sec-ix-hidden: xdx2ixbrl1192">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20230101__20231231_zFXvDXYu5Ip7" style="text-align: right" title="Weighted Average Fair Value Expired"><span style="-sec-ix-hidden: xdx2ixbrl1194">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Forfeited/Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20230101__20231231_zwBClPZLnujl" style="text-align: right" title="Number of Options Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1196">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20231231_zd1Ng1zEiwe7" style="text-align: right" title="Weighted Average Exercise Price Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1198">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20230101__20231231_zTFUmkXTtr18" style="text-align: right" title="Weighted Average Fair Value Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1200">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20230101__20231231_zuMbactPfx61" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1202">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zkYPXudxeDm9" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1204">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_984_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised_pid_c20230101__20231231_zdupCWD85E8i" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1206">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231_zYM2YU3MUxD7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending">1,040,572</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zIDt2NTJUBn7" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Outstanding, Ending">2.19</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231_ziwQBOBnhHK2" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value Outstanding, Ending">1.37</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231_zH2CZFgc5bFh" title="Weighted-average Remaining Contractual Life (years) Outstanding, Ending">4.89</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20231231_zWxTFnPWLR9a" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable Ending">1,040,572</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231_ztiSRsau4fnf" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Exercisable Ending">2.19</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable_iE_pid_c20230101__20231231_zGg4yFlGWn5b" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value, Exercisable Ending">1.37</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_zDZT3VkMjSG3" title="Weighted-average Remaining Contractual Life (years), Exercisable Ending">4.89</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1111363 2.12 1.31 70791 1.10 0.51 1040572 2.19 1.37 P5Y10M17D 1040572 2.19 1.37 P4Y10M20D 1040572 2.19 1.37 P4Y10M20D 0 400000 200000 800000 <p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zqh50fdtRDh4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the years ended December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_znMvlWauzPkb" style="display: none">Schedule of Outstanding Restricted Stock Units and Related Party</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p> <p style="margin-top: 0; margin-bottom: 0">Average Grant Date Fair Value</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Unvested at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhd76MDGHSnb" style="width: 14%; text-align: right" title="Number of Restricted Stock Units, Outstanding Beginning">1,267,415</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLTJ6FWkNsja" style="width: 14%; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding Beginning">9.94</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zcqy0nS3PIU6" style="text-align: right" title="Number of Restricted Stock Units, Granted">1,925,476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhGsGOt2miVh" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">5.66</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKLpNaSAY3e7" style="text-align: right" title="Number of Restricted Stock Units, Vested">(725,166</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zT4XLEetUTSg" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">8.66</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Forfeited/Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zp8kIohbFj32" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Restricted Stock Units, Forfeited/Cancelled">(41,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXAaNI3RYfy9" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited/Cancelled">8.31</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Unvested at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvh3M2dVg7E6" style="text-align: right" title="Number of Restricted Stock Units, Outstanding Beginning">2,426,725</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zC9DruVIeOS5" style="text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding Beginning">6.95</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2CU1ssMzSa8" style="text-align: right" title="Number of Restricted Stock Units, Granted">1,948,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHlTRHZzhzof" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">1.92</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxmXkor33Gc1" style="text-align: right" title="Number of Restricted Stock Units, Vested">(1,354,081</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3EKlGRt0cI3" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">6.17</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Forfeited/Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDBdSdiacP7b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Restricted Stock Units, Forfeited/Cancelled">(95,897</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztIe6HJpuF21" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited/Cancelled">6.16</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Unvested at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9SK3v3Suf97" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Restricted Stock Units, Outstanding Ending">2,925,497</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zY7bM55B1Gc3" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding Ending">3.99</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1267415 9.94 1925476 5.66 725166 8.66 41000 8.31 2426725 6.95 1948750 1.92 1354081 6.17 95897 6.16 2925497 3.99 9500000 P1Y8M12D <p id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zGm6iFaGPpqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes warrant activity during the years ended December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zcp14VjSddQa" style="display: none">Schedule of Warrant Activity</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted Average Exercise</p> <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231_zts8Zk16Tuej" style="width: 11%; text-align: right" title="Number of Warrants Outstanding, Beginning">526,281</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zTJi4Xoe47ra" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, Beginning">8.15</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageFairValue_iS_pid_c20220101__20221231_zbfgcM7p4c3b" style="width: 11%; text-align: right" title="Weighted Average fair value, Beginning">4.01</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zSqLJooZvGxg" title="Weighted-average Remaining Contractual Life (Years) Outstanding">4.7</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Issued for adjustments to contingent purchase consideration</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationIssuedForAdjustmentsToContingentPurchaseConsideration_c20220101__20221231_zwlGyYXTBMbh" style="text-align: right" title="Number of Warrants Outstanding, Issued">8,719</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--IssuedForAdjustmentsToContingentPurchaseConsiderationPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zCVjHaZyPha8" style="text-align: right" title="Weighted Average Exercise Price, Issued">9.13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--IssuedForAdjustmentsToContingentPurchaseConsiderationWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zuN0HNtpr0bi" style="text-align: right" title="Weighted Average Fair Value, Issued">1.88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231_zuToqGPFDhKk" style="text-align: right" title="Number of Warrants Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1290">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zg2Vh5gR2B2e" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1292">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsGrantedWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zc4J1e9iuEe7" style="text-align: right" title="Weighted Average Fair Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1294">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231_zur5hyRwHMPi" style="text-align: right" title="Number of Warrants Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1296">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_znOf6WpWCH0b" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1298">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zkmI5Punj23k" style="text-align: right" title="Weighted Average Fair Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1300">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Forfeited/Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231_zntU1523wll8" style="text-align: right" title="Number of Warrants Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1302">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zQ8mOH6EoWD" style="text-align: right" title="Weighted Average Exercise Price, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1304">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20220101__20221231_z9sLoh8Gasf4" style="text-align: right" title="Weighted Average Fair Value, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1306">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231_zBFMww47hEc7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Exercised">(50,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zajl4XfThVN" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, Exercised">2.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zV6Mtk1w38e3" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value, Exercised">1.22</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231_zgXHOXuQKjda" style="text-align: right" title="Number of Warrants Outstanding, Beginning">485,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zZlM3gjskajf" style="text-align: right" title="Weighted Average Exercise Price, Beginning">8.81</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageFairValue_iS_pid_c20230101__20231231_zgqbwohPfy2b" style="text-align: right" title="Weighted Average fair value, Beginning">2.43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm3_dtY_c20220101__20221231_z0l309U0q73e" title="Weighted-average Remaining Contractual Life (Years) Outstanding">4.0</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231_zYE7CYTTKCs" style="text-align: right" title="Number of Warrants Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1322">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_z09dle1R83N" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1324">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsGrantedWeightedAverageGrantDateFairValue_pid_c20230101__20231231_z54PFd9khL2c" style="text-align: right" title="Weighted Average Fair Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1326">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20230101__20231231_z4hsN4cLXEH3" style="text-align: right" title="Number of Warrants Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1328">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_z5pAabUvms8i" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1330">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zCwoOsxUmgsd" style="text-align: right" title="Weighted Average Fair Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1332">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited/Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20230101__20231231_zPUZaojQHJfh" style="text-align: right" title="Number of Warrants Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1334">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_z7eCJIoo29h" style="text-align: right" title="Weighted Average Exercise Price, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1336">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zkxsIC1cMgFd" style="text-align: right" title="Weighted Average Fair Value, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1338">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20231231_z4KtW0LAFfHb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1340">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zz8fLqqFJv1g" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1342">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_z6cx87XDrqI5" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1344">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231_zcufPtvEXGQ2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Ending">485,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zrXZ2sMlFMbb" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Ending">8.81</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zEdQaU1OIxId" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value, Ending">1.29</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm3_dtY_c20230101__20231231_zi3KSB7ddt5k" title="Weighted-average Remaining Contractual Life (Years) Outstanding">3.0</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 526281 8.15 4.01 P4Y8M12D 8719 9.13 1.88 50000 2.00 1.22 485000 8.81 2.43 P4Y 485000 8.81 1.29 P3Y 0 300000 0 20000 465000 <p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zG1ZO3xHtDAk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized stock-based compensation expense as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zqqGf0Cvi5Ak" style="display: none">Schedule of Recognized Stock-based Compensation Expense</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20230101__20231231_zUyU6PXatIVi" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20220101__20221231_zVwz74A60Wr7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zsZdlhB6NyQj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Cost of sales</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">46,586</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">63,058</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zB8zZJvF8PU7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Sales and marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,153,974</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,866,116</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zDaT9YBOZd1e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,933,822</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,050,967</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zlSekZuMCO85" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,202,473</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,563,082</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_ze6lQOV68Zvl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,336,855</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,543,223</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 46586 63058 2153974 1866116 4933822 4050967 1202473 1563082 8336855 7543223 <p id="xdx_801_eus-gaap--IncomeTaxDisclosureTextBlock_zUStweFEGuw" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11 – <span id="xdx_824_zTHtL1ZUGKZa">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z1fucJCdJeIg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of the provision (benefit) for income taxes consists of the following for the years ended December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zGUo5PTFh062" style="display: none">Schedule of Components Income Tax Provision</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20230101__20231231_zAGMBfigON3k" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023 </b></span></td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220101__20221231_zhzqXw1db6ii" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023 </b></span></td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zybAmLA9ssE" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maCFSALzO40_zhq4Xo6ByWB7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 68%">Federal</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">84,435</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">563,821</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maCFSALzO40_zXB9xEMWmp96" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(540,240</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(266,248</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_i01T_mtCFSALzO40_maITEBzvit_zI4GaPh2vRYc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total current</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(455,805</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">297,573</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zRI4DHI8AHzf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Deferred:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDFSALzIK4_zPcsRrn0OBx9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,228,611</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,945,090</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDFSALzIK4_zGRTr3UemzFh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">State</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,068,509</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(961,468</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_ecustom--ChangeInValuationAllowance_i01N_di_msDFSALzIK4_zYP5ml5iShba" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,975,234</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1407">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_i01T_maITEBzvit_mtDFSALzIK4_zyomCHjiWSF2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total deferred</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,321,886</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,906,558</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzvit_zGMPxeosbt8a" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total income tax benefit</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,777,691</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,608,985</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_8A2_zExRs7olelmi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zxcxpYpE47p3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zO6sMCjuwaDj" style="display: none">Schedule of Benefit from Income Taxes and Effective Tax Rates</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20230101__20231231_ztZOtJBM72Rh" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20220101__20221231_zwqiPSCSGYjh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year Ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_maITEBzvik_zzNHpzp5iq8j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Federal income tax expense at statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maITEBzvik_zmyy9gFPl6G2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income tax expense, net of federal tax benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.6</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.8</td><td style="text-align: left">%</td></tr> <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentAbstract_iB_zpAP1FakDqz" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Permanent differences:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationFdiiPercent_i01_dp_uPure_maITEBzvik_zZgGUczgO9M6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">- Foreign derived intangible income deduction</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.4</td><td style="text-align: left">%</td></tr> <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_i01N_dpi_uPure_msITEBzvik_zffnXSrvG5Cb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">- Stock based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-3.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-3.6</td><td style="text-align: left">%</td></tr> <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationContingentConsiderationRemeasurement_i01_dp_uPure_maITEBzvik_zklfDefw9R3h" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">- Contingent consideration remeasurement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.6</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.8</td><td style="text-align: left">%</td></tr> <tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationGoodwillImpairment_i01_dp_uPure_msITEBzvik_zS63YRrHg9Gg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">- Goodwill impairment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-17.1</td><td style="text-align: left">%</td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_i01_dp_uPure_msITEBzvik_z8AN4aXJUDs3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">- Other permanent differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.6</td><td style="text-align: left">%</td></tr> <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_iN_dpi_uPure_maITEBzvik_zo24qT8qXmr2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research and development credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.6</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11.1</td><td style="text-align: left">%</td></tr> <tr id="xdx_408_ecustom--EffectiveIncomeTaxRateReconciliationChangeInValuationAllowance_iN_dpi_uPure_maITEBzvik_zut6jHrkWaPd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in uncertain tax positions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-2.1</td><td style="text-align: left">%</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_dpi_uPure_msITEBzvik_zKB0zQ4ivcag" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-18.3</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_uPure_maITEBzvik_z4gQRDcEgbxl" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_iT_dp_uPure_mtITEBzvik_zG6dCIgu0Gl5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Effective income tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7.3</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">24.5</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> <p id="xdx_8AE_zk7wcU5sSVxd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zO89HrkwR5tf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax liabilities consist of the following components as of December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zLjlQPnK81x7" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20231231_zphkmz9IKATf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231_zDhAvm69WjHk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zyrkMYjgTq77" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_i01I_maDTAGzwm0_zcAFGCS7EKpb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 68%; text-align: left">Accrued liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">58,158</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">98,141</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_i01I_maDTAGzwm0_z1VFwT9JaNwl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Reserves and allowances</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">734,631</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">765,004</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_i01I_maDTAGzwm0_zKiMkMKh3L93" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Deferred compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">620,551</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">566,076</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--DeferredTaxAssetsCosts_i01I_maDTAGzwm0_zmvgCpdFZSih" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Section 174 costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,337,629</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,460,159</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DeferredTaxAssetsLeaseLiability_i01I_maDTAGzwm0_zgXqPbQiYqw" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">742,131</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">85,899</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--DeferredTaxAssetsUniformCapitalization_i01I_maDTAGzwm0_zFMHKcPhXC11" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">UNICAP</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,943</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">168,936</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_maDTAGzwm0_zFltnaBLECla" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Net operating loss carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,040,601</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1480">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_maDTAGzwm0_z5k9EHYPSkii" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Research and development credits</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,688,255</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1483">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGzwm0_maDTAOzex8_maDTANz2N2_z86vPnRPaNhk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Total gross deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,265,899</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,144,215</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANz2N2_zsT9lRuMgstb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,938,829</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1489">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_i01TI_mtDTANz2N2_maDTALNzo3m_zibIiutP85Ve" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total deferred tax assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,327,070</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,144,215</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zchtSvz00Mo8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i01NI_di_maDITLzTlQ_z0XlaYHQrKNk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Property and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(672,416</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(609,261</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_i01NI_di_maDITLzTlQ_zQxlvov5S3Hf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Intangibles, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,552,255</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,608,914</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_i01NI_di_maDITLzTlQ_zsbmYNBtIL37" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Prepaids</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(329,768</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(156,053</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_i01NI_di_maDITLzTlQ_zHhf1Xg0KWYf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Right of use asset</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(736,226</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(91,873</td><td style="text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxLiabilitiesOtherComprehensiveIncome_i01NI_di_maDITLzTlQ_zfpTpXjKjEse" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Other comprehensive income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(36,405</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(96,101</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_di_maDITLzTlQ_zm104iL3ZuY9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1512">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1513">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredIncomeTaxLiabilities_i01NTI_di_msDTAOzex8_mtDITLzTlQ_msDTALNzo3m_zHNPxPzrBNn9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,327,070</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,562,202</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i01NTI_di_msDTAOzex8_mtDTALNzo3m_zhCIzb3DHAo7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1518">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,417,987</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_8A6_z3nlZBkh68o4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At December 31, 2023, the Company had federal net operating loss carryforwards of $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231_zjNabjX1kw4g" title="Net operating loss carry-forwards">16.3</span> million and federal research and development credit carryforwards of $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn5n6_c20231231_zs2VE6DnZ3Ia" title="Research and development credit carry forwards">1.4</span> million. At December 31, 2023, the Company had state net operating loss carryforwards of $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20231231_z22YidQyzPkf" title="State net operating loss carryforwards">16.9</span> million and $<span id="xdx_907_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_pn5n6_c20231231_zamEApM84vDf" title="State research and development credit carryforwards">0.8</span> million of state research and development credit carryforwards. If unused, the state research credit carryforward will expire in 2037.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">ASC Topic 740-10-05 requires that the impact of a tax position be recognized in the financial statements if that position is more likely than not of being sustained on audit, based on the technical merits of the position. Our unrecognized tax benefit balances included $<span id="xdx_906_eus-gaap--UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_iI_c20231231_zYlogxS4pcrj" title="Unrecognized tax benefits that would impact effective tax rate">1,078,431</span> at December 31, 2023 and $<span id="xdx_90D_eus-gaap--UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_iI_c20221231_ztpTSPsyO3sf" title="Unrecognized tax benefits that would impact effective tax rate">1,469,577</span> at December 31, 2022 of tax positions that, if recognized, would impact our effective tax rate. The Company expects no material changes to the liability for unrecognized tax benefits in the next 12 months. Interest and penalties associated with uncertain tax positions are recorded as a component of income tax expense. A reconciliation of the beginning and ending amount of unrecognized benefits is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zxL0D0hUgfm3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z94xsNZDuCDj" style="display: none">Schedule of Unrecognized Tax Benefits</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Unrecognized tax benefits at the beginning of the year</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--UnrecognizedTaxBenefits_iS_c20230101__20231231_zdb7ekkbKvv4" style="width: 12%; text-align: right" title="Unrecognized tax benefits at the beginning of the year">1,469,577</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--UnrecognizedTaxBenefits_iS_c20220101__20221231_z0bEfHo7DTvh" style="width: 12%; text-align: right" title="Unrecognized tax benefits at the beginning of the year">1,067,853</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Gross increases - current year tax positions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_c20230101__20231231_ziFjioiNamth" style="text-align: right" title="Gross increases- current year tax positions">273,569</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_c20220101__20221231_zJy7yfC8d8T6" style="text-align: right" title="Gross increases- current year tax positions">1,045,590</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross increases - prior year tax positions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_c20230101__20231231_zpCA93p4lOCc" style="text-align: right" title="Gross increases- prior year tax positions">66,127</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_c20220101__20221231_zbszH0jjCNVj" style="text-align: right" title="Gross increases- prior year tax positions">34,035</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Gross decreases - prior year tax positions</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_iN_di_c20230101__20231231_zpOSP1vOP26i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross decreases - prior year tax positions">(730,842</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_iN_di_c20220101__20221231_zStbaXY7KNU9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross decreases - prior year tax positions">(677,901</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Unrecognized tax benefits at end of year</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--UnrecognizedTaxBenefits_iE_c20230101__20231231_z8ToZwoVZqVa" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrecognized tax benefits at end of year">1,078,431</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--UnrecognizedTaxBenefits_iE_c20220101__20221231_zyIeJ6lZ3HC6" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrecognized tax benefits at end of year">1,469,577</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Interest and penalties in year-end balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_iE_c20230101__20231231_zqAmheii70p6" style="border-bottom: Black 2.5pt double; text-align: right" title="Interest and penalties in year-end balance">100,162</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_iE_c20220101__20221231_ze0CB93QBrS9" style="border-bottom: Black 2.5pt double; text-align: right" title="Interest and penalties in year-end balance">34,035</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zl5aqtWyZRUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to taxation in the United States and other state jurisdictions. The tax years from December 31, 2020 through December 31, 2023 remain open to examination for federal income tax purposes and by the other major taxing jurisdictions to which the Company is subject. The Company is not currently under examination by any taxing authority.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z1fucJCdJeIg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of the provision (benefit) for income taxes consists of the following for the years ended December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zGUo5PTFh062" style="display: none">Schedule of Components Income Tax Provision</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20230101__20231231_zAGMBfigON3k" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023 </b></span></td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220101__20221231_zhzqXw1db6ii" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023 </b></span></td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zybAmLA9ssE" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maCFSALzO40_zhq4Xo6ByWB7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 68%">Federal</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">84,435</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">563,821</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maCFSALzO40_zXB9xEMWmp96" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(540,240</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(266,248</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_i01T_mtCFSALzO40_maITEBzvit_zI4GaPh2vRYc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total current</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(455,805</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">297,573</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zRI4DHI8AHzf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Deferred:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDFSALzIK4_zPcsRrn0OBx9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,228,611</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,945,090</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDFSALzIK4_zGRTr3UemzFh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">State</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,068,509</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(961,468</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_ecustom--ChangeInValuationAllowance_i01N_di_msDFSALzIK4_zYP5ml5iShba" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,975,234</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1407">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_i01T_maITEBzvit_mtDFSALzIK4_zyomCHjiWSF2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total deferred</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,321,886</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,906,558</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzvit_zGMPxeosbt8a" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total income tax benefit</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,777,691</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,608,985</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> 84435 563821 -540240 -266248 -455805 297573 -7228611 -3945090 -2068509 -961468 -6975234 -2321886 -4906558 -2777691 -4608985 <p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zxcxpYpE47p3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zO6sMCjuwaDj" style="display: none">Schedule of Benefit from Income Taxes and Effective Tax Rates</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20230101__20231231_ztZOtJBM72Rh" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20220101__20221231_zwqiPSCSGYjh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year Ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_maITEBzvik_zzNHpzp5iq8j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Federal income tax expense at statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maITEBzvik_zmyy9gFPl6G2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income tax expense, net of federal tax benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.6</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.8</td><td style="text-align: left">%</td></tr> <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentAbstract_iB_zpAP1FakDqz" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Permanent differences:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationFdiiPercent_i01_dp_uPure_maITEBzvik_zZgGUczgO9M6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">- Foreign derived intangible income deduction</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.4</td><td style="text-align: left">%</td></tr> <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_i01N_dpi_uPure_msITEBzvik_zffnXSrvG5Cb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">- Stock based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-3.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-3.6</td><td style="text-align: left">%</td></tr> <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationContingentConsiderationRemeasurement_i01_dp_uPure_maITEBzvik_zklfDefw9R3h" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">- Contingent consideration remeasurement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.6</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.8</td><td style="text-align: left">%</td></tr> <tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationGoodwillImpairment_i01_dp_uPure_msITEBzvik_zS63YRrHg9Gg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">- Goodwill impairment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-17.1</td><td style="text-align: left">%</td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_i01_dp_uPure_msITEBzvik_z8AN4aXJUDs3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">- Other permanent differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.6</td><td style="text-align: left">%</td></tr> <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_iN_dpi_uPure_maITEBzvik_zo24qT8qXmr2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research and development credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.6</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11.1</td><td style="text-align: left">%</td></tr> <tr id="xdx_408_ecustom--EffectiveIncomeTaxRateReconciliationChangeInValuationAllowance_iN_dpi_uPure_maITEBzvik_zut6jHrkWaPd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in uncertain tax positions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-2.1</td><td style="text-align: left">%</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_dpi_uPure_msITEBzvik_zKB0zQ4ivcag" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-18.3</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_uPure_maITEBzvik_z4gQRDcEgbxl" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_iT_dp_uPure_mtITEBzvik_zG6dCIgu0Gl5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Effective income tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7.3</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">24.5</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> 0.210 0.210 0.016 0.048 0.000 0.014 0.035 0.036 0.006 0.088 0.000 -0.171 -0.002 -0.006 -0.046 -0.111 -0.012 0.021 0.183 -0.000 0.003 0.008 0.073 0.245 <p id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zO89HrkwR5tf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax liabilities consist of the following components as of December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zLjlQPnK81x7" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20231231_zphkmz9IKATf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231_zDhAvm69WjHk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zyrkMYjgTq77" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_i01I_maDTAGzwm0_zcAFGCS7EKpb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 68%; text-align: left">Accrued liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">58,158</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">98,141</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_i01I_maDTAGzwm0_z1VFwT9JaNwl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Reserves and allowances</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">734,631</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">765,004</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_i01I_maDTAGzwm0_zKiMkMKh3L93" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Deferred compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">620,551</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">566,076</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--DeferredTaxAssetsCosts_i01I_maDTAGzwm0_zmvgCpdFZSih" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Section 174 costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,337,629</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,460,159</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DeferredTaxAssetsLeaseLiability_i01I_maDTAGzwm0_zgXqPbQiYqw" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">742,131</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">85,899</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--DeferredTaxAssetsUniformCapitalization_i01I_maDTAGzwm0_zFMHKcPhXC11" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">UNICAP</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,943</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">168,936</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_maDTAGzwm0_zFltnaBLECla" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Net operating loss carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,040,601</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1480">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_maDTAGzwm0_z5k9EHYPSkii" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Research and development credits</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,688,255</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1483">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGzwm0_maDTAOzex8_maDTANz2N2_z86vPnRPaNhk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Total gross deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,265,899</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,144,215</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANz2N2_zsT9lRuMgstb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,938,829</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1489">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_i01TI_mtDTANz2N2_maDTALNzo3m_zibIiutP85Ve" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total deferred tax assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,327,070</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,144,215</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zchtSvz00Mo8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i01NI_di_maDITLzTlQ_z0XlaYHQrKNk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Property and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(672,416</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(609,261</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_i01NI_di_maDITLzTlQ_zQxlvov5S3Hf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Intangibles, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,552,255</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,608,914</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_i01NI_di_maDITLzTlQ_zsbmYNBtIL37" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Prepaids</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(329,768</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(156,053</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_i01NI_di_maDITLzTlQ_zHhf1Xg0KWYf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Right of use asset</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(736,226</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(91,873</td><td style="text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxLiabilitiesOtherComprehensiveIncome_i01NI_di_maDITLzTlQ_zfpTpXjKjEse" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Other comprehensive income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(36,405</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(96,101</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_di_maDITLzTlQ_zm104iL3ZuY9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1512">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1513">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredIncomeTaxLiabilities_i01NTI_di_msDTAOzex8_mtDITLzTlQ_msDTALNzo3m_zHNPxPzrBNn9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,327,070</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,562,202</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i01NTI_di_msDTAOzex8_mtDTALNzo3m_zhCIzb3DHAo7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1518">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,417,987</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> 58158 98141 734631 765004 620551 566076 7337629 3460159 742131 85899 43943 168936 4040601 1688255 15265899 5144215 6938829 8327070 5144215 672416 609261 6552255 6608914 329768 156053 736226 91873 36405 96101 8327070 7562202 2417987 16300000 1400000 16900000 800000 1078431 1469577 <p id="xdx_896_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zxL0D0hUgfm3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z94xsNZDuCDj" style="display: none">Schedule of Unrecognized Tax Benefits</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Unrecognized tax benefits at the beginning of the year</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--UnrecognizedTaxBenefits_iS_c20230101__20231231_zdb7ekkbKvv4" style="width: 12%; text-align: right" title="Unrecognized tax benefits at the beginning of the year">1,469,577</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--UnrecognizedTaxBenefits_iS_c20220101__20221231_z0bEfHo7DTvh" style="width: 12%; text-align: right" title="Unrecognized tax benefits at the beginning of the year">1,067,853</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Gross increases - current year tax positions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_c20230101__20231231_ziFjioiNamth" style="text-align: right" title="Gross increases- current year tax positions">273,569</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_c20220101__20221231_zJy7yfC8d8T6" style="text-align: right" title="Gross increases- current year tax positions">1,045,590</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross increases - prior year tax positions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_c20230101__20231231_zpCA93p4lOCc" style="text-align: right" title="Gross increases- prior year tax positions">66,127</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_c20220101__20221231_zbszH0jjCNVj" style="text-align: right" title="Gross increases- prior year tax positions">34,035</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Gross decreases - prior year tax positions</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_iN_di_c20230101__20231231_zpOSP1vOP26i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross decreases - prior year tax positions">(730,842</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_iN_di_c20220101__20221231_zStbaXY7KNU9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross decreases - prior year tax positions">(677,901</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Unrecognized tax benefits at end of year</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--UnrecognizedTaxBenefits_iE_c20230101__20231231_z8ToZwoVZqVa" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrecognized tax benefits at end of year">1,078,431</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--UnrecognizedTaxBenefits_iE_c20220101__20221231_zyIeJ6lZ3HC6" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrecognized tax benefits at end of year">1,469,577</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Interest and penalties in year-end balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_iE_c20230101__20231231_zqAmheii70p6" style="border-bottom: Black 2.5pt double; text-align: right" title="Interest and penalties in year-end balance">100,162</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_iE_c20220101__20221231_ze0CB93QBrS9" style="border-bottom: Black 2.5pt double; text-align: right" title="Interest and penalties in year-end balance">34,035</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1469577 1067853 273569 1045590 66127 34035 730842 677901 1078431 1469577 100162 34035 <p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zJ7M0KreUDnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 12 – <span id="xdx_82C_z2r1SbGE2A7l">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lease Obligations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company leases administrative, R&amp;D, sales and marketing and manufacturing facilities under non-cancellable operating leases and leases cancellable with one month notice. The Company expenses the cancelable leases in the period incurred in accordance with the practical expedient elected. During the year December 31, 2023, the Company amended two operating leases to extend the lease term and entered into two new operating leases. As a result, the Company recognized additional operating lease liabilities and corresponding operating right-of-use assets of $<span id="xdx_909_eus-gaap--OperatingLeaseLiability_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--LeaseAmendmentMember_zM9FhLvg21rj" title="Operating lease liabilities">3,203,146</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_z3oEwbNbiydc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2023, components of lease expense are summarized as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zJQLFyzBoWNj" style="display: none">Schedule of Lease Expense</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20230101__20231231_zYmZZ6quuVJg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Year Ended</p> <p style="margin-top: 0; margin-bottom: 0">December 31, 2023</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseCost_maLCz2lp_zKp27a95f3Jd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Operating lease costs</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">813,743</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ShortTermLeaseCost_maLCz2lp_zhFCsRb3Oxyj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Short-term lease costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">198,261</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LeaseCost_iT_mtLCz2lp_zBSkHO5SgUme" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total lease costs</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,012,004</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A2_z2gIVZQ4t6Bd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ztC73cIxjxT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the maturities of the Company’s lease liabilities are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zozi1g7pylXl" style="display: none">Schedule of Maturities on Company Lease Liabilities</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20231231_zNrFQm09Gkqj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Year Ending</p> <p style="margin-top: 0; margin-bottom: 0">December 31,</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz8za_zdd2Ln1JJ3Uj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">996,676</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz8za_zRgaTmUgQgm" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,018,383</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz8za_ziVVgwtDYM4c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">714,630</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz8za_zgJR8iQWFC4l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,591</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_maLOLLPz8za_zCEePENNGnh6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">308,462</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz8za_zFPsdrvcBO6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,338,742</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_zklZpvMvOMAg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">348,175</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zjlC42Y6eqP2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Present value of operating lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,990,567</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_iI_ziw2bZVkVHcb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">838,387</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zvCXYXAPKrz4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Long-term portion</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,152,180</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A8_zXO3U92iatWl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_89C_ecustom--ScheduleOfOperatingLeaseTableTextBlock_zSn9SesXmzPc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other information related to operating leases was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zMwcrWIxhLU2" style="display: none">Schedule of Other Information Related to Operating Lease</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20230101__20231231_z6PZSwsWD1h5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Year Ended</p> <p style="margin-top: 0; margin-bottom: 0">December 31, 2023</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeasePayments_zkIi4uqaEhp6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Cash paid for operating leases included in operating cash flows</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">954,013</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Remaining lease term of operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zmHzsa18Ecaa" title="Remaining lease term of operating leases">3.7</span> years </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Discount rate of operating leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zm4Zwyhl4bT9" style="text-align: right" title="Discount rate of operating leases">6.2</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AD_znHmIu7nyaR7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Litigation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is a defendant in two class action claims and three derivative actions claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The plaintiffs demand compensatory damages sustained as a result of the Company’s alleged wrongdoing in an amount to be proven at trial. The Company is also a party to two civil actions, one in the US and the other in the United Kingdom. Each of the civil actions is based on breach of contract claims against the Company. The Company believes these lawsuits are without merit and intends to defend the cases vigorously. The Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in these cases. As of the date of this report, the Company does not believe it is probable that these cases will result in an unfavorable outcome; however, if an unfavorable outcome were to occur in these cases, it is possible that the impact could be material to the Company’s results of operations in the period(s) in which any such outcome becomes probable and estimable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3203146 <p id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_z3oEwbNbiydc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2023, components of lease expense are summarized as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zJQLFyzBoWNj" style="display: none">Schedule of Lease Expense</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20230101__20231231_zYmZZ6quuVJg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Year Ended</p> <p style="margin-top: 0; margin-bottom: 0">December 31, 2023</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseCost_maLCz2lp_zKp27a95f3Jd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Operating lease costs</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">813,743</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ShortTermLeaseCost_maLCz2lp_zhFCsRb3Oxyj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Short-term lease costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">198,261</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LeaseCost_iT_mtLCz2lp_zBSkHO5SgUme" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total lease costs</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,012,004</td><td style="text-align: left"> </td></tr> </table> 813743 198261 1012004 <p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ztC73cIxjxT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the maturities of the Company’s lease liabilities are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zozi1g7pylXl" style="display: none">Schedule of Maturities on Company Lease Liabilities</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20231231_zNrFQm09Gkqj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Year Ending</p> <p style="margin-top: 0; margin-bottom: 0">December 31,</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz8za_zdd2Ln1JJ3Uj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">996,676</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz8za_zRgaTmUgQgm" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,018,383</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz8za_ziVVgwtDYM4c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">714,630</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz8za_zgJR8iQWFC4l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,591</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_maLOLLPz8za_zCEePENNGnh6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">308,462</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz8za_zFPsdrvcBO6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,338,742</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_zklZpvMvOMAg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">348,175</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zjlC42Y6eqP2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Present value of operating lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,990,567</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_iI_ziw2bZVkVHcb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">838,387</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zvCXYXAPKrz4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Long-term portion</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,152,180</td><td style="text-align: left"> </td></tr> </table> 996676 1018383 714630 300591 308462 3338742 348175 2990567 838387 2152180 <p id="xdx_89C_ecustom--ScheduleOfOperatingLeaseTableTextBlock_zSn9SesXmzPc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other information related to operating leases was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zMwcrWIxhLU2" style="display: none">Schedule of Other Information Related to Operating Lease</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20230101__20231231_z6PZSwsWD1h5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Year Ended</p> <p style="margin-top: 0; margin-bottom: 0">December 31, 2023</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeasePayments_zkIi4uqaEhp6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Cash paid for operating leases included in operating cash flows</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">954,013</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Remaining lease term of operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zmHzsa18Ecaa" title="Remaining lease term of operating leases">3.7</span> years </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Discount rate of operating leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zm4Zwyhl4bT9" style="text-align: right" title="Discount rate of operating leases">6.2</td><td style="text-align: left">%</td></tr> </table> 954013 P3Y8M12D 0.062 <p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z5dd6gga9NL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 13 – <span id="xdx_829_zFXII1MKLcB8">Share Repurchase Program</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2022, the Company’s board of directors authorized a share repurchase program that would allow the Company to repurchase up to $<span id="xdx_909_eus-gaap--StockRepurchaseProgramAuthorizedAmount1_iI_pn5n6_c20220331_zzQproajo8Xc" title="Stock repurchase program authorized amount">30.0</span> million of CODX common stock. The repurchase program does not obligate the Company to acquire any particular number of common shares, and the repurchase program may be suspended or discontinued at any time at the Company’s discretion. The timing and amount of any share repurchases under the share repurchase program will be determined by Co-Diagnostics’ management at its discretion based on ongoing assessments of the capital needs of the business, the market price of the Company’s common stock, corporate and regulatory requirements, and general market conditions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For accounting purposes, common stock repurchased under the stock repurchase program is recorded based upon the transaction date of the applicable trade. Such repurchased shares are held in treasury and are presented using the cost method. These shares are not retired and are considered issued but not outstanding. The following table shows the changes in treasury stock for the periods presented:</span></p> <p id="xdx_897_ecustom--ScheduleOfTreasuryStockTableTextBlock_zv5SP60yESWk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zWSnzLoHAf13" style="display: none">Schedule of Treasury Stock</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Balance, beginning of period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--TreasuryStockCommonShares_iS_pid_d0_c20230101__20231231_z1mksBDxzqM7" style="width: 18%; text-align: right" title="Treasury stock, Beginning Balance">3,881,658</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Repurchases of common stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_ecustom--RepurchasesOfCommonStock_c20230101__20231231_zGoX2iqdpjX8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Repurchases of common stock">967,020</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Balance, end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--TreasuryStockCommonShares_iE_pid_c20230101__20231231_zthDkbmnOdma" style="border-bottom: Black 2.5pt double; text-align: right" title="Treasury stock, Ending Balance">4,848,678</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zoVh7n41wK17" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> 30000000.0 <p id="xdx_897_ecustom--ScheduleOfTreasuryStockTableTextBlock_zv5SP60yESWk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zWSnzLoHAf13" style="display: none">Schedule of Treasury Stock</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Balance, beginning of period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--TreasuryStockCommonShares_iS_pid_d0_c20230101__20231231_z1mksBDxzqM7" style="width: 18%; text-align: right" title="Treasury stock, Beginning Balance">3,881,658</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Repurchases of common stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_ecustom--RepurchasesOfCommonStock_c20230101__20231231_zGoX2iqdpjX8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Repurchases of common stock">967,020</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Balance, end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--TreasuryStockCommonShares_iE_pid_c20230101__20231231_zthDkbmnOdma" style="border-bottom: Black 2.5pt double; text-align: right" title="Treasury stock, Ending Balance">4,848,678</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3881658 967020 4848678 <p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zcRFWQVhV6L8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 14 – <span id="xdx_829_zggX1HhjOkr9">Related Party Transactions</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company employs one person who is related to current or former executive officers. Seth Egan is the Company’s Director of Sales and Marketing, and is the son of Dwight Egan, the Company’s President and Chief Executive Officer and Chairman of the Board. During the year ended December 31, 2023, the total compensation paid to this person, including salaries, bonuses, and the grant date fair value of equity awards which vest over <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SethEganMember_z7AfbhNzBbOd" title="Share based payment, vesting period">three years</span>, was $<span id="xdx_90D_ecustom--PaymentToRelatedParty_pn5n6_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SethEganMember_zUpJY7SSvE32" title="Total compensation paid">0.6</span> million. The Company also uses the services of Winston Egan as an independent contractor for sales operations consulting. Winston Egan is also the son of Dwight Egan, the Company’s President and Chief Executive Officer and Chairman of the Board. During the year ended December 31, 2023, the total compensation paid to this contractor, comprised of consulting fees, was $<span id="xdx_902_ecustom--PaymentToRelatedParty_pn5n6_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WinstonEganMember_zfFOjDSO2HMe" title="Fair value of equity awards">0.1</span> million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2023, the Company entered into a services agreement with CoSara, the Company’s equity method investment, under which CoSara provides certain research and development consulting and support services. During the year ended December 31, 2023, the Company recognized $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CoSaraDiagnosticsPvtLtdMember_z0ytD3iqcZZf" title="Research and development expenses">0.2</span> million of expense related to this agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> P3Y 600000 100000 200000 <p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_zUmyzUAgzKRi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 15 – <span id="xdx_825_zovM81G7HKrj">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p> false false false false Based on weighted-average useful life established as of the acquisition date.